Breast	O
development	O
and	O
gynecomastia	O
induced	O
by	O
bicalutamide	B-Drug
is	O
thought	O
to	O
be	O
mediated	O
increased	O
activation	O
of	O
the	O
ER	O
secondary	O
blockade	O
AR	O
resulting	O
in	O
disinhibition	O
breast	O
tissue	O
levels	O
estradiol	O

7-TS	O
via	O
a	O
reactive	O
metabolite	O
formed	O
by	O
17-hydroxylase	O
is	O
suicide	O
inhibitor	O
of	O
and	O
thought	O
to	O
be	O
involved	O
in	O
the	O
inhibition	O
spironolactone	B-Drug

Illicit	O
use	O
of	O
pharmaceutical	O
fentanyl	B-Drug
and	O
its	O
analogues	O
first	O
appeared	O
in	O
the	O
mid-1970s	O
medical	O
community	O
continues	O
present	O

Heroin	B-Drug
is	O
entirely	O
converted	O
to	O
morphine	B-Drug
by	O
means	O
of	O
first-pass	O
metabolism	O
resulting	O
in	O
deacetylation	O
when	O
ingested	O

A	O
methamphetamine	B-Drug
overdose	O
may	O
result	O
in	O
a	O
wide	O
range	O
of	O
symptoms	O

Respiratory	O
depression	O
is	O
a	O
potentially	O
serious	O
or	O
fatal	O
adverse	O
drug	O
reaction	O
associated	O
with	O
the	O
use	O
of	O
codeine	B-Drug
but	O
mainly	O
danger	O
lies	O
in	O
much	O
more	O
potent	O
and	O
CNS-depressing	O
phenothiazine-related	O
antihistamine	O
promethazine	B-Drug

Lofentanil	B-Drug
is	O
one	O
of	O
the	O
most	O
potent	O
opioid	O
analgesics	O
known	O
and	O
an	O
analogue	O
fentanyl	B-Drug
which	O
was	O
developed	O
in	O
1960	O

A	O
large	O
meta-analysis	O
of	O
pooled	O
results	O
from	O
19	O
trials	O
with	O
33826	O
participants	O
suggests	O
that	O
salmeterol	B-Drug
may	O
increase	O
the	O
small	O
risks	O
asthma-related	O
deaths	O
and	O
this	O
additional	O
risk	O
is	O
not	O
reduced	O
use	O
inhaled	O
steroids	O
e	O

Lorazepam	B-Drug
is	O
also	O
used	O
for	O
other	O
purposes	O
such	O
as	O
recreational	O
use	O
wherein	O
the	O
drug	O
taken	O
to	O
achieve	O
a	O
high	O
or	O
when	O
continued	O
long-term	O
against	O
medical	O
advice	O

A	O
related	O
compound	O
SU11654	O
Toceranib	B-Drug
was	O
also	O
approved	O
for	O
canine	O
tumors	O
and	O
the	O
ALK	O
inhibitor	O
Crizotinib	B-Drug
grew	O
out	O
of	O
a	O
SUGEN	O
program	O

25	O
mg/day	O
levonorgestrel	B-Drug
has	O
no	O
effect	O
on	O
SHBG	O
levels;	O
30	O
g/day	O
EE	O
and	O
0	O

2C-B	B-Drug
4-Bromo-25-dimethoxyphenethylamine	O
is	O
a	O
psychedelic	O
drug	O
first	O
synthesised	O
in	O
1974	O

Celgene	O
has	O
sponsored	O
numerous	O
clinical	O
trials	O
with	O
analogues	O
to	O
thalidomide	B-Drug
such	O
as	O
lenalidomide	B-Drug
that	O
are	O
substantially	O
more	O
powerful	O
and	O
have	O
fewer	O
side	O
effects	O
except	O
for	O
greater	O
myelosuppression	O

The	O
biosynthetic	O
pathway	O
of	O
nicotine	B-Drug
involves	O
a	O
coupling	O
reaction	O
between	O
the	O
two	O
cyclic	O
structures	O
that	O
comprise	O

Typically	O
the	O
base	O
for	O
lean	O
has	O
been	O
prescription	O
cold	O
medicine	O
specifically	O
cough	O
syrup	O
one	O
that	O
contains	O
both	O
promethazine	B-Drug
and	O
codeine	B-Drug
but	O
over-the-counter	O
lists	O
dextromethorphan	B-Drug
as	O
active	O
ingredient	O
also	O
used	O
it	O
can	O
produce	O
similar	O
effects	O
eliminate	O
need	O
a	O
doctor's	O
visit	O

Opium/opioid	O
preparations	O
are	O
used	O
often	O
as	O
a	O
last	O
resort	O
where	O
pain	O
is	O
severe	O
and	O
the	O
bowels	O
organically	O
loose	O
Opium	B-Drug

On	O
October	O
1	O
1957	O
the	O
company	O
launched	O
thalidomide	B-Drug
and	O
began	O
marketing	O
it	O
under	O
trade	O
name	O
Contergan	B-Drug

On	O
August	O
20	O
2020	O
Justin	O
Townes	O
Earle	O
died	O
from	O
an	O
accidental	O
overdose	O
caused	O
by	O
cocaine	B-Drug
laced	O
with	O
fentanyl	B-Drug

Diazepam	B-Drug
does	O
not	O
increase	O
or	O
decrease	O
hepatic	O
enzyme	O
activity	O
and	O
alter	O
the	O
metabolism	O
of	O
other	O
compounds	O

The	O
pharmacological	O
effects	O
of	O
CBD	B-Drug
may	O
involve	O
PPAR	O
agonism	O
inhibition	O
voltage-gated	O
cation	O
channels	O
and	O
intracellular	O
calcium	O
release	O

In	O
2013	O
overdose	O
on	O
amphetamine	B-Drug
methamphetamine	B-Drug
and	O
other	O
compounds	O
implicated	O
in	O
an	O
use	O
disorder	O
resulted	O
estimated	O
3788	O
deaths	O
worldwide	O
34254145	O
95%	O
confidence	O

Phenomorphan	B-Drug
is	O
a	O
highly	O
potent	O
drug	O
due	O
to	O
the	O
N-phenethyl	O
group	O
which	O
boosts	O
affinity	O
-opioid	O
receptor	O
and	O
so	O
phenomorphan	B-Drug
around	O
10x	O
more	O
than	O
levorphanol	B-Drug
itself	O
6-8x	O
potency	O
of	O
morphine	B-Drug

Androstenedione	B-Drug
has	O
been	O
shown	O
to	O
increase	O
serum	O
testosterone	O
levels	O
over	O
an	O
eight-hour	O
period	O
in	O
men	O
when	O
taken	O
as	O
a	O
single	O
oral	O
dose	O
of	O
300	O
mg	O
per	O
day	O
but	O
100	O
had	O
no	O
significant	O
effect	O
on	O

In	O
the	O
case	O
of	O
accidental	O
overdose	O
gamma-hydroxybutyric	O
acid	B-Drug
patients	O
can	O
become	O
drowsy	O
fall	O
asleep	O
and	O
may	O
enter	O
a	O
coma	O

A	O
2019	O
review	O
found	O
that	O
the	O
transition	O
rate	O
from	O
a	O
diagnosis	O
of	O
hallucinogen-induced	O
psychosis	O
which	O
included	O
PCP	B-Drug
to	O
schizophrenia	O
was	O
26%	O

MDMA	B-Drug
is	O
a	O
chiral	O
compound	O
and	O
has	O
been	O
almost	O
exclusively	O
administered	O
as	O
racemate	O

Tylenol	O
1	O
in	O
US/Canada	O
10	O
mg	O
of	O
codeine	B-Drug
phosphate	I-Drug
per	O
tablet	O
12	O

Carisoprodol	B-Drug
is	O
sometimes	O
mixed	O
with	O
date	O
rape	O
drugs	O

They	O
described	O
MDMA	B-Drug
as	O
inducing	O
an	O
easily	O
controlled	O
altered	O
state	O
of	O
consciousness	O
with	O
emotional	O
and	O
sensual	O
overtones	O
comparable	O
to	O
marijuana	O
psilocybin	O
devoid	O
the	O
hallucinatory	O
component	O
or	O
low	O
levels	O
MDA	O

Morphine	B-Drug
sales	O
began	O
in	O
1827	O
by	O
Heinrich	O
Emanuel	O
Merck	O
of	O
Darmstadt	O
and	O
helped	O
him	O
expand	O
his	O
family	O
pharmacy	O
into	O
the	O
KGaA	O
pharmaceutical	O
company	O

Benzoylecgonine	O
is	O
the	O
main	O
metabolite	O
of	O
cocaine	B-Drug
formed	O
by	O
liver	O
and	O
excreted	O
in	O
urine	O

LAAM	B-Drug
or	O
levomethadyl	B-Drug
acetate	I-Drug
is	O
the	O
levo	O
isomer	O
of	O
acetylmethadol	B-Drug
-methadyl	O

Methamphetamine	B-Drug
also	O
interacts	O
with	O
monoamine	O
oxidase	O
inhibitors	O
MAOIs	O
since	O
both	O
and	O
methamphetamine	B-Drug
increase	O
plasma	O
catecholamines;	O
therefore	O
concurrent	O
use	O
of	O
is	O
dangerous	O

It	O
was	O
first	O
synthesised	O
by	O
a	O
team	O
of	O
chemists	O
at	O
Janssen	O
Pharmaceutica	O
led	O
Paul	O
who	O
were	O
investigating	O
the	O
structure-activity	O
relationships	O
fentanyl	B-Drug
family	O
drugs	O

JWH-200	B-Drug
WIN	O
55225	O
is	O
an	O
analgesic	O
chemical	O
from	O
the	O
aminoalkylindole	O
family	O
that	O
acts	O
as	O
a	O
cannabinoid	O
receptor	O
agonist	O

Nevertheless	O
scale-up	O
of	O
healthcare-based	O
opioid	O
overdose	O
interventions	O
is	O
limited	O
by	O
providers'	O
insufficient	O
knowledge	O
and	O
negative	O
attitudes	O
towards	O
prescribing	O
take-home	O
naloxone	B-Drug
to	O
prevent	O

Carfentanil	B-Drug
one	O
of	O
the	O
two	O
fentanyl	B-Drug
derivatives	O
used	O
in	O
Moscow	O
theater	O
hostage	O
crisis	O
was	O
actively	O
marketed	O
by	O
several	O
Chinese	O
chemical	O
companies	O
at	O
time	O

[See	O
cannabis	O
edibles	O
and	O
extracts	B-Drug

To	O
counteract	O
the	O
abuse	O
potential	O
tilidine	B-Drug
is	O
used	O
in	O
combination	O
with	O
opioid	O
receptor	O
antagonist	O
naloxone	B-Drug

Similarly	O
to	O
various	O
other	O
opioids	O
buprenorphine	B-Drug
has	O
also	O
been	O
found	O
act	O
as	O
an	O
agonist	O
of	O
the	O
toll-like	O
receptor	O
4	O
albeit	O
with	O
very	O
low	O
affinity	O

Additionally	O
paracetamol	B-Drug
does	O
not	O
affect	O
the	O
closure	O
of	O
fetal	O
ductus	O
arteriosus	O
as	O
NSAIDs	O
can	O

Clonazepam	B-Drug
is	O
a	O
2'-chlorinated	O
derivative	O
of	O
nitrazepam	B-Drug
which	O
increases	O
its	O
potency	O
due	O
to	O
electron-attracting	O
effect	O
the	O
halogen	O
in	O
ortho-position	O

Prescribing	O
naloxone	B-Drug
should	O
be	O
accompanied	O
by	O
standard	O
education	O
that	O
includes	O
preventing	O
identifying	O
and	O
responding	O
to	O
an	O
overdose;	O
rescue	O
breathing;	O
calling	O
emergency	O
services	O

Long	O
half-life	O
benzodiazepines	O
like	O
diazepam	B-Drug
or	O
chlordiazepoxide	B-Drug
are	O
preferred	O
to	O
minimize	O
rebound	O
effects	O
and	O
available	O
in	O
low	O
dose	O
forms	O

Why	O
some	O
US	O
cities	O
are	O
opening	O
safe	O
spaces	O
for	O
injecting	O
heroin	B-Drug

There	O
are	O
a	O
number	O
of	O
broad	O
classes	O
opioids:	O
Natural	O
opiates:	O
alkaloids	O
contained	O
in	O
the	O
resin	B-Drug
opium	O
poppy	O
primarily	O
morphine	B-Drug
codeine	B-Drug
and	O
thebaine	O
but	O
not	O
papaverine	B-Drug
noscapine	O
which	O
have	O
different	O
mechanism	O
action;	O
The	O
following	O
could	O
be	O
considered	O
natural	O
leaves	O
from	O
Mitragyna	B-Drug
speciosa	I-Drug
also	O
known	O
as	O
kratom	B-Drug
contain	O
few	O
naturally-occurring	O
opioids	O
active	O
via	O
Mu-	O
Delta	O
receptors	O

A	O
common	O
example	O
of	O
an	O
irreversible	O
inhibitor	O
that	O
is	O
used	O
as	O
a	O
drug	O
aspirin	B-Drug
which	O
inhibits	O
the	O
COX-1	O
and	O
COX-2	O
enzymes	O
produce	O
inflammation	O
messenger	O
prostaglandin	O

Throughout	O
most	O
of	O
the	O
1970s	O
and	O
early	O
1980s	O
a	O
majority	O
cocaine	B-Drug
that	O
was	O
smuggled	O
to	O
United	O
States	O
trafficked	O
by	O
Colombian	O
drug	O
cartels	O
through	O
Florida	O
Caribbean	O
Sea	O

894	O
Unlawful	O
possession	O
of	O
methamphetamine	B-Drug

The	O
positions	O
of	O
major	O
tobacco	B-Drug
companies	O
on	O
the	O
issue	O
secondhand	O
smoke	O
is	O
somewhat	O
varied	O

It	O
has	O
similar	O
activity	O
to	O
pethidine	B-Drug
but	O
with	O
a	O
faster	O
onset	O
of	O
action	O
and	O
shorter	O
duration	O

The	O
opioid	O
analogue	O
dextromethorphan	B-Drug
long	O
claimed	O
to	O
be	O
as	O
effective	O
a	O
cough	O
suppressant	O
codeine	B-Drug
has	O
similarly	O
demonstrated	O
little	O
benefit	O
in	O
several	O
recent	O
studies	O

Chlorpromazine	B-Drug
is	O
a	O
tranquilizer	O
that	O
sedates	O
without	O
inducing	O
sleep	O

DOC	O
is	O
sometimes	O
misrepresented	O
as	O
LSD	B-Drug
by	O
unscrupulous	O
dealers	O

Oxandrolone	B-Drug
is	O
a	O
synthetic	O
androstane	O
steroid	O
and	O
17-alkylated	O
derivative	O
of	O
DHT	O

In	O
THC	O
CBD	B-Drug
and	O
CBN	O
this	O
side-chain	O
is	O
a	O
pentyl	O
5-carbon	O
chain	O

An	O
injected	O
mixture	O
of	O
cocaine	B-Drug
and	O
heroin	B-Drug
known	O
as	O
speedball	O
is	O
a	O
particularly	O
dangerous	O
combination	O
the	O
converse	O
effects	O
drugs	O
actually	O
complement	O
each	O
other	O
but	O
may	O
also	O
mask	O
symptoms	O
an	O
overdose	O

The	O
program	O
was	O
counted	O
as	O
a	O
substantial	O
success	O
with	O
cessation	O
of	O
direct	O
British	O
opium	B-Drug
exports	O
to	O
China	O
but	O
not	O
Hong	O
Kong	O
and	O
most	O
provinces	O
declared	O
free	O
production	O

The	O
254	O
pounds	O
115	O
kg	O
of	O
fentanyl	B-Drug
which	O
was	O
estimated	O
to	O
be	O
worth	O
US$3	O

Hydrocodone	B-Drug
causes	O
dilation	O
of	O
peripheral	O
blood	O
vessels	O
which	O
can	O
cause	O
hypotension	O
and	O
syncope	O

Although	O
all	O
patients	O
being	O
treated	O
with	O
delorazepam	B-Drug
should	O
be	O
routinely	O
monitored	O
for	O
signs	O
of	O
abuse	O
and	O
diversion	O
medication	O
increased	O
monitoring	O
a	O
history	O
drug	O
and/or	O
alcohol	O
is	O
always	O
warranted	O

In	O
another	O
case	O
a	O
19-year-old	O
male	O
was	O
admitted	O
to	O
hospital	O
suffering	O
from	O
inflammation	O
of	O
the	O
heart	O
20	O
hours	O
after	O
taking	O
one	O
gram	O
mephedrone	B-Drug

Thalidomide	B-Drug
causes	O
birth	O
defects	O

There	O
is	O
no	O
conclusive	O
evidence	O
that	O
thalidomide	B-Drug
or	O
lenalidomide	B-Drug
useful	O
to	O
bring	O
about	O
maintain	O
remission	O
in	O
Crohn's	O
disease	O

Pain	O
relief:	O
Primarily	O
fentanyl	B-Drug
provides	O
the	O
relief	O
of	O
pain	O
by	O
acting	O
on	O
brain	O
and	O
spinal	O
-receptors	O

Aticaprant	O
failed	O
to	O
meet	O
its	O
main	O
endpoint	O
for	O
nicotine	B-Drug
withdrawal	O
in	O
the	O
study	O

Nandrolone	B-Drug
esters	O
have	O
more	O
recently	O
been	O
proposed	O
for	O
widespread	O
treatment	O
of	O
androgen	O
deficiency	O
in	O
men	O
due	O
to	O
favorable	O
properties	O
including	O
their	O
high	O
ratio	O
anabolic	O
androgenic	O
effect	O
and	O
hence	O
lower	O
or	O
negligible	O
risk	O
scalp	O
hair	O
loss	O
prostate	O
enlargement	O
cancer	O
relative	O
testosterone	O

org	O
an	O
online	O
resource	O
that	O
provides	O
laboratory	O
testing	O
of	O
ecstasy	B-Drug
tablets	O
for	O
a	O
minimal	O
cost	O
which	O
allows	O
users	O
to	O
know	O
exactly	O
what	O
they	O
are	O
ingesting	O
and	O
avoid	O
taking	O
mislabeled	O
or	O
impure	O
substances	O

It	O
is	O
often	O
claimed	O
that	O
BZP	B-Drug
was	O
originally	O
synthesized	O
as	O
a	O
potential	O
antihelminthic	O
anti-parasitic	O
agent	O
for	O
use	O
in	O
farm	O
animals	O

Because	O
of	O
the	O
extremely	O
high	O
strength	O
pure	O
fentanyl	B-Drug
powder	O
it	O
is	O
very	O
difficult	O
to	O
dilute	O
appropriately	O
and	O
often	O
resulting	O
mixture	O
may	O
be	O
far	O
too	O
strong	O
therefore	O
dangerous	O

One	O
of	O
the	O
first	O
mentions	O
this	O
drug	O
can	O
be	O
found	O
in	O
document	O
written	O
by	O
The	O
College	O
on	O
Problem	O
Drug	O
Dependence	O
where	O
it	O
is	O
mentioned	O
as	O
N-butyramide	O
fentanyl	B-Drug
analog	O

Boldenone	B-Drug
undecylenate	I-Drug
is	O
or	O
has	O
been	O
marketed	O
under	O
a	O
number	O
of	O
brand	O
names	O
including	O
Boldane	O
Equipoise	O
Parenabol	O
and	O
Vebonol	O
among	O
others	O

In	O
dogs	O
the	O
phase	O
II	O
metabolites	O
are	O
alfaxalone	B-Drug
glucuronide	O
major	O
metabolite	O
20-hydroxyalfaxalone	O
sulfate	O
and	O
2-hydroxyalfaxalone	O
glucuronid	O

There	O
have	O
been	O
reports	O
of	O
krokodilaccording	O
to	O
media	O
a	O
street	O
name	O
for	O
desomorphine	B-Drug
semi-synthetic	O
opioid	O
which	O
has	O
similar	O
strength	O
and	O
narcotic	O
effect	O
heroin	B-Drug
diacetylmorphine	B-Drug
--	O
appearing	O
with	O
increasing	O
frequency	O
in	O
Russia	O
supposedly	O
more	O
recently	O
the	O
United	O
States	O

Potentiators	O
and	O
adjuvants	O
are	O
often	O
included	O
when	O
dihydrocodeine	B-Drug
is	O
used	O
in	O
an	O
unsupervised	O
fashion	O
especially	O
carisoprodol	B-Drug
glutethimide	B-Drug
hydroxyzine	O
first-generation	O
antihistamines	O
both	O
to	O
intensify	O
the	O
effect	O
lessen	O
side-effects	O
such	O
as	O
itching	O

Also	O
co-administration	O
of	O
eluxadoline	B-Drug
with	O
rosuvastatin	B-Drug
may	O
increase	O
the	O
risk	O
rhabdomyolysis	O

Ritonavir	B-Drug
functions	O
by	O
slowing	O
down	O
the	O
breakdown	O
of	O
lopinavir	B-Drug

Benzodiazepines	O
are	O
usually	O
administered	O
orally;	O
however	O
very	O
occasionally	O
lorazepam	B-Drug
or	O
diazepam	B-Drug
may	O
be	O
given	O
intravenously	O
for	O
the	O
treatment	O
of	O
panic	O
attacks	O

Desocodeine	O
is	O
a	O
semi-synthetic	O
opioid	O
which	O
the	O
penultimate	O
intermediate	O
in	O
manufacture	O
of	O
desomorphine	B-Drug
from	O
codeine	B-Drug

Lorazepam	B-Drug
may	O
not	O
be	O
detected	O
by	O
commonly	O
used	O
urine	O
drug	O
screenings	O
for	O
benzodiazepines	O

Typical	O
antipsychotics	O
such	O
as	O
phenothiazines	O
and	O
haloperidol	B-Drug
have	O
been	O
used	O
to	O
control	O
psychotic	O
symptoms	O
but	O
may	O
produce	O
many	O
undesirable	O
side	O
effects	O
dystonia	O
their	O
use	O
is	O
therefore	O
no	O
longer	O
preferred;	O
are	O
particularly	O
risky	O
they	O
lower	O
the	O
seizure	O
threshold	O
worsen	O
hyperthermia	O
boost	O
anticholinergic	O
of	O
PCP	B-Drug

In	O
certain	O
countries	O
triazolam	B-Drug
flunitrazepam	B-Drug
flutoprazepam	B-Drug
and	O
midazolam	B-Drug
are	O
also	O
restricted	O
or	O
controlled	O
to	O
degrees	O

Today	O
a	O
different	O
form	O
of	O
the	O
drug	O
crystal	B-Drug
methamphetamine	I-Drug
has	O
become	O
popular	O
throughout	O
Europe	O
and	O
United	O
States	O
despite	O
governmental	O
prohibition	O
eradication	O
efforts	O

The	O
safety	O
of	O
the	O
combination	O
during	O
pregnancy	O
has	O
not	O
been	O
established	O
although	O
aspirin	B-Drug
is	O
generally	O
contraindicated	O
and	O
drug	O
placed	O
in	O
category	O
D	O

Unlike	O
the	O
related	O
medication	O
eplerenone	B-Drug
spironolactone	B-Drug
is	O
said	O
to	O
not	O
be	O
metabolized	O
by	O
CYP3A4	O

Thalidomide	B-Drug
is	O
used	O
as	O
a	O
first-line	O
treatment	O
in	O
multiple	O
myeloma	O
combination	O
with	O
dexamethasone	B-Drug
or	O
melphalan	O
and	O
prednisone	B-Drug
to	O
treat	O
acute	O
episodes	O
of	O
erythema	O
nodosum	O
leprosum	O
for	O
maintenance	O
therapy	O

Inderal	B-Drug
propranolol	B-Drug
a	O
beta	O
blocker;	O
it	O
is	O
used	O
for	O
acute	O
anxiety	O
panic	O
attacks	O
hypertension	O

Opioids	O
such	O
as	O
hydrocodone	B-Drug
cross	O
the	O
placenta	O
and	O
can	O
therefore	O
affect	O
fetus	O

The	O
cyclopentyl	O
homologue	O
of	O
PCP	B-Drug
is	O
active	O
with	O
around	O
1/10th	O
the	O
potency	O
while	O
cycloheptyl	O
and	O
cyclooctyl	O
derivatives	O
are	O
inactive	O

Naltrexone	B-Drug
was	O
first	O
synthesized	O
in	O
1963	O
by	O
Metossian	O
at	O
Endo	O
Laboratories	O
a	O
small	O
pharmaceutical	O
company	O
New	O
York	O
City	O

A	O
2014	O
review	O
found	O
evidence	O
of	O
drug-seeking	O
behavior	O
with	O
prescriptions	O
for	O
zolpidem	B-Drug
making	O
up	O
20%	O
falsified	O
or	O
forged	O

However	O
because	O
ibuprofen	B-Drug
is	O
highly	O
protein-bound	O
in	O
the	O
blood	O
kidneys'	O
excretion	O
of	O
unchanged	O
drug	O
minimal	O

Per	O
International	O
Nonproprietary	O
Name	O
INN	O
guidelines	O
for	O
drugs	O
the	O
y	O
was	O
replaced	O
with	O
i	O
so	O
that	O
medication	O
is	O
spelled	O
ciclosporin	B-Drug

Most	O
opium	B-Drug
imported	O
into	O
the	O
United	O
States	O
is	O
broken	O
down	O
its	O
alkaloid	O
constituents	O
and	O
whether	O
legal	O
or	O
illegal	O
most	O
current	O
drug	O
use	O
occurs	O
with	O
processed	O
derivatives	O
such	O
as	O
heroin	B-Drug
rather	O
than	O
unrefined	O

It	O
is	O
the	O
N-methylated	O
derivative	O
of	O
MDAT	O
similarly	O
to	O
relationship	O
MDMA	B-Drug
MDA	O
or	O
MDMAI	O
MDAI	O

No	O
remaining	O
nicomorphine	B-Drug
was	O
found	O
in	O
urine	O

In	O
1956	O
Harris	O
Isbell	O
at	O
the	O
Public	O
Health	O
Service	O
Hospital	O
in	O
Lexington	O
Kentucky	O
experimented	O
with	O
bufotenin	B-Drug
as	O
a	O
snuff	B-Drug

Diphenhydramine	B-Drug
in	O
overdose	O
may	O
occasionally	O
result	O
QT	O
prolongation	O

Morphine-6-glucuronide	O
M6G	O
is	O
a	O
major	O
active	O
metabolite	O
of	O
morphine	B-Drug

No	O
significant	O
difference	O
in	O
glutamate	O
and	O
glycine	O
activity	O
from	O
the	O
effects	O
of	O
chlorpromazine	B-Drug
were	O
reported	O

Trenbolone	B-Drug
carries	O
a	O
rating	O
for	O
both	O
anabolic	O
potency	O
and	O
androgenic	O
of	O
500	O
relative	O
to	O
standard	O
nandrolone	O
acetate	O
100	O

Because	O
of	O
the	O
extremely	O
high	O
strength	O
pure	O
fentanyl	B-Drug
powder	O
it	O
is	O
very	O
difficult	O
to	O
dilute	O
appropriately	O
and	O
often	O
resulting	O
mixture	O
may	O
be	O
far	O
too	O
strong	O
therefore	O
dangerous	O

Amphetamine	B-Drug
has	O
also	O
been	O
shown	O
to	O
pass	O
into	O
breast	O
milk	O
so	O
the	O
IPCS	O
and	O
USFDA	O
advise	O
mothers	O
avoid	O
breastfeeding	O
when	O
using	O
it	O

This	O
changes	O
the	O
core	O
structure	O
of	O
molecule	O
from	O
phenethylamine	B-Drug
to	O
aminoindane	O
and	O
causes	O
pharmacological	O
properties	O
two	O
compounds	O
be	O
substantially	O
different	O

Oxycodone	B-Drug
in	O
combination	O
with	O
naloxone	B-Drug
managed-release	O
tablets	O
has	O
been	O
formulated	O
to	O
both	O
deter	O
abuse	O
and	O
reduce	O
opioid-induced	O
constipation	O

PCP	B-Drug
comes	O
in	O
both	O
powder	O
and	O
liquid	O
forms	O
base	O
is	O
dissolved	O
most	O
often	O
ether	O
but	O
typically	O
it	O
sprayed	O
onto	O
leafy	O
material	O
such	O
as	O
cannabis	O
mint	O
oregano	O
tobacco	B-Drug
parsley	O
or	O
ginger	O
leaves	O
then	O
smoked	O

As	O
of	O
December	O
2009	O
TFMPP	B-Drug
has	O
been	O
made	O
a	O
Class	O
C	O
drug	O
in	O
the	O
United	O
Kingdom	O
along	O
with	O
BZP	B-Drug

2mg	O
of	O
Trenbolone	B-Drug
hexahydrobenzylcaronate	O
and	O
made	O
by	O
Negma	O
Pharmaceuticals	O
France	O

With	O
only	O
14	O
percent	O
of	O
the	O
global	O
coca-leaf	O
market	O
in	O
1991	O
by	O
2004	O
Colombia	O
was	O
responsible	O
for	O
80	O
world's	O
cocaine	B-Drug
production	O

Fewer	O
than	O
30	O
different	O
analogs	O
of	O
PCP	B-Drug
were	O
reported	O
as	O
being	O
used	O
on	O
the	O
street	O
during	O
1970s	O
and	O
1980s	O
mainly	O
in	O
United	O
States	O

8	O
fatalities/100000	O
population	O
This	O
however	O
doesn't	O
affect	O
the	O
ones	O
with	O
a	O
prescription	O
for	O
an	O
illegal	O
drug	O
like	O
amphetamine	B-Drug
known	O
as	O
Adderall	B-Drug
unless	O
stated	O
which	O
is	O
case	O
most	O
dissociatives	O
and	O
other	O
drugs	O
can	O
seriously	O
driving	O
opioids	O

It	O
was	O
developed	O
by	O
screening	O
chemicals	O
similar	O
to	O
pethidine	B-Drug
meperidine	B-Drug
for	O
opioid	O
activity	O

Cocaine	B-Drug
is	O
known	O
to	O
have	O
a	O
number	O
of	O
deleterious	O
effects	O
during	O
pregnancy	O

Expanded	O
expressions	O
for	O
the	O
compound	O
oxycodone	B-Drug
in	O
academic	O
literature	O
include	O
dihydrohydroxycodeinone	O
Eucodal	O
Eukodal	B-Drug
14-hydroxydihydrocodeinone	O
and	O
Nucodan	O

Disadvantages	O
of	O
injections	B-Drug
include	O
potential	O
pain	O
or	O
discomfort	O
for	O
the	O
patient	O
and	O
requirement	O
trained	O
staff	O
using	O
aseptic	O
techniques	O
administration	O

As	O
of	O
2019	O
the	O
minimum	O
age	O
to	O
use	O
tobacco	B-Drug
is	O
21	O
at	O
federal	O
level	O

Metenolone	B-Drug
enanthate	I-Drug
is	O
a	O
metenolone	B-Drug
ester	O
and	O
long-lasting	O
prodrug	O
of	O
in	O
the	O
body	O

As	O
of	O
October	O
31	O
2016;	O
25I-NBOMe	B-Drug
is	O
a	O
controlled	O
substance	O
Schedule	O
III	O
in	O
Canada	O

Scientific	O
studies	O
have	O
shown	O
that	O
oral	O
administration	O
of	O
bolandione	B-Drug
is	O
a	O
very	O
ineffective	O
strategy	O
for	O
stimulating	O
skeletal	O
muscle	O
mass	O
increases	O
but	O
may	O
be	O
associated	O
with	O
side	O
effects	O

They	O
concluded	O
that	O
the	O
agent	O
used	O
in	O
Moscow	O
theater	O
hostage	O
crisis	O
contained	O
two	O
fentanyl	B-Drug
derivatives	O
much	O
stronger	O
than	O
itself	O
sprayed	O
an	O
aerosol	O
mist	O

PCP	B-Drug
comes	O
in	O
both	O
powder	O
and	O
liquid	O
forms	O
base	O
is	O
dissolved	O
most	O
often	O
ether	O
but	O
typically	O
it	O
sprayed	O
onto	O
leafy	O
material	O
such	O
as	O
cannabis	O
mint	O
oregano	O
tobacco	B-Drug
parsley	O
or	O
ginger	O
leaves	O
then	O
smoked	O

I	O
think	O
that	O
in	O
human	O
evolution	O
it	O
has	O
never	O
been	O
as	O
necessary	O
to	O
have	O
this	O
substance	O
LSD	B-Drug

Hash	B-Drug
oil	I-Drug
can	O
be	O
the	O
most	O
potent	O
of	O
main	O
cannabis	O
products	O
because	O
its	O
high	O
level	O
psychoactive	O
compound	O
per	O
volume	O
which	O
vary	O
depending	O
on	O
plant's	O
mix	O
essential	O
oils	O
and	O
compounds	O

A	O
forensic	O
standard	O
of	O
UR-144	B-Drug
is	O
available	O
and	O
the	O
compound	O
has	O
been	O
posted	O
on	O
Forendex	O
website	O
potential	O
drugs	O
abuse	O

Commercial	O
production	O
of	O
methaqualone	B-Drug
was	O
halted	O
in	O
the	O
mid	O
1980s	O
due	O
to	O
widespread	O
abuse	O
and	O
addictiveness	O

EiPT	O
is	O
closely	O
related	O
to	O
the	O
compounds	O
diethyltryptamine	B-Drug
DET	B-Drug
and	O
DIPT	O

Detoxification	O
using	O
methadone	B-Drug
can	O
be	O
accomplished	O
in	O
less	O
than	O
a	O
month	O
or	O
it	O
may	O
done	O
gradually	O
over	O
as	O
long	O
six	O
months	O

Androstenedione	B-Drug
is	O
banned	O
by	O
the	O
World	O
Anti-Doping	O
Agency	O
and	O
from	O
Olympic	O
Games	O

Some	O
research	O
suggests	O
that	O
smoking	O
freebase	O
cocaine	B-Drug
can	O
be	O
even	O
more	O
cardiotoxic	O
than	O
other	O
routes	O
of	O
administration	O
because	O
methylecgonidine's	O
effects	O
on	O
lung	O
tissue	O
and	O
liver	O

0]undeca-581012-tetraen-3-one	O
Lysergic	O
acid	O
also	O
known	O
as	O
910-didehydro-6-methylergoline-8-carboxylic	O
N-acetylanthranilic	O
N-Acetyl-o-aminobenzoic	O
Nitrazepam	B-Drug
may	O
be	O
used	O
to	O
manufacture	O
flunitrazepam	B-Drug
and	O
nimetazepam	B-Drug
9-nitro-6-phenyl-25-diazabicyclo[5	O

Following	O
intake	O
peak	O
levels	O
of	O
tamoxifen	B-Drug
occur	O
after	O
three	O
to	O
seven	O
hours	O

Chemically	O
Adderall	B-Drug
is	O
a	O
mixture	O
of	O
four	O
amphetamine	B-Drug
salts;	O
specifically	O
it	O
composed	O
equal	O
parts	O
by	O
mass	O
aspartate	O
monohydrate	O
sulfate	O
dextroamphetamine	B-Drug
and	O
saccharate	O

In	O
a	O
2001	O
study	O
with	O
naloxone	B-Drug
three	O
of	O
fourteen	O
patients	O
lost	O
their	O
depersonalization	O
symptoms	O
entirely	O
and	O
seven	O
showed	O
marked	O
improvement	O

Other	O
cannabinoids	O
include	O
delta-8-tetrahydrocannabinol	O
cannabidiol	B-Drug
CBD	B-Drug
cannabinol	O
CBN	O
cannabicyclol	B-Drug
CBL	O
cannabichromene	O
CBC	O
and	O
cannabigerol	O
CBG;	O
they	O
have	O
less	O
psychotropic	O
effects	O
than	O
THC	O
but	O
may	O
play	O
a	O
role	O
in	O
the	O
overall	O
effect	O
of	O
cannabis	O

The	O
role	O
of	O
NMDAR	O
antagonism	O
in	O
the	O
effect	O
PCP	B-Drug
ketamine	B-Drug
and	O
related	O
dissociative	O
agents	O
was	O
first	O
published	O
early	O
1980s	O
by	O
David	O
Lodge	O
colleagues	O

Research	O
and	O
an	O
updated	O
reveal	O
of	O
mechanism	O
action	O
diclofenac	B-Drug
shows	O
that	O
its	O
is	O
as	O
with	O
all	O
NSAIDs	O
by	O
inhibition	O
prostaglandin	O
synthesis	O

This	O
occurs	O
because	O
cocaine's	O
absorption	O
is	O
slowed	O
by	O
its	O
constricting	O
effect	O
on	O
the	O
blood	O
vessels	O
of	O
nose	O
cocaine	B-Drug

The	O
bica-	O
prefix	O
corresponds	O
to	O
the	O
fact	O
that	O
bicalutamide	B-Drug
is	O
a	O
bicyclic	O
compound	O
while	O
-lutamide	O
suffix	O
standard	O
for	O
NSAAs	O

On	O
16	O
June	O
2020	O
the	O
RECOVERY	O
Trial	O
announced	O
preliminary	O
results	O
stating	O
that	O
dexamethasone	B-Drug
improves	O
survival	O
rates	O
of	O
hospitalized	O
patients	O
with	O
COVID19	O
receiving	O
oxygen	O
or	O
on	O
a	O
ventilator	O

In	O
the	O
UK	O
fentanyl	B-Drug
is	O
classified	O
as	O
a	O
controlled	O
Class	O
A	O
drug	O
under	O
Misuse	O
of	O
Drugs	O
Act	O
1971	O

This	O
is	O
a	O
list	O
of	O
states	O
and	O
some	O
territories	O
by	O
the	O
annual	O
prevalence	O
cocaine	B-Drug
use	O
as	O
percentage	O
population	O
aged	O
1564	O
unless	O
otherwise	O
indicated	O

Large	O
seizures	O
of	O
cocaine	B-Drug
are	O
not	O
only	O
a	O
success	O
for	O
local	O
and	O
national	O
authorities	O
in	O
getting	O
off	O
the	O
streets	O
but	O
also	O
prevent	O
it	O
from	O
continuing	O
illegal	O
supply	O
chain	O
to	O
other	O
countries	O

Gabapentin	B-Drug
should	O
be	O
used	O
carefully	O
and	O
at	O
lower	O
doses	O
in	O
people	O
with	O
kidney	O
problems	O
due	O
to	O
possible	O
accumulation	O
toxicity	O

Dibenzoylmorphine	O
is	O
an	O
opiate	O
analogue	O
that	O
a	O
derivative	O
of	O
morphine	B-Drug

Gandhi's	O
bill	O
would	O
legalise	O
marijuana	O
and	O
opium	B-Drug

Dealers	O
may	O
cut	O
with	O
or	O
sell	O
heroin	B-Drug
Fentanyl	B-Drug
due	O
to	O
the	O
street	O
cost	O
of	O
versus	O

Fentanyl	B-Drug
works	O
primarily	O
by	O
activating	O
-opioid	O
receptors	O

Most	O
evidence	O
shows	O
that	O
the	O
benefits	O
of	O
alprazolam	B-Drug
in	O
treating	O
panic	O
disorder	O
last	O
only	O
4	O
to	O
10	O
weeks	O

25I-NBOMe	B-Drug
can	O
be	O
consumed	O
in	O
liquid	O
powder	O
or	O
paper	O
form	O
and	O
snorted	O
injected	O
mixed	O
with	O
food	O
smoked	O
but	O
sublingual	O
administration	O
is	O
most	O
common	O

Bleach	O
exposure	O
time	O
and	O
concentration	O
are	O
correlated	O
with	O
destruction	O
of	O
methamphetamine	B-Drug

The	O
birth	O
defects	O
caused	O
by	O
thalidomide	B-Drug
led	O
to	O
the	O
development	O
of	O
greater	O
drug	O
regulation	O
and	O
monitoring	O
in	O
many	O
countries	O

Nimetazepam	B-Drug
also	O
has	O
withdrawal	O
suppression	O
effect	O
and	O
lower	O
drug	O
seeking	O
versus	O
nitrazepam	B-Drug
in	O
rhesus	O
monkey	O
Macaca	O
Mulatta	O

Amphetamine	B-Drug
is	O
frequently	O
measured	O
in	O
urine	O
or	O
blood	O
as	O
part	O
of	O
a	O
drug	O
test	O
for	O
sports	O
employment	O
poisoning	O
diagnostics	O
and	O
forensics	O

The	O
Orange	O
Sunshine	O
variety	O
of	O
LSD	B-Drug
that	O
was	O
widely	O
available	O
in	O
California	O
through	O
1968	O
and	O
1969	O
produced	O
the	O
Sonoma	O
County	O
underground	O
chemistry	O
lab	O
Tim	O
Scully	O
Nicholas	O
Sand	O

In	O
1973	O
Janssen	O
started	O
to	O
promote	O
loperamide	B-Drug
under	O
the	O
brand	O
name	O
Imodium	B-Drug

The	O
effectiveness	O
of	O
this	O
corticosteroid	O
treatment	O
on	O
humans	O
was	O
first	O
demonstrated	O
in	O
1972	O
by	O
Sir	O
Graham	O
Liggins	O
and	O
Ross	O
Howie	O
during	O
a	O
randomized	O
control	O
trial	O
using	O
betamethasone	B-Drug

E-Methyl	O
2-2S3S7aS12bS-3-ethyl-7a-hydroxy-8-methoxy-1234677a12b-octahydroindolo[23-a]quinolizin-2-yl-3-methoxyacrylate	O
7-hydroxymitragynine	O
a	O
main	O
active	O
constituent	O
of	O
the	O
traditional	O
herbal	O
medicine	O
Mitragyna	B-Drug
speciosa	I-Drug
is	O
an	O
indole	O
alkaloid	O
that	O
structurally	O
different	O
from	O
morphine	B-Drug

When	O
enough	O
fentanyl	B-Drug
has	O
been	O
absorbed	O
the	O
sedated	O
person	O
generally	O
lets	O
lollipop	O
fall	O
from	O
mouth	O
indicating	O
sufficient	O
analgesia	O
and	O
somewhat	O
reducing	O
likelihood	O
of	O
overdose	O
associated	O
risks	O

further	O
raising	O
interest	O
in	O
LSD	B-Drug
the	O
mass	O
media	O

Mirtazapine	B-Drug
came	O
into	O
medical	O
use	O
in	O
the	O
United	O
States	O
1996	O

Amphetamine	B-Drug
and	O
methylphenidate:	O
counteracts	O
increased	O
action	O
of	O
norepinephrine	O
dopamine	O
in	O
patients	O
with	O
narcolepsy	O
or	O
ADD/ADHD	O
Epinephrine:	O
antagonized	O
paradoxical	O
decrease	O
blood	O
pressure	O
may	O
result	O
Guanethidine:	O
antihypertensive	O
Levodopa:	O
decreased	O
levodopa	B-Drug
Lithium:	O
rare	O
cases	O
the	O
following	O
symptoms	O
have	O
been	O
noted:	O
encephalopathy	O
early	O
late	O
extrapyramidal	O
side	O
effects	O
other	O
neurologic	O
coma	O
methylphenidate	B-Drug
Levodopa	B-Drug

Mupirocin	B-Drug
is	O
not	O
a	O
viable	O
antibiotic	O
against	O
MuH	O
strains	O

Tyrosine	O
can	O
follow	O
two	O
different	O
routes:	O
by	O
tyrosine	O
hydroxylase	O
it	O
form	O
L-dopamine	O
L-DOPA	B-Drug
or	O
be	O
reduced	O
to	O
4-phenylhydroxyacetaldehyde	O
4-HPAA	O

Participants	O
were	O
randomly	O
assigned	O
to	O
receive	O
oliceridine	B-Drug
placebo	O
or	O
an	O
approved	O
drug	O
treat	O
pain	O
morphine	B-Drug
for	O
24	O
hours	O
through	O
the	O
vein	O

This	O
is	O
in	O
contrast	O
to	O
steroidal	O
antiandrogens	O
like	O
spironolactone	B-Drug
and	O
cyproterone	O
acetate	O

Fentanyl	B-Drug
use	O
has	O
also	O
been	O
associated	O
with	O
aphasia	O

Smoking	O
tobacco	B-Drug
increases	O
caffeine	O
clearance	O
by	O
56%	O

As	O
an	O
AAS	O
fluoxymesterone	B-Drug
is	O
agonist	O
of	O
the	O
androgen	O
receptor	O
AR	O
similarly	O
to	O
androgens	O
like	O
testosterone	O
and	O
DHT	O

Any	O
psychoactive	O
marijuana	O
regardless	O
of	O
its	O
CBD	B-Drug
content	O
is	O
derived	O
from	O
the	O
flower	O
or	O
bud	O
genus	O
Cannabis	O

While	O
not	O
finding	O
his	O
own	O
experiences	O
with	O
MDMA	B-Drug
particularly	O
powerful	O
Shulgin	O
was	O
impressed	O
the	O
drug's	O
disinhibiting	O
effects	O
and	O
thought	O
it	O
could	O
be	O
useful	O
in	O
therapy	O

Because	O
MDMA	B-Drug
is	O
known	O
to	O
affect	O
serotonin	O
and	O
that	O
thought	O
be	O
involved	O
in	O
vision	O
individuals	O
who	O
take	O
may	O
exhibit	O
differences	O
their	O
visual	O
orientation	O
processing	O

PMA	B-Drug
overdose	O
also	O
tends	O
to	O
cause	O
hypoglycaemia	O
and	O
hyperkalaemia	O
which	O
can	O
help	O
distinguish	O
it	O
from	O
MDMA	B-Drug

Many	O
counties	O
offer	O
Narcan	B-Drug
training	O
programs	O
with	O
the	O
aim	O
of	O
educating	O
surrounding	O
community	O
on	O
how	O
to	O
use	O

BMF	O
also	O
received	O
drugs	O
through	O
large	O
containers	O
at	O
the	O
airport	O
containing	O
100150	O
kilograms	O
of	O
cocaine	B-Drug
which	O
they	O
picked	O
up	O
and	O
delivered	O
to	O
stash	O
houses	O

Most	O
commercial	O
opiate	O
screening	O
tests	O
cross-react	O
appreciably	O
with	O
these	O
metabolites	O
as	O
well	O
other	O
biotransformation	O
products	O
likely	O
to	O
be	O
present	O
following	O
usage	O
of	O
street-grade	O
diamorphine	B-Drug
such	O
6-acetylcholine	O
and	O
codeine	B-Drug

Plots	O
denuded	O
of	O
coca	B-Drug
plants	O
are	O
abandoned	O
and	O
cause	O
serious	O
problems	O
with	O
erosion	O
during	O
seasonal	O
rains	O

Phencyclidine	B-Drug
is	O
an	O
NMDA	O
receptor	O
antagonist	O
that	O
blocks	O
the	O
activity	O
of	O
to	O
cause	O
anaesthesia	O
and	O
analgesia	O
without	O
causing	O
cardiorespiratory	O
depression	O

Because	O
of	O
fentanyl's	O
high	O
lipid	O
solubility	O
its	O
effects	O
are	O
more	O
localized	O
than	O
morphine	B-Drug
and	O
some	O
clinicians	O
prefer	O
to	O
use	O
get	O
a	O
wider	O
spread	O
analgesia	O
fentanyl	B-Drug

Brews	O
can	O
also	O
be	O
made	O
with	O
plants	O
that	O
do	O
not	O
contain	O
DMT	O
Psychotria	O
viridis	O
being	O
replaced	O
by	O
such	O
as	O
Justicia	O
pectoralis	O
Brugmansia	O
or	O
sacred	O
tobacco	B-Drug
known	O
mapacho	O
Nicotiana	O
rustica	O
sometimes	O
left	O
out	O
no	O
replacement	O

The	O
closest	O
chemical	O
and	O
structural	O
relatives	O
of	O
piritramide	B-Drug
in	O
clinical	O
use	O
include	O
the	O
diphenoxylate	B-Drug
family	O
fentanyl	B-Drug
both	O
Janssen	O
discoveries	O
somewhat	O
more	O
distantly	O
alphaprodine	B-Drug

Metribolone	O
also	O
known	O
as	O
17-methyltrenbolone	O
well	O
17-methyl-911-19-nortestosterone	O
or	O
17-methylestra-4911-trien-17-ol-3-one	O
is	O
a	O
synthetic	O
estrane	O
steroid	O
and	O
17-alkylated	O
derivative	O
of	O
nandrolone	B-Drug
19-nortestosterone	B-Drug

Norethisterone	B-Drug
and	O
5-DHNET	O
have	O
been	O
found	O
to	O
act	O
as	O
weak	O
irreversible	O
aromatase	O
inhibitors	O
Ki	O
=	O
1	O

Hofmann	O
who	O
had	O
in	O
1938	O
created	O
LSD	B-Drug
led	O
a	O
research	O
group	O
that	O
isolated	O
and	O
identified	O
the	O
psychoactive	O
compounds	O
from	O
Psilocybe	O
mexicana	O

Similarly	O
to	O
other	O
spirolactones	O
like	O
spironolactone	B-Drug
dicirenone	O
also	O
possesses	O
antiandrogen	O
activity	O
albeit	O
with	O
relatively	O
reduced	O
affinity	O

Oral	O
ketoconazole	B-Drug
is	O
now	O
only	O
indicated	O
for	O
use	O
in	O
these	O
countries	O
when	O
the	O
indication	O
a	O
severe	O
or	O
life-threatening	O
systemic	O
infection	O
and	O
alternatives	O
are	O
unavailable	O

Sveriges	O
riksdag	O
added	O
butylone	B-Drug
to	O
schedule	O
I	O
substances	O
plant	O
materials	O
and	O
fungi	O
which	O
normally	O
do	O
not	O
have	O
medical	O
use	O
as	O
narcotics	O
in	O
Sweden	O
of	O
Feb	O
1	O
2010	O
published	O
by	O
Medical	O
Products	O
Agency	O
their	O
regulation	O
LVFS	O
2010:1	O
listed	O
Butylon	O
1-13-bensodioxol-5-yl-2-metylaminobutan-1-on	O

Hydrocodone/paracetamol	B-Drug
is	O
a	O
fixed-dose	O
combination	O
consisting	O
of	O
the	O
opioid	O
hydrocodone	B-Drug
and	O
non-opioid	O
analgesic	O
paracetamol	B-Drug

It	O
has	O
two	O
separate	O
chiral	O
centers	O
meaning	O
that	O
there	O
are	O
four	O
different	O
stereoisomers	O
of	O
ibogaine	B-Drug

Hydrocodone	B-Drug
is	O
available	O
in	O
a	O
variety	O
of	O
formulations	O
for	O
oral	O
administration:	O
The	O
original	O
form	O
hydrocodone	B-Drug
alone	O
Dicodid	O
as	O
immediate-release	O
5	O
and	O
10	O
mg	O
tablets	O
prescription	O
Continental	O
Europe	O
per	O
national	O
drug	O
control	O
laws	O
Title	O
76	O
the	O
Schengen	O
Treaty	O
but	O
dihydrocodeine	B-Drug
has	O
been	O
more	O
widely	O
used	O
same	O
indications	O
since	O
beginning	O
early	O
1920s	O
with	O
being	O
regulated	O
way	O
morphine	B-Drug
German	O
Betubungsmittelgesetz	O
similarly	O
named	O
law	O
Switzerland	O
Austrian	O
Suchtmittelgesetz	O
whereas	O
like	O
codeine	B-Drug

Tetrazepam	B-Drug
is	O
rapidly	O
absorbed	O
after	O
oral	O
administration	O
within	O
45	O
mins	O
and	O
reaches	O
peak	O
plasma	O
levels	O
in	O
less	O
than	O
2	O
hours	O

One	O
US	O
Department	O
of	O
Justice	O
publication	O
lists	O
China	O
White	O
as	O
a	O
synonym	O
for	O
number	O
fentanyl	B-Drug
analogues	O
including	O
3-methylfentanyl	B-Drug
and	O
-methylfentanyl	O
which	O
today	O
are	O
classified	O
Schedule	O
I	O
drugs	O
in	O
the	O
United	O
States	O

A	O
common	O
laxative	O
regimen	O
for	O
OIC	O
is	O
the	O
combination	O
of	O
docusate	B-Drug
and	O
bisacodyl	O

Flumazenil	B-Drug
was	O
also	O
shown	O
to	O
produce	O
significantly	O
fewer	O
withdrawal	O
symptoms	O
than	O
saline	O
in	O
a	O
randomized	O
placebo-controlled	O
study	O
with	O
benzodiazepine-dependent	O
subjects	O

The	O
physician	O
Muhammad	O
ibn	O
Zakariya	O
al-Razi	O
of	O
Persian	O
origin	O
Rhazes	O
845930	O
AD	O
maintained	O
a	O
laboratory	O
and	O
school	O
in	O
Baghdad	O
was	O
student	O
critic	O
Galen;	O
he	O
made	O
use	O
opium	B-Drug
anesthesia	O
recommended	O
its	O
for	O
the	O
treatment	O
melancholy	O
Fi	O
ma-la-yahdara	O
al-tabib	O
In	O
Absence	O
Physician	O
home	O
medical	O
manual	O
directed	O
toward	O
ordinary	O
citizens	O
self-treatment	O
if	O
doctor	O
not	O
available	O

It	O
is	O
reported	O
by	O
LSD	B-Drug
historian	O
Mark	O
McCloud	O
that	O
Pickard	O
worked	O
with	O
a	O
group	O
of	O
traffickers	O
known	O
as	O
the	O
Clear	O
Light	O
System	O
in	O
1960s	O

Synthetic	O
chemicals	O
such	O
as	O
LSD	B-Drug
active	O
at	O
2030	O
g	O
doses	O
can	O
be	O
more	O
potent	O

The	O
1993	O
DEA	O
rule	O
placing	O
cathinone	B-Drug
in	O
the	O
CSA's	O
Schedule	O
I	O
noted	O
that	O
it	O
was	O
effectively	O
also	O
banning	O
khat:	O
Cathinone	B-Drug
is	O
major	O
psychoactive	O
component	O
of	O
plant	O
Catha	O
edulis	O
khat	O

Fentanyl	B-Drug
also	O
spelled	O
fentanil	O
is	O
an	O
opioid	O
used	O
as	O
a	O
pain	O
medication	O
and	O
together	O
with	O
other	O
medications	O
for	O
anesthesia	O

Like	O
its	O
close	O
relatives	O
DMT	O
and	O
bufotenin	B-Drug
5-HO-DMT	B-Drug
it	O
has	O
been	O
used	O
as	O
an	O
entheogen	O
in	O
South	O
America	O

Racemoramide	B-Drug
is	O
itself	O
controlled;	O
in	O
the	O
United	O
States	O
it	O
under	O
Schedule	O
I	O
as	O
a	O
Narcotic	O
with	O
an	O
ACSCN	O
of	O
9645	O
and	O
zero	O
annual	O
aggregate	O
manufacturing	O
quota	O
2014	O

The	O
symptoms	O
include	O
deficits	O
in	O
verbal	O
and	O
non-verbal	O
memory	O
working	O
attention	O
sustained	O
concentration	O
executive	O
function	O
psychomotor	O
speed	B-Drug
academic	O
or	O
occupational	O
performance	O

Dopaminergic	O
stimulants	O
such	O
as	O
amphetamine	B-Drug
ephedrine	B-Drug
and	O
propylhexedrine	B-Drug
work	O
by	O
causing	O
the	O
release	O
of	O
dopamine	O
norepinephrine	O
along	O
with	O
in	O
some	O
cases	O
blocking	O
reuptake	O
these	O
neurotransmitters	O

11-OHP	O
is	O
a	O
more	O
potent	O
inhibitor	O
of	O
11-HSD	O
than	O
enoxolone	B-Drug
glycyrrhetinic	O
acid	O
or	O
carbenoxolone	O
in	O
vitro	O
IC50	O
5	O
nM	O
transfected	O
cells	O

Despite	O
this	O
cases	O
of	O
thalidomide	B-Drug
embryopathy	O
continue	O
with	O
at	O
least	O
100	O
identified	O
in	O
Brazil	O
between	O
2005	O
and	O
2010	O

It	O
has	O
similar	O
activity	O
to	O
pethidine	B-Drug
but	O
with	O
a	O
faster	O
onset	O
of	O
action	O
and	O
shorter	O
duration	O

Lisdexamfetamine	B-Drug
was	O
developed	O
with	O
the	O
goal	O
of	O
providing	O
a	O
long	O
duration	O
effect	O
that	O
is	O
consistent	O
throughout	O
day	O
reduced	O
potential	O
for	O
abuse	O

]	O
dab	O
Slang	O
name	O
for	O
hash	B-Drug
oil	I-Drug
a	O
resin	O
extracted	O
from	O
cannabis	O

Cannabidiol	B-Drug
is	O
classified	O
as	O
a	O
medical	O
product	O
in	O
Sweden	O

It	O
is	O
unclear	O
if	O
there	O
are	O
any	O
benefits	O
to	O
clobazam	B-Drug
over	O
other	O
seizure	O
medications	O
for	O
children	O
with	O
Rolandic	O
epilepsy	O
or	O
epileptic	O
syndromes	O

Medical	O
grade	O
diamorphine	B-Drug
is	O
used	O
as	O
a	O
pure	O
hydrochloride	O
salt	O
which	O
distinguished	O
from	O
black	O
tar	O
heroin	B-Drug
variable	O
admixture	O
of	O
morphine	B-Drug
derivativespredominantly	O
6-MAM	O
6-monoacetylmorphine	O
the	O
result	O
crude	O
acetylation	O
during	O
clandestine	O
production	O
street	O

Scientific	O
studies	O
have	O
shown	O
that	O
oral	O
administration	O
of	O
bolandione	B-Drug
is	O
a	O
very	O
ineffective	O
strategy	O
for	O
stimulating	O
skeletal	O
muscle	O
mass	O
increases	O
but	O
may	O
be	O
associated	O
with	O
side	O
effects	O

USAF	O
Pararescue	O
combat	O
medics	O
in	O
Afghanistan	O
use	O
fentanyl	B-Drug
lozenges	O
the	O
form	O
of	O
lollipops	O
on	O
casualties	O
from	O
IED	O
blasts	O
and	O
other	O
trauma	O

subcutaneous	O
for	O
metoclopramide	B-Drug
rectally	O
domperidone	O

The	O
2010	O
UN	O
World	O
Drug	O
Report	O
concluded	O
that	O
it	O
appears	O
the	O
North	O
American	O
cocaine	B-Drug
market	O
has	O
declined	O
in	O
value	O
from	O
US$47	O
billion	O
1998	O
to	O
US$38	O
2008	O

Fentanyl	B-Drug
patches	O
for	O
cancer	O
pain	O
are	O
on	O
the	O
World	O
Health	O
Organization's	O
List	O
of	O
Essential	O
Medicines	O

Meperidine	B-Drug
is	O
a	O
fully	O
synthetic	O
opioid	O
and	O
other	O
members	O
of	O
the	O
phenylpiperidine	O
family	O
like	O
alfentanil	B-Drug
sufentanil	B-Drug
are	O
complex	O
versions	O
this	O
structure	O

There	O
are	O
also	O
warnings	O
about	O
the	O
threat	O
of	O
breastfeeding:	O
The	O
March	O
Dimes	O
said	O
it	O
is	O
likely	O
that	O
cocaine	B-Drug
will	O
reach	O
baby	O
through	O
breast	O
milk	O
and	O
advises	O
following	O
regarding	O
use	O
during	O
pregnancy:	O
Cocaine	B-Drug
pregnancy	O
can	O
affect	O
a	O
pregnant	O
woman	O
her	O
unborn	O
in	O
many	O
ways	O

The	O
metabolites	O
of	O
bupropion	B-Drug
also	O
act	O
as	O
non-competitive	O
antagonists	O
these	O
nACh	O
receptors	O
and	O
hydroxybupropion	O
is	O
even	O
more	O
potent	O
in	O
comparison	O

In	O
some	O
jurisdictions	O
diphenhydramine	B-Drug
is	O
often	O
present	O
in	O
postmortem	O
specimens	O
collected	O
during	O
investigation	O
of	O
sudden	O
infant	O
deaths;	O
the	O
drug	O
may	O
play	O
a	O
role	O
these	O
events	O

Pregabalin	B-Drug
was	O
also	O
approved	O
for	O
the	O
treatment	O
of	O
generalized	O
anxiety	O
disorder	O
in	O
Europe	O
2005	O
though	O
it	O
has	O
not	O
been	O
this	O
indication	O
United	O
States	O

Don	O
Catlin	O
of	O
the	O
UCLA	O
Olympic	O
Laboratory	O
who	O
conducted	O
studies	O
noted	O
methasterone's	O
similarity	O
to	O
drostanolone	B-Drug
methasterone	B-Drug

In	O
2004	O
the	O
FDA	O
created	O
a	O
ban	O
on	O
ephedrine	B-Drug
alkaloids	O
marketed	O
for	O
reasons	O
other	O
than	O
asthma	O
colds	O
allergies	O
disease	O
or	O
traditional	O
Asian	O
use	O

In	O
a	O
large-scale	O
study	O
of	O
programs	O
where	O
bupropion	B-Drug
was	O
used	O
for	O
smoking	O
cessation	O
or	O
treatment	O
depression	O
no	O
withdrawal	O
symptoms	O
were	O
observed	O

With	O
the	O
exception	O
of	O
35-	O
and	O
35-tetrahydronorethisterone	O
which	O
have	O
significant	O
affinity	O
for	O
ER	O
are	O
estrogenic	O
to	O
some	O
degree	O
35-tetrahydro	O
metabolites	O
norethisterone	B-Drug
inactive	O
in	O
terms	O
sex	O
steroid	O
receptors	O
specifically	O
PR	O
AR	O

Janssen	O
Pharmaceuticals	O
has	O
developed	O
and	O
brought	O
to	O
the	O
market	O
about	O
70	O
new	O
active	O
substances	O
NCE	O
of	O
which	O
most	O
well-known	O
are	O
name	O
may	O
differ:	O
Imodium	B-Drug
against	O
diarrhoea	O

Around	O
1804	O
German	O
pharmacologist	O
Friedrich	O
Sertrner	O
isolated	O
morphine	B-Drug
from	O
opium	B-Drug

16	O
for	O
the	O
final	O
steps	O
of	O
fluoxymesterone	B-Drug
synthesis	O

Conversely	O
food	O
increases	O
the	O
area-under-curve	O
levels	O
of	O
gabapentin	B-Drug
by	O
about	O
10%	O

Serial	O
killer	O
Jeffrey	O
Dahmer	O
admitted	O
to	O
using	O
triazolam	B-Drug
Halcion	B-Drug
and	O
occasionally	O
temazepam	B-Drug
Restoril	B-Drug
in	O
order	O
sedate	O
his	O
victims	O
prior	O
murdering	O
them	O

Cloud-chasers	O
are	O
not	O
always	O
interested	O
in	O
the	O
nicotine	B-Drug
released	O
from	O
vapor	O

After	O
an	O
additional	O
five	O
months	O
the	O
patient	O
was	O
switched	O
from	O
ziprasidone	B-Drug
to	O
aripiprazole	B-Drug

The	O
short	O
term	O
effects	O
of	O
cannabis	O
can	O
be	O
altered	O
if	O
it	O
has	O
been	O
laced	O
with	O
opioid	O
drugs	O
such	O
as	O
heroin	B-Drug
or	O
fentanyl	B-Drug

The	O
eszopiclone/zopiclone	O
difference	O
is	O
in	O
the	O
dosagethe	O
strongest	O
eszopiclone	B-Drug
dosage	O
contains	O
3	O
mg	O
of	O
therapeutic	O
stereoisomer	O
whereas	O
highest	O
zopiclone	B-Drug
10	O
5	O
active	O

Androstenedione	B-Drug
also	O
known	O
as	O
androst-4-ene-317-dione	O
is	O
a	O
naturally	O
occurring	O
androstane	O
steroid	O
and	O
17-ketosteroid	O

Studies	O
on	O
rats	O
indicate	O
that	O
PCP	B-Drug
interacts	O
indirectly	O
with	O
opioid	O
receptors	O
endorphin	O
and	O
enkephalin	O
to	O
produce	O
analgesia	O

McKnight	O
stated	O
at	O
sentencing	O
that	O
when	O
he	O
first	O
met	O
Demetrius	O
Flenory	O
did	O
not	O
show	O
him	O
the	O
other	O
side	O
of	O
his	O
world	O
in	O
reference	O
to	O
cocaine	B-Drug
trafficking	O

spoiler	O
alert	O
In	O
the	O
adaptation	O
Interview	O
with	O
Vampire	O
film	O
1994	O
which	O
was	O
based	O
on	O
1976	O
novel	O
same	O
name	O
Claudia	O
uses	O
laudanum	B-Drug
to	O
try	O
and	O
dispose	O
of	O
Lestat:	O
Under	O
pretext	O
making	O
peace	O
she	O
offers	O
him	O
some	O
drunk	O
noble-blood	O
twins	O
feed	O
when	O
actually	O
had	O
them	O
overdosed	O
said	O
drug	O

Further	O
trials	O
took	O
place	O
in	O
1972	O
when	O
clozapine	B-Drug
was	O
released	O
Switzerland	O
and	O
Austria	O
as	O
Leponex	O

One	O
example	O
is	O
the	O
case	O
of	O
Big	O
Lurch	O
a	O
former	O
rapper	O
with	O
history	O
violent	O
crime	O
who	O
was	O
convicted	O
murdering	O
and	O
cannibalizing	O
his	O
roommate	O
while	O
under	O
influence	O
PCP	B-Drug

The	O
upper	O
Asian	O
belt	O
of	O
Afghanistan	O
Pakistan	O
northern	O
India	O
and	O
Burma	O
still	O
account	O
for	O
the	O
world's	O
largest	O
supply	O
opium	B-Drug

MAPS	O
is	O
committed	O
to	O
exploring	O
the	O
potential	O
use	O
of	O
LSD	B-Drug
and	O
psilocybin-assisted	O
psychotherapy	O
in	O
treatment	O
patients	O
suffering	O
with	O
deep	O
anxiety	O
associated	O
life-threatening	O
illness	O

In	O
addition	O
to	O
its	O
AR	O
agonistic	O
activity	O
unlike	O
many	O
other	O
AAS	O
nandrolone	B-Drug
is	O
also	O
a	O
potent	O
progestogen	O

Oberlin	O
concluded	O
that	O
the	O
effects	O
of	O
MDMA	B-Drug
were	O
not	O
limited	O
to	O
sympathetic	O
nervous	O
system	O

BZP	B-Drug
has	O
a	O
lower	O
potency	O
effect	O
on	O
the	O
noradrenaline	O
reuptake	O
transporter	O
and	O
dopamine	O

In	O
a	O
high-profile	O
case	O
an	O
American	O
who	O
was	O
top	O
Toyota	O
executive	O
living	O
in	O
Tokyo	O
claimed	O
to	O
be	O
unaware	O
of	O
the	O
law	O
arrested	O
for	O
importing	O
oxycodone	B-Drug
into	O
Japan	O

Apalutamide	B-Drug
was	O
first	O
described	O
in	O
2007	O
and	O
approved	O
for	O
the	O
treatment	O
of	O
prostate	O
cancer	O
February	O
2018	O

Stroup	O
decided	O
to	O
take	O
matters	O
into	O
his	O
own	O
hands	O
contacting	O
reporter	O
Gary	O
Cohn	O
and	O
informing	O
him	O
that	O
Bourne	O
had	O
used	O
cocaine	B-Drug
at	O
the	O
annual	O
Christmas	O
party	O
hosted	O
by	O
NORML	O
a	O
few	O
months	O
earlier	O

Reported	O
side	O
effects	O
include	O
anxiety	O
restlessness	O
muscle	O
tension	O
jaw	O
tightness	O
pupil	O
dilation	O
tachycardia	O
headaches	O
nausea	O
and	O
vomiting	O
among	O
other	O
that	O
might	O
commonly	O
be	O
attributed	O
to	O
LSD	B-Drug
psilocybin	O
DMT	O
MDMA	B-Drug
such	O
as	O
open-eye	O
visuals	O
closed	O
eye	O
an	O
altered	O
state	O
of	O
mind	O

Although	O
it	O
has	O
lower	O
affinity	O
for	O
SHBG	O
than	O
endogenous	O
androgens	O
and	O
estrogens	O
Norethisterone	B-Drug
may	O
displace	O
testosterone	O
from	O
thereby	O
increase	O
free	O
levels	O
this	O
action	O
contribute	O
to	O
its	O
weak	O
androgenic	O
effects	O

5F-AMB	B-Drug
is	O
an	O
Anlage	O
II	O
controlled	O
substance	O
in	O
Germany	O
as	O
of	O
May	O
2015	O

Benzedrine	B-Drug
is	O
a	O
trade	O
name	O
for	O
amphetamine	B-Drug

Additionally	O
nociceptin	O
may	O
have	O
lower	O
tolerance	O
development	O
than	O
drugs	O
such	O
as	O
morphine	B-Drug

Acetaminophen	B-Drug
is	O
the	O
name	O
generally	O
used	O
in	O
United	O
States	O
Adopted	O
Name	O
Japan	O
Japanese	O
Accepted	O
Canada	O
Venezuela	O
Colombia	O
and	O
Iran;	O
paracetamol	B-Drug
international	O
venues	O
International	O
Nonproprietary	O
Australian	O
Approved	O
British	O

Cocaine	B-Drug
also	O
causes	O
vasoconstriction	O
thus	O
reducing	O
bleeding	O
during	O
minor	O
surgical	O
procedures	O

The	O
investigators	O
interpreted	O
this	O
to	O
mean	O
that	O
oxycodone	B-Drug
is	O
about	O
50%	O
more	O
potent	O
than	O
hydrocodone	B-Drug

Studies	O
have	O
suggested	O
cocaethylene	B-Drug
is	O
both	O
more	O
euphoric	O
and	O
has	O
a	O
higher	O
cardiovascular	O
toxicity	O
than	O
cocaine	B-Drug
by	O
itself	O

In	O
turn	O
alcohol	O
and	O
tobacco	B-Drug
are	O
typically	O
easier	O
to	O
obtain	O
at	O
an	O
earlier	O
age	O
than	O
is	O
cannabis	O
though	O
the	O
reverse	O
may	O
be	O
true	O
in	O
some	O
areas	O
thus	O
leading	O
gateway	O
sequence	O
those	O
individuals	O
since	O
they	O
most	O
likely	O
experiment	O
with	O
any	O
drug	O
offered	O

Since	O
the	O
DEA	O
arrests	O
of	O
makers	O
a	O
huge	O
percentage	O
United	O
States'	O
LSD	B-Drug
in	O
2000	O
5-MeO-AMT	O
may	O
have	O
occasionally	O
been	O
sold	O
under	O
guise	O
liquid	O
sugar	O
cube	O
or	O
blotter	O
form	O
though	O
this	O
be	O
due	O
to	O
reports	O
finding	O
it	O
on	O
cubes	O
and	O
blotters	O
like	O

In	O
VCaP	O
cells	O
which	O
over-express	O
the	O
AR	O
enzalutamide	B-Drug
induced	O
apoptosis	O
whereas	O
bicalutamide	B-Drug
did	O
not	O

It	O
is	O
only	O
recommended	O
with	O
some	O
combination	O
of	O
ribavirin	B-Drug
peginterferon-alfa	O
simeprevir	B-Drug
ledipasvir	B-Drug
daclatasvir	B-Drug
or	O
velpatasvir	B-Drug

Marc	O
Schaffel	O
said	O
Jackson	O
had	O
used	O
propofol	B-Drug
alprazolam	B-Drug
an	O
antianxiety	O
agent	O
and	O
sertraline	B-Drug
antidepressant	O

The	O
Harrison	O
Narcotics	O
Tax	O
Act	O
of	O
1914	O
restricted	O
the	O
manufacture	O
and	O
distribution	O
opiates	O
including	O
laudanum	B-Drug
coca	B-Drug
derivatives	O
in	O
US	O

The	O
death	O
of	O
Anna	O
Wood	O
nevertheless	O
raised	O
awareness	O
about	O
ecstasy	B-Drug
use	O
in	O
the	O
general	O
community	O
which	O
until	O
that	O
time	O
had	O
been	O
less	O
well-known	O
Australia	O

GBL	O
is	O
a	O
prodrug	O
of	O
GHB	B-Drug
and	O
its	O
recreational	O
use	O
comes	O
entirely	O
as	O
result	O
this	O

Opioid	O
use	O
disorder	O
can	O
be	O
treated	O
in	O
a	O
number	O
of	O
different	O
ways:	O
Medication	O
assisted	O
treatment	O
pathways	O
offer	O
methadone	B-Drug
SuboxoneBuprenorphine/naloxone	O
and	O
Vivitrol	B-Drug
naltrexone	B-Drug
naloxone	B-Drug

The	O
following	O
are	O
succinimides:	O
Ethosuximide	B-Drug
1955	O

5-Reductase	O
inhibitors	O
like	O
finasteride	B-Drug
and	O
dutasteride	B-Drug
can	O
slightly	O
increase	O
circulating	O
levels	O
of	O
testosterone	O
by	O
inhibiting	O
its	O
metabolism	O

Traditional	O
ayahuasca	O
brews	O
are	O
usually	O
made	O
with	O
Banisteriopsis	O
caapi	O
as	O
an	O
MAOI	O
while	O
dimethyltryptamine	B-Drug
sources	O
and	O
other	O
admixtures	O
vary	O
from	O
region	O
to	O

Like	O
all	O
opioids	O
the	O
effects	O
of	O
fentanyl	B-Drug
can	O
be	O
reversed	O
with	O
naloxone	B-Drug
or	O
other	O
opiate	O
antagonists	O

etoposide	B-Drug
and	O
doxorubicin	B-Drug

It	O
is	O
the	O
36-diacetyl	O
ester	O
of	O
nalorphine	O
and	O
therefore	O
heroin	B-Drug
analogue	O

Impairments	O
to	O
memory	O
functions	O
are	O
common	O
with	O
bromazepam	B-Drug
and	O
include	O
a	O
reduced	O
working	O
ability	O
process	O
environmental	O
information	O

As	O
a	O
result	O
of	O
the	O
thalidomide	B-Drug
scandal	O
Health	O
Law	O
in	O
West	O
Germany	O
was	O
strengthened	O
and	O
new	O
requirements	O
for	O
pharmaceutical	O
testing	O
were	O
created;	O
Federal	O
Ministry	O
established	O
1962	O

Because	O
of	O
this	O
chlorine	O
destroys	O
LSD	B-Drug
molecules	O
on	O
contact;	O
even	O
though	O
chlorinated	O
tap	O
water	O
contains	O
only	O
a	O
slight	O
amount	O
the	O
small	O
quantity	O
compound	O
typical	O
to	O
an	O
solution	O
will	O
likely	O
be	O
eliminated	O
when	O
dissolved	O
in	O

Pills	O
being	O
sold	O
as	O
Xanax	B-Drug
or	O
other	O
benzodiazepines	O
that	O
are	O
illicitly	O
manufactured	O
may	O
often	O
contain	O
etizolam	B-Drug
rather	O
than	O
their	O
listed	O
ingredient	O

During	O
a	O
15-year	O
period	O
beginning	O
in	O
1950	O
research	O
on	O
LSD	B-Drug
and	O
other	O
hallucinogens	O
generated	O
over	O
1000	O
scientific	O
papers	O
several	O
dozen	O
books	O
six	O
international	O
conferences	O

Isotretinoin	B-Drug
reduces	O
inflammation	O
via	O
inhibition	O
of	O
chemotactic	O
responses	O
monocytes	O
and	O
neutrophils	O

The	O
mean	O
elimination	O
half-life	O
of	O
apalutamide	B-Drug
at	O
steady-state	O
is	O
3	O
to	O
4	O
days	O

A	O
common	O
misconception	O
about	O
Clenbuterol	B-Drug
is	O
that	O
it	O
has	O
anabolic	O
properties	O
and	O
can	O
increase	O
muscle	O
mass	O
when	O
used	O
in	O
higher	O
dosages	O

Side	O
effects	O
of	O
nandrolone	B-Drug
decanoate	O
may	O
include	O
symptoms	O
masculinization	O
like	O
acne	O
increased	O
hair	O
growth	O
voice	O
changes	O
and	O
decreased	O
sexual	O
desire	O
due	O
to	O
its	O
ability	O
suppress	O
endogenous	O
testosterone	O
synthesis	O
while	O
not	O
being	O
a	O
sufficient	O
androgen	O
itself	O

You	O
understand	O
what	O
I'm	O
saying?	O
We	O
knew	O
we	O
couldn't	O
make	O
it	O
illegal	O
to	O
be	O
either	O
against	O
the	O
war	O
or	O
black	O
but	O
by	O
getting	O
public	O
associate	O
hippies	O
with	O
marijuana	O
and	O
blacks	O
heroin	B-Drug
then	O
criminalizing	O
both	O
heavily	O
could	O
disrupt	O
those	O
communities	O

Ethylamphetamine	O
produces	O
effects	O
similar	O
to	O
amphetamine	B-Drug
and	O
methamphetamine	B-Drug
though	O
its	O
potency	O
is	O
less	O

For	O
opioid	O
agonists	O
and	O
opium	B-Drug
derivatives	O
these	O
are	O
classified	O
differently	O

However	O
it	O
was	O
nonetheless	O
not	O
uncommon	O
for	O
doctors	O
to	O
prescribe	O
Placidyl	B-Drug
and	O
other	O
hypnotics	O
extended	O
periods	O
of	O
time	O
as	O
currently	O
prescribed	O
soporifics	O
are	O
today	O

People	O
who	O
take	O
PMA	B-Drug
are	O
often	O
mistaken	O
for	O
it	O
being	O
identified	O
as	O
MDMA	B-Drug

During	O
the	O
House	O
of	O
Commons	O
debates	O
it	O
is	O
quoted	O
that	O
originally	O
some	O
1700000	O
patients	O
in	O
UK	O
were	O
prescribed	O
co-proxamol	B-Drug

Around	O
the	O
same	O
time	O
Japanese	O
organic	O
chemist	O
Nagai	O
Nagayoshi	O
isolated	O
ephedrine	B-Drug
from	O
Chinese	O
ephedra	O
plant	O
and	O
later	O
developed	O
a	O
method	O
for	O
synthesis	O

On	O
March	O
13	O
2003	O
Caracol	O
pleaded	O
guilty	O
to	O
participating	O
in	O
a	O
narcotics	O
trafficking	O
conspiracy	O
that	O
smuggled	O
tens	O
of	O
thousands	O
kilograms	O
cocaine	B-Drug
into	O
New	O
York	O
and	O
other	O
cities	O

GHB	B-Drug
can	O
be	O
manufactured	O
with	O
little	O
knowledge	O
of	O
chemistry	O
as	O
it	O
involves	O
the	O
mixing	O
its	O
two	O
precursors	O
GBL	O
and	O
an	O
alkali	O
hydroxide	O
such	O
sodium	O
to	O
form	O
salt	O

The	O
bust	O
also	O
uncovered	O
large	O
quantities	O
of	O
DMT	O
2C-B	B-Drug
MDMA	B-Drug
and	O
$500000	O
worth	O
cash	O
gold	O

Diamorphine	B-Drug
may	O
be	O
used	O
as	O
a	O
maintenance	O
drug	O
to	O
assist	O
the	O
treatment	O
of	O
opiate	O
addiction	O
normally	O
in	O
long-term	O
chronic	O
intravenous	O
IV	O
heroin	B-Drug
users	O

A	O
variety	O
of	O
esters	O
nandrolone	B-Drug
have	O
been	O
marketed	O
and	O
used	O
medically	O

It	O
is	O
theorized	O
to	O
be	O
a	O
prodrug	O
of	O
psilocin	B-Drug
as	O
psilocybin	O
which	O
occurs	O
naturally	O
in	O
many	O
species	O
hallucinogenic	O
mushrooms	O

Apalutamide	B-Drug
is	O
metabolized	O
in	O
the	O
liver	O
by	O
CYP2C8	O
and	O
CYP3A4	O

In	O
2010	O
the	O
World	O
Health	O
Organization	O
WHO	O
stated	O
that	O
it	O
did	O
not	O
recommend	O
thalidomide	B-Drug
for	O
leprosy	O
due	O
to	O
difficulty	O
of	O
adequately	O
controlling	O
its	O
use	O
and	O
availability	O
clofazimine	B-Drug

The	O
ability	O
of	O
danazol	B-Drug
to	O
increase	O
free	O
testosterone	O
levels	O
suggests	O
that	O
a	O
portion	O
its	O
weak	O
androgenic	O
effects	O
are	O
mediated	O
indirectly	O
by	O
facilitating	O
the	O
activity	O
and	O
dihydrotestosterone	O
through	O
displacement	O
them	O
from	O
SHBG	O

The	O
Schedule	O
I	O
classification	O
of	O
cannabis	O
remains	O
in	O
place	O
today	O
alongside	O
other	O
drugs	O
such	O
as	O
heroin	B-Drug
LSD	B-Drug
MDMA	B-Drug
DMT	O
and	O
peyote	O
none	O
which	O
can	O
be	O
prescribed	O

Most	O
individuals	O
about	O
7792%	O
are	O
extensive	O
metabolizers	O
and	O
have	O
normal	O
metabolism	O
of	O
amitriptyline	B-Drug

Presumably	O
acetoxyketobemidone	O
produces	O
similar	O
effects	O
to	O
ketobemidone	B-Drug
and	O
other	O
opioids	O
such	O
as	O
analgesia	O
sedation	O
along	O
with	O
side	O
nausea	O
itching	O
vomiting	O
respiratory	O
depression	O
which	O
may	O
be	O
harmful	O
or	O
fatal	O

Benzoyl-CoA	O
then	O
combines	O
the	O
two	O
units	O
to	O
form	O
cocaine	B-Drug

In	O
one	O
case	O
they	O
administered	O
LSD	B-Drug
to	O
a	O
mental	O
patient	O
in	O
Kentucky	O
for	O
174	O
days	O

Cocaine	B-Drug
is	O
also	O
teratogenic	O
meaning	O
that	O
it	O
can	O
cause	O
birth	O
defects	O
and	O
fetal	O
malformations	O

It	O
was	O
reported	O
that	O
in	O
the	O
mid-1980s	O
Chilean	O
dictator	O
Augusto	O
Pinochet	O
ordered	O
his	O
army	O
to	O
build	O
a	O
clandestine	O
cocaine	B-Drug
laboratory	O
Chile	O
where	O
chemists	O
mixed	O
with	O
other	O
chemicals	O
produce	O
what	O
Pinochet's	O
former	O
top	O
aide	O
for	O
intelligence	O
Manuel	O
Contreras	O
described	O
as	O
black	O
capable	O
of	O
being	O
smuggled	O
past	O
drug	O
agents	O
US	O
and	O
Europe	O

Cyclization	O
of	O
N-phthaloyl-L-glutamine	O
occurs	O
using	O
carbonyldiimidazole	O
which	O
then	O
yields	O
thalidomide	B-Drug
3	O

Patients	O
should	O
be	O
cautioned	O
against	O
concomitant	O
use	O
of	O
antacids	O
and	O
phenytoin	B-Drug

By	O
2012	O
33	O
million	O
Americans	O
had	O
taken	O
celecoxib	B-Drug

Metenolone	B-Drug
enanthate	I-Drug
or	O
metenolone	B-Drug
17-enanthate	O
is	O
a	O
synthetic	O
androstane	O
steroid	O
and	O
derivative	O
of	O
DHT	O

In	O
the	O
United	O
States	O
MDEA	O
was	O
introduced	O
recreationally	O
in	O
1985	O
as	O
a	O
legal	O
substitute	O
to	O
newly	O
banned	O
MDMA	B-Drug

It	O
is	O
proposed	O
that	O
ibogaine	B-Drug
deposited	O
in	O
fat	O
and	O
metabolized	O
into	O
noribogaine	B-Drug
as	O
it	O
released	O

Cocaine	B-Drug
sold	O
on	O
the	O
street	O
is	O
commonly	O
mixed	O
with	O
local	O
anesthetics	O
cornstarch	O
quinine	B-Drug
or	O
sugar	O
which	O
can	O
result	O
in	O
additional	O
toxicity	O

In	O
early	O
pregnancy	O
nitrazepam	B-Drug
levels	O
are	O
lower	O
in	O
the	O
baby	O
than	O
mother	O
and	O
later	O
stages	O
of	O
is	O
found	O
equal	O
both	O
unborn	O
child	O

Temazepam	B-Drug
and	O
midazolam	B-Drug
are	O
the	O
most	O
common	O
benzodiazepines	O
used	O
to	O
facilitate	O
date	O
rape	O

It	O
may	O
be	O
used	O
directly	O
or	O
chemically	O
modified	O
to	O
produce	O
synthetic	O
opioids	O
such	O
as	O
heroin	B-Drug

In	O
2004	O
according	O
to	O
the	O
United	O
Nations	O
589	O
tonnes	O
of	O
cocaine	B-Drug
were	O
seized	O
globally	O
by	O
law	O
enforcement	O
authorities	O

Research	O
has	O
suggested	O
that	O
CBD	B-Drug
can	O
safely	O
reduce	O
some	O
symptoms	O
of	O
psychosis	O
in	O
general	O

MDMA	B-Drug
could	O
be	O
purchased	O
via	O
credit	O
card	O
and	O
taxes	O
were	O
paid	O
on	O
sales	O

It	O
is	O
thought	O
that	O
androgenic	O
progestins	O
like	O
medroxyprogesterone	B-Drug
acetate	I-Drug
and	O
norethisterone	B-Drug
may	O
antagonize	O
the	O
beneficial	O
effects	O
of	O
estrogens	O
on	O
biomarkers	O
cardiovascular	O
health	O
e	O

The	O
2013	O
DEA	O
production	O
quota	O
for	O
acetyl-alpha-methylfentanyl	B-Drug
is	O
2	O
grammes	O

The	O
chemical	O
modification	O
of	O
the	O
morphine	B-Drug
molecule	O
to	O
hydromorphone	B-Drug
results	O
in	O
higher	O
lipid	O
solubility	O
and	O
greater	O
ability	O
cross	O
bloodbrain	O
barrier	O
produce	O
more	O
rapid	O
complete	O
central	O
nervous	O
system	O
penetration	O

Because	O
cocaine	B-Drug
is	O
hydrolyzed	O
and	O
rendered	O
inactive	O
in	O
the	O
acidic	O
stomach	O
it	O
not	O
readily	O
absorbed	O
when	O
ingested	O
alone	O

Additionally	O
while	O
cocaine	B-Drug
overdose	O
victims	O
showed	O
a	O
large	O
increase	O
in	O
KORs	O
doubled	O
the	O
NAcc	O
KOR	O
agonist	O
administration	O
is	O
shown	O
to	O
be	O
effective	O
decreasing	O
seeking	O
and	O
self-administration	O

Notably	O
two	O
recent	O
large	O
phase	O
III	O
studies	O
of	O
lisdexamfetamine	B-Drug
a	O
prodrug	O
to	O
amphetamine	B-Drug
as	O
an	O
adjunct	O
SSRI	O
or	O
SNRI	O
in	O
the	O
treatment	O
major	O
depressive	O
disorder	O
showed	O
no	O
further	O
benefit	O
relative	O
placebo	O
effectiveness	O

In	O
the	O
1980s	O
and	O
1990s	O
formula	O
changed	O
to	O
using	O
codeine	B-Drug
promethazine	B-Drug
cough	O
syrup	O
somewhat	O
like	O
Glutethimide	B-Drug
combination	O
that	O
was	O
popular	O
from	O
seventies	O
up	O
early	O
nineties	O

With	O
increased	O
cocaine	B-Drug
use	O
there	O
has	O
been	O
a	O
parallel	O
rise	O
in	O
demand	O
for	O
drug	O
user	O
treatment	O
Mexico	O

In	O
the	O
Netherlands	O
etorphine	B-Drug
is	O
a	O
Schedule	O
I	O
drug	O
of	O
Opium	O
Law	O

Conversely	O
buprenorphine	B-Drug
behaves	O
like	O
a	O
partial	O
agonist	O
of	O
the	O
MOR	O
with	O
respect	O
to	O
respiratory	O
depression	O

It	O
was	O
initially	O
replaced	O
by	O
its	O
analogue	O
phendimetrazine	B-Drug
under	O
the	O
brand	O
name	O
Prelu-2	O
which	O
functions	O
as	O
a	O
prodrug	O
to	O
phenmetrazine	B-Drug
but	O
now	O
it	O
is	O
rarely	O
prescribed	O
due	O
concerns	O
of	O
abuse	O
and	O
addiction	O

District	O
Court	O
for	O
the	O
Norther	O
of	O
Illinois	O
granted	O
a	O
motion	O
invalidity	O
filed	O
by	O
Teva	O
Pharmaceuticals	O
against	O
Knoll's	O
patent	O
on	O
Vicoprofen	B-Drug
ruling	O
was	O
invalid	O
as	O
obvious	O

A	O
2008	O
medical	O
review	O
concluded	O
The	O
available	O
data	O
suggest	O
that	O
pure	O
LSD	B-Drug
does	O
not	O
cause	O
chromosomal	O
abnormalities	O
spontaneous	O
abortions	O
or	O
congenital	O
malformations	O

Since	O
1994	O
the	O
production	O
dispensing	O
and	O
prescription	O
of	O
thalidomide	B-Drug
have	O
been	O
strictly	O
controlled	O
requiring	O
women	O
to	O
use	O
two	O
forms	O
birth	O
control	O
submit	O
regular	O
pregnancy	O
tests	O

There	O
are	O
also	O
published	O
case	O
reports	O
of	O
interstitial	O
pneumonitis	O
or	O
eosinophilic	O
lung	O
disease	O
associated	O
with	O
bicalutamide	B-Drug

In	O
the	O
US	O
Harrison	O
Narcotics	O
Tax	O
Act	O
was	O
passed	O
in	O
1914	O
to	O
control	O
sale	O
and	O
distribution	O
of	O
diacetylmorphine	B-Drug
other	O
opioids	O
which	O
allowed	O
drug	O
be	O
prescribed	O
sold	O
for	O
medical	O
purposes	O

A	O
few	O
radiolabeled	O
derivatives	O
of	O
bicalutamide	B-Drug
have	O
been	O
developed	O
for	O
potential	O
use	O
as	O
radiotracers	O
in	O
medical	O
imaging	O

It	O
also	O
has	O
antitussive	O
effects	O
and	O
reduces	O
the	O
rewarding	O
analgesic	O
of	O
morphine	B-Drug
although	O
it	O
did	O
not	O
prevent	O
development	O
dependence	O

Caution	O
is	O
also	O
advised	O
during	O
breast	O
feeding	O
as	O
chlordiazepoxide	B-Drug
passes	O
into	O
milk	O

Lexotanil	O
bromazepam	B-Drug
for	O
anxiety	O
disorders	O

In	O
contrast	O
Jennifer	O
Cohn	O
of	O
Doctors	O
without	O
Borders	O
and	O
the	O
organization	O
World	O
criticized	O
price	O
sofosbuvir	B-Drug
as	O
reflecting	O
corporate	O
greed	O
ignoring	O
needs	O
people	O
in	O
developing	O
countries	O

Detailed	O
sales	O
logs	O
were	O
required	O
to	O
record	O
marihuana	B-Drug

Merck's	O
patent	O
on	O
finasteride	B-Drug
for	O
the	O
treatment	O
of	O
BPH	O
expired	O
in	O
June	O
2006	O

It	O
is	O
a	O
selective	O
androgen	O
receptor	O
antagonist	O
with	O
reduced	O
brain	O
distribution	O
compared	O
to	O
the	O
structurally	O
related	O
nonsteroidal	O
antiandrogen	O
enzalutamide	B-Drug

It	O
is	O
structurally	O
related	O
to	O
the	O
17-hydroxyprogesterone	O
derivatives	O
megestrol	O
acetate	I-Drug
and	O
medroxyprogesterone	B-Drug

The	O
Colorado	O
Harm	O
Reduction	O
Substance	O
Use	O
Disorders	O
Law	O
requires	O
that	O
the	O
cost	O
of	O
opioid	O
antagonists	O
such	O
as	O
Narcan	B-Drug
and	O
Evzio	O
be	O
covered	O
by	O
health	O
insurance	O

A	O
drug-related	O
crime	O
is	O
a	O
to	O
possess	O
manufacture	O
or	O
distribute	O
drugs	O
classified	O
as	O
having	O
potential	O
for	O
abuse	O
such	O
cocaine	B-Drug
heroin	B-Drug
morphine	B-Drug
and	O
amphetamines	O

Negroponte	O
examines	O
Dimitri	O
Mugianis's	O
long	O
clandestine	O
career	O
of	O
treating	O
heroin	B-Drug
addicts	O
with	O
ibogaine	B-Drug

When	O
LSD	B-Drug
became	O
illegal	O
in	O
California	O
on	O
October	O
6	O
1966	O
Scully	O
decided	O
to	O
set	O
up	O
a	O
new	O
lab	O
Denver	O
Colorado	O

In	O
December	O
2019	O
lemborexant	B-Drug
was	O
approved	O
for	O
use	O
in	O
the	O
United	O
States	O
based	O
on	O
results	O
from	O
SUNRISE	O
1	O
and	O
2	O
Phase	O
III	O
clinical	O
trials	O

The	O
elimination	O
half-life	O
of	O
oxymorphone	B-Drug
is	O
much	O
faster	O
intravenously	O
and	O
as	O
such	O
the	O
drug	O
most	O
commonly	O
used	O
orally	O

Exemestane	B-Drug
is	O
the	O
only	O
steroidal	O
3rd	O
generation	O
aromatase	O
inhibitor	O
and	O
it	O
has	O
advantage	O
over	O
formestane	O
in	O
being	O
more	O
potent	O
can	O
be	O
administrated	O
orally	O

By	O
1932	O
60%	O
of	O
narcotics	O
arrests	O
in	O
Los	O
Angeles	O
involved	O
cannabis	O
which	O
was	O
considered	O
much	O
less	O
serious	O
than	O
the	O
morphine	B-Drug
cases	O

Food	O
and	O
Drug	O
Administration	O
warns	O
that	O
in	O
Spain	O
ketazolam	B-Drug
marketed	O
as	O
Marcen	O
may	O
sometimes	O
be	O
mistakenly	O
confused	O
with	O
Narcan	B-Drug

This	O
review	O
and	O
a	O
second	O
corroborating	O
by	O
different	O
author	O
both	O
concluded	O
that	O
because	O
of	O
MDMA's	O
demonstrated	O
potential	O
to	O
cause	O
lasting	O
harm	O
in	O
humans	O
e	O
MDMA	B-Drug

Research	O
during	O
this	O
time	O
was	O
focused	O
on	O
the	O
search	O
for	O
a	O
painkiller	O
that	O
did	O
not	O
have	O
addictive	O
character	O
or	O
overdose	O
risk	O
of	O
morphine	B-Drug

Due	O
to	O
the	O
fact	O
that	O
memories	O
and	O
their	O
emotional	O
content	O
are	O
reconsolidated	O
in	O
hours	O
after	O
they	O
recalled/re-experienced	O
propranolol	B-Drug
can	O
also	O
diminish	O
impact	O
of	O
already	O
formed	O
memories;	O
for	O
this	O
reason	O
it	O
is	O
being	O
studied	O
treatment	O
specific	O
phobias	O
such	O
as	O
arachnophobia	O
dental	O
fear	O
social	O
phobia	O

Naloxone	B-Drug
is	O
a	O
racemic	O
mixture	O
of	O
two	O
enantiomers	O
-naloxone	O
levonaloxone	O
and	O
+-naloxone	O
dextronaloxone	O
only	O
the	O
former	O
which	O
active	O
at	O
opioid	O
receptors	O

The	O
program	O
relied	O
on	O
the	O
turning	O
of	O
public	O
sentiment	O
against	O
opium	B-Drug
with	O
mass	O
meetings	O
at	O
which	O
paraphernalia	O
were	O
publicly	O
burned	O
as	O
well	O
coercive	O
legal	O
action	O
and	O
granting	O
police	O
powers	O
to	O
organizations	O
such	O
Fujian	O
Anti-Opium	O
Society	O

Celgene	O
has	O
sponsored	O
numerous	O
clinical	O
trials	O
with	O
analogues	O
to	O
thalidomide	B-Drug
such	O
as	O
lenalidomide	B-Drug
that	O
are	O
substantially	O
more	O
powerful	O
and	O
have	O
fewer	O
side	O
effects	O
except	O
for	O
greater	O
myelosuppression	O

Manufacturing	O
LSD	B-Drug
requires	O
laboratory	O
equipment	O
and	O
experience	O
in	O
the	O
field	O
of	O
organic	O
chemistry	O

Bupivacaine	B-Drug
is	O
contraindicated	O
in	O
patients	O
with	O
known	O
hypersensitivity	O
reactions	O
to	O
bupivacaine	B-Drug
or	O
amino-amide	O
anesthetics	O

The	O
third	O
single	O
Cocaine	B-Drug
which	O
features	O
Left	O
Brain	O
had	O
its	O
music	O
video	O
premiere	O
on	O
Odd	O
Future's	O
YouTube	O
page	O
October	O
31	O
2011	O

It	O
was	O
concluded	O
that	O
flunitrazepam	B-Drug
and	O
nitrazepam	B-Drug
might	O
be	O
more	O
toxic	O
than	O
other	O
benzodiazepines	O

Sulfonamide-trimethoprim	O
combinations	O
co-trimoxazole	B-Drug
are	O
still	O
used	O
extensively	O
against	O
opportunistic	O
infections	O
in	O
patients	O
with	O
AIDS	O
urinary	O
and	O
the	O
treatment	O
of	O
burns	O

Low	O
levels	O
of	O
nicotine	B-Drug
stimulate	O
cell	O
proliferation	O
while	O
high	O
are	O
cytotoxic	O

JWH-018	B-Drug
1-pentyl-3-1-naphthoylindole	O
or	O
AM-678	B-Drug
is	O
an	O
analgesic	O
chemical	O
from	O
the	O
naphthoylindole	O
family	O
that	O
acts	O
as	O
a	O
full	O
agonist	O
at	O
both	O
CB1	O
and	O
CB2	O
cannabinoid	O
receptors	O
with	O
some	O
selectivity	O
for	O

In	O
the	O
1970s	O
and	O
1980s	O
drug	O
became	O
particularly	O
popular	O
in	O
disco	O
culture	O
as	O
cocaine	B-Drug
usage	O
was	O
very	O
common	O
many	O
discos	O
such	O
Studio	O
54	O
even	O
spawning	O
open	O
publications	O
Adam	O
Gottlieb's	O
1976	O
book	O
The	O
Pleasures	O
of	O
Cocaine	B-Drug
which	O
appealed	O
to	O
collective	O
experience	O
prohibition	O
call	O
for	O
legalization:	O
path	O
it	O
stands	O
streets	O
north	O
America	O
today	O
offers	O
dangers	O
not	O
only	O
inherent	O
pharmacology	O
alkaloid	O
itself	O
but	O
also	O
bizarre	O
assortment	O
adulterants	O
are	O
added	O
by	O
black	O
market	O
middlemen	O

Its	O
carbon	O
skeleton	O
is	O
identical	O
to	O
pseudoephedrine	O
and	O
methamphetamine	B-Drug

Among	O
their	O
experimental	O
results	O
were	O
the	O
qualitative	O
and	O
quantitative	O
documentation	O
of	O
physical	O
dependence	O
on	O
barbiturates	O
alcoholtolerance	O
to	O
amphetamine	B-Drug
clinical	O
use	O
opiate	O
antagonists	O
e	O

Quazepam	B-Drug
has	O
potent	O
sleep	O
inducing	O
and	O
maintaining	O
properties	O

Within	O
a	O
week	O
of	O
removal	O
the	O
hormones	O
from	O
device	O
leave	O
body	O
and	O
etonogestrel	B-Drug
is	O
undetectable	O
in	O
most	O
users	O

In	O
1986	O
the	O
US	O
Defense	O
Department	O
funded	O
a	O
two-year	O
study	O
by	O
RAND	O
Corporation	O
which	O
found	O
that	O
use	O
of	O
armed	O
forces	O
to	O
interdict	O
drugs	O
coming	O
into	O
United	O
States	O
would	O
have	O
little	O
or	O
no	O
effect	O
on	O
cocaine	B-Drug
traffic	O
and	O
might	O
in	O
fact	O
raise	O
profits	O
cartels	O
manufacturers	O

Ativan	B-Drug
lorazepam	B-Drug
a	O
benzodiazepine	O
used	O
to	O
treat	O
anxiety	O

Levonorgestrel	B-Drug
has	O
no	O
other	O
important	O
hormonal	O
activity	O
including	O
estrogenic	O
glucocorticoid	O
or	O
antimineralocorticoid	O

25I-NBOMe	B-Drug
has	O
been	O
implicated	O
in	O
multiple	O
deaths	O
Australia	O

It	O
is	O
the	O
indole	O
2-methyl	O
derivative	O
of	O
related	O
compound	O
JWH-175	B-Drug
and	O
carbonyl	O
reduced	O
analog	O
JWH-007	B-Drug

Nalmefene	O
is	O
structurally	O
related	O
to	O
naltrexone	B-Drug
and	O
differs	O
from	O
it	O
by	O
substitution	O
of	O
the	O
ketone	O
group	O
at	O
6-position	O
with	O
a	O
methylene	O
CH2	O

Its	O
use	O
is	O
also	O
advised	O
against	O
in	O
individuals	O
with	O
known	O
hypersensitivities	O
to	O
either	O
amoxapine	B-Drug
or	O
other	O
ingredients	O
its	O
oral	O
formulations	O

DOB	O
DOI	O
and	O
other	O
closely	O
related	O
drugs	O
are	O
sometimes	O
sold	O
as	O
LSD	B-Drug

The	O
final	O
step	O
in	O
the	O
synthesis	O
of	O
nicotine	B-Drug
is	O
coupling	O
between	O
N-methyl-1-pyrrollidium	O
cation	O
and	O
niacin	B-Drug

amphetamine	B-Drug
hallucinogens	O
e	O

Kief	O
is	O
a	O
powder	O
rich	O
in	O
trichomes	O
which	O
can	O
be	O
sifted	O
from	O
the	O
leaves	O
flowers	O
and	O
fruits	O
of	O
cannabis	O
plants	O
either	O
consumed	O
form	O
or	O
compressed	O
to	O
produce	O
cakes	O
hashish	B-Drug

In	O
contrast	O
to	O
psilocin	B-Drug
1-methylpsilocin	O
did	O
not	O
activate	O
5-HT1A	O
receptors	O
in	O
mice	O

Side	O
effects	O
of	O
nandrolone	B-Drug
esters	O
include	O
masculinization	O
among	O
others	O

A	O
special	O
LSD	B-Drug
unit	O
was	O
set	O
up	O
in	O
1958	O

Abiraterone	B-Drug
acetate	I-Drug
was	O
approved	O
by	O
the	O
United	O
States	O
Food	O
and	O
Drug	O
Administration	O
on	O
28	O
April	O
2011	O
for	O
mCRPC	O

While	O
methadone	B-Drug
treatments	O
are	O
covered	O
by	O
Medicaid	O
for	O
low-income	O
individuals	O
the	O
extent	O
of	O
coverage	O
depends	O
on	O
which	O
state	O
they	O
in	O
and	O
if	O
has	O
opted	O
into	O
expansion	O
under	O
Affordable	O
Care	O
Act	O

Tramadol	B-Drug
is	O
also	O
used	O
as	O
a	O
coping	O
mechanism	O
in	O
the	O
Gaza	O
Strip	O

Likewise	O
Canadian	O
Psychiatric	O
Association	O
CPA	O
recommends	O
benzodiazepines	O
alprazolam	B-Drug
bromazepam	B-Drug
lorazepam	B-Drug
and	O
diazepam	B-Drug
only	O
as	O
a	O
second-line	O
choice	O
if	O
the	O
treatment	O
with	O
two	O
different	O
antidepressants	O
was	O
unsuccessful	O

lower	O
Ki	O
at	O
CB1	O
than	O
both	O
its	O
4-methyl	O
and	O
4-n-propyl	O
homologues	O
JWH-122	B-Drug
0	O

The	O
term	O
controlled	O
substance	B-Drug
means	O
a	O
drug	O
or	O
other	O
immediate	O
precursor	O
included	O
in	O
schedule	O
I	O
II	O
III	O
IV	O
V	O
of	O
part	O
B	O
this	O
subchapter	O

When	O
taken	O
in	O
prescribed	O
quantities	O
cough	O
syrup	O
is	O
quite	O
safe	O
but	O
dangers	O
arise	O
higher	O
doses	O
since	O
promethazine	B-Drug
a	O
depressant	O
of	O
the	O
central	O
nervous	O
system	O
CNS	O
and	O
codeine	B-Drug
respiratory	O

In	O
the	O
UK	O
alprazolam	B-Drug
is	O
not	O
available	O
on	O
NHS	O
and	O
can	O
only	O
be	O
obtained	O
a	O
private	O
prescription	O

5F-ADB	B-Drug
was	O
added	O
to	O
the	O
Japanese	O
banned	O
drug	O
list	O
in	O
December	O
2014	O

The	O
attorneys	O
general	O
of	O
Connecticut	O
and	O
Pennsylvania	O
have	O
launched	O
investigations	O
into	O
its	O
diversion	O
from	O
the	O
legitimate	O
pharmaceutical	O
market	O
including	O
Cephalon's	O
sales	O
promotional	O
practices	O
for	O
Provigil	B-Drug
Actiq	B-Drug
Gabitril	B-Drug

Sentencing	O
Commission	O
statistics	O
showing	O
that	O
29%	O
of	O
all	O
crack	O
cases	O
from	O
October	O
1	O
2008	O
through	O
September	O
30	O
2009	O
involved	O
a	O
weapon	O
compared	O
to	O
only	O
16%	O
for	O
powder	O
cocaine	B-Drug

Whereas	O
other	O
TCAs	O
are	O
useful	O
for	O
treating	O
insomnia	O
desipramine	B-Drug
can	O
cause	O
as	O
a	O
side	O
effect	O
due	O
to	O
its	O
activating	O
properties	O

Nicotine	B-Drug
is	O
used	O
as	O
a	O
recreational	O
drug	O

Depending	O
on	O
liver	O
and	O
kidney	O
function	O
cocaine	B-Drug
metabolites	O
are	O
detectable	O
in	O
urine	O

3-Methylfentanyl	B-Drug
was	O
also	O
reported	O
by	O
media	O
as	O
the	O
identity	O
of	O
anaesthetic	O
gas	O
Kolokol-1	O
delivered	O
an	O
aerosol	O
during	O
Moscow	O
theater	O
hostage	O
crisis	O
in	O
2002	O
which	O
many	O
hostages	O
died	O
from	O
accidental	O
overdoses	O
3-methylfentanyl	B-Drug
later	O
ruled	O
out	O
primary	O
agent	O
used	O

In	O
particular	O
genetic	O
deregulations	O
affecting	O
genes	O
coding	O
for	O
DPD	O
UGT1A1	O
TPMT	O
CDA	O
and	O
CYP2D6	O
are	O
now	O
considered	O
as	O
critical	O
issues	O
patients	O
treated	O
with	O
5-FU/capecitabine	O
irinotecan	B-Drug
mercaptopurine/azathioprine	O
gemcitabine/capecitabine/AraC	O
tamoxifen	B-Drug
respectively	O
5-FU	B-Drug
capecitabine	B-Drug
azathioprine	B-Drug
gemcitabine	B-Drug

In	O
February	O
2009	O
the	O
UK	O
government	O
was	O
accused	O
by	O
its	O
most	O
senior	O
expert	O
drugs	O
adviser	O
Professor	O
David	O
Nutt	O
of	O
making	O
political	O
decisions	O
with	O
regard	O
to	O
drug	O
classification	O
for	O
example	O
in	O
rejecting	O
scientific	O
advice	O
downgrade	O
ecstasy	B-Drug
from	O
a	O
class	O
A	O

GHB	B-Drug
is	O
also	O
produced	O
as	O
a	O
result	O
of	O
fermentation	O
and	O
so	O
found	O
in	O
small	O
quantities	O
some	O
beers	O
wines	O
particular	O
fruit	O

MDMA	B-Drug
is	O
illegal	O
in	O
most	O
countries	O
and	O
as	O
of	O
2018	O
has	O
no	O
approved	O
medical	O
uses	O

Of	O
the	O
major	O
naturally	O
occurring	O
opiates	O
of	O
morphinan	O
typemorphine	O
codeine	B-Drug
and	O
thebainethebaine	O
has	O
no	O
therapeutic	O
properties	O
it	O
causes	O
seizures	O
in	O
mammals	O
but	O
provides	O
a	O
low-cost	O
feedstock	O
for	O
industrial	O
production	O
at	O
least	O
four	O
semi-synthetic	O
opiate	O
agonists	O
including	O
hydrocodone	B-Drug
hydromorphone	B-Drug
oxycodone	B-Drug
oxymorphone	B-Drug
perhaps	O
more	O
significantly	O
opioid	O
antagonist	O
naloxone	B-Drug

A	O
single	O
amphetamine	B-Drug
dose	O
combines	O
the	O
neutral	O
sulfate	O
salts	O
of	O
dextroamphetamine	B-Drug
and	O
with	O
dextro	O
isomer	O
saccharate	O
D/L-amphetamine	O
aspartate	O
monohydrate	O

UR-144	B-Drug
produces	O
bradycardia	O
and	O
hypothermia	O
in	O
rats	O
at	O
a	O
dose	O
of	O
10	O
mg/kg	O
suggesting	O
weak	O
cannabinoid-like	O
activity	O

In	O
addition	O
some	O
of	O
the	O
all-trans	O
retinal	O
may	O
be	O
converted	O
to	O
retinol	B-Drug
form	O
and	O
then	O
transported	O
with	O
an	O
interphotoreceptor	O
retinol-binding	O
protein	O
IRBP	O
pigment	O
epithelial	O
cells	O

As	O
is	O
supported	O
by	O
the	O
common	O
practice	O
of	O
prescribing	O
low-dose	O
quetiapine	B-Drug
and	O
clozapine	B-Drug
for	O
PDP	O
at	O
doses	O
too	O
low	O
to	O
antagonize	O
D2	O
receptor	O
but	O
sufficiently	O
high	O
inversely	O
agonize	O
5-HT2A	O
receptors	O

There	O
are	O
no	O
expected	O
pharmacokinetic	O
interactions	O
between	O
thalidomide	B-Drug
and	O
other	O
medicines	O
due	O
to	O
its	O
neutral	O
effects	O
on	O
P-glycoprotein	O
the	O
cytochrome	O
P450	O
family	O

Benzodiazepines	O
such	O
as	O
chlordiazepoxide	B-Drug
Librium	B-Drug
diazepam	B-Drug
Valium	B-Drug
lorazepam	B-Drug
Ativan	B-Drug
or	O
oxazepam	B-Drug
Serax	B-Drug
are	O
the	O
most	O
commonly	O
used	O
drugs	O
to	O
reduce	O
alcohol	O
withdrawal	O
symptoms	O

In	O
response	O
to	O
the	O
proposed	O
scheduling	O
Texas	O
Group	O
increased	O
production	O
from	O
1985	O
estimates	O
of	O
30000	O
tablets	O
a	O
month	O
as	O
many	O
8000	O
per	O
day	O
potentially	O
making	O
two	O
million	O
ecstasy	B-Drug
in	O
months	O
before	O
MDMA	B-Drug
was	O
made	O
illegal	O

AC-262356	O
LGD-2226	B-Drug
Affects	O
both	O
muscle	O
and	O
bone	O
LGD-3303	O
S-40503	B-Drug
Selective	O
for	O
tissue	O
particularly	O
low	O
virilization	O
intended	O
osteoporosis	O
may	O
be	O
suitable	O
use	O
in	O
women	O

Desmethyldiazepam	O
has	O
a	O
half-life	O
of	O
36200	O
hours	O
and	O
flurazepam	B-Drug
with	O
the	O
main	O
active	O
metabolite	O
desalkylflurazepam	O
40250	O

Both	O
patients	O
who	O
are	O
new	O
to	O
methadone	B-Drug
treatment	O
and	O
high-risk	O
patientssuch	O
as	O
those	O
using	O
drugs	O
alcohol	O
including	O
cannabismust	O
visit	O
the	O
clinic	O
daily	O
every	O
morning	O

Propylhexedrine	B-Drug
is	O
most	O
commonly	O
found	O
in	O
over-the-counter	O
Benzedrex	B-Drug
inhalers	O

It	O
concluded	O
that	O
[t]he	O
cost	O
of	O
crime	O
committed	O
to	O
support	O
illegal	O
cocaine	B-Drug
and	O
heroin	B-Drug
habits	O
amounts	O
16	O
billion	O
a	O
year	O
in	O
the	O
UK	O
Venezuela	O
has	O
been	O
path	O
United	O
States	O
Europe	O
for	O
drugs	O
originating	O
Colombia	O
through	O
Central	O
America	O
Mexico	O
Caribbean	O
countries	O
such	O
as	O
Haiti	O
Dominican	O
Republic	O
Puerto	O
Rico	O

Betaprodine	B-Drug
was	O
550%	O
as	O
strong	O
morphine	B-Drug
SC	O
and	O
the	O
laevorotary	O
cis	O
isomer	O
350%	O
dextrorotary	O
790%	O

LSD	B-Drug
is	O
also	O
tasteless	O
in	O
normal	O
dosages	O
so	O
detection	O
only	O
possible	O
after	O
ingestion	O
or	O
reagent	O
testing	O

One	O
pound	O
of	O
marijuana	O
yields	O
from	O
1/5	O
to	O
1/10	O
a	O
hash	B-Drug
oil	I-Drug

Opium	B-Drug
was	O
prohibited	O
in	O
many	O
countries	O
during	O
the	O
early	O
20th	O
century	O
leading	O
to	O
modern	O
pattern	O
of	O
opium	O
production	O
as	O
a	O
precursor	O
for	O
illegal	O
recreational	O
drugs	O
or	O
tightly	O
regulated	O
highly	O
taxed	O
legal	O
prescription	O

The	O
process	O
continued	O
until	O
1817	O
when	O
Sertrner	O
published	O
the	O
isolation	O
of	O
pure	O
morphine	B-Drug
from	O
opium	B-Drug
after	O
at	O
least	O
thirteen	O
years	O
research	O
and	O
a	O
nearly	O
disastrous	O
trial	O
on	O
himself	O
three	O
boys	O

In	O
this	O
legislation	O
boldenone	B-Drug
was	O
classified	O
as	O
a	O
controlled	O
substance	O
and	O
boldione	O
remained	O
legal	O

Japan	O
has	O
banned	O
JWH-018	B-Drug
CP	O
47	O
497	O
and	O
homologues	O
HU-210	B-Drug
since	O
October	O
2009	O

In	O
accordance	O
with	O
its	O
antiandrogenic	O
action	O
abiraterone	B-Drug
acetate	O
decreases	O
the	O
weights	O
of	O
prostate	O
gland	O
seminal	O
vesicles	O
and	O
testes	O

HU-331	O
is	O
a	O
quinone	O
anticarcinogenic	O
drug	O
synthesized	O
from	O
cannabidiol	B-Drug
cannabinoid	O
in	O
the	O
Cannabis	O
sativa	O
plant	O

The	O
aromatic	O
component	O
of	O
the	O
quinine	B-Drug
molecule	O
is	O
a	O
quinoline	O
with	O
methoxy	O
substituent	O

In	O
1959	O
the	O
Belgian	O
physician	O
Paul	O
Janssen	O
developed	O
fentanyl	B-Drug
a	O
synthetic	O
drug	O
with	O
30	O
to	O
50	O
times	O
potency	O
of	O
heroin	B-Drug

Thus	O
quazepam	B-Drug
may	O
have	O
less	O
side	O
effects	O
than	O
other	O
benzodiazepines	O
but	O
it	O
has	O
a	O
very	O
long	O
half-life	O
of	O
25	O
hours	O
which	O
reduces	O
its	O
benefits	O
as	O
hypnotic	O
due	O
to	O
likely	O
next	O
day	O
sedation	O

More	O
research	O
is	O
needed	O
to	O
fully	O
define	O
whether	O
krokodil	O
a	O
drug	O
or	O
collection	O
of	O
symptoms	O
associated	O
with	O
injecting	O
toxic	O
chemical	O
by-products	O
home	O
chemistry	O
but	O
since	O
desomorphine	B-Drug
one	O
hundreds	O
known	O
opiates	O
in	O
family	O
no	O
association	O
the	O
it	O
much	O
more	O
likely	O
that	O
set	O
injection	O
household	O
chemicals	O
rather	O
than	O
specific	O
itself	O

Since	O
cabergoline	B-Drug
is	O
not	O
approved	O
in	O
the	O
United	O
States	O
for	O
Parkinson's	O
Disease	O
but	O
hyperprolactinemia	O
drug	O
remains	O
on	O
market	O

Upon	O
discontinuation	O
of	O
treatment	O
levels	O
tamoxifen	B-Drug
and	O
its	O
metabolites	O
persist	O
in	O
the	O
circulation	O
for	O
at	O
least	O
6	O
weeks	O

A	O
cultivar	O
for	O
opium	B-Drug
production	O
Papaver	O
somniferum	O
L	O

Morphine	B-Drug
methylbromide	O
methobromide	I-Drug
bromomethylate	O
Morphosan	O
a	O
derivative	O
of	O
morphine	B-Drug

As	O
of	O
October	O
2015	O
RCS-4	B-Drug
is	O
a	O
controlled	O
substance	O
in	O
China	O

Marijuana	B-Drug
is	O
the	O
most	O
popular	O
illegal	O
drug	O
worldwide	O

Among	O
this	O
group	O
the	O
most	O
closely	O
related	O
compounds	O
are	O
phenethylamine	B-Drug
parent	O
compound	O
of	O
amphetamine	B-Drug
and	O
N-methylphenethylamine	O
an	O
isomer	O
i	O

It	O
is	O
a	O
stereoisomer	O
of	O
betamethasone	B-Drug
the	O
two	O
compounds	O
differing	O
only	O
in	O
spatial	O
configuration	O
methyl	O
group	O
at	O
position	O
16	O
see	O
steroid	O
nomenclature	O

The	O
unique	O
border	O
policing	O
is	O
done	O
under	O
the	O
water	O
line	O
as	O
cocaine	B-Drug
not	O
only	O
smuggled	O
onboard	O
but	O
vessels	O
well	O

ephedrine	B-Drug
as	O
well	O
pseudoephedrine	O
and	O
norephedrine	O
is	O
regulated	O
an	O
UN-controlled	O
drug	O
precursor	O

Later	O
the	O
same	O
substance	O
was	O
found	O
to	O
be	O
usable	O
in	O
production	O
of	O
scopolamine	O
and	O
hyoscyamine	B-Drug
which	O
are	O
used	O
eye	O
surgery	O
a	O
multimillion	O
dollar	O
industry	O
built	O
Queensland	O
based	O
on	O
this	O

25I-NBOMe	B-Drug
is	O
potent	O
being	O
active	O
in	O
sub-milligram	O
doses	O

Desipramine	B-Drug
is	O
primarily	O
used	O
for	O
the	O
treatment	O
of	O
depression	O

The	O
two	O
most	O
common	O
forms	O
of	O
narcotic	O
drugs	O
are	O
morphine	B-Drug
and	O
codeine	B-Drug

PCP	B-Drug
like	O
ketamine	B-Drug
also	O
acts	O
as	O
a	O
potent	O
dopamine	O
D2High	O
receptor	O
partial	O
agonist	O
in	O
rat	O
brain	O
homogenate	O
and	O
has	O
affinity	O
for	O
the	O
human	O
cloned	O

Excessive	O
doses	O
of	O
methylphenidate	B-Drug
above	O
the	O
therapeutic	O
range	O
can	O
interfere	O
with	O
working	O
memory	O
and	O
cognitive	O
control	O

The	O
first	O
study	O
of	O
finasteride	B-Drug
in	O
the	O
treatment	O
hirsutism	O
women	O
was	O
published	O
1994	O

Presumably	O
propylketobemidone	O
produces	O
similar	O
effects	O
to	O
ketobemidone	B-Drug
and	O
other	O
opioids	O
such	O
as	O
analgesia	O
sedation	O
along	O
with	O
side	O
nausea	O
itching	O
vomiting	O
respiratory	O
depression	O
which	O
may	O
be	O
harmful	O
or	O
fatal	O

Research	O
by	O
the	O
Multidisciplinary	O
Association	O
for	O
Psychedelic	O
Studies	O
MAPS	O
has	O
provided	O
evidence	O
that	O
MDMA	B-Drug
can	O
help	O
address	O
trauma-related	O
disease	O
in	O
particular	O
post-traumatic	O
stress	O
disorder	O

In	O
some	O
parts	O
of	O
the	O
United	O
States	O
especially	O
lower	O
states	O
black	O
tar	O
may	O
be	O
only	O
form	O
heroin	B-Drug
that	O
is	O
available	O

Nitrazepam	B-Drug
has	O
been	O
associated	O
with	O
severe	O
hepatic	O
disorders	O
similar	O
to	O
other	O
nitrobenzodiazepines	O

In	O
the	O
United	O
States	O
where	O
patches	O
cannot	O
always	O
be	O
returned	O
through	O
a	O
medication	O
take-back	O
program	O
flushing	O
is	O
recommended	O
for	O
fentanyl	B-Drug
because	O
it	O
fastest	O
and	O
surest	O
way	O
to	O
remove	O
them	O
from	O
home	O
prevent	O
ingestion	O
by	O
children	O
pets	O
or	O
others	O
not	O
intended	O
use	O

These	O
effects	O
were	O
not	O
noted	O
in	O
its	O
medicinal	O
use	O
the	O
1950s	O
and	O
1960s	O
however	O
reports	O
of	O
physical	O
violence	O
on	O
PCP	B-Drug
have	O
often	O
been	O
shown	O
to	O
be	O
unfounded	O

In	O
July	O
2020	O
the	O
WHO	O
stated	O
they	O
are	O
in	O
process	O
of	O
updating	O
treatment	O
guidelines	O
to	O
include	O
dexamethasone	B-Drug
or	O
other	O
steroids	O

Morphine	B-Drug
was	O
the	O
first	O
pharmaceutical	O
isolated	O
from	O
a	O
natural	O
product	O
and	O
this	O
success	O
encouraged	O
isolation	O
of	O
other	O
alkaloids:	O
by	O
1820	O
isolations	O
noscapine	O
strychnine	O
veratrine	O
colchicine	B-Drug
caffeine	O
quinine	B-Drug
were	O
reported	O

Zaleplon	B-Drug
may	O
increase	O
the	O
risk	O
of	O
injury	O
among	O
elderly	O

Fentanyl	B-Drug
citrate	O
entered	O
medical	O
use	O
as	O
a	O
general	O
anaesthetic	O
in	O
1968	O
manufactured	O
by	O
McNeil	O
Laboratories	O
under	O
the	O
trade	O
name	O
Sublimaze	O

The	O
last	O
FDA	O
approved	O
study	O
of	O
LSD	B-Drug
in	O
patients	O
ended	O
1980	O
while	O
a	O
healthy	O
volunteers	O
was	O
made	O
the	O
late	O
1980s	O

On	O
abrupt	O
or	O
overly	O
rapid	O
discontinuation	O
of	O
lorazepam	B-Drug
anxiety	O
and	O
signs	O
physical	O
withdrawal	O
have	O
been	O
observed	O
similar	O
to	O
those	O
seen	O
on	O
from	O
alcohol	O
barbiturates	O

Atlanta/Grady	O
Study	O
Upjohn	O
studied	O
the	O
effect	O
of	O
DMPA	B-Drug
for	O
11	O
years	O
in	O
Atlanta	O
mostly	O
on	O
black	O
women	O
who	O
were	O
receiving	O
public	O
assistance	O
but	O
did	O
not	O
file	O
any	O
required	O
follow-up	O
reports	O
with	O
FDA	O

Flunitrazepam	B-Drug
impairs	O
cognitive	O
functions	O

In	O
most	O
fatalities	O
MDMA	B-Drug
was	O
not	O
the	O
only	O
drug	O
involved	O

Side	O
effects	O
of	O
pyrovalerone	B-Drug
include	O
anorexia	O
or	O
loss	O
appetite	O
anxiety	O
fragmented	O
sleep	O
insomnia	O
and	O
trembling	O
shaking	O
muscle	O
tremors	O

Another	O
approach	O
is	O
Heroin	B-Drug
assisted	O
treatment	O
in	O
which	O
medical	O
prescriptions	O
for	O
pharmaceutical	O
heroin	B-Drug
diacetylmorphine	B-Drug
are	O
provided	O
to	O
heroin-dependent	O
people	O

It	O
is	O
the	O
717-dimethyl	O
derivative	O
of	O
trenbolone	B-Drug
and	O
7-methyl	O
metribolone	O
as	O
well	O
911	O
analogue	O
17-methylated	O
trestolone	O

Co-dydramol	O
BAN	O
is	O
a	O
non-proprietary	O
name	O
used	O
to	O
denote	O
particular	O
compound	O
analgesic	O
combination	O
of	O
dihydrocodeine	B-Drug
tartrate	I-Drug
and	O
paracetamol	B-Drug

Thalidomide	B-Drug
also	O
binds	O
to	O
and	O
acts	O
as	O
an	O
antagonist	O
of	O
the	O
androgen	O
receptor	O
AR	O
hence	O
is	O
a	O
nonsteroidal	O
antiandrogen	O
NSAA	O
some	O
capacity	O

This	O
treaty	O
has	O
since	O
been	O
supplemented	O
by	O
the	O
Convention	O
on	O
Psychotropic	O
Substances	O
which	O
controls	O
LSD	B-Drug
MDMA	B-Drug
and	O
other	O
psychoactive	O
pharmaceuticals	O
United	O
Nations	O
Against	O
Illicit	O
Traffic	O
in	O
Narcotic	O
Drugs	O
strengthens	O
provisions	O
against	O
money	O
laundering	O
drug-related	O
offenses	O

Zopiclone	B-Drug
is	O
less	O
selective	O
to	O
the	O
1	O
site	O
and	O
has	O
higher	O
affinity	O
2	O
than	O
zaleplon	B-Drug

At	O
least	O
one	O
manufacturer	O
Tasmanian	O
Alkaloids	O
produces	O
both	O
high-morphine	O
and	O
high-thebaine/oripavine	O
types	O
of	O
poppy	O
straw	O
concentrate;	O
the	O
latter	O
is	O
used	O
by	O
pharmaceutical	O
manufacturers	O
to	O
make	O
semi-synthetic	O
synthetic	O
opioids	O
such	O
as	O
oxycodone	B-Drug
etorphine	B-Drug
butorphanol	B-Drug
a	O
number	O
others	O

The	O
half-lives	O
of	O
amphetamine	B-Drug
enantiomers	O
differ	O
and	O
vary	O
with	O
urine	O
pH	O

The	O
pharmacological	O
effects	O
of	O
tetrazepam	B-Drug
are	O
significantly	O
less	O
potent	O
when	O
compared	O
against	O
diazepam	B-Drug
in	O
animal	O
studies	O

James	O
Taylor	O
John	O
Lennon	O
Eric	O
Clapton	O
Johnny	O
Winter	O
Keith	O
Richards	O
and	O
Janis	O
Joplin	O
also	O
used	O
heroin	B-Drug

American	O
rapper	O
Lil	O
Peep	O
also	O
died	O
of	O
an	O
accidental	O
fentanyl	B-Drug
overdose	O
on	O
November	O
15	O
2017	O

Researchers	O
have	O
also	O
found	O
that	O
systemic	O
naltrexone	B-Drug
treatment	O
of	O
female	O
prairie	O
voles	O
during	O
initial	O
exposure	O
to	O
a	O
male	O
reduced	O
subsequent	O
mating	O
bouts	O
and	O
nonsexual	O
socialization	O
with	O
this	O
familiar	O
partner	O
when	O
choice	O
test	O
including	O
novel	O
was	O
performed	O
afterwards	O

2]	O
Flurazepam	B-Drug
7-chloro-1-[2-diethylamino	O
ethyl]-5-o-fluorophenyl-13-dihydro-2H-14-benzodiazepin-2-one	O
Halazepam	B-Drug
7-chloro-13-dihydro-5-phenyl-1-222-trifluoroethyl-2H-14-benzodiazepin-2-one	O
Haloxazolam	B-Drug
10-bromo-11b-o-fluorophenyl-23711b-tetrahydrooxazolo[32-d][14]benzodiazepin-65H-one	O
Ketazolam	B-Drug
11-chloro-812b-dihydro-28-dimethyl-12b-phenyl-4H-[13]-oxazino-[32-d][14]	O
benzodiazepine-476H-dione	O
Loprazolam	B-Drug
6-o-chlorophenyl-24-dihydro-2-[4-methyl-1-piperazinylmethylene]-8-nitro-1H-imidazo[12-a][14]benzodiazepin-1-one	O
Lorazepam	B-Drug
7-chloro-5-o-chlorophenyl-13-dihydro-3-hydroxy-2H-14-benzodiazepin-2-one	O
Lormetazepam	B-Drug
7-chloro-5-o-chlorophenyl-13-dihydro-3-hydroxy-1-methyl-2H-14-benzodiazepin-2-one	O
Medazepam	B-Drug
7-chloro-23-dihydro-1-methyl-5-phenyl-1H-14-benzodiazepine	O
Midazolam	B-Drug
8-chloro-6-o-fluorophenyl-1-methyl-4H-imidazo[15-a][14]benzodiazepine	O
Nimetazepam	B-Drug
13-dihydro-1-methyl-7-nitro-5-phenyl-2H-14-benzodiazepin-2-one	O
Nitrazepam	B-Drug
13-dihydro-7-nitro-5-phenyl-2H-14-benzodiazepin-2-one	O
Nordazepam	B-Drug
7-chloro-13-dihydro-5-phenyl-2H-14-benzodiazepin-2-one	O
Oxazepam	B-Drug
7-chloro-13-dihydro-3-hydroxy-5-phenyl-2H-14-benzodiazepin-2-one	O
Oxazolam	B-Drug
10-chloro-23711b-tetrahydro-2-methyl-11b-phenyloxazolo[32-d]	O
[14]benzodiazepin-65H-one	O
Pinazepam	B-Drug
7-chloro-13-dihydro-5-phenyl-1-2-propynyl-2H-14-benzodiazepin-2-one	O
Prazepam	B-Drug
7-chloro-1-cyclopropylmethyl-1	O
3-dihydro-5-phenyl-2H-14-benzodiazepin-2-one	O
Quazepam	B-Drug
7-chloro-5-o-fluorophenyl-13-dihydro-1-222-trifluoroethyl-2H-14-benzodiazepine-2-thione	O
Temazepam	B-Drug
7-chloro-13-dihydro-3-hydroxy-1-methyl-5-phenyl-2H-14-benzodiazepin-2-one	O
Tetrazepam	B-Drug
7-chloro-5-cyclohexen-1-yl-13-dihydro-1-methyl-2H-14-benzodiazepin-2-one	O
Triazolam	B-Drug
8-chloro-6-o-chlorophenyl-1-methyl-4H-s-triazolo[43-a][14]benzodiazepinebut	O
not	O
including:	O
Clozapine	B-Drug
8-chloro-11-4-methyl-1-piperazinyl-5H-dibenzo[be][14]diazepine	O
and	O
any	O
salt	O
thereof	O
Flunitrazepam	B-Drug
5-o-fluorophenyl-13-dihydro-1-methyl-7-nitro-2H-14-benzodiazepin-2-one	O
salts	O
or	O
derivatives	O
Olanzapine	B-Drug
2-methyl-4-4-methyl-1-piperazinyl-10H-thieno[23-b][15]benzodiazepine	O
its	O
N-oxide	O
8-chloro-11-4-methyl-4-oxido-1-piperazinyl-5H-dibenzo[be][14]diazepine	O
saltsCatha	O
edulis	O
Forsk	O

In	O
Australia	O
methylphenidate	B-Drug
is	O
a	O
'Schedule	O
8'	O
controlled	O
substance	O

Doses	O
of	O
200	O
mg	O
or	O
more	O
methamphetamine	B-Drug
are	O
considered	O
fatal	O

Small	O
doses	O
of	O
theophylline	B-Drug
may	O
inhibit	O
the	O
action	O
diazepam	B-Drug

The	O
subsequent	O
coroner's	O
report	O
determined	O
that	O
the	O
cause	O
of	O
death	O
was	O
a	O
cerebral	O
edema	O
caused	O
by	O
water	O
intoxication	O
hyponatraemia	O
secondary	O
to	O
use	O
MDMA	B-Drug

Of	O
these	O
analogues	O
only	O
4-methyl-GHB	O
-hydroxyvaleric	O
acid	B-Drug
GHV	O
and	O
a	O
prodrug	O
form	O
-valerolactone	O
GVL	O
have	O
been	O
reported	O
as	O
drugs	O
of	O
abuse	O
in	O
humans	O
on	O
the	O
available	O
evidence	O
seem	O
to	O
be	O
less	O
potent	O
but	O
more	O
toxic	O
than	O
GHB	B-Drug
with	O
particular	O
tendency	O
cause	O
nausea	O
vomiting	O

Legal	O
opium	B-Drug
production	O
in	O
India	O
is	O
much	O
more	O
traditional	O

6-Naltrexol	O
or	O
6-hydroxynaltrexone	O
is	O
a	O
major	O
active	O
metabolite	O
of	O
naltrexone	B-Drug
formed	O
by	O
hepatic	O
dihydrodiol	O
dehydrogenase	O
which	O
acts	O
as	O
potent	O
peripherally	O
selective	O
opioid	O
neutral	O
antagonist	O

Propylhexedrine	B-Drug
is	O
not	O
an	O
amphetamine	B-Drug
nor	O
even	O
a	O
phenethylamine	B-Drug
but	O
instead	O
can	O
be	O
referred	O
to	O
as	O
cycloalkylamine	O
or	O
more	O
specifically	O
cyclohexylethylamine	O
being	O
the	O
Na-dimethyl	O
derivative	O
of	O
2-cyclohexylethylamine	O

Barbituric	O
acid	O
is	O
a	O
chemical	O
building	O
block	O
in	O
laboratory	O
synthesis	O
riboflavin	O
vitamin	O
B2	O
and	O
method	O
of	O
producing	O
the	O
pharmaceutical	O
drug	O
minoxidil	B-Drug

Oxymorphone	B-Drug
crosses	O
the	O
placenta	O
and	O
holds	O
risk	O
of	O
birth	O
defects	O
poor	O
fetal	O
growth	O
stillbirth	O
preterm	O
delivery	O

Butylone	B-Drug
was	O
first	O
synthesized	O
by	O
Koeppe	O
Ludwig	O
and	O
Zeile	O
which	O
is	O
mentioned	O
in	O
their	O
1967	O
paper	O

Over	O
the	O
following	O
years	O
number	O
of	O
MDMA	B-Drug
samples	O
increased	O
eventually	O
exceeding	O
MDA	O
in	O
early	O
1980s	O

Pentazocine	B-Drug
is	O
used	O
primarily	O
to	O
treat	O
pain	O
although	O
its	O
analgesic	O
effects	O
are	O
subject	O
a	O
ceiling	O
effect	O

As	O
opposed	O
to	O
barbital	B-Drug
BZDs	O
are	O
not	O
GABA-receptor	O
activators	O
and	O
rely	O
on	O
increasing	O
the	O
neurotransmitter's	O
natural	O
activity	O

By	O
the	O
mid-1950s	O
14	O
pharmaceutical	O
companies	O
were	O
marketing	O
thalidomide	B-Drug
in	O
46	O
countries	O
under	O
at	O
least	O
37	O
different	O
trade	O
names	O

One	O
study	O
used	O
a	O
daily	O
dosage	O
of	O
300	O
mg	O
androstenedione	B-Drug
combined	O
with	O
several	O
other	O
supplements	O
and	O
also	O
found	O
no	O
increase	O
in	O
strength	O
when	O
compared	O
to	O
control	O
group	O
that	O
did	O
not	O
take	O
the	O

It	O
was	O
originally	O
a	O
Schedule	O
III	O
drug	O
in	O
the	O
United	O
States	O
under	O
Controlled	O
Substances	O
Act	O
but	O
1991	O
it	O
upgraded	O
to	O
II	O
several	O
years	O
after	O
discovered	O
that	O
misuse	O
combined	O
with	O
codeine	B-Drug
increased	O
effect	O
of	O
and	O
deaths	O
had	O
resulted	O
from	O
combination	O

Since	O
1961	O
the	O
international	O
Single	O
Convention	O
on	O
Narcotic	O
Drugs	O
has	O
required	O
countries	O
to	O
make	O
recreational	O
use	O
of	O
cocaine	B-Drug
a	O
crime	O

Although	O
25I-NBOMe	B-Drug
was	O
discovered	O
in	O
2003	O
it	O
did	O
not	O
emerge	O
as	O
a	O
common	O
recreational	O
drug	O
until	O
2010	O
when	O
first	O
sold	O
by	O
vendors	O
specializing	O
the	O
supply	O
of	O
designer	O
drugs	O

In	O
the	O
United	O
States:	O
Prednisolone	B-Drug
sodium	I-Drug
phosphate	I-Drug
oral	O
solution	O
Pediapred	O
acetate	I-Drug
suspension	O
Flo-Pred	O
tablets	O
Millipred	O
dissolving	O
Orapred	B-Drug
ODT	O
ophthalmic	O
Omnipred	O
Pred	O
Forte	O
As	O
a	O
glucocorticosteroid	O
unauthorized	O
or	O
ad	O
hoc	O
use	O
of	O
prednisolone	B-Drug
during	O
competition	O
via	O
intravenous	O
intramuscular	O
rectal	O
routes	O
is	O
banned	O
under	O
World	O
Anti-Doping	O
Agency	O
WADA	O
anti-doping	O
rules	O

Revlimid	B-Drug
is	O
available	O
only	O
in	O
a	O
restricted	O
distribution	O
setting	O
to	O
avoid	O
its	O
use	O
during	O
pregnancy	O

Nichols	O
in	O
the	O
early	O
1990s	O
while	O
investigating	O
non-neurotoxic	O
MDMA	B-Drug
analogues	O

A	O
number	O
of	O
medications	O
including	O
ondansetron	B-Drug
appear	O
to	O
be	O
effective	O
in	O
controlling	O
postoperative	O
nausea	O
and	O
vomiting	O

Diazepam	B-Drug
and	O
lorazepam	B-Drug
are	O
sometimes	O
used	O

Intranasal	O
fentanyl	B-Drug
appears	O
to	O
be	O
as	O
equally	O
effective	O
IV	O
morphine	B-Drug
and	O
superior	O
intramuscular	O
for	O
management	O
of	O
acute	O
hospital	O
pain	O

In	O
a	O
study	O
about	O
bromazepam's	O
negative	O
effects	O
on	O
psychomotor	O
skills	O
and	O
driving	O
ability	O
it	O
was	O
noted	O
that	O
3	O
mg	O
doses	O
caused	O
minimal	O
impairment	O
bromazepam	B-Drug

Currently	O
sufentanil	B-Drug
is	O
the	O
most	O
potent	O
opioid	O
painkiller	O
available	O
for	O
use	O
in	O
humans	O

British	O
troops	O
used	O
72	O
million	O
amphetamine	B-Drug
tablets	O
in	O
the	O
second	O
world	O
war	O
and	O
RAF	O
so	O
many	O
that	O
Methedrine	B-Drug
won	O
Battle	O
of	O
Britain	O
according	O
to	O
one	O
report	O

In	O
the	O
UK	O
fentanyl	B-Drug
is	O
classified	O
as	O
a	O
controlled	O
Class	O
A	O
drug	O
under	O
Misuse	O
of	O
Drugs	O
Act	O
1971	O

For	O
instance	O
the	O
CYP3A4	O
inducers	O
rifampicin	B-Drug
and	O
bosentan	B-Drug
have	O
been	O
found	O
to	O
decrease	O
norethisterone	B-Drug
exposure	O
by	O
42%	O
23%	O
respectively	O
carbamazepine	B-Drug
St	O

When	O
combined	O
with	O
clonidine	B-Drug
dextromethorphan	B-Drug
reduced	O
the	O
overall	O
time	O
needed	O
for	O
withdrawal	O
symptoms	O
to	O
peak	O
by	O
24	O
hours	O
while	O
reducing	O
severity	O
of	O
compared	O
alone	O

Ibuprofen	B-Drug
and	O
diclofenac	B-Drug
have	O
short	O
half-lives	O
23	O
hours	O

Amphetamine	B-Drug
can	O
enter	O
the	O
presynaptic	O
neuron	O
either	O
through	O
DAT	O
or	O
by	O
diffusing	O
across	O
neuronal	O
membrane	O
directly	O

Licorice	O
which	O
has	O
indirect	O
mineralocorticoid	O
activity	O
by	O
inhibiting	O
metabolism	O
been	O
found	O
to	O
inhibit	O
the	O
antimineralocorticoid	O
effects	O
of	O
spironolactone	B-Drug

Mimosa	O
verrucosa	O
DMT	O
in	O
root	O
bark	O
Mucuna	O
pruriens	O
The	O
leaves	O
seeds	O
stems	O
and	O
roots	O
contain	O
L-Dopa	B-Drug
Serotonin	O
5-HTP	O
Nicotine	B-Drug
as	O
well	O
NN-DMT	O
Bufotenine	B-Drug
5-MeO-DMT	B-Drug

J&J	O
has	O
faced	O
numerous	O
civil	O
lawsuits	O
on	O
behalf	O
of	O
children	O
who	O
were	O
prescribed	O
risperidone	B-Drug
grew	O
breasts	O
a	O
condition	O
called	O
gynecomastia;	O
as	O
July	O
2016	O
there	O
about	O
1500	O
cases	O
in	O
Pennsylvania	O
state	O
court	O
Philadelphia	O
and	O
had	O
been	O
February	O
2015	O
verdict	O
against	O
with	O
$2	O

Julian	O
also	O
announced	O
the	O
synthesis	O
starting	O
with	O
cheap	O
and	O
readily	O
available	O
pregnenolone	O
synthesized	O
from	O
soybean	B-Drug
oil	I-Drug
sterol	O
stigmasterol	O
of	O
steroid	O
cortexolone	O
known	O
as	O
Reichstein's	O
Substance	O
S	O
most	O
often	O
referred	O
11-Deoxycortisol	O
a	O
molecule	O
that	O
differed	O
cortisone	O
by	O
single	O
missing	O
oxygen	O
atom;	O
possibly	O
17-hydroxyprogesterone	O
pregnenetriolone	O
which	O
he	O
hoped	O
might	O
be	O
effective	O
in	O
treating	O
rheumatoid	O
arthritis	O
but	O
unfortunately	O
they	O
were	O
not	O

Intravenous	O
infusion	O
of	O
ketamine	B-Drug
has	O
never	O
been	O
directly	O
compared	O
with	O
intranasal	O
esketamine	B-Drug
but	O
a	O
comparative	O
meta-analysis	O
clinical	O
trials	O
indicates	O
the	O
superiority	O
intravenous	O
which	O
greater	O
overall	O
response	O
and	O
remission	O
rates	O
lower	O
number	O
dropouts	O

Though	O
6-APDB	O
does	O
not	O
substitute	O
for	O
amphetamine	B-Drug
in	O
rats	O
at	O
the	O
doses	O
used	O
referenced	O
study	O
based	O
on	O
its	O
vitro	O
profile	O
it	O
can	O
be	O
suggested	O
that	O
may	O
have	O
amphetamine-like	O
effects	O
higher	O

25I-NBOMe	B-Drug
has	O
been	O
linked	O
to	O
a	O
major	O
case	O
on	O
January	O
20	O
2016	O
in	O
Cork	O
Republic	O
of	O
Ireland	O
which	O
left	O
six	O
teenagers	O
hospitalized	O
one	O
whom	O
later	O
died	O

medical	O
cannabis	O
Cannabis	O
used	O
as	O
a	O
drug	O
for	O
purposes	O
legally	O
named	O
marijuana	O
or	O
marihuana	B-Drug
in	O
some	O
jurisdictions	O

However	O
PCP	B-Drug
has	O
little	O
affinity	O
for	O
the	O
human	O
monoamine	O
transporters	O
including	O
dopamine	O
transporter	O
DAT	O

It	O
was	O
concluded	O
that	O
at	O
least	O
in	O
the	O
models	O
employed	O
vitro	O
profile	O
of	O
fencamfamin	O
is	O
more	O
similar	O
to	O
nomifensine	O
a	O
reportedly	O
pure	O
uptake	O
inhibitor	O
than	O
d-amphetamine	B-Drug

Serious	O
side	O
effects	O
of	O
combined	O
oral	O
contraceptives	O
containing	O
desogestrel	B-Drug
may	O
include	O
venous	O
thromboembolism	O
arterial	O
hormone-dependent	O
tumors	O
e	O

After	O
ingestion	O
of	O
the	O
psilocybin	O
compound	O
alkaline	O
phosphatases	O
present	O
in	O
body's	O
digestive	O
system	O
kidneys	O
and	O
possibly	O
blood	O
readily	O
cleave	O
phosphoryl	O
ester	O
bond	O
from	O
yielding	O
hydroxyl	O
psilocin	B-Drug

Clonazepam	B-Drug
sold	O
under	O
the	O
brand	O
Klonopin	B-Drug
among	O
others	O
is	O
a	O
medication	O
used	O
to	O
prevent	O
and	O
treat	O
seizures	O
panic	O
disorder	O
movement	O
known	O
as	O
akathisia	O

Schneiderlin	O
recommended	O
the	O
use	O
of	O
hyoscine	O
and	O
morphine	B-Drug
for	O
surgical	O
anaesthesia	O
it	O
started	O
to	O
be	O
used	O
sporadically	O
that	O
purpose	O

An	O
estimated	O
17	O
million	O
people	O
as	O
of	O
2015	O
use	O
opiates	O
which	O
heroin	B-Drug
is	O
the	O
most	O
common	O
and	O
opioid	O
resulted	O
in	O
122000	O
deaths	O

Most	O
general	O
benzodiazepine	O
detection	O
tests	O
will	O
not	O
detect	O
Rohypnol:	O
the	O
drug	O
requires	O
a	O
test	O
specifically	O
designed	O
for	O
that	O
purpose	O
Rohypnol	B-Drug

Hyoscyamine	B-Drug
is	O
an	O
antimuscarinic;	O
i	O

Between	O
1992	O
and	O
1997	O
they	O
published	O
three	O
papers	O
on	O
the	O
effects	O
of	O
this	O
drug	O
in	O
rats	O
idea	O
that	O
it	O
could	O
potentially	O
be	O
used	O
treatment	O
depression	O
a	O
potential	O
replacement	O
for	O
Prozac	B-Drug

Diazepam	B-Drug
is	O
used	O
for	O
the	O
emergency	O
treatment	O
of	O
eclampsia	O
when	O
IV	O
magnesium	O
sulfate	O
and	O
blood-pressure	O
control	O
measures	O
have	O
failed	O

The	O
government	O
of	O
Colombian	O
President	O
lvaro	O
Uribe	O
has	O
resisted	O
criticism	O
aerial	O
spraying	O
coca	B-Drug
and	O
poppy	O
seen	O
major	O
reductions	O
in	O
both	O
crops	O
according	O
to	O
the	O
United	O
Nations	O
Office	O
Crime	O
Drugs	O
See	O
also	O
Plan	O
Colombia	O

The	O
presence	O
of	O
6-monoacetylcodeine	O
found	O
in	O
tar	O
heroin	O
has	O
not	O
been	O
tested	O
humans	O
but	O
shown	O
to	O
be	O
toxic	O
alone	O
and	O
more	O
when	O
mixed	O
with	O
mono-	O
or	O
di-	O
acetyl	O
morphine	B-Drug
potentially	O
making	O
than	O
refined	O
diamorphine	B-Drug

In	O
the	O
UK	O
fentanyl	B-Drug
is	O
classified	O
as	O
a	O
controlled	O
Class	O
A	O
drug	O
under	O
Misuse	O
of	O
Drugs	O
Act	O
1971	O

25C-NBOMe	B-Drug
is	O
derived	O
from	O
the	O
psychedelic	O
phenethylamine	B-Drug
2C-C	O
by	O
substitution	O
on	O
amine	O
with	O
a	O
2-methoxybenzyl	O
group	O

Cannabidiol	B-Drug
has	O
been	O
used	O
by	O
professional	O
and	O
amateur	O
athletes	O
across	O
disciplines	O
countries	O
with	O
the	O
World	O
Anti-Doping	O
Agency	O
removing	O
CBD	B-Drug
from	O
its	O
banned	O
substances	O
list	O

A	O
large	O
cohort	O
study	O
in	O
Denmark	O
found	O
addition	O
no	O
association	O
between	O
metoclopramide	B-Drug
exposure	O
and	O
miscarriage	O

Oxycodone	B-Drug
was	O
first	O
made	O
in	O
Germany	O
1916	O
from	O
thebaine	O

The	O
1931	O
Convention	O
for	O
Limiting	O
the	O
Manufacture	O
and	O
Regulating	O
Distribution	O
of	O
Narcotic	O
Drugs	O
League	O
Nations	O
included	O
oxycodone	B-Drug

It	O
is	O
unclear	O
if	O
fentanyl	B-Drug
gives	O
long-term	O
pain	O
relief	O
to	O
people	O
with	O
neuropathic	O

The	O
prescription	O
analgesic	O
tramadol	B-Drug
is	O
also	O
a	O
racemate	O

4	O
mg	O
of	O
intravenous	O
morphine	B-Drug

Pethidine	B-Drug
is	O
the	O
most	O
widely	O
used	O
opioid	O
in	O
labour	O
and	O
delivery	O
but	O
has	O
fallen	O
out	O
of	O
favour	O
some	O
countries	O
such	O
as	O
United	O
States	O
other	O
opioids	O
due	O
to	O
its	O
potential	O
drug	O
interactions	O
especially	O
with	O
serotonergics	O
neurotoxic	O
metabolite	O
norpethidine	B-Drug

Thirty	O
drops	O
of	O
this	O
laudanum	B-Drug
will	O
be	O
equal	O
to	O
one	O
grain	O
opium	B-Drug

Lysergic	O
acid	B-Drug
3-pentyl	O
amide	O
3-Pentyllysergamide	O
LSP	O
is	O
an	O
analogue	O
of	O
LSD	B-Drug
originally	O
researched	O
by	O
David	O
E	O

In	O
Entry	O
26	O
of	O
his	O
compendium	O
TiHKAL	O
which	O
discussed	O
LSD	B-Drug
chemist	O
Alexander	O
Shulgin	O
touched	O
briefly	O
on	O
the	O
subject	O
ALD-52	O

Psychological	O
dependence	O
has	O
also	O
been	O
linked	O
to	O
carisoprodol	B-Drug
use	O
although	O
this	O
is	O
much	O
less	O
severe	O
than	O
with	O
meprobamate	B-Drug
itself	O
presumably	O
due	O
the	O
slower	O
onset	O
of	O
effects	O

Hashish	B-Drug
also	O
spelled	O
hasheesh	O
hashisha	O
or	O
simply	O
hash	B-Drug
is	O
a	O
concentrated	O
resin	O
cake	O
ball	O
produced	O
from	O
pressed	O
kief	O
the	O
detached	O
trichomes	O
and	O
fine	O
material	O
that	O
falls	O
off	O
cannabis	O
fruits	O
flowers	O
leaves	O

In	O
the	O
pilot	O
episode	O
of	O
Breaking	O
Bad	O
a	O
container	O
iodine	O
is	O
visible	O
when	O
Walter	O
White	O
first	O
synthesizes	O
methamphetamine	B-Drug
through	O
Nagai	O
route	O
by	O
using	O
red	O
phosphorus	O
and	O
to	O
reduce	O
pseudoephedrine	O

Another	O
form	O
of	O
fentanyl	B-Drug
that	O
has	O
appeared	O
on	O
the	O
streets	O
is	O
Actiq	B-Drug
lollipop	O
formulation	O

Experiments	O
included	O
administering	O
LSD	B-Drug
to	O
CIA	O
employees	O
military	O
personnel	O
doctors	O
other	O
government	O
agents	O
prostitutes	O
mentally	O
ill	O
patients	O
and	O
members	O
of	O
the	O
general	O
public	O
in	O
order	O
study	O
their	O
reactions	O
usually	O
without	O
subjects'	O
knowledge	O

When	O
used	O
regularly	O
every	O
day	O
as	O
prescribed	O
inhaled	O
salmeterol	B-Drug
decreases	O
the	O
number	O
and	O
severity	O
of	O
asthma	O
attacks	O

The	O
most	O
common	O
side	O
effects	O
associated	O
with	O
alvimopan	B-Drug
are:	O
Alvimopan	B-Drug
is	O
absolutely	O
contraindicated	O
in	O
patients	O
who	O
have	O
taken	O
therapeutic	O
doses	O
of	O
opioids	O
for	O
more	O
than	O
seven	O
consecutive	O
days	O
immediately	O
prior	O
to	O
when	O
would	O
be	O
initiated	O
because	O
individuals	O
recent	O
exposure	O
are	O
expected	O
sensitive	O
the	O
-opioid	O
receptor	O
antagonists	O

This	O
is	O
so	O
that	O
if	O
people	O
take	O
the	O
medication	O
orally	O
which	O
way	O
they	O
are	O
meant	O
to	O
opioid	O
blocker	O
naloxone	B-Drug
has	O
minimal	O
effects	O
on	O
them	O
but	O
inject	O
it	O
becomes	O
bioavailable	O
and	O
hence	O
antagonises	O
of	O
tilidine	B-Drug
producing	O
withdrawal	O

However	O
in	O
spite	O
of	O
this	O
no	O
conclusive	O
evidence	O
an	O
interaction	O
between	O
bicalutamide	B-Drug
and	O
other	O
drugs	O
was	O
found	O
clinical	O
trials	O
nearly	O
3000	O
patients	O

Methamphetamine	B-Drug
was	O
synthesized	O
from	O
ephedrine	B-Drug
in	O
1893	O
by	O
Nagayoshi	O

PMA	B-Drug
first	O
came	O
into	O
circulation	O
in	O
the	O
early	O
1970s	O
where	O
it	O
was	O
used	O
intentionally	O
as	O
a	O
substitute	O
for	O
hallucinogenic	O
properties	O
of	O
LSD	B-Drug

After	O
approximately	O
ten	O
minutes	O
samples	O
with	O
CBD	B-Drug
exhibit	O
a	O
violet/purple/pink	O
color	O

Substituted	O
amphetamines	O
are	O
a	O
class	O
of	O
compounds	O
based	O
upon	O
the	O
amphetamine	B-Drug
structure;	O
it	O
includes	O
all	O
derivative	O
which	O
formed	O
by	O
replacing	O
or	O
substituting	O
one	O
more	O
hydrogen	O
atoms	O
in	O
core	O
structure	O
with	O
substituents	O

Tamoxifen	B-Drug
is	O
used	O
as	O
a	O
research	O
tool	O
to	O
trigger	O
tissue-specific	O
gene	O
expression	O
in	O
many	O
conditional	O
constructs	O
genetically	O
modified	O
animals	O
including	O
version	O
of	O
the	O
Cre-Lox	O
recombination	O
technique	O

Prozac	B-Drug
fluoxetine	B-Drug
an	O
antidepressant	O
of	O
the	O
SSRI	O
class	O

A	O
2007	O
analysis	O
estimated	O
MDMA	B-Drug
to	O
have	O
a	O
psychological	O
dependence	O
and	O
physical	O
potential	O
roughly	O
three-fourths	O
four-fifths	O
that	O
of	O
cannabis	O

Oral	O
levoketoconazole	O
may	O
have	O
a	O
lower	O
risk	O
of	O
liver	O
toxicity	O
than	O
oral	O
ketoconazole	B-Drug

Studies	O
acknowledge	O
that	O
cannabis	O
can	O
in	O
rare	O
cases	O
cause	O
adverse	O
reactions	O
but	O
is	O
generally	O
safer	O
than	O
any	O
commonly	O
consumed	O
drug	O
such	O
as	O
alcohol	O
tobacco	B-Drug
and	O
pharmaceuticals	O

In	O
the	O
United	O
States	O
drugs	O
containing	O
diphenoxylate	B-Drug
combined	O
with	O
atropine	O
salts	O
are	O
classified	O
as	O
Schedule	O
V	O
controlled	O
substances	O

International	O
treaties	O
and	O
the	O
controlled-substances	O
laws	O
of	O
most	O
countries	O
such	O
as	O
German	O
Betubungsmittelgesetz	O
regulate	O
dihydrocodeine	B-Drug
at	O
same	O
level	O
codeine	B-Drug

Dapsone	B-Drug
is	O
effective	O
and	O
safe	O
in	O
persons	O
with	O
moderate	O
severe	O
or	O
refractory	O
cutaneous	O
lupus	O
erythematosis	O

Short-term	O
addiction	O
studies	O
by	O
the	O
same	O
researchers	O
demonstrated	O
that	O
tolerance	O
developed	O
at	O
a	O
similar	O
rate	O
to	O
both	O
heroin	B-Drug
and	O
morphine	B-Drug

A	O
study	O
on	O
forensic	O
psychiatric	O
patients	O
who	O
had	O
abused	O
flunitrazepam	B-Drug
at	O
the	O
time	O
of	O
their	O
crimes	O
found	O
that	O
displayed	O
extreme	O
violence	O
lacked	O
ability	O
to	O
think	O
clearly	O
and	O
experienced	O
a	O
loss	O
empathy	O
for	O
victims	O
while	O
under	O
influence	O
it	O
was	O
abuse	O
alcohol	O
or	O
other	O
drugs	O
in	O
combination	O
with	O
compounded	O
problem	O

Levothyroxine	B-Drug
is	O
safe	O
and	O
effective	O
for	O
children	O
with	O
hypothyroidism;	O
the	O
goal	O
of	O
treatment	O
hypothyroidism	O
to	O
reach	O
preserve	O
normal	O
intellectual	O
physical	O
development	O

Hydrocodone	B-Drug
is	O
excreted	O
in	O
urine	O
mainly	O
the	O
form	O
of	O
conjugates	O

As	O
it	O
becomes	O
converted	O
to	O
psilocin	B-Drug
undergoes	O
a	O
first-pass	O
effect	O
whereby	O
its	O
concentration	O
is	O
greatly	O
reduced	O
before	O
reaches	O
the	O
systemic	O
circulation	O

Recreational	O
drug	O
users	O
commonly	O
use	O
nicotine	B-Drug
for	O
its	O
mood-altering	O
effects	O

Hashish	B-Drug
is	O
made	O
from	O
cannabinoid-rich	O
glandular	O
hairs	O
known	O
as	O
trichomes	O
well	O
varying	O
amounts	O
of	O
cannabis	O
flower	O
and	O
leaf	O
fragments	O

As	O
such	O
women	O
who	O
are	O
pregnant	O
should	O
never	O
take	O
dutasteride	B-Drug

Though	O
the	O
two	O
drugs	O
are	O
very	O
similar	O
in	O
effects	O
morphine	B-Drug
often	O
produces	O
more	O
intense	O
side	O
including	O
euphoria	O
constipation	O
miosis	O
physical	O
dependence	O
psychological	O
potentially	O
life-threatening	O
respiratory	O
depression	O
and	O
a	O
severe	O
addiction	O

It	O
is	O
described	O
as	O
similar	O
in	O
action	O
and	O
effect	O
to	O
danazol	B-Drug
which	O
also	O
used	O
the	O
treatment	O
of	O
endometriosis	O
but	O
reported	O
have	O
fewer	O
androgenic	O
side	O
effects	O
comparison	O

The	O
cocaine	B-Drug
is	O
then	O
broken	O
down	O
into	O
smaller	O
loads	O
for	O
smuggling	O
across	O
the	O
U	O

Therefore	O
patients	O
receiving	O
an	O
opioid	O
analgesic	O
general	O
anesthetics	O
phenothiazines	O
or	O
other	O
tranquilizers	O
sedatives	O
hypnotics	O
CNS	O
depressants	O
including	O
alcohol	O
concomitantly	O
with	O
Nalbuphine	B-Drug
may	O
exhibit	O
additive	O
effect	O

Esters	O
of	O
17-hydroxyprogesterone	O
and	O
19-norprogesterone	O
derivatives	O
like	O
hydroxyprogesterone	O
caproate	O
medroxyprogesterone	B-Drug
acetate	I-Drug
nomegestrol	O
are	O
active	O
themselves	O
not	O
prodrugs	O
whereas	O
esters	O
19-nortestosterone	B-Drug
norethisterone	O
enanthate	O

In	O
2013	O
overdose	O
on	O
amphetamine	B-Drug
methamphetamine	B-Drug
and	O
other	O
compounds	O
implicated	O
in	O
an	O
use	O
disorder	O
resulted	O
estimated	O
3788	O
deaths	O
worldwide	O
34254145	O
95%	O
confidence	O

Acamprosate	B-Drug
is	O
occasionally	O
used	O
in	O
addition	O
to	O
other	O
treatments	O
and	O
then	O
carried	O
on	O
into	O
long-term	O
use	O
reduce	O
the	O
risk	O
of	O
relapse	O

Amphetamine	B-Drug
is	O
eliminated	O
via	O
the	O
kidneys	O
with	O
3040%	O
of	O
drug	O
being	O
excreted	O
unchanged	O
at	O
normal	O
urinary	O
pH	O

Norethisterone	B-Drug
is	O
available	O
both	O
alone	O
brand	O
names	O
Camila	O
Errin	B-Drug
Heather	O
Micronor	B-Drug
Nor-QD	O
others	O
and	O
in	O
combination	O
with	O
EE	O
Norinyl	O
Ortho-Novum	O
or	O
mestranol	O
while	O
NETA	O
only	O
Norlestrin	O

Methylphenidate	B-Drug
is	O
most	O
active	O
at	O
modulating	O
levels	O
of	O
dopamine	O
DA	O
and	O
to	O
a	O
lesser	O
extent	O
norepinephrine	O

In	O
January	O
2010	O
a	O
similar	O
alert	O
was	O
issued	O
for	O
counterfeit	O
versions	O
of	O
the	O
over-the-counter	O
weight	O
loss	O
drug	O
Alli	B-Drug
sold	O
over	O
Internet	O

Salbutamol	B-Drug
has	O
been	O
used	O
to	O
treat	O
acute	O
hyperkalemia	O
as	O
it	O
stimulates	O
potassium	O
flow	O
into	O
cells	O
thus	O
lowering	O
the	O
in	O
blood	O

Examples	O
of	O
related	O
tropane	O
alkaloids	O
include	O
atropine	O
hyoscyamine	B-Drug
and	O
hyoscine	O

But	O
no	O
sooner	O
had	O
the	O
term	O
been	O
invented	O
or	O
Lewin	O
complained	O
that	O
word	O
does	O
not	O
cover	O
all	O
I	O
should	O
wish	O
it	O
to	O
convey	O
and	O
indeed	O
with	O
proliferation	O
of	O
research	O
following	O
discovery	O
LSD	B-Drug
came	O
numerous	O
attempts	O
improve	O
on	O
such	O
as	O
hallucinogen	O
phanerothyme	O
psychedelic	O
psychotomimetic	O
psychogenic	O
schizophrenogenic	O
cataleptogenic	O
mysticomimetic	O
psychodysleptic	O
entheogenic	O

Due	O
to	O
its	O
saturable	O
absorption	O
and	O
lack	O
of	O
acute	O
toxicity	O
overdose	O
darolutamide	B-Drug
is	O
not	O
expected	O
result	O
in	O
systemic	O
people	O
with	O
intact	O
hepatic	O
renal	O
function	O

]	O
sinsemilla	B-Drug
Spanish	O
for	O
without	O
seed	O
a	O
slang	O
name	O
high	O
quality	O
dried	O
cannabis	O

The	O
use	O
of	O
MDMA	B-Drug
in	O
Texas	O
clubs	O
declined	O
rapidly	O
after	O
criminalization	O
although	O
by	O
1991	O
the	O
drug	O
remained	O
popular	O
among	O
young	O
middle-class	O
whites	O
and	O
nightclubs	O

When	O
animals	O
are	O
given	O
morphine	B-Drug
chronically	O
they	O
develop	O
tolerance	O
to	O
its	O
pain-killing	O
effects	O
and	O
this	O
also	O
renders	O
the	O
tolerant	O
analgesic	O
of	O
N2O	O

Cyclization	O
of	O
N-phthaloyl-L-glutamine	O
occurs	O
using	O
carbonyldiimidazole	O
which	O
then	O
yields	O
thalidomide	B-Drug
3	O

For	O
chronic	O
pain	O
ketamine	B-Drug
is	O
used	O
as	O
an	O
intravenous	O
analgesic	O
particularly	O
if	O
the	O
neuropathic	O

Ketamine	B-Drug
principally	O
acts	O
as	O
an	O
antagonist	O
of	O
the	O
NMDA	O
receptor	O
ionotropic	O
glutamate	O

Concentrations	O
of	O
4-methylaminorex	B-Drug
were:	O
in	O
blood	O
21	O

The	O
peptide	O
sequence	O
is	O
Pyr-His-Trp-Ser-Tyr-D-Leu-Leu-Arg-Pro-NHEt	O
Pyr	O
History	O
==	O
Leuprorelin	B-Drug
was	O
discovered	O
and	O
first	O
patented	O
in	O
1973	O
introduced	O
for	O
medical	O
use	O
1985	O

Distribution	O
of	O
naloxone	B-Drug
to	O
individuals	O
likely	O
encounter	O
people	O
who	O
overdose	O
is	O
part	O
the	O
Harm	O
reduction	O
initiatives	O
that	O
have	O
spread	O
throughout	O
US	O
and	O
world	O

It	O
is	O
unlikely	O
that	O
a	O
person	O
would	O
overdose	O
on	O
nicotine	B-Drug
through	O
smoking	O
alone	O

Despite	O
the	O
side	O
effects	O
thalidomide	B-Drug
was	O
sold	O
in	O
pharmacies	O
Canada	O
until	O
1962	O

5F-APINACA	B-Drug
acts	O
as	O
a	O
full	O
agonist	O
with	O
binding	O
affinity	O
of	O
1	O

Hofmann	O
who	O
had	O
in	O
1938	O
created	O
LSD	B-Drug
led	O
a	O
research	O
group	O
that	O
isolated	O
and	O
identified	O
the	O
psychoactive	O
compounds	O
from	O
Psilocybe	O
mexicana	O

It	O
can	O
be	O
usually	O
prevented	O
by	O
potassium	O
supplements	O
or	O
combining	O
hydrochlorothiazide	B-Drug
with	O
a	O
potassium-sparing	O
diuretic	O
Other	O
disturbances	O
in	O
the	O
levels	O
of	O
serum	O
electrolytes	O
including	O
hypomagnesemia	O
low	O
magnesium	O
hyponatremia	O
sodium	O
and	O
hypercalcemia	O
high	O
calcium	O
Hyperuricemia	O
uric	O
acid	O
blood	O

The	O
patient	O
experienced	O
dizziness	O
and	O
sedation	O
so	O
they	O
were	O
tapered	O
off	O
ziprasidone	B-Drug
olanzapine	B-Drug
transitioned	O
to	O
quetiapine	B-Drug

diphenhydramine	B-Drug
9-tetrahydrocannabinol	O
e	O

As	O
of	O
October	O
31	O
2016;	O
25I-NBOMe	B-Drug
is	O
a	O
controlled	O
substance	O
Schedule	O
III	O
in	O
Canada	O

It	O
is	O
sold	O
under	O
many	O
trade	O
names	O
worldwide	O
including	O
Aplenzin	O
Budeprion	O
SR	O
Bup	O
Bupredol	O
Buproban	O
Bupropion	B-Drug
GSK	O
BuPROPion	O
HCL	O
Watson	O
Hydrochloride	O
Anchen	O
Apotex	O
Cadista	O
Mylan	O
Sandoz	O
buPROPion	O
actavis	O
Sun	O
Pharma	O
Torrent	O
Wockhardt	O
XL	O
Sanis	O
Health	O
Bupropionhydrochlorid	O
HEXAL	O
Bupropionhydrochloride	O
Buprotrin	O
Butrin	O
Buxon	O
Carmubine	O
Depnox-SR	O
Elontril	O
Forfivo	O
Funnix	O
Global	O
Le	O
Fu	O
Ting	O
Odranal	O
PMS-Bupropion	O
Prewell	O
Quomem	O
ratio-Bupropion	O
Voxra	O
Wellbutrin	B-Drug
Retard	O
XR	O
Yue	O
Zetron	O
Zyban	B-Drug
LP	O
Zybex	O
ZyGenerics	O
and	O
Zyntabac	O

Chemically	O
PCP	B-Drug
is	O
a	O
member	O
of	O
the	O
arylcyclohexylamine	O
class	O
and	O
pharmacologically	O
it	O
dissociative	O
anesthetic	O

Synonyms	O
used	O
to	O
refer	O
crack	B-Drug
cocaine	I-Drug
include	O
atari;	O
base;	O
bazooka;	O
beamers;	O
beemers;	O
bebe;	O
bee-bee;	O
berry;	O
bing;	O
bolo;	O
bomb;	O
boulder;	O
boulders;	O
butter;	O
caine;	O
cane;	O
Casper;	O
Casper	O
the	O
ghost;	O
cavvy;	O
chemical;	O
chewies;	O
cloud;	O
cloud	O
nine;	O
crills;	O
crunch	O
and	O
munch;	O
dip;	O
famous	O
dimes;	O
fan;	O
fish	O
scale;	O
fries;	O
fry;	O
glo;	O
golfball;	O
gravel;	O
grit;	O
hail;	O
hamburger;	O
helper;	O
hubba;	O
ice	O
cube;	O
kangaroo;	O
kibbles	O
bits;	O
kibbles;	O
krills;	O
lightem;	O
paste;	O
patico;	O
pebbles;	O
pee	O
wee;	O
pony;	O
raw;	O
ready;	O
ready	O
rocks;	O
redi	O
roca;	O
rock;	O
rooster;	O
rox;	O
Roxanne;	O
scud;	O
Scotty;	O
scramble;	O
scruples;	O
seven-up;	O
sherm;	O
sherms;	O
sleet;	O
snowballs;	O
stones;	O
teeth;	O
tension;	O
top	O
gun;	O
tweak;	O
ultimate;	O
wash;	O
white	O
work;	O
yahoo;	O
yale;	O
yay;	O
yayoo;	O
yeah-O;	O
yeyo;	O
yeo;	O
yuck	O

Oxymetholone	B-Drug
is	O
the	O
generic	O
name	O
of	O
drug	O
and	O
its	O
INN	O
USAN	O
USP	O
BAN	O
JAN	O
while	O
oxymtholone	O
DCF	O

Later	O
in	O
the	O
20th	O
century	O
addiction	O
to	O
opiates	O
especially	O
heroin	B-Drug
young	O
people	O
continued	O
rise	O
and	O
so	O
sale	O
prescription	O
of	O
was	O
limited	O
doctors	O
treatment	O
centers	O

The	O
largest	O
reduction	O
was	O
obtained	O
with	O
dexamethasone	B-Drug
36%	O
compared	O
to	O
placebo	O

In	O
1863	O
Mariani	O
started	O
marketing	O
a	O
wine	O
called	O
Vin	O
which	O
had	O
been	O
treated	O
with	O
coca	B-Drug
leaves	O
to	O
become	O
cocawine	O

1-Testosterone	B-Drug
abbreviated	O
and	O
nicknamed	O
as	O
1-Testo	O
1-T	O
also	O
known	O
1-dihydrotestosterone	O
1-DHT	O
well	O
dihydroboldenone	O
is	O
a	O
synthetic	O
anabolicandrogenic	O
steroid	O
AAS	O
5-reduced	O
derivative	O
of	O
boldenone	B-Drug
1-testosterone	B-Drug

Celecoxib	B-Drug
is	O
approximately	O
10-20	O
times	O
more	O
selective	O
for	O
COX-2	O
inhibition	O
over	O
COX-1	O

Miller	O
1971	O
opium	O
McQ	O
1974	O
heroin	B-Drug
and	O
cocaine	I-Drug
MDMA	B-Drug
2010	O
Mean	O
Streets	O
1973	O
The	O
Men	O
Who	O
Stare	O
At	O
Goats	O
2009	O
steroids	O
LSD	B-Drug
cannabis	O
amphetamine	B-Drug
Menace	O
II	O
Society	O
1993	O
crack	B-Drug
Miami	O
Vice	O
2006	O
Middle	O
barbiturates	O
Midnight	O
Cowboy	O
1969	O
marijuana	O
unspecified	O
hallucinogenic	O
pills	O
Express	O
1978	O
hashish	B-Drug
codeine	B-Drug
references	O
to	O
Midsommar	O
2019	O
psilocybin	O
mushrooms	O
A	O
Midsummer	O
Night's	O
Rave	O
2002	O
Mike	O
Dave	O
Need	O
Wedding	O
Dates	O
2016	O
Minority	O
Report	O
fictional	O
psychoactive	O
drug	O
Clarity	O
Missing	O
Link	O
1988	O
unidentified	O
plant	O
Modern	O
Times	O
1936	O
Mondo	O
Mod	O
1967	O
Moneyz	O
methamphetamine	B-Drug
Monkey	O
on	O
My	O
Back	O
1957	O
morphine	B-Drug
More	O
absinthe	O
Dexamyl	O
amphetamine-barbiturate	O
a	O
homemade	O
concoction	O
made	O
from	O
resin	B-Drug
benzedrine	B-Drug
red	O
ibogaine	B-Drug
nutmeg	O
banana	O
peel	O
Morfiy	O
2008	O
Morning	O
Patrol	O
1987	O
alcohol	O
La	O
morte	O
accarezza	O
mezzanotte	O
1972	O
Most	O
High	O
Mouth	O
2005	O
many	O
other	O
drugs	O
Mr	O

In	O
one	O
2002	O
survey	O
of	O
53	O
women	O
who	O
used	O
Rohypnol	B-Drug
recreationally	O
10%	O
said	O
they	O
were	O
physically	O
or	O
sexually	O
assaulted	O
while	O
under	O
its	O
influence	O

Allopregnanolone	B-Drug
SAGE-547	O
is	O
under	O
development	O
as	O
an	O
intravenous	O
therapy	O
for	O
the	O
treatment	O
of	O
super-refractory	O
status	O
epilepticus	O
postpartum	O
depression	O
and	O
essential	O
tremor	O

In	O
2016	O
Australian	O
heavyweight	O
boxing	O
champion	O
Lucas	O
Browne	O
tested	O
positive	O
for	O
clenbuterol	B-Drug

The	O
use	O
and	O
sale	O
of	O
oxycodone	B-Drug
OxyContin	B-Drug
Percocet	B-Drug
Percodan	B-Drug
hydrocodone	B-Drug
Vicodin	B-Drug
Lortab	B-Drug
anabolic	O
steroids	O
are	O
concern	O
to	O
the	O
Drug	O
Enforcement	O
Administration	O

Most	O
clomifene	B-Drug
metabolism	O
occurs	O
in	O
the	O
liver	O
where	O
it	O
undergoes	O
enterohepatic	O
recirculation	O

Wallace	O
Cameron	O
Ultra	O
Saline	O
Minipod	O
are	O
distributed	O
in	O
modern	O
needle-exchange	O
programmes	O
as	O
they	O
can	O
be	O
used	O
efficiently	O
either	O
by	O
injection	O
or	O
ophthalmic	O
if	O
the	O
drug	O
is	O
potent	O
small	O
doses	O
route	O
of	O
administer	O
which	O
compared	O
to	O
intravenous	O
use;	O
demonstration	O
elimination	O
latanoprost	B-Drug
acid	O
from	O
plasma	O
rapid	O
half-life	O
17	O
minutes	O
after	O
administration	O

In	O
March	O
2012	O
a	O
man	O
in	O
Australia	O
died	O
from	O
injuries	O
sustained	O
by	O
running	O
into	O
trees	O
and	O
power	O
poles	O
while	O
intoxicated	O
25I-NBOMe	B-Drug

The	O
other	O
for	O
Dr	O
Bateman's	O
Pectoral	O
Drops	O
is:	O
Opium	B-Drug
in	O
powder	O
catechu	O
camphor	O
gum	O
red	O
saunders	O
rasped	O
of	O
each	O
1/2	O
oz	O

Canada	O
criminalized	O
cannabis	O
in	O
The	O
Opium	B-Drug
and	O
Narcotic	O
Drug	O
Act	O
1923	O
before	O
any	O
reports	O
of	O
the	O
use	O
drug	O
but	O
eventually	O
legalized	O
its	O
consumption	O
for	O
recreational	O
medicinal	O
purposes	O
2018	O

Further	O
the	O
pharmaceutical	O
industry	O
began	O
synthesizing	O
various	O
opioids	O
such	O
as	O
propoxyphene	B-Drug
oxymorphone	B-Drug
and	O
oxycodone	B-Drug

Hence	O
desogestrel	B-Drug
and	O
etonogestrel	B-Drug
have	O
weak	O
glucocorticoid	O
activity	O

Brotizolam	B-Drug
induces	O
impairment	O
of	O
motor	O
function	O
and	O
has	O
hypnotic	O
properties	O

Drug	O
withdrawal	O
dependence	O
and	O
detoxification	O
Negative	O
depressive	O
cognitive	O
symptoms	O
of	O
schizophrenia	O
as	O
an	O
adjunct	O
A	O
case	O
report	O
has	O
been	O
published	O
in	O
which	O
mirtazapine	B-Drug
reduced	O
visual	O
hallucinations	O
a	O
patient	O
with	O
Parkinson's	O
disease	O
psychosis	O
PDP	O

Mirtazapine	B-Drug
is	O
a	O
potent	O
5-HT2A	O
receptor	O
antagonist	O
and	O
cyproheptadine	B-Drug
medication	O
that	O
shares	O
this	O
property	O
mediates	O
recovery	O
from	O
serotonin	O
syndrome	O
an	O
antidote	O
against	O
it	O

as	O
valproate	B-Drug
in	O
urine	O

Since	O
January	O
2009	O
Denmark	O
has	O
prescribed	O
diamorphine	B-Drug
to	O
a	O
few	O
addicts	O
who	O
have	O
tried	O
methadone	B-Drug
and	O
buprenorphine	B-Drug
without	O
success	O

Olanzapine	B-Drug
binds	O
all	O
receptors	O
and	O
is	O
used	O
to	O
treat	O
the	O
positive	O
negative	O
symptoms	O
of	O
schizophrenia	O
as	O
well	O
bipolar	O
disorder	O
depression	O

Manitoba	O
and	O
Quebec	O
are	O
currently	O
the	O
only	O
provinces	O
or	O
territories	O
where	O
legal	O
cannabis	O
age	O
is	O
not	O
identical	O
to	O
alcohol	O
tobacco	B-Drug
purchase	O
19	O
for	O
in	O
21	O
vs	O

Pethidine	B-Drug
has	O
been	O
shown	O
to	O
be	O
less	O
effective	O
than	O
morphine	B-Drug
diamorphine	B-Drug
or	O
hydromorphone	B-Drug
at	O
easing	O
severe	O
pain	O
associated	O
with	O
movement	O
coughing	O

In	O
contrast	O
with	O
several	O
other	O
antidepressant	O
drugs	O
venlafaxine	B-Drug
can	O
induce	O
a	O
rapid	O
onset	O
of	O
action	O
mainly	O
due	O
to	O
subsequent	O
norepinephrine	O
reuptake	O
inhibition	O

Like	O
other	O
opioids	O
diphenoxylate	B-Drug
acts	O
by	O
slowing	O
intestinal	O
contractions	O
allowing	O
the	O
body	O
to	O
consolidate	O
contents	O
and	O
prolong	O
transit	O
time	O
thus	O
intestines	O
draw	O
moisture	O
out	O
of	O
them	O
at	O
a	O
normal	O
or	O
higher	O
rate	O
therefore	O
stop	O
formation	O
loose	O
liquid	O
stools;	O
atropine	O
is	O
an	O
anticholinergic	O
present	O
prevent	O
drug	O
abuse	O
overdose	O

Diazepam	B-Drug
gel	O
was	O
better	O
than	O
placebo	O
in	O
reducing	O
the	O
risk	O
of	O
non-cessation	O
seizures	O

PCP	B-Drug
is	O
most	O
commonly	O
used	O
in	O
the	O
United	O
States	O

The	O
patches	O
should	O
be	O
kept	O
away	O
from	O
children	O
who	O
are	O
most	O
at	O
risk	O
fentanyl	B-Drug
overdose	O

It	O
is	O
more	O
specifically	O
a	O
derivative	O
of	O
norethisterone	B-Drug
17-ethynyl-19-nortestosterone	O
and	O
member	O
the	O
gonane	O
18-methylestrane	O
subgroup	O
19-nortestosterone	B-Drug
family	O
progestins	O

Unknown	O
fractions	O
of	O
both	O
the	O
opium	B-Drug
harvest	O
and	O
poppy	O
straw	O
residue	O
seed	O
were	O
diverted	O
to	O
illicit	O
uses	O

Diazepam	B-Drug
increases	O
the	O
serum	O
levels	O
of	O
phenobarbital	B-Drug

Tramadol	B-Drug
sold	O
under	O
the	O
brand	O
name	O
Ultram	B-Drug
among	O
others	O
is	O
an	O
opioid	O
pain	O
medication	O
used	O
to	O
treat	O
moderate	O
moderately	O
severe	O

The	O
majority	O
of	O
ibuprofen	B-Drug
is	O
metabolised	O
and	O
eliminated	O
within	O
24	O
hours	O
in	O
the	O
urine;	O
however	O
1%	O
unchanged	O
drug	O
removed	O
through	O
biliary	O
excretion	O

As	O
an	O
AAS	O
ethylestrenol	B-Drug
is	O
agonist	O
of	O
the	O
androgen	O
receptor	O
AR	O
similarly	O
to	O
androgens	O
like	O
testosterone	O
and	O
dihydrotestosterone	O
DHT	O

When	O
used	O
in	O
combination	O
with	O
paracetamol	B-Drug
the	O
analgesic	O
effect	O
has	O
been	O
proven	O
to	O
be	O
improved	O

Dexedrine	B-Drug
dextroamphetamine	B-Drug
sulfate	O
used	O
to	O
treat	O
attention	O
deficit	O
hyperactivity	O
disorder	O
and	O
narcolepsy	O

The	O
major	O
metabolite	O
of	O
bromazepam	B-Drug
is	O
hydroxybromazepam	O
which	O
an	O
active	O
agent	O
too	O
and	O
has	O
a	O
half-life	O
approximately	O
equal	O
to	O
that	O

Johnson	O
was	O
not	O
the	O
only	O
participant	O
whose	O
success	O
questioned:	O
Lewis	O
had	O
tested	O
positive	O
at	O
Olympic	O
Trials	O
for	O
pseudoephedrine	O
ephedrine	B-Drug
and	O
phenylpropanolamine	O

Amiloride	B-Drug
may	O
have	O
important	O
drug-drug	O
interactions	O
when	O
combined	O
with	O
other	O
medications	O
that	O
also	O
increase	O
potassium	O
levels	O
in	O
the	O
blood	O
leading	O
to	O
hyperkalemia	O

At	O
first	O
heroin	B-Drug
flowed	O
from	O
countries	O
where	O
it	O
was	O
still	O
legal	O
into	O
no	O
longer	O

In	O
2014	O
researchers	O
demonstrated	O
the	O
immunomodulatory	O
potential	O
of	O
DMT	O
and	O
5-MeO-DMT	B-Drug
through	O
Sigma-1	O
receptor	O
human	O
immune	O
cells	O

People	O
who	O
regularly	O
use	O
oxycodone	B-Drug
recreationally	O
or	O
at	O
higher	O
than	O
prescribed	O
doses	O
are	O
even	O
risk	O
of	O
severe	O
withdrawal	O
symptoms	O

In	O
a	O
variety	O
of	O
animal	O
models	O
PEA	B-Drug
seems	O
to	O
have	O
some	O
promise;	O
researchers	O
been	O
able	O
demonstrate	O
relevant	O
clinical	O
efficacy	O
in	O
disorders	O
from	O
multiple	O
sclerosis	O
neuropathic	O
pain	O

High	O
doses	O
of	O
the	O
antidepressant	O
fluvoxamine	B-Drug
may	O
potentiate	O
adverse	O
effects	O
ethyl	B-Drug
loflazepate	I-Drug

The	O
primary	O
mechanism	O
of	O
action	O
levonorgestrel	B-Drug
as	O
a	O
progestogen-only	O
emergency	O
contraceptive	O
pill	O
is	O
according	O
to	O
International	O
Federation	O
Gynecology	O
and	O
Obstetrics	O
FIGO	O
prevent	O
fertilization	O
by	O
inhibition	O
ovulation	O
thickening	O
cervical	O
mucus	O

A	O
1996	O
randomized	O
controlled	O
trial	O
which	O
involved	O
43	O
men	O
did	O
not	O
find	O
an	O
increase	O
in	O
the	O
occurrence	O
of	O
angry	O
behavior	O
during	O
10	O
weeks	O
administration	O
testosterone	B-Drug
enanthate	I-Drug
at	O
600	O
mg/week	O
but	O
this	O
study	O
screened	O
out	O
subjects	O
that	O
had	O
previously	O
abused	O
steroids	O
or	O
any	O
psychiatric	O
antecedents	O

Hashish	B-Drug
had	O
been	O
made	O
nominally	O
illegal	O
in	O
1957	O
allegedly	O
mostly	O
as	O
a	O
concession	O
to	O
US	O
pressure	O
but	O
persisted	O
common	O
drug	O
the	O
country	O

Club	O
drugs	O
vary	O
by	O
country	O
and	O
region;	O
in	O
some	O
regions	O
even	O
opiates	O
such	O
as	O
heroin	B-Drug
morphine	B-Drug
have	O
been	O
sold	O
at	O
clubs	O
though	O
this	O
practice	O
is	O
relatively	O
uncommon	O

National	O
Center	O
for	O
Health	O
Statistics	O
as	O
well	O
a	O
2006	O
series	O
in	O
the	O
Charleston	O
Gazette	O
West	O
Virginia	O
medical	O
examiners	O
listed	O
methadone	B-Drug
contributing	O
to	O
3849	O
deaths	O
2004	O

The	O
effect	O
on	O
IQ	O
cannot	O
be	O
determined	O
as	O
no	O
study	O
involves	O
phenytoin	B-Drug
monotherapy	O
however	O
poorer	O
language	O
abilities	O
and	O
delayed	O
motor	O
development	O
were	O
associated	O
with	O
use	O
during	O
pregnancy	O

Impaired	O
liver	O
function	O
people	O
with	O
lowered	O
hepatic	O
may	O
have	O
an	O
adverse	O
reaction	O
repeated	O
administration	O
of	O
lidocaine	B-Drug
because	O
the	O
drug	O
is	O
metabolized	O
by	O

25I-NBOMe	B-Drug
effects	O
usually	O
last	O
610	O
hours	O
if	O
taken	O
sublingually	O
or	O
buccally	O
between	O
gum	O
and	O
cheek	O

In	O
the	O
horror	O
video-game	O
Amnesia:	O
Rebirth	O
2020	O
laudanum	B-Drug
can	O
be	O
found	O
scarcely	O
and	O
used	O
to	O
decrease	O
player	O
character's	O
fear	O

In	O
2014	O
the	O
European	O
Association	O
for	O
Palliative	O
Care	O
recommended	O
oxycodone	B-Drug
by	O
mouth	O
as	O
a	O
second-line	O
alternative	O
to	O
morphine	B-Drug
cancer	O
pain	O

5	O
mg/day	O
norethisterone	B-Drug
and	O
NETA	O
respectively	O
did	O
not	O
significantly	O
stimulate	O
sebum	O
production	O
were	O
consequently	O
regarded	O
as	O
devoid	O
of	O
significant	O
androgenicity	O

Low	O
dose	O
morphine	B-Drug
may	O
help	O
chronic	O
cough	O
but	O
its	O
use	O
is	O
limited	O
by	O
side	O
effects	O

For	O
comparison	O
to	O
testosterone	O
methyltestosterone	B-Drug
is	O
at	O
least	O
as	O
potent	O
an	O
AAS	O

The	O
primary	O
pathway	O
involves	O
conversion	O
of	O
17-hydroxypregnenolone	O
to	O
DHEA	O
by	O
way	O
1720-lyase	O
with	O
subsequent	O
androstenedione	B-Drug
via	O
the	O
enzyme	O
3-hydroxysteroid	O
dehydrogenase	O

A	O
national	O
referendum	O
in	O
November	O
2008	O
showed	O
68%	O
of	O
voters	O
supported	O
the	O
plan	O
introducing	O
diamorphine	B-Drug
prescription	O
into	O
federal	O
law	O

The	O
drink	O
includes	O
a	O
massive	O
amount	O
of	O
the	O
opiate	O
codeine	B-Drug
which	O
can	O
be	O
addictive	O
in	O
high	O
doses	O
and	O
Fallieras	O
states	O
that	O
promethazine	B-Drug
has	O
at	O
least	O
anecdotally	O
been	O
noted	O
to	O
intensify	O
euphoric	O
effects	O
brain	O

Severe	O
manifestations	O
are	O
often	O
treated	O
with	O
Cyclophosphamide	B-Drug
or	O
Rituximab	B-Drug
and	O
three	O
doses	O
of	O
methylprednisolone	B-Drug
IV-pulse	O
treatment	O
as	O
recommended	O
by	O
ACR	O
guidelines	O
prior	O
to	O
switching	O
oral	O
prednisolone	B-Drug
azathioprine	B-Drug
for	O
maintenance	O

When	O
administered	O
via	O
intramuscular	O
injection	O
a	O
depot	O
is	O
formed	O
from	O
which	O
boldenone	B-Drug
undecylenate	I-Drug
slowly	O
released	O
into	O
the	O
body	O
and	O
then	O
transformed	O

In	O
April	O
2019	O
the	O
United	O
States	O
Food	O
and	O
Drug	O
Administration	O
FDA	O
stated	O
that	O
there	O
is	O
no	O
evidence	O
kratom	B-Drug
safe	O
or	O
effective	O
for	O
treating	O
any	O
condition	O
are	O
approved	O
clinical	O
uses	O

The	O
duration	O
of	O
action	O
fentanyl	B-Drug
has	O
sometimes	O
been	O
underestimated	O
leading	O
to	O
harm	O
in	O
a	O
medical	O
context	O

Medications	O
containing	O
natural	O
or	O
synthetic	O
cannabinoids	O
cannabinoid	O
analogs:	O
Dronabinol	O
Marinol	O
is	O
9-tetrahydrocannabinol	O
THC	O
used	O
as	O
an	O
appetite	O
stimulant	O
anti-emetic	O
and	O
analgesic	O
Nabilone	B-Drug
Cesamet	B-Drug
Canemes	O
a	O
analog	O
of	O

In	O
mainland	O
China	O
modafinil	B-Drug
is	O
strictly	O
controlled	O
like	O
other	O
stimulants	O
such	O
as	O
amphetamines	O
and	O
methylphenidate	B-Drug

The	O
ACMD	O
gave	O
their	O
advice	O
on	O
23	O
March	O
with	O
the	O
chair	O
commenting	O
that	O
evidence	O
shows	O
use	O
of	O
methoxetamine	B-Drug
can	O
cause	O
harm	O
to	O
users	O
and	O
advises	O
it	O
should	O
be	O
subject	O
a	O
temporary	O
class	O
drug	O
order	O

However	O
PCP	B-Drug
may	O
also	O
interact	O
with	O
allosteric	O
sites	O
on	O
the	O
monoamine	O
transporters	O
to	O
produce	O
inhibition	O
of	O
reuptake	O

Pyrazolam	O
has	O
structural	O
similarities	O
to	O
alprazolam	B-Drug
and	O
bromazepam	B-Drug

Sydenham's	O
1669	O
recipe	O
for	O
laudanum	B-Drug
mixed	O
opium	B-Drug
with	O
wine	O
saffron	O
clove	O
and	O
cinnamon	O

Examples	O
of	O
substituted	O
amphetamines	O
are	O
amphetamine	O
itself	O
methamphetamine	B-Drug
ephedrine	B-Drug
cathinone	B-Drug
phentermine	B-Drug
mephentermine	O
bupropion	B-Drug
methoxyphenamine	O
selegiline	B-Drug
amfepramone	B-Drug
pyrovalerone	B-Drug
MDMA	B-Drug
ecstasy	B-Drug
and	O
DOM	O
STP	O

Even	O
with	O
no	O
drug	O
in	O
production	O
Sanofi	O
sold	O
the	O
stanozolol	B-Drug
business	O
to	O
Ovation	O
Pharmaceuticals	O
2003	O
along	O
two	O
other	O
drugs	O

They	O
called	O
it	O
Brown	O
a	O
mixture	O
of	O
gunpowder	O
and	O
drug	O
cocaine	B-Drug

The	O
suppression	O
of	O
DHT	O
in	O
vivo	O
and	O
the	O
report	O
that	O
dutasteride	B-Drug
inhibits	O
5-R3	O
vitro	O
suggest	O
may	O
be	O
a	O
triple	O
5	O
reductase	O
inhibitor	O

RCS-4	B-Drug
or	O
1-pentyl-3-4-methoxybenzoylindole	O
is	O
a	O
synthetic	O
cannabinoid	O
drug	O
sold	O
under	O
the	O
names	O
SR-19	O
BTM-4	O
Eric-4	O
later	O
shortened	O
to	O
E-4	O
but	O
originally	O
OBT-199	O

Researchers	O
found	O
that	O
replacing	O
one	O
of	O
the	O
ethyl	O
groups	O
milnacipran	B-Drug
with	O
an	O
allyl	O
moiety	O
increases	O
norepinephrine	O
potency	O

Naproxen	B-Drug
may	O
have	O
antiviral	O
activity	O
against	O
influenza	O

In	O
July	O
2014	O
the	O
Medicines	O
and	O
Healthcare	O
products	O
Regulatory	O
Agency	O
MHRA	O
of	O
UK	O
issued	O
a	O
warning	O
about	O
potential	O
for	O
life-threatening	O
harm	O
from	O
accidental	O
exposure	O
to	O
transdermal	O
fentanyl	B-Drug
patches	O
particularly	O
in	O
children	O
advised	O
that	O
they	O
should	O
be	O
folded	O
with	O
adhesive	O
side	O
before	O
being	O
discarded	O

Following	O
application	O
of	O
the	O
patch	O
to	O
humans	O
an	O
average	O
25%	O
30%	O
selegiline	B-Drug
content	O
is	O
delivered	O
systemically	O
over	O
24	O
hours	O

Transdermal	O
fentanyl	B-Drug
has	O
also	O
been	O
used	O
for	O
many	O
years	O
in	O
dogs	O
and	O
cats	O
post-operative	O
analgesia	O

9	O
M	O
and	O
a	O
Ki	O
of	O
2511	O
nM	O
at	O
CB1	O
related	O
in	O
structure	O
to	O
nonsteroidal	O
anti-inflammatory	O
drugs	O
NSAIDs	O
such	O
as	O
indometacin	B-Drug

Lithium	O
though	O
can	O
cause	O
hyperthyroidism	O
but	O
most	O
often	O
hypothyroidism	O
by	O
affecting	O
iodine	O
metabolism	O
of	O
the	O
thyroid	O
itself	O
thus	O
inhibiting	O
synthetic	O
levothyroxine	B-Drug
as	O
well	O

Finasteride	B-Drug
is	O
a	O
5-reductase	O
inhibitor	O

Fresh	O
leaves	O
have	O
a	O
greater	O
ratio	O
of	O
cathinone	B-Drug
to	O
cathine	B-Drug
than	O
dried	O
ones	O
therefore	O
having	O
more	O
psychoactive	O
effects	O

The	O
largest	O
producer	O
today	O
is	O
Afghanistan	O
however	O
studies	O
suggest	O
there	O
a	O
hashish	B-Drug
revival	O
in	O
Morocco	O

All	O
drugs	O
in	O
the	O
NBOMe	O
series	O
including	O
25I-NBOMe	B-Drug
became	O
illegal	O
Russia	O
October	O
2011	O

This	O
is	O
usually	O
done	O
with	O
off-label	O
fentanyl	B-Drug
patches	O
manufactured	O
for	O
humans	O
chronic	O
pain	O

Some	O
individuals	O
contemplating	O
the	O
nature	O
of	O
DEA's	O
charter	O
advise	O
that	O
based	O
on	O
danger	O
DEA	O
should	O
be	O
most	O
focused	O
cocaine	B-Drug

Any	O
medications	O
with	O
the	O
ability	O
to	O
inhibit	O
or	O
induce	O
these	O
enzymes	O
may	O
interact	O
tramadol	B-Drug

Mescaline	B-Drug
induces	O
a	O
psychedelic	O
state	O
similar	O
to	O
those	O
produced	O
by	O
LSD	B-Drug
and	O
psilocybin	O
but	O
with	O
unique	O
characteristics	O

District	O
Court	O
for	O
the	O
of	O
Utah	O
ruled	O
FDA	O
did	O
not	O
have	O
proper	O
evidence	O
that	O
low	O
dosages	O
ephedrine	B-Drug
alkaloids	O
are	O
actually	O
unsafe	O
but	O
on	O
August	O
17	O
2006	O
U	O

In	O
1920	O
hydrocodone	B-Drug
was	O
prepared	O
by	O
Carl	O
Mannich	O
and	O
Helene	O
Lwenheim	O
deriving	O
it	O
from	O
codeine	B-Drug

In	O
this	O
vein	O
the	O
following	O
categories	O
are	O
often	O
used:	O
Psychedelics	O
Serotonergics	O
5-HT2A	O
receptor	O
agonists	O
or	O
classical	O
psychedelics	O
such	O
as	O
mescaline	B-Drug
from	O
peyote	O
Lophophora	O
williamsii	O
Indoles	O
/	O
Tryptamines	O
psilocybin	O
magic	O
mushrooms	O
Psilocybe	O
Ergolines	O
lysergol	O
morning	O
glory	O
Convolvulaceae	O
Lysergamides	O
LSD	B-Drug
acid	B-Drug
derived	O
ergot	O
Claviceps	O
purpurea	O
Beta-carbolines	O
monoamine	O
oxidase	O
inhibitors	O
MAOIs	O
specifically	O
reversible	O
of	O
A	O
RIMAs	O
harmala	O
alkaloids	O
norharman	O
ayahuasca	O
Banisteriopsis	O
caapi	O
Complexly	O
substituted	O
tryptamines	O
ibogaine	B-Drug
iboga	O
Tabernanthe	O
Phenethylamines	O
Empathogenentactogens	O
MDA	O
Substituted	O
methylenedioxyphenethylamines	O
serotonin	O
releasing	O
agents	O
MDMA	B-Drug
ecstasy	B-Drug
Cannabinoidergics	O
CB-1	O
atypical	O
THC	O
cannabis	O
Cannabis	O
Dissociatives	O
Antiglutamatergics	O
NMDA	O
antagonists	O
dissociatives	O
laughing	O
gas	O
nitrous	O
oxide	O
and	O
ketamine	B-Drug
Opioidergics	O
sometimes	O
regarded	O
-Opioid	O
salvinorin	O
Salvia	O
divinorum	O
pentazocine	B-Drug
Deliriants	O
Anticholinergics	O
muscarinic	O
acetylcholine	O
deliriants	O
tropane	O
atropine	O
deadly	O
nightshade	O
Atropa	O
belladonna	O
diphenhydramine	B-Drug
Benadryl	O
GABAergics	O
GABAA	O
some	O
positive	O
allosteric	O
modulators	O
muscimol	O
fly	O
agaric	O
Amanita	O
muscaria	O
zolpidem	B-Drug
Ambien	B-Drug
The	O
word	O
psychedelic	O
From	O
Ancient	O
Greek	O
psych	O
mind	O
soul	O
+	O
dlos	O
manifest	O
reveal	O
-ic	O
was	O
coined	O
to	O
express	O
idea	O
a	O
drug	O
that	O
may	O
hidden	O
but	O
real	O
aspect	O

Hydromorphone	B-Drug
is	O
extensively	O
metabolized	O
in	O
the	O
liver	O
to	O
hydromorphone-3-glucoronide	O
which	O
has	O
no	O
analgesic	O
effects	O

To	O
minimize	O
interactions	O
a	O
manufacturer	O
of	O
levothyroxine	B-Drug
recommends	O
after	O
taking	O
it	O
waiting	O
30	O
minutes	O
to	O
one	O
hour	O
before	O
eating	O
or	O
drinking	O
anything	O
that	O
is	O
not	O
water	O

Since	O
the	O
mid-1990s	O
MDMA	B-Drug
has	O
become	O
most	O
widely	O
used	O
amphetamine-type	O
drug	O
by	O
college	O
students	O
and	O
teenagers	O

Adrenergic	O
agonists	O
such	O
as	O
in	O
part	O
ephedrine	B-Drug
act	O
by	O
directly	O
binding	O
to	O
and	O
activating	O
adrenergic	O
receptors	O
producing	O
sympathomimetic	O
effects	O

In	O
Thailand	O
temazepam	B-Drug
is	O
a	O
Schedule	O
II	O
controlled	O
drug	O
under	O
the	O
Psychotropic	O
Substances	O
Act	O

BZP	B-Drug
and	O
TFMPP;	O
PMA/PMMA;	O
mephedrone	B-Drug
generally	O
used	O
outside	O
the	O
US	O
MDPV	B-Drug
TFMPP	B-Drug
PMA	B-Drug
PMMA	B-Drug

The	O
super-	O
or	O
subcritical	O
fluid	O
is	O
pumped	O
through	O
the	O
natural	O
product	O
and	O
mostly	O
mannitol	B-Drug
easily	O
separated	O
from	O
solvent	O
minute	O
amount	O
of	O
byproduct	O

It	O
was	O
first	O
reported	O
in	O
1915	O
and	O
this	O
followed	O
by	O
the	O
clinical	O
introduction	O
of	O
nalorphine	O
N-allylnormorphine	O
1954	O
naloxone	B-Drug
N-allyloxymorphone	O
1960	O
naltrexone	B-Drug
N-methylcyclopropyloxymorphone	O
1963	O

Isotretinoin	B-Drug
is	O
a	O
teratogen	O
with	O
number	O
of	O
potential	O
side-effects	O

Use	O
of	O
heroin	B-Drug
by	O
mouth	O
is	O
less	O
common	O
than	O
other	O
methods	O
administration	O
mainly	O
because	O
there	O
little	O
to	O
no	O
rush	O
and	O
the	O
effects	O
are	O
potent	O

Since	O
1994	O
the	O
production	O
dispensing	O
and	O
prescription	O
of	O
thalidomide	B-Drug
have	O
been	O
strictly	O
controlled	O
requiring	O
women	O
to	O
use	O
two	O
forms	O
birth	O
control	O
submit	O
regular	O
pregnancy	O
tests	O

However	O
drowsiness	O
hypotonia	O
and	O
most	O
significantly	O
tolerance	O
to	O
anti-seizure	O
effects	O
typically	O
develop	O
with	O
long-term	O
treatment	O
generally	O
limiting	O
Nitrazepam	B-Drug
acute	O
seizure	O
management	O

It	O
is	O
listed	O
under	O
the	O
Single	O
Convention	O
for	O
Control	O
of	O
Narcotic	O
Substances	O
1961	O
and	O
controlled	O
in	O
most	O
countries	O
same	O
fashion	O
as	O
morphine	B-Drug
or	O
heroin	B-Drug

Following	O
the	O
work	O
of	O
Henry	O
Dale	O
and	O
George	O
Barger	O
at	O
Burroughs-Wellcome	O
academic	O
chemist	O
Gordon	O
Alles	O
synthesized	O
amphetamine	B-Drug
tested	O
it	O
in	O
asthma	O
patients	O
1929	O

Excessive	O
consumption	O
of	O
alcohol	O
in	O
combination	O
with	O
nortriptyline	B-Drug
therapy	O
may	O
have	O
a	O
potentiating	O
effect	O
which	O
lead	O
to	O
the	O
danger	O
increased	O
suicidal	O
attempts	O
or	O
overdosage	O
especially	O
patients	O
histories	O
emotional	O
disturbances	O
ideation	O

powdered	O
opium	B-Drug
10	O
g	O

The	O
conjugate	O
base	O
is	O
valproate	B-Drug

Apalutamide	B-Drug
has	O
a	O
high	O
potential	O
for	O
drug	O
interactions	O

The	O
Guadalajara	O
Cartel	O
Spanish:	O
Crtel	O
de	O
was	O
a	O
Mexican	O
drug	O
cartel	O
which	O
formed	O
in	O
the	O
late	O
1970s	O
by	O
Rafael	O
Caro	O
Quintero	O
Miguel	O
ngel	O
Flix	O
Gallardo	O
and	O
Ernesto	O
Fonseca	O
Carrillo	O
order	O
to	O
ship	O
cocaine	B-Drug
marijuana	O
United	O
States	O

Amiloride's	O
chemical	O
structure	O
is	O
composed	O
of	O
a	O
substituted	O
pyrazine	O
ring	O
with	O
carbonylguanidinium	O
substituent	O
Amiloride	B-Drug

Naldemedine	B-Drug
brand	O
name	O
Symproic	O
in	O
the	O
US	O
and	O
Rizmoic	O
European	O
Union	O
is	O
a	O
medication	O
that	O
used	O
for	O
treatment	O
of	O
opioid-induced	O
constipation	O
adults	O
with	O
chronic	O
non-cancer	O
pain	O

Most	O
SNRIs	O
including	O
venlafaxine	B-Drug
desvenlafaxine	B-Drug
and	O
duloxetine	B-Drug
are	O
several	O
fold	O
more	O
selective	O
for	O
serotonin	O
over	O
norepinephrine	O
while	O
milnacipran	B-Drug
is	O
three	O
times	O
than	O

Opium	B-Drug
farming	O
also	O
increased	O
peaking	O
in	O
1930	O
when	O
the	O
League	O
of	O
Nations	O
singled	O
China	O
out	O
as	O
primary	O
source	O
illicit	O
opium	B-Drug
East	O
and	O
Southeast	O
Asia	O

Prucalopride	B-Drug
brand	O
name	O
Resolor	O
is	O
a	O
current	O
drug	O
approved	O
for	O
use	O
in	O
the	O
EU	O
since	O
October	O
15	O
2009	O
Canada	O
Resotran	O
December	O
7	O
2011	O
and	O
United	O
States	O
2018	O

The	O
popularisation	O
of	O
ecstasy	B-Drug
became	O
popular	O
mid	O
1990s	O
because	O
its	O
association	O
with	O
western	O
club	O
culture	O
and	O
Raves	O

A	O
more	O
recent	O
study	O
reported	O
presence	O
of	O
ergometrine	B-Drug
lysergol	O
lysergic	O
acid	B-Drug
and	O
other	O
alkaloids	O
that	O
contribute	O
to	O
its	O
pharmacological	O
effects	O

The	O
degree	O
of	O
tolerance	O
is	O
more	O
pronounced	O
with	O
clonazepam	B-Drug
than	O
chlordiazepoxide	B-Drug

On	O
October	O
24	O
1968	O
possession	O
of	O
LSD	B-Drug
was	O
made	O
illegal	O
in	O
the	O
United	O
States	O

In	O
the	O
UK	O
fentanyl	B-Drug
is	O
classified	O
as	O
a	O
controlled	O
Class	O
A	O
drug	O
under	O
Misuse	O
of	O
Drugs	O
Act	O
1971	O

Author	O
and	O
Yippie	O
Dana	O
Beal	O
co-wrote	O
the	O
1997	O
book	O
The	O
Ibogaine	B-Drug
Story	O

Sweden's	O
public	O
health	O
agency	O
suggested	O
classifying	O
AMB-FUBINACA	B-Drug
as	O
a	O
hazardous	O
substance	O
on	O
November	O
10	O
2014	O

In	O
the	O
United	O
States	O
all	O
CB1	O
receptor	O
agonists	O
of	O
3-1-naphthoylindole	O
class	O
such	O
as	O
JWH-424	B-Drug
are	O
Schedule	O
I	O
Controlled	O
Substances	O

of	O
etorphine	B-Drug
in	O
the	O
United	O
States	O
under	O
Controlled	O
Substances	O
Act	O
1970	O
and/or	O
its	O
pieces	O
morphine	B-Drug
carbon	O
skeleton	O
put	O
it	O
rule	O
thereof	O
1986	O
analogues	O
act;	O
does	O
not	O
have	O
own	O
ACSCN	O

The	O
most	O
popular	O
method	O
for	O
reducing	O
ephedrine	B-Drug
to	O
methamphetamine	B-Drug
is	O
similar	O
the	O
Birch	O
reduction	O
in	O
that	O
it	O
uses	O
anhydrous	O
ammonia	O
and	O
lithium	O
metal	O
reaction	O

Aminorex	B-Drug
has	O
been	O
shown	O
to	O
have	O
locomotor	O
stimulant	O
effects	O
lying	O
midway	O
between	O
dextroamphetamine	B-Drug
and	O
methamphetamine	B-Drug

Alirocumab	B-Drug
is	O
a	O
human	O
monoclonal	O
antibody	O
of	O
the	O
IgG1	O
isotype	O

Most	O
illicit	O
MDMA	B-Drug
is	O
synthesized	O
using	O
MDP2P	O
34-methylenedioxyphenyl-2-propanone	O
as	O
a	O
precursor	O

In	O
the	O
post	O
9/11	O
era	O
trading	O
between	O
borders	O
became	O
difficult	O
and	O
because	O
new	O
international	O
laws	O
were	O
set	O
into	O
place	O
opium	B-Drug
trade	O
more	O
diffused	O

People	O
who	O
regularly	O
use	O
oxycodone	B-Drug
recreationally	O
or	O
at	O
higher	O
than	O
prescribed	O
doses	O
are	O
even	O
risk	O
of	O
severe	O
withdrawal	O
symptoms	O

Clonazepam	B-Drug
is	O
not	O
recommended	O
for	O
patients	O
with	O
chronic	O
schizophrenia	O

Alcohol	O
and	O
nicotine	B-Drug
also	O
prime	O
the	O
brain	O
for	O
a	O
heightened	O
response	O
to	O
other	O
drugs	O
are	O
like	O
marijuana	O
typically	O
used	O
before	O
person	O
progresses	O
more	O
harmful	O
substances	O

Research	O
in	O
these	O
events	O
is	O
complicated	O
because	O
cannabis	O
often	O
used	O
conjunction	O
with	O
tobacco	B-Drug
and	O
drugs	O
such	O
as	O
alcohol	O
cocaine	B-Drug

Because	O
Liddle	O
phenotype	O
usually	O
involves	O
an	O
upregulation	O
of	O
ENaC	O
channels	O
leading	O
to	O
retention	O
sodium	O
and	O
water	O
hypokalemia	O
amiloride	B-Drug
is	O
useful	O
as	O
channel	O
inhibitor	O
due	O
its	O
promotion	O
excretion	O
potassium-sparing	O
effects	O
restoring	O
potassium	O
normal	O
levels	O

On	O
July	O
5	O
2010	O
former	O
Oakland	O
Raiders	O
quarterback	O
JaMarcus	O
Russell	O
was	O
arrested	O
at	O
his	O
home	O
in	O
Mobile	O
Alabama	O
for	O
possession	O
of	O
codeine	B-Drug
syrup	O
without	O
a	O
prescription	O

Early	O
adopters	O
included	O
players	O
for	O
Oklahoma	O
University	O
and	O
San	O
Diego	O
Chargers	O
head	O
coach	O
Sid	O
Gillman	O
who	O
administered	O
Dianabol	B-Drug
to	O
his	O
team	O
starting	O
in	O
1963	O

The	O
newest	O
formulation	O
to	O
come	O
out	O
was	O
in	O
2014	O
when	O
zohydro	O
an	O
increased	O
dosage	O
formula	O
of	O
hydrocodone	B-Drug
released;	O
this	O
it	O
is	O
the	O
strongest	O
yet	O
created	O
for	O
pain	O
management	O
on	O
par	O
with	O
moderate	O
dose	O
oxycodone	B-Drug

These	O
levels	O
of	O
morphine	B-Drug
obtained	O
from	O
exhausted	O
plants	O
suggests	O
that	O
for	O
producers	O
licit	O
opium	O
poppy	O
straw	O
may	O
be	O
a	O
profitable	O
second	O
crop	O

The	O
other	O
hypnotics	O
used	O
as	O
no-go	O
pills	O
are	O
temazepam	B-Drug
and	O
zolpidem	B-Drug
which	O
both	O
have	O
longer	O
mandatory	O
recovery	O
periods	O

Antiandrogens	O
like	O
cyproterone	O
acetate	O
spironolactone	B-Drug
and	O
bicalutamide	B-Drug
can	O
block	O
both	O
the	O
anabolic	O
androgenic	O
effects	O
of	O
NPP	O

Cocaine	B-Drug
written	O
by	O
Sydney	O
Bennett	O
Matthew	O
Martin	O
Anthony	O
Negrete	O
and	O
Vyron	O
Turner;	O
produced	O
The	O
Internet	O

Life-threatening	O
overdose	O
of	O
opium	B-Drug
tincture	O
owes	O
to	O
the	O
preparation's	O
morphine	B-Drug
content	O

The	O
most	O
common	O
antipyretics	O
in	O
the	O
United	O
States	O
are	O
ibuprofen	B-Drug
and	O
aspirin	B-Drug
which	O
nonsteroidal	O
anti-inflammatory	O
drugs	O
NSAIDs	O
used	O
primarily	O
as	O
analgesics	O
pain	O
relievers	O
but	O
also	O
have	O
antipyretic	O
properties;	O
paracetamol	B-Drug
acetaminophen	B-Drug
an	O
analgesic	O
with	O
weak	O
properties	O

Oxycodone	B-Drug
is	O
used	O
for	O
managing	O
moderate	O
to	O
severe	O
acute	O
or	O
chronic	O
pain	O
when	O
other	O
treatments	O
are	O
not	O
sufficient	O

Those	O
convicted	O
of	O
HS	O
11378	O
possession	O
amphetamines	B-Drug
for	O
sale	O
may	O
receive	O
anything	O
from	O
probation	O
up	O
to	O
4	O
years	O
in	O
prison	O

Some	O
gamers	O
have	O
even	O
claimed	O
that	O
pills	B-Drug
are	O
regularly	O
sold	O
at	O
professional	O
tournaments	O

Ketamine	B-Drug
potentiates	O
the	O
sedative	O
effects	O
of	O
propofol	B-Drug
and	O
midazolam	B-Drug

Spironolactone	B-Drug
is	O
also	O
known	O
by	O
its	O
developmental	O
code	O
names	O
SC-9420	O
and	O
NSC-150339	O

In	O
the	O
second	O
half	O
of	O
20th	O
century	O
dealers	O
and	O
chemists	O
loosely	O
associated	O
with	O
Grateful	O
Dead	O
like	O
Owsley	O
Stanley	O
Nicholas	O
Sand	O
Karen	O
Horning	O
Sarah	O
Maltzer	O
Dealer	O
McDope	O
Leonard	O
Pickard	O
played	O
an	O
essential	O
role	O
in	O
distributing	O
LSD	B-Drug

Sveriges	O
riksdag	O
added	O
butylone	B-Drug
to	O
schedule	O
I	O
substances	O
plant	O
materials	O
and	O
fungi	O
which	O
normally	O
do	O
not	O
have	O
medical	O
use	O
as	O
narcotics	O
in	O
Sweden	O
of	O
Feb	O
1	O
2010	O
published	O
by	O
Medical	O
Products	O
Agency	O
their	O
regulation	O
LVFS	O
2010:1	O
listed	O
Butylon	O
1-13-bensodioxol-5-yl-2-metylaminobutan-1-on	O

Chronic	O
cocaine	B-Drug
intake	O
causes	O
strong	O
imbalances	O
of	O
transmitter	O
levels	O
in	O
order	O
to	O
compensate	O
extremes	O

Through	O
the	O
same	O
blockade	O
of	O
NMDA	O
receptor	O
ketamine	B-Drug
is	O
also	O
effective	O
as	O
a	O
painkiller	O

In	O
1956	O
the	O
first	O
antidepressant	O
iproniazid	O
was	O
accidentally	O
created	O
during	O
an	O
experiment	O
while	O
synthesizing	O
isoniazid	B-Drug

Management	O
of	O
GHB	B-Drug
dependence	O
involves	O
considering	O
the	O
person's	O
age	O
comorbidity	O
and	O
pharmacological	O
pathways	O

Its	O
affinity	O
for	O
the	O
androgen	O
receptor	O
is	O
specifically	O
about	O
64%	O
of	O
that	O
norethandrolone	B-Drug

Diazepam	B-Drug
drug	O
misuse	O
can	O
occur	O
either	O
through	O
recreational	O
where	O
the	O
is	O
taken	O
to	O
achieve	O
a	O
high	O
or	O
when	O
continued	O
long	O
term	O
against	O
medical	O
advice	O

The	O
government	O
of	O
North	O
Korea	O
currently	O
operates	O
methamphetamine	B-Drug
production	O
facilities	O

Serotonin	O
depletion	O
following	O
MDMA	B-Drug
use	O
can	O
cause	O
depression	O
in	O
subsequent	O
days	O

The	O
Advisory	O
Council	O
on	O
the	O
Misuse	O
of	O
Drugs	O
ACMD	O
report	O
ecstasy	B-Drug
based	O
a	O
12-month	O
study	O
4000	O
academic	O
papers	O
concluded	O
that	O
it	O
is	O
nowhere	O
near	O
as	O
dangerous	O
other	O
class	O
A	O
drugs	O
such	O
heroin	B-Drug
and	O
crack	O
cocaine	O
should	O
be	O
downgraded	O
to	O
B	O

South	O
Korea	O
officially	O
added	O
JWH-018	B-Drug
CP	O
47497	O
and	O
HU-210	B-Drug
to	O
the	O
controlled	O
substance	O
list	O
on	O
July	O
1	O
2009	O
effectively	O
making	O
these	O
chemicals	O
illegal	O

Continual	O
daily	O
doses	O
of	O
diazepam	B-Drug
quickly	O
build	O
to	O
a	O
high	O
concentration	O
in	O
the	O
body	O
mainly	O
adipose	O
tissue	O
far	O
excess	O
actual	O
dose	O
for	O
any	O
given	O
day	O

In	O
his	O
spare	O
time	O
Hashish	B-Drug
enjoys	O
landscape	O
architecture	O
skiing	O
fishing	O
and	O
travelling	O

The	O
attorneys	O
general	O
of	O
Connecticut	O
and	O
Pennsylvania	O
have	O
launched	O
investigations	O
into	O
its	O
diversion	O
from	O
the	O
legitimate	O
pharmaceutical	O
market	O
including	O
Cephalon's	O
sales	O
promotional	O
practices	O
for	O
Provigil	B-Drug
Actiq	B-Drug
Gabitril	B-Drug

Salmeterol	B-Drug
has	O
an	O
aryl	O
alkyl	O
group	O
with	O
a	O
chain	O
length	O
of	O
11	O
atoms	O
from	O
the	O
amine	O

Major	O
17-alkylated	O
AAS	O
include	O
the	O
testosterone	O
derivatives	O
fluoxymesterone	B-Drug
metandienone	B-Drug
methandrostenolone	B-Drug
and	O
methyltestosterone	B-Drug
DHT	O
oxandrolone	B-Drug
oxymetholone	B-Drug
stanozolol	B-Drug

It	O
is	O
also	O
used	O
as	O
a	O
recreational	O
drug	O
often	O
mixed	O
with	O
heroin	B-Drug
or	O
cocaine	B-Drug

In	O
recent	O
years	O
patients	O
doctors	O
nurses	O
those	O
working	O
in	O
the	O
addiction	O
field	O
and	O
advocates	O
of	O
many	O
kinds	O
have	O
heavily	O
criticized	O
extremely	O
tight	O
regulations	O
regarding	O
take-home	O
methadone	B-Drug

Additionally	O
patients	O
are	O
able	O
to	O
get	O
doses	O
of	O
methadone	B-Drug
and	O
addiction	O
medications	O
like	O
buprenorphine	B-Drug
without	O
an	O
in-person	O
visit	O

In	O
2014	O
however	O
it	O
was	O
reported	O
that	O
the	O
presence	O
of	O
tramadol	B-Drug
in	O
tree	O
roots	O
result	O
having	O
been	O
administered	O
to	O
cattle	O
by	O
farmers	O
region:	O
and	O
its	O
metabolites	O
were	O
present	O
animals'	O
excreta	O
which	O
contaminated	O
soil	O
around	O
trees	O

In	O
common	O
with	O
other	O
opioids	O
oxymorphone	B-Drug
overdosage	O
is	O
characterized	O
by	O
respiratory	O
depression	O
sleepiness	O
progressing	O
to	O
stupor	O
or	O
coma	O
skeletal	O
muscle	O
weakness	O
cold	O
and	O
clammy	O
skin	O
sometimes	O
slow	O
heart	O
rate	O
low	O
blood	O
pressure	O

Lidocaine	B-Drug
is	O
often	O
given	O
intravenously	O
as	O
an	O
antiarrhythmic	O
agent	O
in	O
critical	O
cardiac-care	O
situations	O

The	O
therapeutic	O
activity	O
of	O
dextromethorphan	B-Drug
is	O
believed	O
to	O
be	O
caused	O
by	O
both	O
the	O
drug	O
and	O
this	O
metabolite	O

In	O
addition	O
to	O
epilepsy	O
and	O
severe	O
anxiety	O
clobazam	B-Drug
is	O
also	O
approved	O
as	O
a	O
short-term	O
24	O
weeks	O
adjunctive	O
agent	O
in	O
schizophrenia	O
other	O
psychotic	O
disorders	O
manage	O
or	O
agitation	O

Rifampin	B-Drug
phenytoin	B-Drug
carbamazepine	B-Drug
and	O
phenobarbital	B-Drug
increase	O
the	O
metabolism	O
of	O
diazepam	B-Drug
thus	O
decreasing	O
drug	O
levels	O
effects	O

JWH-018	B-Drug
has	O
an	O
EC50	O
of	O
102	O
nM	O
for	O
human	O
CB1	O
receptors	O
and	O
133	O
CB2	O

Patients	O
should	O
be	O
monitored	O
for	O
decreased	O
therapeutic	O
effects	O
of	O
clozapine	B-Drug
if	O
carbamazepine	B-Drug
is	O
started	O
or	O
increased	O

A	O
study	O
assessed	O
the	O
interaction	O
of	O
spironolactone	B-Drug
and	O
7-TS	O
with	O
sex	O
hormone-binding	O
globulin	O
found	O
that	O
they	O
had	O
very	O
low	O
affinity	O
for	O
this	O
carrier	O
protein	O

The	O
second	O
class	O
of	O
opium	B-Drug
users	O
included	O
doctors	O
nurses	O
and	O
other	O
health	O
professionals	O
who	O
used	O
the	O
drug	O
as	O
a	O
strategy	O
for	O
coping	O
with	O
stress	O
their	O
work	O

In	O
the	O
1960s	O
thalidomide	B-Drug
was	O
successfully	O
marketed	O
as	O
a	O
safer	O
alternative	O
to	O
barbiturates	O

When	O
the	O
term	O
was	O
coined	O
in	O
1980s	O
a	O
wide	O
range	O
of	O
narcotics	O
were	O
being	O
sold	O
as	O
heroin	B-Drug
on	O
black	O
market	O

Delusional	O
aggressive	O
or	O
dissociated	O
behaviour	O
at	O
very	O
high	O
doses	O
20+	O
mg	O
Risk	O
of	O
death	O
If	O
misrepresented	O
as	O
LSD	B-Drug
5-MeO-AMT	O
can	O
be	O
extremely	O
dangerous;	O
users	O
may	O
take	O
a	O
number	O
hits	O
assuming	O
that	O
it	O
is	O

5	O
mg	O
or	O
1	O
of	O
clonazepam	B-Drug

Other	O
transporters	O
that	O
methamphetamine	B-Drug
is	O
known	O
to	O
inhibit	O
are	O
SLC22A3	O
and	O
SLC22A5	O

Apalutamide	B-Drug
is	O
an	O
antiandrogen	O
and	O
acts	O
as	O
antagonist	O
of	O
the	O
androgen	O
receptor	O
biological	O
target	O
androgens	O
like	O
testosterone	O
dihydrotestosterone	O

Benzodiazepines	O
are	O
used	O
initially	O
to	O
control	O
convulsions	O
with	O
stronger	O
anticonvulsants	O
such	O
as	O
phenytoin	B-Drug
or	O
thiopental	B-Drug
if	O
continue	O

On	O
May	O
16	O
1994	O
Roussel-Uclaf	O
announced	O
it	O
was	O
donating	O
without	O
remuneration	O
all	O
rights	O
for	O
medical	O
uses	O
of	O
mifepristone	B-Drug
in	O
the	O
United	O
States	O
to	O
Population	O
Council	O
which	O
subsequently	O
licensed	O
Danco	O
Laboratories	O
a	O
new	O
single-product	O
company	O
immune	O
antiabortion	O
boycotts	O
won	O
FDA	O
approval	O
as	O
Mifeprex	B-Drug
on	O
September	O
28	O
2000	O

25	O
times	O
more	O
potent	O
than	O
morphine	B-Drug
and	O
17	O
U-62066	O

The	O
decision	O
to	O
withdraw	O
co-proxamol	B-Drug
has	O
met	O
with	O
some	O
controversy;	O
it	O
been	O
brought	O
up	O
in	O
the	O
House	O
of	O
Commons	O
on	O
two	O
occasions	O
13	O
July	O
2005	O
and	O
17	O
January	O
2007	O

Nandrolone	B-Drug
also	O
known	O
as	O
19-nortestosterone	B-Drug
19-NT	O
or	O
estrenolone	O
well	O
estra-4-en-17-ol-3-one	O
19-norandrost-4-en-17-ol-3-one	O
is	O
a	O
naturally	O
occurring	O
estrane	O
19-norandrostane	O
steroid	O
and	O
derivative	O
of	O
testosterone	O
androst-4-en-17-ol-3-one	O

Furthermore	O
[the]	O
neurochemical	O
effects	O
[of	O
modafinil]	O
and	O
anatomical	O
pattern	O
of	O
brain	O
area	O
activation	O
differ	O
from	O
typical	O
psychostimulants	O
are	O
consistent	O
with	O
its	O
beneficial	O
on	O
cognitive	O
performance	O
processes	O
such	O
as	O
attention	O
learning	O
memory	O
a	O
study	O
found	O
that	O
modafinil-induced	O
increased	O
locomotor	O
activity	O
in	O
animals	O
was	O
dependent	O
histamine	O
release	O
could	O
be	O
abolished	O
by	O
depletion	O
neuronal	O
whereas	O
those	O
methylphenidate	B-Drug
were	O
not	O
modafinil	B-Drug

Methaqualone	B-Drug
became	O
increasingly	O
popular	O
as	O
a	O
recreational	O
drug	O
in	O
the	O
late	O
1960s	O
and	O
1970s	O
known	O
variously	O
ludes	O
or	O
sopers	O
also	O
soaps	O
United	O
States	O
mandrakes	O
mandies	O
UK	O
Australia	O
New	O
Zealand	O

The	O
price	O
of	O
opium	B-Drug
paste	O
is	O
fixed	O
by	O
the	O
government	O
according	O
to	O
quality	O
and	O
quantity	O
tendered	O

before	O
endoscopic	O
or	O
surgical	O
procedures	O
Treatment	O
of	O
complications	O
with	O
a	O
hallucinogen	O
crisis	O
and	O
stimulant	O
overdoses	O
psychosis	O
such	O
as	O
LSD	B-Drug
cocaine	B-Drug
methamphetamineUsed	O
in	O
treatment	O
organophosphate	O
poisoning	O
reduces	O
the	O
risk	O
seizure	O
induced	O
brain	O
cardiac	O
damage	O

Intravenous	O
injections	B-Drug
may	O
also	O
be	O
used	O
for	O
recreational	O
drugs	O
when	O
a	O
rapid	O
onset	O
of	O
effects	O
is	O
desired	O

In	O
surveys	O
the	O
number	O
of	O
high	O
school	O
students	O
admitting	O
to	O
trying	O
PCP	B-Drug
at	O
least	O
once	O
fell	O
from	O
13%	O
in	O
1979	O
less	O
than	O
3%	O
1990	O

The	O
muscle	O
relaxant	O
properties	O
of	O
diazepam	B-Drug
are	O
produced	O
via	O
inhibition	O
polysynaptic	O
pathways	O
in	O
the	O
spinal	O
cord	O

The	O
natriuretic	O
effects	O
of	O
progesterone	O
were	O
demonstrated	O
in	O
1955	O
and	O
the	O
development	O
spironolactone	B-Drug
as	O
a	O
synthetic	O
antimineralocorticoid	O
analogue	O
shortly	O
followed	O
this	O

Glidden's	O
cost	O
of	O
production	O
cortexolone	O
was	O
relatively	O
high	O
so	O
Upjohn	O
decided	O
to	O
use	O
progesterone	O
available	O
in	O
large	O
quantity	O
at	O
low	O
from	O
Syntex	O
produce	O
cortisone	O
and	O
hydrocortisone	B-Drug

Flutamide	O
has	O
far	O
lower	O
affinity	O
for	O
the	O
AR	O
than	O
do	O
steroidal	O
antiandrogens	O
like	O
spironolactone	B-Drug
and	O
cyproterone	O
acetate	O
it	O
is	O
a	O
relatively	O
weak	O
antiandrogen	O
in	O
terms	O
of	O
potency	O
by	O
weight	O
but	O
large	O
dosages	O
at	O
which	O
flutamide	O
used	O
appear	O
to	O
compensate	O
this	O

Sleeping	O
pills	O
including	O
eszopiclone	B-Drug
have	O
been	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
death	O

Richwood	O
Pharmaceuticals	O
which	O
later	O
merged	O
with	O
Shire	O
plc	O
introduced	O
the	O
current	O
Adderall	B-Drug
brand	O
in	O
1996	O
as	O
an	O
instant-release	O
tablet	O

Analogues	O
of	O
PCP	B-Drug
exhibit	O
varying	O
potency	O
at	O
nACh	O
receptors	O
and	O
NMDA	O

The	O
FDA	O
reported	O
in	O
April	O
2012	O
that	O
twelve	O
young	O
children	O
had	O
died	O
and	O
more	O
made	O
seriously	O
ill	O
from	O
separate	O
accidental	O
exposures	O
to	O
fentanyl	B-Drug
skin	O
patches	O

Jacqui	O
Smith	O
then	O
Home	O
Secretary	O
was	O
also	O
widely	O
criticised	O
by	O
the	O
scientific	O
community	O
for	O
bullying	O
Professor	O
David	O
Nutt	O
into	O
apologising	O
his	O
comments	O
that	O
in	O
course	O
of	O
a	O
normal	O
year	O
more	O
people	O
died	O
from	O
falling	O
off	O
horses	O
than	O
taking	O
ecstasy	B-Drug

Rifampicin	B-Drug
greatly	O
reduces	O
plasma	O
concentrations	O
of	O
oxycodone	B-Drug
due	O
to	O
strong	O
induction	O
CYP3A4	O

Roughly	O
90%	O
of	O
ingested	O
amphetamine	B-Drug
is	O
eliminated	O
3	O
days	O
after	O
the	O
last	O
oral	O
dose	O

Adderall	B-Drug
is	O
generally	O
well	O
tolerated	O
and	O
effective	O
in	O
treating	O
the	O
symptoms	O
of	O
ADHD	O
narcolepsy	O

The	O
only	O
ATS	O
in	O
this	O
category	O
is	O
cathine	B-Drug

Patients	O
appear	O
twice	O
daily	O
at	O
a	O
treatment	O
center	O
where	O
they	O
inject	O
their	O
dose	O
of	O
diamorphine	B-Drug
under	O
the	O
supervision	O
medical	O
staff	O

Notably	O
some	O
Mexican	O
beef	O
farmers	O
are	O
known	O
to	O
add	O
clenbuterol	B-Drug
cattle	O
feed	O

In	O
children	O
intranasal	O
fentanyl	B-Drug
is	O
useful	O
for	O
the	O
treatment	O
of	O
moderate	O
and	O
severe	O
pain	O
well	O
tolerated	O

Clomifene	B-Drug
and	O
its	O
metabolites	O
are	O
excreted	O
primarily	O
through	O
feces	O
42%	O
excretion	O
can	O
occur	O
up	O
to	O
6	O
weeks	O
after	O
discontinuation	O

Although	O
Afghanistan's	O
overall	O
economy	O
is	O
being	O
boosted	O
by	O
opium	B-Drug
profits	O
less	O
than	O
20	O
percent	O
of	O
the	O
$3	O
billion	O
in	O
actually	O
goes	O
to	O
impoverished	O
farmers	O
while	O
more	O
80	O
into	O
pockets	O
Afghan's	O
traffickers	O
and	O
kingpins	O
their	O
political	O
connections	O

In	O
1955	O
English	O
politician	O
Christopher	O
Mayhew	O
took	O
part	O
in	O
an	O
experiment	O
for	O
BBC's	O
Panorama	O
which	O
he	O
ingested	O
400	O
mg	O
of	O
mescaline	B-Drug
under	O
the	O
supervision	O
psychiatrist	O
Humphry	O
Osmond	O

This	O
discovery	O
led	O
to	O
a	O
search	O
for	O
viable	O
antidepressants	O
with	O
similar	O
structures	O
and	O
fewer	O
side	O
effects	O
culminating	O
in	O
the	O
invention	O
of	O
fluoxetine	B-Drug
Prozac	B-Drug
selective	O
serotonin	O
reuptake	O
inhibitor	O
SSRI	O

The	O
net	O
reaction	O
when	O
using	O
sodium	O
bicarbonate	O
is	O
Coc-H+Cl	O
+	O
NaHCO3	O
Coc	O
H2O	O
CO2	O
NaClWith	O
ammonium	O
bicarbonate:	O
NH4HCO3	O
NH4Cl	O
H2OWith	O
carbonate:	O
2Coc-H+Cl	O
NH42CO3	O
2	O
H2OCrack	O
cocaine	B-Drug
frequently	O
purchased	O
already	O
in	O
rock	O
form	O
although	O
it	O
not	O
uncommon	O
for	O
some	O
users	O
to	O
wash	O
up	O
or	O
cook	O
powder	O
into	O
crack	O
themselves	O

Much	O
of	O
the	O
legislative	O
activity	O
has	O
stemmed	O
from	O
Purdue	O
Pharma's	O
decision	O
in	O
2011	O
to	O
begin	O
a	O
modification	O
Oxycontin's	O
composition	O
make	O
it	O
more	O
difficult	O
crush	O
for	O
snorting	O
or	O
injecting	O
Oxycontin	B-Drug

The	O
term	O
spliff	O
is	O
sometimes	O
used	O
to	O
distinguish	O
a	O
joint	O
prepared	O
with	O
both	O
cannabis	O
and	O
tobacco	B-Drug
as	O
commonly	O
done	O
in	O
European	O
countries	O
where	O
joints	O
containing	O
only	O
are	O
uncommon	O

Rebound	O
anxiety	O
more	O
severe	O
than	O
baseline	O
is	O
also	O
a	O
common	O
withdrawal	O
symptom	O
when	O
discontinuing	O
diazepam	B-Drug
or	O
other	O
benzodiazepines	O

Drug	O
Enforcement	O
Administration	O
listed	O
zopiclone	B-Drug
under	O
schedule	O
IV	O
due	O
to	O
evidence	O
that	O
the	O
drug	O
has	O
addictive	O
properties	O
similar	O
benzodiazepines	O

Chests	O
of	O
opium	B-Drug
were	O
sold	O
in	O
auctions	O
Calcutta	O
with	O
the	O
understanding	O
that	O
independent	O
purchasers	O
would	O
then	O
smuggle	O
it	O
into	O
China	O

Diprenorphine	O
Revivon	O
is	O
an	O
opioid	O
receptor	O
antagonist	O
that	O
can	O
be	O
administered	O
in	O
proportion	O
to	O
the	O
amount	O
of	O
etorphine	B-Drug
used	O
1	O

Two	O
other	O
36	O
diesters	O
of	O
morphine	B-Drug
invented	O
in	O
187475	O
along	O
with	O
diamorphine	B-Drug
dibenzoylmorphine	O
and	O
acetylpropionylmorphine	B-Drug
were	O
made	O
as	O
substitutes	O
after	O
it	O
was	O
outlawed	O
1925	O
therefore	O
sold	O
the	O
first	O
designer	O
drugs	O
until	O
they	O
by	O
League	O
Nations	O
1930	O

Since	O
January	O
2009	O
Denmark	O
has	O
prescribed	O
diamorphine	B-Drug
to	O
a	O
few	O
addicts	O
who	O
have	O
tried	O
methadone	B-Drug
and	O
buprenorphine	B-Drug
without	O
success	O

In	O
turn	O
alcohol	O
and	O
tobacco	B-Drug
are	O
typically	O
easier	O
to	O
obtain	O
at	O
an	O
earlier	O
age	O
than	O
is	O
cannabis	O
though	O
the	O
reverse	O
may	O
be	O
true	O
in	O
some	O
areas	O
thus	O
leading	O
gateway	O
sequence	O
those	O
individuals	O
since	O
they	O
most	O
likely	O
experiment	O
with	O
any	O
drug	O
offered	O

Naproxen	B-Drug
was	O
patented	O
in	O
1967	O
and	O
approved	O
for	O
medical	O
use	O
the	O
United	O
States	O
1976	O

The	O
Cartel	O
also	O
diversified	O
into	O
opium	B-Drug
and	O
was	O
reported	O
to	O
have	O
brought	O
in	O
a	O
Japanese	O
chemist	O
help	O
its	O
refining	O
operation	O

Whether	O
NDMA	O
can	O
also	O
be	O
formed	O
from	O
ranitidine	B-Drug
inside	O
the	O
body	O
is	O
unclear	O

By	O
contrast	O
opium	B-Drug
tincture's	O
weaker	O
cousin	O
paregoric	O
also	O
confusingly	O
known	O
as	O
camphorated	O
tincture	O
of	O
is	O
1/25th	O
the	O
strength	O
containing	O
only	O
0	O

Quazepam	B-Drug
and	O
its	O
major	O
active	O
metabolite	O
2-oxoquazepam	O
both	O
show	O
high	O
selectivity	O
for	O
the	O
type1	O
GABAA	O
receptors	O

Preliminary	O
data	O
from	O
the	O
open-label	O
TEAM	O
trial	O
comparing	O
exemestane	B-Drug
with	O
tamoxifen	B-Drug
indicated	O
in	O
2009	O
that	O
25	O
mg/day	O
is	O
also	O
effective	O
primary	O
adjuvant	O
treatment	O
of	O
early-stage	O
breast	O
cancer	O
postmenopausal	O
women	O

The	O
main	O
pharmacological	O
effects	O
of	O
flunitrazepam	B-Drug
are	O
the	O
enhancement	O
GABA	O
an	O
inhibitory	O
neurotransmitter	O
at	O
various	O
receptors	O

In	O
order	O
to	O
curb	O
misuse	O
many	O
health	O
insurers	O
have	O
begun	O
require	O
precertification	O
and/or	O
quantity	O
limits	O
for	O
Actiq	B-Drug
prescriptions	O

As	O
early	O
as	O
the	O
1960s	O
research	O
into	O
medicinal	O
properties	O
of	O
LSD	B-Drug
was	O
being	O
conducted	O

As	O
an	O
anti-inflammatory	O
dapsone	B-Drug
inhibits	O
the	O
myeloperoxidase-H2O2-halide-mediated	O
cytotoxic	O
system	O
in	O
polymorphonucleocytes	O

As	O
of	O
the	O
end	O
2011	O
seizure	O
operations	O
Colombian	O
cocaine	B-Drug
carried	O
out	O
in	O
different	O
countries	O
have	O
totaled	O
351	O

Approximately	O
12	O
percent	O
of	O
opium	B-Drug
is	O
made	O
up	O
the	O
analgesic	O
alkaloid	O
morphine	B-Drug
which	O
processed	O
chemically	O
to	O
produce	O
heroin	B-Drug
and	O
other	O
synthetic	O
opioids	O
for	O
medicinal	O
use	O
illegal	O
drug	O
trade	O

Clonazepam	B-Drug
does	O
however	O
affect	O
glutamate	O
decarboxylase	O
activity	O

Dextromethorphan	B-Drug
is	O
rapidly	O
absorbed	O
from	O
the	O
gastrointestinal	O
tract	O
and	O
converted	O
into	O
active	O
metabolite	O
dextrorphan	B-Drug
in	O
liver	O
by	O
cytochrome	O
P450	O
enzyme	O
CYP2D6	O

JDTic	O
is	O
a	O
4-phenylpiperidine	O
derivative	O
distantly	O
related	O
structurally	O
to	O
analgesics	O
such	O
as	O
pethidine	B-Drug
and	O
ketobemidone	B-Drug
more	O
closely	O
the	O
MOR	O
antagonist	O
alvimopan	B-Drug

In	O
other	O
countries	O
it	O
is	O
more	O
common	O
to	O
use	O
morphine	B-Drug
or	O
strong	O
opioids	O
in	O
these	O
situations	O

Like	O
morphine-N-oxide	O
it	O
was	O
studied	O
as	O
a	O
potential	O
pharmaceutical	O
drug	O
and	O
is	O
considerably	O
weaker	O
than	O
codeine	B-Drug

In	O
2008	O
a	O
popular	O
initiative	O
by	O
the	O
right	O
wing	O
Swiss	O
People's	O
Party	O
aimed	O
at	O
ending	O
heroin	B-Drug
program	O
was	O
rejected	O
more	O
than	O
two	O
thirds	O
of	O
voters	O

6-Chloro-MDMA	O
6-Cl-MDMA	O
2-Cl-45-MDMA	O
is	O
a	O
derivative	O
of	O
the	O
amphetamine	B-Drug
drug	O
MDMA	B-Drug
which	O
has	O
been	O
identified	O
both	O
in	O
seized	O
ecstasy	B-Drug
tablets	O
and	O
urine	O
samples	O
from	O
users	O

Steroidal	O
antiandrogens	O
include	O
compounds	O
like	O
cyproterone	O
acetate	O
spironolactone	B-Drug
estradiol	O
abiraterone	B-Drug
and	O
finasteride;	O
nonsteroidal	O
bicalutamide	B-Drug
elagolix	B-Drug
diethylstilbestrol	O
aminoglutethimide	O
ketoconazole;	O
peptides	O
GnRH	O
analogues	O
leuprorelin	B-Drug
cetrorelix	B-Drug
finasteride	B-Drug
ketoconazole	B-Drug

In	O
France	O
methylphenidate	B-Drug
is	O
covered	O
by	O
the	O
narcotics	O
schedule	O
prescription	O
and	O
distribution	O
conditions	O
are	O
restricted	O
with	O
hospital-only	O
for	O
initial	O
treatment	O
yearly	O
consultations	O

Benzodiazepines	O
are	O
used	O
in	O
the	O
treatment	O
of	O
seizures	O
and	O
subsequently	O
administration	O
flumazenil	B-Drug
may	O
result	O

It	O
may	O
be	O
because	O
tolerance	O
is	O
slower	O
to	O
develop	O
with	O
prazepam	B-Drug
than	O
other	O
benzodiazepines	O

Between	O
July	O
2009	O
and	O
February	O
2010	O
UK	O
health	O
professionals	O
accessed	O
the	O
National	O
Poisons	O
Information	O
Service's	O
NPIS	O
entry	O
on	O
mephedrone	B-Drug
1664	O
times	O
made	O
157	O
telephone	O
inquiries;	O
requests	O
increased	O
month	O
over	O
this	O
period	O

Although	O
the	O
determination	O
of	O
psilocin	B-Drug
levels	O
in	O
urine	O
can	O
be	O
performed	O
without	O
sample	O
clean-up	O
i	O

The	O
summative	O
process	O
is	O
as	O
follows:	O
Methylprednisolone	B-Drug
intercalates	O
in	O
the	O
plasma	O
membrane	O
causes	O
physiochemical	O
changes	O
activates	O
proteins	O
that	O
inhibit	O
calcium	O
and	O
sodium	O
uptake	O
mimicking	O
an	O
energy	O
deficit	O
state	O

A	O
single	O
2	O
mg	O
oral	O
dose	O
of	O
norethisterone	B-Drug
has	O
been	O
found	O
to	O
result	O
in	O
peak	O
circulating	O
levels	O
the	O
drug	O
12	O
ng/mL	O
40	O
nmol/L	O
whereas	O
a	O
1	O
combination	O
with	O
estradiol	O
resulted	O
8	O

Naloxone	B-Drug
should	O
be	O
used	O
with	O
caution	O
in	O
people	O
cardiovascular	O
disease	O
as	O
well	O
those	O
that	O
are	O
currently	O
taking	O
medications	O
could	O
have	O
adverse	O
effects	O
on	O
the	O
system	O
such	O
causing	O
low	O
blood	O
pressure	O
fluid	O
accumulation	O
lungs	O
pulmonary	O
edema	O
and	O
abnormal	O
heart	O
rhythms	O

4	O
mg	O
of	O
morphine	B-Drug
per	O
mL	O

For	O
a	O
time	O
the	O
Cali	O
Cartel	O
supplied	O
80%	O
of	O
United	O
States	O
through	O
Rodriguez's	O
son	O
Jorge	O
Alberto	O
Rodriguez	O
and	O
90%	O
European	O
cocaine	B-Drug
market	O

Some	O
indications	O
exist	O
that	O
naltrexone	B-Drug
might	O
be	O
beneficial	O
in	O
the	O
treatment	O
of	O
impulse-control	O
disorders	O
such	O
as	O
kleptomania	O
compulsive	O
gambling	O
or	O
trichotillomania	O
hair	O
pulling	O
but	O
evidence	O
its	O
effectiveness	O
for	O
is	O
conflicting	O

The	O
metabolic	O
half	O
life	O
of	O
methadone	B-Drug
differs	O
from	O
its	O
duration	O
action	O

Chemical	O
syntheses	O
of	O
norgestrel	B-Drug
have	O
been	O
published	O

MGA	O
differs	O
from	O
medroxyprogesterone	B-Drug
acetate	I-Drug
only	O
by	O
its	O
C67	O
double	O
bond	O

Cocaine	B-Drug
smuggling	O
was	O
previously	O
dominated	O
by	O
drug	O
cartels	O
particularly	O
from	O
Colombia	O

It	O
is	O
also	O
known	O
as	O
L-deprenyl	B-Drug
well	O
R--N-dimethyl-N-2-propynylphenethylamine	O
or	O
R--N-methyl-N-2-propynylamphetamine	O

Buprenorphine/naloxone	B-Drug
may	O
be	O
recommended	O
for	O
socially	O
stable	O
opioid	O
users	O
who	O
not	O
able	O
to	O
retrieve	O
medications	O
from	O
a	O
center	O
daily	O
have	O
another	O
condition	O
requiring	O
regular	O
primary	O
care	O
visits	O
or	O
jobs	O
lives	O
that	O
require	O
they	O
maintain	O
all	O
their	O
faculties	O
and	O
cannot	O
take	O
sedating	O
medication	O

The	O
challenge	O
involves	O
giving	O
a	O
test	O
dose	O
of	O
naloxone	B-Drug
and	O
monitoring	O
for	O
opioid	O
withdrawal	O

Methadone	B-Drug
has	O
a	O
slow	O
metabolism	O
and	O
very	O
high	O
fat	O
solubility	O
making	O
it	O
longer	O
lasting	O
than	O
morphine-based	O
drugs	O

Modified	O
versions	O
of	O
amiloride	B-Drug
known	O
as	O
5'-NN-dimethyl-amiloride	O
DMA	O
5-N-ethyl-N-isopropyl	O
EIPA	O
and	O
5-NN-hexamethylene-amiloride	O
HMA	O
are	O
being	O
studied	O
for	O
the	O
treatment	O
leukemia	O

In	O
1952	O
thalidomide	B-Drug
was	O
synthesised	O
by	O
Chemical	O
Industry	O
Basel	O
CIBA	O
but	O
found	O
to	O
have	O
no	O
effect	O
on	O
animals	O
and	O
discarded	O
that	O
basis	O

Street	O
names	O
for	O
Amobarbital	B-Drug
include	O
blues	O
blue	O
angels	O
birds	O
devils	O
and	O
heavens	O
due	O
to	O
their	O
capsule	O

Efavirenz	B-Drug
is	O
a	O
white	O
to	O
slightly	O
pink	O
crystalline	O
powder	O
with	O
molecular	O
mass	O
of	O
315	O

Flunitrazepam	B-Drug
may	O
cause	O
a	O
paradoxical	O
reaction	O
in	O
some	O
individuals	O
causing	O
symptoms	O
including	O
anxiety	O
aggressiveness	O
agitation	O
confusion	O
disinhibition	O
loss	O
of	O
impulse	O
control	O
talkativeness	O
violent	O
behavior	O
and	O
even	O
convulsions	O

Spironolactone	B-Drug
has	O
also	O
been	O
found	O
to	O
inhibit	O
UGT2B7	O

M1	O
and	O
M6	O
are	O
the	O
two	O
major	O
metabolites	O
of	O
ivacaftor	B-Drug
in	O
humans	O

However	O
its	O
high	O
potency	O
combined	O
with	O
the	O
rapid	O
action	O
of	O
both	O
etorphine	B-Drug
and	O
antagonist	O
diprenorphine	O
means	O
that	O
it	O
has	O
found	O
a	O
place	O
for	O
use	O
in	O
capture	O
large	O
mammals	O
such	O
as	O
rhinoceroses	O
elephants	O
where	O
onset	O
recovery	O
are	O
very	O
important	O

It	O
consists	O
of	O
only	O
the	O
R--enantiomer	O
racemic	O
modafinil	B-Drug

A	O
number	O
of	O
derivatives	O
PCP	B-Drug
have	O
been	O
sold	O
for	O
recreational	O
and	O
non-medical	O
use	O

However	O
because	O
dapsone	B-Drug
causes	O
hemolytic	O
anemia	O
in	O
patients	O
with	O
G6PD	O
deficiency	O
and	O
affects	O
10-25%	O
of	O
the	O
population	O
sub-Saharan	O
Africa	O
it	O
was	O
discovered	O
that	O
Lapdap	B-Drug
is	O
not	O
safe	O
for	O
use	O

The	O
profits	O
of	O
kidnapping	O
helped	O
finance	O
the	O
ring's	O
move	O
to	O
drug	O
trafficking	O
originally	O
beginning	O
in	O
Marijuana	B-Drug
and	O
eventually	O
spreading	O
cocaine	B-Drug

Non-17-alkylated	O
testosterone	O
derivatives	O
such	O
as	O
itself	O
DHT	O
and	O
nandrolone	B-Drug
all	O
have	O
poor	O
oral	O
bioavailability	O
due	O
to	O
extensive	O
first-pass	O
hepatic	O
metabolism	O
hence	O
are	O
not	O
orally	O
active	O

Thalidomide	B-Drug
sold	O
under	O
the	O
brand	O
names	O
Contergan	B-Drug
and	O
Thalomid	B-Drug
among	O
others	O
is	O
a	O
medication	O
used	O
to	O
treat	O
number	O
of	O
cancers	O
including	O
multiple	O
myeloma	O
graft-versus-host	O
disease	O
skin	O
conditions	O
complications	O
leprosy	O

Drugs	O
of	O
abuse	O
that	O
can	O
be	O
detected	O
include	O
Cannabis	O
Cocaine	B-Drug
Amphetamines	O
and	O
drugs	O
new	O
to	O
the	O
UK	O
such	O
as	O
Mephedrone	B-Drug

Additive	O
vasoconstricting	O
effects	O
occur	O
with	O
ergot	O
alkaloids	O
and	O
oxytocin	B-Drug

Because	O
of	O
this	O
favorable	O
ratio	O
experiments	O
in	O
orchiectomized	O
rats	O
have	O
demonstrated	O
that	O
treatment	O
with	O
desoxymethyltestosterone	B-Drug
resulted	O
only	O
a	O
stimulation	O
the	O
weight	O
levator	O
ani	O
muscle;	O
prostate	O
and	O
seminal	O
vesicle	O
weights	O
remained	O
unaffected	O
leading	O
authors	O
one	O
study	O
to	O
characterize	O
as	O
powerful	O
AAS	O
attributes	O
selective	O
androgen	O
receptor	O
modulator	O
SARM	O
some	O
indication	O
toxicity	O

As	O
result	O
of	O
demethylenation	O
followed	O
by	O
O-methylation	O
bk-MBDB	B-Drug
metabolises	O
into	O
4-OH-3-MeO	O
and	O
3-OH-4-MeO	O
metabolites	O
in	O
human	O
urine	O

Embutramide	B-Drug
has	O
however	O
been	O
reported	O
to	O
be	O
used	O
for	O
suicide	O
by	O
people	O
with	O
access	O
the	O
drug	O
and	O
was	O
added	O
list	O
of	O
Schedule	O
III	O
drugs	O
in	O
US	O
2006	O
as	O
a	O
Non-Narcotic	O
ACSCN	O
2020	O
which	O
classifies	O
it	O
depressants	O
such	O
benzodiazepines	O
barbiturates	O
other	O
sedative-hypnotics	O

Many	O
psychoactive	O
drugs	O
can	O
be	O
or	O
have	O
been	O
specifically	O
designed	O
for	O
sublingual	O
administration	O
including	O
barbiturates	O
benzodiazepines	O
opioid	O
analgesics	O
with	O
poor	O
gastrointestinal	O
bioavailability	O
LSD	B-Drug
blotters	O
coca	B-Drug
leaves	O
some	O
hallucinogens	O

For	O
example:	O
LSD	B-Drug
has	O
and	O
weed	O
mushrooms	O
other	O
trapping	O
drugs	O

Toxic	O
epidermal	O
necrolysis	O
has	O
occurred	O
from	O
the	O
use	O
of	O
tetrazepam	B-Drug
including	O
at	O
least	O
one	O
reported	O
death	O

The	O
same	O
concerns	O
do	O
not	O
apply	O
to	O
psychedelics	O
that	O
release	O
neurotransmitters	O
such	O
as	O
LSD	B-Drug
nor	O
dissociatives	O
or	O
deliriants	O

The	O
time	O
to	O
peak	O
levels	O
of	O
lemborexant	B-Drug
is	O
1	O
3	O
hours	O

It	O
is	O
also	O
available	O
in	O
combination	O
with	O
progestins	O
as	O
a	O
transdermal	O
contraceptive	B-Drug
patch	I-Drug
and	O
vaginal	O
ring	O

Heroin	B-Drug
was	O
first	O
made	O
by	O
C	O

Diphenhydramine	B-Drug
is	O
metabolized	O
by	O
the	O
cytochrome	O
P450	O
enzymes	O
CYP2D6	O
CYP1A2	O
CYP2C9	O
and	O
CYP2C19	O

for	O
reducing	O
cardiovascular	O
risk	O
must	O
be	O
careful	O
if	O
they	O
also	O
use	O
other	O
NSAIDs	O
as	O
these	O
may	O
inhibit	O
the	O
cardioprotective	O
effects	O
of	O
aspirin	B-Drug

The	O
Assemblies	O
of	O
God	O
USA	O
as	O
well	O
other	O
Pentecostal	O
and	O
holiness	O
churches	O
have	O
historically	O
advocated	O
abstinence	O
from	O
all	O
alcohol	O
tobacco	B-Drug
narcotics	O

The	O
fresh	O
leaves	O
have	O
a	O
higher	O
concentration	O
of	O
cathinone	B-Drug

By	O
2009	O
in	O
Ontario	O
there	O
were	O
more	O
deaths	O
from	O
oxycodone	B-Drug
overdose	O
than	O
cocaine	B-Drug

1974:	O
Kondo	O
and	O
Mori	O
synthesize	O
racemic	O
vinylic	O
gamma-lactones	O
a	O
key	O
starting	O
material	O
in	O
Stork's	O
2001	O
quinine	B-Drug
synthesis	O

Additionally	O
persons	O
at	O
risk	O
for	O
opioid	O
overdose	O
did	O
not	O
engage	O
in	O
riskier	O
compensatory	O
drug	O
use	O
as	O
a	O
result	O
of	O
having	O
access	O
to	O
naloxone	B-Drug
kits	O

Subject	O
to	O
the	O
provisions	O
of	O
section	O
8	O
Central	O
Government	O
may	O
by	O
rules	O
permit	O
regulate	O
and	O
prescribe	O
any	O
other	O
matter	O
requisite	O
render	O
effective	O
control	O
over	O
matters	O
specified	O
below:	O
cultivation	O
or	O
gathering	O
portion	O
such	O
being	O
only	O
on	O
account	O
coca	B-Drug
plant	O
production	O
possession	O
sale	O
purchase	O
transport	O
import	O
inter-State	O
export	O
use	O
consumption	O
leaves	O
opium	B-Drug
poppy	O
manufacture	O
straw	O
derivatives	O
from	O
factories	O
for	O
India	O
State	O
manufacturing	O
chemists	O
manufactured	O
drugs	O
than	O
prepared	O
but	O
not	O
including	O
medicinal	O
preparation	O
containing	O
drug	O
materials	O
which	O
maker	O
is	O
lawfully	O
entitled	O
possess	O
psychotropic	O
substances;	O
into	O
transhipment	O
narcotic	O
substances	O

Marvin	O
Boggs	O
played	O
by	O
John	O
Malkovich	O
in	O
the	O
films	O
RED	O
2010	O
and	O
2	O
2013	O
had	O
unknowingly	O
been	O
provided	O
daily	O
doses	O
of	O
LSD	B-Drug
over	O
a	O
period	O
11	O
years	O
making	O
him	O
highly	O
paranoid	O
echoing	O
actions	O
MKUltra	O

338	O
was	O
exactly	O
8	O
times	O
the	O
strength	O
of	O
Tincture	O
Opium	B-Drug
Camphorated	O
Paregoric	O
[italics	O
in	O
original]	O
U	O

Ritalin	B-Drug
methylphenidate	B-Drug
a	O
stimulant	O
used	O
to	O
treat	O
ADHD	O

They	O
developed	O
and	O
in	O
1987	O
gained	O
permission	O
to	O
market	O
the	O
pharmaceutical	O
Canasol	O
one	O
of	O
first	O
cannabis	O
extracts	B-Drug

Most	O
commercial	O
cocaine	B-Drug
immunoassay	O
screening	O
tests	O
cross-react	O
appreciably	O
with	O
the	O
major	O
metabolites	O
but	O
chromatographic	O
techniques	O
can	O
easily	O
distinguish	O
and	O
separately	O
measure	O
each	O
of	O
these	O
substances	O

Following	O
the	O
description	O
of	O
structure	O
and	O
activity	O
hyoscine	O
by	O
Ladenburg	O
search	O
for	O
synthetic	O
analogues	O
methods	O
total	O
synthesis	O
and/or	O
atropine	O
in	O
1930s	O
1940s	O
resulted	O
discovery	O
diphenhydramine	B-Drug
an	O
early	O
antihistamine	O
prototype	O
its	O
chemical	O
subclass	O
these	O
drugs	O
pethidine	B-Drug
first	O
fully	O
opioid	O
analgesic	O
known	O
as	O
Dolantin	O
Demerol	B-Drug
amongst	O
many	O
other	O
trade	O
names	O

The	O
treatment	O
was	O
attempted	O
despite	O
the	O
ban	O
on	O
thalidomide's	O
use	O
and	O
results	O
were	O
favourable:	O
patient	O
slept	O
for	O
hours	O
able	O
to	O
get	O
out	O
of	O
bed	O
without	O
aid	O
upon	O
awakening	O
thalidomide	B-Drug

Naloxegol	B-Drug
was	O
previously	O
a	O
Schedule	O
II	O
drug	O
in	O
the	O
United	O
States	O
because	O
of	O
its	O
chemical	O
similarity	O
to	O
opium	B-Drug
alkaloids	O

It	O
is	O
a	O
major	O
metabolite	O
of	O
nandrolone	B-Drug
and	O
formed	O
from	O
it	O
by	O
the	O
actions	O
enzyme	O
5-reductase	O
analogously	O
to	O
formation	O
dihydrotestosterone	O
DHT	O
testosterone	O

ovaries	O
testes	O
eyes	O
adrenals	O
placenta	O
thymus	O
pancreas	O
where	O
PAM	O
and	O
oxytocin	O
by	O
default	O
is	O
found	O
are	O
also	O
known	O
to	O
store	O
higher	O
concentrations	O
of	O
vitamin	B-Drug
C	I-Drug

Examples	O
are	O
alprazolam	B-Drug
estazolam	B-Drug
flunitrazepam	B-Drug
clonazepam	B-Drug
lormetazepam	B-Drug
lorazepam	B-Drug
nitrazepam	B-Drug
and	O
temazepam	B-Drug

He	O
himself	O
used	O
ibogaine	B-Drug
to	O
stop	O
his	O
abuse	O
of	O
narcotics	O

4-HO-MiPT	B-Drug
was	O
presumably	O
first	O
synthesized	O
by	O
Alexander	O
Shulgin	O

PCP	B-Drug
has	O
also	O
been	O
shown	O
to	O
cause	O
schizophrenia-like	O
changes	O
in	O
N-acetylaspartate	O
and	O
N-acetylaspartylglutamate	O
levels	O
the	O
rat	O
brain	O
which	O
are	O
detectable	O
both	O
living	O
rats	O
upon	O
necropsy	O
examination	O
of	O
tissue	O

Another	O
claim	O
is	O
that	O
the	O
drug	O
contains	O
efavirenz	B-Drug
alone	O
or	O
with	O
ingredients	O
mentioned	O
above	O
another	O
antiretroviral	O
which	O
has	O
psychoactive	O
side	O
effects	O

On	O
16	O
June	O
2020	O
the	O
RECOVERY	O
Trial	O
announced	O
preliminary	O
results	O
stating	O
that	O
dexamethasone	B-Drug
improves	O
survival	O
rates	O
of	O
hospitalized	O
patients	O
with	O
COVID19	O
receiving	O
oxygen	O
or	O
on	O
a	O
ventilator	O

Plasma	O
protein	O
binding	O
of	O
alectinib	B-Drug
and	O
M4	O
is	O
over	O
99%	O

Intravenous	O
injection	O
of	O
opiates	O
is	O
most	O
used:	O
by	O
comparison	O
with	O
dragon	O
chasing	O
heating	O
heroin	B-Drug
on	O
a	O
piece	O
foil	O
and	O
madak	O
ack	O
smoking	O
cigarettes	O
containing	O
tobacco	B-Drug
mixed	O
powder	O
are	O
only	O
40	O
percent	O
20	O
efficient	O
respectively	O

Between	O
400	O
and	O
1200	O
AD	O
Arab	O
traders	O
introduced	O
opium	B-Drug
to	O
China	O
India	O
by	O
700	O

Betaprodine	B-Drug
is	O
some	O
five	O
times	O
more	O
potent	O
than	O
alphaprodine	B-Drug
but	O
metabolized	O
rapidly	O
and	O
only	O
was	O
developed	O
for	O
medicinal	O
use	O

These	O
leaves	O
are	O
harvested	O
and	O
cured	O
to	O
allow	O
for	O
the	O
slow	O
oxidation	O
degradation	O
of	O
carotenoids	O
in	O
tobacco	B-Drug
leaf	O

Fluoxymesterone	B-Drug
has	O
approximately	O
80%	O
oral	O
bioavailability	O
unlike	O
testosterone	O
as	O
the	O
C17	O
methyl	O
group	O
of	O
fluoxymesterone	B-Drug
inhibits	O
first-pass	O
metabolism	O

DMHP	B-Drug
is	O
metabolised	O
in	O
a	O
similar	O
manner	O
to	O
THC	O
producing	O
the	O
active	O
metabolite	O
11-hydroxy-DMHP	O
but	O
lipophilicity	O
of	O
even	O
higher	O
than	O
that	O
itself	O
giving	O
it	O
long	O
duration	O
action	O
and	O
an	O
extended	O
half-life	O
body	O
between	O
20	O
39	O
hours	O
with	O
being	O
longer	O
48	O

I	O
fear	O
that	O
the	O
only	O
message	O
will	O
be	O
sent	O
by	O
hasty	O
decision	O
on	O
mephedrone	B-Drug
is	O
drug	O
laws	O
deserve	O
no	O
respect	O

Beginning	O
in	O
February	O
2010	O
addicts	O
Copenhagen	O
and	O
Odense	O
became	O
eligible	O
to	O
receive	O
free	O
diamorphine	B-Drug

Subsequently	O
on	O
April	O
12	O
2004	O
the	O
FDA	O
issued	O
a	O
final	O
rule	O
banning	O
sale	O
of	O
ephedrine	B-Drug
alkaloid-containing	O
dietary	O
supplements	O

It	O
is	O
an	O
effect	O
of	O
dissociatives	O
and	O
psychedelics	O
as	O
well	O
a	O
possible	O
side	O
caffeine	O
alcohol	O
amphetamine	B-Drug
cannabis	O

Like	O
ETH-LAD	O
this	O
drug	O
has	O
been	O
reported	O
to	O
be	O
significantly	O
more	O
potent	O
than	O
LSD	B-Drug
itself	O
and	O
is	O
largely	O
mimic	O
ETH-LAD's	O
psychedelic	O
effects	O

While	O
at	O
work	O
Ace	O
finds	O
some	O
cocaine	B-Drug
in	O
one	O
of	O
his	O
customers	O
pants	O

Indometacin	B-Drug
inhibits	O
the	O
superior	O
salivatory	O
nucleus	O
thus	O
relieving	O
this	O
type	O
of	O
headache	O

However	O
therapeutic	O
concentrations	O
of	O
norethisterone	B-Drug
are	O
in	O
the	O
low	O
nanomolar	O
range	O
so	O
this	O
action	O
may	O
not	O
be	O
clinically	O
relevant	O
at	O
typical	O
dosages	O

Thalidomide	B-Drug
also	O
binds	O
to	O
and	O
acts	O
as	O
an	O
antagonist	O
of	O
the	O
androgen	O
receptor	O
AR	O
hence	O
is	O
a	O
nonsteroidal	O
antiandrogen	O
NSAA	O
some	O
capacity	O

Ketamine	B-Drug
treatment	O
for	O
depression:	O
opportunities	O
clinical	O
innovation	O
and	O
ethical	O
foresight	O

Norethisterone	B-Drug
is	O
partially	O
metabolized	O
via	O
hydroxylation	O
by	O
CYP3A4	O
and	O
inhibitors	O
inducers	O
of	O
can	O
significantly	O
alter	O
circulating	O
levels	O
norethisterone	B-Drug

N-Methylphenethylamine	O
an	O
isomer	O
of	O
amphetamine	B-Drug
is	O
produced	O
in	O
humans	O
via	O
the	O
metabolism	O
phenethylamine	B-Drug
by	O
PNMT	O

For	O
example	O
during	O
the	O
early	O
1970s	O
in	O
United	O
States	O
methamphetamine	B-Drug
became	O
a	O
schedule	O
II	O
controlled	O
substance	O
under	O
Controlled	O
Substances	O
Act	O

Using	O
a	O
similar	O
multi-criteria	O
decision	O
analysis	O
process	O
as	O
the	O
2010	O
drug	O
harm	O
ranking	O
DrugScience	O
looked	O
to	O
rank	O
harms	O
of	O
all	O
nicotine-containing	O
products	O
including	O
cigarettes	O
cigars	O
nicotine	B-Drug
patches	O
and	O
e-cigarettes	O

LPP	O
has	O
a	O
long	O
biological	O
half-life	O
in	O
rats	O
when	O
given	O
as	O
an	O
intramuscular	O
depot	O
injection;	O
its	O
was	O
similar	O
to	O
that	O
of	O
nandrolone	B-Drug
laurate	O
dodecanoate	O
and	O
about	O
2-fold	O
longer	O
than	O
decanoate	O
10-fold	O
lynestrenol	O
phenylpropionate	I-Drug
50-fold	O
progesterone	O
430-fold	O

The	O
opium	B-Drug
paste	O
is	O
dried	O
and	O
processed	O
into	O
government	O
alkaloid	O
factories	O
before	O
it	O
packed	O
cases	O
of	O
60	O
kilograms	O
for	O
export	O

A	O
cytochrome	O
P450	O
classified	O
as	O
Cyp80F1	O
oxidizes	O
and	O
rearranges	O
littorine	O
to	O
hyoscyamine	B-Drug
aldehyde	O

In	O
June	O
2012	O
two	O
teens	O
in	O
Grand	O
Forks	O
North	O
Dakota	O
and	O
East	O
Minnesota	O
fatally	O
overdosed	O
on	O
a	O
substance	O
that	O
was	O
allegedly	O
25I-NBOMe	B-Drug
resulting	O
lengthy	O
sentences	O
for	O
of	O
the	O
parties	O
involved	O
Federal	O
indictment	O
against	O
Texas-based	O
online	O
vendor	O

Apalutamide	B-Drug
was	O
first	O
described	O
in	O
2007	O
and	O
approved	O
for	O
the	O
treatment	O
of	O
prostate	O
cancer	O
February	O
2018	O

Other	O
COX-2-selective	O
inhibitors	O
such	O
as	O
rofecoxib	O
have	O
significantly	O
higher	O
myocardial	O
infarction	O
rates	O
than	O
celecoxib	B-Drug

Though	O
its	O
dopaminergic	O
activity	O
is	O
significantly	O
attenuated	O
compared	O
to	O
PCA	O
unlike	O
the	O
case	O
of	O
MBDB	O
it	O
not	O
abolished	O
and	O
actually	O
similar	O
that	O
MDMA	B-Drug

Pod	O
mod	O
electronic	O
cigarettes	O
use	O
nicotine	B-Drug
in	O
the	O
form	O
of	O
a	O
protonated	O
rather	O
than	O
free-base	O
found	O
earlier	O
generations	O

Trenbolone	B-Drug
also	O
has	O
a	O
negative	O
impact	O
on	O
blood	O
pressure	O
but	O
it	O
does	O
not	O
appear	O
to	O
negatively	O
affect	O
most	O
healthy	O
adult	O
men	O
in	O
this	O
way	O

Darvon	B-Drug
is	O
a	O
pure	O
propoxyphene	B-Drug
preparation	O
that	O
does	O
not	O
contain	O
paracetamol	B-Drug

Its	O
texture	O
will	O
also	O
depend	O
on	O
the	O
adulterants	O
origin	O
and	O
processing	O
of	O
powdered	O
cocaine	B-Drug
method	O
converting	O
base	O

It	O
is	O
also	O
the	O
parent	O
compound	O
of	O
its	O
own	O
structural	O
class	O
substituted	O
amphetamines	O
which	O
includes	O
prominent	O
substances	O
such	O
as	O
bupropion	B-Drug
cathinone	B-Drug
MDMA	B-Drug
and	O
methamphetamine	B-Drug

The	O
effects	O
are	O
similar	O
to	O
those	O
of	O
methamphetamine	B-Drug
though	O
the	O
duration	O
propylhexedrine	B-Drug
is	O
much	O
shorter	O

Cetrorelix	B-Drug
INN	O
BAN	O
or	O
cetrorelix	B-Drug
acetate	O
USAN	O
JAN	O
sold	O
under	O
the	O
brand	O
name	O
Cetrotide	O
is	O
an	O
injectable	O
gonadotropin-releasing	O
hormone	O
GnRH	O
antagonist	O

However	O
in	O
animal	O
studies	O
squirrel	O
monkeys	O
and	O
rats	O
could	O
be	O
induced	O
to	O
self-administer	O
bupropion	B-Drug
intravenously	O
which	O
is	O
often	O
taken	O
as	O
a	O
sign	O
of	O
addiction	O
potential	O

Ketamine	B-Drug
has	O
been	O
found	O
to	O
increase	O
dopaminergic	O
neurotransmission	O
in	O
the	O
brain	O
but	O
instead	O
of	O
being	O
due	O
dopamine	O
reuptake	O
inhibition	O
this	O
may	O
be	O
via	O
indirect/downstream	O
mechanisms	O
namely	O
through	O
antagonism	O
NMDA	O
receptor	O

During	O
the	O
month	O
of	O
fasting	O
however	O
it	O
is	O
forbidden	O
to	O
smoke	O
tobacco	B-Drug

Tramadol	B-Drug
sold	O
under	O
the	O
brand	O
name	O
Ultram	B-Drug
among	O
others	O
is	O
an	O
opioid	O
pain	O
medication	O
used	O
to	O
treat	O
moderate	O
moderately	O
severe	O

25I-NBOMe	B-Drug
has	O
similar	O
effects	O
to	O
LSD	B-Drug
though	O
users	O
report	O
more	O
negative	O
while	O
under	O
the	O
influence	O
and	O
risk	O
of	O
harm	O
following	O
use	O
as	O
compared	O
classical	O
psychedelics	O

Cocaine	B-Drug
hydrochloride	O
Numbrino	O
was	O
approved	O
for	O
medical	O
use	O
in	O
the	O
United	O
States	O
January	O
2020	O

Mitragynine	B-Drug
is	O
an	O
indole-based	O
alkaloid	O
and	O
the	O
most	O
abundant	O
active	O
in	O
Southeast	O
Asian	O
plant	O
Mitragyna	B-Drug
speciosa	I-Drug
commonly	O
known	O
as	O
kratom	B-Drug

it	O
is	O
not	O
a	O
human	O
teratogen	O
but	O
amphetamine	B-Drug
abuse	O
does	O
pose	O
risks	O
to	O
the	O
fetus	O

quinine	B-Drug
antiasthma	O
e	O

In	O
May	O
2020	O
Medavie	O
Health	O
Services	O
provided	O
over	O
250	O
ambulance	O
services	O
for	O
overdoses	O
administering	O
the	O
opioid	O
antagonist	O
nasal	O
spray	O
Narcan	B-Drug
naloxone	B-Drug
in	O
record	O
numbers	O

Only	O
aspirin	B-Drug
was	O
found	O
not	O
to	O
increase	O
the	O
risk	O
of	O
heart	O
disease;	O
however	O
this	O
is	O
known	O
have	O
a	O
higher	O
rate	O
gastric	O
ulceration	O
than	O
diclofenac	B-Drug

Dopamine	O
agonist	O
-	O
levodopa:	O
One	O
of	O
levodopa's	O
chronic	O
side	O
effects	O
that	O
Parkinson's	O
patients	O
experience	O
is	O
the	O
on-off	O
phenomenon	O
motor	O
fluctuations	O
where	O
there	O
will	O
be	O
periods	O
oscillations	O
between	O
on	O
patient	O
experiences	O
symptomatic	O
relief	O
and	O
off	O
therapeutic	O
effect	O
wears	O
early	O
levodopa	B-Drug

Research	O
in	O
these	O
events	O
is	O
complicated	O
because	O
cannabis	O
often	O
used	O
conjunction	O
with	O
tobacco	B-Drug
and	O
drugs	O
such	O
as	O
alcohol	O
cocaine	B-Drug

For	O
gastritis	O
drinking	O
a	O
viscous	O
lidocaine	B-Drug
formulation	O
may	O
help	O
with	O
the	O
pain	O

O-Acetylpsilocin	B-Drug
psilacetin	O
and	O
several	O
other	O
esters	O
of	O
psilocin	B-Drug
were	O
patented	O
on	O
January	O
16	O
1963	O
by	O
Sandoz	O
Ltd	O
via	O
Albert	O
Hofmann	O
&	O
Franz	O
Troxler	O

Opium	B-Drug
is	O
the	O
glue	O
that	O
holds	O
this	O
murky	O
relationship	O
together	O

In	O
2017	O
doctors	O
in	O
the	O
UK	O
began	O
first	O
clinical	O
study	O
of	O
MDMA	B-Drug
alcohol	O
use	O
disorder	O

It	O
is	O
this	O
property	O
of	O
buprenorphine	B-Drug
that	O
can	O
induce	O
acute	O
withdrawal	O
when	O
administered	O
before	O
other	O
opioids	O
have	O
left	O
the	O
body	O

Desipramine	B-Drug
sold	O
under	O
the	O
brand	O
name	O
Norpramin	O
among	O
others	O
is	O
a	O
tricyclic	O
antidepressant	O
TCA	O
used	O
in	O
treatment	O
of	O
depression	O

Opium	B-Drug
enhances	O
the	O
tone	O
in	O
long	O
segments	O
of	O
longitudinal	O
muscle	O
and	O
inhibits	O
propulsive	O
contraction	O
circular	O
muscles	O

Formulations	O
containing	O
8	O
mg	O
or	O
less	O
of	O
codeine	B-Drug
AC&C	O
222	O
are	O
typically	O
available	O
from	O
pharmacies	O
over	O
the	O
counter	O

The	O
mechanism	O
for	O
naloxone's	O
proposed	O
benefit	O
in	O
clonidine	B-Drug
overdose	O
is	O
unclear	O
but	O
it	O
has	O
been	O
suggested	O
that	O
endogenous	O
opioid	O
receptors	O
mediate	O
the	O
sympathetic	O
nervous	O
system	O
brain	O
and	O
elsewhere	O
body	O
naloxone	B-Drug

After	O
prolonged	O
use	O
prednisone	B-Drug
needs	O
to	O
be	O
stopped	O
gradually	O

Stanozolol	B-Drug
is	O
not	O
a	O
substrate	O
for	O
5-reductase	O
as	O
it	O
already	O
5-reduced	O
and	O
so	O
potentiated	O
in	O
so-called	O
androgenic	O
tissues	O
like	O
the	O
skin	O
hair	O
follicles	O
prostate	O
gland	O

Food	O
is	O
one	O
of	O
the	O
most	O
anabolic	O
substances	O
that	O
any	O
living	O
organism	O
can	O
consume	O
and	O
therefore	O
with	O
administration	O
trenbolone	B-Drug
acetate	O
every	O
nutrient	O
in	O
body	O
becomes	O
a	O
lot	O
more	O
valuable	O

furazolidone	O
isocarboxazid	O
moclobemide	O
phenelzine	B-Drug
procarbazine	O
selegiline	B-Drug
tranylcypromine	B-Drug

In	O
October	O
2010	O
it	O
was	O
reported	O
that	O
the	O
use	O
of	O
cocaine	B-Drug
in	O
Australia	O
has	O
doubled	O
since	O
monitoring	O
began	O
2003	O

It	O
is	O
an	O
analogue	O
of	O
lophophine	O
MDA	O
and	O
MDMA	B-Drug

In	O
surveys	O
the	O
number	O
of	O
high	O
school	O
students	O
admitting	O
to	O
trying	O
PCP	B-Drug
at	O
least	O
once	O
fell	O
from	O
13%	O
in	O
1979	O
less	O
than	O
3%	O
1990	O

As	O
a	O
clinical	O
psychologist	O
at	O
Harvard	O
University	O
Leary	O
worked	O
on	O
the	O
Psilocybin	O
Project	O
from	O
1960	O
to	O
1962	O
LSD	B-Drug
and	O
psilocybin	O
were	O
still	O
legal	O
in	O
United	O
States	O
time	O
resulting	O
Concord	O
Prison	O
Experiment	O
Marsh	O
Chapel	O

Tar	O
heroin	B-Drug
injection	O
can	O
also	O
be	O
associated	O
with	O
Clostridium	O
botulinum	O
infection	O

It	O
uses	O
a	O
medication	O
delivery	O
technology	O
called	O
BEMA	O
BioErodible	O
MucoAdhesive	O
small	O
dissolvable	O
polymer	O
film	O
containing	O
various	O
fentanyl	B-Drug
doses	O
applied	O
to	O
the	O
inner	O
lining	O
of	O
cheek	O

Gabapentin	B-Drug
decreases	O
the	O
frequency	O
of	O
hot	O
flashes	O
in	O
both	O
menopausal	O
women	O
and	O
patients	O
with	O
breast	O
cancer	O

Dienolone	O
developmental	O
code	O
name	O
RU-3118;	O
online	O
product	O
names	O
Trenazone	O
Dienazone	O
or	O
nordienolone	O
also	O
known	O
as	O
19-nor-910-testosterone	O
910-nandrolone	O
estra-4910-dien-17-ol-3-one	O
is	O
a	O
synthetic	O
anabolic-androgenic	O
steroid	O
AAS	O
of	O
the	O
19-nortestosterone	B-Drug
group	O
that	O
was	O
never	O
marketed	O
nandrolone	B-Drug

The	O
name	O
Paracelsus	O
was	O
a	O
pseudonym	O
signifying	O
him	O
the	O
equal	O
or	O
better	O
of	O
Aulus	O
Cornelius	O
Celsus	O
whose	O
text	O
which	O
described	O
use	O
opium	B-Drug
similar	O
preparation	O
had	O
recently	O
been	O
translated	O
and	O
reintroduced	O
to	O
medieval	O
Europe	O

Lotsof	O
and	O
his	O
colleagues	O
committed	O
to	O
the	O
traditional	O
administration	O
of	O
ibogaine	B-Drug
developed	O
treatment	O
regimens	O
themselves	O

In	O
addition	O
it	O
tends	O
to	O
cause	O
less	O
vomiting	O
and	O
regurgitation	O
than	O
other	O
pure-opiate	O
codeine	B-Drug
morphine	B-Drug
synthetic	O
pure-opioid	O
agonists	O
oxycodone	B-Drug
hydromorphone	B-Drug
when	O
given	O
as	O
a	O
continuous	O
post-operative	O
infusion	O

Oxycodone	B-Drug
is	O
subject	O
to	O
international	O
conventions	O
on	O
narcotic	O
drugs	O

Methadone	B-Drug
is	O
almost	O
as	O
effective	O
when	O
administered	O
orally	O
by	O
injection	O

Spongia	O
somnifera	O
sponges	O
soaked	O
in	O
opium	B-Drug
were	O
used	O
during	O
surgery	O

Natural	O
drugs	O
refer	O
to	O
which	O
are	O
primarily	O
extracted	O
from	O
a	O
natural	O
source	O
such	O
as	O
cocaine	B-Drug
or	O
cannabis	O

As	O
of	O
October	O
2015	O
25I-NBOMe	B-Drug
is	O
a	O
controlled	O
substance	O
in	O
China	O

Another	O
form	O
of	O
fentanyl	B-Drug
that	O
has	O
appeared	O
on	O
the	O
streets	O
is	O
Actiq	B-Drug
lollipop	O
formulation	O

Changing	O
the	O
SAR	O
in	O
milnacipran	B-Drug
changes	O
stereochemistry	O
of	O
compound	O
and	O
affects	O
norepinephrine	O
serotonin	O
concentration	O

50%	O
levoamphetamine	O
sulfate	O
and	O
dextroamphetamine	B-Drug

Pickard	O
is	O
said	O
to	O
have	O
contributed	O
LSD	B-Drug
chemist	O
Nicholas	O
Sand's	O
legal	O
fund	O
following	O
arrest	O
in	O
1972	O

Oldham	O
Kelsey	O
was	O
given	O
a	O
Presidential	O
award	O
for	O
distinguished	O
service	O
from	O
the	O
federal	O
government	O
not	O
allowing	O
thalidomide	B-Drug
to	O
be	O
approved	O
sale	O
in	O
US	O

Hydromorphone	B-Drug
is	O
a	O
semi-synthetic	O
-opioid	O
agonist	O

CBD	B-Drug
is	O
a	O
5-HT1A	O
receptor	O
agonist	O
which	O
under	O
laboratory	O
research	O
to	O
determine	O
if	O
it	O
has	O
an	O
anxiolytic	O
effect	O

Established	O
programs	O
distribute	O
naloxone	B-Drug
as	O
per	O
WHO's	O
minimum	O
standards	O
to	O
drug	O
users	O
and	O
their	O
peers	O
family	O
members	O
police	O
prisons	O
others	O

Paracetamol	B-Drug
use	O
by	O
the	O
mother	O
during	O
pregnancy	O
is	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
childhood	O
asthma	O

Experts	O
estimate	O
that	O
were	O
thalidomide	B-Drug
led	O
to	O
the	O
death	O
of	O
approximately	O
2000	O
children	O
and	O
serious	O
birth	O
defects	O
in	O
more	O
than	O
10000	O
about	O
5000	O
them	O
West	O
Germany	O

Diphenoxylate	B-Drug
and	O
atropine	O
have	O
been	O
studied	O
in	O
small	O
trials	O
as	O
a	O
treatment	O
for	O
fecal	O
incontinence;	O
it	O
appears	O
to	O
be	O
less	O
efficacious	O
more	O
adverse	O
effects	O
when	O
compared	O
with	O
loperamide	B-Drug
or	O
codeine	B-Drug

Amoxapine	B-Drug
is	O
also	O
a	O
weak	O
GlyT2	O
blocker	O
as	O
well	O
Ki	O
0	O

Ephedrine	B-Drug
is	O
commonly	O
used	O
as	O
a	O
stimulant	O
appetite	O
suppressant	O
concentration	O
aid	O
and	O
decongestant	O
to	O
treat	O
hypotension	O
associated	O
with	O
anaesthesia	O

Like	O
other	O
2C-X-NBOMe	O
molecules	O
25I-NBOMe	B-Drug
is	O
a	O
derivative	O
of	O
the	O
2C	O
family	O
phenethylamines	O
described	O
by	O
chemist	O
Alexander	O
Shulgin	O
in	O
his	O
book	O
PiHKAL	O

MDMA:	O
Commonly	O
known	O
as	O
ecstasy	B-Drug
it	O
is	O
a	O
common	O
club	O
drug	O
in	O
the	O
rave	O
scene	O
MDMA	B-Drug

Thus	O
with	O
both	O
higher	O
the	O
dosage	O
of	O
heroin	B-Drug
used	O
and	O
faster	O
route	O
administration	O
potential	O
risk	O
for	O
psychological	O
dependence/addiction	O

Side	O
effects	O
of	O
laudanum	B-Drug
are	O
generally	O
the	O
same	O
as	O
with	O
morphine	B-Drug
and	O
include	O
euphoria	O
dysphoria	O
pruritus	O
sedation	O
constipation	O
reduced	O
tidal	O
volume	O
respiratory	O
depression	O
well	O
psychological	O
dependence	O
physical	O
miosis	O
xerostomia	O

While	O
oral	O
morphine	B-Drug
has	O
a	O
general	O
bioavailability	O
range	O
is	O
only	O
20-40%	O
properly	O
administered	O
rectal	O
use	O
of	O
liquid	O
an	O
effective	O
roughly	O
70%	O
or	O
more	O
than	O
double	O
the	O
overall	O
potency	O
and	O
two	O
thirds	O
that	O
IV	O

McCaffrey	O
in	O
his	O
capacity	O
as	O
director	O
of	O
the	O
White	O
House	O
Office	O
National	O
Drug	O
Control	O
Policy	O
determined	O
that	O
androstenedione	B-Drug
could	O
not	O
be	O
classified	O
an	O
anabolic	O
steroid	O
because	O
there	O
is	O
no	O
proof	O
it	O
promotes	O
muscle	O
growth	O

Notable	O
studies	O
on	O
non-human	O
primates	O
have	O
been	O
part	O
of	O
the	O
polio	B-Drug
vaccine	I-Drug
development	O
and	O
Deep	O
Brain	O
Stimulation	O
their	O
current	O
heaviest	O
non-toxicological	O
use	O
occurs	O
in	O
monkey	O
AIDS	O
model	O
SIV	O

Morphine	B-Drug
and	O
other	O
poppy-based	O
medicines	O
have	O
been	O
identified	O
by	O
the	O
World	O
Health	O
Organization	O
as	O
essential	O
in	O
treatment	O
of	O
severe	O
pain	O

Revlimid	B-Drug
is	O
available	O
only	O
in	O
a	O
restricted	O
distribution	O
setting	O
to	O
avoid	O
its	O
use	O
during	O
pregnancy	O

There	O
are	O
reports	O
of	O
intravenous	O
injection	O
25I-NBOMe	B-Drug
solution	O
and	O
smoking	O
the	O
drug	O
in	O
powdered	O
form	O

Taken	O
together	O
flutamide	O
appears	O
to	O
be	O
a	O
considerably	O
less	O
potent	O
and	O
efficacious	O
antiandrogen	O
than	O
is	O
bicalutamide	B-Drug

Each	O
subsequent	O
dose	O
of	O
cocaine	B-Drug
continues	O
to	O
increase	O
FosB	O
levels	O
with	O
no	O
ceiling	O
tolerance	O

Mirtazapine	B-Drug
is	O
not	O
considered	O
to	O
have	O
a	O
risk	O
of	O
many	O
the	O
side	O
effects	O
often	O
associated	O
with	O
other	O
antidepressants	O
like	O
SSRIs	O
and	O
may	O
actually	O
improve	O
certain	O
ones	O
when	O
taken	O
in	O
conjunction	O
them	O

In	O
1999	O
Marinol	O
was	O
rescheduled	O
from	O
Schedule	O
II	O
to	O
III	O
of	O
the	O
Controlled	O
Substances	O
Act	O
reflecting	O
a	O
finding	O
that	O
THC	O
had	O
potential	O
for	O
abuse	O
less	O
than	O
cocaine	B-Drug
and	O
heroin	B-Drug

Conversely	O
the	O
toxicity	O
of	O
paracetamol	B-Drug
is	O
due	O
to	O
its	O
metabolism	O
a	O
quinone	O
imine	O
which	O
then	O
reacts	O
with	O
liver	O
proteins	O
cause	O
failure	O

Cesamet	B-Drug
received	O
FDA	O
approval	O
in	O
1985	O
for	O
treatment	O
of	O
chemotherapy-induced	O
nausea	O
and	O
vomiting	O

The	O
difference	O
in	O
mechanism	O
of	O
action	O
between	O
methylphenidate	B-Drug
and	O
amphetamine	B-Drug
results	O
inhibiting	O
amphetamine's	O
effects	O
on	O
monoamine	O
transporters	O
when	O
they	O
are	O
co-administered	O

The	O
same	O
research	O
also	O
recorded	O
a	O
fall	O
of	O
19	O
per	O
cent	O
between	O
2008	O
and	O
2013	O
due	O
to	O
reduction	O
in	O
the	O
sales	O
heroin	B-Drug
cannabis	O

Thebaine	O
was	O
not	O
detected	O
in	O
any	O
of	O
the	O
tested	O
powdered	O
drugs	O
street	O
heroin	B-Drug
morphine	B-Drug
tablet	O
codeine	B-Drug
or	O
urine	O
users	O

The	O
emergency	O
scheduling	O
power	O
has	O
subsequently	O
been	O
used	O
for	O
a	O
variety	O
of	O
other	O
drugs	O
including	O
2C-B	B-Drug
AMT	B-Drug
and	O
BZP	B-Drug

Bayer	O
scientists	O
were	O
not	O
the	O
first	O
to	O
make	O
heroin	B-Drug
but	O
their	O
discovered	O
ways	O
it	O
and	O
led	O
commercialization	O
of	O

In	O
2013	O
cocaine	B-Drug
use	O
directly	O
resulted	O
in	O
4300	O
deaths	O
up	O
from	O
2400	O
1990	O

People	O
should	O
not	O
be	O
discharged	O
from	O
the	O
hospital	O
within	O
24	O
hours	O
of	O
receiving	O
lorazepam	B-Drug
premedication	O
unless	O
accompanied	O
by	O
a	O
caregiver	O

Afghan	O
opium	B-Drug
kills	O
around	O
100000	O
people	O
annually	O

The	O
making	O
and	O
use	O
of	O
opium	B-Drug
was	O
known	O
to	O
the	O
ancient	O
Minoans	O

Clonazepam	B-Drug
has	O
been	O
found	O
to	O
be	O
effective	O
in	O
the	O
acute	O
control	O
of	O
non-convulsive	O
status	O
epilepticus;	O
however	O
benefits	O
tended	O
transient	O
many	O
people	O
and	O
addition	O
phenytoin	B-Drug
for	O
lasting	O
was	O
required	O
these	O
patients	O

Most	O
likely	O
responsible	O
for	O
the	O
psychedelic	O
effects	O
associated	O
with	O
5-HT2A	O
receptor	O
agonists	O
such	O
as	O
LSD	B-Drug
DMT	O
etc	O

Veterinary-strength	O
etorphine	B-Drug
is	O
fatal	O
to	O
humans	O

In	O
the	O
late	O
1950s	O
and	O
early	O
1960s	O
more	O
than	O
10000	O
children	O
in	O
46	O
countries	O
were	O
born	O
with	O
deformities	O
such	O
as	O
phocomelia	O
a	O
consequence	O
of	O
thalidomide	B-Drug
use	O

Fentanyl	B-Drug
can	O
produce	O
the	O
following	O
clinical	O
effects	O
strongly	O
through	O
-receptor	O
agonism	O

PCP	B-Drug
is	O
well	O
known	O
for	O
its	O
primary	O
action	O
on	O
the	O
NMDA	O
receptor	O
an	O
ionotropic	O
glutamate	O
in	O
rats	O
and	O
rat	O
brain	O
homogenate	O

[See	O
cannabis	O
edibles	O
and	O
extracts	B-Drug

Due	O
to	O
its	O
ability	O
lower	O
the	O
seizure	O
threshold	O
patients	O
with	O
known	O
disorders	O
or	O
brain	O
injury	O
should	O
be	O
closely	O
monitored	O
during	O
enzalutamide	B-Drug
treatment	O

In	O
the	O
operation	O
932	O
kg	O
2055	O
lb	O
of	O
high	O
quality	O
heroin	B-Drug
and	O
156	O
344	O
opium	B-Drug
with	O
a	O
street	O
value	O
US$250	O
million	O
large	O
amount	O
technical	O
equipment	O
was	O
destroyed	O

Cocaine	B-Drug
heroin	B-Drug
and	O
increasingly	O
methamphetamine	B-Drug
are	O
also	O
traded	O

Phentermine	B-Drug
is	O
approved	O
for	O
up	O
to	O
12	O
weeks	O
of	O
use	O
and	O
most	O
weight	O
loss	O
occurs	O
in	O
the	O
first	O

In	O
2018	O
Purdue	O
Pharma	O
patented	O
a	O
new	O
form	O
of	O
buprenorphine	B-Drug
which	O
controls	O
cravings	O
and	O
is	O
used	O
to	O
treat	O
addiction	O
opioids	O
such	O
as	O
OxyContin	B-Drug

The	O
Egyptians	O
cultivated	O
opium	B-Drug
thebaicum	O
in	O
famous	O
poppy	O
fields	O
around	O
1300	O
BC	O

Carisoprodol	B-Drug
was	O
approved	O
for	O
medical	O
use	O
in	O
the	O
United	O
States	O
1959	O

Loperamide	B-Drug
is	O
a	O
peripherally	O
selective	O
opioid	O
available	O
without	O
prescription	O
and	O
used	O
to	O
suppress	O
diarrhea	O

These	O
derivatives	O
are	O
hydrolyzed	O
to	O
release	O
free	O
testosterone	O
at	O
the	O
site	O
of	O
injection;	O
absorption	O
rate	O
and	O
thus	O
injection	O
schedule	O
varies	O
among	O
different	O
esters	O
but	O
medical	O
injections	B-Drug
normally	O
done	O
anywhere	O
between	O
semi-weekly	O
once	O
every	O
12	O
weeks	O

A	O
2015	O
review	O
found	O
that	O
therapeutic	O
doses	O
of	O
amphetamine	B-Drug
and	O
methylphenidate	B-Drug
result	O
in	O
modest	O
improvements	O
cognition	O
including	O
working	O
memory	O
episodic	O
inhibitory	O
control	O
normal	O
healthy	O
adults;	O
the	O
cognition-enhancing	O
effects	O
these	O
drugs	O
are	O
known	O
to	O
occur	O
through	O
indirect	O
activation	O
both	O
dopamine	O
receptor	O
D1	O
adrenoceptor	O
2	O
prefrontal	O
cortex	O

The	O
highest	O
levels	O
of	O
tramadol	B-Drug
were	O
observed	O
with	O
the	O
maximum	O
oral	O
daily	O
dosage	O
400	O
mg	O
per	O
day	O
divided	O
into	O
one	O
100-mg	O
dose	O
every	O
6	O
hours	O
i	O

Along	O
with	O
norethisterone	B-Drug
it	O
is	O
one	O
of	O
the	O
only	O
progestins	O
that	O
widely	O
used	O
as	O
a	O
progestogen-only	O
mini	O
pill	O

Methamphetamine	B-Drug
hydrochloride	O
dispensed	O
in	O
the	O
United	O
States	O
is	O
required	O
to	O
include	O
a	O
boxed	O
warning	O
regarding	O
its	O
potential	O
for	O
recreational	O
misuse	O
and	O
addiction	O
liability	O

It	O
has	O
been	O
documented	O
that	O
the	O
threshold	O
dose	O
in	O
some	O
individuals	O
is	O
as	O
much	O
10	O
mg	O
insufflated	O
requiring	O
over	O
24	O
grams	O
of	O
beans	O
for	O
an	O
effective	O
5-MeO-DMT	B-Drug

Fentanyl	B-Drug
works	O
primarily	O
by	O
activating	O
-opioid	O
receptors	O

citizens	O
over	O
the	O
age	O
of	O
12	O
had	O
used	O
marijuana	B-Drug
within	O
a	O
month	O

In	O
2020	O
The	O
Pew	O
Charitable	O
Trusts	O
released	O
research	O
findings	O
which	O
show	O
that	O
increased	O
access	O
to	O
naloxone	B-Drug
saves	O
lives	O
and	O
recommends	O
co-prescribing	O
as	O
a	O
way	O
lower	O
the	O
number	O
of	O
overdose	O
fatalities	O

In	O
humans	O
amphetamine	B-Drug
is	O
metabolized	O
to	O
4-hydroxyamphetamine	O
by	O
CYP2D6	O
which	O
a	O
member	O
of	O
the	O
cytochrome	O
P450	O
superfamily	O
and	O
found	O
in	O
liver	O

The	O
duration	O
and	O
degree	O
of	O
reversal	O
sedative	O
benzodiazepine	O
effects	O
are	O
related	O
to	O
the	O
dose	O
plasma	O
concentrations	O
flumazenil	B-Drug

4-Hydroxy-NN-diisopropyltryptamine	O
4-HO-DiPT	B-Drug
or	O
Iprocin	O
is	O
a	O
synthetic	O
psychedelic	O
drug	O

The	O
amount	O
of	O
cocaine	B-Drug
in	O
a	O
line	O
varies	O
widely	O
from	O
person	O
to	O
and	O
occasion	O
the	O
purity	O
is	O
also	O
factor	O
but	O
one	O
generally	O
considered	O
be	O
single	O
dose	O

In	O
a	O
2004	O
interview	O
Paul	O
McCartney	O
said	O
that	O
The	O
Beatles'	O
songs	O
Day	O
Tripper	O
and	O
Lucy	O
in	O
the	O
Sky	O
with	O
Diamonds	O
were	O
inspired	O
by	O
LSD	B-Drug
trips	O

In	O
2019	O
the	O
cannabis	O
manufacturer	O
Canopy	O
Growth	O
acquired	O
majority	O
ownership	O
of	O
BioSteel	O
Sports	O
Nutrition	O
which	O
is	O
developing	O
CBD	B-Drug
products	O
under	O
endorsement	O
by	O
numerous	O
professional	O
athletes	O

cocaine	B-Drug
caffeine	O
nicotine	B-Drug
theobromine	O
and	O
have	O
been	O
used	O
in	O
entheogenic	O
rituals	O
or	O
as	O
recreational	O
drugs	O

Methohexital	B-Drug
can	O
be	O
synthesized	O
in	O
the	O
classic	O
manner	O
of	O
making	O
barbituric	O
acid	O
derivatives	O
particular	O
by	O
reaction	O
malonic	O
ester	O
with	O
urea	O

The	O
distribution	O
of	O
naloxone	B-Drug
to	O
injection	O
drug	O
users	O
and	O
other	O
opioid	O
decreases	O
the	O
risk	O
death	O
from	O
overdose	O

PCP	B-Drug
is	O
an	O
arylcyclohexylamine	O

The	O
elimination	O
half-life	O
of	O
eszopiclone	B-Drug
is	O
approximately	O
6	O
hours	O
and	O
it	O
extensively	O
metabolized	O
by	O
oxidation	O
demethylation	O

THC	O
tetrahydrocannabinol	O
THCA	O
tetrahydrocannabinolic	O
acid	O
CBD	B-Drug
cannabidiol	B-Drug
CBDA	O
cannabidiolic	O
CBN	O
cannabinol	O
CBG	O
cannabigerol	O
CBC	O
cannabichromene	O
CBL	O
cannabicyclol	B-Drug
CBV	O
cannabivarin	O
THCC	O
tetrahydrocannabiorcol	O
THCV	O
tetrahydrocannabivarin	O
THCP	O
tetrahydrocannabiphorol	O
CBDV	O
cannabidivarin	O
CBCV	O
cannabichromevarin	O
CBGV	O
cannabigerovarin	O
CBGM	O
monomethyl	O
ether	O
CBE	O
cannabielsoin	O
CBT	O
cannabicitran	O
Tetrahydrocannabinol	O
is	O
the	O
primary	O
psychoactive	O
component	O
of	O
Cannabis	O
plant	O

Alcohol	O
and	O
nicotine	B-Drug
also	O
prime	O
the	O
brain	O
for	O
a	O
heightened	O
response	O
to	O
other	O
drugs	O
are	O
like	O
marijuana	O
typically	O
used	O
before	O
person	O
progresses	O
more	O
harmful	O
substances	O

He	O
was	O
awarded	O
the	O
Nobel	O
Prize	O
for	O
Medicine	O
in	O
1988	O
work	O
leading	O
to	O
development	O
of	O
propranolol	B-Drug
and	O
cimetidine	B-Drug

It	O
is	O
an	O
androgen	O
ester;	O
specifically	O
it	O
the	O
C17	O
phenylpropionate	O
ester	O
of	O
nandrolone	B-Drug
19-nortestosterone	B-Drug
which	O
itself	O
19-demethylated	O
analogue	O
testosterone	O

The	O
disposition	O
of	O
MDMA	B-Drug
may	O
also	O
be	O
stereoselective	O
with	O
the	O
S-enantiomer	O
having	O
a	O
shorter	O
elimination	O
half-life	O
and	O
greater	O
excretion	O
than	O
R-enantiomer	O

After	O
the	O
seizure	O
of	O
a	O
methamphetamine	B-Drug
lab	O
low	O
exposure	O
risk	O
to	O
chemical	O
residues	O
often	O
exists	O
but	O
this	O
contamination	O
can	O
be	O
sanitized	O

Norethandrolone	B-Drug
was	O
introduced	O
for	O
medical	O
use	O
as	O
an	O
AAS	O
in	O
1956	O
and	O
the	O
first	O
so-called	O
anabolic	O
steroid	O
or	O
with	O
a	O
favorable	O
separation	O
of	O
androgenic	O
effect	O
to	O
be	O
marketed	O

The	O
UK	O
Home	O
Office	O
accepted	O
the	O
recommendation	O
and	O
enacted	O
legislation	O
to	O
ban	O
UR-144	B-Drug
as	O
a	O
class	O
B	O
drug	O
along	O
with	O
number	O
of	O
other	O
drugs	O
on	O
February	O
26	O
2013	O
part	O
Misuse	O
Drugs	O
Act	O
1971	O
Amendment	O
Order	O

Tincture	O
of	O
Opium	B-Drug
is	O
known	O
as	O
one	O
many	O
unapproved	O
drugs	O
regulated	O
by	O
the	O
U	O

Cocaine	B-Drug
also	O
known	O
as	O
coke	O
is	O
a	O
strong	O
stimulant	O
made	O
from	O
coca	B-Drug
leaves	O

Dinalbuphine	O
sebacate	O
DNS	O
also	O
known	O
as	O
nalbuphine	B-Drug
or	O
sebacoyl	O
dinalbuphine	O
ester	O
SDE	O
and	O
sold	O
under	O
the	O
brand	O
name	O
Naldebain	O
is	O
a	O
non-controlled	O
opioid	O
analgesic	O
which	O
used	O
7-day	O
long-acting	O
injection	O
in	O
treatment	O
of	O
moderate	O
to	O
severe	O
postoperative	O
pain	O

5-fold;	O
a	O
moderate	O
CYP2D6	O
inhibitor	O
fluoxetine	B-Drug
does	O
not	O
seem	O
to	O
have	O
significant	O
effect	O
on	O
the	O
levels	O
of	O
amitriptyline	B-Drug
or	O
nortriptyline	B-Drug

Imipramine	B-Drug
is	O
available	O
in	O
the	O
form	O
of	O
oral	O
tablets	O
and	O
capsules	O

Food	O
and	O
Drug	O
Administration	O
FDA	O
announced	O
that	O
the	O
agency	O
was	O
revoking	O
agency's	O
approval	O
of	O
breast	O
cancer	O
indication	O
for	O
bevacizumab	B-Drug
after	O
concluding	O
drug	O
had	O
not	O
been	O
shown	O
to	O
be	O
safe	O
effective	O
use	O

slurred	O
speech	O
immobilization	O
at	O
higher	O
doses;	O
in	O
addition	O
there	O
are	O
reports	O
of	O
ketamine	B-Drug
being	O
sold	O
as	O
ecstasy	B-Drug

Ketamine	B-Drug
produces	O
a	O
dissociative	O
state	O
characterized	O
by	O
sense	O
of	O
detachment	O
from	O
one's	O
physical	O
body	O
and	O
the	O
external	O
world	O
which	O
is	O
known	O
as	O
depersonalization	O
derealization	O

5F-ADB	B-Drug
was	O
added	O
to	O
the	O
Japanese	O
banned	O
drug	O
list	O
in	O
December	O
2014	O

Alkylation	O
of	O
that	O
amine	O
by	O
means	O
N-2-chloroethylmorpholine	O
gives	O
morpheridine	B-Drug

Antagonists	O
of	O
the	O
5-HT2A	O
receptor	O
like	O
cyproheptadine	B-Drug
and	O
chlorpromazine	B-Drug
are	O
able	O
to	O
reverse	O
mediate	O
recovery	O
from	O
serotonin	O
syndrome	O

Gastrointestinal	O
and	O
urinary	O
pH	O
affect	O
the	O
absorption	O
elimination	O
of	O
amphetamine	B-Drug
respectively	O

These	O
effects	O
appear	O
to	O
be	O
due	O
their	O
local	O
anesthetic	O
activity	O
and	O
are	O
not	O
reversed	O
by	O
naloxone	B-Drug

It	O
produces	O
an	O
intense	O
long	O
lasting	O
euphoria	O
similar	O
to	O
IV	O
heroin	B-Drug
use	O

In	O
England	O
Charles	O
Romley	O
Alder	O
Wright	O
developed	O
hundreds	O
of	O
opiate	O
compounds	O
in	O
his	O
search	O
for	O
a	O
nonaddictive	O
opium	B-Drug
derivative	O

Nortriptyline	B-Drug
the	O
main	O
active	O
metabolite	O
of	O
amitriptyline	B-Drug
is	O
an	O
antidepressant	O
on	O
its	O
own	O
right	O

GHB	B-Drug
tends	O
to	O
cause	O
rapid	O
unconsciousness	O
at	O
doses	O
above	O
3500	O
mg	O
with	O
single	O
over	O
7000	O
often	O
causing	O
life-threatening	O
respiratory	O
depression	O
and	O
higher	O
still	O
inducing	O
bradycardia	O
cardiac	O
arrest	O

This	O
was	O
the	O
first	O
intentional	O
LSD	B-Drug
trip	O

LAAM	B-Drug
undergoes	O
extensive	O
first-pass	O
metabolism	O
to	O
the	O
active	O
demethylated	O
metabolite	O
nor-LAAM	O
which	O
is	O
further	O
a	O
second	O
dinor-LAAM	O

Quazepam	B-Drug
is	O
effective	O
as	O
a	O
premedication	O
prior	O
to	O
surgery	O

While	O
many	O
pharmacies	O
will	O
dispense	O
Narcan	B-Drug
or	O
naloxone	B-Drug
without	O
a	O
prescription	O
is	O
usually	O
required	O
for	O
health	O
insurance	O
reimbursement	O

It	O
is	O
the	O
main	O
foreign	O
supplier	O
of	O
cannabis	O
and	O
an	O
important	O
entry	O
point	O
South	O
American	O
cocaine	B-Drug
Asian	O
methamphetamine	B-Drug
to	O
United	O
States	O

In	O
the	O
final	O
step	O
hyoscyamine	B-Drug
undergoes	O
epoxidation	O
catalyzed	O
by	O
6beta-hydroxyhyoscyamine	O
epoxidase	O
yielding	O
hyoscine	O

Oxendolone	O
also	O
known	O
as	O
16-ethyl-19-nortestosterone	O
or	O
16-ethylestr-4-en-17-ol-3-one	O
is	O
a	O
synthetic	O
estrane	O
steroid	O
and	O
derivative	O
of	O
testosterone	O
19-nortestosterone	B-Drug
nandrolone	B-Drug

In	O
the	O
United	O
States	O
acetylmethadol	B-Drug
and	O
its	O
individual	O
isomers	O
are	O
all	O
Schedule	O
I	O
drugs	O
under	O
Controlled	O
Substances	O
Act	O
except	O
LAAM	B-Drug
which	O
is	O
II	O
was	O
used	O
clinically	O
until	O
2003	O

After	O
annual	O
sales	O
of	O
$166	O
million	O
in	O
January	O
2015	O
Johnson	O
&	O
sold	O
its	O
rights	O
to	O
market	O
tapentadol	B-Drug
the	O
US	O
Depomed	O
for	O
$1	O
billion	O

Pentazocine	B-Drug
is	O
used	O
primarily	O
to	O
treat	O
pain	O
although	O
its	O
analgesic	O
effects	O
are	O
subject	O
a	O
ceiling	O
effect	O

In	O
the	O
United	O
Kingdom	O
diamorphine	B-Drug
is	O
available	O
by	O
prescription	O
though	O
it	O
a	O
restricted	O
Class	O
A	O
drug	O

Bicalutamide	B-Drug
is	O
eliminated	O
in	O
similar	O
proportions	O
feces	O
43%	O
and	O
urine	O
34%	O
while	O
its	O
metabolites	O
are	O
roughly	O
equally	O
bile	O

When	O
smoked	O
cocaine	B-Drug
is	O
sometimes	O
combined	O
with	O
other	O
drugs	O
such	O
as	O
cannabis	O
often	O
rolled	O
into	O
a	O
joint	O
or	O
blunt	O

In	O
turn	O
alcohol	O
and	O
tobacco	B-Drug
are	O
typically	O
easier	O
to	O
obtain	O
at	O
an	O
earlier	O
age	O
than	O
is	O
cannabis	O
though	O
the	O
reverse	O
may	O
be	O
true	O
in	O
some	O
areas	O
thus	O
leading	O
gateway	O
sequence	O
those	O
individuals	O
since	O
they	O
most	O
likely	O
experiment	O
with	O
any	O
drug	O
offered	O

Similarly	O
to	O
trenbolone	B-Drug
undecanoate	O
it	O
was	O
never	O
marketed	O
but	O
has	O
been	O
sold	O
on	O
the	O
black	O
market	O
as	O
a	O
designer	O
steroid	O
for	O
bodybuilders	O
and	O
athletes	O

Users	O
report	O
an	O
intense	O
rush	O
acute	O
transcendent	O
state	O
of	O
euphoria	O
which	O
occurs	O
while	O
diamorphine	B-Drug
is	O
being	O
metabolized	O
into	O
6-monoacetylmorphine	O
6-MAM	O
and	O
morphine	B-Drug
in	O
the	O
brain	O

Typical	O
antipsychotics	O
such	O
as	O
phenothiazines	O
and	O
haloperidol	B-Drug
have	O
been	O
used	O
to	O
control	O
psychotic	O
symptoms	O
but	O
may	O
produce	O
many	O
undesirable	O
side	O
effects	O
dystonia	O
their	O
use	O
is	O
therefore	O
no	O
longer	O
preferred;	O
are	O
particularly	O
risky	O
they	O
lower	O
the	O
seizure	O
threshold	O
worsen	O
hyperthermia	O
boost	O
anticholinergic	O
of	O
PCP	B-Drug

In	O
the	O
United	O
States	O
laws	O
were	O
passed	O
in	O
1966	O
that	O
prohibited	O
production	O
trade	O
or	O
ingestion	O
of	O
hallucinogenic	O
drugs;	O
Sandoz	O
stopped	O
producing	O
LSD	B-Drug
and	O
psilocybin	O
same	O
year	O

As	O
naldemedine	B-Drug
is	O
mainly	O
metabolized	O
by	O
the	O
liver	O
enzyme	O
CYP3A4	O
inhibitors	O
of	O
this	O
can	O
increase	O
its	O
concentrations	O
in	O
body	O
and	O
thus	O
potential	O
for	O
side	O
effects	O

In	O
1888	O
Broomhall	O
formed	O
and	O
became	O
secretary	O
of	O
the	O
Christian	O
Union	O
for	O
Severance	O
British	O
Empire	O
with	O
Opium	B-Drug
Traffic	O
editor	O
its	O
periodical	O
National	O
Righteousness	O

Alternative	O
drug	O
options	O
for	O
opioids	O
include	O
ibuprofen	B-Drug
Tylenol	O
Aspirin	B-Drug
and	O
steroid	O
all	O
of	O
which	O
can	O
be	O
prescribed	O
to	O
patients	O
or	O
provided	O
them	O
over	O
the	O
counter	O

Elemental	O
iodine	O
is	O
slightly	O
soluble	O
in	O
water	O
with	O
one	O
gram	O
dissolving	O
3450	O
ml	O
at	O
20	O
C	O
and	O
1280	O
50	O
C;	O
potassium	B-Drug
iodide	I-Drug
may	O
be	O
added	O
to	O
increase	O
solubility	O
via	O
formation	O
of	O
triiodide	O
ions	O
among	O
other	O
polyiodides	O

A	O
moderate	O
overdose	O
of	O
methamphetamine	B-Drug
may	O
induce	O
symptoms	O
such	O
as:	O
abnormal	O
heart	O
rhythm	O
confusion	O
difficult	O
and/or	O
painful	O
urination	O
high	O
or	O
low	O
blood	O
pressure	O
body	O
temperature	O
over-active	O
over-responsive	O
reflexes	O
muscle	O
aches	O
severe	O
agitation	O
rapid	O
breathing	O
tremor	O
urinary	O
hesitancy	O
and	O
an	O
inability	O
to	O
pass	O
urine	O

However	O
due	O
to	O
the	O
federal	O
ban	O
on	O
androstenedione	B-Drug
supplements	O
it	O
is	O
difficult	O
carry	O
out	O
new	O
research	O
its	O
effects	O

Cocaine	B-Drug
reverse	O
ester	O
however	O
did	O
not	O
produce	O
cocaine-like	O
stimulant	O
effects	O
in	O
animal	O
studies	O
and	O
is	O
also	O
illegal	O
many	O
jurisdictions	O
as	O
a	O
structural	O
isomer	O
of	O
cocaine;	O
nevertheless	O
it	O
has	O
attracted	O
attention	O
from	O
vendors	O
quasi-legal	O
designer	O
drugs	O
potential	O
alternative	O
to	O
cocaine	B-Drug

Drugs	O
in	O
this	O
schedule	O
include:	O
Amphetamine	B-Drug
drugs	O
including	O
Adderall	B-Drug
Dextroamphetamine	B-Drug
Dexedrine	B-Drug
Lisdexamfetamine	B-Drug
Vyvanse:	O
treatment	O
of	O
ADHD	O
narcolepsy	O
severe	O
obesity	O
limited	O
use	O
dextroamphetamine	B-Drug
only	O
binge	O
eating	O
disorder	O
lisdexamfetamine	B-Drug
Vyvanse	B-Drug

The	O
elimination	O
half-life	O
of	O
cathinone	B-Drug
is	O
1	O

Pentobarbital	B-Drug
can	O
cause	O
death	O
when	O
used	O
in	O
high	O
doses	O

Today	O
nicotine	B-Drug
is	O
less	O
commonly	O
used	O
in	O
agricultural	O
insecticides	O
which	O
was	O
a	O
main	O
source	O
of	O
poisoning	O

Purdue	O
Pharma	O
a	O
privately	O
held	O
company	O
based	O
in	O
Stamford	O
Connecticut	O
developed	O
the	O
prescription	O
painkiller	O
OxyContin	B-Drug

Ketamine	B-Drug
use	O
as	O
a	O
recreational	O
drug	O
has	O
been	O
implicated	O
in	O
deaths	O
globally	O
with	O
more	O
than	O
90	O
England	O
and	O
Wales	O
the	O
years	O
of	O
20052013	O

Because	O
of	O
this	O
ibuprofen	B-Drug
should	O
be	O
avoided	O
after	O
30	O
weeks	O
gestation	O

Sofosbuvir	B-Drug
appears	O
to	O
have	O
a	O
high	O
barrier	O
the	O
development	O
of	O
resistance	O

The	O
purpose	O
of	O
these	O
coffee	O
shops	O
are	O
to	O
help	O
people	O
who	O
use	O
soft	O
drugs	O
such	O
as	O
cannabis	O
avoid	O
contact	O
with	O
hard	O
heroin	B-Drug

The	O
patient	O
was	O
treated	O
with	O
1	O
mg	O
of	O
lorazepam	B-Drug
and	O
the	O
sympathomimetic	O
features	O
decreased	O
user	O
discharged	O
within	O
six	O
hours	O
arrival	O

Houston	O
Merritt	O
and	O
Tracy	O
Putnam	O
discovered	O
phenytoin's	O
usefulness	O
for	O
controlling	O
seizures	O
without	O
the	O
sedative	O
effects	O
associated	O
with	O
phenobarbital	B-Drug
phenytoin	B-Drug

Spironolactone	B-Drug
has	O
been	O
found	O
to	O
block	O
EpsteinBarr	O
virus	O
EBV	O
production	O
and	O
that	O
of	O
other	O
human	O
herpesviruses	O
by	O
inhibiting	O
the	O
function	O
an	O
protein	O
SM	O
which	O
is	O
essential	O
for	O
infectious	O

In	O
February	O
2010	O
22	O
men	O
were	O
arrested	O
in	O
connection	O
with	O
importing	O
mephedrone	B-Drug

As	O
the	O
name	O
implies	O
freebase	O
is	O
base	O
form	O
of	O
cocaine	B-Drug
as	O
opposed	O
to	O
salt	O

Psychedelic	O
music	O
sometimes	O
called	O
psychedelia	O
is	O
a	O
wide	O
range	O
of	O
popular	O
styles	O
and	O
genres	O
influenced	O
by	O
1960s	O
subculture	O
people	O
who	O
used	O
psychedelic	O
drugs	O
such	O
as	O
LSD	B-Drug
psilocybin	O
mushrooms	O
mescaline	B-Drug
DMT	O
to	O
experience	O
visual	O
auditory	O
hallucinations	O
synesthesia	O
altered	O
states	O
consciousness	O

In	O
vitro	O
cannabidiol	B-Drug
inhibited	O
the	O
activity	O
of	O
voltage-dependent	O
sodium	O
and	O
potassium	O
channels	O
which	O
may	O
affect	O
neural	O

Additionally	O
recent	O
poppy	O
seed	O
cultivation	O
has	O
decreased	O
while	O
coca	B-Drug
actually	O
not	O

In	O
1998	O
modafinil	B-Drug
was	O
approved	O
by	O
the	O
U	O

Pemoline	B-Drug
as	O
Betanamin	O
continues	O
to	O
be	O
available	O
in	O
Japan	O
where	O
no	O
liver	O
failure	O
cases	O
have	O
been	O
reported	O
associated	O
with	O
its	O
use	O
however	O
it	O
is	O
only	O
prescribed	O
for	O
the	O
niche	O
indication	O
of	O
narcolepsy	O
and	O
at	O
a	O
lower	O
dose	O
than	O
previously	O
used	O
USA	O

More	O
reliable	O
methods	O
for	O
detecting	O
cocaine	B-Drug
exposure	O
involve	O
testing	O
the	O
newborn's	O
hair	O
or	O
meconium	O
infant's	O
earliest	O
stool	O

Between	O
1997	O
and	O
2008	O
Grnenthal	O
declined	O
further	O
payments	O
to	O
thalidomide	B-Drug
victims	O

The	O
most	O
common	O
causative	O
agents	O
are	O
substituted	O
amphetamines	O
including	O
cathinones	O
as	O
well	O
certain	O
dopamine	O
reuptake	O
inhibitors	O
such	O
cocaine	B-Drug
and	O
phenidates	O

Laudanum	B-Drug
worthy	O
of	O
praise	O
was	O
originally	O
the	O
16th-century	O
term	O
for	O
a	O
medicine	O
associated	O
with	O
particular	O
physician	O
that	O
widely	O
well-regarded	O
but	O
became	O
standardized	O
as	O
tincture	O
opium	B-Drug
solution	O
in	O
ethanol	O
which	O
Paracelsus	O
has	O
been	O
credited	O
developing	O

In	O
2018	O
results	O
were	O
first	O
published	O
which	O
suggested	O
that	O
thalidomide's	O
teratogenic	O
effects	O
are	O
mediated	O
through	O
degradation	O
of	O
the	O
transcription	O
factor	O
SALL4	O
an	O
as	O
yet	O
unverified	O
finding	O
thalidomide	B-Drug

Low	O
dose	O
mifepristone	B-Drug
tablets	O
Bi	O
Yun	O
Fu	O
Nai	O
Er	O
Hou	O
Ding	O
Nuo	O
Hua	O
Dian	O
Si	O
Mi	O
An	O
for	O
emergency	O
contraception	O
are	O
available	O
directly	O
from	O
a	O
pharmacist	O
without	O
prescription	O
and	O
with	O
in	O
China	O

3%	O
of	O
secondary	O
school	O
students	O
in	O
Texas	O
had	O
taken	O
codeine	B-Drug
syrup	O
to	O
get	O
high	O

In	O
August	O
2018	O
the	O
United	O
States	O
used	O
fentanyl	B-Drug
for	O
first	O
time	O
to	O
execute	O
a	O
prisoner	O

At	O
least	O
one	O
case	O
of	O
JWH-018	B-Drug
dependence	O
has	O
been	O
reported	O
by	O
the	O
media	O

Sustained	O
aerobic	O
exercise	O
on	O
a	O
regular	O
basis	O
also	O
appears	O
to	O
be	O
an	O
effective	O
treatment	O
for	O
amphetamine	B-Drug
addiction;	O
therapy	O
improves	O
clinical	O
outcomes	O
and	O
may	O
used	O
as	O
adjunct	O
with	O
behavioral	O
therapies	O
addiction	O

Cases	O
of	O
doping	O
with	O
oxandrolone	B-Drug
by	O
professional	O
athletes	O
have	O
been	O
reported	O

Side	O
effects	O
of	O
apalutamide	B-Drug
when	O
added	O
to	O
castration	O
include	O
fatigue	O
nausea	O
abdominal	O
pain	O
diarrhea	O
high	O
blood	O
pressure	O
rash	O
falls	O
bone	O
fractures	O
and	O
an	O
underactive	O
thyroid	O

Analogues	O
of	O
PCP	B-Drug
exhibit	O
varying	O
potency	O
at	O
nACh	O
receptors	O
and	O
NMDA	O

This	O
risk	O
is	O
increased	O
when	O
temazepam	B-Drug
given	O
concomitantly	O
with	O
other	O
drugs	O
that	O
depress	O
the	O
central	O
nervous	O
system	O
CNS	O

In	O
theory	O
diprenorphine	O
could	O
also	O
be	O
used	O
as	O
an	O
antidote	O
for	O
treating	O
overdose	O
of	O
certain	O
opioid	O
derivatives	O
which	O
are	O
in	O
humans	O
particularly	O
buprenorphine	B-Drug
the	O
binding	O
affinity	O
is	O
so	O
high	O
that	O
naloxone	B-Drug
does	O
not	O
reliably	O
reverse	O
narcotic	O
effects	O

Anthropologist	O
Michael	O
Agar	O
once	O
described	O
heroin	B-Drug
as	O
the	O
perfect	O
whatever	O
drug	O

After	O
receiving	O
a	O
bolus	O
dose	O
of	O
fentanyl	B-Drug
people	O
can	O
also	O
experience	O
paradoxical	O
coughing	O
which	O
is	O
phenomenon	O
that	O
not	O
well	O
understood	O

Methadone	B-Drug
was	O
introduced	O
into	O
the	O
United	O
States	O
in	O
1947	O
by	O
Eli	O
Lilly	O
and	O
Company	O
as	O
an	O
analgesic	O
under	O
trade	O
name	O
Dolophine	O

A	O
2007	O
study	O
in	O
the	O
Addictive	O
Behaviors	O
journal	O
found	O
a	O
positive	O
correlation	O
between	O
secondhand	O
tobacco	O
smoke	O
exposure	O
and	O
concentrations	O
of	O
nicotine	B-Drug
and/or	O
biomarkers	O
body	O

Although	O
overall	O
incidence	O
of	O
male	O
breast	O
cancer	O
in	O
clinical	O
trials	O
for	O
finasteride	B-Drug
5	O
mg	O
was	O
not	O
increased	O
there	O
are	O
post-marketing	O
reports	O
association	O
with	O
its	O
use	O
though	O
available	O
evidence	O
does	O
provide	O
clarity	O
as	O
to	O
whether	O
is	O
a	O
causative	O
relationship	O
between	O
and	O
these	O
cancers	O

Unlike	O
enzalutamide	B-Drug
the	O
drug	O
showed	O
low	O
central	O
nervous	O
system	O
distribution	O
and	O
no	O
induction	O
of	O
seizures	O
in	O
animals	O

0]undeca-581012-tetraen-4-yl	O
NN-dimethylcarbamate	O
Clonazepam	B-Drug
also	O
known	O
as	O
6-2-chlorophenyl-9-nitro-25-diazabicyclo[5	O

There	O
is	O
a	O
story	O
in	O
circulation	O
that	O
Wood's	O
wife	O
Rebecca	O
Massey	O
was	O
the	O
first	O
known	O
intravenous	O
morphine	B-Drug
addict	O
and	O
died	O
of	O
an	O
overdose	O
delivered	O
by	O
her	O
husband's	O
invention	O
however	O
Richard	O
Davenport-Hines	O
says	O
'It	O
myth:	O
she	O
outlived	O
him	O
survived	O
until	O
1895	O

O-1918	O
is	O
a	O
synthetic	O
compound	O
related	O
to	O
cannabidiol	B-Drug
which	O
an	O
antagonist	O
at	O
two	O
former	O
orphan	O
receptors	O
GPR18	O
and	O
GPR55	O
that	O
appear	O
be	O
the	O
cannabinoid	O

Various	O
physical	O
and	O
psychological	O
adverse	O
effects	O
have	O
been	O
reported	O
from	O
JWH-018	B-Drug
use	O

The	O
pharmacologically	O
active	O
isomer	O
of	O
naloxone	B-Drug
is	O
-naloxone	O

In	O
Canada	O
the	O
history	O
of	O
thalidomide	B-Drug
dates	O
back	O
to	O
April	O
1	O
1961	O

Despite	O
being	O
a	O
more	O
potent	O
analgesic	O
fentanyl	B-Drug
tends	O
to	O
induce	O
less	O
nausea	O
as	O
well	O
histamine-mediated	O
itching	O
than	O
morphine	B-Drug

Clonazepam	B-Drug
has	O
also	O
been	O
found	O
effective	O
in	O
treating	O
other	O
anxiety	O
disorders	O
such	O
as	O
social	O
phobia	O
but	O
this	O
is	O
an	O
off-label	O
use	O

It	O
was	O
also	O
reported	O
in	O
Joliet	O
Illinois	O
and	O
McHenry	O
October	O
2013	O
but	O
no	O
laboratory	O
tests	O
have	O
confirmed	O
that	O
desomorphine	B-Drug
present	O
the	O
blood	O
urine	O
or	O
tissues	O
of	O
hospitalized	O
krokodil	O
patients	O

Some	O
individuals	O
require	O
a	O
second	O
or	O
third	O
treatment	O
session	O
with	O
ibogaine	B-Drug
over	O
the	O
course	O
of	O
12	O
to	O
18	O
months	O

Cocaine	B-Drug
80's	O
was	O
an	O
American	O
hip	O
hop	O
collective	O
founded	O
in	O
2011	O
by	O
record	O
producer	O
No	O
I	O

In	O
addition	O
some	O
parts	O
of	O
Europe	O
the	O
United	O
States	O
and	O
Australia	O
allow	O
processed	O
cocaine	B-Drug
for	O
medicinal	O
uses	O
only	O

Neurochemically	O
MDMA	B-Drug
activates	O
5-hydroxytryptamine	O
or	O
5-HT	O
serotonin	O
receptors	O
specifically	O
at	O
the	O
5-HT1A	O
and	O
5-HT1B	O
G-protein	O
coupled	O

5	O
mg	O
of	O
dihydrocodeine	B-Drug
per	O
tablet	O

Of	O
the	O
2C-T	O
family	O
there	O
have	O
been	O
a	O
few	O
confirmed	O
deaths	O
due	O
to	O
2C-T-7	O
which	O
involved	O
either	O
insufflating	O
large	O
>30	O
mg	O
doses	O
and	O
in	O
one	O
case	O
an	O
unknown	O
oral	O
dose	O
was	O
combined	O
with	O
200	O
MDMA	B-Drug

Long-term	O
use	O
of	O
laudanum	B-Drug
in	O
nonterminal	O
diseases	O
is	O
discouraged	O
due	O
to	O
the	O
possibility	O
drug	O
tolerance	O
and	O
addiction	O

The	O
right-handed	O
dextrorotatory	O
enantiomer	O
of	O
racemorphan	B-Drug
is	O
dextrorphan	B-Drug
DXO	O
an	O
antitussive	O
potent	O
dissociative	O
hallucinogen	O
NMDA	O
receptor	O
antagonist	O
and	O
weakly	O
active	O
opioid	O

It	O
is	O
not	O
clear	O
whether	O
ketamine	B-Drug
alone	O
sufficient	O
for	O
the	O
antidepressive	O
action	O
or	O
its	O
metabolites	O
are	O
also	O
important	O

The	O
plasma	O
half-life	O
of	O
naltrexone	B-Drug
and	O
its	O
metabolite	O
6-naltrexol	O
are	O
about	O
4	O
hours	O
13	O
respectively	O

Dextroamphetamine	B-Drug
is	O
sometimes	O
prescribed	O
as	O
the	O
inactive	O
prodrug	O
lisdexamfetamine	B-Drug
dimesylate	I-Drug
which	O
converted	O
into	O
dextroamphetamine	B-Drug
after	O
absorption	O

The	O
254	O
pounds	O
115	O
kg	O
of	O
fentanyl	B-Drug
which	O
was	O
estimated	O
to	O
be	O
worth	O
US$3	O

In	O
addition	O
it	O
tends	O
to	O
cause	O
less	O
vomiting	O
and	O
regurgitation	O
than	O
other	O
pure-opiate	O
codeine	B-Drug
morphine	B-Drug
synthetic	O
pure-opioid	O
agonists	O
oxycodone	B-Drug
hydromorphone	B-Drug
when	O
given	O
as	O
a	O
continuous	O
post-operative	O
infusion	O

In	O
2014	O
researchers	O
demonstrated	O
the	O
immunomodulatory	O
potential	O
of	O
DMT	O
and	O
5-MeO-DMT	B-Drug
through	O
Sigma-1	O
receptor	O
human	O
immune	O
cells	O

Life-threatening	O
adverse	O
reactions	O
caused	O
by	O
furanylfentanyl	B-Drug
use	O
have	O
been	O
observed	O
in	O
Sweden	O
and	O
Canada	O

Dextroamphetamine	B-Drug
marketed	O
under	O
the	O
brand	O
names	O
Dexedrine	B-Drug
and	O
Zenzedi	O
is	O
only	O
enantiopure	O
amphetamine	B-Drug
product	O
currently	O
available	O

A	O
reduced	O
quality	O
of	O
life	O
is	O
associated	O
with	O
heavy	O
cannabis	O
use	O
although	O
the	O
relationship	O
inconsistent	O
and	O
weaker	O
than	O
for	O
tobacco	B-Drug
other	O
substances	O

B&O	O
Supprettes	O
the	O
name	O
is	O
derived	O
from	O
generic	O
term	O
'belladonna/opium	O
suppository'	O
an	O
unapproved	O
drug	O
according	O
to	O
Food	O
and	O
Drug	O
Administration	O
FDA	O
that	O
existed	O
before	O
Cosmetic	O
Act	O
of	O
1938	O
opium	B-Drug

Butorphanol	B-Drug
is	O
listed	O
under	O
the	O
Single	O
Convention	O
on	O
Narcotic	O
Drugs	O
1961	O
and	O
in	O
United	O
States	O
a	O
Schedule	O
IV	O
controlled	O
substance	O
with	O
DEA	O
ACSCN	O
of	O
9720;	O
being	O
it	O
not	O
subject	O
to	O
annual	O
aggregate	O
manufacturing	O
quotas	O

In	O
2016	O
three	O
new	O
major	O
metabolites	O
of	O
bupropion	B-Drug
all	O
formed	O
exclusively	O
by	O
CYP2C19	O
were	O
identified	O

While	O
this	O
act	O
is	O
often	O
seen	O
as	O
the	O
start	O
of	O
prohibition	O
itself	O
was	O
not	O
actually	O
a	O
on	O
cocaine	B-Drug
but	O
instead	O
set	O
up	O
regulatory	O
and	O
licensing	O
regime	O

Like	O
all	O
opioids	O
the	O
effects	O
of	O
fentanyl	B-Drug
can	O
be	O
reversed	O
with	O
naloxone	B-Drug
or	O
other	O
opiate	O
antagonists	O

The	O
effects	O
of	O
drinking	O
coca	B-Drug
tea	O
are	O
a	O
mild	O
stimulation	O
and	O
mood	O
lift	O

LSD	B-Drug
can	O
cause	O
pupil	O
dilation	O
reduced	O
appetite	O
profuse	O
sweating	O
and	O
wakefulness	O

Listed	O
as	O
a	O
Schedule	O
1	O
it	O
is	O
an	O
analogue	O
of	O
amphetamine	B-Drug

In	O
Canada	O
the	O
history	O
of	O
thalidomide	B-Drug
dates	O
back	O
to	O
April	O
1	O
1961	O

Internationally	O
DET	B-Drug
is	O
a	O
Schedule	O
I	O
drug	O
under	O
the	O
Convention	O
on	O
Psychotropic	O
Substances	O

In	O
methamphetamine	B-Drug
addicted	O
rats	O
epigenetic	O
regulation	O
through	O
reduced	O
acetylation	O
of	O
histones	O
in	O
brain	O
striatal	O
neurons	O
caused	O
transcription	O
glutamate	O
receptors	O

36	O
diesters	O
and	O
6	O
monoesters	O
of	O
morphine	B-Drug
acetylated	O
analogues	O
closely	O
related	O
drugs	O
like	O
hydromorphone	B-Drug
dihydromorphine	B-Drug
were	O
produced	O
in	O
massive	O
quantities	O
to	O
fill	O
the	O
worldwide	O
demand	O
for	O
diacetylmorphinethis	O
continued	O
until	O
1930	O
when	O
Committee	O
banned	O
diacetylmorphine	B-Drug
with	O
no	O
therapeutic	O
advantage	O
over	O
already	O
use	O
first	O
major	O
legislation	O
this	O
type	O

Of	O
these	O
first	O
famous	O
anesthetics	O
only	O
nitrous	O
oxide	O
is	O
still	O
widely	O
used	O
today	O
with	O
chloroform	O
and	O
ether	O
having	O
been	O
replaced	O
by	O
safer	O
but	O
sometimes	O
more	O
expensive	O
general	O
cocaine	B-Drug
effective	O
local	O
less	O
abuse	O
potential	O

Since	O
methamphetamine	B-Drug
is	O
easy	O
to	O
produce	O
the	O
substance	O
manufactured	O
locally	O
in	O
staggering	O
quantities	O

In	O
2018	O
Adderall	B-Drug
was	O
the	O
24th	O
most	O
commonly	O
prescribed	O
medication	O
in	O
United	O
States	O
with	O
more	O
than	O
25	O
million	O
prescriptions	O

Pentobarbital	B-Drug
previously	O
known	O
as	O
pentobarbitone	O
in	O
Britain	O
and	O
Australia	O
is	O
a	O
short-acting	O
barbiturate	O
typically	O
used	O
sedative	O
preanesthetic	O
to	O
control	O
convulsions	O
emergencies	O

From	O
1964	O
the	O
Merry	O
Pranksters	O
a	O
loose	O
group	O
that	O
developed	O
around	O
novelist	O
Ken	O
Kesey	O
sponsored	O
Acid	B-Drug
Tests	O
series	O
of	O
events	O
based	O
taking	O
LSD	B-Drug
supplied	O
by	O
Stanley	O
accompanied	O
light	O
shows	O
film	O
projection	O
and	O
discordant	O
improvised	O
music	O
known	O
as	O
psychedelic	O
symphony	O

Nitrazepam	B-Drug
is	O
not	O
recommended	O
for	O
use	O
in	O
those	O
under	O
18	O
years	O
of	O
age	O

In	O
the	O
Cannabis	O
plant	O
THC	O
occurs	O
mainly	O
as	O
tetrahydrocannabinolic	O
acid	B-Drug
THCA	O
2-COOH-THC	O
THC-COOH	O

However	O
in	O
2016	O
an	O
investigation	O
by	O
the	O
Los	O
Angeles	O
Times	O
found	O
that	O
drug	O
weans	O
off	O
hours	O
early	O
many	O
people	O
inducing	O
symptoms	O
of	O
opiate	O
withdrawal	O
and	O
intense	O
cravings	O
for	O
OxyContin	B-Drug

Psilocin	B-Drug
is	O
the	O
chemical	O
primarily	O
responsible	O
for	O
hallucinogenic	O
effects	O
of	O
Psilocybe	O

In	O
this	O
scenario	O
dissolved	O
cocaine	B-Drug
is	O
soaked	O
into	O
a	O
ball	O
of	O
cotton	O
wool	O
which	O
placed	O
in	O
the	O
nostril	O
for	O
1015	O
minutes	O
immediately	O
before	O
procedure	O
thus	O
performing	O
dual	O
role	O
both	O
numbing	O
area	O
to	O
be	O
cauterized	O
and	O
vasoconstriction	O

Despite	O
more	O
than	O
$70	O
million	O
in	O
personal	O
financing	O
his	O
push	O
to	O
see	O
phenytoin	B-Drug
evaluated	O
for	O
alternative	O
uses	O
has	O
had	O
little	O
lasting	O
effect	O
on	O
the	O
medical	O
community	O

Marijuana	B-Drug
use	O
is	O
also	O
linked	O
to	O
other	O
substance	O
disorders	O
including	O
nicotine	B-Drug
addiction	O

In	O
modern	O
times	O
much	O
of	O
the	O
thebaine	O
which	O
often	O
serves	O
as	O
raw	O
material	O
for	O
synthesis	O
oxycodone	B-Drug
hydrocodone	B-Drug
hydromorphone	B-Drug
and	O
other	O
semisynthetic	O
opiates	O
originates	O
from	O
extracting	O
Papaver	O
orientale	O
or	O
bracteatum	O

In	O
healthy	O
people	O
at	O
oral	O
therapeutic	O
doses	O
amphetamine	B-Drug
has	O
been	O
shown	O
to	O
increase	O
muscle	O
strength	O
acceleration	O
athletic	O
performance	O
in	O
anaerobic	O
conditions	O
and	O
endurance	O
i	O

The	O
fentanyl	B-Drug
patch	O
is	O
one	O
of	O
a	O
few	O
medications	O
that	O
may	O
be	O
especially	O
harmful	O
and	O
in	O
some	O
cases	O
fatal	O
with	O
just	O
dose	O
if	O
used	O
by	O
someone	O
other	O
than	O
the	O
person	O
for	O
whom	O
medication	O
was	O
prescribed	O

It	O
may	O
be	O
used	O
for:	O
Local	O
anesthesia	O
of	O
oral	O
and	O
pharyngeal	O
mucous	O
membranes	O
sore	O
throat	O
cold	O
sores	O
mouth	O
ulcers	O
toothache	O
gums	O
denture	O
irritation	O
Otic	O
pain	O
earache	O
Surgical	O
or	O
procedural	O
local	O
Benzocaine	B-Drug
is	O
as	O
a	O
key	O
ingredient	O
in	O
numerous	O
pharmaceuticals:	O
Some	O
glycerol-based	O
ear	O
medications	O
for	O
use	O
removing	O
excess	O
wax	O
well	O
relieving	O
conditions	O
such	O
otitis	O
media	O
swimmers	O

Reformulated	O
OxyContin	B-Drug
is	O
causing	O
some	O
recreational	O
users	O
to	O
change	O
heroin	B-Drug
which	O
cheaper	O
and	O
easier	O
obtain	O

The	O
authors	O
state	O
that	O
assuming	O
carfentanil	B-Drug
and	O
remifentanil	B-Drug
were	O
the	O
only	O
active	O
ingredients	O
of	O
knockout	O
gas	O
worst	O
danger	O
to	O
theater	O
victims	O
would	O
have	O
been	O
apnea	O
loss	O
breathing	O
mechanical	O
ventilation	O
and/or	O
treatment	O
with	O
opioid	O
antagonists	O
could	O
saved	O
many	O
lives	O

The	O
attachment	O
of	O
the	O
amino	O
acid	O
lysine	O
slows	O
down	O
relative	O
amount	O
dextroamphetamine	B-Drug
available	O
to	O
blood	O
stream	O

There	O
is	O
also	O
a	O
high	O
risk	O
that	O
thalidomide	B-Drug
can	O
interfere	O
with	O
formation	O
of	O
various	O
kinds	O
new	O
blood	O
cells	O
creating	O
infection	O
via	O
neutropenia	O
leukopenia	O
and	O
lymphopenia	O
risks	O
will	O
not	O
clot	O
thrombocytopenia	O

Clorazepate	B-Drug
like	O
other	O
benzodiazepines	O
is	O
widely	O
distributed	O
and	O
highly	O
bound	O
to	O
plasma	O
proteins;	O
clorazepate	B-Drug
also	O
crosses	O
readily	O
over	O
the	O
placenta	O
into	O
breast	O
milk	O

However	O
it	O
is	O
now	O
known	O
that	O
CBD	B-Drug
and	O
THC	O
are	O
produced	O
independently	O
in	O
the	O
cannabis	O
plant	O
from	O
precursor	O
CBG	O

Norethisterone	B-Drug
has	O
approximately	O
15%	O
of	O
the	O
affinity	O
anabolicandrogenic	O
steroid	O
AAS	O
metribolone	O
R-1881	O
for	O
AR	O
and	O
in	O
accordance	O
is	O
weakly	O
androgenic	O

When	O
amphetamine	B-Drug
enters	O
a	O
neuron	O
and	O
interacts	O
with	O
VMAT2	O
the	O
transporter	O
reverses	O
its	O
direction	O
of	O
transport	O
thereby	O
releasing	O
stored	O
monoamines	O
inside	O
synaptic	O
vesicles	O
back	O
into	O
neuron's	O
intracellular	O
fluid	O

On	O
June	O
11	O
2013	O
just	O
days	O
after	O
being	O
robbed	O
at	O
gunpoint	O
in	O
San	O
Francisco	O
rapper	O
2	O
Chainz	O
was	O
arrested	O
Los	O
Angeles	O
International	O
Airport	O
on	O
charges	O
of	O
possessing	O
promethazine	B-Drug
and	O
codeine	B-Drug
the	O
primary	O
ingredients	O
lean	O
along	O
with	O
marijuana	O

In	O
2009	O
Cymbalta	B-Drug
and	O
Effexor	B-Drug
were	O
the	O
11th-	O
12th-most-prescribed	O
branded	O
drugs	O
in	O
United	O
States	O
respectively	O

Hash	B-Drug
oil	I-Drug
is	O
a	O
resinous	O
matrix	O
of	O
cannabinoids	O
obtained	O
from	O
the	O
Cannabis	O
plant	O
by	O
solvent	O
extraction	O
formed	O
into	O
hardened	O
or	O
viscous	O
mass	O

Quinidine	B-Drug
may	O
interact	O
with	O
chlorpromazine	B-Drug
to	O
increase	O
myocardialdepression	O

Fentanyl	B-Drug
is	O
a	O
highly	O
lipophilic	O
compound	O
which	O
well	O
absorbed	O
sublingually	O
and	O
generally	O
tolerated	O

Acetyldihydrocodeine	B-Drug
can	O
be	O
described	O
as	O
the	O
6-acetyl	O
derivative	O
of	O
dihydrocodeine	B-Drug
and	O
is	O
metabolised	O
in	O
liver	O
by	O
demethylation	O
deacetylation	O
to	O
produce	O
dihydromorphine	B-Drug

Immediate-release	O
oxymorphone	B-Drug
tablets	O
are	O
recommended	O
for	O
breakthrough	O
pain	O
people	O
on	O
the	O
extended-release	O
version	O

Dihydrocodeine	B-Drug
products	O
which	O
can	O
be	O
purchased	O
over	O
the	O
counter	O
in	O
many	O
European	O
and	O
Pacific	O
Rim	O
countries	O
generally	O
contain	O
from	O
2	O
to	O
20	O
mg	O
of	O
dihydrocodeine	B-Drug
per	O
dosing	O
unit	O
combined	O
with	O
one	O
or	O
more	O
other	O
active	O
ingredients	O
such	O
as	O
paracetamol	B-Drug
acetaminophen	B-Drug
aspirin	B-Drug
ibuprofen	B-Drug
antihistamines	O
decongestants	O
vitamins	O
medicinal	O
herb	O
preparations	O

The	O
5-HT2	O
receptor	O
particularly	O
the	O
subtypes	O
5-HT2A	O
5-HT2B	O
and	O
5-HT2C	O
are	O
involved	O
in	O
locomotor-activating	O
effects	O
of	O
cocaine	B-Drug

PCP	B-Drug
may	O
cause	O
hallucinations	O
distorted	O
perceptions	O
of	O
sounds	O
and	O
violent	O
behavior	O

Due	O
to	O
concerns	O
about	O
the	O
potential	O
of	O
JWH-018	B-Drug
and	O
other	O
synthetic	O
cannabinoids	O
cause	O
psychosis	O
in	O
vulnerable	O
individuals	O
it	O
has	O
been	O
recommended	O
that	O
people	O
with	O
risk	O
factors	O
for	O
psychotic	O
illnesses	O
like	O
a	O
past	O
or	O
family	O
history	O
not	O
use	O
these	O
substances	O

Risperidone	B-Drug
and	O
its	O
metabolite	O
paliperidone	B-Drug
are	O
reduced	O
in	O
efficacy	O
by	O
P-glycoprotein	O
inducers	O
such	O
as	O
St	O
John's	O
wort	O
The	O
British	O
National	O
Formulary	O
recommends	O
a	O
gradual	O
withdrawal	O
when	O
discontinuing	O
antipsychotic	O
treatment	O
to	O
avoid	O
acute	O
syndrome	O
or	O
rapid	O
relapse	O

In	O
many	O
areas	O
of	O
South	O
America	O
the	O
coca	B-Drug
leaf	O
has	O
traditionally	O
been	O
chewed	O
and	O
used	O
in	O
tea	O
for	O
religious	O
medicinal	O
nutritional	O
purposes	O
by	O
locals	O

Unlike	O
morphine	B-Drug
and	O
other	O
opioids	O
that	O
are	O
used	O
to	O
alleviate	O
pain	O
nociceptin's	O
role	O
in	O
nociception	O
is	O
not	O
straightforward	O

Toklas	O
included	O
a	O
recipe	O
for	O
haschich	B-Drug
fudge	O
which	O
was	O
contributed	O
by	O
artist	O
and	O
friend	O
Brion	O
Gysin	O
when	O
the	O
book	O
published	O
in	O
1954	O

Bicalutamide	B-Drug
Casodex:	O
Marketed	O
for	O
the	O
treatment	O
of	O
prostate	O
cancer	O
and	O
also	O
used	O
in	O
hirsutism	O
women	O
as	O
a	O
component	O
hormone	O
therapy	O
transgender	O
to	O
delay	O
precocious	O
puberty	O
boys	O
prevent	O
or	O
alleviate	O
priapism	O
other	O
indications	O
Casodex	B-Drug

In	O
the	O
United	O
States	O
GHB	B-Drug
was	O
placed	O
on	O
Schedule	O
I	O
of	O
Controlled	O
Substances	O
Act	O
in	O
March	O
2000	O

When	O
Richwood	O
acquired	O
Rexar	O
the	O
drug's	O
name	O
was	O
changed	O
from	O
Obetrol	B-Drug
to	O
Adderall	B-Drug
and	O
drug	O
marketed	O
for	O
use	O
in	O
treatment	O
of	O
Attention	O
Deficit	O
Disorder	O
both	O
children	O
adults	O

6	O
mg	O
2	O
grains	O
of	O
powdered	O
opium	B-Drug
or	O
the	O
equivalent	O
13	O
anhydrous	O
morphine	B-Drug

It	O
has	O
similar	O
serotonin	O
receptor	O
affinity	O
to	O
the	O
better-known	O
compound	O
25C-NBOMe	B-Drug

JWH-018	B-Drug
is	O
one	O
of	O
these	O
compounds	O
with	O
studies	O
showing	O
an	O
affinity	O
for	O
the	O
cannabinoid	O
CB1	O
receptor	O
five	O
times	O
greater	O
than	O
that	O
THC	O

With	O
a	O
couple	O
of	O
exceptions	O
ketamine	B-Drug
actions	O
at	O
other	O
receptors	O
are	O
far	O
weaker	O
than	O
ketamine's	O
antagonism	O
the	O
NMDA	O
receptor	O
see	O
activity	O
table	O
to	O
right	O

meaning	O
it	O
is	O
a	O
potent	O
agonist	O
therefore	O
subject	O
to	O
abuse	O
similar	O
other	O
C-II	O
opioids	O
such	O
as	O
oxycodone	B-Drug
and	O
morphine	B-Drug

In	O
1964	O
the	O
Brain	O
Committee	O
recommended	O
that	O
only	O
selected	O
approved	O
doctors	O
working	O
at	O
specialized	O
centres	O
be	O
allowed	O
to	O
prescribe	O
diamorphine	B-Drug
and	O
cocaine	B-Drug
users	O

Antihistamines	O
Diphenhydramine	B-Drug
doxylamine	B-Drug
promethazine	B-Drug
etc	O

In	O
October	O
2010	O
the	O
MHRA	O
in	O
UK	O
issued	O
a	O
warning	O
regarding	O
Payouji	O
tea	O
and	O
Pai	O
You	O
Guo	O
Slim	O
Capsules	O
which	O
were	O
found	O
to	O
contain	O
undeclared	O
quantities	O
of	O
sibutramine	B-Drug

As	O
a	O
result	O
of	O
this	O
many	O
other	O
illicit	O
drugs	O
have	O
risen	O
and	O
fallen	O
in	O
popularity	O
to	O
fill	O
void	O
with	O
prescription	O
temazepam	B-Drug
morphine	B-Drug
oxycodone	B-Drug
methamphetamine	B-Drug
cocaine	B-Drug
all	O
being	O
used	O
as	O
substitute	O

For	O
this	O
reason	O
and	O
the	O
fact	O
that	O
it	O
has	O
little	O
or	O
no	O
affinity	O
for	O
adrenaline	O
receptors	O
pemoline	B-Drug
minimal	O
sympathomimetic	O
side	O
effects	O
such	O
as:	O
dry	O
mouth	O
reduction	O
in	O
appetite	O
high	O
blood	O
pressure	O
increased	O
heart	O
rate	O
constriction	O
of	O
smooth	O
muscle	O
cardiac	O
stress	O
dilated	O
pupils	O
insomnia	O

They	O
are	O
also	O
precursors	O
of	O
methamphetamine	B-Drug
synthesis	O

Emergency	O
Medical	O
Service	O
Providers	O
EMS	O
routinely	O
administer	O
naloxone	B-Drug
except	O
where	O
basic	O
Technicians	O
are	O
prohibited	O
by	O
policy	O
or	O
state	O
law	O

While	O
other	O
opioids	O
of	O
recreational	O
use	O
produce	O
only	O
morphine	B-Drug
heroin	B-Drug
also	O
leaves	O
6-MAM	O
a	O
psycho-active	O
metabolite	O

FosB	O
levels	O
have	O
been	O
found	O
to	O
increase	O
upon	O
the	O
use	O
of	O
cocaine	B-Drug

In	O
2006	O
illegally	O
manufactured	O
non-pharmaceutical	O
fentanyl	B-Drug
often	O
mixed	O
with	O
cocaine	B-Drug
or	O
heroin	B-Drug
caused	O
an	O
outbreak	O
of	O
overdose	O
deaths	O
in	O
the	O
United	O
States	O
and	O
Canada	O
heavily	O
concentrated	O
cities	O
Dayton	O
Ohio;	O
Chicago;	O
Detroit;	O
Philadelphia	O

It	O
is	O
the	O
beta-methoxy	O
derivative	O
of	O
mescaline	B-Drug

Mary	O
Todd	O
Lincoln	O
for	O
example	O
the	O
wife	O
of	O
US	O
president	O
Abraham	O
was	O
a	O
laudanum	B-Drug
addict	O
as	O
English	O
poet	O
Samuel	O
Taylor	O
Coleridge	O
who	O
famously	O
interrupted	O
in	O
middle	O
an	O
opium-induced	O
writing	O
session	O
Kubla	O
Khan	O
by	O
person	O
from	O
Porlock	O

Chemically	O
PCP	B-Drug
is	O
a	O
member	O
of	O
the	O
arylcyclohexylamine	O
class	O
and	O
pharmacologically	O
it	O
dissociative	O
anesthetic	O

Illicit	O
manufacturing	O
of	O
nimetazepam	B-Drug
sold	O
as	O
Erimin-5	O
is	O
prevalent	O
in	O
the	O
region	O

Several	O
other	O
synthetic	O
cannabinoids	O
structurally	O
related	O
to	O
JWH-018	B-Drug
like	O
5F-PB-22	B-Drug
were	O
also	O
classified	O
in	O
this	O
amendment	O

In	O
the	O
male	O
HCG	O
injections	B-Drug
are	O
used	O
to	O
stimulate	O
Leydig	O
cells	O
synthesize	O
testosterone	O

Other	O
drugs	O
in	O
the	O
Schedule	O
I	O
category	O
include	O
heroin	B-Drug
LSD	B-Drug
and	O
peyote	O

It	O
is	O
now	O
argued	O
that	O
NMDA	O
receptor	O
antagonism	O
may	O
not	O
be	O
responsible	O
for	O
the	O
antidepressant	O
effects	O
of	O
ketamine	B-Drug

Cannabidiol	B-Drug
is	O
listed	O
in	O
the	O
EU	O
Cosmetics	O
Ingredient	O
Database	O
CosIng	O

PCP	B-Drug
is	O
self-administered	O
and	O
induces	O
FosB	O
expression	O
in	O
the	O
D1-type	O
medium	O
spiny	O
neurons	O
of	O
nucleus	O
accumbens	O
accordingly	O
excessive	O
use	O
known	O
to	O
cause	O
addiction	O

Methylphenidate	B-Drug
Ritalin	B-Drug
Concerta	B-Drug
Dexmethylphenidate	B-Drug
Focalin:	O
treatment	O
of	O
ADHD	O
narcolepsy	O
Morphine	B-Drug
The	O
first	O
painkiller	O
synthetized	O
from	O
the	O
opium	O
poppy	O
Focalin	B-Drug

It	O
involves	O
treatment	O
of	O
racemic	O
methadone	B-Drug
base	O
with	O
d-+-tartaric	O
acid	O
in	O
an	O
acetone/water	O
mixture	O
[which]	O
precipitates	O
almost	O
solely	O
the	O
dextro-methadone	O
levo-tartrate	O
and	O
more	O
potent	O
levo-methadone	O
can	O
easily	O
be	O
retrieved	O
from	O
mother	O
liquor	O
a	O
high	O
state	O
optical	O
purity	O
There	O
is	O
now	O
asymmetric	O
synthesis	O
available	O
to	O
prepare	O
both	O
levomethadone	B-Drug
R--methadone	O
dextromethadone	O
S-+-methadone	O

LSD	B-Drug
historian	O
Mark	O
McCloud	O
reports	O
that	O
Sand	O
then	O
traveled	O
to	O
the	O
ashram	O
of	O
so-called	O
sex	O
guru	O
Rajneesh	O
in	O
west	O
India	O

Examples	O
of	O
other	O
nandrolone	B-Drug
esters	O
that	O
have	O
been	O
marketed	O
and	O
used	O
medically	O
include	O
cyclohexylpropionate	O
cypionate	O
hexyloxyphenylpropionate	O
laurate	O
sulfate	O
undecanoate	O

Epidiolex	O
is	O
a	O
liquid	O
oral	O
formulation	O
of	O
cannabidiol	B-Drug

Meanwhile	O
a	O
member	O
of	O
his	O
lab	O
Robert	O
D'Amato	O
who	O
was	O
looking	O
for	O
angiogenesis	O
inhibitors	O
discovered	O
in	O
1994	O
that	O
thalidomide	B-Drug
inhibited	O
and	O
effective	O
suppressing	O
tumor	O
growth	O
rabbits	O

Since	O
1994	O
the	O
production	O
dispensing	O
and	O
prescription	O
of	O
thalidomide	B-Drug
have	O
been	O
strictly	O
controlled	O
requiring	O
women	O
to	O
use	O
two	O
forms	O
birth	O
control	O
submit	O
regular	O
pregnancy	O
tests	O

In	O
combination	O
with	O
Clidinium	B-Drug
as	O
NORMAXIN-CC	O
and	O
in	O
dicyclomine	B-Drug
NORMAXIN	O
for	O
IBS	O
the	O
anti-depressant	O
Amitriptyline	B-Drug
Limbitrol	B-Drug

The	O
origin	O
of	O
the	O
name	O
crack	O
comes	O
from	O
crackling	O
sound	O
and	O
hence	O
onomatopoeic	O
moniker	O
that	O
is	O
produced	O
when	O
cocaine	B-Drug
its	O
impurities	O
i	O

As	O
such	O
5-reductase	O
inhibitors	O
like	O
finasteride	B-Drug
and	O
dutasteride	B-Drug
do	O
not	O
reduce	O
the	O
androgenic	O
effects	O
of	O
metandienone	B-Drug

Beginning	O
in	O
2015	O
Canada	O
has	O
seen	O
a	O
number	O
of	O
fentanyl	B-Drug
overdoses	O

It	O
was	O
first	O
described	O
in	O
1994	O
and	O
is	O
a	O
natural	O
product	O
derived	O
from	O
the	O
mitragynine	B-Drug
present	O
Kratom	B-Drug
leaf	O

While	O
preparing	O
reagents	O
for	O
the	O
work	O
Mueckter's	O
assistant	O
Wilhelm	O
Kunz	O
isolated	O
a	O
by-product	O
that	O
was	O
recognized	O
by	O
pharmacologist	O
Herbert	O
Keller	O
as	O
an	O
analog	O
of	O
glutethimide	B-Drug
sedative	O

In	O
a	O
sample	O
of	O
16	O
healthy	O
subjects	O
single	O
mid-range	O
200	O
g	O
oral	O
dose	O
LSD	B-Drug
was	O
found	O
to	O
produce	O
mean	O
maximal	O
concentrations	O
4	O

These	O
interactions	O
would	O
be	O
expected	O
to	O
most	O
significant	O
with	O
long-term	O
diazepam	B-Drug
therapy	O
and	O
their	O
clinical	O
significance	O
is	O
variable	O

The	O
structure	O
of	O
bufotenine	B-Drug
was	O
first	O
confirmed	O
in	O
1934	O
by	O
Heinrich	O
Wielands	O
laboratory	O
Munich	O
and	O
the	O
reported	O
synthesis	O
Toshio	O
Hoshino	O
Kenya	O
Shimodaira	O
1935	O

Androstenedione	B-Drug
was	O
legal	O
and	O
able	O
to	O
be	O
purchased	O
over	O
the	O
counter	O
as	O
a	O
consequence	O
it	O
in	O
common	O
use	O
Major	O
League	O
Baseball	O
throughout	O
1990s	O
by	O
record-breaking	O
sluggers	O
like	O
Mark	O
McGwire	O

The	O
fentanyl	B-Drug
patch	O
is	O
one	O
of	O
a	O
few	O
medications	O
that	O
may	O
be	O
especially	O
harmful	O
and	O
in	O
some	O
cases	O
fatal	O
with	O
just	O
dose	O
if	O
used	O
by	O
someone	O
other	O
than	O
the	O
person	O
for	O
whom	O
medication	O
was	O
prescribed	O

DET	B-Drug
is	O
an	O
analogue	O
of	O
the	O
common	O
tryptamine	O
hallucinogen	O
NN-Dimethyltryptamine	O
or	O
DMT	O

The	O
formal	O
generic	O
names	O
of	O
nandrolone	B-Drug
esters	O
include	O
cyclohexylpropionate	O
BANM	O
cyclotate	O
USAN	O
decanoate	O
USP	O
JAN	O
laurate	O
phenpropionate	I-Drug
and	O
phenylpropionate	I-Drug

Amphetamine	B-Drug
was	O
originally	O
sold	O
as	O
a	O
decongestant	O
inhaler	O
in	O
the	O
United	O
States	O
1933	O
and	O
led	O
to	O
widespread	O
ATS	O
abuse	O
military	O
forces	O
civilians	O
later	O
on	O

Similarly	O
to	O
other	O
spirolactones	O
like	O
canrenone	O
and	O
spironolactone	B-Drug
SC-5233	O
has	O
some	O
antiandrogenic	O
activity	O
antagonizes	O
the	O
effects	O
of	O
testosterone	O
in	O
animals	O

Premazepam	O
produces	O
more	O
slow	O
wave	O
and	O
less	O
fast	O
EEG	O
changes	O
than	O
diazepam	B-Drug

Dutasteride	B-Drug
can	O
cause	O
birth	O
defects	O
specifically	O
ambiguous	O
genitalia	O
and	O
undermasculinization	O
in	O
male	O
fetuses	O

At	O
least	O
one	O
case	O
of	O
JWH-018	B-Drug
dependence	O
has	O
been	O
reported	O
by	O
the	O
media	O

In	O
December	O
2002	O
a	O
study	O
by	O
RAND	O
investigating	O
whether	O
cannabis	O
use	O
results	O
in	O
the	O
subsequent	O
of	O
cocaine	B-Drug
and	O
heroin	B-Drug
was	O
published	O
British	O
Journal	O
Addiction	O

Sofosbuvir	B-Drug
is	O
a	O
substrate	O
of	O
P-glycoprotein	O
transporter	O
protein	O
that	O
pumps	O
drugs	O
and	O
other	O
substances	O
from	O
intestinal	O
epithelium	O
cells	O
back	O
into	O
the	O
gut	O

After	O
menopause	O
androstenedione	B-Drug
production	O
is	O
about	O
halved	O
due	O
primarily	O
to	O
the	O
reduction	O
of	O
steroid	O
secreted	O
by	O
ovary	O

Zopiclone	B-Drug
may	O
be	O
more	O
addictive	O
than	O
benzodiazepines	O

DHEA	O
and	O
androstenedione	B-Drug
are	O
androgens	O
precursors	O
of	O
testosterone	O

Cook	O
-	O
Kiwi	O
Seeds	O
Cheese	O
Homegrown	O
Fantaseeds	O
LSD	B-Drug
Amnesia	O
SeedsSativa	O
CupUtopia	O
Haze	O
Barney's	O
DeLaHaze	O
Paradise	O
Cannatonic	O
Resin	O
SeedsNeder	O
HashRoyal	O
Jelly	O
Greenhouse	O
Ice	O
Grey	O
Crystal	O
AreaImport	O
HashTriple	O
Zero	O
Super	O
Palm	O
Shiraz	O
AmnesiaProduct	O
Cuptie	O
1	O

MDPV	B-Drug
is	O
specifically	O
listed	O
as	O
a	O
controlled	O
substance	O
in	O
Finland	O
appendix	O
IV	O
of	O
June	O
28	O
2010	O
Denmark	O
and	O
Sweden	O

This	O
represents	O
the	O
equivalent	O
of	O
between	O
two	O
to	O
three	O
teaspoons	O
1015	O
mL	O
opium	B-Drug
tincture	O

Mianserin	B-Drug
at	O
higher	O
doses	O
30-90mg/day	O
is	O
used	O
for	O
the	O
treatment	O
of	O
major	O
depressive	O
disorder	O

While	O
the	O
smuggling	O
of	O
drugs	O
such	O
as	O
marijuana	O
poppy	O
opium	B-Drug
and	O
heroin	B-Drug
became	O
more	O
ubiquitous	O
during	O
this	O
time	O
period	O
activity	O
cocaine	B-Drug
cartels	O
drove	O
development	O
Latin	O
American	O
drug	O
trade	O

Accordingly	O
it	O
has	O
been	O
found	O
to	O
produce	O
antidepressant-like	O
and	O
anxiolytic-like	O
effects	O
attenuate	O
the	O
behavioral	O
of	O
exposure	O
chronic	O
stress	O
potentiate	O
locomotor	O
activity	O
produced	O
by	O
D-amphetamine	B-Drug

When	O
codeine	B-Drug
is	O
taken	O
in	O
very	O
large	O
amounts	O
it	O
can	O
cause	O
one	O
to	O
stop	O
breathing	O

The	O
Pulp	O
song	O
Sorted	O
for	O
E's	O
&	O
Wizz	O
refers	O
to	O
British	O
slang	O
terms	O
ecstasy	B-Drug
and	O
amphetamines	O

Tramadol	B-Drug
may	O
be	O
used	O
to	O
treat	O
post-operative	O
injury-related	O
and	O
chronic	O
e	O

1P-LSD	O
is	O
a	O
derivative	O
and	O
functional	O
analogue	O
of	O
LSD	B-Drug
homologue	O
ALD-52	O

Unlike	O
many	O
benzodiazepines	O
pharmacokinetic	O
interactions	O
involving	O
the	O
P450	O
system	O
have	O
not	O
been	O
observed	O
with	O
temazepam	B-Drug

Some	O
androstenedione	B-Drug
is	O
also	O
secreted	O
into	O
the	O
plasma	O
and	O
may	O
be	O
converted	O
in	O
peripheral	O
tissues	O
to	O
testosterone	O
estrogens	O

All	O
of	O
these	O
derivatives	O
are	O
likely	O
to	O
share	O
some	O
their	O
psychoactive	O
effects	O
with	O
PCP	B-Drug
itself	O
although	O
a	O
range	O
potencies	O
and	O
varying	O
mixtures	O
anesthetic	O
dissociative	O
stimulant	O
known	O
depending	O
on	O
the	O
particular	O
drug	O
its	O
substituents	O

According	O
to	O
the	O
NIH	O
National	O
Institutes	O
of	O
Health	O
there	O
is	O
no	O
evidence	O
that	O
phentermine	B-Drug
causes	O
PPH	O

Illicit	O
methaqualone	B-Drug
is	O
one	O
of	O
the	O
most	O
commonly	O
used	O
recreational	O
drugs	O
in	O
South	O
Africa	O

Diazepam	B-Drug
may	O
produce	O
less	O
intense	O
withdrawal	O
symptoms	O
due	O
to	O
its	O
long	O
elimination	O
half-life	O

Methyltestosterone	B-Drug
and	O
ethyltestosterone	O
17-ethyltestosterone	O
are	O
the	O
parent	O
structures	O
of	O
all	O
17-alkylated	O
AAS	O

When	O
he	O
tried	O
the	O
drug	O
in	O
1977	O
Zeff	O
was	O
impressed	O
with	O
effects	O
of	O
MDMA	B-Drug
and	O
came	O
out	O
his	O
semi-retirement	O
to	O
promote	O
its	O
use	O
therapy	O

Thalidomide	B-Drug
is	O
provided	O
as	O
a	O
racemic	O
mixture	O
of	O
two	O
enantiomers;	O
while	O
there	O
are	O
reports	O
that	O
only	O
one	O
the	O
enantiomers	O
may	O
cause	O
birth	O
defects	O
body	O
converts	O
each	O
enantiomer	O
into	O
other	O
through	O
mechanisms	O
not	O
well	O
understood	O

Norethisterone	B-Drug
is	O
a	O
potent	O
progestogen	O
and	O
weak	O
androgen	O
estrogen	O

Norethisterone	B-Drug
is	O
marketed	O
widely	O
throughout	O
the	O
world	O

The	O
accused	O
owned	O
a	O
tablet	O
press	O
and	O
ordered	O
fentanyl	B-Drug
in	O
powder	O
form	O
from	O
China	O

It	O
is	O
unclear	O
if	O
fentanyl	B-Drug
gives	O
long-term	O
pain	O
relief	O
to	O
people	O
with	O
neuropathic	O

Hydrocodone/paracetamol	B-Drug
also	O
known	O
as	O
hydrocodone/acetaminophen	O
is	O
the	O
combination	O
of	O
pain	O
medications	O
hydrocodone	B-Drug
and	O
paracetamol	B-Drug
acetaminophen	B-Drug

Clonazepam	B-Drug
may	O
aggravate	O
hepatic	O
porphyria	O

The	O
drug	O
was	O
also	O
identified	O
in	O
2007	O
as	O
a	O
potent	O
antimineralocorticoid	O
with	O
similar	O
affinity	O
for	O
the	O
mineralocorticoid	O
receptor	O
aldosterone	O
and	O
spironolactone	B-Drug

The	O
Marquis	O
Color	O
test	O
may	O
also	O
be	O
used	O
to	O
detect	O
the	O
presence	O
of	O
fentanyl	B-Drug

Treatment	O
for	O
physical	O
withdrawal	O
generally	O
involves	O
switching	O
the	O
patient	O
to	O
a	O
long-acting	O
benzodiazepine	O
such	O
as	O
diazepam	B-Drug
or	O
clonazepam	B-Drug
then	O
slowly	O
titrating	O
them	O
off	O
replacement	O
drug	O
completely	O
at	O
rate	O
which	O
is	O
both	O
reasonably	O
comfortable	O
but	O
rapid	O
enough	O
managing	O
physician	O
consider	O
of	O
progress	O
acceptable	O
overly	O
dose	O
reduction	O
greatly	O
increases	O
risk	O
non-compliance	O
abuse	O
illicitly	O
obtained	O
alternative	O
sedatives	O
and/or	O
alcohol	O

In	O
addition	O
MDMA	B-Drug
has	O
immunosuppressive	O
effects	O
in	O
the	O
peripheral	O
nervous	O
system	O
and	O
pro-inflammatory	O
central	O

The	O
risk	O
of	O
venous	O
thromboembolisms	O
with	O
thalidomide	B-Drug
seems	O
to	O
be	O
increased	O
when	O
patients	O
are	O
treated	O
oral	O
contraceptives	O
or	O
other	O
cytotoxic	O
agents	O
including	O
doxorubicin	B-Drug
and	O
melphalan	O
concurrently	O

Diazepam	B-Drug
increases	O
the	O
central	O
depressive	O
effects	O
of	O
alcohol	O
other	O
hypnotics/sedatives	O
e	O

It	O
is	O
generally	O
less	O
preferred	O
than	O
metformin	B-Drug
and	O
sulfonylureas	O
as	O
an	O
initial	O
treatment	O

As	O
the	O
decades	O
evolved	O
so	O
did	O
composition	O
of	O
Obetrol	B-Drug

MDMA	B-Drug
is	O
unpredictable	O
and	O
produces	O
different	O
responses	O
in	O
people	O

Following	O
the	O
European	O
rule	O
from	O
2014	O
25I-NBOMe	B-Drug
was	O
put	O
in	O
class	O
4	O
of	O
prohibited	O
substances	O

Amphetamine	B-Drug
also	O
has	O
a	O
slight	O
analgesic	O
effect	O
and	O
can	O
enhance	O
the	O
pain	O
relieving	O
effects	O
of	O
opioids	O

For	O
two	O
decades	O
following	O
its	O
discovery	O
LSD	B-Drug
was	O
marketed	O
by	O
Sandoz	O
as	O
an	O
important	O
drug	O
for	O
psychological	O
and	O
neurological	O
research	O

Diphenhydramine	B-Drug
can	O
cause	O
minor	O
psychological	O
dependence	O

Nandrolone	B-Drug
decanoate	I-Drug
was	O
first	O
described	O
in	O
1960	O
and	O
introduced	O
for	O
medical	O
use	O
1962	O

A	O
psychedelic	O
experience	O
known	O
colloquially	O
as	O
a	O
trip	O
is	O
temporary	O
altered	O
state	O
of	O
consciousness	O
induced	O
by	O
the	O
consumption	O
substance	O
such	O
mescaline	B-Drug
LSD	B-Drug
psilocybin	O
or	O
DMT	O

ephedrine	B-Drug
1836?	O
nicotine	B-Drug
1828	O
and	O
many	O
others	O
of	O
all	O
types	O
psychoactive	O
not	O

In	O
vivo	O
studies	O
conducted	O
on	O
the	O
dentate	O
gyrus	O
of	O
hippocampus	O
noted	O
an	O
increase	O
in	O
proliferation	O
BrdU	O
positive	O
cells	O
response	O
to	O
100	O
g	O
5-MeO-DMT	B-Drug
injected	O
intravenously	O
adult	O
mouse	O
brain	O

A	O
1991	O
study	O
indicated	O
that	O
diazepam	B-Drug
in	O
particular	O
had	O
a	O
greater	O
abuse	O
liability	O
among	O
people	O
who	O
were	O
drug	O
abusers	O
than	O
did	O
many	O
of	O
the	O
other	O
benzodiazepines	O

Many	O
commercial	O
opiate	O
screening	O
tests	O
cross-react	O
appreciably	O
with	O
oxycodone	B-Drug
and	O
its	O
metabolites	O
but	O
chromatographic	O
techniques	O
can	O
easily	O
distinguish	O
from	O
other	O
opiates	O

The	O
effect	O
of	O
ketamine	B-Drug
on	O
the	O
respiratory	O
and	O
circulatory	O
systems	O
is	O
different	O
from	O
that	O
other	O
anesthetics	O

or	O
Why	O
I	O
Gave	O
Up	O
Smoking	O
Pot	O
2007	O
cannabis	O
Heavy	O
Metal	O
1981	O
fictional	O
drug	O
Nyborg	O
parody	O
of	O
cocaine	B-Drug
The	O
Heart	O
Is	O
Deceitful	O
Above	O
All	O
Things	O
2004	O
methamphetamine	B-Drug
Hells	O
Angels	O
on	O
Wheels	O
1967	O
amphetamines	O
High	O
Art	O
1998	O
heroin	B-Drug
School	O
Confidential	O
1958	O
1996	O
Hobo	O
With	O
A	O
Shotgun	O
2011	O
Hollywood	O
2003	O
Holy	O
Rollers	O
2010	O
MDMA	B-Drug
El	O
hombre	O
de	O
los	O
hongos	O
aka	O
Mushroom	O
Man	O
1976	O
psychedelic	O
mushrooms	O
Home	O
at	O
the	O
End	O
World	O
LSD	B-Drug
Homegrown	O
Honky	O
1971	O
-	O
marijuana	O
La	O
Horde	O
Horrible	O
Bosses	O
nitrous	O
oxide	O
2	O
2014	O
laughing	O
gas	O
Hot	O
Rod	O
Tub	O
Time	O
Machine	O
psilocybin	O
How	O
2001	O
Howard	O
Marks	O

A	O
2006	O
review	O
paper	O
summarized	O
several	O
studies	O
that	O
examined	O
the	O
effect	O
of	O
androstenedione	B-Drug
on	O
strength	O
training	O

Clonazepam	B-Drug
does	O
however	O
affect	O
glutamate	O
decarboxylase	O
activity	O

The	O
Act	O
aimed	O
to	O
substitute	O
the	O
production	O
of	O
coca	B-Drug
plant	O
with	O
other	O
agricultural	O
products	O

The	O
relative	O
potency	O
of	O
dihydromorphine	B-Drug
is	O
about	O
1	O

An	O
August	O
1970	O
report	O
at	O
a	O
meeting	O
of	O
crime	O
laboratory	O
chemists	O
indicates	O
MDMA	B-Drug
was	O
being	O
used	O
recreationally	O
in	O
the	O
Chicago	O
area	O
by	O

These	O
agencies	O
indicate	O
that	O
people	O
who	O
have	O
experienced	O
allergic	O
reactions	O
to	O
other	O
stimulants	O
or	O
are	O
taking	O
monoamine	O
oxidase	O
inhibitors	O
MAOIs	O
should	O
not	O
take	O
amphetamine	B-Drug
although	O
safe	O
concurrent	O
use	O
of	O
and	O
has	O
been	O
documented	O

JWH-019	B-Drug
is	O
an	O
analgesic	O
chemical	O
from	O
the	O
naphthoylindole	O
family	O
that	O
acts	O
as	O
a	O
cannabinoid	O
agonist	O
at	O
both	O
CB1	O
and	O
CB2	O
receptors	O

At	O
higher	O
therapeutic	O
doses	O
headache	O
diarrhea	O
dizziness	O
dry	O
mouth	O
erectile	O
dysfunction	O
anxiety	O
insomnia	O
irritability	O
lethargy	O
and	O
CNS	O
stimulation	O
have	O
been	O
reported	O
with	O
fenfluramine	B-Drug

Clinical	O
indications	O
for	O
indometacin	B-Drug
include:Joint	O
diseases	O
rheumatoid	O
arthritis	O
ankylosing	O
spondylitis	O
osteoarthritis	O
gouty	O
acute	O
painful	O
shoulder	O
bursitis	O
or	O
tendinitisHeadaches	O
Trigeminal	O
autonomic	O
cephalgias	O
Paroxysmal	O
hemicranias	O
Chronic	O
paroxysmal	O
hemicrania	O
Episodic	O
Hemicrania	O
continua	O
Valsalva-induced	O
headaches	O
Primary	O
cough	O
headache	O
exertional	O
associated	O
with	O
sexual	O
activity	O
preorgasmic	O
and	O
orgasmic	O
stabbing	O
jabs	O
jolts	O
syndrome	O
Hypnic	O
headacheOthers	O
Patent	O
ductus	O
arteriosus	O
Concurrent	O
peptic	O
ulcer	O
history	O
of	O
disease	O
Allergy	O
to	O
aspirin	B-Drug
other	O
NSAIDs	O
Roux-en-Y	O
gastric	O
bypass	O
sleeve	O
patients	O
Patients	O
nasal	O
polyps	O
reacting	O
an	O
angioedema	O
Children	O
under	O
2	O
years	O
age	O
the	O
exception	O
neonates	O
patent	O
Severe	O
pre-existing	O
renal	O
liver	O
damage	O
Caution:	O
bone	O
marrow	O
frequent	O
blood	O
cell	O
counts	O
are	O
indicated	O
bleeding	O
tendencies	O
unknown	O
origin	O
inhibits	O
platelet	O
aggregation	O
Parkinson's	O
epilepsy	O
psychotic	O
disorders	O
may	O
worsen	O
these	O
conditions	O
potassium	O
sparing	O
diuretics	O
who	O
have	O
a	O
dependent	O
heart	O
defect	O
such	O
as	O
transposition	O
great	O
vessels	O
Significant	O
hypertension	O
high	O
pressure	O
Concomitant	O
administration	O
lithium	O
salts	O
carbonate	O
In	O
general	O
adverse	O
effects	O
seen	O
similar	O
all	O

Sofosbuvir	B-Drug
is	O
also	O
used	O
with	O
other	O
medications	O
and	O
longer	O
treatment	O
durations	O
depending	O
on	O
specific	O
circumstances	O
genotype	O
cost-effectivenessbased	O
perspective	O

Muckraking	O
journalists	O
such	O
as	O
Samuel	O
Hopkins	O
Adams	O
targeted	O
the	O
patent	O
medicine	O
industry	O
with	O
its	O
high-alcoholic	O
content	O
medicines	O
soothing	O
syrups	O
for	O
infants	O
opium	B-Drug
derivatives	O
and	O
red	O
clauses	O
in	O
newspaper	O
contracts	O
providing	O
that	O
ads	O
upon	O
which	O
most	O
newspapers	O
of	O
time	O
were	O
dependent	O
would	O
be	O
withdrawn	O
if	O
paper	O
expressed	O
support	O
food	O
drug	O
regulatory	O
legislation	O

No	O
long-term	O
studies	O
to	O
evaluate	O
the	O
carcinogenic	O
potential	O
of	O
mifepristone	B-Drug
have	O
been	O
performed	O

MDMA	B-Drug
ecstasy	B-Drug
is	O
a	O
popular	O
club	O
drug	O
in	O
the	O
rave	O
and	O
electronic	O
dance	O
music	O
scenes	O
nightclubs	O

Contrarily	O
local	O
application	O
of	O
estrogen	O
has	O
been	O
shown	O
to	O
block	O
the	O
ability	O
fluvoxamine	B-Drug
slow	O
serotonin	O
clearance	O
suggesting	O
that	O
same	O
pathways	O
which	O
are	O
involved	O
in	O
SSRI	O
efficacy	O
may	O
also	O
be	O
affected	O
by	O
components	O
signaling	O

MAOIs	O
appear	O
to	O
be	O
particularly	O
indicated	O
for	O
outpatients	O
with	O
dysthymia	O
complicated	O
by	O
panic	O
disorder	O
or	O
hysteroid	O
dysphoriaNewer	O
such	O
as	O
selegiline	B-Drug
typically	O
used	O
in	O
the	O
treatment	O
of	O
Parkinson's	O
disease	O
and	O
reversible	O
MAOI	O
moclobemide	O
provide	O
a	O
safer	O
alternative	O
are	O
now	O
sometimes	O
first-line	O
therapy	O

Metandienone	B-Drug
was	O
originally	O
developed	O
in	O
1955	O
by	O
CIBA	O
and	O
marketed	O
Germany	O
the	O
United	O
States	O

Pregabalin	B-Drug
is	O
generally	O
not	O
regarded	O
as	O
efficacious	O
in	O
the	O
treatment	O
of	O
acute	O
pain	O

Actual	O
full	O
synthesis	O
of	O
cocaine	B-Drug
is	O
rarely	O
done	O

Urged	O
by	O
Senator	O
Lloyd	O
Bentsen	O
the	O
DEA	O
announced	O
an	O
emergency	O
Schedule	O
I	O
classification	O
of	O
MDMA	B-Drug
on	O
31	O
May	O
1985	O

This	O
was	O
not	O
observed	O
with	O
exposure	O
to	O
chlorhexidine	B-Drug
or	O
a	O
hydrogen	O
peroxide-based	O
agent	O
during	O
the	O
conditions	O
in	O
said	O
study	O

In	O
one	O
study	O
the	O
peak	O
levels	O
after	O
a	O
single	O
50	O
mg	O
dose	O
of	O
clomifene	B-Drug
were	O
20	O

For	O
exacerbations	O
that	O
result	O
in	O
a	O
visit	O
to	O
the	O
Emergency	O
Department	O
ED	O
oral	O
methylprednisolone	B-Drug
is	O
preferred	O
over	O
intravenous	O
administration	O
unless	O
there	O
are	O
issues	O
with	O
adherence	O
or	O
vomiting	O

Nonetheless	O
MDMA	B-Drug
in	O
moderate	O
use	O
may	O
still	O
be	O
neurotoxic	O

Additionally	O
the	O
toxicity	O
of	O
mitragynine	B-Drug
and	O
associated	O
kratom	B-Drug
alkaloids	O
have	O
yet	O
to	O
be	O
fully	O
determined	O
in	O
humans	O
nor	O
has	O
risk	O
overdose	O

MDMA	B-Drug
where	O
the	O
R-isomer	O
serves	O
as	O
distomer	O

0%	O
of	O
that	O
metribolone	O
for	O
5-DHLNG	O
and	O
has	O
androgenic	O
effects	O
similarly	O
to	O
levonorgestrel	B-Drug
testosterone	O

Myalgias	O
may	O
occur	O
because	O
of	O
reduced	O
carnitine	B-Drug
production	O

In	O
his	O
autobiography	O
I	O
Had	O
a	O
Hammer	O
which	O
was	O
co-written	O
with	O
Lonnie	O
Wheeler	O
and	O
published	O
in	O
1992	O
outfielder	O
Hank	O
Aaron	O
wrote	O
that	O
he	O
accepted	O
an	O
amphetamine	B-Drug
pill	O
from	O
unnamed	O
teammate	O
taken	O
it	O
before	O
game	O
during	O
the	O
1968	O
season	O
after	O
becoming	O
frustrated	O
about	O
lack	O
of	O
offensive	O
performance	O

Atypical	O
antipsychotic	O
drugs	O
like	O
Lumateperone	B-Drug
clozapine	B-Drug
olanzapine	B-Drug
quetiapine	B-Drug
risperidone	B-Drug
and	O
asenapine	B-Drug
are	O
relatively	O
potent	O
antagonists	O
of	O
5-HT2A	O
as	O
some	O
the	O
lower	O
potency	O
old	O
generation/typical	O
antipsychotics	O

Amphetamine	B-Drug
may	O
also	O
decrease	O
the	O
effects	O
of	O
antihypertensives	O
and	O
antipsychotics	O
due	O
to	O
its	O
on	O
blood	O
pressure	O
dopamine	O
respectively	O

Desogestrel	B-Drug
and	O
etonogestrel	B-Drug
are	O
among	O
the	O
most	O
potent	O
progestogens	O
available	O
along	O
with	O
gestodene	O
levonorgestrel	B-Drug
which	O
have	O
effective	O
ovulation-inhibiting	O
dosages	O
40	O
g/day	O
60	O
respectively	O

In	O
utero	O
exposure	O
to	O
MDMA	B-Drug
is	O
associated	O
with	O
a	O
neuro-	O
and	O
cardiotoxicity	O
impaired	O
motor	O
functioning	O

Dimethylthiambutene	B-Drug
NN-Dimethyl-1-methyl-33-di-2-thienylallylamine	O
DMTB	O
trade	O
names	O
Ohton	O
Aminobutene	O
Dimethibutin	O
Kobaton	O
Takaton	O
is	O
an	O
opioid	O
analgesic	O
drug	O
most	O
often	O
used	O
in	O
veterinary	O
medicine	O
Japan	O
and	O
to	O
a	O
lesser	O
extent	O
other	O
countries	O
the	O
region	O
around	O
world	O

Depending	O
on	O
liver	O
and	O
kidney	O
function	O
cocaine	B-Drug
metabolites	O
are	O
detectable	O
in	O
urine	O

Like	O
most	O
opioids	O
unadulterated	O
heroin	B-Drug
may	O
lead	O
to	O
adverse	O
effects	O

Etorphine	B-Drug
is	O
an	O
extremely	O
potent	O
non-selective	O
full	O
agonist	O
of	O
the	O
-	O
and	O
-opioid	O
receptors	O

JWH-018	B-Drug
has	O
been	O
shown	O
to	O
cause	O
profound	O
changes	O
in	O
CB1	O
receptor	O
density	O
following	O
administration	O
causing	O
desensitization	O
its	O
effects	O
more	O
rapidly	O
than	O
related	O
cannabinoids	O

The	O
illegal	O
sale	O
of	O
opium	B-Drug
became	O
one	O
the	O
world's	O
most	O
valuable	O
single	O
commodity	O
trades	O
and	O
has	O
been	O
called	O
long	O
continued	O
systematic	O
international	O
crime	O
modern	O
times	O

In	O
the	O
United	O
States	O
FUB-144	B-Drug
became	O
a	O
Schedule	O
I	O
Controlled	O
Substance	O
in	O
2019	O

Testosterone	B-Drug
cypionate	I-Drug
was	O
introduced	O
for	O
medical	O
use	O
in	O
1951	O

In	O
surveys	O
the	O
number	O
of	O
high	O
school	O
students	O
admitting	O
to	O
trying	O
PCP	B-Drug
at	O
least	O
once	O
fell	O
from	O
13%	O
in	O
1979	O
less	O
than	O
3%	O
1990	O

A	O
number	O
of	O
ecstasy	B-Drug
manufacturers	O
brand	O
their	O
pills	B-Drug
with	O
a	O
logo	O
often	O
being	O
the	O
an	O
unrelated	O
corporation	O

Despite	O
the	O
side	O
effects	O
thalidomide	B-Drug
was	O
sold	O
in	O
pharmacies	O
Canada	O
until	O
1962	O

Analogues	O
of	O
PCP	B-Drug
exhibit	O
varying	O
potency	O
at	O
nACh	O
receptors	O
and	O
NMDA	O

Drug	O
tolerance	O
develops	O
rapidly	O
in	O
amphetamine	B-Drug
abuse	O
i	O

Drostanolone	B-Drug
is	O
the	O
generic	O
name	O
of	O
drug	O
and	O
its	O
INN	O
BAN	O
DCF	O

Ltd	O
also	O
markets	O
an	O
ibuprofen	B-Drug
with	O
dihydrocodeine	B-Drug
product	O
called	O
S	O

Although	O
anecdotal	O
evidence	O
from	O
illicit	O
drug	O
users	O
reject	O
the	O
claim	O
some	O
researchers	O
assert	O
that	O
potency	O
of	O
heroin	B-Drug
has	O
since	O
been	O
on	O
rise	O
and	O
is	O
nearly	O
comparable	O
to	O
purity	O
prior	O
2000	O

Sedation:	O
Fentanyl	B-Drug
produces	O
sleep	O
and	O
drowsiness	O
as	O
dosage	O
is	O
increased	O
can	O
produce	O
the	O
-waves	O
often	O
seen	O
in	O
natural	O
on	O
electroencephalogram	O

Some	O
of	O
these	O
measures	O
include	O
switching	O
to	O
safer	O
lower	O
tar	O
cigarettes	O
snus	O
or	O
dipping	O
tobacco	O
using	O
a	O
non-tobacco	O
nicotine	B-Drug
delivery	O
systems	O

Dexamethasone	B-Drug
is	O
used	O
to	O
treat	O
many	O
inflammatory	O
and	O
autoimmune	O
disorders	O
such	O
as	O
rheumatoid	O
arthritis	O
bronchospasm	O

After	O
subcutaneous	O
administration	O
of	O
alirocumab	B-Drug
maximal	O
suppression	O
free	O
PCSK9	O
occurs	O
within	O
4	O
to	O
8	O
hours	O
and	O
has	O
an	O
apparent	O
half-life	O
17	O
20	O
days	O

Diphenoxylate	B-Drug
is	O
made	O
by	O
combining	O
a	O
precursor	O
of	O
normethadone	B-Drug
with	O
norpethidine	B-Drug

Until	O
now	O
there	O
has	O
been	O
no	O
medical	O
consensus	O
on	O
which	O
of	O
the	O
two	O
laudanum	B-Drug
or	O
morphine	B-Drug
alone	O
is	O
better	O
choice	O
for	O
treating	O
pain	O

Notably	O
not	O
all	O
medications	O
that	O
reduce	O
fever	O
are	O
anti-inflammatory	O
compounds	O
such	O
as	O
paracetamol	B-Drug

After	O
hydrochloride	O
hydrolysis	O
of	O
the	O
formed	O
O-potassium	O
derivative	O
during	O
which	O
enol	O
ether	O
is	O
also	O
hydrolyzed	O
and	O
remaining	O
double	O
bond	O
shifted	O
desired	O
norethisterone	B-Drug
obtained	O

There	O
is	O
a	O
high	O
risk	O
that	O
thalidomide	B-Drug
can	O
cause	O
excessive	O
blood	O
clots	O

Another	O
form	O
of	O
fentanyl	B-Drug
that	O
has	O
appeared	O
on	O
the	O
streets	O
is	O
Actiq	B-Drug
lollipop	O
formulation	O

In	O
chronic	O
granulomatous	O
pain	O
and	O
inflammation	O
model	O
PEA	B-Drug
could	O
prevent	O
nerve	O
formation	O
sprouting	O
mechanical	O
allodynia	O
inhibited	O
dorsal	O
root	O
ganglia	O
activation	O
which	O
is	O
a	O
hallmark	O
for	O
winding	O
up	O
in	O
neuropathic	O

Pathological	O
overactivation	O
of	O
the	O
mesolimbic	O
pathway	O
a	O
dopamine	O
that	O
connects	O
ventral	O
tegmental	O
area	O
to	O
nucleus	O
accumbens	O
plays	O
central	O
role	O
in	O
amphetamine	B-Drug
addiction	O

In	O
February	O
2009	O
the	O
government	O
was	O
accused	O
by	O
Professor	O
Nutt	O
of	O
making	O
a	O
political	O
decision	O
with	O
regard	O
to	O
drug	O
classification	O
in	O
rejecting	O
scientific	O
advice	O
downgrade	O
ecstasy	B-Drug
from	O
class	O
A	O

Like	O
all	O
opioids	O
used	O
for	O
analgesia	O
hydromorphone	B-Drug
is	O
potentially	O
habit-forming	O
and	O
listed	O
in	O
Schedule	O
II	O
of	O
the	O
United	O
States	O
Controlled	O
Substances	O
Act	O
1970	O
as	O
well	O
similar	O
levels	O
under	O
drugs	O
laws	O
practically	O
other	O
countries	O
it	O
Single	O
Convention	O
On	O
Narcotic	O
Drugs	O

The	O
production	O
of	O
meth	B-Drug
also	O
produces	O
a	O
number	O
toxic	O
gases	O
that	O
can	O
harm	O
the	O
human	O
respiratory	O
system	O
and	O
devastate	O
environment	O

Analogues	O
of	O
DMA	O
include	O
other	O
17-hydroxyprogesterone	O
derivatives	O
such	O
as	O
chlormadinone	O
acetate	I-Drug
cyproterone	O
hydroxyprogesterone	O
caproate	O
medroxyprogesterone	B-Drug
megestrol	O
and	O
osaterone	O

Furthermore	O
tamoxifen	B-Drug
treatment	O
alone	O
has	O
been	O
shown	O
to	O
have	O
anti-angiogenetic	O
effects	O
in	O
animal	O
models	O
of	O
cancer	O
which	O
appear	O
be	O
at	O
least	O
part	O
independent	O
tamoxifen's	O
ER	O
antagonist	O
properties	O

The	O
interaction	O
between	O
sofosbuvir	B-Drug
and	O
a	O
number	O
of	O
other	O
drugs	O
such	O
as	O
ciclosporin	B-Drug
darunavir/ritonavir	O
efavirenz	B-Drug
emtricitabine	B-Drug
methadone	B-Drug
raltegravir	B-Drug
rilpivirine	B-Drug
tacrolimus	B-Drug
or	O
tenofovir	B-Drug
disoproxil	I-Drug
were	O
evaluated	O
in	O
clinical	O
trials	O
no	O
dose	O
adjustment	O
is	O
needed	O
for	O
any	O
these	O
darunavir	B-Drug
ritonavir	B-Drug

This	O
chemical	O
proves	O
very	O
useful	O
for	O
opening	O
up	O
and	O
expressing	O
oneself	O
much	O
like	O
MDMA	B-Drug
34-methylenedioxymethamphetamine	O
may	O
be	O
a	O
in	O
psychedelic	O
therapy	O
methylenedioxymethamphetamine	B-Drug

The	O
combination	O
with	O
cyclizine	B-Drug
leads	O
to	O
a	O
very	O
strong	O
rush	O
if	O
the	O
drug	O
is	O
injected	O
however	O
tablets	O
contain	O
insoluble	O
binders	O
which	O
led	O
many	O
limb	O
amputations	O
and	O
some	O
fatalities	O
as	O
temazepam	B-Drug

If	O
diazepam	B-Drug
is	O
administered	O
concomitantly	O
with	O
other	O
drugs	O
attention	O
should	O
be	O
paid	O
to	O
the	O
possible	O
pharmacological	O
interactions	O

Tiny	O
pieces	O
of	O
leaf	O
matter	O
may	O
be	O
accidentally	O
or	O
even	O
purposely	O
added;	O
adulterants	O
introduced	O
when	O
the	O
hashish	B-Drug
is	O
being	O
produced	O
will	O
reduce	O
purity	O
material	O
and	O
often	O
resulting	O
in	O
green	O
finished	O
product	O

Approximate	O
cocaine	B-Drug
purity	O
can	O
be	O
determined	O
using	O
1	O
mL	O
2%	O
cupric	O
sulfate	O
pentahydrate	O
in	O
dilute	O
HCl	O
potassium	O
thiocyanate	O
and	O
2	O
of	O
chloroform	O

Tolerance	O
also	O
disappeared	O
rapidly;	O
after	O
no	O
LSD	B-Drug
had	O
been	O
given	O
for	O
3	O
days	O
a	O
subsequent	O
dose	O
again	O
large	O
effect	O

The	O
biological	O
responses	O
to	O
PEA	B-Drug
dosing	O
in	O
animal	O
models	O
and	O
humans	O
are	O
being	O
investigated	O
vis--vis	O
its	O
involvement	O
a	O
repair	O
mechanism	O
relevant	O
patient	O
conditions	O
of	O
chronic	O
inflammation	O
pain	O

Indometacin's	O
role	O
in	O
treating	O
certain	O
headaches	O
is	O
unique	O
compared	O
to	O
other	O
NSAIDs	O
Indometacin	B-Drug

Sofosbuvir	B-Drug
in	O
combination	O
with	O
velpatasvir	B-Drug
is	O
recommended	O
for	O
all	O
genotypes	O
a	O
cure	O
rate	O
greater	O
than	O
90%	O
and	O
close	O
to	O
100%	O
most	O
cases	O

PEA	B-Drug
is	O
metabolized	O
by	O
the	O
cellular	O
enzymes	O
fatty	O
acid	O
amide	O
hydrolase	O
FAAH	O
and	O
N-acylethanolamine	O
NAAA	O
latter	O
of	O
which	O
has	O
more	O
specificity	O
toward	O
over	O
other	O
amides	O

Because	O
of	O
the	O
rising	O
deaths	O
across	O
country	O
especially	O
in	O
British	O
Columbia	O
where	O
for	O
2016	O
is	O
668	O
and	O
2017	O
January	O
to	O
October	O
999Health	O
Canada	O
putting	O
a	O
rush	O
on	O
review	O
prescription-only	O
status	O
naloxone	B-Drug
an	O
effort	O
combat	O
overdoses	O
drug	O

Nitrazepam	B-Drug
has	O
demonstrated	O
cortisol-suppressing	O
properties	O
in	O
humans	O

com	O
there	O
is	O
no	O
hard	O
evidence	O
as	O
of	O
October	O
2008	O
that	O
flavored	O
meth	B-Drug
being	O
handed	O
out	O
in	O
schoolyards	O
nor	O
children	O
are	O
mistaking	O
for	O
candy	O

Formal	O
programs	O
in	O
which	O
the	O
opioid	O
inverse	O
agonist	O
drug	O
naloxone	B-Drug
is	O
distributed	O
have	O
been	O
trialled	O
and	O
implemented	O

Progress	O
and	O
promise	O
for	O
the	O
MDMA	B-Drug
drug	O
development	O
program	O

Twenty	O
five	O
kilograms	O
of	O
precursor	O
ergotamine	B-Drug
tartrate	O
can	O
produce	O
56	O
kg	O
pure	O
crystalline	O
LSD;	O
this	O
corresponds	O
to	O
100	O
million	O
doses	O
LSD	B-Drug

While	O
somewhat	O
more	O
biologically	O
plausible	O
than	O
the	O
discredited	O
LSD	B-Drug
legend	O
due	O
to	O
fat-solubility	O
of	O
THC	O
this	O
phenomenon	O
remains	O
scientifically	O
unproven	O

Both	O
Avastin	B-Drug
and	O
Lucentis	B-Drug
were	O
created	O
by	O
Genentech	O
which	O
is	O
owned	O
Roche;	O
Roche	O
markets	O
worldwide	O
also	O
in	O
the	O
US	O

Additionally	O
because	O
cocaine	B-Drug
is	O
a	O
vasoconstrictor	O
and	O
usage	O
often	O
entails	O
multiple	O
injections	O
within	O
several	O
hours	O
or	O
less	O
subsequent	O
are	O
progressively	O
more	O
difficult	O
to	O
administer	O
which	O
in	O
turn	O
may	O
lead	O
injection	O
attempts	O
consequences	O
from	O
improperly	O
performed	O

Steady-state	O
levels	O
of	O
apalutamide	B-Drug
are	O
achieved	O
following	O
4	O
weeks	O
administration	O
with	O
an	O
approximate	O
5-fold	O
accumulation	O

That	O
patent	O
along	O
with	O
others	O
was	O
challenged	O
by	O
generic	O
manufacturers	O
and	O
upheld	O
in	O
2014	O
giving	O
Pfizer	O
exclusivity	O
for	O
Lyrica	B-Drug
the	O
US	O
until	O
2018	O

European	O
countries	O
are	O
set	O
to	O
receive	O
the	O
license	O
for	O
manufacturing	O
of	O
Efavirenz	B-Drug
in	O
May	O
1999	O

Laudanum	B-Drug
is	O
prescribed	O
in	O
Glendon	O
Swarthout's	O
novel	O
The	O
Shootist	O
1975	O
to	O
the	O
character	O
J	O

The	O
recommendation	O
applying	O
to	O
CBD	B-Drug
extracts	O
synthesized	O
and	O
all	O
products	O
including	O
oil	I-Drug
was	O
scheduled	O
for	O
a	O
final	O
ruling	O
by	O
the	O
European	O
Commission	O
in	O
March	O
2019	O

In	O
2010	O
in	O
response	O
to	O
a	O
citizen	O
petition	O
the	O
US	O
FDA	O
determined	O
that	O
Buspar	B-Drug
was	O
not	O
withdrawn	O
for	O
sale	O
because	O
of	O
reasons	O
safety	O
or	O
effectiveness	O

However	O
in	O
1950	O
the	O
actual	O
production	O
of	O
morphine	B-Drug
from	O
poppy	O
straw	O
was	O
reported	O
to	O
be	O
11663	O
kilograms	O
25713	O
lb	O

PCP	B-Drug
is	O
notably	O
a	O
high-affinity	O
ligand	O
of	O
the	O
site	O
2	O
Ki	O
=	O
154	O
nM	O
not-well-characterized	O
associated	O
with	O
monoamine	O
reuptake	O
inhibition	O

From	O
the	O
earliest	O
finds	O
opium	B-Drug
has	O
appeared	O
to	O
have	O
ritual	O
significance	O
and	O
anthropologists	O
speculated	O
ancient	O
priests	O
may	O
used	O
drug	O
as	O
a	O
proof	O
of	O
healing	O
power	O

Due	O
to	O
the	O
frequency	O
and	O
prominence	O
of	O
side	O
effects	O
amitriptyline	B-Drug
is	O
generally	O
considered	O
a	O
second-line	O
therapy	O
for	O
these	O
indications	O

Fentanyl	B-Drug
can	O
produce	O
the	O
following	O
clinical	O
effects	O
strongly	O
through	O
-receptor	O
agonism	O

Ketamine	B-Drug
has	O
similar	O
efficacy	O
to	O
opioids	O
in	O
a	O
hospital	O
emergency	O
department	O
setting	O
for	O
management	O
of	O
acute	O
pain	O
and	O
control	O
procedural	O

Amphetamine	B-Drug
is	O
classified	O
in	O
US	O
pregnancy	O
category	O
C	O

It	O
was	O
the	O
second	O
TCA	O
to	O
be	O
introduced	O
following	O
introduction	O
of	O
imipramine	B-Drug
in	O
1957	O

The	O
known	O
metabolic	O
pathways	O
detectable	O
metabolites	O
and	O
metabolizing	O
enzymes	O
in	O
humans	O
include	O
the	O
following:	O
Amphetamine	B-Drug
has	O
a	O
very	O
similar	O
structure	O
function	O
to	O
endogenous	O
trace	O
amines	O
which	O
are	O
naturally	O
occurring	O
neuromodulator	O
molecules	O
produced	O
human	O
body	O
brain	O

Although	O
rarely	O
prescribed	O
due	O
to	O
the	O
potential	O
risks	O
methamphetamine	B-Drug
hydrochloride	I-Drug
is	O
approved	O
by	O
United	O
States	O
Food	O
and	O
Drug	O
Administration	O
USFDA	O
under	O
trade	O
name	O
Desoxyn	B-Drug

This	O
interest	O
is	O
partly	O
motivated	O
by	O
the	O
strong	O
physiological	O
effects	O
of	O
cocaine	B-Drug
but	O
a	O
further	O
incentive	O
was	O
unusual	O
bicyclic	O
structure	O
molecule	O

Ipratropium	B-Drug
should	O
never	O
be	O
used	O
in	O
place	O
of	O
salbutamol	B-Drug
albuterol	B-Drug
as	O
a	O
rescue	O
medication	O

Zopiclone	B-Drug
increases	O
both	O
stage	O
2	O
and	O
slow-wave	O
sleep	O
SWS	O
while	O
zolpidem	B-Drug
an	O
1-selective	O
compound	O
only	O
causes	O
no	O
effect	O
on	O

Additionally	O
drugs	O
such	O
as	O
stimulants	O
and	O
sympathomimetics	O
should	O
not	O
be	O
taken	O
with	O
propylhexedrine	B-Drug
this	O
can	O
lead	O
to	O
potentially	O
dangerous	O
spikes	O
in	O
blood	O
pressure	O
irregular	O
heart	O
rhythms	O

Both	O
companies	O
still	O
regarded	O
Quaalude	B-Drug
as	O
an	O
excellent	O
sleeping	O
drug	O

demonstrated	O
reduction	O
in	O
cocaine	B-Drug
self-administration	O
rats	O
1993	O
and	O
Rezvani	O
reported	O
reduced	O
alcohol	O
dependence	O
three	O
strains	O
of	O
alcohol-preferring	O
1995	O

The	O
secondary	O
pathway	O
involves	O
conversion	O
of	O
17-hydroxyprogesterone	O
most	O
often	O
a	O
precursor	O
to	O
cortisol	O
androstenedione	B-Drug
directly	O
by	O
way	O
1720-lyase	O

Various	O
surveys	O
conducted	O
between	O
2015	O
and	O
2019	O
found	O
that	O
many	O
users	O
of	O
cannabis	O
substitute	O
it	O
for	O
prescription	O
drugs	O
including	O
opioids	O
alcohol	O
tobacco;	O
most	O
those	O
who	O
used	O
in	O
place	O
or	O
tobacco	B-Drug
either	O
reduced	O
stopped	O
their	O
intake	O
the	O
latter	O
substances	O

PCP	B-Drug
comes	O
in	O
both	O
powder	O
and	O
liquid	O
forms	O
base	O
is	O
dissolved	O
most	O
often	O
ether	O
but	O
typically	O
it	O
sprayed	O
onto	O
leafy	O
material	O
such	O
as	O
cannabis	O
mint	O
oregano	O
tobacco	B-Drug
parsley	O
or	O
ginger	O
leaves	O
then	O
smoked	O

Dextroamphetamine	B-Drug
is	O
used	O
to	O
treat	O
attention	O
deficit	O
hyperactivity	O
disorder	O
ADHD	O
and	O
narcolepsy	O
a	O
sleep	O
sometimes	O
prescribed	O
off-label	O
for	O
its	O
past	O
medical	O
indications	O
such	O
as	O
depression	O
obesity	O

Metformin	B-Drug
an	O
insulin-sensitizing	O
medication	O
has	O
indirect	O
antiandrogenic	O
effects	O
in	O
such	O
women	O
decreasing	O
testosterone	O
levels	O
by	O
50%	O
secondary	O
to	O
its	O
beneficial	O
on	O
insulin	O
sensitivity	O

He	O
speculated	O
So	O
where	O
is	O
it?	O
I	O
fear	O
there	O
may	O
be	O
a	O
more	O
sinister	O
explanation	O
for	O
why	O
the	O
bottom	O
has	O
not	O
fallen	O
out	O
of	O
opium	B-Drug
market:	O
major	O
traffickers	O
are	O
withholding	O
significant	O
amounts	O

6-MP	O
is	O
structurally	O
related	O
to	O
medroxyprogesterone	B-Drug
acetate	I-Drug
MPA;	O
6-methyl-17-acetoxyprogesterone	O
and	O
megestrol	O
MGA;	O
6-dehydro-6-methyl-17-acetoxyprogesterone	O
which	O
possess	O
androgenic	O
and/or	O
antiandrogenic	O
activity	O
varying	O
degrees	O
similarly	O

The	O
FDA	O
also	O
required	O
manufacturers	O
on	O
all	O
paracetamol	B-Drug
containing	O
products	O
to	O
issue	O
a	O
black	O
box	O
warning	O
indicating	O
the	O
potential	O
risk	O
for	O
severe	O
liver	O
injury	O
and	O
highlighting	O
allergic	O
reactions	O

Metoclopramide	B-Drug
also	O
treats	O
gastroparesis	O
Eticlopride	O
binds	O
D2	O
and	O
D3	O
with	O
high	O
affinity	O
but	O
D4	O
Nafadotride	O
Raclopride	O
can	O
be	O
radiolabeled	O
used	O
in	O
PET	O
imaging	O
to	O
identify	O
disease	O
progression	O
Huntington's	O
Disease	O

Treatment	O
of	O
dutasteride	B-Drug
overdose	O
should	O
be	O
based	O
on	O
symptoms	O
and	O
supportive	O

However	O
because	O
Wellbutrin	B-Drug
only	O
increases	O
the	O
libido	O
in	O
special	O
case	O
that	O
it	O
is	O
already	O
impaired	O
by	O
related	O
medications	O
not	O
generally	O
classed	O
as	O
an	O
aphrodisiac	O

Mesterolone	B-Drug
also	O
known	O
as	O
1-methyl-45-dihydrotestosterone	O
1-methyl-DHT	O
or	O
1-methyl-5-androstan-17-ol-3-one	O
is	O
a	O
synthetic	O
androstane	O
steroid	O
and	O
derivative	O
of	O
DHT	O

The	O
drug	O
organization	O
Norconon	O
states	O
that	O
other	O
synthetic	O
drugs	O
used	O
in	O
clubs	O
or	O
which	O
are	O
sold	O
as	O
Ecstasy	B-Drug
include	O
harmaline;	O
piperazines	O
e	O

Therefore	O
succinylcholine	B-Drug
can	O
be	O
given	O
within	O
the	O
first	O
24	O
hours	O
of	O
injury	O

Cocaine	B-Drug
Riot	O
2	O
featured	O
guest	O
appearances	O
from	O
rappers	O
Action	O
Bronson	O
and	O
Chevy	O
Woods	O
among	O
others	O

HIV	O
drug	O
resistance	O
is	O
growing	O
due	O
to	O
recreational	O
use	O
of	O
drugs	O
efavirenz	B-Drug
and	O
ritonavir	B-Drug
rendering	O
them	O
ineffective	O
not	O
only	O
for	O
users	O
but	O
non-users	O
as	O
well	O
with	O
one	O
study	O
showing	O
that	O
3%	O
5%	O
people	O
in	O
areas	O
where	O
whoonga	O
was	O
used	O
were	O
pre-treatment	O
antiretroviral	O
treat	O

Afghanistan	O
has	O
seen	O
a	O
high	O
rate	O
of	O
opium	B-Drug
addiction	O
among	O
refugees	O
returning	O
from	O
Iran	O
and	O
Pakistan	O

Studies	O
on	O
rats	O
indicate	O
that	O
PCP	B-Drug
interacts	O
indirectly	O
with	O
opioid	O
receptors	O
endorphin	O
and	O
enkephalin	O
to	O
produce	O
analgesia	O

Research	O
suggests	O
that	O
when	O
methadone	B-Drug
is	O
used	O
long-term	O
it	O
can	O
build	O
up	O
unpredictably	O
in	O
the	O
body	O
and	O
lead	O
to	O
potentially	O
deadly	O
slowed	O
breathing	O

4-methylaminorex	B-Drug
can	O
be	O
smoked	O
insufflated	O
or	O
taken	O
orally	O

The	O
effects	O
established	O
so	O
far	O
for	O
recreational	O
use	O
of	O
ecstasy	B-Drug
lie	O
in	O
the	O
range	O
moderate	O
to	O
severe	O
serotonin	O
transporter	O
reduction	O

In	O
1995	O
the	O
era	O
of	O
highly	O
active	O
anti-retroviral	O
therapy	O
HAART	O
was	O
initiated	O
by	O
United	O
States	O
FDA's	O
approval	O
Hoffman	O
LaRoche's	O
HIV	O
protease	O
inhibitor	O
saquinavir	B-Drug

Scurvy	O
will	O
improve	O
with	O
doses	O
of	O
vitamin	B-Drug
C	I-Drug
as	O
low	O
10	O
mg	O
per	O
day	O
though	O
around	O
100	O
are	O
typically	O
recommended	O

Prodine	B-Drug
has	O
similar	O
effects	O
to	O
other	O
opioids	O
and	O
produces	O
analgesia	O
sedation	O
euphoria	O

Prostate	O
cancer	O
drug	O
abiraterone	B-Drug
and	O
its	O
analog	O
Galeterone	O
are	O
53-hydroxy	O
steroids	O

The	O
study	O
recommends	O
carbamazepine	B-Drug
to	O
not	O
be	O
used	O
concurrently	O
with	O
clozapine	B-Drug
due	O
increased	O
risk	O
of	O
agranulocytosis	O

For	O
this	O
reason	O
relative	O
to	O
other	O
5-reductase	O
inhibitors	O
like	O
finasteride	B-Drug
and	O
dutasteride	B-Drug
the	O
degree	O
of	O
DHT	O
suppression	O
with	O
epristeride	O
falls	O
short	O
that	O
desirable	O
for	O
full	O
clinical	O
benefit	O

Using	O
rat	O
studies	O
withdrawal	O
after	O
repeated	O
exposure	O
to	O
nicotine	B-Drug
results	O
in	O
less	O
responsive	O
nucleus	O
accumbens	O
cells	O
which	O
produce	O
dopamine	O
responsible	O
for	O
reinforcement	O

In	O
contrast	O
New	O
World	O
vultures	O
such	O
as	O
the	O
turkey	O
vulture	O
can	O
tolerate	O
at	O
least	O
100	O
times	O
level	O
of	O
diclofenac	B-Drug
that	O
is	O
lethal	O
to	O
Gyps	O
species	O

Boldenone	B-Drug
has	O
strong	O
anabolic	O
effects	O
and	O
moderate	O
androgenic	O

Brand	O
names	O
include	O
Risperdal	B-Drug
Consta	O
M-Tab	O
Quicklets	O
and	O
Risperlet	O

Though	O
transient	O
gynecomastia	O
is	O
a	O
natural	O
and	O
common	O
occurrence	O
in	O
pubertal	O
boys	O
the	O
associated	O
with	O
oxandrolone	B-Drug
was	O
of	O
late/delayed	O
onset	O
persistent	O
high	O
percentage	O
cases	O

This	O
act	O
and	O
the	O
stigma	O
of	O
a	O
demon	O
drug	O
on	O
opium	B-Drug
led	O
to	O
criminalization	O
people	O
that	O
used	O
opium-based	O
products	O

prednisone	B-Drug
and	O
some	O
tricyclic	O
antidepressants	O
e	O

Thalidomide	B-Drug
should	O
not	O
be	O
used	O
by	O
women	O
who	O
are	O
breastfeeding	O
or	O
pregnant	O
trying	O
able	O
to	O
conceive	O
a	O
child	O
cannot	O
will	O
follow	O
the	O
risk	O
management	O
program	O
prevent	O
pregnancies	O

Chemically	O
ketorolac	B-Drug
functions	O
as	O
a	O
carboxylic	O
acid	O
derivative	O
serving	O
non-selectively	O
to	O
block	O
the	O
prostaglandin	O
synthesis	O
by	O
inhibition	O
of	O
G/H	O
one	O
and	O
two	O

The	O
UK	O
classified	O
tramadol	B-Drug
as	O
a	O
Class	O
C	O
Schedule	O
3	O
controlled	O
drug	O
on	O
10	O
June	O
2014	O
but	O
exempted	O
it	O
from	O
the	O
safe	O
custody	O
requirement	O

Brand	O
names	O
include	O
Contergan	B-Drug
Thalomid	B-Drug
Talidex	O
Talizer	O
Neurosedyn	B-Drug
Distaval	O
and	O
many	O
others	O

A	O
December	O
1955	O
study	O
of	O
101	O
patients	O
at	O
the	O
Mississippi	O
State	O
Hospital	O
in	O
Whitfield	O
found	O
meprobamate	B-Drug
useful	O
alleviation	O
mental	O
symptoms:	O
3%	O
made	O
a	O
complete	O
recovery	O
29%	O
were	O
greatly	O
improved	O
50%	O
somewhat	O
better	O
while	O
18%	O
realized	O
little	O
change	O

Hypoglycemics	O
acetazolamide	B-Drug
can	O
both	O
increase	O
or	O
decrease	O
blood	O
glucose	O
levels	O

JWH-018	B-Drug
is	O
one	O
of	O
these	O
compounds	O
with	O
studies	O
showing	O
an	O
affinity	O
for	O
the	O
cannabinoid	O
CB1	O
receptor	O
five	O
times	O
greater	O
than	O
that	O
THC	O

Outside	O
of	O
the	O
United	O
States	O
availability	O
oxandrolone	B-Drug
is	O
quite	O
limited	O

In	O
2018	O
results	O
were	O
first	O
published	O
which	O
suggested	O
that	O
thalidomide's	O
teratogenic	O
effects	O
are	O
mediated	O
through	O
degradation	O
of	O
the	O
transcription	O
factor	O
SALL4	O
an	O
as	O
yet	O
unverified	O
finding	O
thalidomide	B-Drug

Norpethidine	B-Drug
normeperidine	O
pethidine	B-Drug
intermediate	I-Drug
B	I-Drug
is	O
a	O
4-phenylpiperidine	O
derivative	O
that	O
both	O
precursor	O
to	O
and	O
the	O
toxic	O
metabolite	O
of	O
meperidine	B-Drug

During	O
his	O
period	O
in	O
South	O
Australia	O
he	O
resumed	O
production	O
and	O
distribution	O
of	O
amphetamine	B-Drug
methamphetamine	B-Drug
conjunction	O
with	O
disgraced	O
former	O
solicitor	O
Justin	O
Birk	O
Hill	O

Trenbolone	B-Drug
acetate	I-Drug
specifically	O
referred	O
to	O
as	O
Finaplix	O
in	O
the	O
livestock	O
industry	O
is	O
available	O
purchase	O
veterinary	O
drug	O
markets	O

Vitamin	O
A	I-Drug
plays	O
a	O
role	O
in	O
variety	O
of	O
functions	O
throughout	O
the	O
body	O
such	O
as:	O
Vision	O
Gene	O
transcription	O
Immune	O
function	O
Embryonic	O
development	O
and	O
reproduction	O
Bone	O
metabolism	O
Haematopoiesis	O
Skin	O
cellular	O
health	O
Teeth	O
Mucous	O
membrane	O
The	O
vitamin	B-Drug
visual	O
cycle	O
is	O
specifically	O
related	O
to	O
retinal	O
form	O

Tizanidine	B-Drug
has	O
been	O
found	O
to	O
have	O
superior	O
tolerability	O
compared	O
diazepam	B-Drug
and	O
baclofen	B-Drug

In	O
1992	O
Romach	O
and	O
colleagues	O
reported	O
that	O
dose	O
escalation	O
is	O
not	O
a	O
characteristic	O
of	O
long-term	O
alprazolam	B-Drug
users	O
the	O
majority	O
change	O
their	O
initial	O
pattern	O
regular	O
use	O
to	O
one	O
symptom	O
control	O
only	O
when	O
required	O

Etilamfetamine	B-Drug
trade	O
names	O
Apetinil	O
and	O
Adiparthrol;	O
also	O
known	O
as	O
N-ethylamphetamine	O
is	O
a	O
stimulant	O
drug	O
of	O
the	O
phenethylamine	O
amphetamine	B-Drug
chemical	O
classes	O

For	O
example	O
several	O
peptide	O
drugs	O
such	O
as	O
Bortezomib	B-Drug
and	O
MG132	O
are	O
artificially	O
synthesized	O
retain	O
their	O
protecting	O
groups	O
which	O
have	O
specific	O
codes	O

Sedation	O
and	O
hypnosis	O
are	O
the	O
principal	O
side	O
effects	O
occasionally	O
they	O
also	O
intended	O
of	O
phenobarbital	B-Drug

Tamoxifen	B-Drug
acts	O
as	O
a	O
selective	O
estrogen	O
receptor	O
modulator	O
SERM	O
or	O
partial	O
agonist	O
of	O
the	O
receptors	O
ERs	O

Farbenkonzern	O
and	O
Farbwerke	O
Hoechst	O
were	O
no	O
longer	O
protected	O
each	O
pharmaceutical	O
company	O
interested	O
in	O
the	O
formula	O
could	O
buy	O
rights	O
for	O
commercial	O
production	O
of	O
methadone	B-Drug
just	O
one	O
dollar	O
MOLL	O
1990	O

It	O
is	O
a	O
substituted	O
methamphetamine	B-Drug
and	O
homolog	O
of	O
25-dimethoxy-4-methylamphetamine	O
DOM	O

CNS	O
depression	O
occurs	O
much	O
more	O
frequently	O
in	O
the	O
elderly	O
and	O
is	O
especially	O
common	O
doses	O
above	O
5	O
mg	O
of	O
nitrazepam	B-Drug

Mifepristone	B-Drug
also	O
known	O
as	O
RU-486	B-Drug
is	O
a	O
medication	O
typically	O
used	O
in	O
combination	O
with	O
misoprostol	B-Drug
to	O
bring	O
about	O
an	O
abortion	O
during	O
pregnancy	O

Hemp	O
has	O
lower	O
concentrations	O
of	O
THC	O
and	O
higher	O
CBD	B-Drug
which	O
gives	O
lesser	O
psychoactive	O
effects	O

Studies	O
have	O
shown	O
that	O
alcohol	O
and	O
tobacco	B-Drug
may	O
additionally	O
be	O
regarded	O
as	O
gateway	O
drugs;	O
however	O
a	O
more	O
parsimonious	O
explanation	O
could	O
cannabis	O
is	O
simply	O
readily	O
available	O
at	O
an	O
earlier	O
age	O
than	O
illegal	O
hard	O
drugs	O

Tolerance	O
to	O
some	O
of	O
the	O
desired	O
and	O
adverse	O
effects	O
MDMA	B-Drug
is	O
expected	O
occur	O
with	O
consistent	O
use	O

The	O
study	O
also	O
noted	O
that	O
effects	O
of	O
DMPA	B-Drug
exposure	O
on	O
puberty	O
require	O
further	O
as	O
so	O
few	O
children	O
over	O
the	O
age	O
10	O
were	O
observed	O

A	O
2014	O
review	O
of	O
the	O
safety	O
and	O
efficacy	O
MDMA	B-Drug
as	O
a	O
treatment	O
for	O
various	O
disorders	O
particularly	O
PTSD	O
indicated	O
that	O
has	O
therapeutic	O
in	O
some	O
patients;	O
however	O
it	O
emphasized	O
issues	O
regarding	O
controlability	O
MDMA-induced	O
experiences	O
neurochemical	O
recovery	O
must	O
be	O
addressed	O

Oral	O
administered	O
nalbuphine	B-Drug
is	O
reported	O
to	O
be	O
three	O
times	O
more	O
potent	O
than	O
codeine	B-Drug
Okun	O
et	O
al	O

PCP	B-Drug
began	O
to	O
emerge	O
as	O
a	O
recreational	O
drug	O
in	O
major	O
cities	O
the	O
United	O
States	O
1960s	O

After	O
the	O
supplements	O
that	O
he	O
had	O
taken	O
were	O
analyzed	O
to	O
prove	O
his	O
claims	O
USOC	O
accepted	O
claim	O
of	O
inadvertent	O
use	O
since	O
a	O
dietary	O
supplement	O
ingested	O
was	O
found	O
contain	O
Ma	O
huang	O
Chinese	O
name	O
for	O
Ephedra	O
ephedrine	B-Drug
is	O
known	O
help	O
weight	O
loss	O

From	O
2013	O
until	O
2016	O
overdose	O
deaths	O
involving	O
fentanyl	B-Drug
increased	O
113%	O
per	O
year	O

The	O
quick	O
metabolism	O
and	O
elimination	O
of	O
alfaxalone	B-Drug
from	O
the	O
body	O
decreases	O
chance	O
overdose	O

Concurrent	O
use	O
of	O
paracetamol	B-Drug
with	O
alcohol	O
products	O
may	O
increase	O
the	O
risk	O
acute	O
liver	O
failure	O

angina	O
history	O
of	O
myocardial	O
infarction	O
congestive	O
heart	O
failure	O
tachycardia	O
peripheral	O
arterial	O
occlusive	O
disease	O
arrhythmia	O
or	O
cerebrovascular	O
stroke	O
transient	O
ischemic	O
attack	O
TIA	O
Stroke	O
Hyperthyroidism	O
overactive	O
thyroid	O
gland	O
Closed	O
angle	O
glaucoma	O
Seizure	O
disorders	O
Enlargement	O
the	O
prostate	O
with	O
urinary	O
retention	O
relative	O
contraindication	O
Pheochromocytoma	O
Pregnant	O
and	O
lactating	O
women	O
A	O
higher	O
number	O
cardiovascular	O
events	O
has	O
been	O
observed	O
in	O
people	O
taking	O
sibutramine	B-Drug
versus	O
control	O
11	O

The	O
benzoyl	O
moiety	O
required	O
for	O
the	O
formation	O
of	O
cocaine	B-Drug
diester	O
is	O
synthesized	O
from	O
phenylalanine	O
via	O
cinnamic	O
acid	O

While	O
diuretics	O
can	O
make	O
lactation	O
difficult	O
it	O
is	O
unlikely	O
that	O
amiloride	B-Drug
would	O
induce	O
this	O
effect	O
in	O
the	O
absence	O
of	O
other	O

In	O
October	O
2013	O
Missouri	O
changed	O
its	O
protocols	O
to	O
allow	O
for	O
a	O
compounded	O
pentobarbital	B-Drug
be	O
used	O
in	O
lethal	O
dose	O
executions	O
and	O
it	O
was	O
first	O
November	O

Synthetic	O
cannabinoids	O
are	O
a	O
class	O
of	O
molecules	O
that	O
bind	O
to	O
the	O
same	O
receptors	O
which	O
THC	O
and	O
CBD	B-Drug
in	O
cannabis	O
plants	O
attach	O

It	O
was	O
first	O
introduced	O
on	O
18	O
June	O
1959	O
by	O
Upjohn	O
in	O
the	O
United	O
States	O
under	O
brand	O
name	O
Provera	B-Drug
2	O

In	O
order	O
to	O
curb	O
misuse	O
many	O
health	O
insurers	O
have	O
begun	O
require	O
precertification	O
and/or	O
quantity	O
limits	O
for	O
Actiq	B-Drug
prescriptions	O

Despite	O
being	O
a	O
more	O
potent	O
analgesic	O
fentanyl	B-Drug
tends	O
to	O
induce	O
less	O
nausea	O
as	O
well	O
histamine-mediated	O
itching	O
than	O
morphine	B-Drug

Because	O
of	O
its	O
high	O
potency	O
the	O
smallest	O
lorazepam	B-Drug
tablet	O
strength	O
0	O

As	O
a	O
result	O
of	O
public	O
pressure	O
and	O
the	O
FDA	O
Walmart	O
Sam's	O
club	O
announced	O
that	O
they	O
were	O
raising	O
minimum	O
age	O
to	O
purchase	O
tobacco	B-Drug
products	O
including	O
all	O
e-cigarettes	O
21	O
starting	O
July	O
1	O
2019	O

Primidone	B-Drug
1952	O

Ketoconazole	B-Drug
was	O
discovered	O
in	O
1976	O
at	O
Janssen	O
Pharmaceutica	O

Androstenedione	B-Drug
is	O
released	O
into	O
the	O
blood	O
by	O
theca	O
cells	O

Drugs	O
produced	O
by	O
Roche	O
include:	O
Accutane/RoAccutane	O
isotretinoin	B-Drug
for	O
severe	O
nodular	O
acne	O
vulgaris	O
-	O
no	O
longer	O
sold	O
under	O
Accutane	B-Drug
brand	O
name	O
but	O
is	O
still	O
available	O
as	O
RoAccutane	B-Drug
other	O
names	O
and	O
Isotretinoin	B-Drug
generics	O

Fludrocortisone	B-Drug
is	O
marketed	O
mainly	O
under	O
the	O
brand	O
names	O
Astonin	O
and	O
Astonin-H	O
whereas	O
more	O
widely	O
used	O
fludrocortisone	B-Drug
acetate	I-Drug
sold	O
as	O
Florinef	O
but	O
also	O
several	O
other	O
including	O
Cortineff	O
Florinefe	O
Fludrocortison	O

Ketoconazole	B-Drug
and	O
sulfaphenazole	O
interfere	O
with	O
the	O
metabolism	O
of	O
zopiclone	B-Drug

They	O
feature	O
a	O
phenethylamine	B-Drug
core	O
with	O
an	O
alkyl	O
group	O
attached	O
to	O
the	O
alpha	O
carbon	O
and	O
ketone	O
beta	O
along	O
additional	O
substitutions	O

For	O
instance	O
etorphine	B-Drug
and	O
acetorphine	B-Drug
were	O
considered	O
sufficiently	O
morphine-like	O
to	O
fall	O
under	O
the	O
treaty's	O
scope	O
although	O
they	O
are	O
many	O
times	O
more	O
potent	O
than	O
morphine	B-Drug

Thalidomide	B-Drug
is	O
provided	O
as	O
a	O
racemic	O
mixture	O
of	O
two	O
enantiomers;	O
while	O
there	O
are	O
reports	O
that	O
only	O
one	O
the	O
enantiomers	O
may	O
cause	O
birth	O
defects	O
body	O
converts	O
each	O
enantiomer	O
into	O
other	O
through	O
mechanisms	O
not	O
well	O
understood	O

Bupropion	B-Drug
inhibits	O
the	O
reuptake	O
of	O
dopamine	O
through	O
human	O
transporter	O
and	O
norepinephrine	O
transporter;	O
inhibition	O
is	O
most	O
pronounced	O
in	O
prefrontal	O
cortex	O
humans	O

Additionally	O
the	O
morphine	B-Drug
syrettes	O
found	O
in	O
combat	O
medical	O
kits	O
issued	O
to	O
military	O
personnel	O
actually	O
contain	O
omnopon	O

Laborers	O
from	O
other	O
races	O
used	O
cocaine	B-Drug
such	O
as	O
in	O
northern	O
cities	O
where	O
was	O
often	O
cheaper	O
than	O
alcohol	O

Recommendations	O
exist	O
for	O
cautious	O
use	O
of	O
ketorolac	B-Drug
in	O
those	O
who	O
have	O
experienced	O
cardiovascular	O
disease	O
myocardial	O
infarction	O
stroke	O
heart	O
failure	O
coagulation	O
disorders	O
renal	O
impairment	O
and	O
hepatic	O

There	O
are	O
many	O
examples	O
of	O
subtype-selective	O
compounds	O
which	O
widely	O
used	O
in	O
scientific	O
research	O
including:	O
CL-218872	O
highly	O
1-selective	O
agonist	O
bretazenil	O
partial	O
imidazenil	O
and	O
L-838417	O
both	O
agonists	O
at	O
some	O
subtypes	O
but	O
weak	O
antagonists	O
others	O
QH-ii-066	O
full	O
selective	O
for	O
5	O
subtype	O
5IA	O
inverse	O
SL-651498	O
2	O
3	O
as	O
a	O
1	O
3-acyl-4-quinolones:	O
over	O
multiple	O
indications	O
that	O
paradoxical	O
reactions	O
upon	O
example	O
benzodiazepines	O
barbiturates	O
inhalational	O
anesthetics	O
propofol	B-Drug
neurosteroids	O
alcohol	O
associated	O
with	O
structural	O
deviations	O
GABAA	O
receptors	O

Marijuana	B-Drug
contains	O
more	O
than	O
400	O
chemicals	O
including	O
the	O
most	O
harmful	O
substances	O
found	O
in	O
tobacco	O
smoke	O

Stanozolol	B-Drug
and	O
other	O
AAS	O
were	O
commonly	O
used	O
to	O
treat	O
hereditary	O
angioedema	O
attacks	O
until	O
several	O
drugs	O
brought	O
market	O
specifically	O
for	O
treatment	O
of	O
that	O
disease	O
the	O
first	O
in	O
2009:	O
Cinryze	B-Drug
Berinert	O
ecallantide	B-Drug
Kalbitor	O
icatibant	O
Firazyr	O
Ruconest	B-Drug

The	O
bioavailability	O
of	O
some	O
vitamins	O
such	O
as	O
thiamin	B-Drug
vitamin	O
B6	O
niacin	B-Drug
folate	O
and	O
carotenoids	O
are	O
increased	O
with	O
cooking	O
by	O
being	O
freed	O
from	O
the	O
food	O
microstructure	O

Sedative	O
drugs	O
including	O
alprazolam	B-Drug
have	O
been	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
death	O

Buprenorphine	B-Drug
has	O
shown	O
antidepressant	O
effects	O
in	O
some	O
human	O
studies	O
thought	O
to	O
be	O
because	O
of	O
its	O
antagonist	O
at	O
the	O
KOR	O
but	O
not	O
been	O
further	O
developed	O
for	O
this	O
application	O
MOR	O
agonist	O
and	O
consequent	O
abuse	O
potential	O

In	O
this	O
plant	O
galenical	O
preparations	O
pills	B-Drug
tablets	O
capsules	O
and	O
other	O
classes	O
of	O
pharmaceutical	O
medical	O
goods	O
were	O
prepared	O

Discontinuation	O
of	O
nitrazepam	B-Drug
produced	O
rebound	O
insomnia	O
after	O
short-term	O
single	O
nightly	O
dose	O
therapy	O

Harsher	O
sentences	O
are	O
given	O
for	O
those	O
convicted	O
of	O
manufacturing	O
amphetamines	O
such	O
as	O
methamphetamine	B-Drug

The	O
phenethylamine	B-Drug
equivalent	O
lacking	O
the	O
alpha-methyl	O
group	O
is	O
2C-C	O

1985	O
reviewed	O
the	O
preclinical	O
pharmacology	O
of	O
nalbuphine	B-Drug
and	O
reported	O
comparative	O
data	O
relative	O
to	O
other	O
types	O
opioid	O
compounds	O

Listed	O
as	O
a	O
Schedule	O
1	O
it	O
is	O
an	O
analogue	O
of	O
amphetamine	B-Drug

According	O
to	O
federal	O
laws	O
methadone	B-Drug
cannot	O
be	O
prescribed	O
by	O
a	O
doctor	O
and	O
obtained	O
from	O
pharmacy	O
in	O
order	O
treat	O
addiction	O

It	O
has	O
been	O
studied	O
in	O
combination	O
with	O
naltrexone	B-Drug

Typical	O
antipsychotics	O
such	O
as	O
phenothiazines	O
and	O
haloperidol	B-Drug
have	O
been	O
used	O
to	O
control	O
psychotic	O
symptoms	O
but	O
may	O
produce	O
many	O
undesirable	O
side	O
effects	O
dystonia	O
their	O
use	O
is	O
therefore	O
no	O
longer	O
preferred;	O
are	O
particularly	O
risky	O
they	O
lower	O
the	O
seizure	O
threshold	O
worsen	O
hyperthermia	O
boost	O
anticholinergic	O
of	O
PCP	B-Drug

Methadone	B-Drug
is	O
usually	O
taken	O
by	O
mouth	O
and	O
rarely	O
injection	O
into	O
a	O
muscle	O
or	O
vein	O

1%	O
Kenalog	O
Aristocort	B-Drug
A	O
ointment	O
Mometasone	O
furoate	O
0	O

analgesia	O
of	O
opioid	O
agonists	O
like	O
morphine	B-Drug
and	O
fentanyl	B-Drug
in	O
animals	O

Black	O
tar	O
heroin	O
is	O
impure	O
diamorphine	B-Drug

The	O
FDA	O
issued	O
a	O
warning	O
in	O
November	O
1990	O
that	O
sale	O
of	O
GHB	B-Drug
was	O
illegal	O

The	O
duration	O
of	O
action	O
MDMA	B-Drug
is	O
usually	O
four	O
to	O
six	O
hours	O
after	O
which	O
serotonin	O
levels	O
in	O
the	O
brain	O
are	O
depleted	O

The	O
subjects	O
received	O
at	O
least	O
one	O
oral	O
dose	O
of	O
benzhydrocodone/APAP	O
APAP	B-Drug

Heroin	B-Drug
may	O
be	O
used	O
for	O
fractures	O
burns	O
finger-tip	O
injuries	O
suturing	O
and	O
wound	O
re-dressing	O
but	O
is	O
inappropriate	O
in	O
head	O

Another	O
more	O
potent	O
analog	O
pomalidomide	B-Drug
is	O
now	O
FDA	O
approved	O

As	O
obstacles	O
to	O
manual	O
eradication	O
the	O
US	O
Department	O
of	O
State	O
listed	O
local	O
level	O
protests	O
blocking	O
access	O
roads	O
coca	B-Drug
fields	O
and	O
security	O
concerns	O
on	O
Ecuador-Colombia	O
border	O
in	O
Catatumbo	O
region	O
near	O
Venezuela-Colombia	O

This	O
infers	O
the	O
hydrogen	O
bond	O
acceptor	O
at	O
2	O
position	O
to	O
not	O
necessarily	O
be	O
of	O
exclusive	O
import	O
in	O
creation	O
higher	O
binding	O
analogues	O
cocaine	B-Drug

Trifluoperazine	B-Drug
can	O
lower	O
the	O
seizure	O
threshold	O

Additionally	O
there	O
are	O
many	O
unanswered	O
questions	O
about	O
the	O
science	O
safety	O
effectiveness	O
and	O
quality	O
of	O
unapproved	O
products	O
containing	O
CBD	B-Drug

Pethidine	B-Drug
also	O
has	O
stimulant	O
effects	O
mediated	O
by	O
its	O
inhibition	O
of	O
the	O
dopamine	O
transporter	O
DAT	O
and	O
norepinephrine	O
NET	O

Two	O
months	O
before	O
the	O
FDA	O
had	O
approved	O
another	O
drug	O
for	O
HepC	O
simeprevir	B-Drug

By	O
the	O
mid-1950s	O
14	O
pharmaceutical	O
companies	O
were	O
marketing	O
thalidomide	B-Drug
in	O
46	O
countries	O
under	O
at	O
least	O
37	O
different	O
trade	O
names	O

In	O
any	O
case	O
the	O
levels	O
of	O
most	O
steroid	O
hormones	O
including	O
testosterone	O
and	O
cortisol	O
are	O
usually	O
unchanged	O
by	O
spironolactone	B-Drug
in	O
humans	O
which	O
may	O
part	O
be	O
related	O
to	O
compensatory	O
upregulation	O
their	O
synthesis	O

Four	O
versions	O
of	O
opium	B-Drug
as	O
a	O
fluid	O
extract	O
were	O
also	O
offered:	O
1	O
Opium	B-Drug
Concentrated	O
assayed	O
For	O
making	O
Tincture	O
Opii	O
Laudanum	B-Drug
U	O

Its	O
popularity	O
with	O
recreational	O
drug	O
users	O
compared	O
to	O
morphine	B-Drug
reportedly	O
stems	O
from	O
its	O
perceived	O
different	O
effects	O

Australia	O
Tasmania	O
Turkey	O
and	O
India	O
are	O
the	O
major	O
producers	O
of	O
poppy	O
for	O
medicinal	O
purposes	O
poppy-based	O
drugs	O
such	O
as	O
morphine	B-Drug
or	O
codeine	B-Drug

With	O
the	O
introduction	O
of	O
laws	O
and	O
policies	O
which	O
prohibited	O
import	O
use	O
opium	B-Drug
taxation	O
income	O
government	O
had	O
previously	O
been	O
earning	O
from	O
imports	O
was	O
redundant	O

Non-psychoactive	O
iso-LSD	O
which	O
has	O
formed	O
during	O
the	O
synthesis	O
can	O
be	O
separated	O
by	O
chromatography	O
and	O
isomerized	O
to	O
LSD	B-Drug

His	O
first	O
arrest	O
for	O
manufacturing	O
LSD	B-Drug
came	O
on	O
December	O
28	O
1988	O
in	O
Mountain	O
View	O
California	O

The	O
2007	O
production	O
consisted	O
of	O
8870	O
metric	O
tons	O
8730	O
long	O
illegal	O
opium	B-Drug
3420	O
3370	O
equivalent	O
from	O
legal	O
poppy	O
straw	O
and	O
300	O

There	O
are	O
reports	O
of	O
intravenous	O
injection	O
25I-NBOMe	B-Drug
solution	O
and	O
smoking	O
the	O
drug	O
in	O
powdered	O
form	O

Phenytoin	B-Drug
was	O
once	O
another	O
first-line	O
therapy	O
although	O
the	O
prodrug	O
fosphenytoin	O
can	O
be	O
administered	O
three	O
times	O
as	O
fast	O
and	O
with	O
far	O
fewer	O
injection	O
site	O
reactions	O

This	O
was	O
broadly	O
similar	O
to	O
the	O
percentage	O
of	O
people	O
who	O
use	O
cocaine	B-Drug
or	O
amphetamines	O
but	O
lower	O
than	O
for	O
cannabis	O
opioids	O

Noribogaine	B-Drug
is	O
a	O
hERG	O
inhibitor	O
and	O
appears	O
at	O
least	O
as	O
potent	O
ibogaine	B-Drug

Benzedrine	B-Drug
was	O
claimed	O
to	O
have	O
been	O
administered	O
by	O
Allied	O
forces	O
during	O
WWII	O
esp	O

Tobacco	B-Drug
has	O
also	O
been	O
described	O
an	O
anaphrodisiac	O
due	O
to	O
its	O
propensity	O
for	O
causing	O
erectile	O
dysfunction	O

In	O
2010	O
the	O
BBC	O
reported	O
that	O
use	O
of	O
MDMA	B-Drug
had	O
decreased	O
in	O
UK	O
previous	O
years	O

When	O
urine	O
pH	O
is	O
abnormal	O
the	O
urinary	O
recovery	O
of	O
amphetamine	B-Drug
may	O
range	O
from	O
a	O
low	O
1%	O
to	O
high	O
75%	O
depending	O
mostly	O
upon	O
whether	O
too	O
basic	O
or	O
acidic	O
respectively	O

Similarly	O
after	O
15	O
days	O
of	O
nicotine	B-Drug
treatment	O
rats	O
the	O
post-translational	O
modification	O
consisting	O
3-fold	O
increased	O
acetylation	O
histone	O
H4	O
occurs	O
at	O
promoter	O
dopamine	O
D1	O
receptor	O
DRD1	O
gene	O
in	O
prefrontal	O
cortex	O
PFC	O

In	O
the	O
US	O
similar	O
descriptions	O
bath	O
salts	O
is	O
most	O
common	O
have	O
been	O
used	O
to	O
describe	O
mephedrone	B-Drug
as	O
well	O
methylone	B-Drug
and	O
methylenedioxypyrovalerone	B-Drug
MDPV	B-Drug

In	O
the	O
late	O
1950s	O
and	O
early	O
1960s	O
more	O
than	O
10000	O
children	O
in	O
46	O
countries	O
were	O
born	O
with	O
deformities	O
such	O
as	O
phocomelia	O
a	O
consequence	O
of	O
thalidomide	B-Drug
use	O

64	O
Drug	O
syndicates	O
have	O
been	O
producing	O
methamphetamine	B-Drug
in	O
small-scale	O
and	O
kitchen-type	O
laboratories	O
to	O
avoid	O
detection	O
by	O
the	O
Philippine	O
authorities	O
since	O
2010	O

Reviewing	O
studies	O
adjusted	O
for	O
age	O
and	O
tobacco	B-Drug
use	O
they	O
said	O
there	O
was	O
a	O
risk	O
of	O
lung	O
cancer	O
even	O
after	O
adjusting	O
but	O
that	O
the	O
period	O
time	O
over	O
which	O
increases	O
is	O
uncertain	O

PCP	B-Drug
may	O
cause	O
hallucinations	O
distorted	O
perceptions	O
of	O
sounds	O
and	O
violent	O
behavior	O

It	O
is	O
an	O
active	O
analgesic	O
in	O
vivo	O
more	O
potent	O
than	O
codeine	B-Drug
or	O
pethidine	B-Drug
but	O
slightly	O
less	O
morphine	B-Drug
and	O
produces	O
similar	O
effects	O
to	O
animals	O
with	O
sedation	O

In	O
the	O
UK	O
its	O
highly	O
likely	O
that	O
this	O
compound	O
would	O
be	O
covered	O
by	O
phenylethylamine	B-Drug
amendment	O
to	O
misuse	O
of	O
drugs	O
act	O
rendering	O
it	O
a	O
Class	O
A	O
controlled	O
drug	O

During	O
phase	O
I	O
human	O
clinical	O
trials	O
for	O
the	O
treatment	O
of	O
cocaine	B-Drug
abuse	O
development	O
JDTic	O
was	O
halted	O
due	O
to	O
incidence	O
non-sustained	O
ventricular	O
tachycardia	O
a	O
type	O
arrhythmia	O
that	O
can	O
potentially	O
be	O
life-threatening	O

Ephedrine	B-Drug
promotes	O
modest	O
short-term	O
weight	O
loss	O
specifically	O
fat	O
but	O
its	O
long-term	O
effects	O
are	O
unknown	O

In	O
sleep	O
laboratory	O
studies	O
temazepam	B-Drug
significantly	O
decreased	O
the	O
number	O
of	O
nightly	O
awakenings	O
but	O
has	O
drawback	O
distorting	O
normal	O
pattern	O

Phencyclidine	B-Drug
or	O
phenylcyclohexyl	O
piperidine	O
PCP	B-Drug
also	O
known	O
as	O
angel	B-Drug
dust	I-Drug
among	O
other	O
names	O
is	O
a	O
drug	O
used	O
for	O
its	O
mind-altering	O
effects	O

MDMA	B-Drug
and	O
metabolites	O
are	O
primarily	O
excreted	O
as	O
conjugates	O
such	O
sulfates	O
glucuronides	O

Nandrolone	B-Drug
esters	O
have	O
been	O
said	O
to	O
be	O
the	O
most	O
popular	O
AAS	O
used	O
by	O
bodybuilders	O
and	O
in	O
sports	O

By	O
this	O
final	O
year	O
of	O
its	O
patent	O
2006	O
Zofran	B-Drug
had	O
become	O
the	O
20th	O
highest-selling	O
brand-name	O
drug	O
in	O
United	O
States	O
with	O
sales	O
US$1	O

recreational	O
amphetamine	B-Drug
use	O
so	O
periods	O
of	O
extended	O
abuse	O
require	O
increasingly	O
larger	O
doses	O
the	O
drug	O
in	O
order	O
to	O
achieve	O
same	O
effect	O

The	O
report	O
recommended	O
that	O
the	O
Victorian	O
Government	O
explore	O
avenues	O
to	O
distribute	O
naloxone	B-Drug
more	O
effectively	O
stated	O
such	O
might	O
include	O
needle	O
and	O
syringe	O
programs	O
other	O
community	O
health	O
services	O
where	O
staff	O
are	O
trained	O
educate	O
others	O
in	O
administering	O
making	O
available	O
first	O
responders	O
overdose	O
calls	O
areas	O
with	O
high	O
concentrations	O
of	O
injecting	O
heroin	B-Drug
use	O
accompanied	O
appropriate	O
training	O

Buprenorphine	B-Drug
was	O
discovered	O
in	O
1972	O

When	O
taken	O
orally	O
heroin	B-Drug
undergoes	O
extensive	O
first-pass	O
metabolism	O
via	O
deacetylation	O
making	O
it	O
a	O
prodrug	O
for	O
the	O
systemic	O
delivery	O
of	O
morphine	B-Drug

Kratom	B-Drug
is	O
commonly	O
used	O
in	O
the	O
United	O
States	O
as	O
self-treatment	O
for	O
pain	O
and	O
opioid	O
withdrawal	O

methylphenidate	B-Drug
Daytrana	O
and	O
fentanylMany	O
drugs	O
are	O
taken	O
through	O
various	O
routes	O

In	O
Switzerland	O
Germany	O
the	O
Netherlands	O
and	O
United	O
Kingdom	O
long-term	O
injecting	O
drug	O
users	O
who	O
do	O
not	O
benefit	O
from	O
methadone	B-Drug
other	O
medication	O
options	O
may	O
be	O
treated	O
with	O
injectable	O
heroin	B-Drug
that	O
is	O
administered	O
under	O
supervision	O
of	O
medical	O
staff	O

The	O
patent	O
protection	O
of	O
bicalutamide	B-Drug
expired	O
in	O
the	O
U	O

15	O
nM	O
butyrfentanyl's	O
ability	O
to	O
displace	O
[3H]	O
fentanyl	B-Drug
is	O
low	O
and	O
it	O
requires	O
high	O
concentrations	O
of	O
the	O
drug	O
butyrfentanyl	B-Drug

It	O
is	O
closely	O
related	O
structurally	O
to	O
androstenediol	O
androst-5-ene-317-diol	O
androstenedione	B-Drug
androst-4-ene-317-dione	O
and	O
testosterone	O
androst-4-en-17-ol-3-one	O

The	O
following	O
reactions	O
are	O
known	O
to	O
be	O
catalyzed	O
by	O
5-reductase:	O
Cholestenone	O
5-Cholestanone	O
Progesterone	O
5-Dihydroprogesterone	O
3-Dihydroprogesterone	O
Allopregnanolone	B-Drug
Isopregnanolone	O
Deoxycorticosterone	O
5-Dihydrodeoxycorticosterone	O
Corticosterone	O
5-Dihydrocorticosterone	O
Cortisol	O
5-Dihydrocortisol	O
Aldosterone	O
5-Dihydroaldosterone	O
Androstenedione	B-Drug
5-Androstanedione	O
Testosterone	O
5-Dihydrotestosterone	O
Nandrolone	B-Drug
5-Dihydronandrolone	O
mechanism	O
of	O
5	O
reductase	O
inhibition	O
is	O
complex	O
but	O
involves	O
the	O
binding	O
NADPH	O
enzyme	O
followed	O
substrate	O

Studies	O
in	O
rodents	O
given	O
a	O
daily	O
maximum	O
dose	O
of	O
10	O
mg	O
naloxone	B-Drug
showed	O
no	O
harmful	O
effects	O
to	O
the	O
fetus	O
although	O
human	O
studies	O
are	O
lacking	O
and	O
drug	O
does	O
cross	O
placenta	O
which	O
may	O
lead	O
precipitation	O
withdrawal	O

Amphetamine	B-Drug
Chinese:	O
;	O
Jyutping:	O
on1	O
fei1	O
taa1	O
ming6	O
is	O
a	O
2010	O
Hong	O
Kong	O
film	O
starring	O
Byron	O
Pang	O
and	O
Thomas	O
Price	O

Compared	O
to	O
ephedrine	B-Drug
Oberlin	O
observed	O
that	O
it	O
had	O
similar	O
effects	O
on	O
vascular	O
smooth	O
muscle	O
tissue	O
stronger	O
at	O
the	O
uterus	O
and	O
no	O
local	O
effect	O
eye	O

When	O
methamphetamine	B-Drug
binds	O
to	O
TAAR1	O
it	O
triggers	O
transporter	O
phosphorylation	O
via	O
protein	O
kinase	O
A	O
PKA	O
and	O
C	O
PKC	O
signaling	O
ultimately	O
resulting	O
in	O
the	O
internalization	O
or	O
reverse	O
function	O
of	O
monoamine	O
transporters	O

Ondansetron	B-Drug
is	O
in	O
pregnancy	O
category	O
B	O
the	O
US	O

Only	O
one	O
non-tryptamine	O
indole	O
has	O
been	O
sold	O
5-IT	B-Drug

In	O
animal	O
studies	O
desoxymethyltestosterone	B-Drug
has	O
been	O
found	O
to	O
bind	O
the	O
androgen	O
receptor	O
AR	O
about	O
half	O
as	O
strongly	O
DHT	O
and	O
cause	O
side	O
effects	O
that	O
are	O
typical	O
of	O
17-alkylated	O
AAS	O
such	O
liver	O
damage	O
left	O
ventricular	O
hypertrophy	O
when	O
taken	O
in	O
higher	O
doses	O

Specifically	O
25I-NBOMe	B-Drug
is	O
an	O
N-benzyl	O
derivative	O
of	O
the	O
phenethylamine	B-Drug
molecule	O
2C-I	O
formed	O
by	O
adding	O
a	O
2-methoxybenzyl	O
BnOMe	O
onto	O
nitrogen	O
N	O
backbone	O

Abiraterone	B-Drug
is	O
the	O
INN	O
and	O
BAN	O
of	O
abiraterone	B-Drug
acetate's	O
major	O
active	O
metabolite	O

In	O
modern	O
times	O
much	O
of	O
the	O
thebaine	O
which	O
often	O
serves	O
as	O
raw	O
material	O
for	O
synthesis	O
oxycodone	B-Drug
hydrocodone	B-Drug
hydromorphone	B-Drug
and	O
other	O
semisynthetic	O
opiates	O
originates	O
from	O
extracting	O
Papaver	O
orientale	O
or	O
bracteatum	O

In	O
November	O
2016	O
the	O
DEA	O
uncovered	O
an	O
operation	O
making	O
counterfeit	O
oxycodone	B-Drug
and	O
Xanax	B-Drug
from	O
a	O
home	O
in	O
Cottonwood	O
Heights	O
Utah	O

According	O
to	O
a	O
2014	O
survey	O
25I-NBOMe	B-Drug
was	O
the	O
most	O
frequently	O
used	O
of	O
NBOMe	O
series	O

In	O
Philippa	O
Gregory's	O
novel	O
Wideacre	O
1987	O
the	O
main	O
character	O
Beatrice	O
Lacey	O
nearly	O
becomes	O
addicted	O
to	O
laudanum	B-Drug
when	O
her	O
eventual	O
husband	O
Dr	O

Methamphetamine	B-Drug
may	O
counteract	O
the	O
effects	O
of	O
antihypertensives	O
and	O
antipsychotics	O
due	O
to	O
its	O
on	O
cardiovascular	O
system	O
cognition	O
respectively	O

Nandrolone	B-Drug
decanoate	I-Drug
is	O
approved	O
in	O
the	O
United	O
States	O
specifically	O
for	O
treatment	O
of	O
anemia	O
chronic	O
kidney	O
disease	O
and	O
Kingdom	O
osteoporosis	O
postmenopausal	O
women	O

Androstanazole	O
androstanazol	O
stanazol	O
stanazolol	B-Drug
and	O
estanazolol	O
are	O
unofficial	O
synonyms	O
of	O
stanozolol	B-Drug

A	O
review	O
of	O
the	O
details	O
194	O
deaths	O
attributed	O
to	O
or	O
related	O
GHB	B-Drug
over	O
a	O
ten-year	O
period	O
found	O
that	O
most	O
were	O
from	O
respiratory	O
depression	O
caused	O
by	O
interaction	O
with	O
alcohol	O
other	O
drugs	O

Nandrolone	B-Drug
has	O
also	O
been	O
found	O
to	O
produce	O
penile	O
growth	O
in	O
prepubertal	O
boys	O

Anticholinergic	O
drugs	O
and	O
deliriants:	O
Atropine	O
racemic	O
hyoscyamine	B-Drug
from	O
the	O
deadly	O
nightshade	O
Atropa	O
belladonna	O
Hyoscyamine	B-Drug
levo-isomer	O
of	O
atropine	O
henbane	O
Hyoscyamus	O
niger	O
mandrake	O
Mandragora	O
officinarum	O
sorcerers'	O
tree	O
Latua	O
pubiflora	O

When	O
subcommittee	O
member	O
Senator	O
Ted	O
Kennedy	O
of	O
Massachusetts	O
asked	O
Leary	O
if	O
LSD	B-Drug
usage	O
was	O
extremely	O
dangerous	O
replied	O
Sir	O
the	O
motor	O
car	O
is	O
used	O
improperly	O

However	O
older	O
people	O
often	O
have	O
decreased	O
liver	O
and	O
kidney	O
function	O
that	O
may	O
lead	O
to	O
an	O
increased	O
level	O
of	O
naloxone	B-Drug
in	O
their	O
body	O

The	O
most	O
commonly	O
used	O
esters	O
are	O
nandrolone	B-Drug
decanoate	O
and	O
to	O
a	O
lesser	O
extent	O
phenylpropionate	I-Drug

Ciclosporin	B-Drug
blocks	O
the	O
formation	O
of	O
mitochondrial	O
permeability	O
transition	O
pore	O
which	O
has	O
been	O
found	O
to	O
cause	O
much	O
damage	O
associated	O
with	O
head	O
injury	O
and	O
neurodegenerative	O
diseases	O

Lidocaine	B-Drug
also	O
known	O
as	O
lignocaine	B-Drug
is	O
a	O
local	O
anesthetic	O
of	O
the	O
amino	O
amide	O
type	O

Therefore	O
the	O
British	O
tried	O
to	O
encourage	O
Chinese	O
opium	B-Drug
use	O
enhance	O
their	O
balance	O
and	O
they	O
delivered	O
it	O
from	O
Indian	O
provinces	O
under	O
control	O

Nimetazepam	B-Drug
marketed	O
under	O
brand	O
name	O
Erimin	O
and	O
Lavol	O
is	O
an	O
intermediate-acting	O
hypnotic	O
drug	O
which	O
a	O
benzodiazepine	O
derivative	O

The	O
phenomenon	O
of	O
unopposed	O
alpha-stimulation	O
in	O
which	O
blood	O
pressure	O
increases	O
or	O
coronary	O
artery	O
vasoconstriction	O
worsens	O
after	O
blockade	O
beta-2	O
vasodilation	O
people	O
using	O
cocaine	B-Drug
is	O
controversial	O

On	O
October	O
4	O
2007	O
Kentucky	O
officials	O
sued	O
Purdue	O
because	O
of	O
widespread	O
OxyContin	B-Drug
abuse	O
in	O
Appalachia	O

A	O
2017	O
UNODC	O
report	O
into	O
the	O
cultivation	O
of	O
illicit	O
crops	O
in	O
Colombia	O
showed	O
that	O
number	O
hectares	O
under	O
coca	B-Drug
leapt	O
from	O
96000	O
2015	O
to	O
146000	O
2016	O

Lorcaserin	B-Drug
is	O
used	O
long	O
term	O
for	O
weight	O
loss	O
in	O
those	O
who	O
are	O
obese	O

The	O
emergency	O
scheduling	O
power	O
has	O
subsequently	O
been	O
used	O
for	O
a	O
variety	O
of	O
other	O
drugs	O
including	O
2C-B	B-Drug
AMT	B-Drug
and	O
BZP	B-Drug

By	O
1905	O
all	O
Australian	O
states	O
and	O
territories	O
had	O
passed	O
similar	O
laws	O
making	O
prohibitions	O
to	O
Opium	B-Drug
sale	O

Many	O
fatal	O
cases	O
of	O
sulfonal	B-Drug
poisoning	O
are	O
on	O
record	O
both	O
from	O
chronic	O
and	O
a	O
single	O
large	O
dose	O

Fentanyl	B-Drug
has	O
a	O
US	O
DEA	O
ACSCN	O
of	O
9801	O
and	O
2013	O
annual	O
aggregate	O
manufacturing	O
quota	O
2108	O

Neither	O
the	O
crown	O
fruit	O
mescal	O
button	O
of	O
Peyote	O
cactus	O
nor	O
roots	O
plant	O
Mimosa	O
hostilis	O
Peganum	O
Harmala	O
that	O
contains	O
alkaloids	O
or	O
Syrian	O
Rue	O
Hawaian	O
Baby	O
Woodrose	O
and	O
morning	O
glory	O
flowers	O
LSA	B-Drug
Lysergic	O
Acid	B-Drug
Amide	O
Chacruna	O
a	O
psychotropic	O
shrub	O
which	O
is	O
used	O
for	O
make	O
Ayahuasca	O
brew	O
[Footnote:	O
An	O
infusion	O
used]	O
Psilocybe	O
mushrooms	O
Beverages	O
made	O
from	O
such	O
are	O
themselves	O
included	O
in	O
Schedule	O
I	O
but	O
only	O
their	O
respective	O
active	O
principles	O
mescaline	B-Drug
DMT	O
psilocybine	O
psilocine	O
psilotsin	O

Laudanum	B-Drug
as	O
Tincture	O
No	O

The	O
most	O
widely	O
used	O
drugs	O
in	O
the	O
world	O
include	O
caffeine	O
nicotine	B-Drug
and	O
alcohol	O
which	O
are	O
also	O
considered	O
recreational	O
since	O
they	O
for	O
pleasure	O
rather	O
than	O
medicinal	O
purposes	O

Onset	O
of	O
pemphigoid	O
has	O
also	O
been	O
associated	O
with	O
certain	O
drugs	O
including	O
furosemide	O
nonsteroidal	O
anti-inflammatory	O
agents	O
DPP-4	O
inhibitors	O
captopril	O
penicillamine	B-Drug
and	O
antibiotics	O

The	O
duration	O
of	O
action	O
fentanyl	B-Drug
has	O
sometimes	O
been	O
underestimated	O
leading	O
to	O
harm	O
in	O
a	O
medical	O
context	O

In	O
the	O
United	O
States	O
like	O
other	O
AAS	O
stanozolol	B-Drug
is	O
classified	O
as	O
a	O
controlled	O
substance	O
under	O
federal	O
regulation;	O
they	O
were	O
included	O
Schedule	O
III	O
substances	O
Anabolic	O
Steroids	O
Act	O
which	O
was	O
passed	O
part	O
of	O
Crime	O
Control	O
1990	O

25I-NBOMe	B-Drug
can	O
be	O
consumed	O
in	O
liquid	O
powder	O
or	O
paper	O
form	O
and	O
snorted	O
injected	O
mixed	O
with	O
food	O
smoked	O
but	O
sublingual	O
administration	O
is	O
most	O
common	O

However	O
although	O
the	O
risk	O
of	O
adverse	O
liver	O
changes	O
with	O
bicalutamide	B-Drug
is	O
low	O
enzalutamide	B-Drug
differs	O
from	O
in	O
having	O
no	O
known	O
elevated	O
enzymes	O
or	O
hepatotoxicity	O

1856:	O
William	O
Henry	O
Perkin	O
attempts	O
quinine	B-Drug
synthesis	O
by	O
oxidation	O
of	O
N-allyltoluidine	O
based	O
on	O
the	O
erroneous	O
idea	O
that	O
two	O
equivalents	O
this	O
compound	O
with	O
chemical	O
formula	O
C10H13N	O
plus	O
three	O
oxygen	O
yield	O
one	O
equivalent	O
C20H24N2O2	O
quinine's	O
and	O
water	O

After	O
the	O
early	O
studies	O
that	O
reported	O
PCE	O
children	O
would	O
be	O
severely	O
disabled	O
came	O
purported	O
to	O
show	O
cocaine	B-Drug
exposure	O
in	O
utero	O
has	O
no	O
important	O
effects	O

PCP	B-Drug
may	O
induce	O
feelings	O
of	O
strength	O
power	O
and	O
invulnerability	O
as	O
well	O
a	O
numbing	O
effect	O
on	O
the	O
mind	O

11-methylated	O
19-nortestosterone	B-Drug
derivatives	O
have	O
no	O
risk	O
of	O
gynecomastia	O

Internationally	O
heroin	B-Drug
is	O
controlled	O
under	O
Schedules	O
I	O
and	O
IV	O
of	O
the	O
Single	O
Convention	O
on	O
Narcotic	O
Drugs	O
it	O
generally	O
illegal	O
to	O
make	O
possess	O
or	O
sell	O
without	O
a	O
license	O

2008:	O
Smith	O
and	O
Williams	O
revisit	O
confirm	O
Rabe's	O
d-quinotoxine	O
to	O
quinine	B-Drug
route	O

Boots	O
diversified	O
into	O
the	O
research	O
and	O
manufacturing	O
of	O
drugs	O
with	O
its	O
development	O
Ibuprofen	B-Drug
painkiller	O
during	O
1960s	O
invented	O
by	O
John	O
Nicholson	O
Stewart	O
Adams	O

As	O
of	O
October	O
2015	O
phenazepam	B-Drug
is	O
a	O
controlled	O
substance	O
in	O
China	O

25C-NBOMe	B-Drug
appeared	O
on	O
online	O
vendor	O
sites	O
in	O
2010	O
but	O
was	O
not	O
reported	O
the	O
literature	O
until	O
2011	O

Some	O
prodrugs	O
such	O
as	O
-butyrolactone	O
GBL	O
convert	O
to	O
GHB	B-Drug
in	O
the	O
stomach	O
and	O
blood	O
stream	O

25-Dimethoxy-4-chloroamphetamine	O
DOC	O
is	O
a	O
psychedelic	O
drug	O
of	O
the	O
phenethylamine	B-Drug
and	O
amphetamine	O
chemical	O
classes	O

It	O
is	O
also	O
used	O
as	O
a	O
recreational	O
drug	O
often	O
mixed	O
with	O
heroin	B-Drug
or	O
cocaine	B-Drug

Children	O
of	O
mothers	O
taking	O
valproate	B-Drug
during	O
pregnancy	O
are	O
at	O
risk	O
for	O
lower	O
IQs	O

Whilst	O
giving	O
a	O
numbing	O
effect	O
similar	O
to	O
cocaine	B-Drug
users	O
prefer	O
Benzocaine	B-Drug
as	O
it	O
is	O
better	O
bulking	O
and	O
binding	O
agent	O
that	O
can't	O
be	O
detected	O
once	O
mixed	O

Medical	O
uses	O
for	O
Semax	B-Drug
include	O
treatment	O
of	O
stroke	O
transient	O
ischemic	O
attack	O
memory	O
and	O
cognitive	O
disorders	O
peptic	O
ulcers	O
optic	O
nerve	O
disease	O
to	O
boost	O
the	O
immune	O
system	O

The	O
symptoms	O
of	O
oxycodone	B-Drug
withdrawal	O
as	O
with	O
other	O
opioids	O
may	O
include	O
anxiety	O
panic	O
attack	O
nausea	O
insomnia	O
muscle	O
pain	O
weakness	O
fevers	O
and	O
flu-like	O

Oral	O
hydrocodone	B-Drug
has	O
a	O
mean	O
equivalent	O
daily	O
dosage	O
MEDD	O
factor	O
of	O
0	O

It	O
has	O
been	O
found	O
to	O
be	O
equally	O
effective	O
as	O
gonadotropin-releasing	O
hormone	O
agonists	O
GnRH	O
such	O
leuprorelin	B-Drug
in	O
the	O
treatment	O
of	O
endometriosis	O

Over	O
the	O
following	O
years	O
number	O
of	O
MDMA	B-Drug
samples	O
increased	O
eventually	O
exceeding	O
MDA	O
in	O
early	O
1980s	O

It	O
is	O
closely	O
related	O
to	O
MDMB-FUBINACA	B-Drug
which	O
caused	O
at	O
least	O
1000	O
hospitalizations	O
and	O
40	O
deaths	O
in	O
Russia	O
as	O
consequence	O
of	O
intoxication	O

Levels	O
higher	O
than	O
this	O
are	O
found	O
in	O
GHB	B-Drug
deaths	O

This	O
activity	O
may	O
be	O
associated	O
with	O
some	O
of	O
the	O
other	O
more	O
psychotic	O
features	O
PCP	B-Drug
intoxication	O
which	O
is	O
evidenced	O
by	O
successful	O
use	O
D2	O
receptor	O
antagonists	O
such	O
as	O
haloperidol	B-Drug
in	O
treatment	O
psychosis	O

In	O
a	O
comparison	O
of	O
suicides	O
and	O
natural	O
deaths	O
the	O
concentrations	O
both	O
flunitrazepam	B-Drug
nitrazepam	B-Drug
sleeping	O
medications	O
were	O
significantly	O
higher	O
among	O

1-3	O
stipulate	O
that	O
methadone	B-Drug
treatment	O
can	O
be	O
initiated	O
by	O
centers	O
whereas	O
buprenorphine	B-Drug
any	O
medical	O
doctor	O
specialized	O
doctors	O
and	O

Vigabatrin	B-Drug
1989	O

JWH-018	B-Drug
usage	O
is	O
readily	O
detected	O
in	O
urine	O
using	O
spice	O
screening	O
immunoassays	O
from	O
several	O
manufacturers	O
focused	O
on	O
both	O
the	O
parent	O
drug	O
and	O
its	O
omega-hydroxy	O
carboxyl	O
metabolites	O

Russia	O
Classified	O
as	O
a	O
Schedule	O
I	O
narcotic	O
including	O
its	O
derivatives	O
see	O
sumatriptan	O
and	O
zolmitriptan	B-Drug

In	O
2018	O
results	O
were	O
first	O
published	O
which	O
suggested	O
that	O
thalidomide's	O
teratogenic	O
effects	O
are	O
mediated	O
through	O
degradation	O
of	O
the	O
transcription	O
factor	O
SALL4	O
an	O
as	O
yet	O
unverified	O
finding	O
thalidomide	B-Drug

Mannitol	B-Drug
and	O
sorbitol	O
are	O
isomers	O
the	O
only	O
difference	O
being	O
orientation	O
of	O
hydroxyl	O
group	O
on	O
carbon	O
2	O

However	O
AAS	O
with	O
a	O
very	O
high	O
ratio	O
of	O
anabolic	O
to	O
androgenic	O
action	O
like	O
nandrolone	B-Drug
still	O
have	O
significant	O
effects	O
and	O
can	O
produce	O
symptoms	O
masculinization	O
hirsutism	O
voice	O
deepening	O
in	O
women	O
children	O
extended	O
use	O

The	O
endogenous	O
-amino	O
acids	O
L-leucine	O
and	O
L-isoleucine	O
which	O
closely	O
resemble	O
pregabalin	B-Drug
the	O
other	O
gabapentinoids	O
in	O
chemical	O
structure	O
are	O
apparent	O
ligands	O
of	O
2	O
VDCC	O
subunit	O
with	O
similar	O
affinity	O
as	O
e	O

Ergometrine	B-Drug
was	O
1-2	O
times	O
more	O
potent	O
than	O
the	O
new	O
alkaloid	O

Due	O
to	O
the	O
absorption	O
of	O
cocaine	B-Drug
from	O
hydrochloride	I-Drug
remaining	O
forms	O
a	O
dilute	O
hydrochloric	O
acid	O

The	O
principal	O
adverse	O
effects	O
of	O
oxymorphone	B-Drug
are	O
similar	O
to	O
other	O
opioids	O
with	O
constipation	O
nausea	O
vomiting	O
dizziness	O
dry	O
mouth	O
and	O
drowsiness	O
being	O
the	O
most	O
common	O

Phenylpiracetam	B-Drug
demonstrates	O
antiamnestic	O
activity	O
by	O
restoring	O
performance	O
in	O
the	O
passive	O
avoidance	O
test	O
and	O
partially	O
reversing	O
each	O
of	O
these	O
scopolamine-induced	O
receptor	O
density	O
changes	O

eszopiclone	B-Drug
do	O
not	O
typically	O
present	O
with	O
convulsions	O
and	O
are	O
therefore	O
considered	O
life-threatening	O
patients	O
may	O
experience	O
such	O
significant	O
agitation	O
or	O
anxiety	O
that	O
they	O
seek	O
emergency	O
medical	O
attention	O

One	O
of	O
the	O
first	O
noticeable	O
effects	O
large-dose	O
ibogaine	B-Drug
ingestion	O
is	O
ataxia	O
a	O
difficulty	O
in	O
coordinating	O
muscle	O
motion	O
which	O
makes	O
standing	O
and	O
walking	O
difficult	O
without	O
assistance	O

This	O
was	O
easily	O
accomplished	O
because	O
Flix	O
Gallardo	O
had	O
already	O
established	O
a	O
marijuana	O
trafficking	O
infrastructure	O
that	O
stood	O
ready	O
to	O
serve	O
the	O
Colombia-based	O
cocaine	B-Drug
traffickers	O

A	O
by	O
mouth	O
formulation	O
of	O
leuprorelin	B-Drug
is	O
under	O
development	O
for	O
the	O
treatment	O
endometriosis	O

While	O
3-methylfentanyl	B-Drug
is	O
considerably	O
more	O
potent	O
than	O
fentanyl	B-Drug
itself	O
lofentanil	B-Drug
only	O
slightly	O
stronger	O
carfentanil	B-Drug

Ephedrine	B-Drug
also	O
decreases	O
gastric	O
emptying	O

Japan	O
is	O
the	O
sole	O
manufacturer	O
of	O
nimetazepam	B-Drug
in	O
world	O

Tobacco	B-Drug
was	O
introduced	O
around	O
1600	O
by	O
French	O
merchants	O
in	O
what	O
today	O
is	O
modern-day	O
Gambia	O
and	O
Senegal	O

Food	O
and	O
Drug	O
Administration	O
FDA	O
approved	O
gabapentin	B-Drug
Neurontin	B-Drug
Pfizer	O
only	O
for	O
treatment	O
of	O
seizures	O

Because	O
of	O
the	O
rising	O
deaths	O
across	O
country	O
especially	O
in	O
British	O
Columbia	O
where	O
for	O
2016	O
is	O
668	O
and	O
2017	O
January	O
to	O
October	O
999Health	O
Canada	O
putting	O
a	O
rush	O
on	O
review	O
prescription-only	O
status	O
naloxone	B-Drug
an	O
effort	O
combat	O
overdoses	O
drug	O

Bromazepam	B-Drug
has	O
also	O
been	O
responsible	O
for	O
accidental	O
poisonings	O
in	O
companion	O
animals	O

Stanley	O
was	O
the	O
first	O
known	O
private	O
individual	O
to	O
manufacture	O
mass	O
quantities	O
of	O
LSD	B-Drug

In	O
people	O
who	O
are	O
difficult	O
to	O
treat	O
an	O
inpatient	O
flumazenil	B-Drug
administration	O
allows	O
for	O
rapid	O
competitive	O
binding	O
of	O
GABAAreceptor	O
as	O
antagonist	O
thus	O
stopping	O
a	O
effectively	O
detoxifying	O
zolpidem	B-Drug
from	O
being	O
able	O
bind	O
agonist	O
on	O
GABAAreceptor;	O
slowly	O
drug	O
dependence	O
or	O
addiction	O
will	O
wane	O

This	O
concoction	O
was	O
one	O
of	O
a	O
series	O
compounds	O
related	O
to	O
the	O
plant	O
derivative	O
ephedrine	B-Drug
which	O
had	O
been	O
isolated	O
from	O
Chinese	O
ephedra	O
that	O
same	O
year	O
by	O
Nagai	O
Nagayoshi	O

Phase	O
0	O
trials	O
are	O
also	O
known	O
as	O
human	O
microdosing	O
studies	O
and	O
designed	O
to	O
speed	B-Drug
up	O
the	O
development	O
of	O
promising	O
drugs	O
or	O
imaging	O
agents	O
by	O
establishing	O
very	O
early	O
on	O
whether	O
drug	O
agent	O
behaves	O
in	O
subjects	O
was	O
expected	O
from	O
preclinical	O

In	O
January	O
2013	O
an	O
18-year-old	O
in	O
Scottsdale	O
Arizona	O
died	O
after	O
consuming	O
25I-NBOMe	B-Drug
sold	O
as	O
LSD;	O
a	O
toxicology	O
screening	O
found	O
no	O
other	O
drugs	O
the	O
person's	O
system	O
LSD	B-Drug

Nitrazepam	B-Drug
and	O
flunitrazepam	B-Drug
were	O
significantly	O
more	O
commonly	O
implicated	O
in	O
suicide	O
related	O
deaths	O
than	O
natural	O

5	O
to	O
11	O
times	O
more	O
potent	O
as	O
an	O
antimineralocorticoid	O
than	O
spironolactone	B-Drug
in	O
animals	O

Nicotine	B-Drug
is	O
also	O
present	O
at	O
concentrations	O
of	O
millionths	O
a	O
percent	O
in	O
the	O
edible	O
family	O
Solanaceae	O
including	O
potatoes	O
tomatoes	O
and	O
eggplants	O
though	O
sources	O
disagree	O
on	O
whether	O
this	O
has	O
any	O
biological	O
significance	O
to	O
human	O
consumers	O

004	O
UR-144	B-Drug
Abbott	O
patent	O
has	O
been	O
detected	O
as	O
an	O
ingredient	O
of	O
synthetic	O
cannabis	O
smoking	O
blends	O
in	O
New	O
Zealand	O
and	O
subsequently	O
banned	O
from	O
sale	O
a	O
temporary	O
class	O
drug	O
on	O
6	O
April	O
2012	O

Levorphanol	B-Drug
is	O
6	O
to	O
8	O
times	O
as	O
potent	O
morphine	B-Drug
at	O
the	O
MOR	O

Likewise	O
in	O
San	O
Francisco	O
Chinese	O
immigrants	O
were	O
permitted	O
to	O
smoke	O
opium	B-Drug
so	O
long	O
as	O
they	O
refrained	O
from	O
doing	O
the	O
presence	O
of	O
whites	O

Khat	O
chewing	O
and	O
the	O
effects	O
of	O
cathinone	B-Drug
on	O
body	O
differ	O
from	O
person	O
to	O
but	O
there	O
is	O
a	O
general	O
pattern	O
behavior	O
that	O
emerges	O
after	O
ingesting	O
fresh	O
cathinone:	O
Feelings	O
euphoria	O
last	O
for	O
one	O
two	O
hours	O
Discussion	O
serious	O
issues	O
increased	O
irritability	O
The	O
chewer's	O
imagination	O
very	O
active	O
Depressive	O
stage	O
Irritability	O
loss	O
appetite	O
insomniaThere	O
are	O
other	O
not	O
related	O
CNS	O

Dutasteride	B-Drug
has	O
an	O
extremely	O
long	O
terminal	O
or	O
elimination	O
half-life	O
of	O
about	O
4	O
5	O
weeks	O

The	O
Sydney	O
facility	O
showed	O
no	O
improvement	O
in	O
public	O
injecting	O
and	O
discarded	O
needles	O
beyond	O
improvements	O
caused	O
by	O
a	O
coinciding	O
heroin	B-Drug
drought	O
while	O
the	O
Vancouver	O
had	O
an	O
observable	O
impact	O

Dalmane/Dalmadorm	O
flurazepam	B-Drug
for	O
insomnia	O
Dalmane	B-Drug
Dalmadorm	B-Drug

health	O
food	O
stores	O
were	O
selling	O
dried	O
coca	B-Drug
leaves	O
to	O
be	O
prepared	O
as	O
an	O
infusion	O
Health	O
Inca	O
Tea	O

The	O
supply	O
of	O
constituent	O
chemicals	O
including	O
lysergic	O
acid	B-Drug
which	O
was	O
used	O
for	O
production	O
LSD	O
in	O
the	O
1960s	O
and	O
ergotamine	B-Drug
tartrate	O
1970s	O
were	O
placed	O
under	O
tight	O
surveillance	O
government	O
funding	O
research	O
almost	O
completely	O
eliminated	O

Carlo	O
Ginzburg	O
and	O
others	O
have	O
argued	O
that	O
flying	O
ointments	O
were	O
preparations	O
meant	O
to	O
encourage	O
hallucinatory	O
dreaming;	O
a	O
possible	O
explanation	O
for	O
the	O
inclusion	O
of	O
belladonna	O
opium	O
poppy	O
in	O
concerns	O
known	O
antagonism	O
between	O
tropane	O
alkaloids	O
scopolamine	O
opiate	O
Papaver	O
somniferum	O
be	O
specific	O
morphine	B-Drug
which	O
produces	O
dream-like	O
waking	O
state	O
hypnagogia	O
or	O
potentiated	O
dreams	O
while	O
user	O
is	O
asleep	O

Progestogens	O
that	O
are	O
used	O
as	O
antigonadotropins	O
include	O
chlormadinone	O
acetate	I-Drug
cyproterone	O
gestonorone	O
caproate	O
hydroxyprogesterone	O
medroxyprogesterone	B-Drug
megestrol	O
and	O
oxendolone	O

AG	O
has	O
largely	O
been	O
superseded	O
by	O
medications	O
with	O
better	O
effectiveness	O
and	O
tolerability	O
reduced	O
toxicity	O
such	O
as	O
ketoconazole	B-Drug
abiraterone	B-Drug
acetate	O
other	O
aromatase	O
inhibitors	O

A	O
physical	O
dependence	O
develops	O
more	O
quickly	O
with	O
higher	O
potency	O
benzodiazepines	O
such	O
as	O
alprazolam	B-Drug
Xanax	B-Drug
than	O
lower	O
chlordiazepoxide	B-Drug
Librium	B-Drug

In	O
2006	O
illegally	O
manufactured	O
non-pharmaceutical	O
fentanyl	B-Drug
often	O
mixed	O
with	O
cocaine	B-Drug
or	O
heroin	B-Drug
caused	O
an	O
outbreak	O
of	O
overdose	O
deaths	O
in	O
the	O
United	O
States	O
and	O
Canada	O
heavily	O
concentrated	O
cities	O
Dayton	O
Ohio;	O
Chicago;	O
Detroit;	O
Philadelphia	O

Though	O
not	O
routinely	O
indicated	O
activated	O
charcoal	O
can	O
be	O
used	O
for	O
decontamination	O
of	O
the	O
stomach	O
following	O
a	O
diazepam	B-Drug
overdose	O

Milnacipran	B-Drug
has	O
low	O
molecular	O
weight	O
and	O
lipophilicity	O

For	O
example	O
morphine	B-Drug
is	O
a	O
Class	O
A	O
drug	O
under	O
the	O
Misuse	O
of	O
Drugs	O
Act	O
1971	O
but	O
when	O
lawfully	O
supplied	O
falls	O
category	O
Schedule	O
2	O
controlled	O

Mestanolone	B-Drug
was	O
available	O
in	O
the	O
form	O
of	O
25	O
mg	O
sublingual	O
tablets	O
brand	O
name	O
Ermalone	O

According	O
to	O
DSM-V	O
criteria	O
9%	O
of	O
those	O
who	O
are	O
exposed	O
cannabis	O
develop	O
use	O
disorder	O
compared	O
20%	O
for	O
cocaine	B-Drug
23%	O
alcohol	O
and	O
68%	O
nicotine	B-Drug

In	O
2017	O
it	O
was	O
found	O
that	O
some	O
pills	O
being	O
sold	O
as	O
MDMA	B-Drug
contained	O
pentylone	B-Drug
which	O
can	O
cause	O
very	O
unpleasant	O
agitation	O
and	O
paranoia	O

Cooper	O
of	O
the	O
DEA	O
thus:	O
Given	O
world	O
wide	O
ready	O
availability	O
marijuana	O
it	O
is	O
somewhat	O
difficult	O
to	O
produce	O
a	O
viable	O
argument	O
for	O
making	O
[controlled	O
substance	O
analogs	O
CsA's]	O
cannabinoids	O
CsA	B-Drug

35	O
per	O
pint;	O
2	O
Opium	B-Drug
Camphorated	O
Conc	O

JWH-019	B-Drug
is	O
Class	O
B	O
in	O
the	O
United	O
Kingdom	O

In	O
late	O
2006	O
the	O
British	O
government	O
permitted	O
pharmaceutical	O
company	O
MacFarlan	O
Smith	O
a	O
Johnson	O
Matthey	O
to	O
cultivate	O
opium	B-Drug
poppies	O
in	O
England	O
for	O
medicinal	O
reasons	O
after	O
Macfarlan	O
Smith's	O
primary	O
source	O
India	O
decided	O
increase	O
price	O
of	O
export	O
latex	O

Non-medical	O
use	O
of	O
fentanyl	B-Drug
by	O
individuals	O
without	O
opiate	O
tolerance	O
can	O
be	O
very	O
dangerous	O
and	O
has	O
resulted	O
in	O
numerous	O
deaths	O

Until	O
the	O
early	O
20th	O
century	O
laudanum	B-Drug
was	O
sold	O
without	O
a	O
prescription	O
and	O
constituent	O
of	O
many	O
patent	O
medicines	O

ONDCP	O
stated	O
in	O
April	O
2011	O
that	O
there	O
has	O
been	O
a	O
46	O
percent	O
drop	O
cocaine	B-Drug
use	O
among	O
young	O
adults	O
over	O
the	O
past	O
five	O
years	O
and	O
65	O
rate	O
of	O
people	O
testing	O
positive	O
for	O
workplace	O
since	O
2006	O

Fentanyl	B-Drug
may	O
be	O
measured	O
in	O
blood	O
or	O
urine	O
to	O
monitor	O
for	O
abuse	O
confirm	O
a	O
diagnosis	O
of	O
poisoning	O
assist	O
medicolegal	O
death	O
investigation	O

It	O
tends	O
to	O
build	O
connections	O
between	O
people	O
who	O
are	O
generally	O
much	O
more	O
in	O
communication	O
than	O
when	O
they	O
use	O
LSD	B-Drug

Scientific	O
studies	O
that	O
report	O
PCE	B-Drug
has	O
significant	O
effects	O
may	O
be	O
more	O
likely	O
to	O
published	O
than	O
those	O
do	O
not	O

Methadone	B-Drug
substitution	O
as	O
a	O
treatment	O
of	O
opioid	O
addiction	O
has	O
been	O
criticized	O
in	O
the	O
social	O
sciences	O
for	O
its	O
role	O
control	O
addicts	O

Meanwhile	O
a	O
member	O
of	O
his	O
lab	O
Robert	O
D'Amato	O
who	O
was	O
looking	O
for	O
angiogenesis	O
inhibitors	O
discovered	O
in	O
1994	O
that	O
thalidomide	B-Drug
inhibited	O
and	O
effective	O
suppressing	O
tumor	O
growth	O
rabbits	O

In	O
addition	O
1-PP	O
may	O
play	O
an	O
important	O
role	O
in	O
the	O
antidepressant	O
effects	O
of	O
buspirone	B-Drug

Levomethadone	B-Drug
sold	O
under	O
the	O
brand	O
name	O
L-Polamidon	O
among	O
others	O
is	O
a	O
synthetic	O
opioid	O
analgesic	O
and	O
antitussive	O
which	O
marketed	O
in	O
Europe	O
used	O
for	O
pain	O
management	O
maintenance	O
therapy	O

Like	O
all	O
opioids	O
the	O
effects	O
of	O
fentanyl	B-Drug
can	O
be	O
reversed	O
with	O
naloxone	B-Drug
or	O
other	O
opiate	O
antagonists	O

Withdrawal	O
symptoms	O
have	O
also	O
been	O
reported	O
in	O
newborns	O
whose	O
mothers	O
had	O
either	O
injecting	O
or	O
orally	O
taking	O
oxycodone	B-Drug
during	O
pregnancy	O

Ibuprofen	B-Drug
is	O
used	O
primarily	O
to	O
treat	O
fever	O
including	O
post-vaccination	O
mild	O
moderate	O
pain	O
relief	O
after	O
surgery	O
painful	O
menstruation	O
osteoarthritis	O
dental	O
headaches	O
and	O
from	O
kidney	O
stones	O

Side	O
effects	O
that	O
have	O
been	O
associated	O
with	O
fluoxymesterone	B-Drug
include	O
acne	O
edema	O
seborrhea/seborrheic	O
dermatitis	O
alopecia	O
hirsutism	O
voice	O
deepening	O
virilization	O
in	O
general	O
flushing	O
gynecomastia	O
breast	O
pain	O
menstrual	O
disturbances	O
hypogonadism	O
testicular	O
atrophy	O
clitoral	O
enlargement	O
penile	O
priapism	O
increased	O
aggressiveness	O
prostate	O
cardiovascular	O
toxicity	O
and	O
hepatotoxicity	O
among	O
others	O

Illicit	O
use	O
of	O
pharmaceutical	O
fentanyl	B-Drug
and	O
its	O
analogues	O
first	O
appeared	O
in	O
the	O
mid-1970s	O
medical	O
community	O
continues	O
present	O

It	O
was	O
also	O
reported	O
that	O
these	O
effects	O
were	O
inhibited	O
by	O
the	O
GABA	O
antagonist	O
flumazenil	B-Drug
and	O
clobazam	B-Drug
acts	O
more	O
efficiently	O
in	O
GABA-deficient	O
brain	O
tissue	O

2	O
lb	O
of	O
fentanyl	B-Drug
can	O
be	O
bought	O
in	O
China	O
for	O
$3000	O
to	O
$5000	O
and	O
then	O
smuggled	O
into	O
the	O
United	O
States	O
by	O
mail	O
or	O
Mexican	O
drug	O
cartels	O
generate	O
over	O
$1	O

As	O
its	O
pure	O
form	O
dextromethorphan	B-Drug
occurs	O
as	O
an	O
odorless	O
opalescent	O
white	O
powder	O

In	O
2015	O
radiocarbon	O
analysis	O
confirmed	O
that	O
the	O
tramadol	B-Drug
found	O
in	O
N	O

Flurazepam	B-Drug
is	O
a	O
Schedule	O
IV	O
drug	O
under	O
the	O
Convention	O
on	O
Psychotropic	O
Substances	O

The	O
new	O
formulation	O
simply	O
replaced	O
the	O
two	O
methamphetamine	B-Drug
components	O
with	O
dextroamphetamine	B-Drug
and	O
amphetamine	B-Drug
of	O
same	O
weight	O
other	O
original	O
were	O
preserved	O
Obetrol	B-Drug
branding	O
despite	O
it	O
utterly	O
lacking	O
FDA	O
approval	O
still	O
made	O
onto	O
market	O
was	O
marketed	O
sold	O
by	O
Rexar	O
for	O
a	O
number	O
years	O

Phentermine	B-Drug
use	O
is	O
contraindicated	O
in	O
those	O
who:	O
have	O
a	O
history	O
of	O
drug	O
abuse	O

Psilocin	B-Drug
and	O
its	O
precursor	O
psilocybin	O
an	O
active	O
chemical	O
in	O
many	O
mushrooms	O
are	O
structurally	O
similar	O
to	O
DMT	O

Another	O
study	O
focused	O
on	O
pharmacokinetics	O
and	O
tissue	O
distribution	O
of	O
the	O
stereoisomers	O
4-methylaminorex	B-Drug
in	O
rats	O

First	O
metabolite	O
3-oxo-4-abiraterone	O
has	O
more	O
potent	O
anti-prostate	O
cancer	O
properties	O
than	O
abiraterone	B-Drug
where	O
galeterone	O
3-oxo-4-galaterone	O
activity	O
comparable	O
to	O
parent	O

Transporters	O
from	O
Mexico	O
usually	O
were	O
given	O
35%	O
to	O
50%	O
of	O
each	O
cocaine	B-Drug
shipment	O

Alectinib	B-Drug
has	O
a	O
low	O
potential	O
for	O
interactions	O

Noribogaine	B-Drug
is	O
most	O
potent	O
as	O
a	O
serotonin	O
reuptake	O
inhibitor	O

Afghan	O
farmers	O
claimed	O
that	O
government	O
officials	O
take	O
bribes	O
for	O
turning	O
a	O
blind	O
eye	O
to	O
the	O
drug	O
trade	O
while	O
punishing	O
poor	O
opium	B-Drug
growers	O

PF-04457845	B-Drug
is	O
a	O
potent	O
and	O
exquisitely	O
selective	O
inhibitor	O
of	O
the	O
enzyme	O
fatty	O
acid	O
amide	O
hydrolase	O
FAAH	O
with	O
an	O
IC50	O
7	O

Intake	O
of	O
danazol	B-Drug
with	O
food	O
>30	O
grams	O
fat	O
has	O
been	O
found	O
to	O
increase	O
the	O
bioavailability	O
and	O
peak	O
levels	O
by	O
3-	O
4-fold	O
a	O
single	O
dose	O
2-	O
2	O

Temazepam	B-Drug
was	O
the	O
most	O
commonly	O
used	O
benzodiazepine	O
in	O
a	O
study	O
published	O
1994	O
of	O
injecting	O
drug	O
users	O
seven	O
cities	O
and	O
had	O
been	O
injected	O
from	O
preparations	O
capsules	O
tablets	O
syrup	O

LSD	B-Drug
is	O
typically	O
either	O
swallowed	O
or	O
held	O
under	O
the	O
tongue	O

One	O
of	O
his	O
preparations	O
a	O
pill	O
which	O
he	O
extolled	O
as	O
archanum	O
or	O
laudanum	B-Drug
may	O
have	O
contained	O
opium	B-Drug

Hash	B-Drug
pressing	O
tours	O
consumption	O
of	O
the	O
drug	O
and	O
sales	O
are	O
still	O
illegal	O
but	O
unofficially	O
combination	O
these	O
services	O
has	O
made	O
North	O
African	O
region	O
one	O
largest	O
exporters	O
hashish	B-Drug
which	O
is	O
a	O
produced	O
from	O
female	O
cannabis	O
plants	O
through	O
compression	O
heating	O
resin	B-Drug
glands	O
known	O
as	O
trichomes	O

In	O
2007	O
33	O
pounds	O
of	O
meth	B-Drug
were	O
seized	O
by	O
federal	O
authorities	O
down	O
from	O
101	O

Lorcaserin	B-Drug
has	O
shown	O
100x	O
selectivity	O
for	O
5-HT2C	O
versus	O
the	O
closely	O
related	O
5-HT2B	O
receptor	O
and	O
17x	O
over	O
5-HT2A	O

Meprodine	B-Drug
is	O
considered	O
a	O
Schedule	O
9	O
prohibited	O
substance	O
in	O
Australia	O
under	O
the	O
Poisons	O
Standard	O
February	O
2017	O

Despite	O
the	O
fact	O
that	O
gabapentin	B-Drug
is	O
a	O
structural	O
GABA	O
analogue	O
and	O
in	O
spite	O
of	O
its	O
name	O
it	O
does	O
not	O
bind	O
to	O
receptors	O
convert	O
into	O
or	O
another	O
receptor	O
agonist	O
vivo	O
modulate	O
transport	O
metabolism	O

Chemically	O
PCP	B-Drug
is	O
a	O
member	O
of	O
the	O
arylcyclohexylamine	O
class	O
and	O
pharmacologically	O
it	O
dissociative	O
anesthetic	O

In	O
November	O
2020	O
Egypt	O
managed	O
to	O
seize	O
two	O
shipments	O
of	O
Captagon	B-Drug
pills	O
at	O
Damietta	O
port	O
coming	O
from	O
Syria	O
the	O
first	O
had	O
3251500	O
tablets	O
while	O
second	O
contained	O
11	O
million	O

Withdrawal	O
symptoms	O
typically	O
occur	O
1-2	O
days	O
after	O
abruptly	O
stopping	O
gabapentin	B-Drug

Cathinone	B-Drug
is	O
a	O
similar	O
molecule	O
to	O
cathine	B-Drug
but	O
much	O
more	O
abundant	O
in	O
younger	O
plants	O

Their	O
treatment	O
included	O
a	O
combination	O
of	O
ziprasidone	B-Drug
olanzapine	B-Drug
trazodone	B-Drug
and	O
benztropine	B-Drug

Turner	O
and	O
David	O
Woodard	O
amongst	O
others	O
have	O
written	O
extensively	O
about	O
their	O
own	O
entheogenic	O
use	O
of	O
psychonautic	O
experiences	O
with	O
ketamine	B-Drug

However	O
thalidomide	B-Drug
is	O
a	O
teratogenic	O
substance	O
and	O
proportion	O
of	O
children	O
born	O
during	O
the	O
1960s	O
were	O
afflicted	O
with	O
syndrome	O
known	O
as	O
embryopathy	O
TE	O

On	O
July	O
20	O
1988	O
Surez	O
was	O
arrested	O
by	O
the	O
Bolivian	O
National	O
Police	O
and	O
his	O
hacienda	O
raided;	O
more	O
than	O
one	O
a	O
half	O
tons	O
of	O
cocaine	B-Drug
found	O

Its	O
call	O
is	O
described	O
as	O
a	O
weak	O
low-pitched	O
toot	B-Drug
lasting	O
less	O
than	O
second	O

Alfatradiol	B-Drug
is	O
marketed	O
under	O
the	O
brand	O
names	O
Avicis	O
Avixis	O
Ell-Cranell	O
Alpha	O
and	O
Pantostin	O

In	O
2000	O
Pickard	O
was	O
arrested	O
for	O
manufacturing	O
LSD	B-Drug
in	O
Kansas	O
and	O
serving	O
two	O
life	O
sentences	O
at	O
United	O
States	O
Penitentiary	O
Tucson	O

Brotizolam	B-Drug
is	O
a	O
highly	O
potent	O
and	O
short-acting	O
hypnotic	O
with	O
typical	O
dose	O
ranging	O
from	O
0	O

The	O
level	O
of	O
needle	O
sharing	O
among	O
methamphetamine	B-Drug
users	O
is	O
similar	O
to	O
that	O
other	O
drug	O
injection	O

CNS	O
depressants	O
may	O
enhance	O
the	O
depressant	O
effects	O
of	O
hydromorphone	B-Drug
such	O
as	O
other	O
opioids	O
anesthetics	O
sedatives	O
hypnotics	O
barbiturates	O
benzodiazepines	O
phenothiazines	O
chloral	O
hydrate	O
dimenhydrinate	B-Drug
and	O
glutethimide	B-Drug

Norethandrolone	B-Drug
is	O
marketed	O
under	O
the	O
brand	O
names	O
Nilevar	O
and	O
Pronabol	O

However	O
their	O
structures	O
are	O
rigidified	O
such	O
that	O
the	O
analogous	O
structural	O
modification	O
was	O
done	O
with	O
bicalutamide	B-Drug
to	O
create	O
5N-bicalutamide	O
could	O
not	O
be	O
used	O
increase	O
affinity	O
or	O
potency	O
them	O

Less	O
frequently	O
in	O
3-10%	O
of	O
people	O
fentanyl	B-Drug
can	O
cause	O
abdominal	O
pain	O
headache	O
fatigue	O
anorexia	O
and	O
weight	O
loss	O
dizziness	O
nervousness	O
hallucinations	O
anxiety	O
depression	O
flu-like	O
symptoms	O
dyspepsia	O
indigestion	O
shortness	O
breath	O
hypoventilation	O
apnoea	O
urinary	O
retention	O

Both	O
in	O
US	O
Controlled	O
Substances	O
Act	O
1970	O
Schedule	O
I	O
the	O
two	O
isomers	O
both	O
have	O
annual	O
manufacturing	O
quotas	O
of	O
2	O
grammes	O
and	O
ACSCNs	O
9605	O
for	O
alphamethadol	B-Drug
9609	O
betamethadol	B-Drug

Spironolactone	B-Drug
is	O
used	O
primarily	O
to	O
treat	O
heart	O
failure	O
edematous	O
conditions	O
such	O
as	O
nephrotic	O
syndrome	O
or	O
ascites	O
in	O
people	O
with	O
liver	O
disease	O
essential	O
hypertension	O
low	O
blood	O
levels	O
of	O
potassium	O
secondary	O
hyperaldosteronism	O
occurs	O
cirrhosis	O
and	O
Conn's	O
primary	O

After	O
the	O
war	O
Pervitin	B-Drug
remained	O
easily	O
accessible	O
both	O
on	O
black	O
market	O
and	O
as	O
a	O
prescription	O
drug	O

NMDA	O
receptor	O
antagonists	O
such	O
as	O
ketamine	B-Drug
SNRIs	O
milnacipran	B-Drug
Anticonvulsants	O
gabapentin	B-Drug
or	O
pregabalin	B-Drug
Clinical	O
studies	O
have	O
consistently	O
associated	O
medical	O
and	O
recreational	O
opioid	O
use	O
with	O
hypogonadism	O
low	O
sex	O
hormone	O
levels	O
in	O
different	O
sexes	O

Thalidomide	B-Drug
may	O
be	O
helpful	O
in	O
some	O
cases	O
where	O
standard	O
TB	O
drugs	O
and	O
corticosteroids	O
are	O
not	O
sufficient	O
to	O
resolve	O
severe	O
inflammation	O
the	O
brain	O

Initially	O
Cocaine	B-Drug
was	O
a	O
personal	O
project	O
for	O
Sibiryov	O

Medications	O
containing	O
natural	O
or	O
synthetic	O
cannabinoids	O
cannabinoid	O
analogs:	O
Dronabinol	O
Marinol	O
is	O
9-tetrahydrocannabinol	O
THC	O
used	O
as	O
an	O
appetite	O
stimulant	O
anti-emetic	O
and	O
analgesic	O
Nabilone	B-Drug
Cesamet	B-Drug
Canemes	O
a	O
analog	O
of	O

Oxandrolone	B-Drug
has	O
about	O
322	O
to	O
633%	O
of	O
the	O
anabolic	O
potency	O
and	O
24%	O
androgenic	O
methyltestosterone	B-Drug

Similarly	O
to	O
nilutamide	O
bicalutamide	B-Drug
and	O
enzalutamide	B-Drug
flutamide	O
crosses	O
the	O
bloodbrain	O
barrier	O
exerts	O
central	O
antiandrogen	O
actions	O

A	O
binding	O
study	O
assessed	O
PCP	B-Drug
at	O
56	O
sites	O
including	O
neurotransmitter	O
receptors	O
and	O
transporters	O
found	O
that	O
had	O
Ki	O
values	O
of	O
>10000	O
nM	O
all	O
except	O
the	O
dizocilpine	O
MK-801	O
site	O
NMDA	O
receptor	O
136	O
serotonin	O
transporter	O
=	O
2234	O

Following	O
the	O
discovery	O
at	O
a	O
Jordanian	O
airport	O
of	O
toner	O
cartridge	O
that	O
had	O
been	O
modified	O
into	O
an	O
improvised	O
explosive	O
device	O
resultant	O
increased	O
level	O
airfreight	O
scrutiny	O
led	O
to	O
major	O
shortage	O
drought	O
heroin	B-Drug
from	O
October	O
2010	O
until	O
April	O
2011	O

Although	O
the	O
2018	O
United	O
States	O
Farm	O
Bill	O
led	O
some	O
states	O
to	O
interpret	O
bill	O
as	O
enabling	O
private	O
farmers	O
grow	O
hemp	O
for	O
extraction	O
and	O
retail	O
of	O
CBD	B-Drug
federal	O
agencies	O
including	O
FDA	O
DEA	O
retained	O
regulatory	O
authority	O
over	O
hemp-derived	O
a	O
Schedule	O
I	O
substance	O

DPT	O
is	O
not	O
scheduled	O
at	O
the	O
federal	O
level	O
in	O
United	O
States	O
but	O
it	O
could	O
be	O
considered	O
an	O
analog	O
of	O
5-MeO-DiPT	O
DMT	O
or	O
DET	B-Drug
which	O
case	O
purchase	O
sale	O
possession	O
prosecuted	O
under	O
Federal	O
Analogue	O
Act	O

Buspirone	B-Drug
is	O
not	O
effective	O
as	O
a	O
treatment	O
for	O
benzodiazepine	O
withdrawal	O
barbiturate	O
or	O
alcohol	O
withdrawal/delirium	O
tremens	O

PCE	B-Drug
was	O
reported	O
in	O
1953	O
and	O
PCMo	O
1954	O
with	O
the	O
latter	O
compound	O
described	O
as	O
a	O
potent	O
sedative	O

A	O
potent	O
central	O
nervous	O
system	O
stimulant	O
in	O
the	O
1940s	O
and	O
50s	O
methamphetamine	B-Drug
was	O
used	O
by	O
Axis	O
Allied	O
troops	O
World	O
War	O
II	O
later	O
on	O
other	O
armies	O
Japanese	O
factory	O
workers	O

In	O
2003	O
the	O
Drug	O
Enforcement	O
Administration	O
found	O
that	O
Purdue's	O
aggressive	O
methods	O
had	O
very	O
much	O
exacerbated	O
OxyContin's	O
widespread	O
abuse	O
OxyContin	B-Drug

The	O
provisions	O
as	O
to	O
how	O
much	O
a	O
coca	B-Drug
farmer	O
can	O
yield	O
annually	O
is	O
protected	O
by	O
laws	O
such	O
the	O
Bolivian	O
Cato	O
accord	O

In	O
2011	O
the	O
abuse	O
or	O
misuse	O
of	O
hydrocodone	B-Drug
was	O
responsible	O
for	O
more	O
than	O
97000	O
visits	O
to	O
emergency	O
room	O

The	O
pathway	O
by	O
which	O
clonazepam	B-Drug
is	O
metabolized	O
usually	O
impaired	O
in	O
newborns	O

It	O
is	O
commonly	O
applied	O
to	O
any	O
drug	O
with	O
perception-altering	O
psychedelic	O
effects	O
such	O
as	O
LSD	B-Drug
and	O
other	O
ergotamine	B-Drug
derivatives	O
DMT	O
tryptamines	O
including	O
the	O
alkaloids	O
of	O
Psilocybe	O
spp	O

The	O
simple	O
bridged	O
oripavine	O
parent	O
compound	O
614-Endoethenotetrahydrooripavine	O
is	O
already	O
40	O
times	O
the	O
potency	O
of	O
morphine	B-Drug
but	O
adding	O
a	O
branched	O
tertiary	O
alcohol	O
substituent	O
on	O
C7	O
position	O
results	O
in	O
wide	O
range	O
highly	O
potent	O
compounds	O

methyltestosterone	B-Drug
and	O
fluoxymesterone	B-Drug

In	O
August	O
the	O
company	O
acquired	O
remaining	O
rights	O
to	O
CD20	O
monoclonal	O
antibody	O
Ofatumumab	B-Drug
from	O
GlaxoSmithKline	O
for	O
up	O
$1	O
billion	O

In	O
animal	O
studies	O
6-APDB	O
fully	O
substitutes	O
for	O
MBDB	O
and	O
MMAI	O
but	O
not	O
amphetamine	B-Drug
or	O
LSD	B-Drug

selegiline	B-Drug
6	O
mg/24	O
hours	O
transdermal	O
patch	O

5	O
mg/kg	O
fenfluramine	B-Drug
from	O
saline	O
generalized	O
to	O
aminorex	B-Drug
as	O
amphetamine	B-Drug
stimulus	O
but	O
not	O

In	O
May	O
2019	O
the	O
United	O
States	O
Court	O
of	O
Appeals	O
for	O
Federal	O
Circuit	O
upheld	O
a	O
Patent	O
Trial	O
and	O
Appeal	O
Board	O
decision	O
invalidating	O
patent	O
by	O
Johnson	O
&	O
on	O
abiraterone	B-Drug
acetate	O

Belsomra	B-Drug
Suvorexant	B-Drug
used	O
to	O
treat	O
insomnia	O

The	O
newer	O
semi-synthetic	O
chemotherapeutic	O
agent	O
vinorelbine	B-Drug
is	O
used	O
in	O
the	O
treatment	O
of	O
non-small-cell	O
lung	O
cancer	O

LSD	B-Drug
is	O
commonly	O
used	O
as	O
a	O
recreational	O
drug	O
in	O
the	O
company	O
of	O
friends	O
large	O
crowds	O
or	O
by	O
oneself	O

PCP	B-Drug
has	O
been	O
shown	O
to	O
produce	O
conditioned	O
place	O
aversion	O
and	O
preference	O
in	O
animal	O
studies	O

The	O
third	O
subtype	O
of	O
opioid	O
type	O
is	O
the	O
mu-3	O
receptor	O
which	O
may	O
be	O
a	O
commonality	O
to	O
other	O
six-position	O
monoesters	O
morphine	B-Drug

Fentanyl	B-Drug
is	O
a	O
highly	O
lipophilic	O
compound	O
which	O
well	O
absorbed	O
sublingually	O
and	O
generally	O
tolerated	O

The	O
production	O
of	O
adrenal	O
androstenedione	B-Drug
is	O
governed	O
by	O
adrenocorticotrophic	O
hormone	O
ACTH	O
whereas	O
gonadal	O
under	O
control	O
the	O
gonadotropins	O

In	O
the	O
US	O
alprazolam	B-Drug
is	O
FDA-approved	O
for	O
management	O
of	O
anxiety	O
disorders	O
a	O
condition	O
corresponding	O
most	O
closely	O
to	O
APA	O
Diagnostic	O
and	O
Statistical	O
Manual	O
DSM-IV-TR	O
diagnosis	O
generalized	O
disorder	O
or	O
short-term	O
relief	O
symptoms	O

Esters	O
of	O
morphine	B-Drug
opiates:	O
slightly	O
chemically	O
altered	O
but	O
more	O
natural	O
than	O
the	O
semi-synthetics	O
as	O
most	O
are	O
prodrugs	O
diacetylmorphine	B-Drug
diacetate;	O
heroin	B-Drug
nicomorphine	B-Drug
dinicotinate	B-Drug
dipropanoylmorphine	B-Drug
dipropionate	O
desomorphine	B-Drug
acetylpropionylmorphine	B-Drug
dibenzoylmorphine	O
diacetyldihydromorphine;	O
Semi-synthetic	O
opioids:	O
created	O
from	O
either	O
opiates	O
or	O
esters	O
such	O
hydromorphone	B-Drug
hydrocodone	B-Drug
oxycodone	B-Drug
oxymorphone	B-Drug
ethylmorphine	B-Drug
and	O
buprenorphine;	O
Fully	O
synthetic	O
fentanyl	B-Drug
pethidine	B-Drug
levorphanol	B-Drug
methadone	B-Drug
tramadol	B-Drug
tapentadol	B-Drug
dextropropoxyphene;	O
Endogenous	O
opioid	O
peptides	O
produced	O
naturally	O
in	O
body	O
endorphins	O
enkephalins	O
dynorphins	O
endomorphins	O
diacetyldihydromorphine	B-Drug
buprenorphine	B-Drug
dextropropoxyphene	B-Drug

Opioid	O
overdoses	O
can	O
be	O
rapidly	O
reversed	O
through	O
the	O
use	O
of	O
opioid	O
antagonists	O
naloxone	B-Drug
being	O
most	O
widely	O
used	O
example	O

Moramide	B-Drug
intermediate	I-Drug
3-methyl-4-morpholin-4-yl-22-diphenylbutanoic	O
acid	O
on	O
INCB	O
Yellow	O
List	O
as	O
2-methyl-3-morpholino-11-diphenylpropane	O
carboxylic	O
is	O
a	O
moramide	O
precursor	O
scheduled	O
by	O
UN	O
Single	O
Convention	O
Narcotic	O
Drugs	O

However	O
adverse	O
effects	O
are	O
uncommon	O
in	O
infants	O
breastfed	O
from	O
mother	O
taking	O
naproxen	B-Drug

Medical	O
examiners	O
concluded	O
that	O
author	O
journalist	O
Michelle	O
McNamara	O
died	O
on	O
April	O
21	O
2016	O
from	O
an	O
accidental	O
overdose	O
where	O
Fentanyl	B-Drug
was	O
a	O
contributing	O
factor	O

Etonogestrel	B-Drug
is	O
used	O
in	O
hormonal	O
contraception	O
form	O
of	O
the	O
etonogestrel	O
contraceptive	O
implant	O
and	O
vaginal	O
ring	O
brand	O
names	O
NuvaRing	B-Drug
Circlet	O
latter	O
combination	O
with	O
ethinylestradiol	O

The	O
patches	O
should	O
be	O
kept	O
away	O
from	O
children	O
who	O
are	O
most	O
at	O
risk	O
fentanyl	B-Drug
overdose	O

Drug	O
tolerance	O
develops	O
rapidly	O
in	O
amphetamine	B-Drug
abuse	O
i	O

CD3:	O
temazepam	B-Drug
flunitrazepam	B-Drug
etc	O

In	O
countries	O
where	O
its	O
purchase	O
is	O
legal	O
BZP	B-Drug
products	O
are	O
often	O
produced	O
in	O
small	O
specialist	O
laboratories	O

Alfentanil	B-Drug
is	O
a	O
restricted	O
drug	O
which	O
classified	O
as	O
Schedule	O
II	O
in	O
the	O
US	O
according	O
to	O
U	O

On	O
24	O
December	O
1912	O
Merck	O
filed	O
two	O
patent	O
applications	O
that	O
described	O
the	O
synthesis	O
and	O
some	O
chemical	O
properties	O
of	O
MDMA	B-Drug
its	O
subsequent	O
conversion	O
to	O
methylhydrastinine	O

As	O
such	O
PCP	B-Drug
is	O
an	O
NMDA	O
receptor	O
antagonist	O

Darvon	B-Drug
a	O
dextropropoxyphene	B-Drug
formulation	O
made	O
by	O
Eli	O
Lilly	O
which	O
had	O
been	O
on	O
the	O
market	O
for	O
25	O
years	O
came	O
under	O
heavy	O
fire	O
in	O
1978	O
consumer	O
groups	O
that	O
said	O
it	O
was	O
associated	O
with	O
suicide	O

The	O
results	O
of	O
the	O
study	O
support	O
idea	O
that	O
serotonin	O
damage	O
due	O
to	O
MDMA	B-Drug
use	O
causes	O
lateral	O
inhibition	O
diminish	O
amongst	O
orientation	O
sensitive	O
neurons	O
in	O
occipital	O
lobe	O

PCP	B-Drug
was	O
initially	O
made	O
in	O
1926	O
and	O
brought	O
to	O
market	O
as	O
an	O
anesthetic	O
medication	O
the	O
1950s	O

Critics	O
of	O
the	O
Act	O
such	O
as	O
David	O
Nutt	O
say	O
that	O
its	O
classification	O
is	O
not	O
based	O
on	O
how	O
harmful	O
or	O
addictive	O
substances	O
are	O
and	O
it	O
unscientific	O
to	O
omit	O
like	O
tobacco	B-Drug
alcohol	O

Metabolism	O
of	O
pethidine	B-Drug
to	O
norpethidine	B-Drug
is	O
carried	O
out	O
mainly	O
by	O
the	O
CYP	O
enzymes	O
CYP2B6	O
CYP2C19	O
and	O
CYP3A4	O
in	O
liver	O
since	O
activity	O
these	O
can	O
vary	O
between	O
individuals	O
be	O
influenced	O
concurrent	O
use	O
other	O
drugs	O
rate	O
extent	O
production	O
difficult	O
predict	O

Regardless	O
of	O
route	O
administration	O
methylprednisolone	B-Drug
integrates	O
systemically	O
as	O
exhibited	O
by	O
its	O
effectiveness	O
to	O
quickly	O
reduce	O
inflammation	O
during	O
acute	O
flares	O

Cocaine	B-Drug
is	O
readily	O
available	O
in	O
all	O
major	O
countries'	O
metropolitan	O
areas	O

JWH-018	B-Drug
may	O
cause	O
intense	O
anxiety	O
agitation	O
and	O
in	O
rare	O
cases	O
generally	O
with	O
non-regular	O
JWH	O
users	O
has	O
been	O
assumed	O
to	O
have	O
the	O
of	O
seizures	O
convulsions	O
by	O
inhibiting	O
GABA	O
neurotransmission	O
more	O
effectively	O
than	O
THC	O

An	O
Australian	O
study	O
of	O
non-fatal	O
heroin	B-Drug
overdoses	O
noted	O
that	O
26%	O
users	O
had	O
consumed	O
temazepam	B-Drug
at	O
the	O
time	O
their	O
overdose	O

Fentanyl	B-Drug
analogs	O
have	O
killed	O
hundreds	O
of	O
people	O
throughout	O
Europe	O
and	O
the	O
former	O
Soviet	O
republics	O
since	O
most	O
recent	O
resurgence	O
in	O
use	O
began	O
Estonia	O
early	O
2000s	O
novel	O
derivatives	O
continue	O
to	O
appear	O

Also	O
reports	O
indicate	O
that	O
acetic	O
anhydride	O
is	O
diverted	O
from	O
China	O
to	O
morphine/heroin	O
refineries	O
found	O
in	O
the	O
Golden	O
Triangle	O
morphine	B-Drug
heroin	B-Drug

Amiloride	B-Drug
is	O
not	O
metabolized	O
by	O
the	O
liver	O

It	O
was	O
never	O
marketed	O
as	O
such	O
however	O
probably	O
due	O
to	O
a	O
combination	O
of	O
the	O
facts	O
that	O
norlevorphanol	O
has	O
low	O
bioavailability	O
and	O
its	O
potency	O
is	O
diminished	O
compared	O
N-methylated	O
analogue	O
levorphanol	B-Drug

People	O
with	O
cardiovascular	O
disease	O
should	O
not	O
use	O
propylhexedrine	B-Drug

In	O
Canada	O
4-Methylaminorex	B-Drug
is	O
listed	O
as	O
Schedule	O
III	O

Fentanyl	B-Drug
works	O
primarily	O
by	O
activating	O
-opioid	O
receptors	O

These	O
compounds	O
are	O
similar	O
in	O
chemical	O
structure	O
to	O
nilutamide	O
which	O
is	O
related	O
flutamide	O
bicalutamide	B-Drug
and	O
enzalutamide	B-Drug
all	O
of	O
NSAAs	O
similarly	O

The	O
committee	O
made	O
this	O
recommendation	O
on	O
the	O
basis	O
of	O
pharmacological	O
similarity	O
MDMA	B-Drug
to	O
previously	O
scheduled	O
drugs	O
reports	O
illicit	O
trafficking	O
in	O
Canada	O
drug	O
seizures	O
United	O
States	O
and	O
lack	O
well-defined	O
therapeutic	O
use	O

Idazoxan	O
may	O
lead	O
to	O
the	O
release	O
of	O
endogenous	O
opioid	O
peptides	O
and	O
increase	O
food	O
intake	O
this	O
effect	O
is	O
attenuated	O
by	O
--naloxone	O
but	O
not	O
mu/delta-antagonist	O
cyprenorphine	B-Drug

PCP's	O
rewarding	O
and	O
reinforcing	O
effects	O
are	O
at	O
least	O
partly	O
mediated	O
by	O
blocking	O
the	O
NMDA	O
receptors	O
in	O
glutamatergic	O
inputs	O
to	O
D1-type	O
medium	O
spiny	O
neurons	O
nucleus	O
accumbens	O
PCP	B-Drug

A	O
pinch	O
of	O
coca	B-Drug
leaves	O
was	O
included	O
in	O
John	O
Styth	O
Pemberton's	O
original	O
1886	O
recipe	O
for	O
Coca-Cola	O
though	O
the	O
company	O
began	O
using	O
decocainized	O
1906	O
when	O
Pure	O
Food	O
and	O
Drug	O
Act	O
passed	O

The	O
effect	O
of	O
MDMA	B-Drug
increasing	O
sociability	O
is	O
consistent	O
while	O
its	O
effects	O
on	O
empathy	O
have	O
been	O
more	O
mixed	O

Nabiximols	O
a	O
combined	O
THC	O
and	O
cannabidiol	B-Drug
CBD	B-Drug
product	O
that	O
is	O
formulated	O
as	O
an	O
oral	O
buccal	O
spray	O
has	O
been	O
shown	O
to	O
improve	O
withdrawal	O
symptoms	O
without	O
improving	O
abstinence	O
rates	O

The	O
data	O
are	O
also	O
inconclusive	O
on	O
whether	O
benzodiazepines	O
such	O
as	O
clonazepam	B-Drug
cause	O
developmental	O
deficits	O
or	O
decreases	O
in	O
IQ	O
the	O
developing	O
fetus	O
when	O
taken	O
by	O
mother	O
during	O
pregnancy	O

The	O
compound	O
is	O
a	O
diester	O
of	O
nalbuphine	B-Drug
Nubain	B-Drug
joined	O
via	O
sebacic	O
acid	O
linker	O
and	O
acts	O
as	O
long-lasting	O
prodrug	O
slow	O
hydrolysis	O

MDMA	B-Drug
has	O
been	O
used	O
as	O
an	O
adjunct	O
to	O
New	O
Age	O
spiritual	O
practices	O

Drug	O
Enforcement	O
Administration	O
indicated	O
that	O
illicit	O
fentanyl	B-Drug
analogs	O
have	O
no	O
medically	O
valid	O
use	O
and	O
thus	O
applied	O
a	O
Schedule	O
I	O
classification	O
to	O
them	O

This	O
ban	O
affects	O
several	O
products	O
some	O
of	O
which	O
were	O
sold	O
at	O
retail	O
stores	O
under	O
the	O
guise	O
air	O
freshener	O
or	O
similar	O
containing	O
phenazepam	B-Drug
yet	O
claiming	O
not	O
to	O
be	O
for	O
human	O
use	O

On	O
insistence	O
of	O
Allen	O
Ginsberg	O
Leary	O
together	O
with	O
his	O
younger	O
colleague	O
Richard	O
Alpert	O
Ram	O
Dass	O
also	O
made	O
LSD	B-Drug
available	O
to	O
students	O

25I-NBOMe	B-Drug
can	O
be	O
consumed	O
in	O
liquid	O
powder	O
or	O
paper	O
form	O
and	O
snorted	O
injected	O
mixed	O
with	O
food	O
smoked	O
but	O
sublingual	O
administration	O
is	O
most	O
common	O

The	O
substances	O
with	O
the	O
2nd	O
shortest	O
period	O
which	O
is	O
of	O
24	O
hours	O
are	O
zolpidem	B-Drug
and	O
ramelteon	B-Drug

Cocaine	B-Drug
Riot	O
2	O
featured	O
the	O
significant	O
Montana	O
and	O
Drugz	O
collaboration	O
I'm	O
A	O
Coke	O
Boy	O

Naltrexone	B-Drug
is	O
not	O
as	O
widely	O
used	O
buprenorphine	B-Drug
or	O
methadone	B-Drug
for	O
OUD	O
due	O
to	O
low	O
rates	O
of	O
patient	O
acceptance	O
non-adherence	O
daily	O
dosing	O
and	O
difficulty	O
achieving	O
abstinence	O
from	O
opioids	O
before	O
beginning	O
treatment	O

The	O
metabolism	O
of	O
nandrolone	B-Drug
occurs	O
in	O
the	O
liver	O
and	O
is	O
very	O
similar	O
to	O
that	O
testosterone	O
including	O
reduction	O
by	O
5-reductase	O
dehydrogenation	O
3-hydroxysteroid	O
dehydrogenase	O
17-hydroxysteroid	O
conjugation	O

Gabapentin	B-Drug
undergoes	O
little	O
or	O
no	O
metabolism	O

The	O
most	O
extensively	O
studied	O
effect	O
of	O
cocaine	B-Drug
on	O
the	O
central	O
nervous	O
system	O
is	O
blockade	O
dopamine	O
transporter	O
protein	O

022%	O
5-MeO-DMT	B-Drug
0	O

Forty-two	O
hospital	O
patients	O
admitted	O
for	O
acute	O
and	O
chronic	O
alcoholism	O
various	O
psychoses	O
neuroses	O
were	O
treated	O
with	O
chlordiazepoxide	B-Drug

Many	O
choose	O
mixtures	O
that	O
are	O
made	O
without	O
propylene	O
glycol	O
and	O
nicotine	B-Drug
but	O
use	O
higher	O
amounts	O
of	O
glycerin	O
to	O
produce	O
larger	O
plumes	O
vapor	O

Other	O
related	O
AAS	O
include	O
bolenol	O
3-deketo-17-ethyl-19-nor-5-androstenediol	O
ethyldienolone	O
17-ethyl-9-19-NT	O
norboletone	O
17-ethyl-18-methyl-19-NT	O
propetandrol	O
17-ethyl-19-NT	O
3-propionate	O
and	O
tetrahydrogestrinone	B-Drug
THG;	O
17-ethyl-18-methyl-911-19-NT	O
THG	B-Drug

Brand	O
names	O
for	O
hyoscyamine	B-Drug
include	O
Symax	B-Drug
HyoMax	O
Anaspaz	O
Egazil	O
Buwecon	O
Cystospaz	O
Levsin	O
Levbid	O
Levsinex	O
Donnamar	O
NuLev	O
Spacol	O
T/S	O
and	O
Neoquess	O

CBD	B-Drug
may	O
show	O
antipsychotic	O
and	O
neuroprotective	O
properties	O
acting	O
as	O
an	O
antagonist	O
to	O
some	O
of	O
the	O
effects	O
THC	O

The	O
Health	O
Committee	O
of	O
the	O
League	O
Nations	O
banned	O
diacetylmorphine	B-Drug
in	O
1925	O
although	O
it	O
took	O
more	O
than	O
three	O
years	O
for	O
this	O
to	O
be	O
implemented	O

Pregnant	O
women	O
with	O
hepatitis	O
C	O
who	O
take	O
ribavirin	B-Drug
have	O
shown	O
some	O
cases	O
of	O
birth	O
defects	O
and	O
death	O
in	O
their	O
fetus	O

Hemp	O
essential	O
oil	I-Drug
is	O
distinct	O
from	O
hemp	O
seed	O
and	O
hash	B-Drug
oil:	O
the	O
former	O
a	O
vegetable	O
that	O
cold-pressed	O
seeds	O
of	O
low-THC	O
varieties	O
latter	O
THC-rich	O
extract	O
dried	O
female	O
flowers	O
marijuana	O
or	O
resin	B-Drug
hashish	B-Drug

Percocet	B-Drug
is	O
a	O
prescription	O
opioid	O
containing	O
oxycodone	B-Drug
and	O
acetaminophen	B-Drug

After	O
experiencing	O
long-term	O
in-patient	O
treatment	O
only	O
22	O
percent	O
returned	O
to	O
the	O
use	O
of	O
cocaine	B-Drug

In	O
overdose	O
propranolol	B-Drug
is	O
associated	O
with	O
seizures	O

However	O
relative	O
to	O
other	O
19-nortestosterone	B-Drug
progestins	O
the	O
androgenic	O
activity	O
of	O
tibolone	O
is	O
high	O
with	O
a	O
potency	O
comparable	O
that	O
testosterone	O

Side	O
effects	O
of	O
nandrolone	B-Drug
esters	O
include	O
masculinization	O
among	O
others	O

For	O
example	O
at	O
a	O
buprenorphine/naloxone	O
dose	O
of	O
8	O
mg/2	O
mg	O
the	O
buprenorphine	B-Drug
Cmax	O
after	O
single	O
original	O
tablet	O
formulation	O
is	O
around	O
3	O
ng/mL	O
whereas	O
that	O
film	O
naloxone	B-Drug

In	O
addition	O
it	O
tends	O
to	O
cause	O
less	O
vomiting	O
and	O
regurgitation	O
than	O
other	O
pure-opiate	O
codeine	B-Drug
morphine	B-Drug
synthetic	O
pure-opioid	O
agonists	O
oxycodone	B-Drug
hydromorphone	B-Drug
when	O
given	O
as	O
a	O
continuous	O
post-operative	O
infusion	O

The	O
pharmaceutical	O
company	O
Rexar	O
reformulated	O
their	O
popular	O
weight	O
loss	O
drug	O
Obetrol	B-Drug
following	O
its	O
mandatory	O
withdrawal	O
from	O
the	O
market	O
in	O
1973	O
under	O
Kefauver	O
Harris	O
Amendment	O
to	O
Federal	O
Food	O
Drug	O
and	O
Cosmetic	O
Act	O
due	O
results	O
of	O
Efficacy	O
Study	O
Implementation	O
DESI	O
program	O
which	O
indicated	O
a	O
lack	O
efficacy	O

Opium	B-Drug
production	O
continued	O
under	O
the	O
Babylonians	O
and	O
Egyptians	O

The	O
duration	O
of	O
action	O
fentanyl	B-Drug
has	O
sometimes	O
been	O
underestimated	O
leading	O
to	O
harm	O
in	O
a	O
medical	O
context	O

Gabapentin	B-Drug
alleviates	O
itching	O
in	O
kidney	O
failure	O
uremic	O
pruritus	O
and	O
of	O
other	O
causes	O

Adverse	O
drug	O
reactions	O
associated	O
with	O
the	O
use	O
of	O
pregabalin	B-Drug
include:	O
Very	O
common	O
>10%	O
people	O
pregabalin:	O
dizziness	O
drowsiness	O

Developed	O
in	O
1933	O
Germany	O
it	O
has	O
approximately	O
ten	O
times	O
the	O
potency	O
of	O
morphine	B-Drug

Jacqui	O
Smith	O
then	O
Home	O
Secretary	O
was	O
also	O
widely	O
criticised	O
by	O
the	O
scientific	O
community	O
for	O
bullying	O
Professor	O
David	O
Nutt	O
into	O
apologising	O
his	O
comments	O
that	O
in	O
course	O
of	O
a	O
normal	O
year	O
more	O
people	O
died	O
from	O
falling	O
off	O
horses	O
than	O
taking	O
ecstasy	B-Drug

Sale	O
of	O
tobacco	B-Drug
and	O
nicotine-containing	O
products	O
is	O
regulated	O
a	O
license	O
must	O
be	O
granted	O
by	O
the	O
state	O
before	O
store	O
may	O
sell	O

Under	O
its	O
Head	O
of	O
Research	O
Heinrich	O
Mckter	O
a	O
former	O
Nazi	O
scientist	O
Grnenthal	O
synthesised	O
thalidomide	B-Drug
in	O
1954	O
and	O
acquired	O
20-year	O
patent	O

Rural	O
farmers	O
in	O
the	O
poor	O
regions	O
which	O
coca	B-Drug
has	O
historically	O
been	O
cultivated	O
often	O
find	O
themselves	O
at	O
difficult	O
and	O
potentially	O
violent	O
intersection	O
of	O
government-sponsored	O
eradication	O
efforts	O
illegal	O
cocaine	B-Drug
producers	O
&	O
traffickers	O
seeking	O
supplies	O
anti-government	O
paramilitary	O
forces	O
trafficking	O
as	O
a	O
source	O
revolutionary	O
funding	O
historical	O
hardships	O
rural	O
subsistence	O
farming	O
or	O
its	O
typical	O
alternative	O
abandoning	O
their	O
land	O
fleeing	O
to	O
an	O
urban	O
slum	O

Its	O
LC-HRMS	O
testing	O
method	O
does	O
not	O
use	O
elevated	O
temperatures	O
and	O
has	O
shown	O
the	O
presence	O
of	O
much	O
lower	O
levels	O
NDMA	O
in	O
ranitidine	B-Drug
medicines	O
than	O
were	O
reported	O
by	O
third-party	O
laboratory	O

Nalbuphine	B-Drug
is	O
marketed	O
primarily	O
under	O
the	O
brand	O
names	O
Nubain	B-Drug
Nalpain	O
and	O
Nalbuphin	O

They	O
found	O
about	O
70000	O
pills	B-Drug
in	O
the	O
appearance	O
of	O
oxycodone	B-Drug
and	O
more	O
than	O
25000	O
Xanax	B-Drug

After	O
MDMA	B-Drug
was	O
criminalized	O
most	O
medical	O
use	O
stopped	O
although	O
some	O
therapists	O
continued	O
to	O
prescribe	O
the	O
drug	O
illegally	O

Hemp	O
has	O
lower	O
concentrations	O
of	O
THC	O
and	O
higher	O
CBD	B-Drug
which	O
gives	O
lesser	O
psychoactive	O
effects	O

Flutamide	O
was	O
followed	O
by	O
nilutamide	O
in	O
1989	O
and	O
bicalutamide	B-Drug
1995	O

In	O
2014	O
despite	O
the	O
introduction	O
of	O
abiraterone	B-Drug
acetate	O
in	O
2011	O
and	O
enzalutamide	B-Drug
2012	O
bicalutamide	B-Drug
was	O
still	O
most	O
commonly	O
prescribed	O
drug	O
treatment	O
metastatic	O
castration-resistant	O
prostate	O
cancer	O
mCRPC	O

This	O
conclusion	O
is	O
based	O
on	O
the	O
fact	O
that	O
5-DHMNT	O
4	O
to	O
8	O
times	O
as	O
potent	O
11-MNT	O
in	O
terms	O
of	O
androgenicity	O
animal	O
bioassays	O
yet	O
co-administration	O
5-reductase	O
inhibitor	O
dutasteride	B-Drug
with	O
had	O
no	O
influence	O
its	O
potency	O
assays	O
using	O
tissues	O
express	O
like	O
ventral	O
prostate	O
and	O
seminal	O
vesicles	O

0g	O
is	O
the	O
amount	O
of	O
cocaine	B-Drug
required	O
for	O
purposes	O
drug	O
trafficking	O

There	O
is	O
no	O
conclusive	O
evidence	O
that	O
thalidomide	B-Drug
or	O
lenalidomide	B-Drug
useful	O
to	O
bring	O
about	O
maintain	O
remission	O
in	O
Crohn's	O
disease	O

In	O
some	O
people	O
diazepam	B-Drug
may	O
increase	O
the	O
propensity	O
toward	O
self-harming	O
behaviours	O
and	O
in	O
extreme	O
cases	O
provoke	O
suicidal	O
tendencies	O
or	O
acts	O

Ich	O
hab'	O
ein	O
Arcanum	O
heiss'	O
ich	O
Laudanum	B-Drug
ist	O
ber	O
das	O
Alles	O
wo	O
es	O
zum	O
Tode	O
reichen	O
will	O

Fentanyl's	O
most	O
common	O
side	O
effects	O
which	O
affect	O
more	O
than	O
10%	O
of	O
people	O
include	O
diarrhea	O
nausea	O
constipation	O
dry	O
mouth	O
somnolence	O
confusion	O
asthenia	O
weakness	O
sweating	O
Fentanyl	B-Drug

Three	O
years	O
later	O
chlordiazepoxide	B-Drug
was	O
marketed	O
as	O
a	O
therapeutic	O
benzodiazepine	O
medication	O
under	O
the	O
brand	O
name	O
Librium	B-Drug

The	O
approval	O
was	O
based	O
on	O
a	O
study	O
of	O
the	O
addition	O
bevacizumab	B-Drug
to	O
carboplatin	O
and	O
paclitaxel	B-Drug

discontinued	O
Orlaam	B-Drug
in	O
the	O
US	O

Using	O
formaldehyde	O
and	O
sulfuric	O
acid	O
the	O
solution	O
will	O
turn	O
purple	O
when	O
introduced	O
to	O
opium	B-Drug
drugs	O

Wellbutrin	B-Drug
SR	O
or	O
XL	O
bupropion	B-Drug
an	O
antidepressant	O
of	O
the	O
norepinephrine-dopamine	O
reuptake	O
inhibitor	O
class	O
used	O
to	O
treat	O
depression	O
and	O
seasonal	O
affective	O
disorder	O

When	O
the	O
drug	O
is	O
injected	O
however	O
it	O
avoids	O
this	O
first-pass	O
effect	O
very	O
rapidly	O
crossing	O
bloodbrain	O
barrier	O
because	O
of	O
presence	O
acetyl	O
groups	O
which	O
render	O
much	O
more	O
fat	O
soluble	O
than	O
morphine	B-Drug
itself	O

Buspirone	B-Drug
acts	O
as	O
an	O
agonist	O
of	O
the	O
serotonin	O
5-HT1A	O
receptor	O
with	O
high	O
affinity	O

The	O
other	O
major	O
pathway	O
in	O
the	O
metabolism	O
of	O
valproate	B-Drug
is	O
mitochondrial	O
beta-oxidation	O
which	O
typically	O
accounts	O
for	O
over	O
40%	O
an	O
administered	O
dose	O

In	O
the	O
Film	O
Winchester	O
2018	O
Doctor	O
Eric	O
Price	O
is	O
addicted	O
to	O
laudanum	B-Drug
due	O
his	O
wife's	O
suicide	O

Conversely	O
dosages	O
of	O
norethisterone	B-Drug
0	O

Phencyclidine	B-Drug
enters	O
the	O
ion	O
channel	O
and	O
binds	O
reversibly	O
non-competitively	O
inside	O
pore	O
to	O
block	O
entry	O
of	O
positive	O
ions	O
cell	O
thereby	O
inhibiting	O
depolarisation	O

Its	O
popularity	O
with	O
recreational	O
drug	O
users	O
compared	O
to	O
morphine	B-Drug
reportedly	O
stems	O
from	O
its	O
perceived	O
different	O
effects	O

After	O
a	O
single	O
dose	O
of	O
apalutamide	B-Drug
its	O
clearance	O
rate	O
CL/F	O
was	O
1	O

Several	O
large	O
quantities	O
of	O
illicitly	O
produced	O
fentanyl	B-Drug
have	O
been	O
seized	O
by	O
U	O

265	O
Possible	O
side	O
effects	O
of	O
secobarbital	B-Drug
include:	O
Somnolence	O
Impaired	O
motor	O
functions	O
coordination	O
balanceAtaxia	O
Dizziness	O
Anxiety	O
Confusion	O
Agitation	O
irritability	O
or	O
excitability	O
Headache	O
Hunger	O
Nausea	O
Vomiting	O
Nightmares	O
Increased	O
sensitivity	O
to	O
pain	O
Allergic	O
reactions	O
Difficulty	O
breathing	O
Edema	O
Urticaria	O
Secobarbital	B-Drug
may	O
produce	O
psychological	O
addiction	O
and	O
produces	O
physical	O
dependence	O
if	O
used	O
for	O
an	O
extended	O
period	O
time	O

Sofosbuvir	B-Drug
is	O
activated	O
in	O
the	O
liver	O
to	O
triphosphate	O
GS-461203	O
by	O
hydrolysis	O
of	O
carboxylate	O
ester	O
either	O
enzymes	O
cathepsin	O
A	O
or	O
carboxylesterase	O
1	O
followed	O
cleaving	O
phosphoramidate	O
enzyme	O
histidine	O
triad	O
nucleotide-binding	O
protein	O
HINT1	O
and	O
subsequent	O
repeated	O
phosphorylation	O

Submarine	O
vessels	O
are	O
a	O
common	O
method	O
that	O
cocaine	B-Drug
smugglers	O
use	O
to	O
avoid	O
detection	O

Doses	O
of	O
naltrexone	B-Drug
take	O
longer	O
to	O
be	O
eliminated	O
from	O
the	O
person's	O
system	O

Others	O
that	O
have	O
also	O
been	O
available	O
and	O
used	O
commonly	O
but	O
to	O
a	O
lesser	O
extent	O
include	O
methyltestosterone	B-Drug
oxandrolone	B-Drug
mesterolone	B-Drug
oxymetholone	B-Drug
as	O
well	O
drostanolone	O
propionate	O
dromostanolone	O
metenolone	B-Drug
methylandrostenolone	O
esters	O
specifically	O
acetate	O
enanthate	O
fluoxymesterone	B-Drug

It	O
can	O
be	O
cut	O
into	O
or	O
even	O
replace	O
entirely	O
the	O
supply	O
of	O
heroin	B-Drug
and	O
other	O
opiates	O

From	O
2013	O
until	O
2016	O
overdose	O
deaths	O
involving	O
fentanyl	B-Drug
increased	O
113%	O
per	O
year	O

He	O
does	O
not	O
state	O
however	O
that	O
nalbuphine's	O
pharmacological	O
mechanism	O
of	O
action	O
for	O
pruritus	O
is	O
the	O
result	O
this	O
interaction	O
between	O
two	O
opioid	O
receptors	O
nalbuphine	B-Drug

Ondansetron	B-Drug
is	O
used	O
off-label	O
to	O
treat	O
morning	O
sickness	O
and	O
hyperemesis	O
gravidarum	O
of	O
pregnancy	O

Among	O
other	O
achievements	O
Szra	O
and	O
his	O
colleagues	O
characterized	O
the	O
biochemistry	O
of	O
first	O
three	O
psychedelic	O
cogeners	O
tryptamine:	O
dimethyl-	O
diethyl-	O
dipropyl-tryptamine	O
DMT	O
DET	B-Drug
DPT	O
describing	O
their	O
pharmacokinetics	O
effects	O

Homomeroquinene	O
the	O
second	O
relay	O
molecule	O
in	O
Woodward/Doering	O
claim	O
is	O
obtained	O
several	O
steps	O
from	O
biomolecule	O
cinchonine	O
related	O
to	O
quinidine	B-Drug
but	O
without	O
methoxy	O
group:The	O
key	O
step	O
assembly	O
of	O
quinotoxine	O
a	O
Claisen	O
condensation:1944:	O
Bob	O
Woodward	O
and	O
W	O

para-Methoxyamphetamine	B-Drug
PMA;	O
Death	O
Dr	O
PMA	B-Drug

Clomifene	B-Drug
has	O
been	O
associated	O
with	O
liver	O
abnormalities	O
and	O
a	O
couple	O
of	O
cases	O
hepatotoxicity	O

12	O
when	O
dispensing	O
methadone	B-Drug
for	O
the	O
treatment	O
of	O
opioid	O
addiction	O
or	O
detoxification	O

Additionally	O
there	O
are	O
many	O
unanswered	O
questions	O
about	O
the	O
science	O
safety	O
effectiveness	O
and	O
quality	O
of	O
unapproved	O
products	O
containing	O
CBD	B-Drug

U-47700	B-Drug
was	O
emergency	O
scheduled	O
in	O
Ohio	O
on	O
May	O
3	O
2016	O
by	O
executive	O
order	O
of	O
Governor	O
John	O
Kasich	O

Moore	O
received	O
a	O
lethal	O
injection	O
administered	O
as	O
an	O
intravenous	O
series	O
of	O
four	O
drugs	O
that	O
included	O
fentanyl	B-Drug
citrate	O
to	O
inhibit	O
breathing	O
and	O
render	O
the	O
subject	O
unconscious	O

LSD	B-Drug
and	O
other	O
drugs	O
were	O
often	O
administered	O
without	O
the	O
subject's	O
knowledge	O
or	O
informed	O
consent	O
a	O
violation	O
of	O
Nuremberg	O
Code	O
U	O

During	O
studies	O
chlordiazepoxide	B-Drug
induced	O
muscle	O
relaxation	O
and	O
a	O
quieting	O
effect	O
on	O
laboratory	O
animals	O
like	O
mice	O
rats	O
cats	O
dogs	O

Dextromethadone	O
developmental	O
code	O
name	O
REL-1017	O
is	O
the	O
S-enantiomer	O
of	O
methadone	B-Drug

Older	O
people	O
with	O
dementia-related	O
psychosis	O
are	O
at	O
a	O
higher	O
risk	O
of	O
death	O
if	O
they	O
take	O
risperidone	B-Drug
compared	O
to	O
those	O
who	O
do	O
not	O

Diazepam	B-Drug
along	O
with	O
oxazepam	B-Drug
nitrazepam	B-Drug
and	O
temazepam	B-Drug
represents	O
82%	O
of	O
the	O
benzodiazepine	O
market	O
in	O
Australia	O

In	O
1997	O
a	O
group	O
of	O
Australian	O
researchers	O
proposed	O
based	O
on	O
study	O
in	O
rats	O
that	O
oxycodone	B-Drug
acts	O
KORs	O
unlike	O
morphine	B-Drug
which	O
upon	O
MORs	O

Ganesha	O
25-dimethoxy-34-dimethylamphetamine	O
is	O
a	O
lesser-known	O
psychedelic	O
drug	O
dimethylamphetamine	B-Drug

Nine	O
deaths	O
occurred	O
in	O
Sweden	O
during	O
201011	O
relating	O
to	O
use	O
of	O
Krypton	O
a	O
mixture	O
kratom	B-Drug
caffeine	O
and	O
O-desmethyltramadol	O
prescription	O
opioid	O
analgesic	O

Mild	O
withdrawal	O
symptoms	O
from	O
the	O
discontinuation	O
of	O
amphetamine	B-Drug
treatment	O
at	O
therapeutic	O
doses	O
can	O
be	O
avoided	O
by	O
tapering	O
dose	O

VKORC1	O
along	O
with	O
CYP2C9	O
are	O
useful	O
for	O
identifying	O
the	O
risk	O
of	O
bleeding	O
during	O
warfarin	B-Drug
administration	O

Conversely	O
thalidomide	B-Drug
causes	O
serious	O
birth	O
defects	O
in	O
humans	O
but	O
not	O
animals	O

The	O
idea	O
of	O
combining	O
the	O
structures	O
4-chlorotestosterone	O
clostebol	O
and	O
metandienone	B-Drug
originated	O
from	O
chemist	O
Albert	O
Stachowiak	O

They	O
described	O
a	O
patient	O
whose	O
delusion	O
was	O
thought	O
to	O
be	O
caused	O
by	O
an	O
altered	O
state	O
of	O
consciousness	O
brought	O
on	O
LSD	B-Drug
and	O
strychnine	O
continued	O
casual	O
marijuana	O
use	O

One	O
fatal	O
poisoning	O
caused	O
by	O
intravenous	O
injection	O
of	O
a	O
bath	O
salt	O
product	O
containing	O
acetylfentanyl	B-Drug
and	O
4'-Methoxy--pyrrolidinoheptiophenone	O
has	O
been	O
reported	O
in	O
2016	O

In	O
higher	O
doses	O
the	O
sedative	O
effects	O
of	O
GHB	B-Drug
can	O
induce	O
sleep	O
which	O
potentially	O
lead	O
to	O
a	O
coma	O

Effective	O
May	O
2008	O
Sweden	O
classified	O
tramadol	B-Drug
as	O
a	O
controlled	O
substance	O
in	O
the	O
same	O
category	O
codeine	B-Drug
and	O
dextropropoxyphene	B-Drug
but	O
allows	O
normal	O
prescription	O
to	O
be	O
used	O

Supreme	O
Court	O
ruled	O
that	O
they	O
had	O
failed	O
to	O
prove	O
midazolam	B-Drug
was	O
cruel	O
and	O
unusual	O
when	O
compared	O
known	O
available	O
alternatives	O

MDMA	B-Drug
likely	O
emerged	O
as	O
a	O
substitute	O
for	O
its	O
analog	O
methylenedioxyamphetamine	O
MDA	O
drug	O
at	O
the	O
time	O
popular	O
among	O
users	O
of	O
psychedelics	O
which	O
was	O
made	O
Schedule	O
1	O
substance	O
in	O
United	O
States	O
1970	O

Tramadol	B-Drug
can	O
interact	O
with	O
other	O
medications	O
similar	O
mechanisms	O
of	O
action	O

A	O
fentanyl	B-Drug
patient-controlled	O
transdermal	O
system	O
PCTS	O
is	O
under	O
development	O
which	O
aims	O
to	O
allow	O
patients	O
control	O
administration	O
of	O
through	O
the	O
skin	O
treat	O
postoperative	O
pain	O

Thalidomide	B-Drug
was	O
studied	O
in	O
a	O
Phase	O
II	O
trial	O
for	O
Kaposi's	O
sarcoma	O
rare	O
soft-tissue	O
cancer	O
most	O
commonly	O
seen	O
the	O
immunocompromised	O
that	O
is	O
caused	O
by	O
sarcoma-associated	O
herpesvirus	O
KSHV	O

Desogestrel	B-Drug
is	O
a	O
progestogen	O
or	O
an	O
agonist	O
of	O
the	O
progesterone	O
receptor	O
PR	O

There	O
have	O
been	O
several	O
media	O
reports	O
of	O
the	O
Canadian	O
police	O
seizing	O
mephedrone	B-Drug
but	O
no	O
any	O
successful	O
prosecution	O
a	O
Controlled	O
Drugs	O
and	O
Substances	O
Act	O
offence	O
implicating	O

Unlike	O
pethidine	B-Drug
prodine	B-Drug
does	O
not	O
produce	O
toxic	O
metabolites	O
and	O
is	O
therefore	O
more	O
suitable	O
for	O
high-dose	O
therapy	O

Trenbolone	B-Drug
was	O
first	O
synthesized	O
in	O
1963	O

Studies	O
conducted	O
in	O
the	O
1990s	O
found	O
MDEA	O
present	O
approximately	O
four	O
percent	O
of	O
ecstasy	B-Drug
tablets	O

Also	O
in	O
1884	O
Jellinek	O
demonstrated	O
the	O
effects	O
of	O
cocaine	B-Drug
as	O
a	O
respiratory	O
system	O
anesthetic	O

The	O
latter	O
may	O
be	O
involved	O
in	O
the	O
effectiveness	O
of	O
propranolol	B-Drug
treatment	O
migraine	O
at	O
high	O
doses	O

electricity	O
gas	O
and	O
water	O
supply	O
26%	O
of	O
total	O
industrial	O
output	O
manufacture	O
food	O
beverages	O
tobacco	B-Drug
products	O
22%	O
chemical	O
17%	O
mechanical	O
engineering	O
13%	O
paper	O
including	O
publishing	O
printing	O
reproduction	O
recorded	O
media	O
11%	O

Replacing	O
the	O
N-methyl	O
group	O
with	O
cyclopropylmethyl	O
results	O
in	O
opioid	O
antagonists	O
such	O
as	O
diprenorphine	O
M5050	O
which	O
is	O
used	O
an	O
antidote	O
to	O
reverse	O
effects	O
of	O
etorphine	B-Drug
M99	O
and	O
partial	O
agonists	O
buprenorphine	B-Drug
widely	O
treatment	O
addiction	O

Naloxone	B-Drug
is	O
an	O
opioid	O
antagonist	O
and	O
reverses	O
the	O
central	O
nervous	O
depressive	O
effects	O
seen	O
in	O
overdose	O

There	O
is	O
no	O
evidence	O
that	O
the	O
law	O
was	O
ever	O
used	O
or	O
intended	O
to	O
restrict	O
pharmaceutical	O
cannabis;	O
instead	O
it	O
a	O
legislative	O
mistake	O
and	O
in	O
1915	O
another	O
amendment	O
forbade	O
sale	O
possession	O
of	O
flowering	O
tops	O
leaves	O
extracts	B-Drug
tinctures	O
other	O
narcotic	O
preparations	O
hemp	O
loco	O
weed	O
Cannabis	O
sativa	O
Indian	O
except	O
with	O
prescription	O

5%	O
THC	O
and	O
17%	O
CBD	B-Drug
that	O
it	O
is	O
as	O
legal	O
other	O
hemp	O
products	O
already	O
sold	O
in	O
stores	O
across	O
Utah	O
including	O
oils	O
clothing	O
hand	O
creams	O
but	O
illegal	O
federally	O
to	O
take	O
state	O
lines	O

Bactrim	B-Drug
trimethoprim/sulfamethoxazole	O
a	O
sulphonamide	O
antibacterial	O
sulfamethoxazole	B-Drug

According	O
to	O
David	O
Nutt	O
MDMA	B-Drug
was	O
widely	O
used	O
in	O
the	O
western	O
US	O
couples	O
counseling	O
and	O
called	O
empathy	O

Desogestrel	B-Drug
has	O
a	O
very	O
short	O
terminal	O
half-life	O
of	O
about	O
1	O

Any	O
stereoisomeric	O
form	O
of	O
a	O
substance	O
for	O
the	O
time	O
being	O
specified	O
in	O
paragraph	O
1	O
above	O
not	O
dextromethorphan	B-Drug
or	O
dextrorphan	B-Drug

Testosterone	B-Drug
cypionate	I-Drug
Depo-Testosterone	O
Cypionate	O
generic	O
testosterone	B-Drug
enanthate	I-Drug
Delatestryl	B-Drug
PMS-Testosterone	O
Enanthate	O
and	O
propionate	O
Propionate	O
are	O
available	O
as	O
oil	O
solutions	O
for	O
intramuscular	O
injection	O
undecanoate	O
Andriol	B-Drug
Taro-Testosterone	O
is	O
in	O
the	O
form	O
of	O
oral	O
capsules	O

The	O
attorneys	O
general	O
of	O
Connecticut	O
and	O
Pennsylvania	O
have	O
launched	O
investigations	O
into	O
its	O
diversion	O
from	O
the	O
legitimate	O
pharmaceutical	O
market	O
including	O
Cephalon's	O
sales	O
promotional	O
practices	O
for	O
Provigil	B-Drug
Actiq	B-Drug
Gabitril	B-Drug

At	O
typical	O
clinical	O
dosages	O
such	O
as	O
those	O
used	O
to	O
treat	O
peptic	O
ulcer	O
disease	O
the	O
incidence	O
of	O
gynecomastia	O
breast	O
development	O
with	O
cimetidine	B-Drug
is	O
very	O
low	O
at	O
less	O
than	O
1%	O

Hash	B-Drug
oil	I-Drug
can	O
be	O
the	O
most	O
potent	O
of	O
main	O
cannabis	O
products	O
because	O
its	O
high	O
level	O
psychoactive	O
compound	O
per	O
volume	O
which	O
vary	O
depending	O
on	O
plant's	O
mix	O
essential	O
oils	O
and	O
compounds	O

Pain	O
relief:	O
Primarily	O
fentanyl	B-Drug
provides	O
the	O
relief	O
of	O
pain	O
by	O
acting	O
on	O
brain	O
and	O
spinal	O
-receptors	O

Cocaine	O
dependence	O
is	O
a	O
biopsychosocial	O
disorder	O
characterized	O
by	O
persistent	O
use	O
of	O
cocaine	B-Drug
despite	O
substantial	O
harm	O
and	O
adverse	O
consequences	O

Compared	O
to	O
other	O
chemicals	O
available	O
18th	O
century	O
regular	O
physicians	O
opium	B-Drug
was	O
a	O
benign	O
alternative	O
the	O
arsenics	O
mercuries	O
or	O
emetics	O
and	O
it	O
remarkably	O
successful	O
in	O
alleviating	O
wide	O
range	O
of	O
ailments	O

Members	O
of	O
the	O
East	O
India	O
Company	O
saw	O
opium	B-Drug
trade	O
as	O
an	O
investment	O
opportunity	O
beginning	O
in	O
1683	O

25I-NBOMe	B-Drug
also	O
has	O
weaker	O
interactions	O
with	O
multiple	O
other	O
receptors	O

This	O
helps	O
avoid	O
detection	O
but	O
reduces	O
the	O
CBD	B-Drug
production	O
of	O
plant	O

Repeated	O
heroin	B-Drug
use	O
changes	O
the	O
physical	O
structure	O
and	O
physiology	O
of	O
brain	O
creating	O
long-term	O
imbalances	O
in	O
neuronal	O
hormonal	O
systems	O
that	O
are	O
not	O
easily	O
reversed	O

Certain	O
parties	O
have	O
urged	O
the	O
government	O
to	O
penalize	O
use	O
of	O
kratom	B-Drug
under	O
Dangerous	O
Drugs	O
Act	O
instead	O
Poisons	O
which	O
would	O
carry	O
heavier	O
penalties	O

In	O
countries	O
where	O
possession	O
of	O
mescaline	B-Drug
and	O
related	O
compounds	O
is	O
illegal	O
highly	O
penalized	O
cultivation	O
for	O
the	O
purposes	O
consumption	O
most	O
likely	O
also	O

After	O
receiving	O
a	O
bolus	O
dose	O
of	O
fentanyl	B-Drug
people	O
can	O
also	O
experience	O
paradoxical	O
coughing	O
which	O
is	O
phenomenon	O
that	O
not	O
well	O
understood	O

Some	O
examples	O
include	O
the	O
testosterone	O
17-ethers	O
cloxotestosterone	O
quinbolone	B-Drug
and	O
silandrone	O
which	O
are	O
prodrugs	O
to	O
boldenone	B-Drug
1-testosterone	B-Drug
respectively	O
DHT	O
mepitiostane	O
mesabolone	O
prostanozol	O
also	O
1-methylated	O
derivatives	O
mesterolone	B-Drug
metenolone	B-Drug
although	O
these	O
relatively	O
weak	O
AAS	O
19-nortestosterone	B-Drug
dimethandrolone	O
11-MNT	O
have	O
improved	O
resistance	O
first-pass	O
hepatic	O
metabolism	O
due	O
their	O
11-methyl	O
groups	O
in	O
contrast	O
them	O
related	O
trestolone	O
7-methyl-19-nortestosterone	O
is	O
not	O
orally	O
active	O

In	O
the	O
United	O
States	O
it	O
has	O
since	O
become	O
associated	O
with	O
opiates	O
and	O
opioids	O
commonly	O
morphine	B-Drug
heroin	B-Drug
as	O
well	O
derivatives	O
of	O
many	O
compounds	O
found	O
within	O
raw	O
opium	B-Drug
latex	O

Nitrazepam	B-Drug
is	O
commonly	O
taken	O
in	O
overdose	O
by	O
drug	O
abusers	O
or	O
suicidal	O
individuals	O
sometimes	O
leading	O
to	O
death	O

However	O
as	O
of	O
2014	O
it	O
remains	O
unclear	O
to	O
what	O
extent	O
is	O
covered	O
by	O
the	O
UK	O
phenylethylamine	B-Drug
catch-all	O
clause	O
with	O
commentators	O
noting	O
both	O
structural	O
similarities	O
and	O
differences	O
class	O

Two	O
classes	O
of	O
drugs	O
target	O
the	O
mevalonate	O
pathway:	O
statins	O
like	O
rosuvastatin	B-Drug
which	O
are	O
used	O
to	O
reduce	O
elevated	O
cholesterol	O
levels	O
and	O
bisphosphonates	O
zoledronate	O
treat	O
a	O
number	O
bone-degenerative	O
diseases	O

Seven	O
strengths	O
are	O
available:	O
8	O
mg	O
of	O
codeine	B-Drug
phosphate	I-Drug
per	O
tablet	O
e	O

Despite	O
being	O
a	O
more	O
potent	O
analgesic	O
fentanyl	B-Drug
tends	O
to	O
induce	O
less	O
nausea	O
as	O
well	O
histamine-mediated	O
itching	O
than	O
morphine	B-Drug

In	O
Europe	O
addicts	O
use	O
mostly	O
heroin	B-Drug
from	O
Western	O
Asia	O
Afghanistan	O
and	O
neighboring	O
countries	O
that	O
is	O
less	O
likely	O
to	O
be	O
contaminated	O
with	O
fentanyl	B-Drug

Mark	O
McCloud	O
is	O
a	O
recognized	O
authority	O
on	O
the	O
history	O
of	O
LSD	B-Drug
blotter	O
art	O

One	O
example	O
of	O
an	O
antibiotic	O
that	O
may	O
be	O
applied	O
topically	O
is	O
chloramphenicol	B-Drug

Oberlin	O
concluded	O
that	O
the	O
effects	O
of	O
MDMA	B-Drug
were	O
not	O
limited	O
to	O
sympathetic	O
nervous	O
system	O

4-Fluoropethidine	O
is	O
a	O
drug	O
that	O
derivative	O
of	O
pethidine	B-Drug
meperidine	B-Drug
which	O
combines	O
pethidine's	O
opioid	O
analgesic	O
effects	O
with	O
increased	O
monoamine	O
reuptake	O
inhibition	O

Ketoconazole	B-Drug
was	O
patented	O
in	O
1977	O
and	O
came	O
into	O
medical	O
use	O
1981	O

Illicitly	O
synthesized	O
fentanyl	B-Drug
powder	O
has	O
also	O
appeared	O
on	O
the	O
United	O
States	O
market	O

In	O
1927	O
Max	O
Oberlin	O
studied	O
the	O
pharmacology	O
of	O
MDMA	B-Drug
while	O
searching	O
for	O
substances	O
with	O
effects	O
similar	O
to	O
adrenaline	O
or	O
ephedrine	B-Drug
latter	O
being	O
structurally	O

Norclostebol	O
INN;	O
brand	O
name	O
Lentabol;	O
former	O
developmental	O
code	O
names	O
SKF-6611	O
CP-73	O
is	O
a	O
synthetic	O
androgen	O
and	O
anabolic	O
steroid	O
AAS	O
that	O
was	O
derived	O
from	O
nandrolone	B-Drug

In	O
2018	O
82%	O
of	O
cocaine-related	O
deaths	O
occurred	O
in	O
combination	O
with	O
fentanyl	B-Drug

Fentanyl	B-Drug
was	O
among	O
many	O
substances	O
identified	O
in	O
counterfeit	O
pills	O
recovered	O
from	O
his	O
home	O
especially	O
some	O
that	O
were	O
mislabeled	O
as	O
Watson	O
385	O
a	O
combination	O
of	O
hydrocodone	B-Drug
and	O
paracetamol	B-Drug

Following	O
further	O
metabolism	O
of	O
etonogestrel	B-Drug
which	O
occurs	O
mainly	O
by	O
reduction	O
the	O
4-3-keto	O
group	O
5-	O
and	O
5-reductases	O
hydroxylation	O
monooxygenases	O
major	O
metabolite	O
desogestrel	B-Drug
is	O
35-tetrahydroetonogestrel	O

A	O
seizure	O
of	O
a	O
record	O
amount	O
fentanyl	B-Drug
occurred	O
on	O
February	O
2	O
2019	O
by	O
U	O

Side	O
effects	O
of	O
testosterone	B-Drug
cypionate	I-Drug
include	O
virilization	O
among	O
others	O

The	O
efficiency	O
of	O
absorption	O
orally	O
administered	O
cocaine	B-Drug
is	O
limited	O
by	O
two	O
additional	O
factors	O

The	O
role	O
of	O
the	O
therapist	O
was	O
minimized	O
in	O
favor	O
patient	O
self-discovery	O
accompanied	O
by	O
MDMA	B-Drug
induced	O
feelings	O
empathy	O

Indomethacin	B-Drug
ketoprofen	B-Drug
and	O
piroxicam	B-Drug
use	O
appear	O
to	O
lead	O
the	O
highest	O
rate	O
of	O
gastric	O
adverse	O
effects	O
while	O
ibuprofen	B-Drug
lower	O
doses	O
diclofenac	B-Drug
have	O
rates	O

]	O
dabbing	O
A	O
slang	O
term	O
for	O
smoking	O
or	O
vape-ing	O
hash	B-Drug
oil	I-Drug
dabs	O
extracted	O
from	O
cannabis	O

Beginning	O
in	O
the	O
1970s	O
emphasis	O
shifted	O
to	O
abstinence	O
and	O
use	O
of	O
methadone;	O
currently	O
only	O
a	O
small	O
number	O
users	O
UK	O
are	O
prescribed	O
diamorphine	B-Drug
methadone	B-Drug

In	O
November	O
2016	O
the	O
DEA	O
uncovered	O
an	O
operation	O
making	O
counterfeit	O
oxycodone	B-Drug
and	O
Xanax	B-Drug
from	O
a	O
home	O
in	O
Cottonwood	O
Heights	O
Utah	O

Prednisolone	B-Drug
acetate	I-Drug
ophthalmic	O
suspension	O
eye	O
drops	O
is	O
an	O
adrenocortical	O
steroid	O
product	O
prepared	O
as	O
a	O
sterile	O
and	O
used	O
to	O
reduce	O
swelling	O
redness	O
itching	O
allergic	O
reactions	O
affecting	O
the	O

This	O
activity	O
may	O
be	O
associated	O
with	O
some	O
of	O
the	O
other	O
more	O
psychotic	O
features	O
PCP	B-Drug
intoxication	O
which	O
is	O
evidenced	O
by	O
successful	O
use	O
D2	O
receptor	O
antagonists	O
such	O
as	O
haloperidol	B-Drug
in	O
treatment	O
psychosis	O

JWH-018	B-Drug
and	O
its	O
N-dealkylated	O
metabolite	O
were	O
only	O
detected	O
in	O
small	O
amounts	O
with	O
hydroxylated	O
metabolites	O
comprising	O
the	O
primary	O
signal	O

Recreational	O
LSD	B-Drug
use	O
among	O
young	O
people	O
was	O
on	O
a	O
par	O
with	O
that	O
in	O
other	O
countries	O
Australia	O
by	O
the	O
early	O
1970s	O
and	O
continued	O
until	O
late	O
decade	O

The	O
short	O
term	O
effects	O
of	O
cannabis	O
can	O
be	O
altered	O
if	O
it	O
has	O
been	O
laced	O
with	O
opioid	O
drugs	O
such	O
as	O
heroin	B-Drug
or	O
fentanyl	B-Drug

Early	O
studies	O
of	O
oral	O
norethisterone	B-Drug
in	O
men	O
employing	O
doses	O
20	O
to	O
50	O
mg/day	O
observed	O
suppression	O
17-ketosteroid	O
excretion	O
increased	O
estrogen	O
due	O
conversion	O
into	O
ethinylestradiol	O
spermatogenesis	O
libido	O
and	O
erectile	O
function	O
incidence	O
gynecomastia	O

Wagner	O
was	O
a	O
dedicated	O
non-smoker	O
and	O
objected	O
when	O
America's	O
biggest	O
tobacco	B-Drug
corporation	O
planned	O
to	O
picture	O
him	O
on	O
cigarette	O
card	O
without	O
his	O
permission	O

Common	O
side	O
effects	O
of	O
oxycodone	B-Drug
include	O
constipation	O
23%	O
nausea	O
vomiting	O
12%	O
somnolence	O
dizziness	O
13%	O
itching	O
dry	O
mouth	O
6%	O
and	O
sweating	O
5%	O

Another	O
form	O
of	O
fentanyl	B-Drug
that	O
has	O
appeared	O
on	O
the	O
streets	O
is	O
Actiq	B-Drug
lollipop	O
formulation	O

The	O
primary	O
clinical	O
applications	O
of	O
oxymetholone	B-Drug
include	O
treatment	O
anemia	O
and	O
osteoporosis	O
as	O
well	O
stimulating	O
muscle	O
growth	O
in	O
malnourished	O
or	O
underdeveloped	O
patients	O

Adverse	O
reactions	O
from	O
the	O
use	O
of	O
prednisolone	B-Drug
include:	O
Increased	O
appetite	O
weight	O
gain	O
nausea	O
and	O
malaise	O
risk	O
infection	O
Cardiovascular	O
events	O
Dermatological	O
effects	O
including	O
reddening	O
face	O
bruising/skin	O
discoloration	O
impaired	O
wound	O
healing	O
thinning	O
skin	O
rash	O
fluid	O
build	O
up	O
abnormal	O
hair	O
growth	O
Hyperglycemia;	O
patients	O
with	O
diabetes	O
may	O
need	O
increased	O
insulin	O
or	O
diabetic	O
therapies	O
Menstrual	O
abnormalities	O
Less	O
response	O
to	O
hormones	O
especially	O
during	O
stressful	O
instances	O
such	O
as	O
surgery	O
illness	O
Change	O
in	O
electrolytes:	O
rise	O
blood	O
pressure	O
sodium	O
low	O
potassium	O
leading	O
alkalosis	O
GI	O
system	O
effects:	O
swelling	O
stomach	O
lining	O
reversible	O
increase	O
liver	O
enzymes	O
ulcers	O
Muscular	O
skeletal	O
muscle	O
weakness/muscle	O
loss	O
osteoporosis	O
see	O
steroid-induced	O
long	O
bone	O
fractures	O
tendon	O
rupture	O
back	O
Neurological	O
involuntary	O
movements	O
convulsions	O
headaches	O
vertigo	O
Behavioral	O
disturbances	O
Nasal	O
septum	O
perforation	O
bowel	O
some	O
pathologic	O
conditions	O

Healthcare	O
institution-based	O
naloxone	B-Drug
prescription	O
programs	O
have	O
also	O
helped	O
reduce	O
rates	O
of	O
opioid	O
overdose	O
in	O
the	O
U	O

DMHP	B-Drug
and	O
its	O
O-acetate	O
ester	O
were	O
extensively	O
investigated	O
by	O
the	O
US	O
military	O
chemical	O
weapons	O
program	O
in	O
Edgewood	O
Arsenal	O
experiments	O
as	O
possible	O
non-lethal	O
incapacitating	O
agents	O

The	O
availability	O
of	O
ethylestrenol	B-Drug
is	O
very	O
limited	O

Using	O
formaldehyde	O
and	O
sulfuric	O
acid	O
the	O
solution	O
will	O
turn	O
purple	O
when	O
introduced	O
to	O
opium	B-Drug
drugs	O

Propranolol	B-Drug
is	O
a	O
beta	O
blocker	O
that	O
has	O
been	O
approved	O
to	O
treat	O
hypertension	O
angina	O
anxiety	O
and	O
other	O
related	O
psychological	O
problems	O

In	O
a	O
comparison	O
study	O
rapid	O
taper	O
using	O
benzodiazepines	O
was	O
found	O
to	O
be	O
superior	O
phenobarbital	B-Drug

In	O
particular	O
addiction	O
to	O
opium	B-Drug
became	O
widespread	O
among	O
soldiers	O
fighting	O
in	O
the	O
Civil	O
War	O
who	O
very	O
often	O
required	O
painkillers	O
and	O
thus	O
were	O
prescribed	O
morphine	B-Drug

Unlike	O
the	O
case	O
of	O
testosterone	O
and	O
DHT	O
5-DHN	O
is	O
a	O
much	O
weaker	O
agonist	O
androgen	O
receptor	O
AR	O
than	O
nandrolone	B-Drug

Opium	O
poppy	O
cultivation	O
in	O
the	O
United	O
Kingdom	O
does	O
not	O
need	O
a	O
licence	O
but	O
is	O
required	O
for	O
those	O
wishing	O
to	O
extract	O
opium	B-Drug
medicinal	O
products	O

In	O
children	O
aged	O
6	O
to	O
8	O
years	O
old	O
there	O
is	O
a	O
rise	O
in	O
androstenedione	B-Drug
secretion	O
along	O
with	O
DHEA	O
during	O
adrenarche	O

Abuse	O
of	O
nimetazepam	B-Drug
continued	O
to	O
rise	O
throughout	O
the	O
2010s	O

Fentanyl	B-Drug
can	O
produce	O
the	O
following	O
clinical	O
effects	O
strongly	O
through	O
-receptor	O
agonism	O

The	O
beginning	O
of	O
the	O
21st	O
century	O
saw	O
drug	O
use	O
increase	O
in	O
North	O
America	O
and	O
Europe	O
with	O
a	O
particularly	O
increased	O
demand	O
for	O
marijuana	O
cocaine	B-Drug

Although	O
phenazepam	B-Drug
is	O
currently	O
not	O
controlled	O
sale	O
for	O
human	O
use	O
remains	O
illegal	O
in	O
the	O
United	O
States	O

It	O
is	O
generally	O
less	O
expensive	O
than	O
other	O
forms	O
of	O
heroin	B-Drug

Indane	O
and	O
tetralin-type	O
phenethylamines	O
are	O
vaguely	O
related	O
to	O
their	O
amphetamine	B-Drug
analogues	O

2	O
times	O
more	O
potent	O
than	O
morphine	B-Drug
by	O
weight	O
with	O
a	O
similar	O
duration;	O
at	O
these	O
relative	O
quantities	O
they	O
could	O
distinguish	O
the	O
drugs	O
subjectively	O
but	O
had	O
no	O
preference	O

Sufentanil	B-Drug
a	O
powerful	O
fentanyl	B-Drug
analog	O
is	O
the	O
only	O
drug	O
enough	O
to	O
relieve	O
pain	O
in	O
emergency	O
settings	O
because	O
it	O
opioid	O
that	O
has	O
potency	O
and	O
binding	O
affinity	O
strong	O
displace	O
buprenorphine	B-Drug
from	O
receptors	O
CNS	O
provide	O
analgesia	O

The	O
relationship	O
between	O
a	O
single	O
dose	O
of	O
spironolactone	B-Drug
and	O
plasma	O
levels	O
canrenone	O
major	O
active	O
metabolite	O
has	O
been	O
found	O
to	O
be	O
linear	O
across	O
range	O
25	O
200	O
mg	O

Due	O
to	O
its	O
low	O
lipophilicity	O
gabapentin	B-Drug
requires	O
active	O
transport	O
across	O
the	O
bloodbrain	O
barrier	O

There	O
is	O
no	O
specific	O
antidote	O
for	O
bicalutamide	B-Drug
or	O
NSAA	O
overdose	O
and	O
treatment	O
should	O
be	O
based	O
on	O
symptoms	O
if	O
any	O
are	O
present	O

Roberto	O
Surez	O
Gmez	O
January	O
8	O
1932	O
July	O
20	O
2000	O
also	O
known	O
as	O
the	O
King	O
of	O
Cocaine	B-Drug
was	O
a	O
Bolivian	O
drug	O
lord	O
and	O
trafficker	O
who	O
played	O
major	O
role	O
in	O
expansion	O
cocaine	B-Drug
trafficking	O
Bolivia	O

Levonorgestrel	B-Drug
is	O
marketed	O
alone	O
or	O
in	O
combination	O
with	O
an	O
estrogen	O
specifically	O
ethinylestradiol	O
estradiol	O
valerate	O
under	O
a	O
multitude	O
of	O
brand	O
names	O
throughout	O
the	O
world	O
including	O
Alesse	O
Altavera	O
Alysena	O
Amethia	O
Amethyst	O
Ashlyna	O
Aviane	B-Drug
Camrese	O
Chateal	O
Climara	B-Drug
Pro	O
Cycle	O
21	O
Daysee	O
Emerres	O
Enpresse	O
Erlibelle	O
Escapelle	O
Falmina	O
Introvale	O
Isteranda	O
Jadelle	O
Jaydess	O
Jolessa	O
Klimonorm	O
Kurvelo	O
Kyleena	O
Lessina	O
Levlen	O
Levodonna	O
Levonelle	O
Levonest	O
Levosert	O
Levora	O
Liletta	O
Loette	O
Logynon	O
LoSeasonique	O
Lutera	B-Drug
Lybrel	O
Marlissa	O
Microgynon	O
Microlut	O
Microvlar	O
Min-Ovral	O
Miranova	O
Mirena	O
My	O
Way	O
Myzilra	O
Next	O
Choice	O
Nordette	O
Norgeston	O
NorLevo	B-Drug
Norplant	O
One	O
Pill	O
Option	O
2	O
Orsythia	O
Ovima	O
Ovranette	O
Plan	B-Drug
B	I-Drug
One-Step	I-Drug
Portia	O
Postinor	O
Postinor-2	O
Preventeza	O
Ramonna	O
Rigevidon	O
Quartette	O
Quasense	O
Seasonale	O
Seasonique	O
Skyla	O
Sronyx	O
Tri-Levlen	O
Trinordiol	O
Triphasil	O
Triquilar	O
Tri-Regol	O
Trivora	O
and	O
Upostelle	O
among	O
many	O
others	O

Intravenous	O
injection	O
of	O
opiates	O
is	O
most	O
used:	O
by	O
comparison	O
with	O
dragon	O
chasing	O
heating	O
heroin	B-Drug
on	O
a	O
piece	O
foil	O
and	O
madak	O
ack	O
smoking	O
cigarettes	O
containing	O
tobacco	B-Drug
mixed	O
powder	O
are	O
only	O
40	O
percent	O
20	O
efficient	O
respectively	O

Colombia	O
served	O
as	O
the	O
dominant	O
force	O
in	O
distribution	O
and	O
sale	O
of	O
cocaine	B-Drug
by	O
1980s	O

In	O
patients	O
with	O
CYP2C19	O
who	O
take	O
clopidogrel	B-Drug
cardiovascular	O
risk	O
is	O
elevated	O
leading	O
to	O
medication	O
package	O
insert	O
updates	O
by	O
regulators	O

Fludrocortisone	B-Drug
was	O
patented	O
in	O
1953	O

The	O
likelihood	O
of	O
dependence	O
is	O
relatively	O
high	O
with	O
lorazepam	B-Drug
compared	O
to	O
other	O
benzodiazepines	O

In	O
2013	O
the	O
barbiturates	O
phenobarbital	B-Drug
and	O
butabarbital	B-Drug
are	O
still	O
used	O
as	O
sedatives	O
in	O
certain	O
cases	O
well	O
to	O
antagonize	O
effects	O
of	O
drugs	O
ephedrine	B-Drug
theophylline	B-Drug

In	O
a	O
separate	O
filing	O
Purdue	O
claims	O
that	O
controlled-release	O
oxycodone	B-Drug
provides	O
pain	O
relief	O
in	O
said	O
patient	O
for	O
at	O
least	O
12	O
hours	O
after	O
administration	O

In	O
young	O
people	O
nitrazepam	B-Drug
has	O
a	O
half-life	O
of	O
about	O
29	O
hours	O
and	O
much	O
longer	O
40	O
in	O
the	O
elderly	O

In	O
the	O
1970s	O
recreational	O
drug	O
users	O
discovered	O
that	O
combining	O
pentazocine	B-Drug
with	O
tripelennamine	O
a	O
first-generation	O
ethylenediamine	O
antihistamine	O
most	O
commonly	O
dispensed	O
under	O
brand	O
names	O
Pelamine	O
and	O
Pyribenzamine	O
produced	O
euphoric	O
sensation	O

Similarly	O
to	O
the	O
related	O
second-generation	O
NSAA	O
enzalutamide	B-Drug
but	O
unlike	O
first-generation	O
NSAAs	O
like	O
flutamide	O
and	O
bicalutamide	B-Drug
elevated	O
liver	O
enzymes	O
hepatotoxicity	O
have	O
not	O
been	O
reported	O
with	O
apalutamide	B-Drug

Following	O
the	O
discovery	O
at	O
a	O
Jordanian	O
airport	O
of	O
toner	O
cartridge	O
that	O
had	O
been	O
modified	O
into	O
an	O
improvised	O
explosive	O
device	O
resultant	O
increased	O
level	O
airfreight	O
scrutiny	O
led	O
to	O
major	O
shortage	O
drought	O
heroin	B-Drug
from	O
October	O
2010	O
until	O
April	O
2011	O

5%	O
when	O
midazolam	B-Drug
is	O
administered	O
alone	O
at	O
normal	O
doses	O
the	O
concomitant	O
use	O
with	O
CNS	O
acting	O
drugs	O
mainly	O
analgesic	O
opiates	O
may	O
increase	O
possibility	O
of	O
hypotension	O
respiratory	O
depression	O
arrest	O
and	O
death	O
even	O
therapeutic	O

It	O
is	O
commonly	O
used	O
in	O
the	O
form	O
of	O
a	O
salt	O
such	O
as	O
sodium	B-Drug
-hydroxybutyrate	O
NaGHB	O
oxybate	B-Drug
or	O
Xyrem	B-Drug
potassium	O
KGHB	O

Therefore	O
the	O
British	O
tried	O
to	O
encourage	O
Chinese	O
opium	B-Drug
use	O
enhance	O
their	O
balance	O
and	O
they	O
delivered	O
it	O
from	O
Indian	O
provinces	O
under	O
control	O

Nicotine	B-Drug
effect	O
on	O
weight	O
appears	O
to	O
result	O
from	O
nicotine's	O
stimulation	O
of	O
34	O
nAChR	O
receptors	O
located	O
in	O
the	O
POMC	O
neurons	O
arcuate	O
nucleus	O
and	O
subsequently	O
melanocortin	O
system	O
especially	O
melanocortin-4	O
second-order	O
paraventricular	O
hypothalamus	O
thus	O
modulating	O
feeding	O
inhibition	O
nicotine	B-Drug

Israel:	O
GBL	O
was	O
classified	O
as	O
a	O
proscribed	O
substance	B-Drug
from	O
2007	O

In	O
mammals	O
GnRH	O
injections	B-Drug
facilitate	O
sexual	O
behavior	O
of	O
female	O
display	O
behaviors	O
as	O
shown	O
with	O
the	O
musk	O
shrews	O
Suncus	O
murinus	O
reduced	O
latency	O
in	O
displaying	O
rump	O
presents	O
and	O
tail	O
wagging	O
towards	O
males	O

As	O
a	O
Schedule	O
I	O
substance	O
under	O
the	O
Controlled	O
Drugs	O
and	O
Substances	O
Act	O
crack	B-Drug
is	O
not	O
differentiated	O
from	O
cocaine	B-Drug
other	O
coca	B-Drug
products	O

Pinazepam	B-Drug
marketed	O
under	O
the	O
brand	O
name	O
Domar	O
and	O
Duna	O
is	O
a	O
benzodiazepine	O
drug	O

A	O
2018	O
systematic	O
review	O
of	O
the	O
relationship	O
between	O
progestin-based	O
contraception	O
and	O
depression	O
included	O
three	O
large	O
studies	O
DMPA	B-Drug
reported	O
no	O
association	O

Dependence	O
liability	O
is	O
similar	O
to	O
morphine	B-Drug
but	O
with	O
a	O
less	O
severe	O
withdrawal	O
syndrome	O

Oxandrolone	B-Drug
improves	O
both	O
short-term	O
and	O
long-term	O
outcomes	O
in	O
people	O
recovering	O
from	O
severe	O
burns	O
is	O
well-established	O
as	O
a	O
safe	O
treatment	O
for	O
this	O
indication	O

Flurazepam	B-Drug
is	O
officially	O
indicated	O
for	O
mild	O
to	O
moderate	O
insomnia	O
and	O
as	O
such	O
it	O
used	O
short-term	O
treatment	O
of	O
patients	O
with	O
difficulty	O
falling	O
asleep	O
frequent	O
awakening	O
early	O
awakenings	O
or	O
a	O
combination	O
each	O

On-demand	O
pain	O
medications	O
typically	O
include	O
either	O
opioid	O
or	O
non-steroidal	O
anti-inflammatory	O
drugs	O
but	O
can	O
also	O
make	O
use	O
of	O
novel	O
approaches	O
such	O
as	O
inhaled	O
nitrous	O
oxide	O
ketamine	B-Drug

Large	O
amounts	O
of	O
crack	B-Drug
cocaine	I-Drug
several	O
hundred	O
milligrams	O
or	O
more	O
intensify	O
the	O
user's	O
high	O
but	O
may	O
also	O
lead	O
to	O
bizarre	O
erratic	O
and	O
violent	O
behavior	O

During	O
the	O
1960s	O
and	O
1970s	O
dextromethorphan	B-Drug
became	O
available	O
in	O
an	O
over-the-counter	O
tablet	O
form	O
by	O
brand	O
name	O
Romilar	O

In	O
1956	O
researchers	O
involved	O
in	O
clinical	O
trials	O
at	O
SKF	O
noted	O
that	O
even	O
when	O
used	O
very	O
high	O
doses	O
thalidomide	B-Drug
could	O
not	O
induce	O
sleep	O
mice	O

Soon	O
the	O
demand	O
for	O
cocaine	B-Drug
was	O
greatly	O
increasing	O
in	O
United	O
States	O
and	O
Escobar	O
organized	O
more	O
smuggling	O
shipments	O
routes	O
distribution	O
networks	O
South	O
Florida	O
California	O
Puerto	O
Rico	O
other	O
parts	O
of	O
country	O

As	O
a	O
2	O
agonist	O
salbutamol	B-Drug
also	O
has	O
use	O
in	O
obstetrics	O

Neonicotinoids	O
which	O
are	O
derived	O
from	O
and	O
structurally	O
similar	O
to	O
nicotine	B-Drug
widely	O
used	O
as	O
agricultural	O
veterinary	O
pesticides	O
of	O
2016	O

As	O
such	O
testosterone	B-Drug
cypionate	I-Drug
and	O
enanthate	I-Drug
are	O
considered	O
to	O
be	O
functionally	O
interchangeable	O
as	O
medications	O

PCP	B-Drug
is	O
metabolized	O
into	O
PCHP	O
PPC	O
and	O
PCAA	O

The	O
prototypical	O
example	O
of	O
a	O
17-alkylated	O
AAS	O
is	O
methyltestosterone	B-Drug
17-methyltestosterone	O

Lexapro	B-Drug
escitalopram	B-Drug
an	O
antidepressant	O
of	O
the	O
SSRI	O
class	O

Nosebleeds	O
after	O
cocaine	B-Drug
insufflation	O
are	O
due	O
to	O
irritation	O
and	O
damage	O
of	O
mucus	O
membranes	O
by	O
foreign	O
particles	O
adulterants	O
not	O
the	O
itself;	O
as	O
a	O
vasoconstrictor	O
acts	O
reduce	O
bleeding	O

JWH-018	B-Drug
1-pentyl-3-1-naphthoylindole	O
or	O
AM-678	B-Drug
is	O
an	O
analgesic	O
chemical	O
from	O
the	O
naphthoylindole	O
family	O
that	O
acts	O
as	O
a	O
full	O
agonist	O
at	O
both	O
CB1	O
and	O
CB2	O
cannabinoid	O
receptors	O
with	O
some	O
selectivity	O
for	O

S-23	B-Drug
is	O
an	O
investigational	O
selective	O
androgen	O
receptor	O
modulator	O
SARM	O
developed	O
by	O
GTX	O
Inc	O
as	O
a	O
potential	O
male	O
hormonal	O
contraceptive	O

As	O
early	O
as	O
the	O
1960s	O
research	O
into	O
medicinal	O
properties	O
of	O
LSD	B-Drug
was	O
being	O
conducted	O

In	O
the	O
clinical	O
studies	O
88%	O
of	O
patients	O
treated	O
with	O
darolutamide	B-Drug
were	O
age	O
65	O
years	O
or	O
older	O

The	O
triamterene	B-Drug
ring	O
system	O
is	O
found	O
in	O
many	O
naturally	O
occurring	O
compounds	O
such	O
as	O
folic	O
acid	O
and	O
riboflavin	O

A	O
common	O
but	O
untrue	O
belief	O
is	O
that	O
the	O
smoking	O
of	O
cocaine	B-Drug
chemically	O
breaks	O
down	O
tooth	O
enamel	O
and	O
causes	O
decay	O

In	O
November	O
2001	O
through	O
a	O
plea	O
bargain	O
Bleeth	O
pleaded	O
guilty	O
to	O
possessing	O
less	O
than	O
25	O
grams	O
of	O
cocaine	B-Drug
and	O
driving	O
while	O
impaired	O

Amobarbital	B-Drug
5-ethyl-5-isoamylbarbituric	O
acid	O
like	O
all	O
barbiturates	O
is	O
synthesized	O
by	O
reacting	O
malonic	O
derivatives	O
with	O
urea	O

Death	O
as	O
a	O
result	O
of	O
LSD	B-Drug
overdose	O
is	O
virtually	O
unknown;	O
on	O
extremely	O
rare	O
occasions	O
however	O
death	O
can	O
be	O
the	O
accidents	O
or	O
reckless	O
behavior	O

In	O
1992	O
Mike	O
Dirnt	O
of	O
Green	O
Day	O
wrote	O
the	O
famous	O
Longview	O
bass	O
line	O
while	O
under	O
influence	O
LSD	B-Drug

Ethylestrenol	B-Drug
was	O
described	O
in	O
the	O
literature	O
1959	O
and	O
approved	O
for	O
medical	O
use	O
1961	O
United	O
States	O
1964	O

triage	O
8	O
that	O
detects	O
amphetamines	O
benzodiazepines	O
cocaine	B-Drug
methadone	B-Drug
opiates	O
cannabis	O
barbiturates	O
and	O
tricyclic	O
antidepressants	O

Thirteen	O
other	O
states	O
have	O
more	O
restrictive	O
laws	O
limiting	O
THC	O
content	O
for	O
the	O
purpose	O
of	O
allowing	O
access	O
to	O
products	O
that	O
are	O
rich	O
in	O
cannabidiol	B-Drug
CBD	B-Drug
a	O
non-psychoactive	O
component	O
cannabis	O

In	O
response	O
the	O
Anti-Drug	O
Abuse	O
Act	O
of	O
1986	O
included	O
a	O
provision	O
that	O
created	O
disparity	O
between	O
federal	O
penalties	O
for	O
crack	O
cocaine	B-Drug
and	O
powder	O
offenses	O
imposing	O
same	O
possession	O
an	O
amount	O
as	O
100	O
times	O

Novel	O
with	O
Cocaine	B-Drug
is	O
a	O
Dostoevskyan	O
psychological	O
novel	O
of	O
ideas	O
which	O
explores	O
the	O
interaction	O
between	O
psychology	O
philosophy	O
and	O
ideology	O
in	O
its	O
frank	O
portrayal	O
an	O
adolescent's	O
cocaine	B-Drug
addiction	O

For	O
this	O
reason	O
prevention	O
of	O
neurosteroid	O
formation	O
may	O
be	O
involved	O
in	O
the	O
sexual	O
dysfunction	O
and	O
depression	O
that	O
has	O
been	O
associated	O
with	O
5-reductase	O
inhibitors	O
like	O
dutasteride	B-Drug

25I-NBOMe	B-Drug
has	O
similar	O
effects	O
to	O
LSD	B-Drug
though	O
users	O
report	O
more	O
negative	O
while	O
under	O
the	O
influence	O
and	O
risk	O
of	O
harm	O
following	O
use	O
as	O
compared	O
classical	O
psychedelics	O

Fentanyl	B-Drug
is	O
sometimes	O
sold	O
on	O
the	O
black	O
market	O
in	O
form	O
of	O
transdermal	O
fentanyl	B-Drug
patches	O
such	O
as	O
Duragesic	B-Drug
diverted	O
from	O
legitimate	O
medical	O
supplies	O

Ibogaine	B-Drug
catalyzes	O
an	O
altered	O
state	O
of	O
consciousness	O
reminiscent	O
dreaming	O
while	O
fully	O
conscious	O
and	O
aware	O
so	O
that	O
memories	O
life	O
experiences	O
issues	O
trauma	O
can	O
be	O
processed	O

A	O
2019	O
review	O
found	O
that	O
the	O
transition	O
rate	O
from	O
a	O
diagnosis	O
of	O
hallucinogen-induced	O
psychosis	O
which	O
included	O
PCP	B-Drug
to	O
schizophrenia	O
was	O
26%	O

The	O
approval	O
of	O
mifepristone	B-Drug
under	O
subsection	O
H	O
included	O
a	O
black	O
box	O
warning	O

Bottles	O
of	O
opium	B-Drug
tincture	O
are	O
required	O
by	O
the	O
FDA	O
to	O
bear	O
a	O
bright	O
red	O
POISON	O
label	O
given	O
potency	O
drug	O
and	O
potential	O
for	O
overdose	O
see	O
discussion	O
about	O
confusion	O
with	O
Paregoric	O
below	O

The	O
related	O
NSAA	O
bicalutamide	B-Drug
has	O
also	O
been	O
found	O
to	O
be	O
effective	O
in	O
the	O
treatment	O
of	O
hirsutism	O
women	O
and	O
appears	O
have	O
comparable	O
effectiveness	O
that	O
flutamide	O
but	O
a	O
far	O
lower	O
only	O
small	O
risk	O
hepatotoxicity	O
comparison	O

Metandienone	B-Drug
along	O
with	O
other	O
AAS	O
is	O
a	O
schedule	O
III	O
controlled	O
substance	O
in	O
the	O
United	O
States	O
under	O
Controlled	O
Substances	O
Act	O

The	O
list	O
of	O
capitalists	O
who	O
have	O
joined	O
Soros	O
and	O
Lewis	O
in	O
the	O
cause	O
Marijuana	B-Drug
reform	O
include	O
John	O
Sperling	O
is	O
founder	O
University	O
Phoenix	O
George	O
Zimmer	O
former	O
CEO	O
Men's	O
Wearhouse	O

Prior	O
to	O
2004	O
Trussell's	O
typical	O
use	O
failure	O
rate	O
for	O
DMPA	B-Drug
was	O
the	O
same	O
as	O
his	O
perfect	O
rate:	O
0	O

In	O
a	O
separate	O
study	O
conducted	O
by	O
the	O
CDC	O
82%	O
of	O
fentanyl	B-Drug
overdose	O
deaths	O
involved	O
illegally	O
manufactured	O
while	O
only	O
4%	O
were	O
suspected	O
to	O
originate	O
from	O
prescription	O

Ziegler's	O
work	O
resulted	O
in	O
the	O
production	O
of	O
methandrostenolone	B-Drug
which	O
Ciba	O
Pharmaceuticals	O
marketed	O
as	O
Dianabol	B-Drug

The	O
benzodiazepines	O
are	O
also	O
far	O
less	O
dangerous;	O
death	O
rarely	O
results	O
from	O
diazepam	B-Drug
overdose	O
except	O
in	O
cases	O
where	O
it	O
is	O
consumed	O
with	O
large	O
amounts	O
of	O
other	O
depressants	O
such	O
as	O
alcohol	O
or	O
opioids	O

The	O
primary	O
purpose	O
of	O
these	O
laws	O
is	O
to	O
allow	O
for	O
the	O
use	O
cannabidiol	B-Drug
CBD	B-Drug
a	O
non-psychoactive	O
cannabinoid	O
that	O
has	O
been	O
shown	O
be	O
effective	O
in	O
treatment	O
seizure	O
disorders	O
particularly	O
children	O

If	O
the	O
D	O
ring	O
is	O
below	O
core	O
dextrorotatory	O
analgesic	O
and	O
euphoric	O
properties	O
are	O
eliminated	O
or	O
dramatically	O
reduced	O
but	O
cough-suppressant	O
property	O
retained	O
as	O
in	O
dextromethorphan	B-Drug

Typical	O
antipsychotics	O
such	O
as	O
phenothiazines	O
and	O
haloperidol	B-Drug
have	O
been	O
used	O
to	O
control	O
psychotic	O
symptoms	O
but	O
may	O
produce	O
many	O
undesirable	O
side	O
effects	O
dystonia	O
their	O
use	O
is	O
therefore	O
no	O
longer	O
preferred;	O
are	O
particularly	O
risky	O
they	O
lower	O
the	O
seizure	O
threshold	O
worsen	O
hyperthermia	O
boost	O
anticholinergic	O
of	O
PCP	B-Drug

It	O
is	O
the	O
C17	O
enanthate	O
heptanoate	O
ester	O
of	O
metenolone	B-Drug
which	O
itself	O
1-methyl-1-45-dihydrotestosterone	O
1-methyl-1-DHT	O
or	O
1-methyl-5-androst-1-en-17-ol-3-one	O

This	O
side-effect	O
is	O
not	O
unique	O
to	O
flunitrazepam	B-Drug
but	O
also	O
occurs	O
with	O
other	O
hypnotic	O
drugs	O

Although	O
the	O
therapeutic	O
effects	O
of	O
empathogens	O
may	O
be	O
promising	O
drugs	O
such	O
as	O
MDMA	B-Drug
have	O
potential	O
for	O
negative	O
that	O
are	O
counter	O
productive	O
in	O
a	O
therapy	O
setting	O

Nicotine	B-Drug
use	O
as	O
a	O
tool	O
for	O
quitting	O
smoking	O
has	O
good	O
safety	O
history	O

Unlike	O
bicalutamide	B-Drug
the	O
newer	O
NSAA	O
enzalutamide	B-Drug
is	O
still	O
on-patent	O
and	O
for	O
this	O
reason	O
considerably	O
more	O
expensive	O
in	O
comparison	O

In	O
2019	O
Spanish	O
authorities	O
apprehended	O
a	O
20m	O
privately-owned	O
semi-submersible	O
off	O
Galicia	O
Spain	O
containing	O
3000	O
kg	O
of	O
cocaine	B-Drug
in	O
the	O
first	O
known	O
incident	O
submarine	O
crossing	O
Atlantic	O
Ocean	O

Individuals	O
with	O
an	O
opioid	O
use	O
disorder	O
are	O
often	O
treated	O
replacement	O
therapy	O
using	O
methadone	B-Drug
or	O
buprenorphine	B-Drug

Nortriptyline	B-Drug
desipramine	B-Drug
and	O
amoxapine	B-Drug
are	O
tricyclic	O
antidepressants	O
secondary	O
amines	O

The	O
acquired	O
F876L	O
mutation	O
of	O
the	O
AR	O
identified	O
in	O
advanced	O
prostate	O
cancer	O
cells	O
has	O
been	O
found	O
to	O
confer	O
resistance	O
both	O
enzalutamide	B-Drug
and	O
apalutamide	B-Drug

Thalidomide	B-Drug
can	O
prevent	O
menstruation	O

A	O
methylphenidate	B-Drug
skin	O
patch	O
is	O
sold	O
under	O
the	O
brand	O
name	O
Daytrana	O
in	O
United	O
States	O

Prolixin	B-Drug
fluphenazine	B-Drug
typical	O
antipsychotic	O

Though	O
various	O
websites	O
on	O
the	O
internet	O
report	O
that	O
acetazolamide	B-Drug
can	O
be	O
used	O
to	O
treat	O
dural	O
ectasia	O
in	O
individuals	O
with	O
Marfan	O
Syndrome	O
only	O
supporting	O
evidence	O
for	O
this	O
assertion	O
exists	O
from	O
a	O
small	O
study	O
of	O
14	O
patients	O
which	O
was	O
not	O
peer-reviewed	O
or	O
submitted	O
publication	O

Ludlow	O
recognized	O
also	O
the	O
lack	O
of	O
physical	O
symptoms	O
during	O
withdrawal	O
and	O
difference	O
from	O
opium	B-Drug
in	O
this	O
respect	O

2C-N	O
25-dimethoxy-4-nitrophenethylamine	O
is	O
a	O
psychedelic	O
phenethylamine	B-Drug
of	O
the	O
2C	O
family	O

If	O
vasoconstriction	O
is	O
desired	O
for	O
a	O
procedure	O
as	O
it	O
reduces	O
bleeding	O
the	O
anesthetic	B-Drug
combined	O
with	O
vasoconstrictor	O
such	O
phenylephrine	B-Drug
or	O
epinephrine	O

Functional	O
groups	O
which	O
are	O
added	O
to	O
morphine	B-Drug
and	O
its	O
esters	O
make	O
active	O
opioids	O
include	O
the	O
benzoyl	O
acetyl	O
formyl	O
propionyl	O
butroyl	O
butyl	O
salicoyl	O
nicotinoyl	O
cinnamoyl	O
others	O

The	O
synthesis	O
and	O
structure	O
elucidation	O
of	O
cocaine	B-Drug
was	O
reported	O
by	O
Richard	O
Willsttter	O
in	O
1898	O

As	O
of	O
October	O
2015	O
5F-AMB	B-Drug
is	O
a	O
controlled	O
substance	O
in	O
China	O

However	O
studies	O
suggest	O
people	O
who	O
use	O
cocaine	B-Drug
do	O
not	O
show	O
normal	O
age-related	O
loss	O
of	O
striatal	O
dopamine	O
transporter	O
DAT	O
sites	O
suggesting	O
has	O
neuroprotective	O
properties	O
for	O
neurons	O

may	O
develop	O
in	O
patients	O
treated	O
with	O
metoclopramide	B-Drug
and	O
warned	O
against	O
use	O
longer	O
than	O
12	O
weeks	O
as	O
that	O
was	O
how	O
long	O
the	O
drug	O
has	O
been	O
tested	O

There	O
are	O
four	O
common	O
forms	O
in	O
which	O
AAS	O
administered:	O
oral	O
pills;	O
injectable	O
steroids;	O
creams/gels	O
for	O
topical	O
application;	O
and	O
skin	O
patches	B-Drug

Cephalon's	O
2011	O
attempt	O
to	O
merge	O
with	O
Teva	O
was	O
approved	O
by	O
the	O
FTC	O
under	O
a	O
number	O
of	O
conditions	O
including	O
granting	O
generic	O
US	O
rights	O
another	O
company;	O
ultimately	O
Par	O
Pharmaceutical	O
acquired	O
modafinil	B-Drug
as	O
well	O
some	O
others	O

Fiona	O
Measham	O
a	O
criminologist	O
at	O
The	O
University	O
of	O
Lancaster	O
thought	O
the	O
emergence	O
mephedrone	B-Drug
was	O
also	O
related	O
to	O
decreasing	O
purity	O
ecstasy	B-Drug
and	O
cocaine	B-Drug
on	O
sale	O
in	O
UK	O
view	O
reinforced	O
report	O
by	O
National	O
Treatment	O
Agency	O
for	O
Substance	O
Misuse	O

At	O
steady	O
state	O
with	O
600	O
mg/day	O
darolutamide	B-Drug
mean	O
levels	O
of	O
are	O
4	O

Hemp	O
has	O
lower	O
concentrations	O
of	O
THC	O
and	O
higher	O
CBD	B-Drug
which	O
gives	O
lesser	O
psychoactive	O
effects	O

Codeine	B-Drug
is	O
more	O
commonly	O
used;	O
however	O
as	O
codeine	B-Drug
in	O
essence	O
a	O
prodrug	O
that	O
requires	O
vivo	O
metabolism	O
to	O
morphine	B-Drug
via	O
demethylation	O
for	O
efficacy	O
it	O
ineffective	O
some	O
individuals	O
with	O
the	O
poor	O
metabolizer	O
genotype	O
of	O
liver	O
cytochrome	O
P450	O
enzyme	O
CYP2D6	O

Isotretinoin	B-Drug
reduces	O
bacterial	O
numbers	O
in	O
both	O
the	O
ducts	O
and	O
skin	O
surface	O

It	O
may	O
be	O
involved	O
in	O
a	O
reaction	O
similar	O
to	O
disulfiram	B-Drug
when	O
alcohol	O
is	O
consumed	O
after	O
it	O
used	O
particular	O
combination	O
with	O
sulfamethoxazole	B-Drug

In	O
2017	O
it	O
was	O
found	O
that	O
some	O
pills	O
being	O
sold	O
as	O
MDMA	B-Drug
contained	O
pentylone	B-Drug
which	O
can	O
cause	O
very	O
unpleasant	O
agitation	O
and	O
paranoia	O

Its	O
sap	O
was	O
later	O
named	O
opion	O
by	O
the	O
ancient	O
Greeks	O
from	O
where	O
it	O
gained	O
its	O
modern	O
name	O
of	O
opium	B-Drug

Although	O
mannitol	B-Drug
has	O
a	O
higher	O
heat	O
of	O
solution	O
than	O
most	O
sugar	O
alcohols	O
its	O
comparatively	O
low	O
solubility	O
reduces	O
the	O
cooling	O
effect	O
usually	O
found	O
in	O
mint	O
candies	O
and	O
gums	O

One	O
example	O
is	O
the	O
case	O
of	O
Big	O
Lurch	O
a	O
former	O
rapper	O
with	O
history	O
violent	O
crime	O
who	O
was	O
convicted	O
murdering	O
and	O
cannibalizing	O
his	O
roommate	O
while	O
under	O
influence	O
PCP	B-Drug

Naloxone	B-Drug
abolishes	O
the	O
central	O
depressant	O
and	O
peripheral	O
effects	O
of	O
tilidine	B-Drug

In	O
the	O
United	O
Kingdom	O
it	O
is	O
usually	O
less	O
preferred	O
than	O
methylphenidate	B-Drug

There	O
is	O
a	O
high	O
risk	O
that	O
thalidomide	B-Drug
can	O
cause	O
excessive	O
blood	O
clots	O

JWH-018	B-Drug
is	O
one	O
of	O
these	O
compounds	O
with	O
studies	O
showing	O
an	O
affinity	O
for	O
the	O
cannabinoid	O
CB1	O
receptor	O
five	O
times	O
greater	O
than	O
that	O
THC	O

The	O
product	O
has	O
been	O
described	O
as	O
the	O
country's	O
most	O
famous	O
brand	O
of	O
CBD	B-Drug
oil	I-Drug
largest	O
selling	O
in	O
country	O
and	O
number	O
one	O
with	O
7%	O
market	O

Opium	B-Drug
production	O
has	O
led	O
to	O
rising	O
tensions	O
in	O
Afghan	O
villages	O

Songs	O
allegedly	O
referring	O
to	O
LSD	B-Drug
include	O
John	O
Prine's	O
Illegal	O
Smile	O
and	O
the	O
Beatles'	O
song	O
Lucy	O
in	O
Sky	O
with	O
Diamonds	O
although	O
authors	O
of	O
latter	O
repeatedly	O
denied	O
this	O
claim	O

The	O
lab	O
was	O
allegedly	O
producing	O
a	O
kilogram	O
of	O
LSD	B-Drug
every	O
five	O
weeks	O
and	O
the	O
U	O

Most	O
people	O
who	O
were	O
exposed	O
to	O
cocaine	B-Drug
in	O
utero	O
are	O
normal	O
or	O
close	O
it	O

Intracellular	O
MDMA	B-Drug
binds	O
to	O
VMAT2-proteins	O
on	O
synaptic	O
vesicles	O
as	O
an	O
inhibitor	O

The	O
effects	O
of	O
bretazenil	O
can	O
also	O
be	O
quickly	O
reversed	O
by	O
the	O
action	O
flumazenil	B-Drug
which	O
is	O
used	O
as	O
an	O
antidote	O
to	O
benzodiazepine	O
overdose	O
in	O
contrast	O
alcohol	O
for	O
there	O
no	O
effective	O
and	O
reliable	O

Sometime	O
after	O
2000	O
Shire	O
closed	O
the	O
Rexar	O
manufacturing	O
facility	O
and	O
outsourced	O
of	O
brand	O
name	O
Adderall	B-Drug
to	O
a	O
vendor	O
in	O
North	O
Carolina	O

It	O
is	O
related	O
to	O
other	O
acetylated	O
morphone	O
derivatives	O
including	O
36-diacetyloxymorphone	O
3814-triacetyloxymorphone	O
36814-tetraacetyloxymorphone	O
noroxymorphone	B-Drug
analogs	O
of	O
all	O
or	O
most	O
the	O
above	O
and	O
3614-triacetyloxymorphone	O
a	O
derivative	O
oxymorphone	B-Drug
whose	O
structure-activity	O
relationship	O
suggests	O
800%	O
potency	O
parent	O
drug	O
versus	O
250%	O
for	O
314-diacetyoxymorphone	O

After	O
restricting	O
its	O
manufacture	O
and	O
distribution	O
in	O
1965	O
the	O
US	O
government	O
fully	O
criminalized	O
LSD	B-Drug
1968	O
after	O
which	O
European	O
nations	O
hosted	O
psychedelic	O
research	O
followed	O
suit	O

Ibogaine	B-Drug
decreases	O
body	O
temperature	O

Heroin	B-Drug
is	O
also	O
known	O
by	O
many	O
street	O
names	O
including	O
dope	O
H	O
smack	B-Drug
junk	B-Drug
horse	O
scag	O
and	O
brown	O
among	O
others	O

PCP	B-Drug
like	O
ketamine	B-Drug
also	O
acts	O
as	O
a	O
potent	O
dopamine	O
D2High	O
receptor	O
partial	O
agonist	O
in	O
rat	O
brain	O
homogenate	O
and	O
has	O
affinity	O
for	O
the	O
human	O
cloned	O

Though	O
direct	O
conflict	O
has	O
yet	O
to	O
occur	O
the	O
opinions	O
of	O
new	O
class	O
young	O
rich	O
men	O
involved	O
in	O
opium	B-Drug
trade	O
are	O
at	O
odds	O
with	O
those	O
traditional	O
village	O
leaders	O

The	O
syringe	O
went	O
to	O
Don	O
Catlin	O
MD	O
the	O
founder	O
and	O
then-director	O
of	O
UCLA	O
Olympic	O
Analytical	O
Laboratory	O
who	O
had	O
developed	O
a	O
testing	O
process	O
for	O
substance	O
tetrahydrogestrinone	B-Drug
THG	B-Drug

The	O
Na-H	O
transporter	O
is	O
also	O
found	O
in	O
the	O
Jejunum	O
of	O
small	O
intestine	O
as	O
a	O
result	O
amiloride	B-Drug
blocks	O
reabsoprtion	O
Na	O
and	O
thereby	O
water	O
intestines	O

Opium	B-Drug
has	O
been	O
actively	O
collected	O
since	O
approximately	O
3400	O
BC	O

Progesterone	O
and	O
its	O
neurosteroid	O
active	O
metabolite	O
allopregnanolone	B-Drug
appear	O
to	O
be	O
importantly	O
involved	O
in	O
libido	O
females	O

Prazepam	B-Drug
is	O
metabolised	O
into	O
descyclopropylmethylprazepam	O
also	O
known	O
as	O
desmethyldiazepam	B-Drug
and	O
3-hydroxyprazepam	O
which	O
further	O
oxazepam	B-Drug

CBD	B-Drug
does	O
not	O
have	O
the	O
same	O
psychoactivity	O
as	O
THC	O
and	O
may	O
change	O
effects	O
of	O
on	O
body	O
if	O
both	O
are	O
present	O

After	O
absorption	O
ketamine	B-Drug
is	O
rapidly	O
distributed	O
into	O
the	O
brain	O
and	O
other	O
tissues	O

The	O
main	O
active	O
metabolite	O
of	O
diazepam	B-Drug
is	O
desmethyldiazepam	B-Drug
also	O
known	O
as	O
nordazepam	B-Drug
or	O
nordiazepam	B-Drug

Tricyclic	O
antidepressants	O
TCAs:	O
amitriptyline	B-Drug
butriptyline	O
clomipramine	B-Drug
desipramine	B-Drug
dosulepin	O
doxepin	B-Drug
imipramine	B-Drug
lofepramine	O
nortriptyline	B-Drug
protriptyline	O
trimipramine	B-Drug

It	O
is	O
available	O
in	O
the	O
UK	O
as	O
Ketoflam	O
and	O
Oruvail	O
Ireland	O
Fastum	O
Gel	O
Estonia	O
Keto	O
Ketonal	O
Finland	O
Ketorin	O
Ketomex	O
Orudis;	O
France	O
Profnid	O
Bi-Profnid	O
Ketum;	O
Italy	O
Ketodol	O
Lasonil	O
Orudis	O
Oki;	O
Poland	O
active	O
Ketolek	O
Serbia	O
Slovenia	O
Croatia	O
Knavon	O
Ketonal;	O
Romania	O
Gel;	O
Mexico	O
Arthril;	O
Norway	O
Zon	O
Russia	O
OKI	O
Spain	O
Actron	B-Drug
Albania	O
Oki	O
Venezuela	O
Ketoprofeno	O
an	O
injectable	O
solution	O
of	O
100	O
mg	O
150	O
capsules	O

A	O
single	O
nucleotide	O
polymorphism	O
SNP	O
in	O
the	O
protein	O
NEDD4L	O
may	O
impact	O
how	O
amiloride	B-Drug
affects	O
a	O
person's	O
blood	O
pressure	O
people	O
with	O
high	O

Obetrol	B-Drug
was	O
abused	O
by	O
a	O
character	O
named	O
Chris	O
Fogle	O
in	O
David	O
Foster	O
Wallace's	O
novel	O
The	O
Pale	O
King	O

Similar	O
anxiety-ridden	O
reports	O
appeared	O
throughout	O
cities	O
in	O
the	O
South	O
leading	O
some	O
to	O
declare	O
that	O
cocaine	B-Drug
habit	O
has	O
assumed	O
proportions	O
of	O
an	O
epidemic	O
among	O
colored	O
people	O

On	O
July	O
15	O
2016	O
the	O
extended	O
release	O
version	O
of	O
lorcaserin	B-Drug
was	O
approved	O
for	O
use	O
in	O
United	O
States	O

Pyrrolidinylthiambutene	O
is	O
an	O
opioid	O
analgesic	O
drug	O
from	O
the	O
thiambutene	O
family	O
with	O
around	O
3/4	O
of	O
potency	O
morphine	B-Drug

62	O
mg	O
of	O
oxycodone	B-Drug
hydrochloride	O
and	O
0	O

Internationally	O
pentazocine	B-Drug
is	O
a	O
Schedule	O
III	O
drug	O
under	O
the	O
Convention	O
on	O
Psychotropic	O
Substances	O

The	O
molecular	O
and	O
crystal	O
structure	O
of	O
dexamethasone	B-Drug
has	O
been	O
determined	O
by	O
X-ray	O
crystallography	O

While	O
the	O
price	O
of	O
cocaine	B-Drug
is	O
higher	O
in	O
Chile	O
than	O
Peru	O
and	O
Bolivia	O
final	O
destination	O
usually	O
Europe	O
especially	O
Spain	O
where	O
drug	O
dealing	O
networks	O
exist	O
among	O
South	O
American	O
immigrants	O

The	O
first	O
commercially	O
feasible	O
synthesis	O
of	O
prednisone	B-Drug
was	O
carried	O
out	O
in	O
1955	O
the	O
laboratories	O
Schering	O
Corporation	O
which	O
later	O
became	O
Schering-Plough	O
by	O
Arthur	O
Nobile	O
and	O
coworkers	O

By	O
being	O
structurally	O
similar	O
to	O
enzyme	O
targets	O
exemestane	B-Drug
permanently	O
binds	O
the	O
enzymes	O
preventing	O
them	O
from	O
converting	O
androgen	O
into	O
estrogen	O

Many	O
19-nortestosterone	B-Drug
derivatives	O
including	O
nandrolone	B-Drug
trenbolone	B-Drug
ethylestrenol	B-Drug
ethylnandrol	O
metribolone	O
R-1881	O
trestolone	O
11-MNT	O
dimethandrolone	O
and	O
others	O
are	O
potent	O
agonists	O
of	O
the	O
progesterone	O
receptor	O
AR	O
hence	O
progestogens	O
in	O
addition	O
to	O
AAS	O

Examples	O
include:	O
Serotonin	O
antagonists	O
and	O
reuptake	O
inhibitorsTrazodoneTricyclic	O
antidepressantsAmitriptyline	O
Doxepin	B-Drug
TrimipramineTetracyclic	O
antidepressantsMianserin	O
Mirtazapine	B-Drug
of	O
antipsychotics	O
with	O
sedation	O
as	O
a	O
side	O
effect:	O
First-generationChlorpromazineSecond-generationClozapine	O
Olanzapine	B-Drug
Quetiapine	B-Drug
Risperidone	B-Drug
Zotepine	O
Alpha-adrenergic	O
agonistClonidine	O
GuanfacineCannabinoidsCannabidiol	O
TetrahydrocannabinolOrexin	O
receptor	O
antagonistSuvorexantGabapentinoidsPregabalin	O
Phenibut	B-Drug
Imagabalin	O
The	O
use	O
sedative	O
medications	O
in	O
older	O
people	O
generally	O
should	O
be	O
avoided	O

Before	O
taking	O
temazepam	B-Drug
one	O
should	O
ensure	O
that	O
at	O
least	O
8	O
hours	O
are	O
available	O
to	O
dedicate	O
sleep	O

In	O
that	O
same	O
year	O
Peru	O
surpassed	O
Colombia	O
as	O
the	O
main	O
producer	O
of	O
coca	B-Drug
leaves	O
in	O
world	O

In	O
the	O
19th	O
century	O
hashish	B-Drug
was	O
embraced	O
in	O
some	O
European	O
literary	O
circles	O

Fospropofol	B-Drug
INN	O
often	O
used	O
as	O
the	O
disodium	O
salt	O
trade	O
name	O
Lusedra	O
is	O
an	O
intravenous	O
sedative-hypnotic	O
agent	O

PCP	B-Drug
like	O
ketamine	B-Drug
also	O
acts	O
as	O
a	O
potent	O
dopamine	O
D2High	O
receptor	O
partial	O
agonist	O
in	O
rat	O
brain	O
homogenate	O
and	O
has	O
affinity	O
for	O
the	O
human	O
cloned	O

A	O
2018	O
report	O
by	O
The	O
Guardian	O
indicated	O
that	O
many	O
major	O
drug	O
suppliers	O
on	O
the	O
dark	O
web	O
have	O
voluntarily	O
banned	O
trafficking	O
of	O
fentanyl	B-Drug

Another	O
harm	O
reduction	O
measure	O
employed	O
for	O
example	O
in	O
Europe	O
Canada	O
and	O
Australia	O
are	O
safe	O
injection	O
sites	O
where	O
users	O
can	O
inject	O
diamorphine	B-Drug
cocaine	B-Drug
under	O
the	O
supervision	O
of	O
medically	O
trained	O
staff	O

In	O
December	O
2013	O
the	O
government	O
of	O
India	O
in	O
response	O
to	O
rising	O
recreational	O
use	O
and	O
ketamine	B-Drug
as	O
a	O
date	O
rape	O
drug	O
has	O
added	O
it	O
Schedule	O
X	O
Drug	O
Cosmetics	O
Act	O
requiring	O
special	O
license	O
for	O
sale	O
maintenance	O
records	O
all	O
sales	O
two	O
years	O

Temazepam	B-Drug
was	O
synthesized	O
in	O
1964	O
but	O
it	O
came	O
into	O
use	O
1981	O
when	O
its	O
ability	O
to	O
counter	O
insomnia	O
realized	O

The	O
speed	B-Drug
of	O
onset	O
action	O
a	O
particular	O
benzodiazepine	O
correlates	O
well	O
with	O
the	O
popularity	O
that	O
drug	O
for	O
abuse	O

Powder	O
is	O
either	O
the	O
pure	O
drug	O
by	O
itself	O
talcum	O
powder	O
or	O
made	O
of	O
mixed	O
in	O
a	O
carrier	O
such	O
as	O
corn	O
starch	O
cob	O
Zeosorb	O
AF	O
-	O
miconazole	B-Drug

It	O
was	O
also	O
studied	O
to	O
treat	O
alcohol	O
addiction;	O
while	O
the	O
evidence	O
for	O
this	O
use	O
is	O
weak	O
however	O
sodium	B-Drug
oxybate	I-Drug
marketed	O
in	O
Italy	O

Naltrexone	B-Drug
is	O
a	O
pure	O
opioid	O
antagonist	O
which	O
further	O
augments	O
bupropion's	O
activation	O
of	O
the	O
POMC	O
bupropion	B-Drug

Drugs	O
such	O
as	O
ephedrine	B-Drug
pseudoephedrine	O
amphetamine	B-Drug
and	O
methylphenidate	B-Drug
have	O
well	O
documented	O
ergogenic	O
effects	O
while	O
cocaine	B-Drug
has	O
the	O
opposite	O
effect	O

Ecstasy	B-Drug
pills	O
might	O
also	O
contain	O
a	O
low	O
dose	O
of	O
2C-I	O
to	O
potentiate	O
its	O
euphoric	O
effects	O

In	O
addition	O
they	O
found	O
that	O
it	O
is	O
completely	O
removed	O
from	O
opiate	O
receptors	O
by	O
naloxone	B-Drug
an	O
identified	O
morphine	B-Drug
antagonist	O

On	O
September	O
11	O
2007	O
Sepracor	O
signed	O
a	O
marketing	O
deal	O
with	O
British	O
pharmaceutical	O
company	O
GlaxoSmithKline	O
for	O
the	O
rights	O
to	O
sell	O
eszopiclone	B-Drug
under	O
name	O
Lunivia	O
rather	O
than	O
Lunesta	B-Drug
in	O
Europe	O

1	O
mg	O
which	O
was	O
associated	O
with	O
a	O
plasma	O
tramadol	B-Drug
level	O
of	O
about	O
330	O
ng/ml	O
1300	O
nM	O

Mephedrone	B-Drug
was	O
scheduled	O
to	O
be	O
classified	O
as	O
a	O
dangerous	O
substance	B-Drug
in	O
Sweden	O
even	O
before	O
the	O
woman's	O
death	O
at	O
Karolinska	O
University	O
Hospital	O
on	O
14	O
December	O
but	O
brought	O
more	O
media	O
attention	O
drug	O

The	O
prescribing	O
information	O
for	O
Provigil	B-Drug
notes	O
that	O
There	O
were	O
no	O
clinically	O
significant	O
differences	O
in	O
body	O
weight	O
change	O
patients	O
treated	O
with	O
compared	O
to	O
placebo-treated	O
the	O
placebo-controlled	O
clinical	O
trials	O

In	O
the	O
absence	O
of	O
Taliban	O
warlords	O
largely	O
control	O
opium	B-Drug
trade	O
but	O
are	O
also	O
highly	O
useful	O
to	O
US	O
forces	O
in	O
scouting	O
providing	O
local	O
intelligence	O
keeping	O
their	O
own	O
territories	O
clean	O
from	O
Al-Qaeda	O
and	O
insurgents	O
even	O
taking	O
part	O
military	O
operations	O

Alvimopan	B-Drug
is	O
not	O
a	O
substrate	O
for	O
the	O
cytochrome	O
P450	O
enzyme	O
system	O

Benzocaine	B-Drug
mucoadhesive	O
patches	O
have	O
been	O
used	O
in	O
reducing	O
orthodontic	O
pain	O

The	O
medications	O
included	O
prednisone	B-Drug
and	O
methylprednisolone	B-Drug
plus	O
albuterol	B-Drug
beclomethasone	O
dexamethasone	B-Drug
cromolyn	B-Drug
salmeterol	B-Drug
clarithromycin	O

Hallucinogen	O
was	O
popularized	O
by	O
Aldous	O
Huxley's	O
experiences	O
with	O
mescaline	B-Drug
which	O
were	O
published	O
as	O
The	O
Doors	O
of	O
Perception	O
in	O
1954	O

1%	O
have	O
used	O
cocaine	B-Drug
at	O
least	O
once	O
and	O
3	O

Intramuscular	O
injections	B-Drug
should	O
not	O
be	O
administered	O
to	O
those	O
with	O
idiopathic	O
thrombocytopenic	O
purpura	O

The	O
effect	O
of	O
hepatic	O
impairment	O
on	O
the	O
pharmacokinetics	O
benzhydrocodone/APAP	O
has	O
not	O
been	O
determined	O
APAP	B-Drug

The	O
Commentary	O
gives	O
alcohol	O
and	O
tobacco	B-Drug
as	O
examples	O
of	O
psychoactive	O
drugs	O
that	O
were	O
deemed	O
to	O
not	O
fit	O
the	O
above	O
criteria	O
by	O
1971	O
Conference	O
which	O
negotiated	O
Convention	O

As	O
early	O
as	O
1919	O
Akira	O
Ogata	O
synthesized	O
methamphetamine	B-Drug
via	O
reduction	O
of	O
ephedrine	B-Drug
using	O
red	O
phosphorus	O
and	O
iodine	O

Fentanyl	B-Drug
was	O
first	O
synthesized	O
in	O
Belgium	O
by	O
Paul	O
Janssen	O
under	O
the	O
label	O
of	O
his	O
relatively	O
newly	O
formed	O
Pharmaceutica	O
1959	O

For	O
example	O
in	O
an	O
MDMA	B-Drug
ecstasy	B-Drug
comedown	O
if	O
the	O
user	O
experiences	O
severe	O
persisting	O
emotional	O
distress	O
such	O
as	O
panic	O
attacks	O
generalized	O
anxiety	O
or	O
insomnia	O
following	O
session	O
a	O
physician	O
may	O
prescribe	O
benzodiazepine	O
specifically	O
lorazepam	B-Drug
and/or	O
sleep	O
aid	O
e	O

each	O
year	O
that	O
were	O
attributed	O
to	O
acetaminophen	B-Drug
overdose	O
and	O
associated	O
liver	O
damage	O

There	O
was	O
low-	O
to	O
moderate-strength	O
evidence	O
of	O
no	O
benefit	O
for	O
most	O
the	O
other	O
medications	O
used	O
in	O
RCTs	O
which	O
included	O
antidepressants	O
bupropion	B-Drug
mirtazapine	B-Drug
sertraline	B-Drug
antipsychotics	O
aripiprazole	B-Drug
anticonvulsants	O
topiramate	B-Drug
baclofen	B-Drug
gabapentin	B-Drug
naltrexone	B-Drug
varenicline	B-Drug
citicoline	O
ondansetron	B-Drug
prometa	O
riluzole	B-Drug
atomoxetine	B-Drug
dextroamphetamine	B-Drug
and	O
modafinil	B-Drug

However	O
intravenous	O
lorazepam	B-Drug
has	O
advantages	O
over	O
diazepam	B-Drug
including	O
a	O
higher	O
rate	O
of	O
terminating	O
seizures	O
and	O
more	O
prolonged	O
anticonvulsant	O
effect	O

A	O
century	O
later	O
Li	O
Shizhen	O
listed	O
standard	O
medical	O
uses	O
of	O
opium	B-Drug
in	O
his	O
renowned	O
Compendium	O
Materia	O
Medica	O
1578	O
but	O
also	O
wrote	O
that	O
lay	O
people	O
use	O
it	O
for	O
the	O
art	O
sex	O
particular	O
ability	O
to	O
arrest	O
seminal	O
emission	O

Sales	O
of	O
bicalutamide	B-Drug
as	O
Casodex	B-Drug
worldwide	O
peaked	O
at	O
US$1	O

An	O
example	O
of	O
this	O
is	O
diphenhydramine	B-Drug
Benadryl	O
an	O
anti-histamine	O
which	O
once	O
required	O
a	O
prescription	O
but	O
now	O
available	O
OTC	O
nearly	O
everywhere	O

Listed	O
as	O
a	O
Schedule	O
1	O
it	O
is	O
an	O
analogue	O
of	O
amphetamine	B-Drug

The	O
patches	O
work	O
by	O
slowly	O
releasing	O
fentanyl	B-Drug
through	O
the	O
skin	O
into	O
bloodstream	O
over	O
48	O
to	O
72	O
hours	O
allowing	O
for	O
long-lasting	O
pain	O
management	O

k-2C-B	O
beta-keto	O
2C-B	B-Drug
bk-2C-B	O
is	O
a	O
psychedelic	O
drug	O
which	O
structurally	O
related	O
to	O
and	O
BOB	O
has	O
been	O
sold	O
online	O
as	O
designer	O

In	O
2008	O
the	O
European	O
Monitoring	O
Centre	O
for	O
Drugs	O
and	O
Drug	O
Addiction	O
noted	O
that	O
although	O
there	O
were	O
some	O
reports	O
of	O
tablets	O
being	O
sold	O
as	O
little	O
1	O
most	O
countries	O
in	O
Europe	O
then	O
reported	O
typical	O
retail	O
prices	O
range	O
3	O
to	O
9	O
per	O
tablet	O
typically	O
containing	O
2565	O
mg	O
MDMA	B-Drug

This	O
may	O
play	O
a	O
role	O
in	O
explaining	O
diazepam's	O
anticonvulsant	O
properties	O
diazepam	B-Drug

It	O
was	O
also	O
marketed	O
in	O
several	O
countries	O
as	O
a	O
combination	O
drug	O
with	O
mecobalamin	B-Drug
under	O
the	O
brand	O
names	O
Agemax-P	O
Alphamix-PG	O
Freenerve-P	O
Gaben	O
Macraberin-P	O
Mecoblend-P	O
Mecozen-PG	O
Meex-PG	O
Methylnuron-P	O
Nervolin	O
Nervopreg	O
Neurica-M	O
Neuroprime-PG	O
Neutron-OD	O
Nuroday-P	O
Nurodon-PG	O
Nuwin-P	O
Pecomin-PG	O
Prebel-M	O
Predic-GM	O
Pregacent-M	O
Pregamet	O
Preganerv-M	O
Pregeb-M	O
OD	O
Pregmic	O
Prejunate	O
Plus	O
Preneurolin	O
Pretek-GM	O
Rejusite	O
Renerve-P	O
Safyvit-PR	O
and	O
Vitcobin-P	O
Voltanerv	O
Methylcobalamin	B-Drug
ALA	O
by	O
Cogentrix	O
Pharma	O

Unlike	O
most	O
other	O
anabolic	O
steroids	O
THG	B-Drug
also	O
binds	O
with	O
high	O
affinity	O
to	O
the	O
glucocorticoid	O
receptor	O
and	O
while	O
this	O
effect	O
may	O
cause	O
additional	O
weight	O
loss	O
it	O
is	O
likely	O
side	O
effects	O
such	O
as	O
immunosuppression	O
that	O
are	O
not	O
seen	O

Oxymorphone	B-Drug
is	O
10	O
times	O
more	O
potent	O
than	O
morphine	B-Drug

Hydromorphone	B-Drug
is	O
known	O
in	O
various	O
countries	O
around	O
the	O
world	O
by	O
brand	O
names	O
Hydal	O
Dimorphone	O
Exalgo	O
Sophidone	O
LP	O
Dilaudid	B-Drug
Hydrostat	O
Hydromorfan	O
Hydromorphan	O
Hymorphan	O
Laudicon	O
Opidol	O
Palladone	B-Drug
Hydromorph	O
Contin	O
and	O
others	O

Nalbuphine	B-Drug
binds	O
with	O
high	O
affinity	O
to	O
the	O
MOR	O
and	O
KOR	O
has	O
relatively	O
low	O
for	O
DOR	O

Four	O
products	O
sold	O
in	O
Irish	O
head	O
shops	O
were	O
tested	O
2010	O
and	O
found	O
to	O
contain	O
between	O
82%	O
14%	O
mephedrone	B-Drug
with	O
some	O
containing	O
benzocaine	B-Drug
caffeine	O

DrugScience	O
initially	O
focused	O
on	O
reviewing	O
official	O
risk	O
estimates	O
for	O
psychedelic	O
drugs	O
ecstasy	B-Drug
and	O
cannabis	O
increasing	O
warnings	O
of	O
the	O
dangers	O
ketamine	B-Drug

Moreover	O
ketamine	B-Drug
was	O
discovered	O
and	O
better	O
tolerated	O
as	O
an	O
anesthetic	O

Amphetamine	B-Drug
was	O
synthesized	O
in	O
1887	O
by	O
Lazar	O
Edeleanu	O
Germany	O

PCP	B-Drug
is	O
well	O
known	O
for	O
its	O
primary	O
action	O
on	O
the	O
NMDA	O
receptor	O
an	O
ionotropic	O
glutamate	O
in	O
rats	O
and	O
rat	O
brain	O
homogenate	O

-	O
tmax	O
is	O
the	O
time	O
to	O
peak	O
plasma	O
levels	O
after	O
oral	O
administration	O
of	O
amoxapine	B-Drug

Indeed	O
the	O
Ottoman	O
Empire	O
supplied	O
West	O
with	O
opium	B-Drug
long	O
before	O
China	O
and	O
India	O

Examples	O
of	O
progestins	O
each	O
these	O
subgroups	O
include	O
medroxyprogesterone	B-Drug
acetate	I-Drug
dydrogesterone	O
nomegestrol	O
and	O
drospirenone	O
respectively	O

Apalutamide	B-Drug
has	O
been	O
found	O
to	O
be	O
well	O
tolerated	O
in	O
clinical	O
trials	O
with	O
the	O
most	O
common	O
side	O
effects	O
reported	O
when	O
added	O
surgical	O
or	O
medical	O
castration	O
including	O
fatigue	O
nausea	O
abdominal	O
pain	O
and	O
diarrhea	O

A	O
2011	O
article	O
reported	O
that	O
this	O
single	O
trial	O
of	O
naltrexone	B-Drug
was	O
performed	O
not	O
by	O
comparing	O
it	O
to	O
the	O
best	O
available	O
evidence-based	O
treatment	O
methadone	B-Drug
or	O
buprenorphine	B-Drug
but	O
with	O
a	O
placebo	O

Snorting	O
cocaine	B-Drug
produces	O
maximum	O
physiological	O
effects	O
within	O
40	O
minutes	O
and	O
psychotropic	O
20	O
however	O
a	O
more	O
realistic	O
activation	O
period	O
is	O
closer	O
to	O
5	O
10	O

Boldenone	B-Drug
undecylenate	I-Drug
is	O
a	O
prodrug	O
of	O
boldenone	B-Drug

The	O
eye	O
drops	O
are	O
associated	O
with	O
decreased	O
development	O
of	O
macular	O
edema	O
after	O
cataract	O
surgery	O
and	O
is	O
more	O
effective	O
alone	O
than	O
as	O
an	O
opioid/ketorolac	O
combination	O
treatment	O
ketorolac	B-Drug

This	O
produces	O
certain	O
compounds	O
in	O
the	O
tobacco	B-Drug
leaves	O
which	O
can	O
be	O
attributed	O
to	O
sweet	O
hay	O
tea	O
rose	O
oil	O
or	O
fruity	O
aromatic	O
flavors	O

As	O
a	O
result	O
coca	B-Drug
farming	O
has	O
spread	O
throughout	O
Colombia	O
and	O
the	O
Colombian	O
government	O
even	O
reported	O
that	O
between	O
1999	O
2002	O
number	O
of	O
provinces	O
where	O
was	O
being	O
grown	O
rose	O
from	O
twelve	O
to	O
twenty-two	O

Caution	O
should	O
be	O
observed	O
when	O
combining	O
bupropion	B-Drug
with	O
a	O
monoamine	O
oxidase	O
inhibitor	O
MAOI	O
as	O
it	O
may	O
result	O
in	O
hypertensive	O
crisis	O

Beginning	O
in	O
1975	O
Pablo	O
started	O
developing	O
his	O
cocaine	B-Drug
operation	O
flying	O
out	O
planes	O
several	O
times	O
mainly	O
between	O
Colombia	O
and	O
Panama	O
along	O
smuggling	O
routes	O
into	O
the	O
United	O
States	O

In	O
line	O
with	O
its	O
dopaminergic	O
neurotoxicity	O
methamphetamine	B-Drug
use	O
is	O
associated	O
a	O
higher	O
risk	O
of	O
Parkinson's	O
disease	O

Participants	O
with	O
moderate	O
to	O
severe	O
post-surgical	O
pain	O
were	O
randomly	O
assigned	O
receive	O
oliceridine	B-Drug
placebo	O
or	O
an	O
approved	O
drug	O
treat	O
morphine	B-Drug
for	O
48	O
hours	O
through	O
the	O
vein	O

There	O
soon	O
appeared	O
reports	O
of	O
abnormalities	O
in	O
children	O
being	O
born	O
to	O
mothers	O
using	O
thalidomide	B-Drug

According	O
to	O
the	O
Community	O
Epidemiology	O
Work	O
Group	O
number	O
of	O
clandestine	O
methamphetamine	B-Drug
laboratory	O
incidents	O
reported	O
National	O
Clandestine	O
Laboratory	O
Database	O
decreased	O
from	O
1999	O
2009	O

05%	O
Moderate	O
225	O
times	O
as	O
potent	O
hydrocortisone	B-Drug
Clobetasone	O
butyrate	O
Eumovate	O
Cream	O
Triamcinolone	O
acetonide	O
Aristocort	B-Drug
Cream/Ointment	O
Viaderm	O
KC	O
Kenacomb	O
Ointment	O
Mild	O
Hydrocortisone	B-Drug
0	O

There	O
soon	O
appeared	O
reports	O
of	O
abnormalities	O
in	O
children	O
being	O
born	O
to	O
mothers	O
using	O
thalidomide	B-Drug

Fentanyl	B-Drug
use	O
has	O
also	O
been	O
associated	O
with	O
aphasia	O

It	O
is	O
not	O
clear	O
which	O
drug	O
or	O
drugs	O
caused	O
his	O
death	O
what	O
quantities	O
of	O
vecuronium	B-Drug
bromide	I-Drug
and	O
potassium	O
chloride	O
were	O
released	O
before	O
the	O
execution	O
was	O
cancelled	O

One	O
group	O
of	O
drugs	O
that	O
efavirenz	B-Drug
affects	O
is	O
protease	O
inhibitors	O
which	O
are	O
used	O
for	O
HIV/AIDS	O

Buspirone	B-Drug
a	O
serotonin	O
1A	O
receptor	O
5-HT1A	O
agonist	O
has	O
shown	O
limited	O
efficacy	O
for	O
treating	O
anxiety	O
in	O
people	O
with	O
cannabis	O
use	O
disorder	O
though	O
there	O
may	O
be	O
better	O
males	O
than	O
females	O

Diamorphine	B-Drug
may	O
be	O
used	O
as	O
a	O
maintenance	O
drug	O
to	O
assist	O
the	O
treatment	O
of	O
opiate	O
addiction	O
normally	O
in	O
long-term	O
chronic	O
intravenous	O
IV	O
heroin	B-Drug
users	O

Bicalutamide	B-Drug
was	O
patented	O
in	O
1982	O
and	O
approved	O
for	O
medical	O
use	O
1995	O

A	O
popular	O
children's	O
toy	O
Bindeez	O
also	O
known	O
as	O
Aqua	O
Dots	O
in	O
the	O
United	O
States	O
produced	O
by	O
Melbourne	O
company	O
Moose	O
was	O
banned	O
Australia	O
early	O
November	O
2007	O
when	O
it	O
discovered	O
that	O
14-butanediol	O
14-B	O
which	O
is	O
metabolized	O
into	O
GHB	B-Drug
had	O
been	O
substituted	O
for	O
non-toxic	O
plasticiser	O
15-pentanediol	O
bead	O
manufacturing	O
process	O

Lorazepam	B-Drug
is	O
one	O
such	O
pharmacological	O
agent	O
that	O
can	O
cause	O
anterograde	O
amnesia	O

The	O
salt	O
which	O
has	O
been	O
used	O
for	O
immediate-release	O
formulations	O
is	O
phenmetrazine	B-Drug
hydrochloride	O
Preludin	B-Drug

11-Methyl-19-nortestosterone	O
11-MNT	O
is	O
a	O
synthetic	O
and	O
orally	O
active	O
anabolicandrogenic	O
steroid	O
AAS	O
derivative	O
of	O
nandrolone	B-Drug
19-nortestosterone	B-Drug
which	O
was	O
developed	O
by	O
the	O
Contraceptive	O
Development	O
Branch	O
CDB	O
National	O
Institute	O
Child	O
Health	O
Human	O
NICHD	O
has	O
not	O
been	O
marketed	O
at	O
this	O
time	O

The	O
challenge	O
involves	O
giving	O
a	O
test	O
dose	O
of	O
naloxone	B-Drug
and	O
monitoring	O
for	O
opioid	O
withdrawal	O

For	O
legal	O
research	O
and	O
statistical	O
reference	O
marijuana	O
generally	O
refers	O
to	O
the	O
dried	O
leaves	O
flowering	O
tops	O
herbal	O
cannabis	O
with	O
by-products	O
such	O
as	O
hashish	B-Drug
or	O
hash	B-Drug
oil	I-Drug
being	O
uniquely	O
defined	O
regulated	O

The	O
results	O
indicated	O
that	O
nimetazepam	B-Drug
was	O
the	O
most	O
common	O
active	O
ingredient	O
in	O
vast	O
majority	O
of	O
tablets	O
seized	O

A	O
number	O
of	O
European	O
countries	O
prescribe	O
heroin	B-Drug
for	O
treatment	O
addiction	O

Because	O
of	O
the	O
drug's	O
potential	O
for	O
addiction	O
and	O
overdose	O
cocaine	B-Drug
is	O
generally	O
treated	O
as	O
a	O
hard	O
drug	O
with	O
severe	O
penalties	O
possession	O
trafficking	O

Nortriptyline	B-Drug
is	O
the	O
English	O
and	O
French	O
generic	O
name	O
of	O
drug	O
its	O
INN	O
BAN	O
DCF	O
while	O
nortriptyline	B-Drug
hydrochloride	O
USAN	O
USP	O
BANM	O
JAN	O

In	O
2019	O
the	O
cannabis	O
manufacturer	O
Canopy	O
Growth	O
acquired	O
majority	O
ownership	O
of	O
BioSteel	O
Sports	O
Nutrition	O
which	O
is	O
developing	O
CBD	B-Drug
products	O
under	O
endorsement	O
by	O
numerous	O
professional	O
athletes	O

Examples:	O
desogestrel	B-Drug
nomegestrol	O
acetate	O
norgestimate	B-Drug

Clozapine	B-Drug
is	O
an	O
antagonist	O
at	O
the	O
5-HT2A	O
subunit	O
of	O
serotonin	O
receptor	O
putatively	O
improving	O
depression	O
anxiety	O
and	O
negative	O
cognitive	O
symptoms	O
associated	O
with	O
schizophrenia	O

Although	O
the	O
Bureau	O
of	O
Narcotics	O
and	O
Dangerous	O
Drugs	O
BNDD	O
had	O
already	O
reduced	O
amphetamine	B-Drug
aggregate	O
production	O
quota	O
APQ	O
for	O
pharmaceutical	O
manufacturers	O
by	O
approximately	O
90%	O
throughout	O
prior	O
two	O
years	O
these	O
combination	O
drugs	O
rapidly	O
grown	O
in	O
popularity	O
preceding	O
decades	O

Some	O
countries	O
in	O
North	O
America	O
use	O
ibogaine	B-Drug
as	O
an	O
alternative	O
medicine	O
treatment	O
for	O
opioid	O
drug	O
addiction	O

Human	O
intravenous	O
tests	O
using	O
bufotenin	B-Drug
suggest	O
the	O
LD50	O
may	O
be	O
much	O
lower	O
in	O
humans	O
with	O
subjects	O
showing	O
signs	O
of	O
peripheral	O
toxicity	O
purple	O
face	O
tachycardia	O
difficulty	O
breathing	O
etc	O

Haloxazolam	B-Drug
marketed	O
in	O
Japan	O
under	O
the	O
brand	O
name	O
Somelin	O
is	O
a	O
drug	O
which	O
benzodiazepine	O
derivative	O

Naltrexone	B-Drug
is	O
the	O
generic	O
name	O
of	O
drug	O
and	O
its	O
INN	O
USAN	O
BAN	O
DCF	O
DCIT	O
while	O
naltrexone	B-Drug
hydrochloride	I-Drug
USP	O
BANM	O

Trimeperidine	B-Drug
is	O
in	O
Schedule	O
I	O
of	O
the	O
Controlled	O
Substances	O
Act	O
1970	O
United	O
States	O
as	O
a	O
Narcotic	O
with	O
ACSCN	O
9646	O
an	O
annual	O
aggregate	O
manufacturing	O
quota	O
2	O
grammes	O
2014	O

When	O
first	O
released	O
thalidomide	B-Drug
was	O
promoted	O
for	O
anxiety	O
trouble	O
sleeping	O
tension	O
and	O
morning	O
sickness	O

In	O
surveys	O
the	O
number	O
of	O
high	O
school	O
students	O
admitting	O
to	O
trying	O
PCP	B-Drug
at	O
least	O
once	O
fell	O
from	O
13%	O
in	O
1979	O
less	O
than	O
3%	O
1990	O

The	O
Fair	O
Sentencing	O
Act	O
of	O
2010	O
amended	O
the	O
Controlled	O
Substances	O
and	O
Import	O
Export	O
by	O
increasing	O
amount	O
a	O
controlled	O
substance	O
or	O
mixture	O
containing	O
cocaine	B-Drug
base	O
i	O

50	O
mg/day	O
of	O
hydrochlorothiazide	B-Drug
were	O
evaluated	O
in	O
geriatric	O
patients	O
n	O
=	O
51	O
with	O
isolated	O
systolic	O
hypertension	O

It	O
was	O
also	O
found	O
in	O
combination	O
with	O
4-MePPP	B-Drug
being	O
sold	O
as	O
NRG-3	O

In	O
2015	O
Afghanistan	O
produced	O
about	O
66%	O
of	O
the	O
world's	O
opium	B-Drug

The	O
illegal	O
sale	O
of	O
opium	B-Drug
became	O
one	O
the	O
world's	O
most	O
valuable	O
single	O
commodity	O
trades	O
and	O
has	O
been	O
called	O
long	O
continued	O
systematic	O
international	O
crime	O
modern	O
times	O

Methamphetamine	B-Drug
cooks	O
their	O
families	O
and	O
first	O
responders	O
are	O
at	O
high	O
risk	O
of	O
experiencing	O
acute	O
health	O
effects	O
from	O
chemical	O
exposure	O
including	O
lung	O
damage	O
burns	O
to	O
the	O
body	O

JWH-018	B-Drug
may	O
cause	O
intense	O
anxiety	O
agitation	O
and	O
in	O
rare	O
cases	O
generally	O
with	O
non-regular	O
JWH	O
users	O
has	O
been	O
assumed	O
to	O
have	O
the	O
of	O
seizures	O
convulsions	O
by	O
inhibiting	O
GABA	O
neurotransmission	O
more	O
effectively	O
than	O
THC	O

A	O
recent	O
study	O
using	O
X-ray	O
crystallography	O
showed	O
that	O
CBD	B-Drug
binds	O
inside	O
the	O
sodium	O
channel	O
pore	O
at	O
a	O
novel	O
site	O
interface	O
of	O
fenestrations	O
and	O
central	O
hydrophobic	O
cavity	O

During	O
this	O
time	O
of	O
popularity	O
users	O
called	O
opium	B-Drug
God's	O
Own	O
Medicine	O

Flurazepam	B-Drug
is	O
a	O
drug	O
with	O
potential	O
for	O
misuse	O

Strains	O
used	O
in	O
medicine	O
are	O
often	O
bred	O
for	O
high	O
CBD	B-Drug
content	O
and	O
strains	O
recreational	O
purposes	O
usually	O
THC	O
or	O
a	O
specific	O
chemical	O
balance	O

The	O
elimination	O
half-life	O
of	O
nalbuphine	B-Drug
is	O
approximately	O
5	O
hours	O
on	O
average	O
and	O
in	O
clinical	O
studies	O
the	O
duration	O
analgesic	O
activity	O
has	O
been	O
reported	O
to	O
range	O
from	O
3	O
6	O

The	O
oral	O
LD50	O
lethal	O
dose	O
in	O
50%	O
of	O
the	O
population	O
diazepam	B-Drug
is	O
720	O
mg/kg	O
mice	O
and	O
1240	O
rats	O

It	O
was	O
reported	O
that	O
benzodiazepines	O
may	O
be	O
the	O
third-	O
or	O
fourth-largest	O
drug	O
problem	O
in	O
UK	O
largest	O
being	O
alcohol	O
and	O
tobacco	B-Drug

Darvon	B-Drug
was	O
never	O
withdrawn	O
from	O
the	O
market	O
until	O
recently	O
but	O
Lilly	O
has	O
waged	O
a	O
sweeping	O
and	O
largely	O
successful	O
campaign	O
among	O
doctors	O
pharmacists	O
users	O
to	O
defend	O
drug	O
as	O
safe	O
when	O
it	O
is	O
used	O
in	O
proper	O
doses	O
not	O
mixed	O
with	O
alcohol	O

Mahmoud	O
El	O
Sohly	O
of	O
Laboratories	O
test	O
results	O
indicated	O
that	O
flunitrazepam	B-Drug
was	O
only	O
used	O
in	O
around	O
1%	O
reported	O
date	O
rapes	O
according	O
to	O
Robertson	O
and	O
0	O

As	O
such	O
it	O
was	O
characterized	O
as	O
a	O
highly	O
potent	O
antimineralocorticoid	O
with	O
far	O
fewer	O
hormonal	O
side	O
effects	O
relative	O
to	O
spironolactone	B-Drug

Cocaine	B-Drug
also	O
constricts	O
the	O
blood	O
vessels	O
in	O
fetus	O
which	O
is	O
potentially	O
linked	O
to	O
slowed	O
fetal	O
growth	O
and	O
abnormal	O
development	O
of	O
genitourinary	O
cardiovascular	O
digestive	O
musculoskeletal	O
systems	O

Oxandrolone	B-Drug
was	O
first	O
described	O
in	O
1962	O
and	O
introduced	O
for	O
medical	O
use	O
1964	O

Like	O
many	O
other	O
drugs	O
PCP	B-Drug
has	O
been	O
known	O
to	O
alter	O
mood	O
states	O
in	O
an	O
unpredictable	O
fashion	O
causing	O
some	O
individuals	O
become	O
detached	O
and	O
others	O
animated	O

Celecoxib	B-Drug
was	O
discovered	O
and	O
developed	O
by	O
G	O

Oxycodone	B-Drug
sold	O
under	O
the	O
brand	O
name	O
OxyContin	B-Drug
which	O
is	O
extended	O
release	O
form	O
among	O
others	O
an	O
opioid	O
medication	O
used	O
for	O
treatment	O
of	O
moderate	O
to	O
severe	O
pain	O
and	O
a	O
common	O
drug	O
abuse	O

The	O
cocaine	B-Drug
typically	O
is	O
poured	O
onto	O
a	O
flat	O
hard	O
surface	O
such	O
as	O
mirror	O
CD	O
case	O
or	O
book	O
and	O
divided	O
into	O
bumps	O
lines	O
rails	O
then	O
insufflated	O

Serious	O
side	O
effects	O
of	O
oxycodone	B-Drug
include	O
reduced	O
sensitivity	O
to	O
pain	O
beyond	O
the	O
drug	O
is	O
taken	O
reduce	O
euphoria	O
anxiolysis	O
feelings	O
relaxation	O
and	O
respiratory	O
depression	O

For	O
example	O
Bupropion	B-Drug
Wellbutrin	B-Drug
is	O
known	O
as	O
an	O
antidepressant	O
that	O
can	O
counteract	O
other	O
co-prescribed	O
antidepressants	O
having	O
libido-diminishing	O
effects	O

On	O
September	O
11	O
1941	O
Bockmhl	O
and	O
Ehrhart	O
filed	O
an	O
application	O
for	O
a	O
patent	O
synthetic	O
substance	O
they	O
called	O
Hoechst	O
10820	O
or	O
Polamidon	O
name	O
still	O
in	O
regular	O
use	O
Germany	O
whose	O
structure	O
had	O
only	O
slight	O
relation	O
to	O
morphine	B-Drug
the	O
opiate	O
alkaloids	O

The	O
drug	O
is	O
highly	O
lipophilic	O
allowing	O
it	O
to	O
rapidly	O
penetrate	O
the	O
brain	O
and	O
achieve	O
a	O
far	O
greater	O
serum	O
ratio	O
than	O
that	O
of	O
morphine	B-Drug

According	O
to	O
Cocaine's	O
official	O
website	O
the	O
drink	O
is	O
now	O
being	O
sold	O
in	O
three	O
varieties:	O
one	O
Original	O
Cut	O
which	O
lacks	O
purported	O
throat-burning	O
sensation	O
of	O
and	O
Free	O
contains	O
no	O
sugar	O
Cocaine	B-Drug

High	O
quality	O
hashish	B-Drug
in	O
India	O
comes	O
from	O
cannabis	O
grown	O
the	O
mountains	O

As	O
a	O
-receptor	O
agonist	O
fentanyl	B-Drug
binds	O
50	O
to	O
100	O
times	O
more	O
potently	O
than	O
morphine	B-Drug

In	O
2016	O
fentanyl	B-Drug
and	O
analogues	O
were	O
the	O
most	O
common	O
cause	O
of	O
overdose	O
deaths	O
in	O
United	O
States	O
at	O
more	O
than	O
20000	O
about	O
half	O
all	O
opioid-related	O

Therefore	O
when	O
co-administered	O
with	O
carbamazepine	B-Drug
or	O
other	O
potent	O
CYP3A4	O
inducers	O
via	O
IV	O
it	O
is	O
necessary	O
to	O
increase	O
the	O
dose	O
of	O
clomethiazole	O

A	O
24-hour	O
kinetic	O
examination	O
in	O
dogs	O
showed	O
that	O
the	O
absorption	O
of	O
cannabidiolic	O
acid	O
CBDA	O
does	O
occur	O
and	O
this	O
molecule	O
is	O
absorbed	O
least	O
twice	O
as	O
well	O
CBD	B-Drug
post	O
oral	O
ingestion	O

UR-144	B-Drug
was	O
detected	O
in	O
Korea	O
2012	O

The	O
TEXT	O
and	O
SOFT	O
trials	O
demonstrated	O
improved	O
disease	O
free	O
survival	O
in	O
patients	O
treated	O
with	O
exemestane	B-Drug
ovarian	O
suppression	O
compared	O
to	O
the	O
tamoxifen	B-Drug
group	O

In	O
1909	O
Ernest	O
Shackleton	O
took	O
Forced	O
March	O
brand	O
cocaine	B-Drug
tablets	O
to	O
Antarctica	O
as	O
did	O
Captain	O
Scott	O
a	O
year	O
later	O
on	O
his	O
ill-fated	O
journey	O
the	O
South	O
Pole	O

Listed	O
as	O
a	O
Schedule	O
1	O
it	O
is	O
an	O
analogue	O
of	O
amphetamine	B-Drug

Lorazepam	B-Drug
is	O
present	O
in	O
breast	O
milk	O
so	O
caution	O
must	O
be	O
exercised	O
about	O
breastfeeding	O

Other	O
benzodiazepines	O
and	O
nonbenzodiazepines	O
anxiolytic	O
or	O
hypnotic	O
such	O
as	O
zolpidem	B-Drug
zopiclone	B-Drug
well	O
cyclopyrrolones	O
imidazopyridines	O
pyrazolopyrimidines	O
are	O
also	O
found	O
in	O
high	O
numbers	O
of	O
suspected	O
drugged	O
drivers	O

Both	O
morphine	B-Drug
and	O
6-MAM	O
are	O
-opioid	O
agonists	O
that	O
bind	O
to	O
receptors	O
present	O
throughout	O
the	O
brain	O
spinal	O
cord	O
gut	O
of	O
all	O
mammals	O

Pregabalin	B-Drug
undergoes	O
little	O
or	O
no	O
metabolism	O

As	O
of	O
2018	O
Thailand	O
will	O
produce	O
efavirenz	B-Drug
domestically	O

Ephedrine	B-Drug
may	O
decrease	O
motion	O
sickness	O
but	O
it	O
has	O
mainly	O
been	O
used	O
to	O
the	O
sedating	O
effects	O
of	O
other	O
medications	O
for	O

Authorities	O
learned	O
months	O
later	O
that	O
the	O
drug	O
wasn't	O
LSD	B-Drug
but	O
a	O
designer	O
identified	O
as	O
5-MeO-AMT	O

Both	O
acetaminophen	B-Drug
and	O
paracetamol	B-Drug
come	O
from	O
a	O
chemical	O
name	O
for	O
the	O
compound:	O
para-acetylaminophenol	O

In	O
video	O
games	O
for	O
example	O
drugs	O
are	O
portrayed	O
in	O
a	O
variety	O
of	O
ways:	O
including	O
power-ups	O
cocaine	B-Drug
gum	O
replenishes	O
stamina	O
Red	O
Dead	O
Redemption	O
2	O
obstacles	O
to	O
be	O
avoided	O
such	O
as	O
the	O
Fuzzies	O
Super	O
Mario	O
World	O
2:	O
Yoshi's	O
Island	O
that	O
distort	O
player's	O
view	O
when	O
accidentally	O
consumed	O
items	O
bought	O
and	O
sold	O
in-game	O
currency	O
coke	O
dealing	O
is	O
big	O
part	O
Scarface:	O
The	O
Is	O
Yours	O

Aspirin	B-Drug
other	O
NSAIDs	O
and	O
paracetamol	B-Drug
acetaminophen	B-Drug
had	O
no	O
effect	O
on	O
the	O
risk	O
for	O
Parkinson's	O

All	O
drugs	O
in	O
the	O
NBOMe	O
series	O
including	O
25I-NBOMe	B-Drug
became	O
illegal	O
Russia	O
October	O
2011	O

Analogues	O
of	O
GHB	B-Drug
such	O
as	O
3-methyl-GHB	O
4-methyl-GHB	O
and	O
4-phenyl-GHB	O
have	O
been	O
shown	O
to	O
produce	O
similar	O
effects	O
in	O
some	O
animal	O
studies	O
but	O
these	O
compounds	O
are	O
even	O
less	O
well	O
researched	O
than	O
itself	O

The	O
Texas	O
Group	O
advertised	O
Ecstasy	B-Drug
parties	O
at	O
bars	O
and	O
discos	O
describing	O
MDMA	B-Drug
as	O
a	O
fun	O
drug	O
good	O
to	O
dance	O

The	O
conversion	O
is	O
rate-limited	O
by	O
the	O
enzyme	O
which	O
prevents	O
high	O
blood	O
concentrations	O
of	O
dextroamphetamine	B-Drug
and	O
reduces	O
lisdexamfetamine's	O
drug	O
liking	O
abuse	O
potential	O
at	O
clinical	O
doses	O
lisdexamfetamine	B-Drug

It	O
is	O
being	O
investigated	O
as	O
a	O
potential	O
treatment	O
for	O
nicotine	B-Drug
addiction	O
to	O
assist	O
smoking	O
cessation	O

Depressive	O
non-smokers	O
experience	O
mood	O
improvements	O
under	O
nicotine	B-Drug
administration;	O
however	O
subsequent	O
withdrawal	O
has	O
a	O
negative	O
effect	O
on	O
both	O
and	O
sleep	O

Nicotine	B-Drug
addiction	O
seems	O
to	O
worsen	O
mental	O
health	O
problems	O

Powdered	O
cocaine	B-Drug
is	O
also	O
sometimes	O
smoked	O
though	O
heat	O
destroys	O
much	O
of	O
the	O
chemical;	O
smokers	O
often	O
sprinkle	O
it	O
on	O
cannabis	O

These	O
retailers	O
along	O
with	O
CVS	O
removed	O
Zantac	B-Drug
and	O
some	O
generics	O
from	O
their	O
shelves	O

Impressed	O
Ace	O
goes	O
back	O
to	O
Lulu	O
for	O
more	O
cocaine	B-Drug
sell	O

2	O
Congress	O
has	O
the	O
power	O
to	O
reclassify	O
cocaine	B-Drug

A	O
2014	O
review	O
of	O
the	O
probability	O
added	O
benefit	O
perampanel	B-Drug
to	O
standard	O
care	O
was	O
unable	O
come	O
any	O
conclusions	O
as	O
no	O
trial	O
conducted	O
by	O
Eisai	O
compared	O
a	O
drug	O
within	O
but	O
only	O
placebo	O

In	O
the	O
1960s	O
thalidomide	B-Drug
was	O
successfully	O
marketed	O
as	O
a	O
safer	O
alternative	O
to	O
barbiturates	O

The	O
use	O
of	O
mianserin	B-Drug
to	O
help	O
people	O
with	O
schizophrenia	O
who	O
are	O
being	O
treated	O
antipsychotics	O
has	O
been	O
studied	O
in	O
clinical	O
trials;	O
the	O
outcome	O
is	O
unclear	O

In	O
Russia	O
methadone	B-Drug
treatment	O
is	O
illegal	O

Morphine	B-Drug
and	O
heroin	B-Drug
were	O
also	O
much	O
more	O
likely	O
to	O
produce	O
euphoria	O
other	O
positive	O
subjective	O
effects	O
when	O
compared	O
these	O
opioids	O

PMA	B-Drug
is	O
part	O
of	O
the	O
Appendix	O
1	O
Betubungsmittelgesetz	O

A	O
formulation	O
of	O
amphetamine	B-Drug
mixed	I-Drug
salts	I-Drug
that	O
included	O
methamphetamine	B-Drug
was	O
approved	O
by	O
the	O
U	O

Desogestrel	B-Drug
also	O
has	O
antigonadotropic	O
effects	O
which	O
are	O
similarly	O
due	O
to	O
its	O
progestogenic	O
activity	O

In	O
adrenal	O
insufficiency	O
and	O
Addison's	O
disease	O
dexamethasone	B-Drug
is	O
prescribed	O
when	O
the	O
patient	O
does	O
not	O
respond	O
well	O
to	O
prednisone	B-Drug
or	O
methylprednisolone	B-Drug

The	O
mean	O
elimination	O
half-lives	O
of	O
its	O
enantiomers	O
have	O
been	O
found	O
to	O
be	O
19	O
hours	O
for	O
dexfenfluramine	B-Drug
and	O
25	O
levfenfluramine	O

The	O
rave-influenced	O
scene	O
is	O
widely	O
seen	O
as	O
heavily	O
influenced	O
by	O
drugs	O
especially	O
ecstasy	B-Drug
MDMA	B-Drug
and	O
it	O
Erchard	O
central	O
to	O
a	O
wider	O
phenomenon	O
of	O
what	O
he	O
calls	O
rock	O
rave	O
crossover	O
in	O
the	O
late	O
80s	O
early	O
90s	O
UK	O
indie	O
which	O
also	O
included	O
Screamadelica	O
album	O
Scottish	O
band	O
Primal	O
Scream	O

Psychedelic	O
in	O
contrast	O
is	O
a	O
Greek	O
neologism	O
for	O
mind	O
manifest	O
and	O
was	O
coined	O
by	O
psychiatrist	O
Humphry	O
Osmond;	O
Huxley	O
volunteer	O
experiments	O
Osmond	O
conducting	O
on	O
mescaline	B-Drug

35%	O
to	O
the	O
highly	O
potent	O
estrogen	O
EE	O
and	O
for	O
this	O
reason	O
unlike	O
most	O
other	O
progestins	O
norethisterone	B-Drug
has	O
some	O
estrogenic	O
activity	O

Ciclosporin	B-Drug
is	O
the	O
INN	O
and	O
British	O
Approved	O
Name	O
BAN	O
while	O
cyclosporine	B-Drug
United	O
States	O
Adopted	O
USAN	O
cyclosporin	B-Drug
a	O
former	O

The	O
chemical	O
structure	O
of	O
cyclosporin	B-Drug
was	O
determined	O
in	O
1976	O
also	O
at	O
Sandoz	O

Pharmaceutical	O
drugs	O
that	O
are	O
substituted	O
phenethylamines	O
include	O
phenelzine	B-Drug
phenformin	O
and	O
fanetizole	O
among	O
many	O
others	O

This	O
highly	O
impure	O
brown	O
heroin	B-Drug
base	O
may	O
then	O
undergo	O
further	O
purification	O
steps	O
which	O
produces	O
a	O
white-colored	O
product;	O
the	O
final	O
products	O
have	O
different	O
appearance	O
depending	O
on	O
purity	O
and	O
names	O

Difenoxin	B-Drug
is	O
a	O
Schedule	O
I	O
drug	O
by	O
itself	O
in	O
the	O
US;	O
combination	O
with	O
atropine	O
less-restrictive	O
category	O
IV	O
on	O
account	O
of	O
adulterant	O
practice	O
making	O
opioids	O
more	O
easily	O
available	O
including	O
an	O
abuse-deterring	O
adulterating	O
agent	O
standard	O
United	O
States	O

Other	O
NMDA	O
receptor	O
antagonists	O
include	O
ketamine	B-Drug
tiletamine	B-Drug
dextromethorphan	B-Drug
nitrous	O
oxide	O
and	O
dizocilpine	O
MK-801	O

The	O
street	O
name	O
in	O
Russia	O
for	O
homemade	O
desomorphine	B-Drug
is	O
krokodil	O
Russian:	O
crocodile	O
possibly	O
related	O
to	O
the	O
chemical	O
of	O
precursor	O
-chlorocodide	O
or	O
resemblance	O
skin	O
damage	O
caused	O
by	O
drug	O
a	O
crocodile's	O
leather	O

Diphenhydramine	B-Drug
is	O
a	O
potent	O
anticholinergic	O
agent	O

DMT	O
is	O
also	O
found	O
as	O
a	O
minor	O
alkaloid	O
in	O
bark	O
pods	O
and	O
beans	O
of	O
Anadenanthera	O
peregrina	O
colubrina	O
used	O
to	O
make	O
Yopo	O
Vilca	O
snuff	B-Drug
which	O
bufotenin	B-Drug
the	O
main	O
active	O

A	O
2016	O
meta-analysis	O
found	O
that	O
bupropion	B-Drug
therapy	O
for	O
depression	O
is	O
superior	O
to	O
placebo	O

UR-144	B-Drug
TMCP-018	O
KM-X1	O
MN-001	O
YX-17	O
is	O
a	O
drug	O
invented	O
by	O
Abbott	O
Laboratories	O
that	O
acts	O
as	O
selective	O
full	O
agonist	O
of	O
the	O
peripheral	O
cannabinoid	O
receptor	O
CB2	O
but	O
with	O
much	O
lower	O
affinity	O
for	O
psychoactive	O
CB1	O

This	O
effectively	O
destroys	O
some	O
of	O
the	O
cocaine	B-Drug
and	O
yields	O
a	O
sharp	O
acrid	O
foul-tasting	O
smoke	O

It	O
is	O
used	O
under	O
the	O
brand	O
name	O
Klimonorm	O
as	O
a	O
combined	O
oral	O
tablet	O
with	O
estradiol	O
valerate	O
and	O
Climara	B-Drug
Pro	O
transdermal	O
patch	O

RCS-4	B-Drug
was	O
banned	O
in	O
Sweden	O
on	O
1	O
October	O
2010	O
as	O
a	O
hazardous	O
good	O
harmful	O
to	O
health	O
after	O
being	O
identified	O
an	O
ingredient	O
herbal	O
synthetic	O
cannabis	O
products	O

As	O
of	O
October	O
2015	O
25I-NBOMe	B-Drug
is	O
a	O
controlled	O
substance	O
in	O
China	O

It	O
may	O
be	O
used	O
to	O
reduce	O
the	O
risk	O
of	O
premature	O
ovarian	O
failure	O
in	O
women	O
receiving	O
cyclophosphamide	B-Drug
for	O
chemotherapy	O

DET	B-Drug
is	O
sometimes	O
preferred	O
over	O
DMT	O
because	O
it	O
can	O
be	O
taken	O
orally	O
whereas	O
cannot	O

Clomifene	B-Drug
appears	O
to	O
act	O
mostly	O
in	O
the	O
hypothalamus	O
where	O
it	O
depletes	O
hypothalamic	O
ERs	O
and	O
blocks	O
negative	O
feedback	O
effect	O
of	O
circulating	O
endogenous	O
estradiol	O
which	O
turn	O
results	O
an	O
increase	O
gonadotropin-releasing	O
hormone	O
GnRH	O
pulse	O
frequency	O
concentrations	O
follicle-stimulating	O
FSH	O
luteinizing	O
LH	O

In	O
the	O
United	O
States	O
GHB	B-Drug
was	O
placed	O
on	O
Schedule	O
I	O
of	O
Controlled	O
Substances	O
Act	O
in	O
March	O
2000	O

This	O
relationship	O
is	O
alternatively	O
expressed	O
by	O
the	O
retinol	B-Drug
equivalent	O
RE:	O
one	O
RE	O
corresponded	O
to	O
1	O
g	O
2	O
-carotene	O
dissolved	O
in	O
oil	O
it	O
only	O
partly	O
most	O
supplement	O
pills	O
due	O
very	O
poor	O
solubility	O
any	O
medium	O
6	O
normal	O
food	O
because	O
not	O
absorbed	O
as	O
well	O
when	O
oils	O
and	O
12	O
of	O
either	O
or	O
-cryptoxanthin	O

There	O
are	O
known	O
cases	O
of	O
doping	O
in	O
sports	O
with	O
metenolone	B-Drug
esters	O
by	O
professional	O
athletes	O

While	O
acute/initial	O
nicotine	B-Drug
intake	O
causes	O
activation	O
of	O
neuronal	O
receptors	O
chronic	O
low	O
doses	O
use	O
leads	O
to	O
desensitization	O
those	O
due	O
the	O
development	O
tolerance	O
and	O
results	O
in	O
an	O
antidepressant	O
effect	O
with	O
early	O
research	O
showing	O
dose	O
patches	O
could	O
be	O
effective	O
treatment	O
major	O
depressive	O
disorder	O
non-smokers	O

Cocaine	B-Drug
is	O
known	O
to	O
have	O
a	O
number	O
of	O
deleterious	O
effects	O
during	O
pregnancy	O

Members	O
of	O
the	O
cartel	O
smuggle	O
cocaine	B-Drug
to	O
distribution	O
cells	O
in	O
Arizona	O
California	O
Illinois	O
and	O
New	O
York	O

Another	O
member	O
of	O
the	O
Medelln	O
Cartel	O
Carlos	O
Lehder	O
used	O
his	O
cocaine	B-Drug
wealth	O
to	O
make	O
a	O
push	O
for	O
political	O
power	O

Boldenone	B-Drug
undecylenate	I-Drug
is	O
an	O
androgen	O
ester	O
and	O
a	O
long-lasting	O
prodrug	O
of	O
boldenone	B-Drug
in	O
the	O
body	O

In	O
their	O
book	O
TiHKAL	O
Alexander	O
and	O
Ann	O
Shulgin	O
describe	O
it	O
as	O
being	O
an	O
order	O
of	O
magnitude	O
less	O
potent	O
than	O
LSD	B-Drug
itself	O

On	O
December	O
15	O
2008	O
it	O
was	O
reported	O
by	O
German	O
pharmaceutical	O
companies	O
that	O
JWH-018	B-Drug
found	O
as	O
one	O
of	O
the	O
active	O
components	O
in	O
at	O
least	O
three	O
versions	O
grey	O
market	O
drug	O
Spice	O
which	O
has	O
been	O
sold	O
an	O
incense	O
a	O
number	O
countries	O
around	O
world	O
since	O
2002	O

Chewing	O
releases	O
juices	O
from	O
the	O
leaves	O
which	O
include	O
alkaloid	O
cathinone	B-Drug

Unlike	O
other	O
comparable	O
Western	O
developed	O
countries	O
sofosbuvir	B-Drug
is	O
far	O
more	O
affordable	O
in	O
Japan	O
and	O
South	O
Korea	O
at	O
approximately	O
$300	O
$5900	O
respectively	O
for	O
a	O
12-week	O
treatment	O
with	O
each	O
government	O
covering	O
99%	O
70%	O
of	O
the	O
cost	O

Bayer	O
lost	O
some	O
of	O
its	O
trademark	O
rights	O
to	O
heroin	B-Drug
as	O
well	O
aspirin	B-Drug
under	O
the	O
1919	O
Treaty	O
Versailles	O
following	O
German	O
defeat	O
in	O
World	O
War	O
I	O

Trenbolone	B-Drug
acetate	I-Drug
has	O
androgenic	O
activity	O

This	O
drug	O
mixture	O
has	O
slightly	O
stronger	O
CNS	O
effects	O
than	O
racemic	O
amphetamine	B-Drug
due	O
to	O
the	O
higher	O
proportion	O
of	O
dextroamphetamine	B-Drug

Other	O
studies	O
have	O
indicated	O
the	O
risk	O
of	O
a	O
scleroderma-like	O
condition	O
resulting	O
from	O
combination	O
5-HTP	O
and	O
carbidopa	B-Drug

Some	O
studies	O
found	O
that	O
like	O
other	O
NMDA	O
receptor	O
antagonists	O
PCP	B-Drug
can	O
cause	O
a	O
kind	O
of	O
brain	O
damage	O
called	O
Olney's	O
lesions	O
in	O
rats	O

Like	O
other	O
benzodiazepines	O
diazepam	B-Drug
can	O
impair	O
short-term	O
memory	O
and	O
learning	O
of	O
new	O
information	O

Convulsive	O
seizures	O
sometimes	O
observed	O
in	O
patients	O
receiving	O
parenteral	O
pethidine	B-Drug
on	O
a	O
chronic	O
basis	O
have	O
been	O
attributed	O
to	O
accumulation	O
plasma	O
of	O
the	O
metabolite	O
norpethidine	B-Drug
normeperidine	O

N-Desalkylflurazepam	O
also	O
known	O
as	O
norflurazepam	O
is	O
a	O
benzodiazepine	O
analog	O
and	O
an	O
active	O
metabolite	O
of	O
several	O
other	O
drugs	O
including	O
flurazepam	B-Drug
flutoprazepam	B-Drug
fludiazepam	B-Drug
midazolam	B-Drug
flutazolam	B-Drug
quazepam	B-Drug
ethyl	B-Drug
loflazepate	I-Drug

Typical	O
antipsychotics	O
such	O
as	O
phenothiazines	O
and	O
haloperidol	B-Drug
have	O
been	O
used	O
to	O
control	O
psychotic	O
symptoms	O
but	O
may	O
produce	O
many	O
undesirable	O
side	O
effects	O
dystonia	O
their	O
use	O
is	O
therefore	O
no	O
longer	O
preferred;	O
are	O
particularly	O
risky	O
they	O
lower	O
the	O
seizure	O
threshold	O
worsen	O
hyperthermia	O
boost	O
anticholinergic	O
of	O
PCP	B-Drug

In	O
this	O
paper	O
he	O
declared	O
coca	B-Drug
and	O
cocaine	B-Drug
at	O
the	O
time	O
they	O
were	O
assumed	O
to	O
be	O
same	O
as	O
being	O
useful	O
medicinally	O
in	O
treatment	O
of	O
a	O
furred	O
tongue	O
morning	O
flatulence	O
whitening	O
teeth	O

Cases	O
of	O
etizolam	B-Drug
dependence	O
have	O
been	O
documented	O
in	O
the	O
medical	O
literature	O

Similarly	O
pregabalin	B-Drug
has	O
been	O
given	O
2	O
to	O
3	O
times	O
per	O
day	O
in	O
clinical	O
studies	O

Although	O
Mexico	O
accounts	O
for	O
only	O
a	O
small	O
share	O
of	O
worldwide	O
heroin	B-Drug
production	O
it	O
supplies	O
large	O
the	O
distributed	O
in	O
United	O
States	O

There	O
is	O
no	O
data	O
on	O
the	O
use	O
of	O
amiloride	B-Drug
in	O
women	O
that	O
are	O
breastfeeding	O

Oxycodone	B-Drug
has	O
a	O
volume	O
of	O
distribution	O
2	O

In	O
1980	O
they	O
launched	O
Feldene	O
piroxicam	B-Drug
a	O
prescription	O
anti-inflammatory	O
medication	O
that	O
became	O
Pfizer's	O
first	O
product	O
to	O
reach	O
one	O
billion	O
dollars	O
in	O
total	O
sales	O

It	O
is	O
formed	O
either	O
through	O
the	O
addition	O
of	O
acetic	O
anhydride	O
which	O
can	O
only	O
acetylate	O
6	O
position	O
on	O
codeine	B-Drug
or	O
as	O
a	O
result	O
acid	O
with	O
catalyst	O
in	O
an	O
attempt	O
to	O
create	O
6-monoacetylmorphine	O
equivalent	O
ester	O
morphine	B-Drug
slightly	O
more	O
potent	O
than	O
heroin	B-Drug
itself	O

In	O
1979	O
the	O
Thai	O
government	O
placed	O
kratom	B-Drug
along	O
with	O
marijuana	O
in	O
Category	O
V	O
of	O
a	O
five	O
category	O
classification	O
narcotics	O

MDMA	B-Drug
Ecstasy	B-Drug
has	O
been	O
used	O
for	O
cognitive	O
enhancement	O
in	O
people	O
with	O
Parkinson's	O
disease	O
and	O
shown	O
potential	O
treating	O
posttraumatic	O
stress	O
disorder	O

Cimetidine	B-Drug
approved	O
by	O
the	O
FDA	O
for	O
inhibition	O
of	O
gastric	O
acid	O
secretion	O
has	O
been	O
advocated	O
a	O
number	O
dermatological	O
diseases	B-Drug

Sofosbuvir	B-Drug
also	O
is	O
an	O
excellent	O
example	O
of	O
both	O
the	O
benefit	O
and	O
challenge	O
specialty	O
medications	O

Armodafinil	B-Drug
exhibits	O
linear	O
time-independent	O
kinetics	O
following	O
single	O
and	O
multiple	O
oral	O
dose	O
administration	O

A	O
common	O
laxative	O
regimen	O
for	O
OIC	O
is	O
the	O
combination	O
of	O
docusate	B-Drug
and	O
bisacodyl	O

100-grams	O
of	O
milk	O
chocolate	O
is	O
an	O
excellent	O
source	O
over	O
19%	O
the	O
Daily	O
Value	O
DV	O
riboflavin	O
vitamin	B-Drug
B12	I-Drug
and	O
dietary	O
minerals	O
manganese	O
phosphorus	O
zinc	O

Amobarbital	B-Drug
undergoes	O
both	O
hydroxylation	O
to	O
form	O
3'-hydroxyamobarbital	O
and	O
N-glucosidation	O
1-beta-D-glucopyranosylamobarbital	O

This	O
is	O
similar	O
to	O
how	O
isolated	O
THC	O
produces	O
very	O
different	O
effects	O
than	O
an	O
extract	O
that	O
retains	O
the	O
many	O
cannabinoids	O
of	O
plant	O
such	O
as	O
cannabidiol	B-Drug
and	O
cannabinol	O

Lysergic	O
acid	B-Drug
24-dimethylazetidide	O
LA-SS-Az	O
LSZ	O
is	O
an	O
analog	O
of	O
LSD	B-Drug
developed	O
by	O
the	O
team	O
led	O
David	O
E	O

Nicotine	B-Drug
can	O
modulate	O
the	O
firing	O
rate	O
of	O
ventral	O
tegmental	O
area	O
neurons	O

He	O
began	O
working	O
on	O
LSD	B-Drug
in	O
the	O
1950s	O

At	O
first	O
he	O
smuggled	O
the	O
cocaine	B-Drug
in	O
old	O
plane	O
tires	O
and	O
a	O
pilot	O
could	O
return	O
as	O
much	O
US$500000	O
per	O
flight	O
dependent	O
on	O
quantity	O

Barbital	B-Drug
or	O
barbitone	B-Drug
marketed	O
under	O
the	O
brand	O
names	O
Veronal	B-Drug
for	O
pure	O
acid	O
and	O
Medinal	O
sodium	O
salt	O
was	O
first	O
commercially	O
available	O
barbiturate	B-Drug

After	O
menopause	O
androstenedione	B-Drug
production	O
is	O
about	O
halved	O
due	O
primarily	O
to	O
the	O
reduction	O
of	O
steroid	O
secreted	O
by	O
ovary	O

Some	O
heroin	B-Drug
users	O
may	O
take	O
them	O
either	O
to	O
supplement	O
their	O
drug	O
or	O
substitute	O
for	O
it	O

English	O
is	O
an	O
opiate	O
derivative	O
the	O
36-dipropanoyl	O
ester	O
of	O
morphine	B-Drug

Effective	O
18	O
August	O
2014	O
tramadol	B-Drug
has	O
been	O
placed	O
into	O
Schedule	O
IV	O
of	O
the	O
federal	O
Controlled	O
Substances	O
Act	O
in	O
United	O
States	O

Grnenthal	O
provided	O
thalidomide	B-Drug
to	O
more	O
than	O
1000	O
patients	O
with	O
leprosy	O
in	O
the	O
United	O
States	O
until	O
a	O
few	O
months	O
before	O
July	O
1986	O

The	O
story	O
was	O
later	O
shown	O
to	O
be	O
an	O
online	O
joke	O
posted	O
on	O
mephedrone	B-Drug

Early	O
MDMA	B-Drug
distributors	O
were	O
deterred	O
from	O
large	O
scale	O
operations	O
by	O
the	O
threat	O
of	O
possible	O
legislation	O

Testing	O
or	O
use	O
of	O
DMPA	B-Drug
was	O
focused	O
almost	O
exclusively	O
on	O
women	O
in	O
developing	O
countries	O
and	O
poor	O
the	O
United	O
States	O
raising	O
serious	O
questions	O
about	O
coercion	O
lack	O
informed	O
consent	O
particularly	O
for	O
illiterate	O
mentally	O
challenged	O
who	O
some	O
reported	O
cases	O
were	O
given	O
long-term	O
reasons	O
menstrual	O
hygiene	O
although	O
they	O
not	O
sexually	O
active	O

divinorum	O
indicate	O
that	O
salvia	O
disrupts	O
certain	O
facets	O
of	O
consciousness	O
much	O
more	O
than	O
the	O
largely	O
serotonergic	O
hallucinogen	O
[LSD]	O
and	O
it	O
has	O
been	O
postulated	O
inhibition	O
a	O
brain	O
area	O
is	O
apparently	O
as	O
fundamentally	O
involved	O
in	O
higher	O
cognitive	O
function	O
claustrum	O
may	O
explain	O
this	O
LSD	B-Drug

Venlafaxine	B-Drug
is	O
marginally	O
more	O
toxic	O
in	O
overdose	O
than	O
duloxetine	B-Drug
or	O
the	O
SSRIs	O

Bicalutamide	B-Drug
influences	O
the	O
HPG	O
axis	O
and	O
increases	O
hormone	O
levels	O
only	O
in	O
men	O
not	O
also	O
women	O

If	O
laxatives	O
are	O
insufficiently	O
effective	O
which	O
is	O
often	O
the	O
case	O
opioid	O
formulations	O
or	O
regimens	O
that	O
include	O
a	O
peripherally-selective	O
antagonist	O
such	O
as	O
methylnaltrexone	B-Drug
bromide	I-Drug
naloxegol	B-Drug
alvimopan	B-Drug
naloxone	B-Drug
in	O
oxycodone/naloxone	B-Drug
may	O
be	O
tried	O

Since	O
6-MAM	O
is	O
a	O
metabolite	O
unique	O
to	O
heroin	B-Drug
its	O
presence	O
in	O
the	O
urine	O
confirms	O
use	O

Aldous	O
Huxley's	O
1953	O
essay	O
The	O
Doors	O
of	O
Perception	O
describing	O
his	O
experiences	O
with	O
mescaline	B-Drug
and	O
R	O

In	O
January	O
2013	O
an	O
18-year-old	O
in	O
Scottsdale	O
Arizona	O
died	O
after	O
consuming	O
25I-NBOMe	B-Drug
sold	O
as	O
LSD;	O
a	O
toxicology	O
screening	O
found	O
no	O
other	O
drugs	O
the	O
person's	O
system	O
LSD	B-Drug

It	O
takes	O
15	O
to	O
60	O
minutes	O
for	O
the	O
effects	O
of	O
PCP	B-Drug
manifest	O

Snorting	O
heroin	B-Drug
becomes	O
an	O
often	O
unwanted	O
route	O
once	O
a	O
user	O
begins	O
to	O
inject	O
the	O
drug	O

From	O
the	O
WHO	O
Expert	O
Committee	O
assessment	O
of	O
MBDB:	O
Although	O
MBDB	O
is	O
both	O
structurally	O
and	O
pharmacologically	O
similar	O
to	O
MDMA	B-Drug
limited	O
available	O
data	O
indicate	O
that	O
its	O
stimulant	O
euphoriant	O
effects	O
are	O
less	O
pronounced	O
than	O
those	O

5	O
mg	O
norgestrel	B-Drug
for	O
9	O
days	O

It	O
has	O
similar	O
effects	O
to	O
morphine	B-Drug
such	O
as	O
sedation	O
analgesia	O
and	O
respiratory	O
depression	O

Commonly	O
used	O
illegal	O
drugs	O
include	O
heroin	B-Drug
cocaine	B-Drug
methamphetamine	B-Drug
and	O
marijuana	O

On	O
October	O
18	O
2012	O
the	O
Advisory	O
Council	O
on	O
Misuse	O
of	O
Drugs	O
in	O
United	O
Kingdom	O
released	O
a	O
report	O
about	O
methoxetamine	B-Drug
saying	O
that	O
harms	O
are	O
commensurate	O
with	O
Class	O
B	O
Act	O
1971	O
despite	O
fact	O
act	O
does	O
not	O
classify	O
drugs	O
based	O
harm	O

Nicotine	B-Drug
acetylcholine	O
stimulation	O
is	O
not	O
directly	O
addictive	O

Drug	O
tolerance	O
develops	O
rapidly	O
in	O
amphetamine	B-Drug
abuse	O
i	O

In	O
a	O
rat	O
study	O
nimetazepam	B-Drug
showed	O
slight	O
enlargement	O
of	O
the	O
liver	O
and	O
adrenals	O
atrophy	O
testes	O
ovaries	O
were	O
found	O
in	O
high	O
dose	O
groups	O
both	O
drugs	O
at	O
4th	O
12th	O
week	O
however	O
histopathological	O
examination	O
there	O
no	O
change	O

In	O
the	O
1960s	O
thalidomide	B-Drug
was	O
successfully	O
marketed	O
as	O
a	O
safer	O
alternative	O
to	O
barbiturates	O

ref	O
name	O
Society	O
and	O
culture	O
Generic	O
names	O
Brand	O
===	O
Norgestrel	B-Drug
has	O
been	O
marketed	O
under	O
a	O
variety	O
of	O
brand	O
including	O
Cyclacur	O
Cryselle	O
Cyclo-Progynova	O
Duoluton	O
Elinest	O
Eugynon	O
Microgynon	O
Lo/Ovral	O
Low-Ogestrel	O
Logynon	O
Microlut	O
Minicon	O
Nordette	O
Neogest	O
Ogestrel	O
Ovral	O
Ovran	O
Ovranette	O
Ovrette	B-Drug
Planovar	O
Prempak	O
Progyluton	O
Trinordiol	O
among	O
others	O

Its	O
effects	O
have	O
been	O
described	O
as	O
comparable	O
with	O
ethanol	O
alcohol	O
and	O
MDMA	B-Drug
use	O
such	O
euphoria	O
disinhibition	O
enhanced	O
libido	O
empathogenic	O
states	O

leuprorelin	B-Drug
or	O
surgical	O
castration	O

The	O
terms	O
laudanum	B-Drug
and	O
tincture	O
of	O
opium	B-Drug
are	O
generally	O
interchangeable	O
but	O
in	O
contemporary	O
medical	O
practice	O
the	O
latter	O
is	O
used	O
almost	O
exclusively	O

It	O
may	O
be	O
used	O
in	O
generic	O
labels	O
and	O
store	O
brands	O
Benylin	O
DM	O
Mucinex	B-Drug
Camydex-20	O
tablets	O
Robitussin	O
NyQuil	O
Dimetapp	O
Vicks	O
Coricidin	O
Delsym	O
TheraFlu	O
Charcoal	O
D	O
Cinfats	O
others	O

It	O
is	O
thought	O
that	O
this	O
can	O
result	O
in	O
sustained	O
and	O
higher	O
concentrations	O
of	O
MDMA	B-Drug
if	O
the	O
user	O
takes	O
consecutive	O
doses	O
drug	O

Like	O
other	O
AAS	O
oxandrolone	B-Drug
may	O
worsen	O
hypercalcemia	O
by	O
increasing	O
osteolytic	O
bone	O
resorption	O

The	O
anticonvulsant	O
properties	O
of	O
diazepam	B-Drug
and	O
other	O
benzodiazepines	O
may	O
be	O
in	O
part	O
or	O
entirely	O
due	O
to	O
binding	O
voltage-dependent	O
sodium	O
channels	O
rather	O
than	O
benzodiazepine	O
receptors	O

LAAM	B-Drug
is	O
not	O
approved	O
for	O
use	O
in	O
Australia	O
and	O
Canada	O

A	O
human	O
study	O
comparing	O
the	O
subjective	O
effects	O
and	O
abuse	O
potential	O
of	O
adinazolam	O
30	O
mg	O
50	O
with	O
diazepam	B-Drug
lorazepam	B-Drug
a	O
placebo	O
showed	O
that	O
causes	O
most	O
mental	O
physical	O
sedation	O
greatest	O
unpleasantness	O

Nonmedical	O
use	O
of	O
zolpidem	B-Drug
is	O
increasingly	O
common	O
in	O
the	O
US	O
Canada	O
and	O
UK	O

Subsequently	O
it	O
was	O
determined	O
that	O
modafinil	B-Drug
binds	O
to	O
the	O
same	O
site	O
on	O
DAT	O
as	O
cocaine	B-Drug
but	O
in	O
a	O
different	O
manner	O

Testosterone	B-Drug
enanthate	I-Drug
was	O
described	O
as	O
early	O
1952	O
and	O
first	O
introduced	O
for	O
medical	O
use	O
in	O
the	O
United	O
States	O
1954	O
under	O
brand	O
name	O
Delatestryl	B-Drug

Fresh	O
undried	O
plant	O
material	O
is	O
less	O
suited	O
for	O
hash	B-Drug
oil	I-Drug
production	O
because	O
much	O
THC	O
and	O
CBD	B-Drug
will	O
be	O
present	O
in	O
their	O
carboxylic	O
acid	O
forms	O
THCA	O
CBDA	O
which	O
may	O
not	O
highly	O
soluble	O
some	O
solvents	O

PCP	B-Drug
is	O
classified	O
as	O
a	O
schedule	O
II	O
drug	O
in	O
the	O
United	O
States	O

Psilocybin	O
mushrooms	O
are	O
which	O
contain	O
the	O
hallucinogenic	O
substances	O
psilocybin	O
psilocin	B-Drug
baeocystin	O
and	O
norbaeocystin	B-Drug

The	O
discovery	O
of	O
antidepressive	O
action	O
ketamine	B-Drug
in	O
2000	O
has	O
been	O
described	O
as	O
the	O
single	O
most	O
important	O
advance	O
treatment	O
depression	O
over	O
50	O
years	O

Many	O
species	O
contain	O
a	O
variety	O
of	O
alkaloids	O
that	O
can	O
be	O
more	O
or	O
less	O
active	O
poisonous	O
such	O
as	O
scopolamine	O
atropine	O
hyoscyamine	B-Drug
and	O
nicotine	B-Drug

drug-induced	O
compulsive	O
sexual	O
behaviors	O
are	O
associated	O
with	O
a	O
dopamine	O
dysregulation	O
syndrome	O
which	O
occurs	O
in	O
some	O
patients	O
taking	O
dopaminergic	O
drugs	O
such	O
as	O
amphetamine	B-Drug
or	O
methamphetamine	B-Drug

Excess	O
doses	O
may	O
result	O
in:	O
Difficulty	O
staying	O
awake	O
Mental	O
confusion	O
Nausea	O
Impaired	O
motor	O
functions	O
reflexes	O
coordination	O
balance	O
Dizziness	O
Respiratory	O
depression	O
Low	O
blood	O
pressure	O
ComaComa	O
can	O
be	O
cyclic	O
with	O
the	O
individual	O
alternating	O
from	O
a	O
comatose	O
state	O
to	O
hyper-alert	O
of	O
consciousness	O
which	O
occurred	O
in	O
four-year-old	O
boy	O
who	O
suffered	O
an	O
overdose	O
clonazepam	B-Drug

The	O
missionary	O
organizations	O
were	O
outraged	O
over	O
the	O
Royal	O
Commission	O
on	O
Opium's	O
conclusions	O
and	O
set	O
up	O
Anti-Opium	O
League	O
in	O
China;	O
league	O
gathered	O
data	O
from	O
every	O
Western-trained	O
medical	O
doctor	O
China	O
published	O
Opinions	O
of	O
Over	O
100	O
Physicians	O
Use	O
Opium	B-Drug

The	O
majority	O
of	O
tablets	O
contain	O
7085	O
mg	O
MDMA	B-Drug

Its	O
abuse	O
liability	O
is	O
similar	O
to	O
morphine	B-Drug
and	O
less	O
than	O
oxycodone	B-Drug

Syntex	O
first	O
marketed	O
naproxen	B-Drug
in	O
1976	O
as	O
the	O
prescription	O
drug	O
Naprosyn	B-Drug

However	O
most	O
studies	O
on	O
MDMA	B-Drug
and	O
serotonergic	O
neurotoxicity	O
in	O
humans	O
focus	O
the	O
heaviest	O
users	O
those	O
who	O
consume	O
more	O
than	O
seven	O
times	O
average	O

This	O
resulted	O
in	O
the	O
creation	O
of	O
methandrostenolone	B-Drug
which	O
appeared	O
on	O
market	O
1960	O
under	O
brand	O
name	O
Dianabol	B-Drug

The	O
second-generation	O
NSAAs	O
enzalutamide	B-Drug
RD-162	O
and	O
apalutamide	B-Drug
were	O
derived	O
from	O
RU-59063	O

According	O
to	O
a	O
2014	O
survey	O
25I-NBOMe	B-Drug
was	O
the	O
most	O
frequently	O
used	O
of	O
NBOMe	O
series	O

As	O
of	O
2002	O
seven	O
countries	O
USA	O
UK	O
Italy	O
Australia	O
France	O
Spain	O
and	O
Japan	O
use	O
77%	O
the	O
world's	O
morphine	B-Drug
supplies	O
leaving	O
many	O
emerging	O
lacking	O
in	O
pain	O
relief	O
medication	O

Tamoxifen	B-Drug
is	O
available	O
as	O
a	O
generic	O
medication	O

Possession	O
of	O
diamorphine	B-Drug
without	O
a	O
license	O
from	O
the	O
Department	O
Health	O
is	O
illegal	O
with	O
$1000000	O
HKD	O
fine	O
and	O
7	O
years	O
jail	O
time	O

He	O
claimed	O
he	O
received	O
a	O
tainted	O
vitamin	B-Drug
b12	I-Drug
shot	O
from	O
Miguel	O
Tejada	O

Oxymorphone	B-Drug
can	O
be	O
acetylated	O
like	O
morphine	B-Drug
hydromorphone	B-Drug
and	O
some	O
other	O
opioids	O

Spironolactone	B-Drug
can	O
be	O
considered	O
as	O
a	O
first-line	O
treatment	O
for	O
acne	O
in	O
those	O
who	O
have	O
failed	O
other	O
standard	O
treatments	O
such	O
topical	O
therapies	O
and	O
under	O
certain	O
circumstances	O
although	O
this	O
is	O
controversial	O
due	O
to	O
the	O
side	O
effects	O
of	O
spironolactone	B-Drug
its	O
teratogenicity	O

Alfentanil	B-Drug
R-39209	O
trade	O
name	O
Alfenta	O
Rapifen	O
in	O
Australia	O
is	O
a	O
potent	O
but	O
short-acting	O
synthetic	O
opioid	O
analgesic	O
drug	O
used	O
for	O
anaesthesia	O
surgery	O

Once	O
it	O
has	O
passed	O
first-pass	O
metabolism	O
6-MAM	O
is	O
then	O
metabolized	O
into	O
morphine	B-Drug
or	O
excreted	O
in	O
urine	O

NSAIDs	O
such	O
as	O
aspirin	B-Drug
and	O
ibuprofen	B-Drug
are	O
also	O
analgesics	O

There	O
are	O
various	O
medications	O
on	O
the	O
market	O
to	O
ease	O
cocaine	B-Drug
withdrawal	O
symptoms	O

A	O
19992005	O
Australian	O
police	O
survey	O
of	O
detainees	O
reported	O
preliminary	O
findings	O
that	O
self-reported	O
users	O
benzodiazepines	O
were	O
less	O
likely	O
than	O
non-user	O
to	O
work	O
full-time	O
and	O
more	O
receive	O
government	O
benefits	O
use	O
methamphetamine	B-Drug
or	O
heroin	B-Drug
be	O
arrested	O
imprisoned	O

The	O
possession	O
of	O
crystal	B-Drug
meth	I-Drug
can	O
result	O
in	O
a	O
punishment	O
varying	O
from	O
fine	O
to	O
jail	O
sentence	O

The	O
concentration	O
of	O
naphyrone	B-Drug
required	O
to	O
inhibit	O
the	O
transporters	O
by	O
50%	O
is	O
46	O

Project	O
objectives	O
have	O
been	O
threefold:	O
To	O
reduce	O
frequency	O
of	O
sharing	O
needles	O
and	O
syringes	O
to	O
change	O
other	O
IDU	O
Intravenous	O
Drug	O
User	O
behaviors	O
that	O
create	O
negative	O
attitudes	O
among	O
the	O
population	O
in	O
general	O
towards	O
IDUs	B-Drug
facilitate	O
addiction	O
prevention	O
treatment	O

MDMA	B-Drug
acts	O
by	O
targeting	O
the	O
body's	O
stress	O
response	O
in	O
order	O
to	O
cause	O
this	O
therapeutic	O
effect	O

This	O
advisory	O
was	O
based	O
on	O
a	O
review	O
of	O
anti-smoking	O
products	O
that	O
identified	O
75	O
reports	O
suicidal	O
adverse	O
events	O
for	O
bupropion	B-Drug
over	O
ten	O
years	O

In	O
the	O
EU	O
bevacizumab	B-Drug
in	O
addition	O
to	O
platinum-based	O
chemotherapy	O
is	O
indicated	O
for	O
first-line	O
treatment	O
of	O
adults	O
with	O
unresectable	O
advanced	O
metastatic	O
or	O
recurrent	O
non-small	O
cell	O
lung	O
cancer	O
other	O
than	O
predominantly	O
squamous	O
histology	O

Prosidol	O
is	O
an	O
opioid	O
analgesic	O
that	O
analogue	O
of	O
prodine	B-Drug

Moses	O
Baca	O
Laborer	O
caught	O
by	O
authorities	O
in	O
1937	O
with	O
one-quarter	O
ounce	O
of	O
cannabis	O
one	O
the	O
first	O
people	O
convicted	O
under	O
federal	O
Marihuana	B-Drug
Tax	O
Act	O

This	O
led	O
authorities	O
of	O
various	O
countries	O
to	O
place	O
temazepam	B-Drug
under	O
a	O
more	O
restrictive	O
legal	O
status	O

Butorphanol	B-Drug
is	O
frequently	O
used	O
for	O
post-operative	O
and	O
accident-related	O
pain	O
in	O
small	O
mammals	O
such	O
as	O
dogs	O
cats	O
ferrets	O
coatis	O
raccoons	O
mongooses	O
various	O
marsupials	O
some	O
rodents	O
perhaps	O
larger	O
birds	O
both	O
the	O
operating	O
suite	O
a	O
regular	O
prescription	O
medication	O
home	O
use	O
management	O
of	O
moderate	O
to	O
severe	O

The	O
lawsuit	O
alleged	O
that	O
Chemie	O
Grnenthal	O
was	O
negligent	O
in	O
the	O
testing	O
of	O
thalidomide	B-Drug
and	O
they	O
failed	O
to	O
warn	O
its	O
effects	O
on	O
unborn	O
children	O

In	O
certain	O
brain	O
regions	O
amphetamine	B-Drug
increases	O
the	O
concentration	O
of	O
dopamine	O
in	O
synaptic	O
cleft	O

Phenobarbital	B-Drug
a	O
barbiturate	O
is	O
used	O
at	O
detox	O
or	O
other	O
inpatient	O
facilities	O
to	O
prevent	O
seizures	O
during	O
rapid	O
withdrawal	O
cold	O
turkey	O

Updated	O
guidelines	O
published	O
by	O
Britain's	O
NHS	O
Migraine	O
Trust	O
in	O
2014	O
recommended	O
Methysergide	B-Drug
medicines	O
are	O
now	O
only	O
to	O
be	O
used	O
for	O
preventing	O
severe	O
intractable	O
migraine	O
and	O
cluster	O
headache	O
when	O
standard	O
have	O
failed	O

However	O
its	O
report	O
did	O
recommend	O
more	O
MDMA	B-Drug
research:	O
the	O
Expert	O
Committee	O
held	O
extensive	O
discussions	O
concerning	O
therapeutic	O
usefulness	O
of	O
34	O
Methylenedioxymethamphetamine	B-Drug

It	O
is	O
on	O
the	O
list	O
of	O
substances	O
prohibited	O
by	O
World	O
Anti-Doping	O
Agency	O
since	O
it	O
a	O
detectable	O
metabolite	O
nandrolone	B-Drug
an	O
anabolic-androgenic	O
steroid	O
AAS	O

This	O
has	O
been	O
found	O
by	O
measuring	O
sodium-dependent	O
high-affinity	O
choline	O
uptake	O
in	O
mouse	O
brain	O
cells	O
vitro	O
after	O
pretreatment	O
of	O
the	O
mice	O
with	O
diazepam	B-Drug
vivo	O

PCP	B-Drug
is	O
self-administered	O
and	O
induces	O
FosB	O
expression	O
in	O
the	O
D1-type	O
medium	O
spiny	O
neurons	O
of	O
nucleus	O
accumbens	O
accordingly	O
excessive	O
use	O
known	O
to	O
cause	O
addiction	O

Aspirin	B-Drug
inhibits	O
platelet	O
aggregation	O
by	O
inhibiting	O
the	O
action	O
of	O
thromboxane	O
A2	O

There	O
is	O
also	O
a	O
high	O
risk	O
that	O
thalidomide	B-Drug
can	O
interfere	O
with	O
formation	O
of	O
various	O
kinds	O
new	O
blood	O
cells	O
creating	O
infection	O
via	O
neutropenia	O
leukopenia	O
and	O
lymphopenia	O
risks	O
will	O
not	O
clot	O
thrombocytopenia	O

In	O
its	O
injectable	O
form	O
trade	O
name	O
Citanest	B-Drug
it	O
is	O
often	O
used	O
in	O
dentistry	O

High	O
on	O
Crack	O
Street:	O
Lost	O
Lives	O
in	O
Lowell	O
1995	O
Cocaine	B-Drug
Cowboys	O
2006	O
Crackheads	O
Gone	O
Wild	O
American	O
Drug	O
War:	O
The	O
Last	O
White	O
Hope	O
2007	O
2	O
2008	O
Freakonomics	O
2010	O
Planet	O
Rock:	O
Story	O
of	O
Hip-Hop	O
and	O
the	O
Generation	O
2011	O
Seven	O
Five	O
2014	O
Freeway:	O
System	O
2015	O
13th	O
2016	O
Crack:	O
Corruption	O
&	O
Conspiracy	O
2021	O
Drugs	O
Inc	O

The	O
acceptable	O
level	O
has	O
been	O
raised	O
to	O
ten	O
parts	O
per	O
million	O
for	O
ephedrine	B-Drug
and	O
twenty-five	O
other	O
substances	O

A	O
related	O
drug	O
prochlorperazine	B-Drug
is	O
more	O
often	O
used	O
although	O
it	O
has	O
similar	O
risks	O

54%	O
of	O
the	O
androgenicity	O
androstenedione	B-Drug
and	O
0	O

Following	O
passage	O
of	O
a	O
Colonial	O
Australian	O
law	O
in	O
1895	O
Queensland's	O
Aboriginals	O
Protection	O
and	O
Restriction	O
the	O
Sale	O
Opium	O
Act	O
1897	O
addressed	O
opium	B-Drug
addiction	O
among	O
Aboriginal	O
people	O
though	O
it	O
soon	O
became	O
general	O
vehicle	O
for	O
depriving	O
them	O
basic	O
rights	O
by	O
administrative	O
regulation	O

LSD	B-Drug
and	O
psilocybin	O
for	O
many	O
of	O
the	O
experiments	O
was	O
supplied	O
by	O
Sandoz	O
Pharmaceuticals	O
both	O
these	O
substances	O
were	O
legal	O
at	O
time	O

LSD	B-Drug
manufacturers	O
and	O
traffickers	O
in	O
the	O
United	O
States	O
can	O
be	O
categorized	O
into	O
two	O
groups:	O
A	O
few	O
large-scale	O
producers	O
an	O
equally	O
limited	O
number	O
of	O
small	O
clandestine	O
chemists	O
consisting	O
independent	O
who	O
operating	O
on	O
a	O
comparatively	O
scale	O
found	O
throughout	O
country	O

For	O
heroin	B-Drug
withdrawal	O
symptoms	O
are	O
typically	O
greatest	O
at	O
two	O
to	O
four	O
days	O
and	O
can	O
last	O
for	O
up	O
weeks	O

Due	O
to	O
the	O
availability	O
of	O
precursor	O
chemicals	O
traffickers	O
produce	O
large	O
amounts	O
crystal	B-Drug
methamphetamine	I-Drug

In	O
many	O
jurisdictions	O
police	O
had	O
no	O
laws	O
under	O
which	O
to	O
prosecute	O
users	O
and	O
traffickers	O
of	O
these	O
new	O
drugs;	O
LSD	B-Drug
for	O
instance	O
was	O
not	O
prohibited	O
federally	O
in	O
the	O
U	O

The	O
Office	O
of	O
Security	O
used	O
LSD	B-Drug
in	O
interrogations	O
but	O
Dr	O

Gabapentin	B-Drug
an	O
indirect	O
GABA	O
modulator	O
has	O
shown	O
some	O
preliminary	O
benefit	O
for	O
reducing	O
cravings	O
and	O
cannabis	O
use	O

Methyltestosterone	B-Drug
was	O
discovered	O
in	O
1935	O
and	O
introduced	O
for	O
medical	O
use	O
1936	O

For	O
individuals	O
who	O
wish	O
to	O
completely	O
move	O
away	O
from	O
drugs	O
they	O
can	O
start	O
a	O
methadone	B-Drug
reduction	O
program	O

Fentanyl's	O
most	O
common	O
side	O
effects	O
which	O
affect	O
more	O
than	O
10%	O
of	O
people	O
include	O
diarrhea	O
nausea	O
constipation	O
dry	O
mouth	O
somnolence	O
confusion	O
asthenia	O
weakness	O
sweating	O
Fentanyl	B-Drug

A	O
cytochrome	O
P450	O
classified	O
as	O
Cyp80F1	O
oxidizes	O
and	O
rearranges	O
littorine	O
to	O
hyoscyamine	B-Drug
aldehyde	O

JWH-176	B-Drug
is	O
the	O
E-stereoisomer	O
of	O
1-[3-pentylinden-1-ylidine]methylnaphthalene	O
whereas	O
JWH-171	B-Drug
mixture	O
E-	O
and	O
Z-isomers	O

The	O
authors	O
did	O
not	O
evaluate	O
or	O
rate	O
the	O
negative	O
impact	O
of	O
ecstasy	B-Drug
on	O
cognitive	O
health	O
users	O
e	O

Side	O
effects	O
of	O
the	O
tablet	O
form	O
in	O
conjunction	O
with	O
levodopa	B-Drug
include	O
decreasing	O
order	O
frequency	O
nausea	O
hallucinations	O
confusion	O
depression	O
loss	O
balance	O
insomnia	O
increased	O
involuntary	O
movements	O
agitation	O
slow	O
or	O
irregular	O
heart	O
rate	O
delusions	O
hypertension	O
new	O
angina	O
pectoris	O
and	O
syncope	O

Upjohn	O
looked	O
for	O
the	O
key	O
moieties	O
which	O
gave	O
greatest	O
activity	O
and	O
posted	O
over	O
a	O
dozen	O
patents	O
on	O
related	O
compounds	O
each	O
optimizing	O
one	O
moiety	O
until	O
they	O
discovered	O
that	O
U-47700	B-Drug
was	O
most	O
active	O

Before	O
August	O
1993	O
LAAM	B-Drug
was	O
classified	O
as	O
a	O
schedule	O
I	O
drug	O
in	O
the	O
United	O
States	O

This	O
activity	O
may	O
be	O
associated	O
with	O
some	O
of	O
the	O
other	O
more	O
psychotic	O
features	O
PCP	B-Drug
intoxication	O
which	O
is	O
evidenced	O
by	O
successful	O
use	O
D2	O
receptor	O
antagonists	O
such	O
as	O
haloperidol	B-Drug
in	O
treatment	O
psychosis	O

Cocaine	B-Drug
is	O
also	O
carried	O
in	O
small	O
concealed	O
kilogram	O
quantities	O
across	O
the	O
border	O
by	O
couriers	O
known	O
as	O
mules	O
or	O
mulas	O
who	O
cross	O
a	O
either	O
legally	O
for	O
example	O
through	O
port	O
airport	O
illegally	O
elsewhere	O

The	O
following	O
substances	O
namely:a	O
aa	O
Any	O
compound	O
not	O
being	O
bupropion	B-Drug
cathinone	B-Drug
diethylpropion	B-Drug
pyrovalerone	B-Drug
or	O
a	O
for	O
the	O
time	O
specified	O
in	O
subparagraph	O
above	O
structurally	O
derived	O
from	O
2amino1phenyl1propanone	O
by	O
modification	O
any	O
of	O
ways	O
that	O
is	O
to	O
say	O
i	O
substitution	O
phenyl	O
ring	O
extent	O
with	O
alkyl	O
alkoxy	O
alkylenedioxy	O
haloalkyl	O
halide	O
substituents	O
whether	O
further	O
substituted	O
one	O
more	O
other	O
univalent	O
substituents;	O
ii	O
at	O
3position	O
an	O
substituent;	O
iii	O
nitrogen	O
atom	O
dialkyl	O
groups	O
inclusion	O
cyclic	O
structureab	O
2aminopropan1one	O
1-position	O
monocyclic	O
fusedpolycyclic	O
system	O
alkylenedioxyphenyl	O
modified	O
substituents;ii	O
substituent;iii	O
2amino	O
structureb	O
55	O
disubstituted	O
barbituric	O
acid	O
c	O
[23Dihydro5methyl34morpholinylmethylpyrrolo[1	O
2	O
3de]14benzoxazin6yl]1naphthalenylmethanone	O

That	O
problem	O
however	O
serious	O
therefore	O
does	O
not	O
'warrant'	O
the	O
placing	O
of	O
tobacco	B-Drug
'under	O
international'	O
control	O
i	O

Mebicar	B-Drug
decreases	O
the	O
brain	O
noradrenaline	O
level	O
exerts	O
no	O
effect	O
on	O
dopaminergic	O
systems	O
and	O
increases	O
serotonin	O

Nabilone	B-Drug
Cesamet	B-Drug
A	O
synthetic	O
cannabinoid	O

Typical	O
antipsychotics	O
such	O
as	O
phenothiazines	O
and	O
haloperidol	B-Drug
have	O
been	O
used	O
to	O
control	O
psychotic	O
symptoms	O
but	O
may	O
produce	O
many	O
undesirable	O
side	O
effects	O
dystonia	O
their	O
use	O
is	O
therefore	O
no	O
longer	O
preferred;	O
are	O
particularly	O
risky	O
they	O
lower	O
the	O
seizure	O
threshold	O
worsen	O
hyperthermia	O
boost	O
anticholinergic	O
of	O
PCP	B-Drug

The	O
duration	O
of	O
action	O
fentanyl	B-Drug
has	O
sometimes	O
been	O
underestimated	O
leading	O
to	O
harm	O
in	O
a	O
medical	O
context	O

Bicalutamide	B-Drug
is	O
a	O
modification	O
of	O
flutamide	O
in	O
which	O
4-fluorophenylsulfonyl	O
moiety	O
has	O
been	O
added	O
and	O
the	O
nitro	O
group	O
on	O
original	O
phenyl	O
ring	O
replaced	O
with	O
cyano	O

Due	O
to	O
their	O
similar	O
proposed	O
mechanisms	O
of	O
action	O
this	O
factor	O
may	O
provide	O
further	O
support	O
for	O
the	O
proposition	O
that	O
O-acetylpsilocin	B-Drug
might	O
serve	O
as	O
an	O
appropriate	O
substitute	O
psilocybin	O
in	O
research	O
application	O
psychedelic	O
compounds	O
medicine	O

Costing	O
up	O
to	O
two	O
million	O
dollars	O
each	O
construct	O
submarines	O
can	O
move	O
enough	O
cocaine	B-Drug
in	O
a	O
single	O
trip	O
generate	O
more	O
than	O
100	O
USD	O
illicit	O
proceeds	O
for	O
the	O
traffickers	O

Ketamine	B-Drug
is	O
an	O
option	O
in	O
children	O
as	O
the	O
sole	O
anesthetic	O
for	O
minor	O
procedures	O
or	O
induction	O
agent	O
followed	O
by	O
neuromuscular	O
blocker	O
and	O
tracheal	O
intubation	O
In	O
particular	O
with	O
cyanotic	O
heart	O
disease	O
disorders	O
are	O
good	O
candidates	O
ketamine	B-Drug
anesthesia	O

5-MeO-MiPT	O
is	O
in	O
a	O
class	O
of	O
compounds	O
commonly	O
known	O
as	O
tryptamines	O
and	O
the	O
N-methyl-N-isopropyl	O
homologue	O
psychedelic	O
5-MeO-DMT	B-Drug

The	O
inhibition	O
of	O
these	O
enzymes	O
can	O
thus	O
alter	O
the	O
efficacy	O
and	O
tolerability	O
profile	O
tilidine	B-Drug

The	O
cyclization	O
step	O
releases	O
cyclosporin	B-Drug
from	O
the	O
enzyme	O

Although	O
not	O
present	O
in	O
humans	O
5-HT5B	O
receptors	O
found	O
rodents	O
also	O
have	O
a	O
high	O
affinity	O
for	O
LSD	B-Drug

Administration	O
of	O
flumazenil	B-Drug
by	O
sublingual	O
lozenge	O
and	O
topical	O
cream	O
has	O
also	O
been	O
tested	O

Fentanyl	B-Drug
a	O
synthetic	O
opioid	O
painkiller	O
is	O
50	O
to	O
100	O
times	O
more	O
potent	O
than	O
morphine	B-Drug
and	O
30	O
heroin	B-Drug
with	O
only	O
2	O
mg	O
becoming	O
lethal	O
dose	O

Low	O
concentrations	O
of	O
paracetamol	B-Drug
is	O
excreted	O
through	O
breast	O
milk	O
however	O
hydrocodone's	O
excretion	O
unknown	O
hydrocodone	B-Drug

1959c	O
investigated	O
the	O
psychological	O
and	O
physical	O
effects	O
of	O
13	O
different	O
congeners	O
LSD	B-Drug
correlated	O
these	O
with	O
their	O
potency	O
as	O
a	O
serotonin	O
antagonist	O
in	O
smooth	O
muscle	O

Clorazepate	B-Drug
exerts	O
its	O
pharmacological	O
properties	O
via	O
increasing	O
the	O
opening	O
frequency	O
of	O
chloride	O
ion	O
channel	O
GABAA	O
receptors	O

Various	O
surveys	O
conducted	O
between	O
2015	O
and	O
2019	O
found	O
that	O
many	O
users	O
of	O
cannabis	O
substitute	O
it	O
for	O
prescription	O
drugs	O
including	O
opioids	O
alcohol	O
tobacco;	O
most	O
those	O
who	O
used	O
in	O
place	O
or	O
tobacco	B-Drug
either	O
reduced	O
stopped	O
their	O
intake	O
the	O
latter	O
substances	O

Unlike	O
most	O
injectable	O
AAS	O
stanozolol	B-Drug
is	O
not	O
esterified	O
and	O
sold	O
as	O
an	O
aqueous	O
suspension	O
or	O
in	O
oral	O
tablet	O
form	O

Drugs	O
in	O
this	O
schedule	O
include:	O
Benzodiazepines	O
such	O
as	O
alprazolam	B-Drug
Xanax	B-Drug
chlordiazepoxide	B-Drug
Librium	B-Drug
clonazepam	B-Drug
Klonopin	B-Drug
diazepam	B-Drug
Valium	B-Drug
and	O
Lorazepam	B-Drug
Ativan	B-Drug
well	O
as:	O
temazepam	B-Drug
Restoril	B-Drug
note	O
that	O
some	O
states	O
require	O
specially	O
coded	O
prescriptions	O
for	O
flunitrazepam	B-Drug
Rohypnol	B-Drug
is	O
not	O
FDA	O
approved	O
so	O
an	O
illegal	O
drug	O
the	O
United	O
States	O
oxazepam	B-Drug
Serax	B-Drug
Serepax	O
Seresta	O
Alepam	O
Opamox	O
Oxamin	O
The	O
benzodiazepine-like	O
Z-drugs:	O
zolpidem	B-Drug
Ambien	B-Drug
zopiclone	B-Drug
Imovane	B-Drug
eszopiclone	B-Drug
Lunesta	B-Drug
zaleplon	B-Drug
Sonata	B-Drug
commercially	O
available	O
U	O

Gold	O
to	O
distinguish	O
these	O
drugs	O
from	O
psychedelics	O
and	O
dissociatives	O
such	O
as	O
LSD	B-Drug
ketamine	B-Drug
respectively	O
due	O
their	O
primary	O
effect	O
of	O
causing	O
delirium	O
opposed	O
the	O
more	O
lucid	O
states	O
produced	O
by	O
other	O
hallucinogens	O

coli	O
IleRS	O
a	O
single	O
amino	O
acid	O
mutation	O
was	O
shown	O
to	O
alter	O
mupirocin	B-Drug
resistance	O

The	O
police	O
were	O
looking	O
for	O
methamphetamine	B-Drug
but	O
found	O
only	O
LSD	B-Drug
which	O
was	O
not	O
illegal	O
at	O
the	O
time	O

6	O
billion	O
in	O
fines	O
to	O
federal	O
and	O
state	O
governments	O
for	O
illegal	O
promotion	O
of	O
off-label	O
uses	O
Depakote	B-Drug
including	O
the	O
sedation	O
elderly	O
nursing	O
home	O
residents	O

Drug	O
Enforcement	O
Administration	O
indicated	O
that	O
illicit	O
fentanyl	B-Drug
analogs	O
have	O
no	O
medically	O
valid	O
use	O
and	O
thus	O
applied	O
a	O
Schedule	O
I	O
classification	O
to	O
them	O

This	O
represents	O
the	O
equivalent	O
of	O
between	O
two	O
to	O
three	O
teaspoons	O
1015	O
mL	O
opium	B-Drug
tincture	O

Some	O
patients	O
who	O
use	O
danazol	B-Drug
experience	O
weight	O
gain	O
and	O
fluid	O
retention	O

As	O
of	O
October	O
2015	O
the	O
Sinaloa	O
Cartel	O
is	O
most	O
active	O
drug	O
cartel	O
involved	O
in	O
smuggling	O
methamphetamine	B-Drug
and	O
other	O
illicit	O
drugs	O
into	O
United	O
States	O
trafficking	O
wholesale	O
quantities	O
throughout	O

Subsequently	O
gabapentin	B-Drug
was	O
approved	O
in	O
the	O
United	O
States	O
for	O
treatment	O
of	O
postherpetic	O
neuralgia	O
2002	O

Many	O
fitness	O
models	O
and	O
bodybuilders	O
use	O
trenbolone	B-Drug
acetate	O
particularly	O
when	O
preparing	O
to	O
compete	O
in	O
an	O
upcoming	O
bodybuilding	O
competition	O

Following	O
its	O
introduction	O
ketoconazole	B-Drug
was	O
the	O
only	O
systemic	O
antifungal	O
available	O
for	O
almost	O
a	O
decade	O

In	O
fact	O
in	O
China	O
isolation	O
from	O
seaweed	O
is	O
the	O
most	O
common	O
form	O
of	O
mannitol	B-Drug
production	O

Also	O
cross-sensitization	O
is	O
not	O
unique	O
to	O
marijuana	B-Drug

Starting	O
in	O
1927	O
with	O
Kurt	O
Beringer's	O
Der	O
Meskalinrausch	O
The	O
Mescaline	B-Drug
Intoxication	O
more	O
intensive	O
effort	O
began	O
to	O
be	O
focused	O
on	O
studies	O
of	O
psychoactive	O
plants	O

The	O
elimination	O
half-life	O
of	O
nalbuphine	B-Drug
is	O
approximately	O
5	O
hours	O
on	O
average	O
and	O
in	O
clinical	O
studies	O
the	O
duration	O
analgesic	O
activity	O
has	O
been	O
reported	O
to	O
range	O
from	O
3	O
6	O

Urine	O
was	O
collected	O
for	O
24	O
hours	O
followed	O
by	O
extraction	O
of	O
JWH-018	B-Drug
metabolites	O
using	O
both	O
liquid-liquid	O
and	O
solid-phase	O

Prior	O
to	O
the	O
October	O
2005	O
raids	O
DEA	O
had	O
arrested	O
17	O
BMF	O
members	O
seized	O
632	O
kilograms	O
of	O
cocaine	B-Drug
$5	O

Many	O
fentanyl	B-Drug
overdoses	O
are	O
initially	O
classified	O
as	O
heroin	B-Drug

For	O
those	O
reasons	O
DMT	O
was	O
known	O
as	O
the	O
business	O
trip	O
during	O
1960s	O
in	O
United	O
States	O
a	O
user	O
could	O
access	O
full	O
depth	O
of	O
psychedelic	O
experience	O
considerably	O
less	O
time	O
than	O
with	O
other	O
substances	O
such	O
LSD	B-Drug
or	O
magic	O
mushrooms	O

In	O
the	O
mid-1990s	O
Janssen	O
Pharmaceutica	O
developed	O
and	O
introduced	O
into	O
clinical	O
trials	O
Duragesic	B-Drug
patch	O
which	O
is	O
a	O
formulation	O
of	O
an	O
inert	O
alcohol	O
gel	O
infused	O
with	O
select	O
fentanyl	B-Drug
doses	O
are	O
worn	O
to	O
provide	O
constant	O
administration	O
opioid	O
over	O
period	O
48	O
72	O
hours	O

Recreationally	O
methamphetamine	B-Drug
is	O
used	O
to	O
increase	O
sexual	O
desire	O
lift	O
the	O
mood	O
and	O
energy	O
allowing	O
some	O
users	O
engage	O
in	O
activity	O
continuously	O
for	O
several	O
days	O
straight	O

Unlike	O
NSAIDs	O
such	O
as	O
aspirin	B-Drug
paracetamol	B-Drug
does	O
not	O
appear	O
to	O
inhibit	O
the	O
function	O
of	O
any	O
cyclooxygenase	O
COX	O
enzyme	O
outside	O
central	O
nervous	O
system	O
and	O
this	O
appears	O
be	O
reason	O
why	O
it	O
is	O
useful	O
an	O
anti-inflammatory	O

Both	O
analgesia	O
and	O
drug	O
addiction	O
are	O
functions	O
of	O
the	O
mu	O
opioid	O
receptor	O
class	O
first	O
identified	O
as	O
responsive	O
to	O
morphine	B-Drug

In	O
Europe	O
an	O
estimated	O
37%	O
of	O
regular	O
club-goers	O
aged	O
14	O
to	O
35	O
used	O
MDMA	B-Drug
in	O
the	O
past	O
year	O
according	O
2015	O
European	O
Drug	O
report	O

Beginning	O
in	O
2015	O
Canada	O
has	O
seen	O
a	O
number	O
of	O
fentanyl	B-Drug
overdoses	O

Fludiazepam	B-Drug
marketed	O
under	O
the	O
brand	O
name	O
Erispan	O
is	O
a	O
potent	O
benzodiazepine	O
and	O
2-fluoro	O
derivative	O
of	O
diazepam	B-Drug
originally	O
developed	O
by	O
Hoffman-La	O
Roche	O
in	O
1960s	O

Reported	O
effects	O
include:	O
Feelings	O
of	O
euphoria	O
Increased	O
alertness	O
Slurred	O
speech	O
Shaking	O
the	O
limbs	O
heart	O
rate	O
blood	O
pressure	O
risk	O
stroke	O
or	O
attack	O
empathy	O
and	O
sense	O
communication	O
Both	O
decreased	O
increased	O
sexual	O
function	O
desire	O
BruxismThe	O
methcathinone	B-Drug
usually	O
last	O
from	O
four	O
to	O
six	O
hours	O

Apalutamide	B-Drug
has	O
a	O
high	O
potential	O
for	O
drug	O
interactions	O

The	O
subjective	O
effects	O
of	O
sativas	O
and	O
indicas	O
are	O
said	O
to	O
differ	O
but	O
the	O
ratio	O
tetrahydrocannabinol	O
THC	O
cannabidiol	B-Drug
CBD	B-Drug
in	O
most	O
named	O
drug	O
varieties	O
both	O
types	O
is	O
similar	O
averaging	O
about	O
200:1	O

Of	O
the	O
European	O
Union	O
EU	O
member	O
states	O
12	O
countries	O
Bulgaria	O
Cyprus	O
Denmark	O
Estonia	O
France	O
Ireland	O
Latvia	O
Lithuania	O
Malta	O
Poland	O
Romania	O
Slovenia	O
allow	O
sale	O
of	O
OTC	O
codeine	B-Drug
solid	O
dosage	O
forms	O

In	O
2001	O
Connecticut	O
Attorney	O
General	O
Richard	O
Blumenthal	O
issued	O
a	O
statement	O
urging	O
Purdue	O
to	O
take	O
action	O
regarding	O
abuse	O
of	O
Oxycontin	B-Drug

The	O
molecular	O
formula	O
of	O
phentermine	B-Drug
is	O
C10H15N	O

In	O
November	O
2017	O
it	O
was	O
reported	O
that	O
Israeli	O
Ministry	O
of	O
Health	O
considering	O
to	O
withdraw	O
its	O
objection	O
making	O
CBD	B-Drug
component	O
cannabis	O
legal	O

The	O
major	O
metabolites	O
of	O
oxycodone	B-Drug
are	O
noroxycodone	O
70%	O
noroxymorphone	B-Drug
relatively	O
high	O
concentrations	O
and	O
oxymorphone	B-Drug
5%	O

It	O
is	O
provided	O
unmodified	O
and	O
as	O
a	O
testosterone	B-Drug
ester	O
such	O
cypionate	I-Drug
enanthate	I-Drug
propionate	O
or	O
undecanoate	O
which	O
act	O
prodrugs	O
of	O

In	O
an	O
animal	O
study	O
mitragynine	B-Drug
withdrawal	O
symptoms	O
were	O
observed	O
following	O
14	O
days	O
of	O
i	O

Others	O
such	O
as	O
former	O
Republican	O
congressman	O
Ron	O
Paul	O
the	O
Cato	O
Institute	O
The	O
Libertarian	O
Party	O
and	O
Drug	O
Policy	O
Alliance	O
criticize	O
very	O
existence	O
of	O
DEA	O
War	O
on	O
Drugs	O
both	O
hostile	O
contrary	O
to	O
concept	O
civil	O
liberties	O
by	O
arguing	O
that	O
anybody	O
should	O
be	O
free	O
put	O
any	O
substance	O
they	O
choose	O
into	O
their	O
own	O
bodies	O
for	O
reason	O
particularly	O
when	O
legal	O
drugs	O
alcohol	O
tobacco	B-Drug
prescription	O
are	O
also	O
open	O
abuse	O
harm	O
caused	O
a	O
drug	O
user	O
or	O
addict	O
general	O
public	O
is	O
case	O
conflicting	O
rights	O

carisoprodol	B-Drug
meprobamate	B-Drug
lorbamate	O
thienodiazepines	O
alcohol	O
ethanol	O
etomidate	B-Drug
glutethimide	B-Drug
kavalactones	O
quinazolinones	O
ex	O

By	O
May	O
2010	O
mephedrone	B-Drug
had	O
been	O
detected	O
in	O
all	O
22	O
EU	O
member	O
states	O
that	O
reported	O
to	O
Europol	O
as	O
well	O
Croatia	O
and	O
Norway	O

Parallels	O
were	O
drawn	O
between	O
the	O
media	O
coverage	O
of	O
mephedrone	B-Drug
and	O
a	O
piece	O
satire	O
by	O
Chris	O
Morris	O
in	O
1997	O
on	O
Brass	O
Eye	O
when	O
he	O
tricked	O
public	O
figures	O
into	O
talking	O
dangers	O
taking	O
fictional	O
legal	O
drug	O
cake	O

Consequently	O
several	O
opioid/antihistamine	O
combination	O
products	O
have	O
been	O
marketed	O
such	O
as	O
Meprozine	O
meperidine/promethazine	O
and	O
Diconal	O
dipipanone/cyclizine	O
these	O
may	O
also	O
reduce	O
opioid	O
induced	O
nausea	O
meperidine	B-Drug
promethazine	B-Drug
dipipanone	B-Drug
cyclizine	B-Drug

See	O
for	O
example	O
the	O
list	O
of	O
phenyltropanes	O
or	O
synthesis	O
paroxetine	B-Drug
further	O
examples	O
this	O

Norethisterone	B-Drug
is	O
a	O
substrate	O
for	O
and	O
known	O
to	O
be	O
an	O
inhibitor	O
of	O
5-reductase	O
with	O
4	O

Buprenorphine	B-Drug
binds	O
strongly	O
to	O
opioid	O
receptors	O
and	O
acts	O
as	O
a	O
pain-reducing	O
medication	O
in	O
the	O
central	O
nervous	O
system	O
CNS	O

AB-CHMINACA	B-Drug
is	O
an	O
Anlage	O
II	O
controlled	O
substance	O
in	O
Germany	O
as	O
of	O
May	O
2015	O

In	O
2010	O
Grnenthal	O
granted	O
Johnson	O
&	O
the	O
right	O
to	O
market	O
tapentadol	B-Drug
in	O
about	O
80	O
additional	O
countries	O

In	O
1999	O
an	O
FDA	O
official	O
explained	O
to	O
Congress:	O
Rohypnol	B-Drug
is	O
not	O
approved	O
or	O
available	O
for	O
medical	O
use	O
in	O
the	O
United	O
States	O
but	O
it	O
temporarily	O
controlled	O
Schedule	O
IV	O
pursuant	O
a	O
treaty	O
obligation	O
under	O
1971	O
Convention	O
on	O
Psychotropic	O
Substances	O

The	O
LAT1	O
is	O
easily	O
saturable	O
so	O
the	O
pharmacokinetics	O
of	O
gabapentin	B-Drug
are	O
dose-dependent	O
with	O
diminished	O
bioavailability	O
and	O
delayed	O
peak	O
levels	O
at	O
higher	O
doses	O

The	O
slow	O
evaporation	O
of	O
freebase	O
propylhexedrine	B-Drug
allows	O
it	O
to	O
be	O
administered	O
via	O
inhalation	O

The	O
third	O
called	O
charas	O
or	O
hashish	B-Drug
consists	O
of	O
the	O
resinous	O
buds	O
and/or	O
extracted	O
resin	O
from	O
leaves	O
marijuana	O
plant	O

Opium	B-Drug
tincture	O
is	O
indicated	O
for	O
the	O
treatment	O
of	O
severe	O
fulminant	O
intense	O
prolific	O
diarrhea	O
that	O
does	O
not	O
respond	O
to	O
standard	O
therapy	O
e	O

Baclofen	B-Drug
was	O
first	O
suggested	O
as	O
an	O
adjunct	O
because	O
benzodiazepines	O
do	O
not	O
affect	O
GABAB	O
receptors	O
and	O
therefore	O
have	O
no	O
cross-tolerance	O
with	O
GHB	O
while	O
baclofen	B-Drug
which	O
works	O
via	O
is	O
cross-tolerant	O
may	O
be	O
more	O
effective	O
in	O
alleviating	O
withdrawal	O
effects	O
of	O

Though	O
this	O
is	O
somewhat	O
controversial	O
among	O
proponents	O
of	O
a	O
zero-tolerance	O
drug	O
policy	O
it	O
has	O
proven	O
superior	O
to	O
methadone	B-Drug
in	O
improving	O
the	O
social	O
and	O
health	O
situations	O
addicts	O

Marijuana	B-Drug
has	O
seen	O
a	O
renaissance	O
in	O
its	O
utopian	O
representation	O
films	O
such	O
as	O
the	O
suburban	O
satire	O
American	O
Beauty	O
1999	O
dir	O

Danazol	B-Drug
is	O
described	O
as	O
a	O
possessing	O
high	O
affinity	O
for	O
the	O
androgen	O
receptor	O
AR	O
moderate	O
progesterone	O
PR	O
and	O
glucocorticoid	O
GR	O
poor	O
estrogen	O
ER	O

PCP	B-Drug
has	O
also	O
been	O
shown	O
to	O
cause	O
schizophrenia-like	O
changes	O
in	O
N-acetylaspartate	O
and	O
N-acetylaspartylglutamate	O
levels	O
the	O
rat	O
brain	O
which	O
are	O
detectable	O
both	O
living	O
rats	O
upon	O
necropsy	O
examination	O
of	O
tissue	O

Drugs	O
have	O
different	O
effects	O
some	O
can	O
be	O
relaxing	O
or	O
harmful	O
both	O
it	O
depends	O
on	O
how	O
much	O
a	O
person	O
took;	O
narcotic	O
like	O
heroin	B-Drug
and	O
other	O
opiates	O
but	O
also	O
alcohol	O
sleeping	O
pills	O

Elevated	O
levels	O
of	O
inhibitory	O
neurosteroids	O
namely	O
allopregnanolone	B-Drug
can	O
produce	O
paradoxical	O
effects	O
such	O
as	O
negative	O
mood	O
anxiety	O
irritability	O
and	O
aggression	O

Eddie	O
promises	O
Buddy	O
that	O
he	O
has	O
quit	O
cold	O
turkey	O
but	O
when	O
a	O
major	O
sale	O
opportunity	O
comes	O
up	O
steals	O
Buddys	O
college	O
money	O
to	O
purchase	O
cocaine	B-Drug
from	O
Bruce	O

These	O
derivatives	O
are	O
hydrolyzed	O
to	O
release	O
free	O
testosterone	O
at	O
the	O
site	O
of	O
injection;	O
absorption	O
rate	O
and	O
thus	O
injection	O
schedule	O
varies	O
among	O
different	O
esters	O
but	O
medical	O
injections	B-Drug
normally	O
done	O
anywhere	O
between	O
semi-weekly	O
once	O
every	O
12	O
weeks	O

In	O
addition	O
to	O
the	O
classical	O
nuclear	O
AR	O
bicalutamide	B-Drug
has	O
been	O
assessed	O
at	O
membrane	O
androgen	O
receptors	O
mARs	O
and	O
found	O
act	O
as	O
a	O
potent	O
antagonist	O
of	O
ZIP9	O
IC50	O
=	O
66	O

The	O
hallucinogen	O
LSD	B-Drug
is	O
a	O
psychoactive	O
drug	O
commonly	O
used	O
as	O
recreational	O

Additionally	O
in	O
2018	O
American	O
rapper	O
Mac	O
Miller	O
died	O
from	O
an	O
accidental	O
overdose	O
of	O
fentanyl	B-Drug
cocaine	B-Drug
and	O
alcohol	O

The	O
compound	O
is	O
a	O
derivative	O
of	O
levomethamphetamine	B-Drug
L-methamphetamine	B-Drug
with	O
propargyl	O
group	O
attached	O
to	O
the	O
nitrogen	O
atom	O

However	O
illegal	O
network	O
in	O
Europe	O
and	O
United	O
States	O
provide	O
ibogaine	B-Drug
for	O
treating	O
drug	O
addiction	O

The	O
Mao	O
Zedong	O
government	O
is	O
generally	O
credited	O
with	O
eradicating	O
both	O
consumption	O
and	O
production	O
of	O
opium	B-Drug
during	O
the	O
1950s	O
using	O
unrestrained	O
repression	O
social	O
reform	O

As	O
a	O
member	O
of	O
Parliament	O
Gladstone	O
called	O
it	O
most	O
infamous	O
and	O
atrocious	O
referring	O
to	O
the	O
opium	B-Drug
trade	O
between	O
China	O
British	O
India	O
in	O
particular	O

In	O
May	O
2007	O
the	O
company	O
pleaded	O
guilty	O
to	O
misleading	O
public	O
about	O
OxyContin's	O
risk	O
of	O
addiction	O
and	O
agreed	O
pay	O
$600	O
million	O
equivalent	O
approximately	O
$740M	O
in	O
2019	O
one	O
largest	O
pharmaceutical	O
settlements	O
U	O
OxyContin	B-Drug

It	O
is	O
assumed	O
that	O
if	O
the	O
patient	O
underwent	O
a	O
pharmacogenomic	O
test	O
it	O
would	O
have	O
revealed	O
she	O
may	O
had	O
duplication	O
of	O
gene	O
CYP2D6	O
placing	O
her	O
in	O
Ultra-rapid	O
metabolizer	O
UM	O
category	O
explaining	O
ADRs	O
to	O
codeine	B-Drug
use	O

It	O
is	O
also	O
used	O
as	O
a	O
precursor	O
chemical	O
in	O
the	O
illegal	O
production	O
of	O
methamphetamine	B-Drug

According	O
to	O
a	O
2014	O
survey	O
25I-NBOMe	B-Drug
was	O
the	O
most	O
frequently	O
used	O
of	O
NBOMe	O
series	O

There	O
is	O
no	O
good	O
evidence	O
that	O
trifluoperazine	B-Drug
more	O
effective	O
for	O
schizophrenia	O
than	O
lower-potency	O
antipsychotics	O
like	O
chlorpromazine	B-Drug
chlorprothixene	O
thioridazine	O
and	O
levomepromazine	O
but	O
appears	O
to	O
cause	O
adverse	O
effects	O
these	O
drugs	O

Its	O
structure	O
is	O
similar	O
to	O
that	O
of	O
other	O
morphine	B-Drug
esters	O
such	O
as	O
heroin	B-Drug
and	O
nicomorphine	B-Drug

Flurazepam	B-Drug
is	O
lipophilic	O
metabolized	O
hepatically	O
via	O
oxidative	O
pathways	O

Like	O
prodine	B-Drug
it	O
has	O
two	O
stereocenters	O
and	O
four	O
possible	O
enantiomers	O
but	O
the	O
activity	O
of	O
these	O
not	O
been	O
tested	O
separately	O

Ibuprofen	B-Drug
has	O
been	O
shown	O
more	O
effective	O
as	O
an	O
antipyretic	O
than	O
paracetamol	B-Drug
acetaminophen	B-Drug

Dexamethasone	B-Drug
and	O
most	O
glucocorticoids	O
are	O
banned	O
by	O
sporting	O
bodies	O
including	O
the	O
World	O
Anti-Doping	O
Agency	O

Cocaine	B-Drug
use	O
also	O
increases	O
the	O
risk	O
of	O
having	O
a	O
heart	O
attack	O

Preliminary	O
evaluation	O
Evaluation	O
of	O
the	O
eyes	O
Psychomotor	O
tests	O
Vital	O
signs	O
Dark	O
room	O
examinations	O
Muscle	O
tone	O
Injection	O
sites	O
for	O
injection	O
heroin	B-Drug
or	O
other	O
drugs	O
Interrogation	O
suspect	O
Opinion	O
evaluator	O
Toxicological	O
examinationDREs	O
are	O
qualified	O
to	O
offer	O
expert	O
testimony	O
in	O
court	O
that	O
pertains	O
impaired	O
driving	O
on	O

A	O
number	O
of	O
the	O
effects	O
that	O
had	O
been	O
thought	O
after	O
early	O
studies	O
to	O
be	O
attributable	O
prenatal	O
exposure	O
cocaine	B-Drug
are	O
actually	O
due	O
partially	O
or	O
wholly	O
other	O
factors	O
such	O
as	O
substances	O
including	O
tobacco	B-Drug
alcohol	O
marijuana	O
environment	O
in	O
which	O
child	O
is	O
raised	O

The	O
onset	O
of	O
heroin's	O
effects	O
depends	O
upon	O
the	O
route	O
administration	O
heroin	B-Drug

When	O
enough	O
fentanyl	B-Drug
has	O
been	O
absorbed	O
the	O
sedated	O
person	O
generally	O
lets	O
lollipop	O
fall	O
from	O
mouth	O
indicating	O
sufficient	O
analgesia	O
and	O
somewhat	O
reducing	O
likelihood	O
of	O
overdose	O
associated	O
risks	O

However	O
the	O
active	O
metabolite	O
of	O
midazolam	B-Drug
is	O
minor	O
and	O
contributes	O
to	O
only	O
10	O
percent	O
biological	O
activity	O

Triamcinolone	B-Drug
is	O
a	O
synthetic	O
pregnane	O
corticosteroid	O
and	O
derivative	O
of	O
cortisol	O
hydrocortisone	B-Drug
also	O
known	O
as	O
1-dehydro-9-fluoro-16-hydroxyhydrocortisone	O
or	O
9-fluoro-16-hydroxyprednisolone	O
well	O
9-fluoro-11161721-tetrahydroxypregna-14-diene-320-dione	O

Bromazepam	B-Drug
has	O
also	O
been	O
responsible	O
for	O
accidental	O
poisonings	O
in	O
companion	O
animals	O

Androstenedione	B-Drug
was	O
legal	O
and	O
able	O
to	O
be	O
purchased	O
over	O
the	O
counter	O
as	O
a	O
consequence	O
it	O
in	O
common	O
use	O
Major	O
League	O
Baseball	O
throughout	O
1990s	O
by	O
record-breaking	O
sluggers	O
like	O
Mark	O
McGwire	O

Adverse	O
drug	O
reactions	O
most	O
commonly	O
associated	O
with	O
loperamide	B-Drug
are	O
constipation	O
which	O
occurs	O
in	O
1	O

If	O
high	O
boluses	O
of	O
fentanyl	B-Drug
are	O
administered	O
quickly	O
muscle	O
rigidity	O
the	O
vocal	O
cords	O
can	O
make	O
bag-mask	O
ventilation	O
very	O
difficult	O

The	O
opiate	O
antidote	O
naloxone	B-Drug
was	O
on-hand	O
to	O
treat	O
the	O
victims	O
of	O
crisis	O
but	O
whether	O
due	O
their	O
incarceration	O
lack	O
food	O
or	O
water	O
sleep	O
novel	O
nature	O
still-unconfirmed	O
compound	O
used	O
acute	O
symptoms	O
continued	O
develop	O
resulting	O
in	O
many	O
fatalities	O
despite	O
administration	O

Enzalutamide	B-Drug
apalutamide	B-Drug
and	O
abiraterone	B-Drug
acetate	O
are	O
specifically	O
approved	O
for	O
use	O
in	O
combination	O
with	O
castration	O
to	O
treat	O
castration-resistant	O
prostate	O
cancer	O

Clorazepate	B-Drug
produces	O
the	O
active	O
metabolite	O
desmethyl-diazepam	B-Drug
which	O
is	O
a	O
partial	O
agonist	O
of	O
GABAA	O
receptor	O
and	O
has	O
half	O
life	O
20	O
179	O
hours;	O
small	O
amount	O
desmethyldiazepam	B-Drug
further	O
metabolised	O
into	O
oxazepam	B-Drug

In	O
humans	O
MDMA	B-Drug
increases	O
the	O
amount	O
of	O
serotonin	O
in	O
synaptic	O
clefts	O
serotonergic	O
neurons	O
by	O
inhibiting	O
its	O
uptake	O
into	O
and	O
directly	O
releasing	O
it	O
from	O

The	O
most	O
common	O
mutation	O
observed	O
after	O
efavirenz	B-Drug
treatment	O
is	O
K103N	O
which	O
also	O
with	O
other	O
NNRTIs	O

Fludrocortisone	B-Drug
also	O
known	O
as	O
9-fluorocortisol	O
9-fluorohydrocortisone	O
or	O
9-fluoro-111721-trihydroxypregn-4-ene-320-dione	O
is	O
a	O
synthetic	O
pregnane	O
steroid	O
and	O
halogenated	O
derivative	O
of	O
cortisol	O
111721-trihydroxypregn-4-ene-320-dione	O

Hydromorphone	B-Drug
2	O
mg	O
by	O
mouth	O
is	O
equivalent	O
to	O
approximately	O
10	O
morphine	B-Drug

They	O
point	O
out	O
that	O
during	O
cooking	O
of	O
vegetables	O
and	O
fruit	O
containing	O
vitamin	B-Drug
C	I-Drug
the	O
elutes	O
into	O
water	O
becomes	O
degraded	O
through	O
oxidation	O

Alfaxalone	B-Drug
has	O
been	O
noted	O
to	O
be	O
a	O
good	O
anesthetic	O
agent	O
for	O
dogs	O
with	O
ventricular	O
arrhythmias	O
and	O
sighthounds	O

There	O
is	O
currently	O
no	O
evidence	O
that	O
the	O
relevant	O
actions	O
of	O
gabapentin	B-Drug
and	O
pregabalin	B-Drug
are	O
mediated	O
by	O
any	O
mechanism	O
other	O
than	O
inhibition	O
2-containing	O
VDCCs	O

GHB	B-Drug
is	O
also	O
produced	O
as	O
a	O
result	O
of	O
fermentation	O
and	O
found	O
in	O
small	O
quantities	O
some	O
beers	O
wines	O
beef	O
citrus	O
fruits	O

The	O
same	O
concerns	O
do	O
not	O
apply	O
to	O
psychedelics	O
that	O
release	O
neurotransmitters	O
such	O
as	O
LSD	B-Drug
nor	O
dissociatives	O
or	O
deliriants	O

China	O
is	O
a	O
source	O
country	O
for	O
significant	O
amounts	O
of	O
the	O
ephedrine	B-Drug
and	O
pseudoephedrine	O
exported	O
to	O
Mexico	O
subsequently	O
used	O
manufacture	O
methamphetamine	B-Drug
destined	O
United	O
States	O

]	O
hash	B-Drug
oil	I-Drug
A	O
resin	O
extracted	O
from	O
cannabis	O
or	O
hashish	B-Drug

Enzalutamide	B-Drug
was	O
developed	O
and	O
marketed	O
by	O
Medivation	O
for	O
the	O
treatment	O
of	O
prostate	O
cancer	O

A	O
class	O
of	O
lactic	O
acid	O
bacteria	O
labeled	O
heterofermentive	O
because	O
their	O
multiple	O
fermentation	O
pathways	O
convert	O
either	O
three	O
fructose	O
molecules	O
or	O
two	O
and	O
one	O
glucose	O
molecule	O
into	O
mannitol	B-Drug
each	O
acetic	O
carbon	O
dioxide	O

A	O
pinch	O
of	O
coca	B-Drug
leaves	O
was	O
included	O
in	O
John	O
Styth	O
Pemberton's	O
original	O
1886	O
recipe	O
for	O
Coca-Cola	O
though	O
the	O
company	O
began	O
using	O
decocainized	O
1906	O
when	O
Pure	O
Food	O
and	O
Drug	O
Act	O
passed	O

Cotellic	O
cobimetinib	B-Drug
for	O
melanoma	O

In	O
case	O
of	O
serious	O
medical	O
reasons	O
nordazepam	B-Drug
can	O
be	O
given	O
in	O
late	O
pregnancy	O
but	O
the	O
foetus	O
due	O
to	O
pharmacological	O
action	O
drug	O
may	O
experience	O
side	O
effects	O
such	O
as	O
hypothermia	O
hypotonia	O
and	O
sometimes	O
mild	O
respiratory	O
depression	O

Japan	O
In	O
dihydrocodeine	B-Drug
is	O
available	O
without	O
a	O
prescription;	O
used	O
in	O
cough	O
medicines	O
such	O
as	O
New	O
Bron	O
Solution-ACE	O

Cannabidiol	B-Drug
was	O
isolated	O
and	O
identified	O
from	O
Cannabis	O
sativa	O
in	O
1940	O
THC	O
its	O
structure	O
elucidated	O
by	O
synthesis	O
1964	O

Many	O
people	O
who	O
smoke	O
cannabis	O
also	O
tobacco	B-Drug

Several	O
large	O
quantities	O
of	O
illicitly	O
produced	O
fentanyl	B-Drug
have	O
been	O
seized	O
by	O
U	O

Brazil	O
is	O
a	O
major	O
destination	O
and	O
transit	O
country	O
for	O
cocaine	B-Drug
smugglers	O
this	O
supply	O
goes	O
onto	O
Western	O
Central	O
Europe	O
South	O
Africa	O
West	O
Asia	O

Examples	O
are	O
plants	O
from	O
the	O
genus	O
Anadenanthera	O
that	O
used	O
in	O
hallucinogenic	O
yopo	O
snuff	B-Drug

Chemically	O
PCP	B-Drug
is	O
a	O
member	O
of	O
the	O
arylcyclohexylamine	O
class	O
and	O
pharmacologically	O
it	O
dissociative	O
anesthetic	O

Metabolites	O
of	O
nandrolone	B-Drug
include	O
5-dihydronandrolone	O
19-norandrosterone	O
and	O
19-noretiocholanolone	O
these	O
metabolites	O
may	O
be	O
detected	O
in	O
urine	O

Also	O
coca	B-Drug
leaves	O
have	O
been	O
used	O
by	O
South	O
American	O
Indians	O
since	O
ancient	O
times	O

Phendimetrazine	B-Drug
Tartrate	O
a	O
stimulant	O
synthesized	O
for	O
use	O
as	O
an	O
anorexiant	O

The	O
FDA	O
required	O
that	O
Celgene	O
Corporation	O
which	O
planned	O
to	O
market	O
thalidomide	B-Drug
under	O
the	O
brand	O
name	O
Thalomid	B-Drug
establish	O
a	O
system	O
for	O
education	O
and	O
prescribing	O
safety	O
STEPS	O
oversight	O
program	O

Flunitrazepam	B-Drug
is	O
subject	O
to	O
more	O
stringent	O
regulations	O
in	O
certain	O
states	O
and	O
temazepam	B-Drug
prescriptions	O
require	O
specially	O
coded	O
pads	O

In	O
addition	O
oxycodone	B-Drug
is	O
a	O
Schedule	O
2	O
drug	O
per	O
the	O
Misuse	O
of	O
Drugs	O
Regulations	O
2001	O
which	O
provide	O
certain	O
exemptions	O
from	O
provisions	O
Act	O
1971	O

5	O
kg	O
of	O
pasta	O
approximately	O
4060%	O
cocaine	B-Drug

Its	O
popularity	O
with	O
recreational	O
drug	O
users	O
compared	O
to	O
morphine	B-Drug
reportedly	O
stems	O
from	O
its	O
perceived	O
different	O
effects	O

President	O
Morales	O
opposed	O
the	O
decriminalization	O
of	O
drugs	O
but	O
saw	O
coca	B-Drug
crop	O
as	O
an	O
important	O
piece	O
indigenous	O
history	O
and	O
a	O
pillar	O
community	O
because	O
traditional	O
use	O
chewing	O
leaves	O

Diminution	O
of	O
morphine	B-Drug
self-administration	O
was	O
reported	O
in	O
preclinical	O
studies	O
by	O
Glick	O
et	O
al	O

The	O
review	O
authors	O
conclude	O
that	O
individuals	O
should	O
not	O
use	O
androstenedione	B-Drug
supplements	O
due	O
to	O
the	O
lack	O
of	O
evidence	O
beneficial	O
effects	O
wide	O
variation	O
in	O
individual	O
responses	O
supplement	O
and	O
risk	O
unknown	O
side	O

Diacetyldihydromorphine	B-Drug
is	O
fast-acting	O
and	O
longer-lasting	O
than	O
diamorphine	B-Drug
with	O
a	O
duration	O
of	O
action	O
around	O
4-7	O
hours	O

The	O
yield	O
of	O
nonpollinated	O
sinsemilla	B-Drug
hemp	O
at	O
18	O
L/ha	O
was	O
more	O
than	O
twofold	O
compared	O
with	O
pollinated	O
8	O

Although	O
the	O
organization	O
started	O
out	O
as	O
a	O
smuggling	O
network	O
in	O
early	O
1970s	O
it	O
wasn't	O
until	O
1976	O
that	O
turned	O
to	O
trafficking	O
cocaine	B-Drug

Mitragyna	B-Drug
speciosa	I-Drug
is	O
indigenous	O
to	O
Thailand	O
Indonesia	O
Malaysia	O
Myanmar	O
and	O
Papua	O
New	O
Guinea	O

33-azo	O
analogue	O
of	O
mestanolone	B-Drug
17-methyl-DHT	O

Estonia	O
has	O
the	O
highest	O
rate	O
of	O
3-methylfentanyl	B-Drug
overdose	O
deaths	O
in	O
EU	O
due	O
to	O
its	O
high	O
recreational	O
use	O

Transdermal	O
fentanyl	B-Drug
has	O
also	O
been	O
used	O
for	O
many	O
years	O
in	O
dogs	O
and	O
cats	O
post-operative	O
analgesia	O

The	O
NAACP	O
has	O
been	O
strong	O
supporters	O
of	O
the	O
Respect	O
State	O
Marijuana	B-Drug
Laws	O
Act	O
H	O

The	O
concomitant	O
use	O
of	O
methotrexate	B-Drug
in	O
particular	O
may	O
lead	O
to	O
severe	O
or	O
even	O
fatal	O
liver-damage	O
hepatotoxicity	O

On	O
August	O
20	O
2020	O
Justin	O
Townes	O
Earle	O
died	O
from	O
an	O
accidental	O
overdose	O
caused	O
by	O
cocaine	B-Drug
laced	O
with	O
fentanyl	B-Drug

Enzalutamide	B-Drug
may	O
cause	O
seizures	O
in	O
overdose	O

It	O
was	O
developed	O
as	O
a	O
rigid	O
analog	O
of	O
LSD	B-Drug
with	O
the	O
diethylamide	O
group	O
constrained	O
into	O
an	O
azetidine	O
ring	O
in	O
order	O
to	O
map	O
binding	O
site	O
at	O
5-HT2A	O
receptor	O

The	O
trade	O
name	O
Dolophine	O
was	O
created	O
by	O
Eli	O
Lilly	O
after	O
World	O
War	O
II	O
and	O
used	O
in	O
the	O
United	O
States;	O
claim	O
that	O
Nazi	O
leader	O
Adolf	O
Hitler	O
ordered	O
manufacture	O
of	O
methadone	B-Drug
or	O
brand	O
'Dolophine'	O
named	O
him	O
is	O
an	O
urban	O
legend	O

However	O
because	O
MDMA	B-Drug
excretion	O
and	O
metabolism	O
have	O
nonlinear	O
kinetics	O
the	O
half-lives	O
would	O
be	O
higher	O
at	O
more	O
typical	O
doses	O
100	O
mg	O
is	O
sometimes	O
considered	O
a	O
dose	O

A	O
mixture	O
of	O
mannitol	B-Drug
and	O
fentanyl	B-Drug
or	O
analogs	O
in	O
ratio	O
1:10	O
is	O
labeled	O
sold	O
as	O
China	O
white	O
a	O
popular	O
heroin	B-Drug
substitute	O

Dextromethorphan	B-Drug
is	O
the	O
dextrorotatory	O
enantiomer	O
of	O
levomethorphan	B-Drug
which	O
methyl	O
ether	O
levorphanol	B-Drug
both	O
opioid	O
analgesics	O

Yohimbine	B-Drug
was	O
used	O
for	O
the	O
treatment	O
of	O
erectile	O
dysfunction	O
in	O
men	O
until	O
emergence	O
more	O
efficient	O
drugs	O

A	O
whistleblower	O
suit	O
was	O
filed	O
in	O
2005	O
against	O
Wyeth	O
which	O
acquired	O
by	O
Pfizer	O
2009	O
alleging	O
that	O
the	O
company	O
illegally	O
marketed	O
their	O
drug	O
Rapamune	B-Drug

Mifepristone	B-Drug
200	O
mg	O
tablets	O
Mifegyne	O
Linepharma	O
Medabon	O
have	O
marketing	O
authorizations	O
in	O
the	O
European	O
Economic	O
Area	O
from	O
Medicines	O
Agency	O
EMA	O
for:	O
Early	O
first	O
trimester	O
medical	O
abortion	O
when	O
followed	O
by	O
a	O
prostaglandin	O
analog	O
misoprostol	B-Drug
or	O
gemeprost	O
through	O
63	O
days	O
gestational	O
age	O
Second	O
Cervical	O
softening	O
and	O
dilation	O
prior	O
to	O
surgical	O
Induction	O
of	O
labor	O
after	O
fetal	O
death	O
utero	O
analogs	O
oxytocin	O
are	O
contraindicated	O
was	O
banned	O
Australia	O
1996	O

A	O
preprint	O
containing	O
the	O
full	O
dataset	O
was	O
published	O
on	O
22	O
June	O
2020	O
and	O
demand	O
for	O
dexamethasone	B-Drug
surged	O
after	O
publication	O
of	O

Alder	O
Wright	O
in	O
1874	O
from	O
morphine	B-Drug
a	O
natural	O
product	O
of	O
the	O
opium	O
poppy	O

Subsequently	O
after	O
buying	O
an	O
old	O
school	O
bus	O
painting	O
it	O
with	O
psychedelic	O
graffiti	O
and	O
attracting	O
a	O
group	O
of	O
similarly	O
minded	O
individuals	O
he	O
dubbed	O
the	O
Merry	O
Pranksters	O
Kesey	O
his	O
traveled	O
across	O
country	O
often	O
hosting	O
acid	B-Drug
tests	O
where	O
they	O
would	O
fill	O
large	O
container	O
diluted	O
low	O
dose	O
form	O
drug	O
give	O
out	O
diplomas	O
to	O
those	O
who	O
passed	O
their	O
test	O

Flunitrazepam	B-Drug
has	O
been	O
implicated	O
as	O
the	O
cause	O
of	O
one	O
serial	O
killer's	O
violent	O
rampage	O
triggering	O
off	O
extreme	O
aggression	O
with	O
anterograde	O
amnesia	O

CBD	B-Drug
also	O
acts	O
as	O
an	O
allosteric	O
modulator	O
of	O
the	O
-	O
and	O
-opioid	O
receptors	O

11-methylated	O
19-nortestosterone	B-Drug
derivatives	O
have	O
no	O
risk	O
of	O
gynecomastia	O

As	O
methamphetamine	B-Drug
is	O
associated	O
with	O
a	O
high	O
potential	O
for	O
misuse	O
the	O
drug	O
regulated	O
under	O
Controlled	O
Substances	O
Act	O
and	O
listed	O
Schedule	O
II	O
in	O
United	O
States	O

This	O
led	O
GlaxoSmithKline	O
to	O
develop	O
Lapdap	B-Drug
a	O
combination	O
drug	O
consisting	O
of	O
chlorproguanil	O
and	O
dapsone	B-Drug

Based	O
on	O
heroin	B-Drug
production	O
statistics	O
compiled	O
by	O
the	O
United	O
Nations	O
Office	O
Drugs	O
and	O
Crime	O
in	O
2006	O
Bagcho's	O
activities	O
accounted	O
for	O
approximately	O
20	O
percent	O
of	O
world's	O
total	O
that	O
year	O

Colombias	O
reputation	O
as	O
the	O
cocaine	B-Drug
capital	O
of	O
world	O
has	O
attracted	O
tourists	O
to	O
dismay	O
locals	O

In	O
2012	O
the	O
company	O
garnered	O
extensive	O
local	O
and	O
global	O
media	O
coverage	O
as	O
result	O
of	O
developing	O
a	O
strain	O
medical	O
marijuana	O
that	O
contains	O
higher-than-normal	O
amount	O
Cannabidiol	B-Drug
less	O
than	O
2%	O
psychoactive	O
substance	O
THC	O
which	O
was	O
new	O
development	O
in	O
industry	O

A	O
systematic	O
review	O
did	O
not	O
find	O
any	O
evidence	O
of	O
benefit	O
in	O
preventing	O
vision	O
loss	O
eyes	O
treated	O
with	O
triamcinolone	B-Drug
acetonide	O
over	O
placebo	O
for	O
patients	O
age-related	O
macular	O
degeneration	O

34-Methylenedioxymethamphetamine	O
MDMA	B-Drug
is	O
Schedule	O
1	O
on	O
the	O
California	O
Uniform	O
Controlled	O
Substances	O
Act	O
Methylenedioxymethamphetamine	B-Drug

Tobacco	B-Drug
in	O
that	O
time	O
was	O
frequently	O
mixed	O
with	O
other	O
herbs	O
this	O
continues	O
clove	O
cigarettes	O
to	O
the	O
modern	O
day	O
and	O
opium	B-Drug
one	O
component	O
mixture	O

Dextromethamphetamine	B-Drug
is	O
a	O
stronger	O
CNS	O
stimulant	O
than	O
levomethamphetamine;	O
however	O
both	O
are	O
addictive	O
and	O
produce	O
the	O
same	O
toxicity	O
symptoms	O
at	O
high	O
doses	O
levomethamphetamine	B-Drug

Other	O
tests	O
for	O
Rohypnol	B-Drug
include	O
blood	O
and	O
hair	O

PCP	B-Drug
not	O
only	O
produced	O
symptoms	O
similar	O
to	O
schizophrenia	O
it	O
also	O
yielded	O
electroencephalogram	O
changes	O
in	O
the	O
thalamocortical	O
pathway	O
increased	O
delta	O
decreased	O
alpha	O
and	O
hippocampus	O
increase	O
theta	O
bursts	O
that	O
were	O
those	O

Concerns	O
about	O
possible	O
induction	O
of	O
desmosterolosis	O
and	O
associated	O
symptoms	O
such	O
as	O
cataracts	O
ichthyosis	O
with	O
extended	O
exposure	O
precluded	O
the	O
use	O
clomifene	B-Drug
in	O
treatment	O
breast	O
cancer	O

Food	O
and	O
Drug	O
Administration	O
FDA	O
approved	O
ivacaftor	B-Drug
in	O
January	O
2012	O
soon	O
afterwards	O
so	O
too	O
did	O
the	O
European	O
Medicines	O
Agency	O
EMA	O
Canada	O
across	O
some	O
countries	O

In	O
2009	O
the	O
FDA	O
issued	O
a	O
health	O
advisory	O
warning	O
that	O
prescription	O
of	O
bupropion	B-Drug
for	O
smoking	O
cessation	O
has	O
been	O
associated	O
with	O
reports	O
about	O
unusual	O
behavior	O
changes	O
agitation	O
and	O
hostility	O

Recent	O
reports	O
demonstrated	O
that	O
KORs	O
are	O
required	O
for	O
stress-induced	O
reinstatement	O
of	O
cocaine	B-Drug
seeking	O

The	O
effectiveness	O
increases	O
to	O
greater	O
than	O
90%	O
if	O
misoprostol	B-Drug
is	O
given	O
after	O
the	O
mifepristone	B-Drug

PCP's	O
rewarding	O
and	O
reinforcing	O
effects	O
are	O
at	O
least	O
partly	O
mediated	O
by	O
blocking	O
the	O
NMDA	O
receptors	O
in	O
glutamatergic	O
inputs	O
to	O
D1-type	O
medium	O
spiny	O
neurons	O
nucleus	O
accumbens	O
PCP	B-Drug

In	O
July	O
2014	O
the	O
Medicines	O
and	O
Healthcare	O
products	O
Regulatory	O
Agency	O
MHRA	O
of	O
UK	O
issued	O
a	O
warning	O
about	O
potential	O
for	O
life-threatening	O
harm	O
from	O
accidental	O
exposure	O
to	O
transdermal	O
fentanyl	B-Drug
patches	O
particularly	O
in	O
children	O
advised	O
that	O
they	O
should	O
be	O
folded	O
with	O
adhesive	O
side	O
before	O
being	O
discarded	O

The	O
toxicity	O
of	O
carfentanil	B-Drug
has	O
been	O
compared	O
to	O
that	O
nerve	O
gas	O
according	O
the	O
Associated	O
Press'	O
article	O
Chemical	O
weapon	O
for	O
sale:	O
China's	O
unregulated	O
narcotic	O

In	O
the	O
United	O
States	O
Pure	O
Food	O
and	O
Drug	O
Act	O
of	O
1906	O
required	O
that	O
certain	O
specified	O
drugs	O
including	O
alcohol	O
cocaine	B-Drug
heroin	B-Drug
morphine	B-Drug
cannabis	O
be	O
accurately	O
labeled	O
with	O
contents	O
dosage	O

Tranylcypromine	B-Drug
sold	O
under	O
the	O
trade	O
name	O
Parnate	B-Drug
among	O
others	O
is	O
a	O
monoamine	O
oxidase	O
inhibitor	O
MAOI;	O
more	O
specifically	O
tranylcypromine	B-Drug
acts	O
as	O
nonselective	O
and	O
irreversible	O
of	O
enzyme	O
MAO	O

Naltrexone	B-Drug
should	O
not	O
be	O
confused	O
with	O
naloxone	B-Drug
which	O
is	O
used	O
in	O
emergency	O
cases	O
of	O
opioid	O
overdose	O

Furthermore	O
it	O
is	O
not	O
clear	O
yet	O
whether	O
typical	O
users	O
of	O
MDMA	B-Drug
1	O
to	O
2	O
pills	O
75	O
125	O
mg	O
or	O
analogue	O
every	O
4	O
weeks	O
will	O
develop	O
neurotoxic	O
brain	O
lesions	O

Because	O
of	O
the	O
extremely	O
high	O
strength	O
pure	O
fentanyl	B-Drug
powder	O
it	O
is	O
very	O
difficult	O
to	O
dilute	O
appropriately	O
and	O
often	O
resulting	O
mixture	O
may	O
be	O
far	O
too	O
strong	O
therefore	O
dangerous	O

Methyldesorphine	B-Drug
is	O
listed	O
as	O
a	O
Schedule	O
I	O
Narcotic	O
controlled	O
substance	O
under	O
the	O
Controlled	O
Substances	O
Act	O
1970	O
in	O
United	O
States	O
with	O
DEA	O
ACSCN	O
of	O
9302	O
and	O
zero	O
annual	O
aggregate	O
manufacturing	O
quota	O

Clonazepam	B-Drug
is	O
generally	O
not	O
recommended	O
for	O
use	O
in	O
elderly	O
people	O
insomnia	O
due	O
to	O
its	O
high	O
potency	O
relative	O
other	O
benzodiazepines	O

By	O
the	O
end	O
of	O
20th	O
century	O
anti-smoking	O
campaigns	O
in	O
Germany	O
were	O
unable	O
to	O
exceed	O
effectiveness	O
Nazi-era	O
climax	O
years	O
193941	O
and	O
German	O
tobacco	B-Drug
health	O
research	O
was	O
described	O
by	O
Robert	O
N	O

Actor	O
Peter	O
Fonda	O
repeatedly	O
said	O
I	O
know	O
what	O
it's	O
like	O
to	O
be	O
dead	O
John	O
Lennon	O
during	O
an	O
LSD	B-Drug
trip	O

Another	O
way	O
in	O
which	O
norethisterone	B-Drug
may	O
be	O
acting	O
to	O
reduce	O
endometrial	O
pain	O
is	O
via	O
inhibition	O
of	O
ovulation	O

Crude	O
cocaine	B-Drug
preparation	O
intermediates	O
are	O
marketed	O
as	O
cheaper	O
alternatives	O
to	O
pure	O
local	O
markets	O
while	O
the	O
more	O
expensive	O
end	O
product	O
is	O
exported	O
United	O
States	O
and	O
European	O

The	O
longer	O
half-life	O
of	O
quazepam	B-Drug
may	O
have	O
the	O
advantage	O
however	O
causing	O
less	O
rebound	O
insomnia	O
than	O
shorter	O
acting	O
subtype	O
selective	O
nonbenzodiazepines	O

The	O
hash	B-Drug
oils	O
made	O
in	O
the	O
nineteenth	O
century	O
were	O
from	O
hand	O
collected	O
hashish	B-Drug
called	O
charas	O
and	O
kief	O

Ibuprofen	B-Drug
is	O
administered	O
as	O
a	O
racemic	O
mixture	O

Thalidomide	B-Drug
may	O
interfere	O
with	O
various	O
contraceptives	O
and	O
hence	O
it	O
is	O
advised	O
that	O
women	O
of	O
reproductive	O
age	O
use	O
at	O
least	O
two	O
different	O
means	O
contraception	O
to	O
ensure	O
no	O
child	O
will	O
be	O
conceived	O
while	O
they	O
are	O
taking	O
thalidomide	B-Drug

Compared	O
to	O
heroin	B-Drug
it	O
is	O
more	O
potent	O
has	O
higher	O
profit	O
margins	O
and	O
because	O
compact	O
simpler	O
logistics	O

The	O
substitutions	O
in	O
the	O
general	O
structure	O
for	O
naphyrone	B-Drug
analogues	O
subject	O
to	O
ban	O
may	O
be	O
described	O
as	O
follows:	O
Cyc	O
=	O
any	O
monocyclic	O
or	O
fused-polycyclic	O
ring	O
system	O
not	O
being	O
a	O
phenyl	O
alkylenedioxyphenyl	O
including	O
where	O
is	O
substituted	O
extent	O
with	O
alkyl	O
alkoxy	O
haloalkyl	O
halide	O
substituents	O
whether	O
further	O
by	O
one	O
more	O
other	O
univalent	O
R1	O
hydrogen	O
group	O
incorporation	O
cyclic	O
R3	O
structureMore	O
new	O
derivatives	O
have	O
however	O
continued	O
appear	O
UK	O
reporting	O
novel	O
cathinone	B-Drug
detected	O
2010	O
than	O
country	O
Europe	O
most	O
of	O
them	O
first	O
identified	O
after	O
generic	O
had	O
gone	O
into	O
effect	O
and	O
thus	O
already	O
illegal	O
despite	O
never	O
having	O
been	O
previously	O
reported	O

I	O
have	O
listened	O
to	O
tapes	O
done	O
by	O
highly	O
articulate	O
people	O
under	O
LSD	B-Drug
for	O
example	O
and	O
they	O
talk	O
absolute	O
drivel	O

Diazepam	B-Drug
is	O
rarely	O
used	O
for	O
the	O
long-term	O
treatment	O
of	O
epilepsy	O
because	O
tolerance	O
to	O
its	O
anticonvulsant	O
effects	O
usually	O
develops	O
within	O
six	O
12	O
months	O
effectively	O
rendering	O
it	O
useless	O
that	O
purpose	O

He	O
determined	O
the	O
place	O
of	O
double	O
bond	O
in	O
hexene	O
obtained	O
from	O
mannitol	B-Drug
and	O
proved	O
that	O
it	O
is	O
a	O
derivative	O
normal	O

Tardive	O
dyskinesia	O
involuntary	O
repetitive	O
body	O
movements	O
and	O
akathisia	O
a	O
feeling	O
of	O
inner	O
restlessness	O
inability	O
to	O
stay	O
still	O
are	O
less	O
commonly	O
seen	O
with	O
chlorpromazine	B-Drug
than	O
they	O
high	O
potency	O
typical	O
antipsychotics	O
such	O
as	O
haloperidol	B-Drug
or	O
trifluoperazine	B-Drug
some	O
evidence	O
suggests	O
that	O
conservative	O
dosing	O
the	O
incidence	O
effects	O
for	O
may	O
be	O
comparable	O
newer	O
agents	O
risperidone	B-Drug
olanzapine	B-Drug

Fentanyl	B-Drug
has	O
a	O
therapeutic	O
index	O
of	O
270	O

According	O
to	O
the	O
current	O
Cochrane	O
review	O
on	O
drug	O
dependence	O
and	O
withdrawal	O
in	O
recreational	O
users	O
of	O
methamphetamine	B-Drug
when	O
chronic	O
heavy	O
abruptly	O
discontinue	O
[methamphetamine]	O
use	O
many	O
report	O
a	O
time-limited	O
syndrome	O
that	O
occurs	O
within	O
24	O
hours	O
their	O
last	O
dose	O

Similar	O
to	O
dopamine	O
amphetamine	B-Drug
dose-dependently	O
increases	O
the	O
level	O
of	O
synaptic	O
norepinephrine	O
direct	O
precursor	O
epinephrine	O

See	O
psilocin	B-Drug
for	O
more	O
details	O

He	O
also	O
told	O
the	O
BBC	O
all	O
we	O
can	O
say	O
is	O
[mephedrone]	O
probably	O
as	O
harmful	O
ecstasy	B-Drug
and	O
amphetamines	O
wait	O
until	O
have	O
some	O
better	O
scientific	O
evidence	O
to	O
support	O
that	O
mephedrone	B-Drug

Medical	O
examiners	O
concluded	O
that	O
musician	O
Prince	O
died	O
on	O
April	O
21	O
2016	O
from	O
an	O
accidental	O
fentanyl	B-Drug
overdose	O

Frequent	O
use	O
of	O
high	O
doses	O
kratom	B-Drug
may	O
cause	O
tremors	O
anorexia	O
weight	O
loss	O
seizures	O
and	O
psychosis	O

5-MeS-DMT	O
has	O
been	O
the	O
subject	O
of	O
only	O
limited	O
clinical	O
testing	O
with	O
several	O
small	O
behavioral	O
studies	O
in	O
rats	O
indicating	O
that	O
it	O
is	O
a	O
less	O
potent	O
than	O
5-MeO-DMT	B-Drug
or	O
4-hydroxy-DMT	O
psilocin	B-Drug
but	O
more	O
effective	O
either	O
4-MeO-DMT	O
4-MeS-DMT	O

Another	O
human	O
PET	O
imaging	O
study	O
similarly	O
found	O
that	O
modafinil	B-Drug
occupied	O
the	O
DAT	O
and	O
also	O
determined	O
it	O
significantly	O
elevated	O
extracellular	O
levels	O
of	O
dopamine	O
in	O
brain	O
including	O
nucleus	O
accumbens	O

They	O
have	O
claimed	O
that	O
19-nortestosterone	B-Drug
derivatives	O
like	O
tibolone	O
due	O
to	O
lacking	O
a	O
C19	O
methyl	O
group	O
indeed	O
are	O
not	O
substrates	O
of	O
the	O
classical	O
aromatase	O
enzyme	O
but	O
instead	O
still	O
transformed	O
into	O
corresponding	O
estrogens	O
by	O
other	O
cytochrome	O
P450	O
monooxygenases	O

The	O
optical	O
isomers	O
of	O
amphetamine	B-Drug
i	O

In	O
severe	O
chronic	O
kidney	O
failure	O
the	O
area	O
under	O
curve	O
value	O
for	O
zopiclone	B-Drug
was	O
larger	O
and	O
half-life	O
associated	O
with	O
elimination	O
rate	O
constant	O
longer	O
but	O
these	O
changes	O
were	O
not	O
considered	O
to	O
be	O
clinically	O
significant	O

Methylone	B-Drug
was	O
first	O
classified	O
by	O
Sveriges	O
riksdags	O
health	O
ministry	O
Statens	O
folkhlsoinstitut	O
as	O
hazard	O
under	O
the	O
act	O
Lagen	O
om	O
frbud	O
mot	O
vissa	O
hlsofarliga	O
varor	O
translated	O
Act	O
on	O
Prohibition	O
of	O
Certain	O
Goods	O
Dangerous	O
to	O
Health	O
Nov	O
1	O
2005	O
in	O
their	O
regulation	O
SFS	O
2005:733	O
listed	O
34-metylendioximetkatinon	O
Metylon	O

Paracetamol	B-Drug
acetaminophen	B-Drug
is	O
generally	O
not	O
considered	O
an	O
NSAID	O
because	O
it	O
has	O
only	O
minor	O
anti-inflammatory	O
activity	O

The	O
carbon-11	O
labelled	O
version	O
of	O
25I-NBOMe	B-Drug
[11C]Cimbi-5	O
was	O
synthesized	O
and	O
validated	O
as	O
a	O
radiotracer	O
for	O
positron	O
emission	O
tomography	O
PET	O
in	O
Copenhagen	O

Reuben	O
was	O
also	O
a	O
former	O
paid	O
spokesperson	O
for	O
the	O
drug	O
company	O
Pfizer	O
which	O
owns	O
intellectual	O
property	O
rights	O
marketing	O
celecoxib	B-Drug
in	O
United	O
States	O

There	O
is	O
also	O
a	O
high	O
risk	O
that	O
thalidomide	B-Drug
can	O
interfere	O
with	O
formation	O
of	O
various	O
kinds	O
new	O
blood	O
cells	O
creating	O
infection	O
via	O
neutropenia	O
leukopenia	O
and	O
lymphopenia	O
risks	O
will	O
not	O
clot	O
thrombocytopenia	O

Other	O
factors	O
that	O
increase	O
the	O
risk	O
of	O
respiratory	O
depression	O
are:	O
High	O
fentanyl	B-Drug
doses	O
Sleep	O
Older	O
age	O
Concomitant	O
use	O
CNS	O
depressants	O
like	O
benzodiazepines	O
barbiturates	O
alcohol	O
and	O
inhaled	O
anesthetics	O
Hyperventilation	O
Decreased	O
CO2	O
levels	O
in	O
serum	O
Respiratory	O
acidosis	O
clearance	O
from	O
body	O
blood	O
flow	O
to	O
liver	O
Renal	O
insufficiencySustained	O
release	O
preparations	O
such	O
as	O
patches	O
may	O
also	O
produce	O
unexpected	O
delayed	O

By	O
mid	O
1967	O
Pentazocine	B-Drug
was	O
already	O
being	O
sold	O
in	O
Mexico	O
England	O
and	O
Argentina	O
under	O
different	O
trade	O
names	O

There	O
have	O
been	O
reports	O
associating	O
chronic	O
fenfluramine	B-Drug
treatment	O
with	O
emotional	O
instability	O
cognitive	O
deficits	O
depression	O
psychosis	O
exacerbation	O
of	O
pre-existing	O
schizophrenia	O
and	O
sleep	O
disturbances	O

Demetrius	O
Flenory	O
and	O
Terry	O
were	O
charged	O
under	O
the	O
Continuing	O
Criminal	O
Enterprise	O
Statute	O
conspiracy	O
to	O
distribute	O
5	O
kilograms	O
or	O
more	O
of	O
cocaine	B-Drug
possession	O
with	O
intent	O
than	O
500	O
grams	O
launder	O
monetary	O
instruments	O
two	O
counts	O

Drugs	O
that	O
increase	O
the	O
transit	O
time	O
of	O
gabapentin	B-Drug
in	O
small	O
intestine	O
can	O
its	O
oral	O
bioavailability;	O
when	O
was	O
co-administered	O
with	O
morphine	B-Drug
bioavailability	O
a	O
600	O
mg	O
dose	O
increased	O
by	O
50%	O

A	O
review	O
comparing	O
ethanol	O
to	O
GHB	B-Drug
concluded	O
that	O
the	O
dangers	O
of	O
two	O
drugs	O
were	O
similar	O

Side	O
effects	O
of	O
ethylestrenol	B-Drug
include	O
symptoms	O
masculinization	O
like	O
acne	O
increased	O
hair	O
growth	O
voice	O
changes	O
and	O
sexual	O
desire	O

Oxidation	O
of	O
pseudoephedrine	O
to	O
methcathinone	B-Drug
requires	O
little	O
chemistry	O
experience	O
making	O
it	O
relatively	O
easy	O
synthesize	O

Alternatively	O
coca	B-Drug
leaves	O
can	O
be	O
infused	O
in	O
liquid	O
and	O
consumed	O
like	O
tea	O

Street	O
cocaine	B-Drug
is	O
often	O
adulterated	O
or	O
cut	O
with	O
talc	O
lactose	O
sucrose	O
glucose	O
mannitol	B-Drug
inositol	O
caffeine	O
procaine	O
phencyclidine	B-Drug
phenytoin	B-Drug
lignocaine	B-Drug
strychnine	O
amphetamine	B-Drug
heroin	B-Drug

Cocaine	B-Drug
use	O
is	O
prevalent	O
across	O
all	O
socioeconomic	O
strata	O
including	O
age	O
demographics	O
economic	O
social	O
political	O
religious	O
and	O
livelihood	O

Exemestane	B-Drug
is	O
an	O
irreversible	O
steroidal	O
aromatase	O
inactivator	O
of	O
type	O
I	O
structurally	O
related	O
to	O
the	O
natural	O
substrate	O
4-androstenedione	B-Drug

PCP	B-Drug
is	O
classified	O
as	O
a	O
schedule	O
II	O
drug	O
in	O
the	O
United	O
States	O

It	O
was	O
estimated	O
that	O
around	O
230	O
addicts	O
would	O
be	O
able	O
to	O
receive	O
free	O
diamorphine	B-Drug

Selectively	O
noradrenergic	O
drugs	O
are	O
minimally	O
psychoactive	O
but	O
as	O
demonstrated	O
by	O
ephedrine	B-Drug
may	O
be	O
distinguished	O
from	O
placebo	O
and	O
trends	O
towards	O
liking	O

Examples	O
of	O
notable	O
designer	O
steroids	O
include	O
1-testosterone	B-Drug
dihydroboldenone	O
methasterone	B-Drug
trenbolone	B-Drug
enanthate	I-Drug
desoxymethyltestosterone	B-Drug
tetrahydrogestrinone	B-Drug
and	O
methylstenbolone	O

USAF	O
Pararescue	O
combat	O
medics	O
in	O
Afghanistan	O
use	O
fentanyl	B-Drug
lozenges	O
the	O
form	O
of	O
lollipops	O
on	O
casualties	O
from	O
IED	O
blasts	O
and	O
other	O
trauma	O

Recreational	O
use	O
of	O
nitrazepam	B-Drug
is	O
common	O

In	O
emergency	O
medicine	O
safe	O
administration	O
of	O
intranasal	O
fentanyl	B-Drug
with	O
a	O
low	O
rate	O
side	O
effects	O
and	O
promising	O
pain	O
reducing	O
effect	O
was	O
demonstrated	O
in	O
prospective	O
observational	O
study	O
about	O
900	O
out-of-hospital	O
patients	O

Long-term	O
amphetamine	B-Drug
exposure	O
at	O
sufficiently	O
high	O
doses	O
in	O
some	O
animal	O
species	O
is	O
known	O
to	O
produce	O
abnormal	O
dopamine	O
system	O
development	O
or	O
nerve	O
damage	O
but	O
humans	O
with	O
ADHD	O
pharmaceutical	O
amphetamines	B-Drug
therapeutic	O
dosages	O
appear	O
improve	O
brain	O
and	O
growth	O

As	O
such	O
5-reductase	O
inhibitors	O
like	O
finasteride	B-Drug
and	O
dutasteride	B-Drug
do	O
not	O
reduce	O
the	O
androgenic	O
effects	O
of	O
metandienone	B-Drug

There	O
is	O
no	O
validated	O
peer-reviewed	O
publication	O
showing	O
the	O
effectiveness	O
of	O
ibuprofen	B-Drug
in	O
treatment	O
COVID19	O

Bufotenine	B-Drug
a	O
plant	O
extract	O
can	O
also	O
be	O
synthesized	O
into	O
DMT	O

For	O
instance	O
whereas	O
the	O
AR	O
activity	O
of	O
testosterone	O
is	O
greatly	O
potentiated	O
by	O
local	O
conversion	O
via	O
5-reductase	O
into	O
DHT	O
in	O
tissues	O
where	O
expressed	O
an	O
AAS	O
that	O
not	O
metabolized	O
or	O
already	O
5-reduced	O
such	O
as	O
itself	O
a	O
derivative	O
like	O
mesterolone	B-Drug
drostanolone	B-Drug
would	O
undergo	O
potentiation	O
said	O

It	O
acts	O
as	O
an	O
antagonist	O
of	O
the	O
-opioid	O
receptor	O
MOR	O
and	O
agonist	O
KOR	O
a	O
result	O
blocks	O
effects	O
stronger	O
agents	O
with	O
greater	O
intrinsic	O
activity	O
such	O
morphine	B-Drug
whilst	O
simultaneously	O
producing	O
analgesia	O

Sustained	O
aerobic	O
exercise	O
on	O
a	O
regular	O
basis	O
also	O
appears	O
to	O
be	O
an	O
effective	O
treatment	O
for	O
amphetamine	B-Drug
addiction;	O
therapy	O
improves	O
clinical	O
outcomes	O
and	O
may	O
used	O
as	O
adjunct	O
with	O
behavioral	O
therapies	O
addiction	O

It	O
is	O
more	O
specifically	O
a	O
derivative	O
of	O
norethisterone	B-Drug
17-ethynyl-19-nortestosterone	O
and	O
member	O
the	O
gonane	O
18-methylestrane	O
subgroup	O
19-nortestosterone	B-Drug
family	O
progestins	O

Nonsteroidal	O
androgen	O
synthesis	O
inhibitors	O
like	O
ketoconazole	B-Drug
can	O
also	O
be	O
described	O
as	O
NSAAs	O
although	O
the	O
term	O
is	O
usually	O
reserved	O
to	O
describe	O
AR	O
antagonists	O

This	O
causes	O
confounding	O
factors	O
where	O
questions	O
arise	O
as	O
to	O
whether	O
the	O
tobacco	B-Drug
cannabis	O
or	O
both	O
that	O
have	O
caused	O
a	O
cancer	O

Reports	O
of	O
perioral	O
dermatitis	O
in	O
renal	O
transplant	O
recipients	O
treated	O
with	O
oral	O
corticosteroids	O
and	O
azathioprine	B-Drug
have	O
been	O
documented	O

It	O
contains	O
loperamide	B-Drug
and	O
simethicone	O

In	O
the	O
Netherlands	O
midazolam	B-Drug
is	O
a	O
List	O
II	O
drug	O
of	O
Opium	O
Law	O

Among	O
the	O
early	O
cultivators	O
of	O
cannabis	O
for	O
recreational	O
use	O
in	O
California	O
were	O
Arabs	O
Armenians	O
and	O
Turks	O
who	O
grew	O
as	O
1895	O
to	O
make	O
hashish	B-Drug
local	O
consumption	O

Bromazepam	B-Drug
alters	O
the	O
electrical	O
status	O
of	O
brain	O
causing	O
an	O
increase	O
in	O
beta	O
activity	O
and	O
a	O
decrease	O
alpha	O
EEG	O
recordings	O

More	O
than	O
12	O
different	O
analogues	O
of	O
fentanyl	B-Drug
all	O
unapproved	O
and	O
clandestinely	O
produced	O
have	O
been	O
identified	O
in	O
the	O
U	O

AAS	O
like	O
methyltestosterone	B-Drug
stimulate	O
erythropoiesis	O
red	O
blood	O
cell	O
production	O
and	O
increase	O
hematocrit	O
levels	O
at	O
high	O
dosages	O
can	O
cause	O
polycythemia	O
overproduction	O
of	O
cells	O
which	O
greatly	O
the	O
risk	O
thrombic	O
events	O
such	O
as	O
embolism	O
stroke	O

The	O
acquired	O
F876L	O
mutation	O
of	O
the	O
AR	O
identified	O
in	O
advanced	O
prostate	O
cancer	O
cells	O
has	O
been	O
found	O
to	O
confer	O
resistance	O
both	O
enzalutamide	B-Drug
and	O
apalutamide	B-Drug

Julije	O
Domac	O
elucidated	O
the	O
structure	O
of	O
hexene	O
and	O
mannitol	B-Drug
obtained	O
from	O
Caspian	O
manna	O

PCP	B-Drug
hydrochloride	O
can	O
be	O
insufflated	O
snorted	O
depending	O
upon	O
the	O
purity	O

Ephedrine	B-Drug
exports	O
from	O
China	O
to	O
the	O
West	O
grew	O
4	O
216	O
tonnes	O
between	O
1926	O
and	O
1928	O

If	O
overdose	O
of	O
opium	B-Drug
tincture	O
is	O
suspected	O
rapid	O
professional	O
intervention	O
required	O

Research	O
efforts	O
have	O
been	O
focused	O
on	O
determining	O
how	O
thalidomide	B-Drug
causes	O
birth	O
defects	O
and	O
its	O
other	O
activities	O
in	O
the	O
human	O
body	O
to	O
develop	O
safer	O
analogs	O
find	O
further	O
uses	O
for	O

When	O
being	O
used	O
on	O
an	O
as-needed	O
basis	O
the	O
need	O
for	O
delorazepam	B-Drug
therapy	O
should	O
be	O
re-evaluated	O
each	O
time	O
a	O
new	O
prescription	O
is	O
issued	O
and	O
alternative	O
medications	O
considered	O
if	O
patients	O
begin	O
to	O
take	O
habitually	O
many	O
days	O
in	O
row	O

After	O
pharmacological	O
studies	O
research	O
on	O
MDMA	B-Drug
was	O
not	O
continued	O

Bayer	O
lost	O
some	O
of	O
its	O
trademark	O
rights	O
to	O
heroin	B-Drug
as	O
well	O
aspirin	B-Drug
under	O
the	O
1919	O
Treaty	O
Versailles	O
following	O
German	O
defeat	O
in	O
World	O
War	O
I	O

Harm	O
reduction	O
and	O
public	O
health	O
agencies	O
may	O
distribute	O
packets	O
of	O
citric	O
acid	O
or	O
ascorbic	O
Vitamin	B-Drug
C	I-Drug
for	O
this	O
purpose	O

Oxycodone	B-Drug
is	O
a	O
controlled	O
substance	O
under	O
Schedule	O
I	O
of	O
the	O
Controlled	O
Drugs	O
and	O
Substances	O
Act	O
CDSA	O

Prior	O
to	O
starting	O
buprenorphine	B-Drug
individuals	O
should	O
wait	O
long	O
enough	O
after	O
their	O
last	O
dose	O
of	O
opioid	O
until	O
they	O
have	O
some	O
withdrawal	O
symptoms	O
allow	O
for	O
the	O
medication	O
bind	O
receptors	O
but	O
if	O
taken	O
too	O
soon	O
can	O
displace	O
other	O
opioids	O
bound	O
and	O
precipitate	O
an	O
acute	O

There	O
is	O
a	O
paucity	O
of	O
research	O
on	O
the	O
use	O
gabapentin	B-Drug
for	O
treatment	O
anxiety	O
disorders	O

AMB-FUBINACA	B-Drug
was	O
the	O
most	O
common	O
synthetic	O
cannabinoid	O
identified	O
in	O
drug	O
seizures	O
by	O
Drug	O
Enforcement	O
Administration	O
2017	O
and	O
first	O
half	O
of	O
2018	O

Following	O
the	O
description	O
of	O
structure	O
and	O
activity	O
hyoscine	O
by	O
Ladenburg	O
search	O
for	O
synthetic	O
analogues	O
methods	O
total	O
synthesis	O
and/or	O
atropine	O
in	O
1930s	O
1940s	O
resulted	O
discovery	O
diphenhydramine	B-Drug
an	O
early	O
antihistamine	O
prototype	O
its	O
chemical	O
subclass	O
these	O
drugs	O
pethidine	B-Drug
first	O
fully	O
opioid	O
analgesic	O
known	O
as	O
Dolantin	O
Demerol	B-Drug
amongst	O
many	O
other	O
trade	O
names	O

There	O
are	O
many	O
known	O
cases	O
of	O
doping	O
in	O
sports	O
with	O
metandienone	B-Drug
by	O
professional	O
athletes	O

In	O
1879	O
cocaine	B-Drug
began	O
to	O
be	O
used	O
treat	O
morphine	B-Drug
addiction	O

JWH-307	B-Drug
is	O
an	O
analgesic	O
drug	O
used	O
in	O
scientific	O
research	O
which	O
acts	O
as	O
a	O
cannabinoid	O
agonist	O
at	O
both	O
the	O
CB1	O
and	O
CB2	O
receptors	O

The	O
short	O
term	O
effects	O
of	O
cannabis	O
can	O
be	O
altered	O
if	O
it	O
has	O
been	O
laced	O
with	O
opioid	O
drugs	O
such	O
as	O
heroin	B-Drug
or	O
fentanyl	B-Drug

One	O
study	O
used	O
a	O
daily	O
dosage	O
of	O
300	O
mg	O
androstenedione	B-Drug
combined	O
with	O
several	O
other	O
supplements	O
and	O
also	O
found	O
no	O
increase	O
in	O
strength	O
when	O
compared	O
to	O
control	O
group	O
that	O
did	O
not	O
take	O
the	O

Revlimid	B-Drug
is	O
available	O
only	O
in	O
a	O
restricted	O
distribution	O
setting	O
to	O
avoid	O
its	O
use	O
during	O
pregnancy	O

As	O
MDMA	B-Drug
was	O
now	O
deemed	O
illegal	O
held	O
in	O
the	O
same	O
category	O
as	O
such	O
substances	O
heroin	B-Drug
only	O
way	O
for	O
it	O
to	O
be	O
employed	O
scientific	O
inquiry	O
would	O
through	O
lengthy	O
and	O
expensive	O
FDA	O
approval	O
process	O

Other	O
activities	O
of	O
spironolactone	B-Drug
may	O
include	O
very	O
weak	O
interactions	O
with	O
the	O
estrogen	O
and	O
progesterone	O
receptors	O
agonism	O
pregnane	O
X	O
receptor	O

Owing	O
to	O
synergism	O
between	O
remifentanil	B-Drug
and	O
hypnotic	O
drugs	O
such	O
as	O
propofol	B-Drug
the	O
dose	O
of	O
can	O
be	O
substantially	O
reduced	O

Nandrolone	B-Drug
was	O
probably	O
among	O
the	O
first	O
AAS	O
to	O
be	O
used	O
as	O
a	O
doping	O
agent	O
in	O
sports	O
1960s	O

High-dose	O
or	O
prolonged	O
parenterally	O
administered	O
lorazepam	B-Drug
is	O
sometimes	O
associated	O
with	O
propylene	O
glycol	O
poisoning	O

The	O
latex	O
of	O
Papaver	O
somniferum	O
the	O
opium	O
poppy	O
has	O
been	O
shown	O
to	O
convert	O
tyrosine	O
into	O
alkaloid	O
morphine	B-Drug
and	O
bio-synthetic	O
pathway	O
established	O
from	O
by	O
using	O
Carbon-14	O
radio-labelled	O
trace	O
in-vivo	O
synthetic	O
route	O

2%	O
last-year	O
users	O
of	O
BZP	B-Drug
in	O
New	O
Zealand	O
is	O
classed	O
as	O
dependent	O
upon	O
it	O
although	O
97	O

diazepam	B-Drug
nitrazepam	B-Drug
low	O
dose	O
methylphenobarbitone	O
CD5:	O
low-dose	O
codeine	B-Drug
etc	O

Calls	O
for	O
reform	O
of	O
restrictions	O
on	O
the	O
use	O
prescription	O
cognitive-enhancement	O
drugs	O
also	O
called	O
smart	O
or	O
nootropics	O
such	O
as	O
Prozac	B-Drug
Ritalin	B-Drug
and	O
Adderall	B-Drug
have	O
been	O
made	O
grounds	O
cognitive	O
liberty	O

This	O
helped	O
reassure	O
them	O
they	O
could	O
sleep	O
without	O
their	O
pills	B-Drug

After	O
a	O
set	O
of	O
successful	O
clinical	O
trials	O
Duragesic	B-Drug
fentanyl	B-Drug
patches	O
were	O
introduced	O
into	O
medical	O
practice	O

The	O
regulatory	O
authorities	O
in	O
East	O
Germany	O
did	O
not	O
approve	O
thalidomide	B-Drug

This	O
is	O
the	O
largest	O
nimetazepam	B-Drug
seizure	O
recorded	O
since	O
became	O
a	O
controlled	O
drug	O
under	O
Misuse	O
of	O
Drugs	O
Act	O
in	O
1992	O

Black	O
market	O
ecstasy	B-Drug
pills	O
are	O
frequently	O
found	O
to	O
contain	O
other	O
drugs	O
in	O
place	O
of	O
or	O
addition	O
methylenedioxymethylamphetamine	O
MDMA	B-Drug

When	O
midazolam	B-Drug
is	O
used	O
alone	O
it	O
has	O
few	O
side	O
effects	O
but	O
can	O
cause	O
respiratory	O
depression	O
if	O
being	O
together	O
with	O
fentanyl	B-Drug

1918:	O
Paul	O
Rabe	O
and	O
Karl	O
Kindler	O
synthesize	O
quinine	B-Drug
from	O
quinotoxine	O
reversing	O
the	O
Pasteur	O
chemistry	O

Hydrocodone	B-Drug
was	O
declared	O
the	O
most	O
widely	O
prescribed	O
opioid	O
between	O
2007	O
and	O
2016	O
in	O
2015	O
International	O
Narcotics	O
Control	O
Board	O
reported	O
that	O
greater	O
than	O
98%	O
of	O
hydrocodone	B-Drug
consumed	O
entire	O
world	O
by	O
Americans	O

Between	O
1984	O
and	O
1987	O
cocaine	B-Drug
incidents	O
increased	O
to	O
94000	O

Ketoconazole	B-Drug
has	O
been	O
marketed	O
under	O
a	O
large	O
number	O
of	O
brand	O
names	O

Tar	O
heroin	B-Drug
injection	O
can	O
also	O
be	O
associated	O
with	O
Clostridium	O
botulinum	O
infection	O

The	O
efficacy	O
profile	O
of	O
lidocaine	B-Drug
as	O
a	O
local	O
anaesthetic	O
is	O
characterized	O
by	O
rapid	O
onset	O
action	O
and	O
intermediate	O
duration	O

Pentobarbital	B-Drug
also	O
has	O
an	O
application	O
in	O
reducing	O
intracranial	O
pressure	O
Reye's	O
syndrome	O
traumatic	O
brain	O
injury	O
and	O
induction	O
of	O
coma	O
cerebral	O
ischemia	O
patients	O

However	O
the	O
reduction	O
of	O
seizure	O
threshold	O
could	O
be	O
attributed	O
to	O
tramadol's	O
putative	O
inhibition	O
GABAA	O
receptors	O
at	O
high	O
doses	O
significant	O
100	O
M	O
tramadol	B-Drug

Around	O
3%	O
of	O
people	O
taking	O
zolpidem	B-Drug
are	O
likely	O
to	O
break	O
a	O
bone	O
as	O
result	O
fall	O
due	O
impaired	O
coordination	O
caused	O
by	O
the	O
drug	O

In	O
the	O
1660s	O
laudanum	B-Drug
was	O
recommended	O
for	O
pain	O
sleeplessness	O
and	O
diarrhea	O
by	O
Thomas	O
Sydenham	O
renowned	O
father	O
of	O
English	O
medicine	O
or	O
Hippocrates	O
to	O
whom	O
is	O
attributed	O
quote	O
Among	O
remedies	O
which	O
it	O
has	O
pleased	O
Almighty	O
God	O
give	O
man	O
relieve	O
his	O
sufferings	O
none	O
so	O
universal	O
efficacious	O
as	O
opium	B-Drug

Recent	O
reports	O
demonstrated	O
that	O
KORs	O
are	O
required	O
for	O
stress-induced	O
reinstatement	O
of	O
cocaine	B-Drug
seeking	O

Alfentanil	B-Drug
was	O
discovered	O
at	O
Janssen	O
Pharmaceutica	O
in	O
1976	O

One	O
study	O
found	O
that	O
only	O
10%	O
of	O
the	O
people	O
presenting	O
with	O
a	O
benzodiazepine	O
overdose	O
are	O
suitable	O
candidates	O
for	O
treatment	O
flumazenil	B-Drug

Ketamine	B-Drug
can	O
be	O
absorbed	O
by	O
many	O
different	O
routes	O
due	O
to	O
both	O
its	O
water	O
and	O
lipid	O
solubility	O

Approximately	O
20%	O
of	O
amphetamine	B-Drug
circulating	O
in	O
the	O
bloodstream	O
is	O
bound	O
to	O
plasma	O
proteins	O

Oxycodone	B-Drug
is	O
diverted	O
through	O
doctor	O
shopping	O
prescription	O
forgery	O
pharmacy	O
theft	O
and	O
overprescribing	O

7x	O
and	O
the	O
rest	O
are	O
all	O
around	O
same	O
potency	O
as	O
morphine	B-Drug

PCP	B-Drug
is	O
classified	O
as	O
a	O
schedule	O
II	O
drug	O
in	O
the	O
United	O
States	O

In	O
particular	O
amphetamine	B-Drug
may	O
decrease	O
the	O
effects	O
of	O
sedatives	O
and	O
depressants	O
increase	O
stimulants	O
antidepressants	O

In	O
people	O
previously	O
treated	O
with	O
docetaxel	B-Drug
survival	O
is	O
increased	O
by	O
3	O

Remifentanil	B-Drug
has	O
been	O
used	O
with	O
some	O
success	O
to	O
circumvent	O
naltrexone	B-Drug
in	O
patients	O
who	O
are	O
need	O
of	O
pain	O
management	O

Deloenen	O
visually	O
contrasts	O
this	O
Western	O
clinical	O
use	O
of	O
ibogaine	B-Drug
with	O
the	O
Bwiti	O
iboga	O
root	O
but	O
emphasizes	O
context	O

Harold	O
Bornstein	O
the	O
former	O
personal	O
physician	O
of	O
United	O
States	O
President	O
Donald	O
Trump	O
stated	O
in	O
2017	O
that	O
was	O
taking	O
finasteride	B-Drug
to	O
promote	O
hair	O
growth	O

The	O
LAT1	O
is	O
highly	O
expressed	O
at	O
the	O
bloodbrain	O
barrier	O
and	O
transports	O
gabapentin	B-Drug
across	O
into	O
brain	O

In	O
addition	O
about	O
a	O
six-fold	O
increase	O
in	O
mortality	O
necrotizing	O
enterocolitis	O
and	O
infection	O
such	O
as	O
sepsis	O
pneumonia	O
urinary	O
tract	O
was	O
reported	O
patients	O
receiving	O
ranitidine	B-Drug
cohort	O
analysis	O
of	O
274	O
VLBW	O
neonates	O

Other	O
common	O
gastrointestinal	O
complaints	O
including	O
dyspepsia	O
heartburn	O
and	O
mild	O
diarrhea	O
are	O
less	O
serious	O
rarely	O
require	O
discontinuation	O
of	O
indometacin	B-Drug

Other	O
primary	O
metabolites	O
include	O
nicotine	B-Drug
N'-oxide	O
nornicotine	O
isomethonium	O
ion	O
2-hydroxynicotine	O
and	O
glucuronide	O

While	O
opiates	O
function	O
similarly	O
with	O
respect	O
to	O
analgesia	O
the	O
pharmacokinetics	O
of	O
remifentanil	B-Drug
allows	O
for	O
quicker	O
post-operative	O
recovery	O

She	O
called	O
Walker's	O
psychiatrist	O
who	O
arrived	O
and	O
administered	O
amobarbital	B-Drug
for	O
sedation	O

One	O
study	O
found	O
that	O
the	O
depressed	O
testosterone	O
levels	O
of	O
heroin	B-Drug
addicts	O
returned	O
to	O
normal	O
within	O
one	O
month	O
abstinence	O
suggesting	O
effect	O
is	O
readily	O
reversible	O
and	O
not	O
permanent	O

A	O
publication	O
asked	O
in	O
1981	O
if	O
lorazepam	B-Drug
is	O
more	O
toxic	O
than	O
diazepam	B-Drug

However	O
two	O
19-nortestosterone	B-Drug
derivatives	O
of	O
vinyltestosterone	O
norvinisterone	O
17-vinyl-19-nortestosterone	O
and	O
norgesterone	O
17-vinyl-510-19-nortestosterone	O
have	O
been	O
marketed	O

While	O
the	O
CYP3A4	O
inhibitor	O
ketoconazole	B-Drug
had	O
no	O
significant	O
effect	O
on	O
exemestane	B-Drug
levels	O
in	O
a	O
clinical	O
trial	O
strong	O
inductor	O
rifampicin	B-Drug
significantly	O
cut	O
exemenstane	O
about	O
half	O
AUC	O
54%	O
Cmax	O
41%	O
for	O
single	O
dose	O
potentially	O
compromising	O
its	O
effectiveness	O

This	O
classification	O
was	O
established	O
in	O
the	O
2018	O
Farm	O
Bill	O
and	O
refined	O
to	O
include	O
hemp-sourced	O
extracts	B-Drug
cannabinoids	O
derivatives	O
definition	O
of	O
hemp	O

Chlorodehydromethyltestosterone	B-Drug
CDMT;	O
brand	O
name	O
Oral	B-Drug
Turinabol	I-Drug
also	O
known	O
as	O
4-chloro-17-hydroxy17-methylandrosta-14-dien-3-one	O
is	O
an	O
anabolicandrogenic	O
steroid	O
AAS	O

Tamoxifen	B-Drug
is	O
used	O
for	O
the	O
treatment	O
of	O
both	O
early	O
and	O
advanced	O
estrogen	O
receptor-positive	O
ER-positive	O
or	O
ER+	O
breast	O
cancer	O
in	O
pre-	O
postmenopausal	O
women	O

The	O
vast	O
majority	O
of	O
animals	O
and	O
plants	O
are	O
able	O
to	O
synthesize	O
vitamin	B-Drug
C	I-Drug
through	O
a	O
sequence	O
enzyme-driven	O
steps	O
which	O
convert	O
monosaccharides	O

Nimetazepam	B-Drug
has	O
a	O
particular	O
reputation	O
in	O
South	O
East	O
Asia	O
for	O
recreational	O
use	O
at	O
around	O
USD	O
7	O
per	O
tab	O
and	O
is	O
particularly	O
popular	O
among	O
persons	O
addicted	O
to	O
amphetamines	O
or	O
opioids	O

Bob	O
Dylan's	O
song	O
Just	O
Like	O
a	O
Woman	O
includes	O
the	O
line	O
her	O
fog	O
amphetamine	B-Drug
and	O
pearls	O

Lee	O
died	O
of	O
a	O
cerebral	O
edema	O
several	O
hours	O
after	O
taking	O
the	O
painkiller	O
and	O
muscle	O
relaxant	O
equagesic	B-Drug

In	O
1634	O
the	O
Patriarch	O
of	O
Moscow	O
forbade	O
sale	O
tobacco	B-Drug
and	O
sentenced	O
men	O
women	O
who	O
flouted	O
ban	O
to	O
have	O
their	O
nostrils	O
slit	O
backs	O
flayed	O

Teare	O
a	O
professor	O
of	O
forensic	O
medicine	O
at	O
the	O
University	O
London	O
who	O
was	O
flown	O
in	O
to	O
be	O
chief	O
expert	O
coroner's	O
report	O
said	O
that	O
it	O
both	O
irresponsible	O
and	O
irrational	O
attribute	O
either	O
edema	O
cannabis	O
concluded	O
fatal	O
due	O
rare	O
reaction	O
equagesic	B-Drug

The	O
conditions	O
required	O
under	O
the	O
program	O
include	O
limiting	O
prescription	O
and	O
dispensing	O
rights	O
to	O
authorized	O
prescribers	O
pharmacies	O
only	O
keeping	O
a	O
registry	O
of	O
all	O
patients	O
prescribed	O
thalidomide	B-Drug
providing	O
extensive	O
patient	O
education	O
about	O
risks	O
associated	O
with	O
drug	O
periodic	O
pregnancy	O
tests	O
for	O
women	O
who	O
take	O

Thus	O
interactions	O
are	O
to	O
be	O
expected	O
with	O
known	O
P-glycoprotein	O
inhibitors	O
such	O
as	O
amiodarone	B-Drug
bepridil	O
diltiazem	B-Drug
ciclosporin	B-Drug
itraconazole	B-Drug
quinine	B-Drug
quinidine	B-Drug
spironolactone	B-Drug
and	O
verapamil	B-Drug

For	O
example	O
a	O
vaginal	O
formulation	O
of	O
miconazole	B-Drug
antifungal	O
cream	O
might	O
irritate	O
the	O
skin	O
less	O
than	O
an	O
athlete	O
foot	O

When	O
fermentation	O
begins	O
add	O
to	O
it	O
a	O
solution	O
of	O
4	O
ounces	O
selected	O
opium	B-Drug
in	O
12	O
water	O

Coadministration	O
with	O
modafinil	B-Drug
alongside	O
opioids	O
such	O
as	O
hydrocodone	B-Drug
oxycodone	B-Drug
and	O
fentanyl	B-Drug
well	O
various	O
other	O
drugs	O
may	O
experience	O
a	O
drop	O
in	O
plasma	O
concentrations	O

Alphaprodine	B-Drug
has	O
a	O
duration	O
of	O
action	O
1	O
to	O
2	O
hours	O
and	O
40	O
60	O
mg	O
is	O
equal	O
10	O
morphine	B-Drug
via	O
the	O
subcutaneous	O
route	O

It	O
has	O
been	O
implicated	O
in	O
addictions	O
to	O
alcohol	O
cannabinoids	O
cocaine	B-Drug
methylphenidate	B-Drug
nicotine	B-Drug
opioids	O
phencyclidine	B-Drug
propofol	B-Drug
and	O
substituted	O
amphetamines	O
among	O
others	O

Unlike	O
morphine	B-Drug
and	O
other	O
opioids	O
that	O
are	O
used	O
to	O
alleviate	O
pain	O
nociceptin's	O
role	O
in	O
nociception	O
is	O
not	O
straightforward	O

Buprenorphine	B-Drug
was	O
patented	O
in	O
1965	O
and	O
approved	O
for	O
medical	O
use	O
the	O
United	O
States	O
1981	O

Lorazepam	B-Drug
may	O
also	O
be	O
slower	O
to	O
clear	O
in	O
the	O
elderly	O
leading	O
potentially	O
accumulation	O
and	O
enhanced	O
effects	O

Abiraterone	B-Drug
acetate	I-Drug
is	O
available	O
in	O
the	O
form	O
of	O
250	O
mg	O
and	O
500	O
film-coated	O
oral	O
tablets	O
uncoated	O

The	O
effects	O
of	O
amphetamine	B-Drug
on	O
the	O
gastrointestinal	O
tract	O
are	O
unpredictable	O

Anderson	O
also	O
revealed	O
the	O
names	O
of	O
numerous	O
Olympic	O
athletes	O
that	O
had	O
been	O
provided	O
with	O
The	B-Drug
Clear	I-Drug
boasting	O
neither	O
they	O
nor	O
Bonds	O
would	O
fail	O
drug	O
tests	O
because	O
substance	O
was	O
undetectable	O

In	O
the	O
United	O
Kingdom	O
methcathinone	B-Drug
is	O
listed	O
as	O
a	O
Class	O
B	O
drug	O
with	O
no	O
clinical	O
uses	O

APINACA	B-Drug
has	O
been	O
banned	O
in	O
Latvia	O
since	O
14	O
November	O
2013	O

While	O
the	O
predominant	O
drugs	O
of	O
abuse	O
examined	O
have	O
been	O
cocaine	B-Drug
44%	O
ethanol	O
35%	O
and	O
opioids	O
24%	O

The	O
regulatory	O
authorities	O
in	O
East	O
Germany	O
did	O
not	O
approve	O
thalidomide	B-Drug

Rats	O
forced	O
to	O
consume	O
massive	O
doses	O
of	O
GHB	B-Drug
will	O
intermittently	O
prefer	O
solution	O
water	O
but	O
after	O
experiments	O
on	O
rats	O
it	O
was	O
noted	O
that	O
no	O
rat	O
showed	O
any	O
sign	O
withdrawal	O
when	O
finally	O
removed	O
at	O
the	O
end	O
20-week	O
period	O
or	O
during	O
periods	O
voluntary	O
abstinence	O

Nortilidine	O
is	O
the	O
major	O
active	O
metabolite	O
of	O
tilidine	B-Drug

Psilocybin	O
is	O
chemically	O
far	O
more	O
stable	O
than	O
psilocin	B-Drug
the	O
latter	O
compound	O
being	O
largely	O
lost	O
when	O
mushroom	O
heated	O
or	O
dried	O

In	O
the	O
Netherlands	O
etorphine	B-Drug
is	O
a	O
Schedule	O
I	O
drug	O
of	O
Opium	O
Law	O

Other	O
metabolites	O
detected	O
were	O
lorazepam	B-Drug
and	O
lormetazepam	B-Drug
which	O
detectable	O
in	O
urine	O
for	O
19	O
11	O
days	O
respectively	O
indicating	O
hydroxylation	O
by	O
cytochrome	O
P450	O
enzymes	O
occurring	O
concurrently	O
with	O
N-demethylation	O

diethyl	O
ether	O
halothane	O
isoflurane	B-Drug
Etomidate	B-Drug
Propofol	B-Drug
Neurosteroids	O
e	O

NFEPP	O
N-3-fluoro-1-phenethylpiperidin-4-yl-N-phenylpropionamide	O
is	O
an	O
analgesic	O
opioid	O
chemical	O
similar	O
in	O
structure	O
to	O
fentanyl	B-Drug
designed	O
2016	O
by	O
Spahn	O
et	O
al	O

government	O
classified	O
oxycodone	B-Drug
as	O
a	O
schedule	O
II	O
drug	O

For	O
example	O
the	O
induction	O
of	O
metabolism	O
caused	O
by	O
smoking	O
means	O
that	O
smokers	O
require	O
up	O
to	O
double	O
dose	O
clozapine	B-Drug
compared	O
with	O
non-smokers	O
achieve	O
an	O
equivalent	O
plasma	O
concentration	O

Cyclization	O
of	O
N-phthaloyl-L-glutamine	O
occurs	O
using	O
carbonyldiimidazole	O
which	O
then	O
yields	O
thalidomide	B-Drug
3	O

As	O
of	O
2017	O
fentanyl	B-Drug
was	O
the	O
most	O
widely	O
used	O
synthetic	O
opioid	O
in	O
medicine	O

Bifluranol	O
has	O
also	O
been	O
found	O
to	O
act	O
as	O
a	O
17-hydroxylase/1720	O
lyase	O
inhibitor	O
though	O
with	O
less	O
potency	O
than	O
ketoconazole	B-Drug
and	O
this	O
action	O
may	O
contribute	O
its	O
efficacy	O
in	O
benign	O
prostatic	O
hyperplasia	O
by	O
further	O
helping	O
lower	O
androgen	O
levels	O

Still	O
pending	O
in	O
the	O
state	O
Senate	O
New	O
Jersey	O
Opioid	O
Antidote	O
Prescription	O
Bill	O
would	O
require	O
a	O
co-prescription	O
of	O
naloxone	B-Drug
or	O
other	O
opioid	O
overdose	O
agent	O
with	O
prescriptions	O
for	O
medications	O
all	O
patients	O
who	O
have	O
high	O
risk	O
overdosing	O
and	O
tightens	O
restrictions	O
on	O
dispensing	O
within	O

In	O
1959	O
Wolfgang	O
Fruhstorfer	O
synthesized	O
MDMA	B-Drug
for	O
pharmacological	O
testing	O
while	O
researching	O
stimulants	O

A	O
binding	O
study	O
assessed	O
PCP	B-Drug
at	O
56	O
sites	O
including	O
neurotransmitter	O
receptors	O
and	O
transporters	O
found	O
that	O
had	O
Ki	O
values	O
of	O
>10000	O
nM	O
all	O
except	O
the	O
dizocilpine	O
MK-801	O
site	O
NMDA	O
receptor	O
136	O
serotonin	O
transporter	O
=	O
2234	O

After	O
1860	O
opium	B-Drug
use	O
continued	O
to	O
increase	O
with	O
widespread	O
domestic	O
production	O
in	O
China	O

Spironolactone	B-Drug
is	O
available	O
in	O
the	O
form	O
of	O
tablets	O
25	O
mg	O
50	O
100	O
mg;	O
brand	O
name	O
Aldactone	B-Drug
others	O
and	O
suspensions	O
mg/5	O
mL;	O
CaroSpir	O
for	O
use	O
by	O
mouth	O

A	O
2010	O
study	O
utilized	O
a	O
mass	O
spectrometry	O
approach	O
to	O
detect	O
levels	O
of	O
bufotenin	B-Drug
in	O
the	O
urine	O
individuals	O
with	O
severe	O
autism	O
spectrum	O
disorder	O
ASD	O
schizophrenia	O
and	O
asymptomatic	O
subjects	O

Cocaine	B-Drug
was	O
created	O
by	O
Jamey	O
Kirby	O
who	O
used	O
to	O
work	O
as	O
a	O
software	O
executive	O

A	O
later	O
study	O
confirmed	O
the	O
d-threo-methylphenidate	B-Drug
dexmethylphenidate	B-Drug
binding	O
to	O
5HT1A	O
receptor	O
but	O
no	O
significant	O
activity	O
on	O
5HT2B	O
was	O
found	O

Because	O
of	O
the	O
hypothesis	O
that	O
NMDA	O
receptor	O
antagonism	O
underlies	O
antidepressant	O
effects	O
ketamine	B-Drug
esketamine	B-Drug
was	O
developed	O
as	O
an	O

Sibutramine	B-Drug
was	O
originally	O
developed	O
in	O
1988	O
by	O
Boots	O
Nottingham	O
U	O

In	O
September	O
2012	O
the	O
deaths	O
of	O
two	O
men	O
in	O
County	O
Cork	O
Ireland	O
have	O
been	O
linked	O
to	O
PMMA	B-Drug
overdoses	O

Metazocine	B-Drug
is	O
in	O
Schedule	O
II	O
of	O
the	O
Controlled	O
Substances	O
Act	O
1970	O
United	O
States	O
as	O
a	O
Narcotic	O
with	O
ACSCN	O
9240	O
19	O
gram	O
aggregate	O
manufacturing	O
quota	O
2014	O

Plasma	O
serum	O
or	O
blood	O
concentrations	O
of	O
pregabalin	B-Drug
may	O
be	O
measured	O
to	O
monitor	O
therapy	O
confirm	O
a	O
diagnosis	O
poisoning	O
in	O
hospitalized	O
people	O

It	O
also	O
has	O
a	O
higher	O
bioavailability	O
than	O
codeine	B-Drug

2019	O
a	O
privately-owned	O
submarine	O
was	O
captured	O
by	O
the	O
Peruvian	O
Navy	O
on	O
8	O
December	O
carrying	O
over	O
2000	O
kg	O
of	O
cocaine	B-Drug
off	O
coast	O
Department	O
Piura	O
in	O
Peru	O

Finasteride	B-Drug
is	O
also	O
marketed	O
under	O
a	O
variety	O
of	O
other	O
brand	O
names	O
throughout	O
the	O
world	O

Trimethoprim	B-Drug
was	O
first	O
used	O
in	O
1962	O

Thalidomide	B-Drug
causes	O
birth	O
defects	O

Although	O
it	O
remained	O
legal	O
in	O
some	O
countries	O
until	O
after	O
World	O
War	O
II	O
health	O
risks	O
addiction	O
and	O
widespread	O
recreational	O
use	O
led	O
most	O
western	O
to	O
declare	O
heroin	B-Drug
a	O
controlled	O
substance	O
by	O
the	O
latter	O
half	O
of	O
20th	O
century	O

In	O
the	O
UK	O
following	O
ACMD's	O
report	O
on	O
substituted	O
cathinone	O
derivatives	O
MDPV	B-Drug
is	O
a	O
Class	O
B	O
drug	O
under	O
The	O
Misuse	O
of	O
Drugs	O
Act	O
1971	O
Amendment	O
Order	O
2010	O
making	O
it	O
illegal	O
to	O
sell	O
buy	O
or	O
possess	O
without	O
license	O

In	O
general	O
there	O
are	O
far	O
lower	O
risks	O
of	O
pulmonary	O
complications	O
for	O
regular	O
cannabis	O
smokers	O
when	O
compared	O
with	O
those	O
tobacco	B-Drug

1%	O
incidence	O
adverse	O
effects	O
include:	O
Constipation	O
Urinary	O
retention	O
Hallucinations	O
Agitation	O
Confusion	O
Restlessness	O
SeizuresUnknown	O
frequency	O
Anaphylactic	O
shock	O
or	O
reactions	O
Dyspnea	O
shortness	O
of	O
breath	O
Rash	O
Erythema	O
Other	O
hypersensitivity	O
Blurred	O
vision	O
Mydriasis	O
dilated	O
pupils	O
Drowsiness	O
Dizziness	O
Somnolence	O
Physostigmine	B-Drug
a	O
cholinergic	O
drug	O
that	O
readily	O
crosses	O
the	O
blood-brain	O
barrier	O
has	O
been	O
used	O
as	O
an	O
antidote	O
to	O
treat	O
central	O
nervous	O
system	O
depression	O
symptoms	O
hyoscine	O
overdose	O

Because	O
the	O
stimulant	O
effects	O
of	O
cocaine	B-Drug
wear	O
off	O
far	O
more	O
quickly	O
than	O
depressant	O
heroin	B-Drug
or	O
morphine	B-Drug
fatal	O
respiratory	O
depression	O
often	O
occurs	O
when	O
full	O
a	O
overdosage	O
are	O
felt	O
in	O
isolation	O

The	O
product	O
is	O
a	O
combination	O
of	O
esterified	O
estrogens	O
an	O
estrogen	O
and	O
low-dose	O
methyltestosterone	B-Drug
androgen/anabolic	O
steroid	O
in	O
single	O
tablet	O

The	O
It's	O
Toasted	O
slogan	O
refers	O
to	O
the	O
product's	O
tobacco	B-Drug
being	O
toasted	O
instead	O
of	O
sun-dried	O
making	O
a	O
supposedly	O
better-tasting	O
product	O

The	O
drug	O
was	O
marketed	O
for	O
use	O
as	O
a	O
psychostimulant	O
under	O
the	O
brand	O
names	O
Captagon	B-Drug
Biocapton	O
and	O
Fitton	O

Mescaline	B-Drug
345-trimethoxyphenethylamine	O
is	O
a	O
psychedelic	O
drug	O
and	O
entheogen	O
which	O
also	O
found	O
in	O
some	O
other	O
species	O
of	O
genus	O
Echinopsis	O
i	O

Pemoline	B-Drug
free	O
base	O
and	O
pemoline	B-Drug
cobalt	O
strontium	O
silver	O
barium	O
lithium	O
sodium	O
potassium	O
zinc	O
manganese	O
caesium	O
are	O
research	O
chemicals	O
which	O
can	O
be	O
produced	O
in	O
situ	O
for	O
experiments	O

As	O
it	O
is	O
a	O
prodrug	O
lisdexamfetamine	B-Drug
structurally	O
different	O
from	O
dextroamphetamine	B-Drug
and	O
inactive	O
until	O
metabolizes	O
into	O

Ingested	O
aloe	O
products	O
may	O
have	O
adverse	O
interactions	O
with	O
prescription	O
drugs	O
such	O
as	O
those	O
used	O
to	O
treat	O
blood	O
clots	O
diabetes	O
heart	O
disease	O
and	O
potassium-lowering	O
agents	O
Digoxin	B-Drug
diuretics	O
among	O
others	O

Another	O
case	O
report	O
reported	O
similar	O
phenomenon	O
in	O
a	O
female	O
patient	O
who	O
abruptly	O
reduced	O
her	O
diazepam	B-Drug
dosage	O
from	O
30	O
mg	O
to	O
5	O
per	O
day	O

Sub-paragraphs	O
b	O
c	O
d	O
and	O
e	O
all	O
refer	O
to	O
anabolic	O
steroids	O
that	O
were	O
banned	O
in	O
1996	O
unless	O
referenced	O
otherwise:b	O
any	O
compound	O
not	O
being	O
Trilostane	O
or	O
a	O
for	O
the	O
time	O
specified	O
sub-paragraph	O
above	O
structurally	O
derived	O
from	O
17-hydroxyandrostan-3-one	O
17-hydroxyestran-3-one	O
by	O
modification	O
of	O
following	O
ways	O
is	O
say	O
i	O
further	O
substitution	O
at	O
position	O
17	O
methyl	O
ethyl	O
group;	O
ii	O
extent	O
one	O
more	O
positions	O
1	O
2	O
4	O
6	O
7	O
9	O
11	O
16	O
but	O
no	O
other	O
position;	O
iii	O
unsaturation	O
carbocyclic	O
ring	O
system	O
provided	O
there	O
are	O
than	O
two	O
ethylenic	O
bonds	O
ring;	O
iv	O
fusion	O
A	O
with	O
heterocyclic	O
system;	O
substance	O
which	O
an	O
ester	O
ether	O
where	O
hydroxyl	O
function	O
available	O
both	O
described	O
above;	O
Chorionic	O
gonadotropin	O
Clenbuterol	B-Drug
Non-human	O
chorionic	O
gonadotrophin	O
Somatropin	O
Somatrem	O
Somatropinf	O
1benzylpiperazine	O
13chlorophenylpiperazine	O
13chlorophenyl43chloropropylpiperazine	O
1phenylpiperazine	O
second	O
nitrogen	O
atom	O
piperazine	O
alkyl	O
benzyl	O
haloalkyl	O
phenyl	O
groups;	O
aromatic	O
alkoxy	O
alkylenedioxy	O
halide	O

The	O
first	O
Drug	O
court	O
in	O
the	O
United	O
States	O
took	O
shape	O
Miami-Dade	O
County	O
Florida	O
1989	O
as	O
a	O
response	O
to	O
growing	O
crack-cocaine	B-Drug
problem	O
plaguing	O
city	O

Phenoperidine	B-Drug
was	O
first	O
synthesized	O
in	O
1957	O
by	O
Paul	O
Janssen	O
of	O
the	O
company	O
now	O
known	O
as	O
Pharmaceutica	O
who	O
seeking	O
better	O
opioid	O
pain-killers	O

Heavy	O
drinking	O
tobacco	B-Drug
use	O
and	O
of	O
illegal	O
drugs	O
are	O
common	O
in	O
the	O
US	O
military	O

Soto's	O
death	O
at	O
age	O
35	O
was	O
attributed	O
to	O
a	O
mixture	O
of	O
alcohol	O
fentanyl	B-Drug
very	O
potent	O
opioid	O
morphine-like	O
substance	O
and	O
alprazolam	B-Drug
also	O
known	O
as	O
Xanax	B-Drug
sedative	O
benzodiazepine	O
anti-anxiety	O
medication	O

A	O
recent	O
study	O
using	O
X-ray	O
crystallography	O
showed	O
that	O
CBD	B-Drug
binds	O
inside	O
the	O
sodium	O
channel	O
pore	O
at	O
a	O
novel	O
site	O
interface	O
of	O
fenestrations	O
and	O
central	O
hydrophobic	O
cavity	O

Similarly	O
to	O
bicalutamide	B-Drug
the	O
drug	O
acts	O
as	O
a	O
selective	O
antagonist	O
of	O
androgen	O
receptor	O
AR	O

Triamcinolone	B-Drug
is	O
used	O
to	O
treat	O
a	O
number	O
of	O
different	O
medical	O
conditions	O
such	O
as	O
eczema	O
alopecia	O
areata	O
lichen	O
sclerosus	O
psoriasis	O
arthritis	O
allergies	O
ulcerative	O
colitis	O
lupus	O
sympathetic	O
ophthalmia	O
temporal	O
arteritis	O
uveitis	O
ocular	O
inflammation	O
keloids	O
urushiol-induced	O
contact	O
dermatitis	O
aphthous	O
ulcers	O
usually	O
triamcinolone	B-Drug
acetonide	O
central	O
retinal	O
vein	O
occlusion	O
visualization	O
during	O
vitrectomy	O
and	O
the	O
prevention	O
asthma	O
attacks	O

Atropine	O
may	O
also	O
be	O
used	O
as	O
a	O
premedication	O
agent	O
in	O
pediatrics	O
to	O
prevent	O
bradycardia	O
caused	O
by	O
hypoxia	O
laryngoscopy	O
and	O
succinylcholine	B-Drug

Increased	O
use	O
of	O
naloxone	B-Drug
particularly	O
the	O
nasal	O
spray	O
version	O
Narcan	B-Drug
along	O
with	O
a	O
growing	O
awareness	O
hazards	O
opioid	O
ingestion	O
has	O
reduced	O
overdose	O
mortality	O

Cocaine	B-Drug
heroin	B-Drug
cannabis	O
and	O
other	O
such	O
drugs	O
continued	O
to	O
be	O
legally	O
available	O
without	O
prescription	O
as	O
long	O
they	O
were	O
labeled	O

When	O
administered	O
orally	O
ketoconazole	B-Drug
is	O
best	O
absorbed	O
at	O
highly	O
acidic	O
levels	O
so	O
antacids	O
or	O
other	O
causes	O
of	O
decreased	O
stomach	O
acid	O
will	O
lower	O
the	O
drug's	O
absorption	O

government	O
classified	O
oxycodone	B-Drug
as	O
a	O
schedule	O
II	O
drug	O

Chinese	O
men	O
were	O
deported	O
for	O
playing	O
keno	O
and	O
sentenced	O
to	O
hard	O
labor	O
opium	B-Drug
possession	O

The	O
plasma	O
protein	O
binding	O
of	O
tamoxifen	B-Drug
and	O
afimoxifene	O
is	O
greater	O
than	O
99%	O

Methylnaltrexone	B-Drug
MNTX	O
brand	O
name	O
Relistor	B-Drug
used	O
in	O
form	O
of	O
methylnaltrexone	B-Drug
bromide	I-Drug
INN	O
USAN	O
BAN	O
is	O
a	O
medication	O
that	O
acts	O
as	O
peripherally	O
acting	O
-opioid	O
receptor	O
antagonist	O
to	O
reverse	O
some	O
the	O
side	O
effects	O
opioid	O
drugs	O
such	O
constipation	O
without	O
significantly	O
affecting	O
pain	O
relief	O
or	O
precipitating	O
withdrawals	O

Fentanyl	B-Drug
may	O
be	O
measured	O
in	O
blood	O
or	O
urine	O
to	O
monitor	O
for	O
abuse	O
confirm	O
a	O
diagnosis	O
of	O
poisoning	O
assist	O
medicolegal	O
death	O
investigation	O

Physicians	O
often	O
treat	O
MDPV	B-Drug
overdose	O
cases	O
with	O
anxiolytics	O
such	O
as	O
benzodiazepines	O
to	O
lessen	O
the	O
drug-induced	O
activity	O
in	O
brain	O
and	O
body	O

Methysergide	B-Drug
is	O
one	O
of	O
the	O
most	O
effective	O
medications	O
for	O
prevention	O
migraine	O
but	O
not	O
intended	O
treatment	O
an	O
acute	O
attack	O
it	O
to	O
be	O
taken	O
daily	O
as	O
a	O
preventative	O
medication	O

Various	O
physical	O
and	O
psychological	O
adverse	O
effects	O
have	O
been	O
reported	O
from	O
JWH-018	B-Drug
use	O

In	O
females	O
synthesis	O
of	O
estrogens	O
starts	O
in	O
theca	O
interna	O
cells	O
the	O
ovary	O
by	O
androstenedione	B-Drug
from	O
cholesterol	O

Opium	B-Drug
became	O
a	O
major	O
colonial	O
commodity	O
moving	O
legally	O
and	O
illegally	O
through	O
trade	O
networks	O
on	O
the	O
Indian	O
subcontinent	O
Colonial	O
America	O
Qing	O
China	O
others	O

The	O
Black	O
Mafia	O
Family	O
under	O
Demetrius	O
Flenory	O
entered	O
the	O
hip-hop	O
music	O
business	O
as	O
BMF	O
Entertainment	O
in	O
early	O
2000s	O
a	O
front	O
organization	O
to	O
launder	O
money	O
from	O
cocaine	B-Drug
sales	O
and	O
legitimize	O
itself	O

Specifically	O
nociceptin	O
acts	O
to	O
inhibit	O
neural	O
rewards	O
induced	O
by	O
drugs	O
such	O
as	O
amphetamines	O
morphine	B-Drug
cocaine	B-Drug
and	O
especially	O
alcohol	O
in	O
animal	O
models	O
though	O
the	O
exact	O
mechanism	O
of	O
this	O
has	O
not	O
yet	O
been	O
proven	O

This	O
enzyme	O
was	O
found	O
to	O
metabolize	O
amphetamine	B-Drug
tyramine	O
and	O
phenethylamine	B-Drug
with	O
roughly	O
the	O
same	O
binding	O
affinity	O
for	O
all	O
three	O
compounds	O

Dextromethamphetamine	B-Drug
is	O
a	O
stronger	O
CNS	O
stimulant	O
than	O
levomethamphetamine	B-Drug

Albert	O
Hofmann	O
and	O
his	O
colleagues	O
at	O
Sandoz	O
Laboratories	O
were	O
convinced	O
immediately	O
after	O
its	O
discovery	O
in	O
1943	O
of	O
the	O
power	O
promise	O
LSD	B-Drug

Recreational	O
use	O
of	O
25I-NBOMe	B-Drug
carries	O
a	O
significant	O
risk	O
both	O
pharmacological	O
and	O
behavioral	O
toxicity	O

Other	O
drugs	O
included	O
omeprazole	B-Drug
hydrocodone	B-Drug
paroxetine	B-Drug
carisoprodol	B-Drug
and	O
hydromorphone	B-Drug

Additionally	O
in	O
a	O
warning	O
letter	O
to	O
manufacturer	O
of	O
opium	B-Drug
tincture	O
late	O
2009	O
the	O
FDA	O
noted	O
that	O
we	O
found	O
your	O
firm	O
is	O
manufacturing	O
and	O
distributing	O
prescription	O
drug	O
Opium	B-Drug
Tincture	O
USP	O
Deodorized	O
10	O
mg/mL	O

for	O
reducing	O
cardiovascular	O
risk	O
must	O
be	O
careful	O
if	O
they	O
also	O
use	O
other	O
NSAIDs	O
as	O
these	O
may	O
inhibit	O
the	O
cardioprotective	O
effects	O
of	O
aspirin	B-Drug

When	O
given	O
by	O
injection	O
into	O
a	O
vein	O
heroin	B-Drug
has	O
two	O
to	O
three	O
times	O
the	O
effect	O
of	O
similar	O
dose	O
morphine	B-Drug

An	O
exception	O
is	O
medroxyprogesterone	B-Drug
acetate	I-Drug
as	O
a	O
progestogen-only	O
injectable	O
contraceptive	O
which	O
has	O
been	O
associated	O
with	O
2-	O
to	O
4-fold	O
increase	O
in	O
risk	O
of	O
VTE	O
relative	O
other	O
progestogens	O
and	O
non-use	O

The	O
effects	O
of	O
dexamethasone	B-Drug
are	O
frequently	O
seen	O
within	O
a	O
day	O
and	O
last	O
for	O
about	O
three	O
days	O

5F-ADB	B-Drug
is	O
believed	O
to	O
be	O
extremely	O
potent	O
based	O
on	O
the	O
very	O
low	O
levels	O
detected	O
in	O
tissue	O
samples	O
and	O
appears	O
significantly	O
more	O
toxic	O
than	O
earlier	O
synthetic	O
cannabinoid	O
drugs	O
that	O
had	O
previously	O
been	O
sold	O

Analogues	O
of	O
OHPC	O
include	O
other	O
17-hydroxyprogesterone	O
derivatives	O
such	O
as	O
algestone	O
acetophenide	O
dihydroxyprogesterone	O
chlormadinone	O
acetate	I-Drug
cyproterone	O
hydroxyprogesterone	O
heptanoate	O
medroxyprogesterone	B-Drug
and	O
megestrol	O
well	O
the	O
caproate	O
esters	O
gestonorone	O
norhydroxyprogesterone	O
methenmadinone	O

Women	O
taking	O
danazol	B-Drug
should	O
practice	O
effective	O
contraception	O
to	O
prevent	O
pregnancy	O
if	O
sexually	O
active	O

Naloxone	B-Drug
can	O
completely	O
or	O
partially	O
reverse	O
an	O
opioid	O
overdose	O

Ephedrine	B-Drug
though	O
binds	O
better	O
than	O
N-methylephedrine	O
which	O
has	O
an	O
additional	O
methyl	O
group	O
at	O
the	O
nitrogen	O
atom	O

Thalidomide	B-Drug
was	O
first	O
marketed	O
in	O
1957	O
West	O
Germany	O
where	O
it	O
available	O
over	O
the	O
counter	O

PCP	B-Drug
was	O
initially	O
made	O
in	O
1926	O
and	O
brought	O
to	O
market	O
as	O
an	O
anesthetic	O
medication	O
the	O
1950s	O

Pyrolysis	O
products	O
of	O
cocaine	B-Drug
that	O
occur	O
only	O
when	O
heated/smoked	O
have	O
been	O
shown	O
to	O
change	O
the	O
effect	O
profile	O
i	O

PCP	B-Drug
comes	O
in	O
both	O
powder	O
and	O
liquid	O
forms	O
base	O
is	O
dissolved	O
most	O
often	O
ether	O
but	O
typically	O
it	O
sprayed	O
onto	O
leafy	O
material	O
such	O
as	O
cannabis	O
mint	O
oregano	O
tobacco	B-Drug
parsley	O
or	O
ginger	O
leaves	O
then	O
smoked	O

Methamphetamine	B-Drug
suppresses	O
autonomic	O
response	O
and	O
can	O
cause	O
sores	O
abrasions	O
in	O
the	O
mouth	O

The	O
personal	O
notes	O
of	O
Adolf	O
Hitler's	O
physician	O
Theodor	O
Morell	O
indicate	O
Hitler	O
received	O
repeated	O
injections	O
eukodal	B-Drug
oxycodone	B-Drug
and	O
Scophedal	O
as	O
well	O
Dolantin	O
pethidine	B-Drug
codeine	B-Drug
morphine	B-Drug
less	O
frequently;	O
could	O
not	O
be	O
obtained	O
after	O
late	O
January	O
1945	O

Increased	O
doses	O
of	O
tapentadol	B-Drug
should	O
be	O
anticipated	O
to	O
slightly	O
stronger	O
than	O
predicted	O
by	O
linear	O
functions	O
the	O
previous	O
dose-response	O
relation	O

In	O
these	O
early	O
years	O
Purdue	O
Pharma	O
was	O
aware	O
of	O
OxyContin	B-Drug
abuse	O
including	O
reports	O
that	O
the	O
pills	O
were	O
being	O
crushed	O
and	O
snorted;	O
stolen	O
from	O
pharmacies;	O
some	O
doctors	O
charged	O
with	O
selling	O
prescriptions	O
according	O
to	O
The	O
New	O
York	O
Times	O
based	O
on	O
a	O
confidential	O
Justice	O
Department	O
report	O
revealed	O
in	O
May	O
2018	O

One	O
review	O
highlighted	O
a	O
nine-month	O
randomized	O
controlled	O
trial	O
of	O
amphetamine	B-Drug
treatment	O
for	O
ADHD	O
in	O
children	O
that	O
found	O
an	O
average	O
increase	O
4	O

In	O
an	O
Australian	O
study	O
of	O
210	O
heroin	B-Drug
users	O
who	O
used	O
temazepam	B-Drug
48%	O
had	O
injected	O
it	O

Ibuprofen	B-Drug
is	O
being	O
researched	O
in	O
Crdoba	O
Argentina	O
as	O
a	O
treatment	O
for	O
COVID19	O
using	O
it	O
hypertonic	O
solution	O
and	O
inhaling	O

Diazepam	B-Drug
however	O
showed	O
relatively	O
weak	O
fetal	O
toxicities	O

By	O
treating	O
normal	O
and	O
knockout	O
mice	O
lacking	O
the	O
serotonin	O
transporter	O
with	O
fluoxetine	B-Drug
scientists	O
showed	O
that	O
emotional	O
reactions	O
in	O
adulthood	O
like	O
a	O
short	O
latency	O
to	O
escape	O
foot	O
shocks	O
inclination	O
explore	O
new	O
environments	O
were	O
dependent	O
on	O
active	O
transporters	O
during	O
neonatal	O
period	O

The	O
ovulation-inhibiting	O
dosage	O
of	O
both	O
oral	O
norethisterone	B-Drug
and	O
NETA	O
is	O
about	O
0	O

In	O
2017	O
kratom	B-Drug
was	O
designated	O
a	O
Schedule	O
1	O
illegal	O
drug	O
the	O
highest	O
level	O
in	O
Republic	O
of	O
Ireland	O
under	O
names	O
7-hydroxymitragynine	O
and	O
mitragynine	B-Drug

Since	O
the	O
mid-1990s	O
MDMA	B-Drug
has	O
become	O
a	O
popular	O
entactogenic	O
drug	O
among	O
youth	O
and	O
quite	O
often	O
non-MDMA	O
substances	O
were	O
sold	O
as	O
ecstasy	B-Drug

Ketamine	B-Drug
remains	O
uncontrolled	O
internationally	O
although	O
many	O
nations	O
e	O

In	O
addition	O
laudanum	B-Drug
an	O
opioid	O
was	O
a	O
common	O
part	O
of	O
the	O
home	O
medicine	O
cabinet	O

Examples	O
include	O
mescaline	B-Drug
adrenaline	O
and	O
ephedrine	B-Drug

25TFM-NBOMe	O
also	O
known	O
as	O
NBOMe-2C-TFM	O
2C-TFM-NBOMe	O
and	O
Cimbi-138	O
is	O
a	O
derivative	O
of	O
the	O
phenethylamine	B-Drug
hallucinogen	O
2C-TFM	O
discovered	O
in	O
2004	O
by	O
Ralf	O
Heim	O
at	O
Free	O
University	O
Berlin	O

As	O
with	O
all	O
drugs	O
from	O
legal	O
like	O
alcohol	O
to	O
illegal	O
BZP	B-Drug
usage	O
can	O
increase	O
the	O
risk	O
of	O
injury	O
due	O
falls	O
dangerous	O
or	O
risky	O
behavior	O
e	O

Etizolam	B-Drug
also	O
called	O
Depas	O
is	O
restricted	O
as	O
a	O
benzodiazepine	O
analog	O
in	O
Japan	O
from	O
October	O
2016	O
onwards	O

In	O
contrast	O
the	O
newer	O
NSAAs	O
nilutamide	O
bicalutamide	B-Drug
and	O
enzalutamide	B-Drug
all	O
have	O
much	O
longer	O
half-lives	O
this	O
allows	O
for	O
once-daily	O
administration	O
in	O
their	O
cases	O

An	O
additional	O
example	O
is	O
the	O
usefulness	O
of	O
spironolactone	B-Drug
as	O
an	O
antiandrogen	O
in	O
transgender	O
women	O

Mescaline	B-Drug
has	O
a	O
wide	O
array	O
of	O
suggested	O
medical	O
usage	O
including	O
treatment	O
alcoholism	O
and	O
depression	O
due	O
to	O
these	O
disorders	O
having	O
links	O
serotonin	O
deficiencies	O

In	O
the	O
developing	O
world	O
tobacco	B-Drug
consumption	O
is	O
rising	O
by	O
3	O

While	O
psychiatrists	O
continue	O
to	O
prescribe	O
diazepam	B-Drug
for	O
the	O
short-term	O
relief	O
of	O
anxiety	O
neurology	O
has	O
taken	O
lead	O
in	O
prescribing	O
palliative	O
treatment	O
certain	O
types	O
epilepsy	O
and	O
spastic	O
activity	O
example	O
forms	O
paresis	O

Tyrosine	O
is	O
first	O
oxidized	O
to	O
L-DOPA	B-Drug
by	O
hydroxylase	O
this	O
the	O
rate-limiting	O
step	O

During	O
the	O
1970s	O
and	O
early	O
1980s	O
Colombia's	O
Pablo	O
Escobar	O
was	O
main	O
exporter	O
of	O
cocaine	B-Drug
dealt	O
with	O
organized	O
criminal	O
networks	O
all	O
over	O
world	O

After	O
nighttime	O
administration	O
of	O
midazolam	B-Drug
residual	O
'hangover'	O
effects	O
such	O
as	O
sleepiness	O
and	O
impaired	O
psychomotor	O
cognitive	O
functions	O
may	O
persist	O
into	O
the	O
next	O
day	O

There	O
are	O
therefore	O
diversified	O
drug	O
trafficking	O
routes	O
available	O
today	O
particularly	O
in	O
the	O
heroin	B-Drug
trade	O
and	O
these	O
thrive	O
due	O
to	O
continuous	O
development	O
of	O
new	O
markets	O

Bupropion	B-Drug
has	O
shown	O
no	O
effectiveness	O
in	O
the	O
treatment	O
of	O
cocaine	O
dependence	O
but	O
there	O
is	O
weak	O
evidence	O
that	O
it	O
may	O
be	O
useful	O
treating	O
methamphetamine	B-Drug

Adverse	O
drug	O
reactions	O
associated	O
with	O
the	O
use	O
of	O
triazolam	B-Drug
include:	O
Relatively	O
common	O
>1%	O
patients:	O
somnolence	O
dizziness	O
feeling	O
lightness	O
coordination	O
problems	O
Less	O
0	O

Later	O
the	O
same	O
substance	O
was	O
found	O
to	O
be	O
usable	O
in	O
production	O
of	O
scopolamine	O
and	O
hyoscyamine	B-Drug
which	O
are	O
used	O
eye	O
surgery	O
a	O
multimillion	O
dollar	O
industry	O
built	O
Queensland	O
based	O
on	O
this	O

When	O
compared	O
with	O
oxycodone	B-Drug
hydromorphone	B-Drug
and	O
placebo	O
pethidine	B-Drug
was	O
consistently	O
associated	O
more	O
euphoria	O
difficulty	O
concentrating	O
confusion	O
impaired	O
psychomotor	O
cognitive	O
performance	O
when	O
administered	O
to	O
healthy	O
volunteers	O

It	O
has	O
been	O
suggested	O
that	O
some	O
birth	O
defects	O
could	O
be	O
due	O
to	O
cocaine's	O
disruption	O
of	O
blood	O
vessel	O
growth	O
cocaine	B-Drug

Adrenal	O
androgens	O
function	O
as	O
weak	O
steroids	O
though	O
some	O
are	O
precursors	O
and	O
the	O
subset	O
includes	O
dehydroepiandrosterone	O
DHEA	O
sulfate	O
DHEA-S	O
androstenedione	B-Drug
A4	O
androstenediol	O
A5	O

recalled	O
one	O
lot	O
and	O
later	O
additional	O
lots	O
of	O
fentanyl	B-Drug
brand	O
name:	O
Duragesic	B-Drug
patches	O
because	O
seal	O
breaches	O
which	O
might	O
have	O
allowed	O
the	O
medication	O
to	O
leak	O
from	O
patch	O

People	O
who	O
intravenously	O
inject	O
black	O
tar	O
heroin	B-Drug
are	O
at	O
higher	O
risk	O
of	O
venous	O
sclerosis	O
than	O
those	O
injecting	O
powder	O

Extracts	O
of	O
toad	O
venom	O
containing	O
bufotenin	B-Drug
and	O
other	O
bioactive	O
compounds	O
have	O
been	O
used	O
in	O
some	O
traditional	O
medicines	O
such	O
as	O
chan	O
su	O
probably	O
derived	O
from	O
Bufo	O
gargarizans	O
which	O
has	O
medicinally	O
for	O
centuries	O
China	O

In	O
June	O
2013	O
the	O
United	O
States	O
Centers	O
for	O
Disease	O
Control	O
and	O
Prevention	O
CDC	O
issued	O
a	O
health	O
advisory	O
to	O
emergency	O
departments	O
alerting	O
14	O
overdose	O
deaths	O
among	O
intravenous	O
drug	O
users	O
in	O
Rhode	O
Island	O
associated	O
with	O
acetylfentanyl	B-Drug
synthetic	O
opioid	O
analog	O
of	O
fentanyl	B-Drug
that	O
has	O
never	O
been	O
licensed	O
medical	O
use	O

Metenolone	B-Drug
enanthate	I-Drug
or	O
methenolone	B-Drug
sold	O
under	O
the	O
brand	O
names	O
Primobolan	O
Depot	O
and	O
Nibal	O
Injection	O
is	O
an	O
androgen	O
anabolic	O
steroid	O
AAS	O
medication	O
which	O
used	O
mainly	O
in	O
treatment	O
of	O
anemia	O
due	O
to	O
bone	O
marrow	O
failure	O

A	O
2019	O
review	O
of	O
a	O
single-dose	O
modafinil	B-Drug
on	O
mental	O
function	O
in	O
healthy	O
non-sleep	O
deprived	O
people	O
found	O
small	O
effect	O
and	O
thus	O
limited	O
usefulness	O
as	O
cognitive	O
enhancer	O

Norpethidine	B-Drug
can	O
be	O
used	O
as	O
a	O
precursor	O
in	O
synthesis	O
of	O
other	O
drugs	O
including	O
etoxeridine	B-Drug
benzethidine	B-Drug
furethidine	B-Drug
morpheridine	B-Drug
anileridine	B-Drug
phenoperidine	B-Drug
piminodine	O
and	O
oxpheneridine	O

The	O
injectable	O
form	O
is	O
reportedly	O
difficult	O
to	O
use	O
due	O
painful	O
administration	O
higher	O
doses	O
requiring	O
injection	O
into	O
multiple	O
sites	O
simultaneously	O
and	O
even	O
more	O
stringent	O
monitoring	O
than	O
oral	O
clozapine	B-Drug
with	O
the	O
additional	O
difficulty	O
of	O
withdrawing	O
blood	O
samples	O
for	O
testing	O
from	O
agitated	O
individuals	O

In	O
addition	O
to	O
its	O
actions	O
as	O
an	O
AR	O
antagonist	O
darolutamide	B-Drug
has	O
been	O
found	O
act	O
a	O
silent	O
of	O
the	O
progesterone	O
receptor	O
PR	O
with	O
approximately	O
1%	O
potency	O
antagonism	O

They	O
also	O
show	O
dramatically	O
increased	O
antiandrogenic	O
potency	O
relative	O
to	O
bicalutamide	B-Drug
in	O
vivo	O
assays	O

It	O
is	O
also	O
used	O
as	O
a	O
recreational	O
drug	O
often	O
mixed	O
with	O
heroin	B-Drug
or	O
cocaine	B-Drug

Oxazepam	B-Drug
and	O
lorazepam	B-Drug
are	O
often	O
used	O
in	O
patients	O
at	O
risk	O
of	O
drug	O
accumulation	O
particular	O
the	O
elderly	O
those	O
with	O
cirrhosis	O
because	O
they	O
metabolized	O
differently	O
from	O
other	O
benzodiazepines	O
through	O
conjugation	O

In	O
response	O
Colombia's	O
drug	O
cartels	O
purchased	O
land	O
in	O
Colombia	O
to	O
expand	O
local	O
production	O
pushing	O
coca	B-Drug
cultivation	O
into	O
areas	O
of	O
southern	O
controlled	O
by	O
the	O
Revolutionary	O
Armed	O
Forces	O
FARC	O

Following	O
the	O
patch	O
a	O
flavoured	O
lollipop	O
of	O
fentanyl	B-Drug
citrate	O
mixed	O
with	O
inert	O
fillers	O
was	O
introduced	O
in	O
1998	O
under	O
brand	O
name	O
Actiq	B-Drug
becoming	O
first	O
quick-acting	O
formation	O
for	O
use	O
chronic	O
breakthrough	O
pain	O

Foremost	O
amongst	O
these	O
are	O
nefopam	O
orphenadrine	B-Drug
and	O
perhaps	O
phenyltoloxamine	O
or	O
some	O
other	O
antihistamines	O

Fentanyl	B-Drug
has	O
a	O
US	O
DEA	O
ACSCN	O
of	O
9801	O
and	O
2013	O
annual	O
aggregate	O
manufacturing	O
quota	O
2108	O

The	O
coca	B-Drug
leaf	O
was	O
and	O
still	O
is	O
chewed	O
almost	O
universally	O
by	O
some	O
indigenous	O
communities	O

Clobazam	B-Drug
is	O
used	O
for	O
its	O
anxiolytic	O
effect	O
and	O
as	O
an	O
adjunctive	O
therapy	O
in	O
epilepsy	O

Drospirenone	O
differs	O
structurally	O
from	O
spironolactone	B-Drug
only	O
in	O
that	O
the	O
C7	O
acetylthio	O
substitution	O
of	O
has	O
been	O
removed	O
and	O
two	O
methylene	O
groups	O
have	O
substituted	O
at	O
C67	O
C1516	O
positions	O

Gabapentinoids	O
produce	O
euphoria	O
at	O
high	O
doses	O
with	O
effects	O
similar	O
to	O
GABAergic	O
central	O
nervous	O
system	O
depressants	O
such	O
as	O
alcohol	O
-hydroxybutyric	O
acid	B-Drug
GHB	B-Drug
and	O
benzodiazepines	O
are	O
used	O
recreational	O
drugs	O
320	O
times	O
typical	O
clinical	O

In	O
September	O
2008	O
the	O
US	O
Food	O
and	O
Drug	O
Administration	O
FDA	O
sent	O
a	O
notice	O
to	O
Novartis	O
Pharmaceuticals	O
regarding	O
its	O
advertising	O
of	O
Focalin	B-Drug
XR	O
an	O
ADHD	O
drug	O
in	O
which	O
company	O
overstated	O
efficacy	O
while	O
marketing	O
public	O
medical	O
professionals	O

A	O
newer	O
synthetic	O
drug	O
SCH-50911	O
which	O
acts	O
as	O
a	O
selective	O
GABAB	O
antagonist	O
quickly	O
reverses	O
GHB	B-Drug
overdose	O
in	O
mice	O

As	O
such	O
levomethorphan	B-Drug
has	O
similar	O
effects	O
to	O
levorphanol	B-Drug
but	O
is	O
less	O
potent	O
as	O
it	O
must	O
be	O
demethylated	O
the	O
active	O
form	O
by	O
liver	O
enzymes	O
before	O
being	O
able	O
produce	O
its	O

If	O
an	O
antipsychotic	O
is	O
given	O
intramuscular	O
haloperidol	B-Drug
has	O
been	O
recommended	O

The	O
chemical	O
analysis	O
of	O
opium	B-Drug
in	O
the	O
19th	O
century	O
revealed	O
that	O
most	O
its	O
activity	O
could	O
be	O
ascribed	O
to	O
alkaloids	O
codeine	B-Drug
and	O
morphine	B-Drug

DMBPP	O
differs	O
from	O
25B-NBOMe	B-Drug
by	O
having	O
a	O
piperidine	O
ring	O
conformed	O
to	O
the	O
amine	O
making	O
for	O
more	O
rigid	O
molecular	O
structure	O
than	O
that	O
of	O
open-chain	O

Blood	O
or	O
plasma	O
fentanyl	B-Drug
concentrations	O
are	O
expected	O
to	O
be	O
in	O
a	O
range	O
of	O
0	O

Although	O
abuse	O
of	O
benzodiazepines	O
has	O
decreased	O
over	O
the	O
past	O
few	O
years	O
temazepam	B-Drug
continues	O
to	O
be	O
a	O
major	O
drug	O
in	O
Australia	O

The	O
tyrosine	O
residue	O
at	O
position	O
1	O
is	O
thought	O
to	O
be	O
analogous	O
the	O
3-hydroxyl	O
group	O
on	O
morphine	B-Drug

It	O
is	O
the	O
active	O
metabolite	O
which	O
responsible	O
for	O
most	O
of	O
pharmacological	O
effects	O
rather	O
than	O
ethyl	B-Drug
loflazepate	I-Drug

Hyperekplexia	O
Many	O
forms	O
of	O
parasomnia	O
and	O
other	O
sleep	O
disorders	O
are	O
treated	O
with	O
clonazepam	B-Drug

Aside	O
from	O
the	O
toxic	O
effects	O
of	O
cocaine	B-Drug
there	O
is	O
also	O
danger	O
circulatory	O
emboli	O
insoluble	O
substances	O
that	O
may	O
be	O
used	O
to	O
cut	O
drug	O

Prednisolone	B-Drug
should	O
be	O
used	O
in	O
pregnant	O
women	O
when	O
benefits	O
outweigh	O
the	O
risks	O
and	O
children	O
born	O
from	O
mothers	O
using	O
prednisolone	B-Drug
during	O
pregnancy	O
monitored	O
for	O
impaired	O
adrenal	O
function	O

They	O
include	O
corticosteroids	O
which	O
consist	O
of	O
glucocorticoids	O
like	O
cortisol	O
and	O
mineralocorticoids	O
aldosterone	O
adrenal	O
androgens	O
dehydroepiandrosterone	O
DHEA	O
sulfate	O
DHEA-S	O
androstenedione	B-Drug
A4	O
neurosteroids	O
as	O
well	O
pregnenolone	O
P5-S	O

The	O
price	O
of	O
white	O
heroin	B-Drug
is	O
reported	O
only	O
by	O
a	O
few	O
European	O
countries	O
and	O
ranged	O
between	O
27	O
110	O
per	O
gram	O

Psilocin	B-Drug
is	O
glucuronated	O
by	O
the	O
glucuronosyltransferase	O
enzymes	O
UGT1A9	O
in	O
liver	O
and	O
UGT1A10	O
small	O
intestine	O

His	O
toxicology	O
results	O
revealed	O
high	O
levels	O
of	O
MDPV	B-Drug
in	O
addition	O
to	O
marijuana	O
and	O
prescription	O
drugs	O

Common	O
side	O
effects	O
of	O
buspirone	B-Drug
include	O
nausea	O
headaches	O
dizziness	O
and	O
difficulty	O
concentrating	O

Notorious	O
cocaine	B-Drug
cartels	O
such	O
as	O
Medellin	O
cartel	O
and	O
Cali	O
have	O
both	O
dominated	O
the	O
illicit	O
trade	O
well	O
their	O
country	O
of	O
Colombia	O

Oral	O
contraceptives:	O
may	O
reduce	O
plasma	O
concentrations	O
of	O
valproate	B-Drug

Sodium	B-Drug
valproate	I-Drug
has	O
been	O
associated	O
with	O
paroxysmal	O
tonic	O
upgaze	O
of	O
childhood	O
also	O
known	O
as	O
OuvrierBillson	O
syndrome	O
from	O
or	O
fetal	O
exposure	O

Exemestane	B-Drug
is	O
the	O
first	O
oral	O
aromatase	O
inactivator	O

However	O
propranolol	B-Drug
is	O
highly	O
bound	O
to	O
proteins	O
in	O
the	O
bloodstream	O
and	O
distributed	O
into	O
breast	O
milk	O
at	O
very	O
low	O
levels	O

concentrate	O
of	O
poppy	I-Drug
straw	O
the	O
material	O
arising	O
when	O
all	O
parts	O
opium	B-Drug
except	O
seeds	O
after	O
mowing	O
has	O
entered	O
into	O
a	O
process	O
for	O
concentration	O
its	O
alkaloids	O
such	O
is	O
made	O
available	O
in	O
tradeNote	O
on	O
preparations:	O
preparations	O
direct	O
from	O
are	O
considered	O
to	O
be	O
if	O
not	O
itself	O
but	O
obtained	O
by	O
mixture	O
as	O
case	O
example	O
with	O
pantopon	O
omnopon	O
and	O
papaveretum	O
they	O
should	O
morphine	B-Drug
Natural	O
opioids:	O
oripavine	O
principal	O
alkaloid	O
thebaine	O
an	O
opium;	O
also	O
found	O
Papaver	O
bracteatumSemisynthetic	O
acetorphine	B-Drug
benzylmorphine	B-Drug
codoxime	B-Drug
desomorphine	B-Drug
dihydroetorphine	B-Drug
dihydromorphine	B-Drug
drotebanol	B-Drug
etorphine	B-Drug
heroin	B-Drug
hydrocodone	B-Drug
hydromorphinol	B-Drug
hydromorphone	B-Drug
methyldesorphine	B-Drug
methyldihydromorphine	B-Drug
metopon	B-Drug
myrophine	B-Drug
nicomorphine	B-Drug
oxycodone	B-Drug
oxymorphone	B-Drug
thebaconSome	O
derivatives	O
including	O
some	O
natural	O
metabolites	O
codeine:	O
methobromide	I-Drug
other	O
pentavalent	O
nitrogen	O
particular	O
genomorphine	O
one	O
which	O
genocodeine	O
codeine-N-oxide	O
morphine-N-oxide	O
normorphineSynthetic	O
opioids	O
morphinan	O
derivatives:	O
levomethorphan	B-Drug
levophenacylmorphan	B-Drug
levorphanol	B-Drug
norlevorphanol	O
phenomorphan	B-Drug
racemethorphan	B-Drug
racemorphanSynthetic	O
fentanyl	B-Drug
acetyl-alpha-methylfentanyl	B-Drug
alfentanil	B-Drug
alpha-methylfentanyl	B-Drug
alpha-methylthiofentanyl	B-Drug
beta-hydroxyfentanyl	B-Drug
beta-hydroxy-3-methylfentanyl	B-Drug
3-methylfentanyl	B-Drug
3-methylthiofentanyl	B-Drug
para-fluorofentanyl	B-Drug
remifentanil	B-Drug
sufentanil	B-Drug
thiofentanylSynthetic	O
4-phenylpiperidine	O
pethidines	O
meperidines:	O
anileridine	B-Drug
benzethidine	B-Drug
difenoxin	B-Drug
diphenoxylate	B-Drug
etoxeridine	B-Drug
furethidine	B-Drug
hydroxypethidine	B-Drug
morpheridine	B-Drug
pethidine	B-Drug
intermediate	I-Drug
A	I-Drug
norpethidine	B-Drug
B	I-Drug
pethidinic	O
acid	O
C	I-Drug
phenoperidine	B-Drug
piminodine	O
properidineSynthetic	O
prodines:	O
allylprodine	B-Drug
alphameprodine	B-Drug
alphaprodine	B-Drug
betameprodine	B-Drug
betaprodine	B-Drug
desmethylprodine	B-Drug
MPPP	B-Drug
PEPAP	B-Drug
trimeperidineSynthetic	O
ketobemidones:	O
ketobemidoneSynthetic	O
open	O
chain	O
amidones:	O
dipipanone	B-Drug
isomethadone	B-Drug
methadone	B-Drug
4-cyano-2-dimethylamino-44-diphenylbutane	O
normethadone	B-Drug
norpipanone	B-Drug
phenadoxoneSynthetic	O
methadols:	O
acetylmethadol	B-Drug
alphacetylmethadol	B-Drug
alphamethadol	B-Drug
betacetylmethadol	B-Drug
betamethadol	B-Drug
noracymethadol	B-Drug
dimepheptanolSynthetic	O
moramides:	O
dextromoramide	B-Drug
levomoramide	B-Drug
scheduled	O
despite	O
being	O
inactive	O
isomer	O
racemoramide	B-Drug
moramide	B-Drug
2-methyl-3-morpholino-11-diphenylpropane	O
carboxylic	O
acidSynthetic	O
thiambutenes:	O
diethylthiambutene	B-Drug
dimethylthiambutene	B-Drug
ethylmethylthiambuteneSynthetic	O
phenalkoxams:	O
dimenoxadol	B-Drug
dioxaphetyl	O
butyrateSynthetic	O
ampromides:	O
diampromide	B-Drug
phenampromideSynthetic	O
benzimidazoles:	O
clonitazene	B-Drug
etonitazeneSynthetic	O
benzomorphans:	O
metazocine	B-Drug
phenazocineSynthetic	O
pirinitramides:	O
bezitramide	B-Drug
piritramideSynthetic	O
phenazepanes:	O
proheptazineOther	O
synthetic	O
tilidineAnd:	O
isomers	O
unless	O
specifically	O
excepted	O
drugs	O
this	O
Schedule	O
whenever	O
existence	O
possible	O
within	O
specific	O
chemical	O
designation;	O
esters	O
ethers	O
appearing	O
another	O
or	O
possible;	O
salts	O
listed	O
provided	O
above	O
codeine	B-Drug

Long-acting	O
benzodiazepines	O
such	O
as	O
diazepam	B-Drug
are	O
not	O
recommended	O
for	O
the	O
elderly	O

PCP	B-Drug
was	O
initially	O
made	O
in	O
1926	O
and	O
brought	O
to	O
market	O
as	O
an	O
anesthetic	O
medication	O
the	O
1950s	O

Fluorine-substituted	O
ethers	O
are	O
volatile	O
anesthetics	O
including	O
the	O
commercial	O
products	O
methoxyflurane	O
enflurane	O
isoflurane	B-Drug
sevoflurane	B-Drug
and	O
desflurane	B-Drug

The	O
People's	O
Pharmacy	O
received	O
multiple	O
reports	O
of	O
increased	O
side	O
effects	O
and	O
decreased	O
efficacy	O
generic	O
bupropion	B-Drug
which	O
prompted	O
it	O
to	O
ask	O
ConsumerLab	O

Remifentanil	B-Drug
is	O
used	O
for	O
sedation	O
as	O
well	O
combined	O
with	O
other	O
medications	O
use	O
in	O
general	O
anesthesia	O

Following	O
China's	O
defeat	O
in	O
the	O
Second	O
Opium	O
War	O
1858	O
China	O
was	O
forced	O
to	O
legalize	O
opium	B-Drug
and	O
began	O
massive	O
domestic	O
production	O

Side	O
effects	O
of	O
oxandrolone	B-Drug
include	O
symptoms	O
masculinization	O
such	O
as	O
acne	O
increased	O
hair	O
growth	O
voice	O
changes	O
and	O
sexual	O
desire	O

The	O
class	O
includes	O
the	O
well	O
known	O
anaesthetic	O
ketamine	B-Drug

Four	O
versions	O
of	O
opium	B-Drug
as	O
a	O
fluid	O
extract	O
were	O
also	O
offered:	O
1	O
Opium	B-Drug
Concentrated	O
assayed	O
For	O
making	O
Tincture	O
Opii	O
Laudanum	B-Drug
U	O

Along	O
with	O
the	O
similar	O
2-iodomorphine	O
as	O
well	O
iodinated	O
analogs	O
of	O
dihydromorphine	B-Drug
dihydrocodeine	B-Drug
heroin	B-Drug
and	O
fluorinated	O
chlorinated	O
brominated	O
analogues	O
this	O
series	O
change	O
may	O
not	O
impact	O
activity	O
drug	O
to	O
a	O
notable	O
extent	O
but	O
1-	O
are	O
used	O
in	O
pharmacological	O
neurological	O
metabolic	O
endocrine	O
research	O
it	O
allows	O
tagging	O
morphine	B-Drug
iodine-131	O
or	O
iodine-129	O

Additionally	O
indomethacin	B-Drug
is	O
used	O
in	O
pregnancy	O
to	O
treat	O
polyhydramnios	O
by	O
reducing	O
fetal	O
urine	O
production	O
via	O
inhibiting	O
kidney	O
blood	O
flow	O

It	O
is	O
sold	O
under	O
the	O
tradenames	O
Aloperidin	O
Bioperidolo	O
Brotopon	O
Dozic	O
Duraperidol	O
Germany	O
Einalon	O
S	O
Eukystol	O
Haldol	B-Drug
common	O
tradename	O
in	O
US	O
and	O
UK	O
Halol	O
Halosten	O
Keselan	O
Linton	O
Peluces	O
Serenace	O
Sigaperidol	O

Dexamethasone	B-Drug
is	O
used	O
in	O
transvenous	O
screw-in	O
cardiac	O
pacing	O
leads	O
to	O
minimize	O
the	O
inflammatory	O
response	O
of	O
myocardium	O

The	O
plasma	O
protein	O
binding	O
of	O
norethisterone	B-Drug
is	O
97%	O

USAF	O
Pararescue	O
combat	O
medics	O
in	O
Afghanistan	O
use	O
fentanyl	B-Drug
lozenges	O
the	O
form	O
of	O
lollipops	O
on	O
casualties	O
from	O
IED	O
blasts	O
and	O
other	O
trauma	O

Amides	O
of	O
lysergic	O
acid	B-Drug
are	O
collectively	O
known	O
as	O
lysergamides	O
and	O
include	O
a	O
number	O
compounds	O
with	O
potent	O
agonist	O
and/or	O
antagonist	O
activity	O
at	O
various	O
serotonin	O
dopamine	O
receptors	O

For	O
example	O
diazepam	B-Drug
requires	O
hepatic	O
oxidization	O
whereas	O
its	O
oxidized	O
metabolite	O
oxazepam	B-Drug
does	O
not	O

Milnacipran's	O
lack	O
of	O
drug-drug	O
interactions	O
via	O
cytochrome	O
P450	O
enzymes	O
is	O
thought	O
to	O
be	O
an	O
attractive	O
feature	O
because	O
many	O
the	O
central	O
nervous	O
system	O
drugs	O
are	O
highly	O
lipophilic	O
and	O
mainly	O
eliminated	O
by	O
liver	O
Milnacipran	B-Drug

Although	O
there	O
are	O
no	O
major	O
human	O
studies	O
of	O
prednisolone	B-Drug
use	O
in	O
pregnant	O
women	O
several	O
animals	O
show	O
that	O
it	O
may	O
cause	O
birth	O
defects	O
including	O
increase	O
cleft	O
palate	O

In	O
Tiwanaku	O
culture	O
a	O
snuff	B-Drug
tray	O
was	O
used	O
along	O
with	O
an	O
inhaling	O
tube	O

Methadone	B-Drug
is	O
a	O
-opioid	O
receptor	O
agonist	O

Diamorphine	B-Drug
was	O
first	O
synthesized	O
in	O
1874	O
by	O
C	O

A	O
1970	O
Bulletin	O
on	O
Narcotics	O
report	O
notes:	O
LSD	B-Drug
mescaline	B-Drug
etc	O

Trichocereus	O
pachanoi	O
Mescaline	B-Drug
0	O

In	O
January	O
2015	O
the	O
Faculty	O
of	O
Sexual	O
&	O
Reproductive	O
Healthcare	O
Royal	O
College	O
Obstetricians	O
and	O
Gynaecologists	O
issued	O
a	O
statement	O
reaffirming	O
that	O
there	O
is	O
no	O
reason	O
to	O
advise	O
against	O
use	O
DMPA	B-Drug
in	O
United	O
Kingdom	O
even	O
for	O
women	O
at	O
'high	O
risk'	O
HIV	O
infection	O

Chronic	O
cocaine	B-Drug
intake	O
causes	O
strong	O
imbalances	O
of	O
transmitter	O
levels	O
in	O
order	O
to	O
compensate	O
extremes	O

6-Hydroxybuspirone	O
has	O
been	O
identified	O
as	O
the	O
predominant	O
hepatic	O
metabolite	O
of	O
buspirone	B-Drug
with	O
plasma	O
levels	O
that	O
are	O
40-fold	O
greater	O
than	O
those	O
after	O
oral	O
administration	O
to	O
humans	O

Overdoses	O
of	O
kratom	B-Drug
are	O
managed	O
similarly	O
to	O
opioid	O
overdoses	O
and	O
naloxone	B-Drug
can	O
be	O
considered	O
treat	O
an	O
overdose	O
that	O
results	O
in	O
a	O
reduced	O
impulse	O
breathe	O
despite	O
mixed	O
for	O
its	O
utility	O
based	O
on	O
animal	O
models	O

Marijuana	B-Drug
trade	O
not	O
only	O
happens	O
in	O
college	O
but	O
also	O
gradually	O
spreads	O
to	O
middle	O
schools	O
and	O
even	O
primary	O

Buspirone	B-Drug
and	O
pregabalin	B-Drug
are	O
second-line	O
treatments	O
for	O
people	O
who	O
do	O
not	O
respond	O
to	O
SSRIs	O
or	O
SNRIs;	O
there	O
is	O
also	O
evidence	O
that	O
benzodiazepines	O
including	O
diazepam	B-Drug
clonazepam	B-Drug
effective	O
but	O
have	O
fallen	O
out	O
of	O
favor	O
due	O
the	O
risk	O
dependence	O
abuse	O

They	O
were	O
solely	O
responsible	O
for	O
identification	O
of	O
assets	O
stemming	O
from	O
their	O
cocaine	B-Drug
trafficking	O

Karl	O
Koller	O
a	O
close	O
associate	O
of	O
Sigmund	O
Freud	O
who	O
would	O
write	O
about	O
cocaine	B-Drug
later	O
experimented	O
with	O
for	O
ophthalmic	O
usage	O

The	O
drug	O
was	O
pure	O
hydrocodone	B-Drug
in	O
small	O
5	O
and	O
10	O
mg	O
tablets	O
physically	O
similar	O
to	O
the	O
Dilaudid	B-Drug

Japan's	O
war	O
with	O
China	O
had	O
cut	O
the	O
normal	O
distribution	O
routes	O
for	O
heroin	B-Drug
and	O
generally	O
disrupted	O
movement	O
of	O
opium	B-Drug

As	O
for	O
bupivacaine	B-Drug
Celepid	O
a	O
commonly	O
available	O
intravenous	O
lipid	O
emulsion	O
can	O
be	O
effective	O
in	O
treating	O
severe	O
cardiotoxicity	O
secondary	O
to	O
local	O
anaesthetic	O
overdose	O
animal	O
experiments	O
and	O
humans	O
process	O
called	O
rescue	O

Morphine	B-Drug
is	O
the	O
predominant	O
alkaloid	O
found	O
in	O
cultivated	O
varieties	O
of	O
opium	B-Drug
poppy	O
that	O
are	O
used	O
for	O
production	O

In	O
2009	O
Public	O
Citizen	O
released	O
a	O
list	O
of	O
recommendations	O
that	O
included	O
numerous	O
alternative	O
second-generation	O
birth	O
control	O
pills	O
women	O
could	O
take	O
in	O
place	O
oral	O
contraceptives	O
containing	O
desogestrel	B-Drug

The	O
study	O
also	O
found	O
that	O
up	O
to	O
20%	O
of	O
gay	O
men	O
from	O
central	O
London	O
gyms	O
had	O
tried	O
methamphetamine	B-Drug
the	O
drug	O
most	O
associated	O
with	O
PNPing	O

Oral	O
methylprednisolone	B-Drug
has	O
a	O
moderate	O
distribution	O
into	O
tissue	O
at	O
1	O

The	O
renowned	O
Andalusian	O
ophthalmologic	O
surgeon	O
Abu	O
al-Qasim	O
al-Zahrawi	O
Abulcasis	O
9361013	O
AD	O
relied	O
on	O
opium	B-Drug
and	O
mandrake	O
as	O
surgical	O
anaesthetics	O
wrote	O
a	O
treatise	O
al-Tasrif	O
that	O
influenced	O
medical	O
thought	O
well	O
into	O
the	O
16th	O
century	O

Some	O
psychoactive	O
drugs	O
were	O
already	O
grown	O
in	O
Colombia	O
at	O
limited	O
level	O
by	O
local	O
indigenous	O
groups	O
who	O
mostly	O
employed	O
marijuana	O
and	O
coca	B-Drug
leaves	O
for	O
ceremonial	O
traditional	O
medical	O
uses	O
as	O
part	O
of	O
their	O
culture	O

As	O
with	O
other	O
pure-opioid	O
agonists	O
fentanyl	B-Drug
can	O
be	O
associated	O
dysphoria	O
in	O
both	O
dogs	O
and	O
cats	O

Laudanum	B-Drug
remained	O
largely	O
unknown	O
until	O
the	O
1660s	O
when	O
English	O
physician	O
Thomas	O
Sydenham	O
16241689	O
compounded	O
a	O
proprietary	O
opium	B-Drug
tincture	O
that	O
he	O
also	O
named	O
laudanum	B-Drug
although	O
it	O
differed	O
substantially	O
from	O
of	O
Paracelsus	O

Zolpidem	B-Drug
was	O
used	O
in	O
Europe	O
starting	O
1988	O
and	O
brought	O
to	O
market	O
there	O
by	O
Synthelabo	O

Laudanum	B-Drug
Thebaic	O
Tincture	O
or	O
Tinctura	O
Thebaica	O
and	O
adjusted	O
to	O
contain	O
1%	O
w/v	O
of	O
anhydrous	O
morphine	B-Drug

Androstenedione	B-Drug
is	O
converted	O
to	O
either	O
testosterone	O
or	O
estrone	O

JWH-018	B-Drug
1-pentyl-3-1-naphthoylindole	O
or	O
AM-678	B-Drug
is	O
an	O
analgesic	O
chemical	O
from	O
the	O
naphthoylindole	O
family	O
that	O
acts	O
as	O
a	O
full	O
agonist	O
at	O
both	O
CB1	O
and	O
CB2	O
cannabinoid	O
receptors	O
with	O
some	O
selectivity	O
for	O

2	O
billion	O
for	O
illegally	O
marketing	O
risperidone	B-Drug
use	O
in	O
people	O
with	O
dementia	O

Like	O
most	O
opioids	O
unadulterated	O
heroin	B-Drug
may	O
lead	O
to	O
adverse	O
effects	O

Natural	O
opioids:	O
codeine	B-Drug
alkaloid	O
contained	O
in	O
opium	O
and	O
poppy	O
strawSemisynthetic	O
acetyldihydrocodeine	B-Drug
dihydrocodeine	B-Drug
ethylmorphine	B-Drug
nicocodine	B-Drug
nicodicodine	O
pholcodineNatural	O
metabolite:	O
norcodeineSynthetic	O
open	O
chain	O
opioids	O
phenalkoxams:	O
dextropropoxypheneSynthetic	O
ampromides:	O
propiramAnd:	O
the	O
isomers	O
unless	O
specifically	O
excepted	O
of	O
drugs	O
this	O
schedule	O
whenever	O
existence	O
such	O
is	O
possible	O
within	O
specific	O
chemical	O
designation;	O
salts	O
listed	O
including	O
as	O
provided	O
above	O

More	O
potent	O
progestins	O
such	O
as	O
norethisterone	B-Drug
were	O
developed	O
and	O
started	O
to	O
be	O
used	O
in	O
birth	O
control	O
the	O
1950s	O

Oral	O
methylprednisolone	B-Drug
is	O
readily	O
absorbed	O
from	O
the	O
gastrointestinal	O
tract	O
with	O
a	O
bioavailability	O
of	O
89	O

This	O
is	O
followed	O
by	O
NSAIDs	O
and	O
anticholinergics	O
if	O
the	O
response	O
insufficient	O
tramadol	B-Drug

In	O
one	O
study	O
the	O
drug	O
sensitivity	O
of	O
people	O
who	O
had	O
used	O
temazepam	B-Drug
for	O
to	O
20	O
years	O
was	O
no	O
different	O
from	O
that	O
controls	O

Psilocin	B-Drug
binds	O
with	O
high	O
affinity	O
to	O
5-HT2A	O
receptors	O
and	O
low	O
5-HT1	O
including	O
5-HT1A	O
5-HT1D;	O
effects	O
are	O
also	O
mediated	O
via	O
5-HT2C	O

Heroin	B-Drug
addicts	O
were	O
bribed	O
into	O
taking	O
LSD	B-Drug
with	O
offers	O
of	O
more	O
heroin	B-Drug

In	O
the	O
1980s	O
and	O
1990s	O
formula	O
changed	O
to	O
using	O
codeine	B-Drug
promethazine	B-Drug
cough	O
syrup	O
somewhat	O
like	O
Glutethimide	B-Drug
combination	O
that	O
was	O
popular	O
from	O
seventies	O
up	O
early	O
nineties	O

The	O
combination	O
of	O
BZP	B-Drug
and	O
TFMPP	B-Drug
has	O
been	O
associated	O
with	O
a	O
range	O
side	O
effects	O
including	O
insomnia	O
anxiety	O
nausea	O
vomiting	O
headaches	O
muscle	O
aches	O
which	O
may	O
resemble	O
migraine	O
seizures	O
impotence	O
rarely	O
psychosis	O
as	O
well	O
prolonged	O
unpleasant	O
hangover	O
effect	O

Celgene	O
Corporation	O
originally	O
synthesized	O
thalidomide	B-Drug
using	O
a	O
three-step	O
sequence	O
starting	O
with	O
L-glutamic	O
acid	O
treatment	O
but	O
this	O
has	O
since	O
been	O
reformed	O
by	O
the	O
use	O
of	O
L-glutamine	B-Drug

Zoloft	B-Drug
sertraline	B-Drug
is	O
an	O
antidepressant	O
of	O
the	O
selective	O
serotonin	O
reuptake	O
inhibitor	O
SSRI	O
class	O

Although	O
it	O
is	O
not	O
commonly	O
used	O
methyltestosterone	B-Drug
one	O
of	O
the	O
few	O
AAS	O
that	O
remains	O
available	O
for	O
medical	O
use	O
in	O
United	O
States	O

Songs	O
such	O
as	O
Eric	O
Clapton's	O
1977	O
release	O
Cocaine	B-Drug
was	O
written	O
by	O
J	O

Sub-paragraphs	O
b	O
c	O
d	O
and	O
e	O
all	O
refer	O
to	O
anabolic	O
steroids	O
that	O
were	O
banned	O
in	O
1996	O
unless	O
referenced	O
otherwise:b	O
any	O
compound	O
not	O
being	O
Trilostane	O
or	O
a	O
for	O
the	O
time	O
specified	O
sub-paragraph	O
above	O
structurally	O
derived	O
from	O
17-hydroxyandrostan-3-one	O
17-hydroxyestran-3-one	O
by	O
modification	O
of	O
following	O
ways	O
is	O
say	O
i	O
further	O
substitution	O
at	O
position	O
17	O
methyl	O
ethyl	O
group;	O
ii	O
extent	O
one	O
more	O
positions	O
1	O
2	O
4	O
6	O
7	O
9	O
11	O
16	O
but	O
no	O
other	O
position;	O
iii	O
unsaturation	O
carbocyclic	O
ring	O
system	O
provided	O
there	O
are	O
than	O
two	O
ethylenic	O
bonds	O
ring;	O
iv	O
fusion	O
A	O
with	O
heterocyclic	O
system;	O
substance	O
which	O
an	O
ester	O
ether	O
where	O
hydroxyl	O
function	O
available	O
both	O
described	O
above;	O
Chorionic	O
gonadotropin	O
Clenbuterol	B-Drug
Non-human	O
chorionic	O
gonadotrophin	O
Somatropin	O
Somatrem	O
Somatropinf	O
1benzylpiperazine	O
13chlorophenylpiperazine	O
13chlorophenyl43chloropropylpiperazine	O
1phenylpiperazine	O
second	O
nitrogen	O
atom	O
piperazine	O
alkyl	O
benzyl	O
haloalkyl	O
phenyl	O
groups;	O
aromatic	O
alkoxy	O
alkylenedioxy	O
halide	O

The	O
acute	O
toxicity	O
LD50	O
of	O
bufotenin	B-Drug
in	O
rodents	O
has	O
been	O
estimated	O
at	O
200	O
to	O
300	O
mg/kg	O

4-HTMPIPO	O
is	O
the	O
product	O
resulting	O
from	O
electrophilic	O
addition	O
of	O
water	O
to	O
cyclopropane	O
moiety	O
synthetic	O
cannabinoid	O
UR-144	B-Drug

A	O
chemical	O
synthesis	O
of	O
methyltestosterone	B-Drug
from	O
dehydroepiandrosterone	O
DHEA	O
with	O
methandriol	O
as	O
an	O
intermediate	O
proceeds	O
follows:	O
Methyltestosterone	B-Drug
was	O
first	O
synthesized	O
in	O
1935	O
along	O
and	O
mestanolone	B-Drug

-Endorphin	O
has	O
approximately	O
18	O
to	O
33	O
times	O
the	O
analgesic	O
potency	O
of	O
morphine	B-Drug
though	O
its	O
hormonal	O
effect	O
is	O
species	O
dependent	O

He	O
was	O
the	O
first	O
to	O
synthesize	O
natural	O
product	O
physostigmine	B-Drug
plus	O
a	O
pioneer	O
in	O
industrial	O
large-scale	O
chemical	O
synthesis	O
of	O
human	O
hormones	O
progesterone	O
and	O
testosterone	O
from	O
plant	O
sterols	O
such	O
as	O
stigmasterol	O
sitosterol	O

This	O
can	O
result	O
in	O
fatal	O
overdoses	O
from	O
drugs	O
such	O
as	O
codeine	B-Drug
tramadol	B-Drug
and	O
carisoprodol	B-Drug
which	O
become	O
considerably	O
more	O
potent	O
after	O
being	O
metabolized	O
by	O
CYP	O
enzymes	O

Teriflunomide	B-Drug
is	O
the	O
main	O
active	O
in	O
vivo	O
metabolite	O
of	O
leflunomide	B-Drug

Studies	O
conducted	O
using	O
psilocybin	O
in	O
a	O
psychotherapeutic	O
setting	O
reveal	O
that	O
psychedelic	O
drugs	O
may	O
assist	O
with	O
treating	O
depression	O
and	O
alcohol	O
addiction	O
possibly	O
also	O
nicotine	B-Drug

Carisoprodol	B-Drug
is	O
metabolized	O
by	O
the	O
liver	O
and	O
excreted	O
kidneys	O
so	O
this	O
drug	O
must	O
be	O
used	O
with	O
caution	O
patients	O
that	O
have	O
impaired	O
hepatic	O
or	O
renal	O
function	O

Impaired	O
liver	O
function	O
as	O
haloperidol	B-Drug
is	O
metabolized	O
and	O
eliminated	O
mainly	O
by	O
the	O
In	O
patients	O
with	O
hyperthyroidism	O
action	O
of	O
intensified	O
side	O
effects	O
are	O
more	O
likely	O

However	O
according	O
to	O
the	O
authors	O
even	O
relatively	O
safe	O
drug	O
MDMA	B-Drug
causes	O
heart	O
disease	O
and	O
incidence	O
being	O
reported	O
for	O
fenfluramine	B-Drug
was	O
not	O
that	O
great	O
though	O
evidence	O
presented	O
indisputable	O

Legal	O
opium	B-Drug
importation	O
from	O
India	O
and	O
Turkey	O
is	O
conducted	O
by	O
Mallinckrodt	O
Noramco	O
Abbott	O
Laboratories	O
Purdue	O
Pharma	O
Cody	O
Inc	O

1	O
Edogestrone	O
edogesterone;	O
PH-218	O
Hydromadinone	O
acetate	O
chloroacetoxyprogesterone;	O
CAP;	O
NSC-33170	O
Hydroxyprogesterone	O
heptanoate	O
benzilic	O
acid	O
hydrazone	O
Medroxyprogesterone	B-Drug
caproate	O
Megestrol	O
Methenmadinone	O
Lutofollin	O
in	O
combination	O
with	O
estradiol	O
valerate	O
The	O
following	O
progestogen	O
esters	O
have	O
been	O
marketed:	O
Gestonorone	O
gestronol	O
hexanoate;	O
Depostat	O
Primostat	O
Nomegestrol	O
Lutenyl	O
Naemis	O
Zoely	O
Segesterone	O
Nestorone	O
ElcometrineAnd	O
the	O
veterinary-only	O
also	O
Norgestomet	O
norgestamet;	O
Syncro-Mate	O
B;	O
SC-21009	O
Amadinone	O
19-norchlormadinone	O
acetate;	O
RS-2208	O
Gestadienol	O
CIBA-31458-Ba	O
CIBA-31458	O
18-Methylsegesterone	O
18-methylnestorone	O
Oxogestone	O
phenpropionate	I-Drug
xinogestone	O
Etynodiol	O
diacetate	O
ethynodiol	O
diacetate;	O
Continuin	O
Femulen	O
Luteonorm	O
Luto-Metrodiol	O
Metrodiol	O
Norethisterone	O
norethindrone	O
Primolut-Nor	O
Norlestrin	O
Aygestin	O
Norlutate	O
Minovlar	O
Anovlar	O
enanthate	O
enanthate;	O
Noristerat	O
Norigest	O
Norgestimate	B-Drug
Ortho-Cyclen	O
Ortho	O
Tri-Cyclen	O
Previfem	O
Sprintec	O
Prefest	O
Quingestanol	O
Demovis	O
Pilomin	O
Riglovis	O
UnovisMany	O
19-nortestosterone	B-Drug
androgen	O
such	O
as	O
nandrolone	B-Drug
like	O
decanoate	O
Deca-Durabolin	B-Drug
and	O
Durabolin	B-Drug
potent	O
progestogenic	O
activity	O

After	O
providing	O
a	O
significant	O
portion	O
of	O
the	O
world's	O
poppy	O
for	O
use	O
in	O
heroin	B-Drug
production	O
Afghanistan	O
went	O
from	O
producing	O
practically	O
no	O
illegal	O
drugs	O
2000	O
following	O
banning	O
by	O
Taliban	O
to	O
cultivating	O
what	O
is	O
now	O
as	O
much	O
90%	O
opium	O

Little	O
further	O
work	O
was	O
done	O
with	O
thalidomide	B-Drug
in	O
cancer	O
until	O
the	O
1990s	O

The	O
1970s	O
saw	O
the	O
debut	O
of	O
these	O
compounds	O
especially	O
PCP	B-Drug
and	O
its	O
analogues	O
as	O
illicitly	O
used	O
recreational	O
drugs	O
due	O
to	O
their	O
dissociative	O
hallucinogenic	O
euphoriant	O
effects	O

According	O
to	O
the	O
International	O
Programme	O
on	O
Chemical	O
Safety	O
IPCS	O
and	O
United	O
States	O
Food	O
Drug	O
Administration	O
USFDA	O
amphetamine	B-Drug
is	O
contraindicated	O
in	O
people	O
with	O
a	O
history	O
of	O
drug	O
abuse	O
cardiovascular	O
disease	O
severe	O
agitation	O
or	O
anxiety	O

In	O
response	O
New	O
Zealand	O
experts	O
called	O
for	O
wider	O
availability	O
of	O
naloxone	B-Drug

DJ	O
Screw's	O
invoking	O
lean	O
in	O
his	O
lyrics	O
and	O
use	O
of	O
slow	O
tempos	O
had	O
caused	O
style	O
to	O
be	O
characterized	O
[a]s	O
if	O
the	O
song	O
itself	O
has	O
taken	O
too	O
much	O
codeine	B-Drug
promethazine	B-Drug

Acetylmethadol	B-Drug
has	O
an	O
ACSCN	O
of	O
9601	O

After	O
receiving	O
a	O
bolus	O
dose	O
of	O
fentanyl	B-Drug
people	O
can	O
also	O
experience	O
paradoxical	O
coughing	O
which	O
is	O
phenomenon	O
that	O
not	O
well	O
understood	O

The	O
reaction	O
forms	O
magnetite	O
Fe3O4	B-Drug
quartz	O
SiO2	O
and	O
hydrogen	O
H2:	O
3Fe2SiO4	O
+	O
2	O
H2O	O
3	O
H2	O
fayalite	O
water	O
hydrogenThis	O
closely	O
resembles	O
the	O
Schikorr	O
observed	O
in	O
anaerobic	O
oxidation	O
of	O
ferrous	O
hydroxide	O
contact	O
with	O

Nine	O
percent	O
of	O
ingested	O
PCP	B-Drug
is	O
excreted	O
in	O
its	O
unchanged	O
form	O

While	O
desomorphine	B-Drug
was	O
found	O
to	O
be	O
faster	O
acting	O
and	O
more	O
effective	O
than	O
morphine	B-Drug
for	O
the	O
rapid	O
relief	O
of	O
severe	O
pain	O
its	O
shorter	O
duration	O
action	O
relatively	O
respiratory	O
depression	O
produced	O
at	O
equianalgesic	O
doses	O
as	O
well	O
a	O
high	O
incidence	O
other	O
side	O
effects	O
such	O
hypotension	O
urinary	O
retention	O
were	O
felt	O
outweigh	O
any	O
potential	O
advantages	O

On	O
decarboxylation	O
the	O
following	O
major	O
cannabinoids	O
THC	O
CBD	B-Drug
CBC	O
CBCV	O
CBDV	O
CBGV	O
THCV	O
are	O
formed	O

Trenbolone	B-Drug
acetate	I-Drug
is	O
used	O
in	O
veterinary	O
medicine	O
livestock	O
to	O
increase	O
muscle	O
growth	O
and	O
appetite	O
while	O
trenbolone	O
hexahydrobenzylcarbonate	O
was	O
formerly	O
clinically	O
humans	O
but	O
now	O
no	O
longer	O
marketed	O

Similar	O
changes	O
occur	O
with	O
a	O
moderate	O
inhibitor	O
of	O
CYP2C19	O
and	O
other	O
cytochromes	O
cimetidine:	O
amitriptyline	B-Drug
level	O
increases	O
by	O
about	O
70%	O
while	O
nortriptyline	B-Drug
decreases	O
50%	O
cimetidine	B-Drug

However	O
there	O
is	O
controversy	O
regarding	O
naloxone's	O
efficacy	O
in	O
treating	O
the	O
symptoms	O
of	O
clonidine	B-Drug
overdose	O
namely	O
slow	O
heart	O
rate	O
low	O
blood	O
pressure	O
and	O
confusion/somnolence	O
naloxone	B-Drug

Relative	O
to	O
catecholaminergic	O
transmission	O
MDMA	B-Drug
enhances	O
serotonergic	O
significantly	O
more	O
when	O
compared	O
classical	O
stimulants	O
like	O
amphetamine	B-Drug

Furthermore	O
both	O
psychostimulants	O
MDPV	B-Drug
and	O
cocaine	B-Drug
restore	O
drug-seeking	O
behavior	O
with	O
respect	O
to	O
each	O
other	O
although	O
relapse	O
into	O
drug-taking	O
is	O
always	O
more	O
pronounced	O
the	O
conditioning	O
drug	O

Following	O
the	O
patch	O
a	O
flavoured	O
lollipop	O
of	O
fentanyl	B-Drug
citrate	O
mixed	O
with	O
inert	O
fillers	O
was	O
introduced	O
in	O
1998	O
under	O
brand	O
name	O
Actiq	B-Drug
becoming	O
first	O
quick-acting	O
formation	O
for	O
use	O
chronic	O
breakthrough	O
pain	O

There	O
are	O
however	O
multiple	O
indications	O
that	O
paradoxical	O
reactions	O
upon	O
for	O
example	O
benzodiazepines	O
barbiturates	O
inhalational	O
anesthetics	O
propofol	B-Drug
neurosteroids	O
and	O
alcohol	O
associated	O
with	O
structural	O
deviations	O
of	O
GABAA	O
receptors	O

Karl	O
Koller	O
a	O
close	O
associate	O
of	O
Sigmund	O
Freud	O
who	O
would	O
write	O
about	O
cocaine	B-Drug
later	O
experimented	O
with	O
for	O
ophthalmic	O
usage	O

Ethylestrenol	B-Drug
was	O
first	O
described	O
in	O
1959	O
and	O
introduced	O
for	O
medical	O
use	O
1961	O

The	O
psychological	O
effects	O
of	O
methamphetamine	B-Drug
can	O
include	O
euphoria	O
dysphoria	O
changes	O
in	O
libido	O
alertness	O
apprehension	O
and	O
concentration	O
decreased	O
sense	O
fatigue	O
insomnia	O
or	O
wakefulness	O
self-confidence	O
sociability	O
irritability	O
restlessness	O
grandiosity	O
repetitive	O
obsessive	O
behaviors	O

On	O
11	O
November	O
she	O
took	O
an	O
ecstasy	B-Drug
MDMA	B-Drug
tablet	O
and	O
then	O
drank	O
approximately	O
7	O
litres	O
12	O
imp	O
pt;	O
1	O

As	O
a	O
type	O
of	O
emergency	O
contraception	O
levonorgestrel	B-Drug
is	O
used	O
after	O
unprotected	O
intercourse	O
to	O
reduce	O
the	O
risk	O
pregnancy	O

There	O
is	O
probably	O
no	O
single	O
reference	O
that	O
lists	O
all	O
the	O
pharmaceutical	O
variations	O
of	O
laudanum	B-Drug
were	O
created	O
and	O
used	O
in	O
different	O
countries	O
during	O
centuries	O
since	O
it	O
was	O
initially	O
formulated	O

Zinc	O
deficiency	O
can	O
also	O
impair	O
absorption	O
transport	O
and	O
metabolism	O
of	O
vitamin	B-Drug
A	I-Drug
because	O
it	O
is	O
essential	O
for	O
the	O
synthesis	O
proteins	O
as	O
cofactor	O
in	O
conversion	O
retinol	B-Drug
to	O
retinal	O

The	O
compound	O
is	O
inactive	O
itself	O
showing	O
more	O
than	O
100-fold	O
lower	O
affinity	O
for	O
the	O
androgen	O
and	O
progesterone	O
receptors	O
trenbolone	B-Drug

Magnetic	O
resonance	O
imaging	O
MRI	O
studies	O
suggest	O
that	O
long-term	O
treatment	O
with	O
ADHD	O
stimulants	O
specifically	O
amphetamine	B-Drug
and	O
methylphenidate	B-Drug
decreases	O
abnormalities	O
in	O
brain	O
structure	O
function	O
found	O
subjects	O

Use	O
of	O
heroin	B-Drug
by	O
mouth	O
is	O
less	O
common	O
than	O
other	O
methods	O
administration	O
mainly	O
because	O
there	O
little	O
to	O
no	O
rush	O
and	O
the	O
effects	O
are	O
potent	O

Furthermore	O
ambulance	O
callouts	O
for	O
heroin	B-Drug
overdoses	O
were	O
1	O

The	O
cocaine	B-Drug
alkaloid	O
was	O
first	O
isolated	O
by	O
the	O
German	O
chemist	O
Friedrich	O
Gaedcke	O
in	O
1855	O

Naloxone	B-Drug
can	O
completely	O
or	O
partially	O
reverse	O
an	O
opioid	O
overdose	O

Because	O
of	O
its	O
relatively	O
long	O
duration	O
action	O
and	O
evidence	O
safety	O
efficacy	O
diazepam	B-Drug
is	O
preferred	O
over	O
other	O
benzodiazepines	O
for	O
treatment	O
persons	O
experiencing	O
moderate	O
to	O
severe	O
alcohol	O
withdrawal	O

Half	O
lives	O
of	O
the	O
metabolites	O
were	O
315	O
minutes	O
for	O
nicotinoyl	O
metabolite	O
and	O
135190	O
morphine	B-Drug

As	O
opposed	O
to	O
Adderall	B-Drug
which	O
contains	O
roughly	O
equal	O
parts	O
of	O
racemic	O
amphetamine	B-Drug
and	O
dextroamphetamine	B-Drug
salts	O
lisdexamfetamine	B-Drug
is	O
a	O
single-enantiomer	O
formula	O

Cannabidiol	B-Drug
was	O
isolated	O
and	O
identified	O
from	O
Cannabis	O
sativa	O
in	O
1940	O
THC	O
its	O
structure	O
elucidated	O
by	O
synthesis	O
1964	O

Linagliptin	B-Drug
is	O
the	O
INN	O

On	O
20	O
March	O
2001	O
the	O
UN	O
Commission	O
on	O
Narcotic	O
Drugs	O
placed	O
GHB	B-Drug
in	O
Schedule	O
IV	O
of	O
1971	O
Convention	O
Psychotropic	O
Substances	O

Also	O
cross-sensitization	O
is	O
not	O
unique	O
to	O
marijuana	B-Drug

Gabapentin	B-Drug
does	O
not	O
bind	O
to	O
other	O
drug	O
transporters	O
such	O
as	O
P-glycoprotein	O
ABCB1	O
or	O
OCTN2	O
SLC22A5	O

The	O
overabundance	O
of	O
5-HT3	O
receptors	O
in	O
cocaine	B-Drug
conditioned	O
rats	O
display	O
this	O
trait	O
however	O
the	O
exact	O
effect	O
process	O
is	O
unclear	O

Likewise	O
a	O
10-year	O
observational	O
study	O
found	O
that	O
the	O
incidence	O
of	O
depression	O
in	O
196	O
transgender	O
women	O
taking	O
high-dose	O
spironolactone	B-Drug
combination	O
with	O
an	O
estrogen	O
was	O
less	O
than	O
1%	O

Cimetidine	B-Drug
is	O
widely	O
distributed	O
throughout	O
all	O
tissues	O

It	O
is	O
an	O
analogue	O
of	O
hydrocodone	B-Drug
substituted	O
with	O
8-ethyl	O
group	O
and	O
N-cyclopropylmethyl	O

Both	O
drugs	O
produce	O
analgesia	O
even	O
when	O
naloxone	B-Drug
an	O
opioid	O
antagonist	O
is	O
administered	O

Fenethylline	B-Drug
is	O
metabolized	O
by	O
the	O
body	O
to	O
form	O
two	O
drugs	O
amphetamine	B-Drug
24	O

One	O
study	O
found	O
approximately	O
15%	O
of	O
chronic	O
MDMA	B-Drug
users	O
met	O
the	O
DSM-IV	O
diagnostic	O
criteria	O
for	O
substance	O
dependence	O

Hydrochlorothiazide	B-Drug
belongs	O
to	O
thiazide	O
class	O
of	O
diuretics	O

Given	O
the	O
fact	O
that	O
population	O
of	O
United	O
States	O
is	O
largest	O
user	O
illegal	O
drugs	O
in	O
world	O
with	O
one	O
six	O
citizens	O
claiming	O
to	O
have	O
used	O
cocaine	B-Drug
their	O
life	O
Nations	O
Office	O
on	O
Drugs	O
and	O
Crime	O
UNODC	O
after	O
reviewing	O
efficiency	O
actions	O
taken	O
by	O
Colombian	O
government	O
for	O
more	O
than	O
20	O
years	O
has	O
called	O
consuming	O
countries	O
-	O
mostly	O
Europe	O
North	O
America	O
take	O
share	O
responsibility	O
reduce	O
demand	O
explaining	O
there	O
are	O
limits	O
what	O
Andean	O
governments	O
can	O
do	O
if	O
consumption	O
continues	O
unabated	O
a	O
position	O
been	O
maintained	O
many	O
was	O
later	O
accepted	O

The	O
active	O
metabolite	O
of	O
delorazepam	B-Drug
is	O
lorazepam	B-Drug
and	O
represents	O
about	O
15	O
-	O
24	O
percent	O
the	O
parent	O
drug	O

In	O
contrast	O
to	O
minoxidil	B-Drug
alfatradiol	B-Drug
did	O
not	O
result	O
in	O
an	O
increase	O
of	O
hair	O
density	O
or	O
thickness	O
but	O
only	O
slowing	O
down	O
stabilization	O
loss	O
this	O
study	O

In	O
1994	O
Morabito	O
was	O
sentenced	O
to	O
a	O
30-year	O
prison	O
sentence	O
as	O
result	O
of	O
the	O
Fortaleza	O
operation	O
trafficking	O
over	O
600	O
kilograms	O
cocaine	B-Drug
between	O
Brazil	O
and	O
Italy	O

Some	O
of	O
the	O
strangest	O
urban	O
legends	O
told	O
are	O
those	O
about	O
lysergic	O
acid	B-Drug
diethylamide	O
LSD	B-Drug
a	O
potent	O
psychedelic	O
drug	O
that	O
gained	O
popularity	O
in	O
several	O
countries	O
1960s	O
and	O
1970s	O
experienced	O
resurgence	O
mid	O
2010s	O
to	O
present	O

R-30490	B-Drug
was	O
found	O
to	O
be	O
the	O
most	O
selective	O
agonist	O
for	O
-opioid	O
receptor	O
out	O
of	O
all	O
fentanyl	B-Drug
analogues	O
tested	O
but	O
it	O
has	O
never	O
been	O
introduced	O
medical	O
use	O
in	O
humans	O
although	O
closely	O
related	O
drug	O
sufentanil	B-Drug
is	O
widely	O
used	O
analgesia	O
and	O
anesthesia	O
during	O
major	O
surgery	O

Mercdes	O
Benegbi	O
born	O
with	O
phocomelia	O
of	O
both	O
arms	O
drove	O
the	O
successful	O
campaign	O
for	O
compensation	O
from	O
her	O
government	O
Canadians	O
who	O
were	O
affected	O
by	O
thalidomide	B-Drug

0]undeca-581012-tetraen-3-one	O
Piperonal	O
also	O
known	O
as	O
34-Methylenedioxybenzaldehyde	O
or	O
Piperonylaldehyde	O
Prazepam	B-Drug
may	O
be	O
used	O
to	O
manufacture	O
flutoprazepam	B-Drug
9-chloro-2-cyclopropylmethyl-6-phenyl-25-diazabicyclo[5	O

In	O
response	O
to	O
the	O
ever-growing	O
number	O
of	O
Chinese	O
people	O
becoming	O
addicted	O
opium	B-Drug
Qing	O
Daoguang	O
Emperor	O
took	O
strong	O
action	O
halt	O
smuggling	O
including	O
seizure	O
cargo	O

The	O
1961	O
Single	O
Convention	O
on	O
Narcotic	O
Drugs	O
of	O
the	O
United	O
Nations	O
which	O
replaced	O
1931	O
convention	O
categorized	O
oxycodone	B-Drug
in	O
Schedule	O
I	O

Benzphetamine	B-Drug
is	O
an	O
anorectic	O
primarily	O
promoting	O
weight	O
loss	O
through	O
reduced	O
appetite	O

Blockade	O
of	O
the	O
KOR	O
by	O
naltrexone	B-Drug
and	O
naloxone	B-Drug
is	O
thought	O
to	O
be	O
responsible	O
for	O
their	O
effectiveness	O
in	O
ameliorating	O
depersonalization	O
derealization	O

Lamictal	B-Drug
lamotrigine	B-Drug
an	O
anticonvulsant	O
used	O
as	O
a	O
mood	O
stabilizer	O

Non-clinical	O
use	O
of	O
opium	B-Drug
was	O
criminalized	O
in	O
the	O
United	O
States	O
by	O
Harrison	O
Narcotics	O
Tax	O
Act	O
1914	O
and	O
many	O
other	O
laws	O

A	O
1999	O
report	O
found	O
In	O
some	O
papers	O
it	O
is	O
suggested	O
that	O
the	O
contribution	O
of	O
dietary	O
nicotine	B-Drug
intake	O
significant	O
when	O
compared	O
with	O
exposure	O
to	O
ETS	O
[environmental	O
tobacco	O
smoke]	O
or	O
by	O
active	O
smoking	O
small	O
numbers	O
cigarettes	O

It	O
is	O
the	O
primary	O
intravenous	O
anaesthetic	O
agent	O
used	O
in	O
equine	O
surgery	O
often	O
conjunction	O
with	O
detomidine	O
and	O
thiopental	B-Drug
or	O
sometimes	O
guaifenesin	B-Drug

Etizolam	B-Drug
a	O
thienodiazepine	O
derivative	O
is	O
absorbed	O
fairly	O
rapidly	O
with	O
peak	O
plasma	O
levels	O
achieved	O
between	O
30	O
minutes	O
and	O
2	O
hours	O

The	O
most	O
commonly	O
reported	O
side	O
effects	O
of	O
tapentadol	B-Drug
therapy	O
in	O
clinical	O
trials	O
were	O
nausea	O
vomiting	O
dizziness	O
sleepiness	O
itchiness	O
dry	O
mouth	O
headache	O
and	O
fatigue	O

Tales	O
of	O
the	O
corruption	O
youth	O
by	O
cocaine	B-Drug
were	O
common	O
but	O
there	O
is	O
little	O
evidence	O
to	O
support	O
their	O
veracity	O

Herceptin	B-Drug
trastuzumab	B-Drug
for	O
HER-2	O
positive	O
breast	O
cancer	O

5	O
mg	O
dutasteride	B-Drug
each	O

At	O
dosages	O
of	O
50	O
mg	O
or	O
100	O
per	O
day	O
androstenedione	B-Drug
had	O
no	O
effect	O
on	O
muscle	O
strength	O
size	O
body	O
fat	O
levels	O

Due	O
to	O
this	O
both	O
the	O
immigrant	O
population	O
and	O
social	O
use	O
of	O
opium	B-Drug
fell	O
into	O
decline	O

The	O
half-life	O
of	O
duloxetine	B-Drug
is	O
about	O
12	O
hours	O
range:	O
817	O
and	O
steady-state	O
achieved	O
after	O
3	O
days	O

Etizolam	B-Drug
is	O
licensed	O
for	O
the	O
treatment	O
of	O
anxiety	O
insomnia	O
and	O
neurosis	O
as	O
a	O
prescription-only	O
medication	O

Mephedrone	B-Drug
also	O
known	O
as	O
4-methyl	O
methcathinone	B-Drug
4-MMC	O
or	O
ephedrone	O
is	O
a	O
synthetic	O
stimulant	O
drug	O
of	O
the	O
amphetamine	O
and	O
cathinone	B-Drug
classes	O

The	O
UK	O
term	O
mandy	O
and	O
the	O
US	O
molly	B-Drug
colloquially	O
refer	O
to	O
MDMA	B-Drug
in	O
a	O
crystalline	O
powder	O
form	O
that	O
is	O
thought	O
be	O
free	O
of	O
adulterants	O

Actress	O
Carole	O
Landis	O
and	O
journalist	O
Dorothy	O
Kilgallen	O
both	O
allegedly	O
committed	O
suicide	O
or	O
accidentally	O
overdosed	O
on	O
secobarbital	B-Drug
in	O
1948	O
1965	O
respectively	O

However	O
athletes	O
and	O
bodybuilders	O
have	O
been	O
using	O
trenbolone	B-Drug
acetate	O
as	O
a	O
physique-	O
performance-enhancing	O
drug	O
for	O
decades	O

Conversion	O
of	O
androstenedione	B-Drug
to	O
estrone	O
requires	O
the	O
enzyme	O
aromatase	O

The	O
attorneys	O
general	O
of	O
Connecticut	O
and	O
Pennsylvania	O
have	O
launched	O
investigations	O
into	O
its	O
diversion	O
from	O
the	O
legitimate	O
pharmaceutical	O
market	O
including	O
Cephalon's	O
sales	O
promotional	O
practices	O
for	O
Provigil	B-Drug
Actiq	B-Drug
Gabitril	B-Drug

Both	O
drugs	O
produce	O
analgesia	O
even	O
when	O
naloxone	B-Drug
an	O
opioid	O
antagonist	O
is	O
administered	O

Papaverine	B-Drug
is	O
available	O
as	O
a	O
conjugate	O
of	O
hydrochloride	O
codecarboxylate	O
adenylate	O
and	O
teprosylate	O

Three	O
common	O
street	O
names	O
are	O
meth	B-Drug
crank	O
and	O
ice	O

In	O
addition	O
unlike	O
morphine	B-Drug
cebranopadol	O
has	O
not	O
been	O
found	O
to	O
affect	O
motor	O
coordination	O
or	O
reduce	O
respiration	O
in	O
animals	O
at	O
doses	O
over	O
the	O
dosage	O
range	O
for	O
analgesia	O

However	O
typical	O
clinical	O
dosages	O
of	O
bicalutamide	B-Drug
result	O
in	O
circulating	O
levels	O
the	O
drug	O
that	O
are	O
thousands	O
times	O
higher	O
than	O
those	O
testosterone	O
and	O
DHT	O
allowing	O
it	O
to	O
powerfully	O
prevent	O
them	O
from	O
binding	O
activating	O
receptor	O

Sinsemilla	B-Drug
Spanish	O
for	O
without	O
seed	O
is	O
the	O
dried	O
seedless	O
i	O

In	O
people	O
with	O
castration-refractory	O
prostate	O
cancer	O
but	O
who	O
had	O
not	O
received	O
chemotherapy	O
those	O
abiraterone	B-Drug
acetate	O
a	O
progression-free	O
survival	O
of	O
16	O

The	O
bill	O
includes	O
Medicare	O
and	O
Medicaid	O
reform	O
in	O
order	O
to	O
improve	O
treatment	O
recovery	O
prevention	O
efforts	O
while	O
also	O
strengthening	O
the	O
fight	O
against	O
synthetic	O
drugs	O
like	O
fentanyl	B-Drug

Dimethyltrienolone	O
developmental	O
code	O
name	O
RU-2420	O
is	O
a	O
synthetic	O
orally	O
active	O
and	O
extremely	O
potent	O
anabolicandrogenic	O
steroid	O
AAS	O
17-alkylated	O
19-nortestosterone	B-Drug
nandrolone	B-Drug
derivative	O
which	O
was	O
never	O
marketed	O
for	O
medical	O
use	O

It	O
can	O
be	O
described	O
as	O
an	O
analogue	O
of	O
JWH-250	B-Drug
with	O
the	O
1-pentyl	O
group	O
replaced	O
by	O
1-2-cyclohexylethyl	O
and	O
expected	O
to	O
less	O
potent	O
than	O
cf	O

Cooking	O
often	O
decreases	O
vitamin	B-Drug
C	I-Drug
in	O
foods	O

Ergotamine	B-Drug
tartrate	O
a	O
precursor	O
to	O
lysergic	O
acid	B-Drug
is	O
regulated	O
under	O
the	O
Chemical	O
Diversion	O
and	O
Trafficking	O
Act	O

Approximately	O
half	O
of	O
all	O
adult	O
Americans	O
have	O
tried	O
marijuana	B-Drug

In	O
contrast	O
to	O
oxycodone	B-Drug
and	O
oxymorphone	B-Drug
noroxycodone	O
noroxymorphone	B-Drug
while	O
also	O
potent	O
MOR	O
agonists	O
poorly	O
cross	O
the	O
bloodbrain	O
barrier	O
into	O
central	O
nervous	O
system	O
for	O
this	O
reason	O
are	O
only	O
minimally	O
analgesic	O
in	O
comparison	O

As	O
such	O
methyltestosterone	B-Drug
has	O
a	O
relatively	O
low	O
ratio	O
of	O
anabolic	O
to	O
androgenic	O
activity	O
with	O
similar	O
that	O
testosterone	O
close	O
1:1	O
and	O
this	O
makes	O
it	O
among	O
the	O
most	O
AAS	O

For	O
example	O
Michigan	O
law	O
allowed	O
over-the-counter	O
non-prescription	O
sale	O
of	O
paregoric	O
until	O
April	O
1964	O
but	O
still	O
OTC	O
sales	O
certain	O
exempt	O
cough	O
medication	O
preparations	O
that	O
contain	O
60	O
mg	O
codeine	B-Drug
per	O
fluid	O
ounce	O

Arnold	O
Klein	O
said	O
that	O
Jackson	O
used	O
an	O
anesthesiologist	O
to	O
administer	O
propofol	B-Drug
help	O
him	O
sleep	O
while	O
he	O
was	O
on	O
tour	O
in	O
Germany	O

Formoterol	B-Drug
another	O
long-acting	O
2-agonist	O
was	O
marketed	O
shortly	O
after	O

for	O
treatment	O
of	O
depression	O
or	O
bipolar	O
disorder	O
less	O
toxic	O
NSAIDs	O
such	O
as	O
sulindac	B-Drug
aspirin	B-Drug
are	O
preferred	O

Afghanistan's	O
economy	O
has	O
thus	O
evolved	O
to	O
the	O
point	O
where	O
it	O
is	O
now	O
highly	O
dependent	O
on	O
opium	B-Drug

However	O
maternal	O
use	O
of	O
marijuana	O
during	O
pregnancy	O
does	O
not	O
appear	O
to	O
be	O
associated	O
with	O
low	O
birth	O
weight	O
or	O
early	O
delivery	O
after	O
controlling	O
for	O
tobacco	B-Drug
and	O
other	O
confounding	O
factors	O

During	O
this	O
time	O
the	O
use	O
of	O
opium	B-Drug
had	O
little	O
stigma;	O
drug	O
was	O
used	O
freely	O
until	O
1882	O
when	O
a	O
law	O
passed	O
to	O
confine	O
smoking	O
specific	O
dens	O

Clobazam	B-Drug
is	O
widely	O
used	O
by	O
specialist	O
epilepsy	O
clinics	O
worldwide	O
and	O
clonazepam	B-Drug
popular	O
in	O
the	O
Netherlands	O
Belgium	O
France	O

Medical	O
historians	O
also	O
suspect	O
that	O
Solomon	O
Northup	O
a	O
free	O
black	O
man	O
who	O
was	O
kidnapped	O
and	O
sold	O
into	O
slavery	O
in	O
1841	O
poisoned	O
using	O
combination	O
of	O
Atropa	O
belladonna	O
laudanum	B-Drug

Cannabis	O
has	O
been	O
cultivated	O
in	O
Morocco	O
for	O
centuries	O
and	O
the	O
country	O
is	O
currently	O
among	O
world's	O
top	O
producers	O
of	O
hashish	B-Drug

Extracts	O
such	O
as	O
hashish	B-Drug
and	O
hash	B-Drug
oil	I-Drug
typically	O
contain	O
more	O
THC	O
than	O
high	O
potency	O
cannabis	O
infructescences	O

After	O
absorption	O
diazepam	B-Drug
is	O
redistributed	O
into	O
muscle	O
and	O
adipose	O
tissue	O

opium	B-Drug
means:	O
a	O
the	O
coagulated	O
juice	O
of	O
poppy;	O
and	O
b	O
any	O
mixture	O
with	O
or	O
without	O
neutral	O
material	O
poppy	O
but	O
does	O
not	O
include	O
preparation	O
containing	O
more	O
than	O
0	O

Preferences	O
between	O
opium	B-Drug
and	O
heroin/morphine	O
methods	O
of	O
administration	O
differ	O
from	O
region	O
to	O
within	O
China	O
heroin	B-Drug
morphine	B-Drug

Due	O
to	O
the	O
low	O
weight	O
of	O
a	O
dose	O
alprazolam	B-Drug
in	O
one	O
case	O
was	O
distributed	O
on	O
blotter	O
paper	O
manner	O
similar	O
LSD	B-Drug

Finally	O
HCl	O
gas	O
is	O
bubbled	O
through	O
the	O
mixture	O
to	O
produce	O
4-methylmethcathinone	B-Drug
hydrochloride	O

This	O
organization	O
which	O
had	O
elected	O
national	O
officers	O
and	O
held	O
an	O
annual	O
meeting	O
was	O
instrumental	O
in	O
gathering	O
data	O
from	O
every	O
Western-trained	O
medical	O
doctor	O
China	O
then	O
published	O
as	O
William	O
Hector	O
Park	O
compiled	O
Opinions	O
of	O
Over	O
100	O
Physicians	O
on	O
the	O
Use	O
Opium	B-Drug
Shanghai:	O
American	O
Presbyterian	O
Mission	O
Press	O
1899	O

Remaining	O
opium	B-Drug
production	O
shifted	O
south	O
of	O
the	O
Chinese	O
border	O
into	O
Golden	O
Triangle	O
region	O

Most	O
provinces	O
have	O
set	O
the	O
minimum	O
age	O
to	O
purchase	O
and	O
consume	O
cannabis	O
19	O
years	O
old	O
although	O
Alberta	O
Quebec	O
it	O
18	O
in	O
line	O
with	O
their	O
alcohol	O
tobacco	B-Drug
laws	O

In	O
the	O
UK	O
part	O
of	O
tension	O
was	O
between	O
on	O
one	O
hand	O
both	O
European	O
Medicines	O
Agency	O
and	O
Healthcare	O
products	O
Regulatory	O
which	O
had	O
approved	O
Lucentis	B-Drug
but	O
not	O
Avastin	B-Drug
for	O
wet	O
AMD	O
their	O
interest	O
in	O
ensuring	O
that	O
doctors	O
to	O
do	O
use	O
medicines	O
off-label	O
when	O
there	O
are	O
other	O
medications	O
same	O
indication	O
NICE	O
sets	O
treatment	O
guidelines	O
has	O
been	O
unable	O
so	O
far	O
appraise	O
as	O
a	O
first-line	O
order	O
save	O
money	O
National	O
Health	O
Service	O

Because	O
of	O
these	O
pharmacokinetic	O
differences	O
GBL	O
tends	O
to	O
be	O
more	O
potent	O
and	O
faster-acting	O
than	O
GHB	B-Drug
but	O
has	O
a	O
shorter	O
duration;	O
whereas	O
the	O
related	O
compound	O
14-butanediol	O
14-B	O
slightly	O
less	O
slower	O
take	O
effect	O
longer-acting	O

The	O
elimination	O
half-life	O
of	O
metandienone	B-Drug
is	O
about	O
3	O
to	O
6	O
hours	O

For	O
example	O
phenylacetic	O
acid	O
is	O
used	O
legally	O
in	O
the	O
production	O
of	O
penicillin	O
flavourings	O
perfume	O
and	O
cleaning	O
solutions	O
but	O
it	O
can	O
also	O
be	O
illegal	O
manufacture	O
amphetamines	O
methamphetamines	B-Drug

The	O
risk	O
of	O
respiratory	O
depression	O
is	O
especially	O
high	O
with	O
potent	O
fentanyl	B-Drug
analogues	O
such	O
as	O
alfentanil	B-Drug
and	O
brifentanil	O
these	O
drugs	O
pose	O
a	O
significant	O
death	O
if	O
used	O
outside	O
hospital	O
setting	O
without	O
an	O
appropriate	O
artificial	O
breathing	O
apparatus	O
available	O

Some	O
psychoactive	O
species	O
contain	O
baeocystin	O
norbaeocystin	B-Drug
and	O
carboline	O
monoamine	O
oxidase	O
inhibitors	O
in	O
addition	O
to	O
psilocin	B-Drug
psilocybin	O

Despite	O
this	O
less	O
than	O
a	O
month	O
later	O
Lawn	O
reviewed	O
the	O
evidence	O
and	O
reclassified	O
MDMA	B-Drug
as	O
Schedule	O
I	O
again	O
claiming	O
that	O
expert	O
testimony	O
of	O
several	O
psychiatrists	O
over	O
200	O
cases	O
where	O
had	O
been	O
used	O
in	O
therapeutic	O
context	O
with	O
positive	O
results	O
could	O
be	O
dismissed	O
because	O
they	O
weren't	O
published	O
medical	O
journals	O

Finasteride	B-Drug
is	O
most	O
effective	O
on	O
the	O
crown	O
but	O
can	O
reduce	O
hair	O
loss	O
in	O
all	O
areas	O
of	O
scalp	O

Management	O
of	O
ketamine-induced	O
cystitis	O
involves	O
ketamine	B-Drug
cessation	O
as	O
the	O
first	O
step	O

This	O
is	O
because	O
LSD	B-Drug
almost	O
always	O
present	O
in	O
a	O
medium	O
e	O

If	O
lorazepam	B-Drug
is	O
not	O
available	O
or	O
intravenous	O
access	O
possible	O
then	O
diazepam	B-Drug
should	O
be	O
given	O

Sports	O
Illustrated	O
credits	O
Patrick	O
Arnold	O
with	O
introducing	O
androstenedione	B-Drug
to	O
the	O
North	O
American	O
market	O

Intravenous	O
acetaminophen	B-Drug
is	O
sold	O
under	O
the	O
brand	O
name	O
Ofirmev	O
in	O
United	O
States	O

Findings	O
of	O
cross-tolerance	O
with	O
nicotine	B-Drug
in	O
animal	O
models	O
suggest	O
that	O
it	O
is	O
also	O
possible	O
humans	O
and	O
may	O
explain	O
why	O
the	O
two	O
drugs	O
are	O
often	O
used	O
together	O

While	O
a	O
study	O
showed	O
no	O
significant	O
difference	O
in	O
birth	O
weights	O
or	O
incidence	O
of	O
defects	O
and	O
alternation	O
immunity	O
to	O
infectious	O
disease	O
caused	O
by	O
breast	O
milk	O
containing	O
DMPA	B-Drug
subgroup	O
babies	O
whose	O
mothers	O
started	O
at	O
2	O
days	O
postpartum	O
had	O
75%	O
higher	O
doctor	O
visits	O
for	O
diseases	O
during	O
their	O
first	O
year	O
life	O

Between	O
those	O
years	O
lifetime	O
use	O
of	O
cocaine	B-Drug
went	O
from	O
3	O

Lithium	O
and	O
chronic	O
treatment	O
with	O
barbiturates	O
can	O
increase	O
chlorpromazine	B-Drug
clearance	O
significantly	O

Remeron	B-Drug
mirtazapine	B-Drug
an	O
atypical	O
antidepressant	O
which	O
is	O
often	O
used	O
as	O
a	O
sleep	O
aid	O

Dronabinol	O
does	O
not	O
include	O
any	O
other	O
tetrahydrocannabinol	O
THC	O
isomers	O
or	O
cannabidiol	B-Drug

In	O
the	O
United	O
Kingdom	O
MDMA	B-Drug
was	O
made	O
illegal	O
in	O
1977	O
by	O
a	O
modification	O
order	O
to	O
existing	O
Misuse	O
of	O
Drugs	O
Act	O
1971	O

The	O
Governor	O
of	O
Afghanistan's	O
Helmand	O
Province	O
Hayatullah	O
Hayat	O
is	O
a	O
proponent	O
eventually	O
legalizing	O
opium	B-Drug
production	O
to	O
create	O
morphine	B-Drug

Little	O
further	O
work	O
was	O
done	O
with	O
thalidomide	B-Drug
in	O
cancer	O
until	O
the	O
1990s	O

MDA	O
is	O
rarely	O
sought	O
after	O
as	O
a	O
recreational	O
drug	O
compared	O
to	O
other	O
drugs	O
in	O
the	O
amphetamine	B-Drug
family;	O
however	O
it	O
remains	O
an	O
important	O
and	O
widely	O
used	O
due	O
being	O
primary	O
metabolite	O
product	O
of	O
hepatic	O
N-dealkylation	O
MDMA	B-Drug
ecstasy	B-Drug
In	O
addition	O
common	O
find	O
adulterant	O
illicitly	O
produced	O

This	O
led	O
to	O
widespread	O
morphine	B-Drug
addiction	O
among	O
veterans	O
of	O
the	O
war	O

Spironolactone	B-Drug
produces	O
an	O
irregular	O
and	O
anovulatory	O
pattern	O
of	O
menstrual	O
cycles	O

chlorpromazine	B-Drug
as	O
they	O
lower	O
the	O
seizure	O
threshold	O
and	O
can	O
worsen	O
withdrawal	O
effects;	O
if	O
used	O
extreme	O
caution	O
is	O
required	O

Fentanyl	B-Drug
was	O
first	O
made	O
by	O
Paul	O
Janssen	O
in	O
1960	O
and	O
approved	O
for	O
medical	O
use	O
the	O
United	O
States	O
1968	O

nalorphine/Nalline	O
and	O
naloxone/Narcan	O
as	O
treatment	O
for	O
opiate	O
overdoses	O
the	O
ability	O
of	O
methadone	B-Drug
to	O
alleviate	O
withdrawal	O
symptoms	O
rapid	O
tolerance	O
but	O
lack	O
physical	O
dependence	O
with	O
LSD	B-Drug
cross-tolerance	O
between	O
psilocybin	O
pure	O
THC	O
cause	O
marijuana-like	O
effects	O
naloxone	B-Drug
Narcan	B-Drug

A	O
further	O
110	O
tons	O
of	O
heroin	B-Drug
and	O
morphine	B-Drug
from	O
neighboring	O
Afghanistan	O
are	O
trafficked	O
through	O
Pakistan	O
to	O
international	O
markets	O

A	O
common	O
legend	O
that	O
surfaced	O
around	O
the	O
year	O
2000	O
was	O
ecstasy	B-Drug
can	O
put	O
holes	O
in	O
brain	O
akin	O
to	O
Swiss	O
cheese	O
which	O
are	O
presumed	O
be	O
permanent	O

It	O
may	O
also	O
be	O
mixed	O
with	O
cannabis	O
or	O
tobacco	B-Drug

AM-1235	B-Drug
1-5-fluoropentyl-3-naphthalen-1-oyl-6-nitroindole	O
is	O
a	O
drug	O
that	O
acts	O
as	O
potent	O
and	O
reasonably	O
selective	O
agonist	O
for	O
the	O
cannabinoid	O
receptor	O
CB1	O

The	O
dextrorotatory	O
stereoisomer	O
of	O
the	O
compound	O
is	O
an	O
active	O
metabolite	O
dextromethorphan	B-Drug
dextrorphan	B-Drug
and	O
3-methoxymorphinan	B-Drug
similarly	O
to	O
them	O
has	O
potent	O
neuroprotective	O
neurotrophic	O
effects	O
on	O
LTS-	O
MPTP-treated	O
dopaminergic	O
neurons	O
nigrostriatal	O
pathway	O
but	O
notably	O
without	O
producing	O
any	O
neuropsychotoxic	O
side	O
e	O

Because	O
MDMA	B-Drug
releases	O
dopamine	O
in	O
the	O
striatum	O
mechanisms	O
by	O
which	O
it	O
induces	O
FosB	O
nucleus	O
accumbens	O
are	O
analogous	O
to	O
other	O
dopaminergic	O
psychostimulants	O

In	O
a	O
study	O
of	O
cocaine	B-Drug
users	O
the	O
average	O
time	O
taken	O
to	O
reach	O
peak	O
subjective	O
effects	O
was	O
3	O

The	O
quantity	O
of	O
poppy	O
straw	O
produced	O
is	O
typically	O
given	O
as	O
opium	B-Drug
equivalents	O

In	O
Canada	O
the	O
history	O
of	O
thalidomide	B-Drug
dates	O
back	O
to	O
April	O
1	O
1961	O

Nitrazepam	B-Drug
at	O
doses	O
of	O
5	O
mg	O
or	O
higher	O
impairs	O
driving	O
skills	O
and	O
like	O
other	O
hypnotic	O
drugs	O
it	O
is	O
associated	O
with	O
an	O
increased	O
risk	O
traffic	O
accidents	O

Due	O
to	O
its	O
strong	O
anticholinergic	O
effects	O
diphenhydramine	B-Drug
is	O
on	O
the	O
Beers	O
list	O
of	O
drugs	O
avoid	O
in	O
elderly	O

On	O
the	O
international	O
scene	O
benzodiazepines	O
are	O
categorized	O
as	O
Schedule	O
IV	O
controlled	O
drugs	O
by	O
INCB	O
apart	O
from	O
flunitrazepam	B-Drug
which	O
is	O
a	O
III	O
drug	O
under	O
Convention	O
on	O
Psychotropic	O
Substances	O

Both	O
agents	O
show	O
much	O
higher	O
affinity	O
and	O
more	O
potent	O
inhibition	O
of	O
the	O
AR	O
relative	O
to	O
other	O
NSAAs	O
enzalutamide	B-Drug
apalutamide	B-Drug
although	O
they	O
also	O
possess	O
shorter	O
comparatively	O
less	O
favorable	O
elimination	O
half-lives	O

On	O
decarboxylation	O
the	O
following	O
major	O
cannabinoids	O
THC	O
CBD	B-Drug
CBC	O
CBCV	O
CBDV	O
CBGV	O
THCV	O
are	O
formed	O

This	O
drug	O
has	O
tight	O
binding	O
properties	O
which	O
means	O
it	O
a	O
long	O
half-life	O
and	O
like	O
other	O
antipsychotics	O
risperidone	B-Drug
blocks	O
the	O
mesolimbic	O
pathway	O
prefrontal	O
cortex	O
limbic	O
tuberoinfundibular	O
in	O
central	O
nervous	O
system	O

Cocaine	B-Drug
was	O
first	O
isolated	O
from	O
the	O
leaves	O
in	O
1860	O

Increasing	O
the	O
dosage	O
of	O
naloxone	B-Drug
or	O
its	O
frequency	O
administration	O
may	O
be	O
required	O
to	O
counteract	O
respiratory	O
depression	O

Potent	O
benzodiazepines	O
with	O
a	O
relatively	O
short	O
half	O
life	O
such	O
as	O
lorazepam	B-Drug
alprazolam	B-Drug
and	O
triazolam	B-Drug
have	O
the	O
highest	O
risk	O
of	O
causing	O
dependence	O

Pain	O
relief:	O
Primarily	O
fentanyl	B-Drug
provides	O
the	O
relief	O
of	O
pain	O
by	O
acting	O
on	O
brain	O
and	O
spinal	O
-receptors	O

Using	O
same	O
data-set	O
as	O
above	O
table	O
the	O
following	O
compounds	O
were	O
found	O
to	O
compare	O
as:	O
CFT	O
@	O
DAT	O
5	O
fluoxetine	B-Drug
SERT	O
3	O
desipramine	B-Drug
NET	O
3Cocaine	O
analogs	O
substituting	O
C1-tropane	O
ring	O
position	O
requiring	O
sulfinimine	O
N-sulfinyl-imine	O
chemistry	O
before	O
innovation	O
of	O
which	O
untenable	O
bind	O
unlike	O
typical	O
configuration	O
at	O
open	O
out	O
cocaine	B-Drug
with	O
its	O
terminal	O
D79-Y156	O
distance	O
6	O

Approximately	O
96%	O
of	O
bicalutamide	B-Drug
prescriptions	O
were	O
written	O
for	O
diagnosis	O
codes	O
that	O
clearly	O
indicated	O
neoplasm	O

Symptoms	O
of	O
delirium	O
in	O
hospitalized	O
AIDS	O
patients	O
have	O
been	O
effectively	O
treated	O
with	O
low	O
doses	O
chlorpromazine	B-Drug

The	O
CDSA	O
was	O
updated	O
as	O
a	O
result	O
of	O
the	O
Safe	O
Streets	O
and	O
Communities	O
Act	O
changing	O
amphetamines	B-Drug
from	O
Schedule	O
III	O
to	O
I	O
in	O
March	O
2012	O

In	O
Alberta	O
the	O
Blood	O
Tribe	O
police	O
claimed	O
that	O
from	O
fall	O
of	O
2014	O
through	O
January	O
2015	O
oxycodone	B-Drug
pills	O
or	O
a	O
lethal	O
fake	O
variation	O
referred	O
to	O
as	O
Oxy	O
80s	O
containing	O
fentanyl	B-Drug
made	O
in	O
illegal	O
labs	O
by	O
members	O
organized	O
crime	O
were	O
responsible	O
for	O
ten	O
deaths	O
on	O
Reserve	O
which	O
is	O
located	O
southwest	O
Lethbridge	O

Pholcodine	B-Drug
is	O
a	O
drug	O
which	O
an	O
opioid	O
cough	O
suppressant	O
antitussive	O

The	O
National	O
Drug	O
Strategy	O
Household	O
Survey	O
2019	O
suggests	O
overall	O
rates	O
of	O
methamphetamine	B-Drug
use	O
have	O
declined	O
over	O
recent	O
years	O
but	O
among	O
those	O
who	O
do	O
'ice'	O
is	O
the	O
more	O
popular	O
form	O
drug	O
and	O
as	O
opposed	O
to	O
other	O
forms	O
are	O
likely	O
it	O
regularly	O

Researchers	O
like	O
pioneering	O
mescaline	B-Drug
researcher	O
Heinrich	O
Klver	O
looked	O
to	O
Ludlows	O
seminal	O
writings	O
on	O
the	O
psychedelic	O
experience	O
for	O
insight	O
new	O
drugs	O
that	O
were	O
being	O
discovered	O
and	O
synthesized	O

The	O
data	O
suggest	O
that	O
clozapine	B-Drug
may	O
be	O
more	O
likely	O
to	O
cause	O
adverse	O
metabolic	O
effects	O
than	O
some	O
of	O
the	O
other	O
atypical	O
antipsychotics	O

Death	O
from	O
fentanyl	B-Drug
overdose	O
continues	O
to	O
be	O
a	O
public	O
health	O
of	O
national	O
concern	O
in	O
Canada	O
since	O
September	O
2015	O

Information	O
on	O
their	O
use	O
is	O
largely	O
anecdotal	O
with	O
reports	O
of	O
increased	O
sexual	O
pleasure	O
and	O
the	O
effects	O
drug	O
lasting	O
longer	O
though	O
as	O
methamphetamine	B-Drug
centrally	O
active	O
in	O
brain	O
these	O
are	O
likely	O
experienced	O
through	O
higher	O
bioavailability	O
bloodstream	O
faster	O
onset	O
action	O
than	O
many	O
other	O
routes	O
administration	O

The	O
most	O
common	O
salt	O
of	O
MDMA	B-Drug
is	O
the	O
hydrochloride	O
salt;	O
pure	O
water-soluble	O
and	O
appears	O
as	O
a	O
white	O
or	O
off-white	O
powder	O
crystal	O

Bicalutamide	B-Drug
has	O
been	O
studied	O
in	O
the	O
treatment	O
of	O
benign	O
prostatic	O
hyperplasia	O
BPH	O
a	O
24-week	O
trial	O
15	O
patients	O
at	O
dosage	O
50	O
mg/day	O

Other	O
efforts	O
of	O
alfatradiol	B-Drug
had	O
been	O
directed	O
at	O
neurodegenerative	O
diseases	O
including	O
Parkinson's	O

There	O
have	O
been	O
incidents	O
reported	O
where	O
desomorphine	B-Drug
had	O
supposedly	O
present	O
within	O
either	O
country	O
but	O
no	O
confirmed	O
by	O
any	O
drug	O
testing	O
or	O
analytical	O
results	O
and	O
use	O
in	O
North	O
America	O
is	O
still	O
considered	O
unconfirmed	O

Amphetamine	B-Drug
and	O
other	O
dopaminergic	O
drugs	O
also	O
increase	O
power	O
output	O
at	O
fixed	O
levels	O
of	O
perceived	O
exertion	O
by	O
overriding	O
a	O
safety	O
switch	O
allowing	O
the	O
core	O
temperature	O
limit	O
to	O
in	O
order	O
access	O
reserve	O
capacity	O
that	O
is	O
normally	O
off-limits	O

Reports	O
of	O
deaths	O
and	O
significant	O
injuries	O
have	O
been	O
attributed	O
to	O
the	O
use	O
25I-NBOMe	B-Drug
prompting	O
some	O
governments	O
control	O
its	O
possession	O
production	O
sale	O

Initially	O
a	O
working	O
class	O
drug	O
laudanum	B-Drug
was	O
cheaper	O
than	O
bottle	O
of	O
gin	O
or	O
wine	O
because	O
it	O
treated	O
as	O
medication	O
for	O
legal	O
purposes	O
and	O
not	O
taxed	O
an	O
alcoholic	O
beverage	O

However	O
androstenedione	B-Drug
was	O
legally	O
defined	O
as	O
an	O
anabolic	O
steroid	O
even	O
though	O
there	O
is	O
scant	O
evidence	O
that	O
itself	O
in	O
nature	O

Methadone	B-Drug
has	O
a	O
slow	O
metabolism	O
and	O
very	O
high	O
fat	O
solubility	O
making	O
it	O
longer	O
lasting	O
than	O
morphine-based	O
drugs	O

George	O
Carlin	O
mentions	O
mescaline	B-Drug
use	O
during	O
his	O
youth	O
while	O
being	O
interviewed	O

Another	O
form	O
of	O
fentanyl	B-Drug
that	O
has	O
appeared	O
on	O
the	O
streets	O
is	O
Actiq	B-Drug
lollipop	O
formulation	O

The	O
same	O
fetotoxicity	O
of	O
nitrazepam	B-Drug
could	O
not	O
be	O
observed	O
in	O
mice	O
and	O
is	O
likely	O
due	O
to	O
the	O
particular	O
metabolism	O
drug	O
rat	O

In	O
the	O
United	O
Kingdom	O
it	O
is	O
listed	O
as	O
a	O
Class	O
B	O
drug	O
but	O
Home	O
Office	O
considering	O
reclassifying	O
A	O
when	O
dissolved	O
in	O
water	O
for	O
injection	O
amphetamine	B-Drug

Youdim	O
visited	O
Knoll	O
in	O
Budapest	O
and	O
took	O
selegiline	B-Drug
from	O
him	O
to	O
Vienna	O

Long	O
before	O
abuse	O
of	O
the	O
drug	O
was	O
sufficiently	O
widespread	O
in	O
United	O
States	O
to	O
meet	O
Act's	O
control	O
criteria	O
rohypnol	B-Drug
added	O
Schedules	O
Convention	O
on	O
Psychotropic	O
Substances	O
and	O
U	O

Tamoxifen	B-Drug
a	O
selective	O
estrogen	O
receptor	O
modulator	O
SERM	O
with	O
predominantly	O
antiestrogenic	O
actions	O
can	O
counteract	O
flutamide-induced	O
gynecomastia	O
and	O
breast	O
pain	O
in	O
men	O

One	O
of	O
the	O
earliest	O
uses	O
amphetamine	B-Drug
and	O
methamphetamine	B-Drug
was	O
during	O
World	O
War	O
II	O
when	O
they	O
were	O
used	O
by	O
Axis	O
Allied	O
forces	O

The	O
common	O
side	O
effects	O
from	O
nicotine	B-Drug
exposure	O
are	O
listed	O
in	O
the	O
table	O
below	O

In	O
Wistar	O
rats	O
with	O
gravitational	O
cerebral	O
ischemia	O
Phenylpiracetam	B-Drug
reduced	O
the	O
extent	O
of	O
neuralgic	O
deficiency	O
manifestations	O
retained	O
locomotor	O
research	O
and	O
memory	O
functions	O
increased	O
survival	O
rate	O
lead	O
to	O
favoring	O
local	O
flow	O
restoration	O
upon	O
occlusion	O
carotid	O
arteries	O
a	O
greater	O
than	O
did	O
piracetam	B-Drug

However	O
because	O
MDMA	B-Drug
excretion	O
and	O
metabolism	O
have	O
nonlinear	O
kinetics	O
the	O
half-lives	O
would	O
be	O
higher	O
at	O
more	O
typical	O
doses	O
100	O
mg	O
is	O
sometimes	O
considered	O
a	O
dose	O

Hydrocortisone	B-Drug
is	O
a	O
glucocorticoid	O
and	O
works	O
as	O
an	O
anti-inflammatory	O
by	O
immune	O
suppression	O

If	O
overdose	O
of	O
opium	B-Drug
tincture	O
is	O
suspected	O
rapid	O
professional	O
intervention	O
required	O

In	O
Hong	O
Kong	O
GHB	B-Drug
is	O
regulated	O
under	O
Schedule	O
1	O
of	O
Kong's	O
Chapter	O
134	O
Dangerous	O
Drugs	O
Ordinance	O

The	O
Commentary	O
notes	O
that	O
Whether	O
the	O
prohibition	O
of	O
drugs	O
in	O
Schedule	O
IV	O
cannabis	O
and	O
resin	B-Drug
desomorphine	B-Drug
heroin	B-Drug
ketobemidone	B-Drug
should	O
be	O
mandatory	O
or	O
only	O
recommended	O
was	O
a	O
controversial	O
question	O
at	O
Plenipotentiary	O
Conference	O

In	O
March	O
2009	O
a	O
DEA	O
agent	O
who	O
gained	O
access	O
to	O
the	O
site	O
successfully	O
purchased	O
25	O
hits	O
of	O
LSD	B-Drug
sending	O
money	O
Budapest	O
and	O
receiving	O
drugs	O
in	O
Los	O
Angeles	O

Amphetamine	B-Drug
itself	O
has	O
comparatively	O
low	O
affinity	O
for	O
SERT	O
relative	O
to	O
DAT	O
and	O
NET	O

In	O
countries	O
where	O
possession	O
of	O
mescaline	B-Drug
and	O
related	O
compounds	O
is	O
illegal	O
highly	O
penalized	O
cultivation	O
for	O
the	O
purposes	O
consumption	O
most	O
likely	O
also	O

Taking	O
again	O
statistics	O
from	O
Australia	O
97%	O
disapprove	O
of	O
the	O
regular	O
use	O
heroin	B-Drug
96%	O
amphetamines	O
or	O
cocaine	B-Drug
and	O
76	O

Zolpidem	B-Drug
is	O
available	O
legally	O
by	O
prescription	O
and	O
unlike	O
gamma-hydroxybutyrate	O
which	O
used	O
to	O
treat	O
a	O
rare	O
form	O
of	O
narcolepsy	O
flunitrazepam	B-Drug
Rohypnol	B-Drug
only	O
prescribed	O
as	O
second-line	O
choice	O
for	O
insomnia	O
zolpidem	B-Drug
broadly	O

Initially	O
a	O
working	O
class	O
drug	O
laudanum	B-Drug
was	O
cheaper	O
than	O
bottle	O
of	O
gin	O
or	O
wine	O
because	O
it	O
treated	O
as	O
medication	O
for	O
legal	O
purposes	O
and	O
not	O
taxed	O
an	O
alcoholic	O
beverage	O

Hydromorphone	B-Drug
is	O
used	O
to	O
treat	O
moderate	O
severe	O
pain	O

After	O
winning	O
the	O
100m	O
gold	O
at	O
1988	O
Summer	O
Olympics	O
in	O
Seoul	O
Canadian	O
sprinter	O
Ben	O
Johnson	O
tested	O
positive	O
for	O
anabolic	O
steroid	O
Stanozolol	B-Drug
was	O
later	O
stripped	O
of	O
his	O
medal	O
and	O
banned	O
from	O
competition	O
two	O
years	O

Drugs	O
that	O
are	O
sniffed	O
or	O
snorted	O
include	O
powdered	O
amphetamines	O
cocaine	B-Drug
heroin	B-Drug
ketamine	B-Drug
MDMA	B-Drug
snuff	B-Drug
tobacco	B-Drug
Subcutaneous	O
injection:	O
also	O
known	O
as	O
Skin	O
popping	O

In	O
the	O
United	O
States	O
during	O
2016	O
there	O
were	O
more	O
than	O
42000	O
deaths	O
due	O
to	O
opioid	O
overdose	O
of	O
which	O
15000	O
result	O
heroin	B-Drug
use	O

For	O
example	O
neuronal	O
nAChR	O
channels	O
are	O
blocked	O
by	O
clinically	O
relevant	O
anaesthetic	O
concentrations	O
of	O
both	O
thiopental	B-Drug
and	O
pentobarbital	B-Drug

In	O
contrast	O
inhalation	O
of	O
cocaine	B-Drug
leads	O
to	O
the	O
shortest	O
duration	O
its	O
effects	O
515	O
minutes	O

Conversely	O
hydrocodone	B-Drug
inhibits	O
adrenocorticotropic	O
hormone	O
ACTH	O
cortisol	O
and	O
luteinizing	O
LH	O
secretion	O

4%	O
the	O
most	O
common	O
are	O
ephedrine	B-Drug
and	O
pseudoephedrine	O
which	O
sources	O
of	O
its	O
stimulant	O
thermogenic	O
effects	O

LSD	B-Drug
causes	O
visual	O
hallucinations	O
audiovisual	O
synaesthesia	O
and	O
experiences	O
of	O
de-realisation	O

Its	O
molecular	O
structure	O
and	O
pharmacological	O
effects	O
somewhat	O
resemble	O
those	O
of	O
the	O
tryptamine	O
psilocin	B-Drug
which	O
is	O
primary	O
psychoactive	O
chemical	O
in	O
magic	O
mushrooms	O

Unlike	O
THC	O
cannabidiol	B-Drug
CBD	B-Drug
and	O
cannabichromene	O
CBC	O
THCV	O
doesnt	O
begin	O
as	O
cannabigerolic	O
acid	O
CBGA	O

It	O
is	O
unclear	O
if	O
fentanyl	B-Drug
gives	O
long-term	O
pain	O
relief	O
to	O
people	O
with	O
neuropathic	O

Furthermore	O
some	O
testing	O
procedures	O
employ	O
a	O
hydrolysis	O
step	O
before	O
quantitation	O
that	O
converts	O
many	O
of	O
the	O
metabolic	O
products	O
to	O
morphine	B-Drug
yielding	O
result	O
may	O
be	O
2	O
times	O
larger	O
than	O
with	O
method	O
examines	O
each	O
product	O
individually	O

Orally	O
administered	O
cocaine	B-Drug
takes	O
approximately	O
30	O
minutes	O
to	O
enter	O
the	O
bloodstream	O

Phencyclidine	B-Drug
is	O
used	O
for	O
its	O
ability	O
to	O
induce	O
a	O
dissociative	O
state	O

Trilafon	B-Drug
Perphenazine-	O
an	O
antipsychotic	O
used	O
to	O
treat	O
schizophrenia	O

Food	O
and	O
Drug	O
Administration	O
FDA	O
granted	O
the	O
application	O
for	O
fenfluramine	B-Drug
priority	O
review	O
orphan	O
drug	O
designations	O

Androstenedione	B-Drug
is	O
currently	O
banned	O
by	O
the	O
U	O

It	O
acts	O
as	O
a	O
moderately	O
potent	O
and	O
selective	O
agonist	O
for	O
the	O
5-HT2A	O
5-HT2C	O
receptors	O
but	O
unlike	O
corresponding	O
benzocyclobutene	O
derivative	O
TCB-2	O
which	O
is	O
considerably	O
more	O
than	O
parent	O
compound	O
2C-B	B-Drug
2CB-Ind	O
several	O
times	O
weaker	O
with	O
racemic	O
having	O
Ki	O
of	O
47nM	O
at	O
human	O
receptor	O
only	O
slightly	O
mescaline	B-Drug
analogue	O
R-jimscaline	O

In	O
France	O
marketing	O
authorization	O
was	O
granted	O
for	O
Zyban	B-Drug
on	O
3	O
August	O
2001	O
with	O
a	O
maximum	O
daily	O
dose	O
of	O
300	O
mg;	O
only	O
sustained-release	O
bupropion	B-Drug
is	O
available	O
and	O
as	O
smoking	O
cessation	O
aid	O

This	O
was	O
demonstrated	O
by	O
the	O
Ecstasy	B-Drug
group	O
showing	O
a	O
greater	O
increase	O
in	O
magnitude	O
of	O
TAE	O
illusion	O
compared	O
to	O
controls	O

For	O
individuals	O
who	O
have	O
a	O
defect	O
in	O
the	O
gene	O
encoding	O
CYP2D6	O
clearance	O
of	O
drug	O
will	O
be	O
lower	O
and	O
less	O
metabolite	O
such	O
as	O
hydromorphone	B-Drug
formed;	O
however	O
effect	O
on	O
analgesia	O
remains	O
unknown	O

It	O
is	O
also	O
estimated	O
that	O
up	O
to	O
44	O
tons	O
of	O
processed	O
heroin	B-Drug
are	O
consumed	O
annually	O
in	O
Pakistan	O

In	O
2015	O
a	O
systematic	O
review	O
and	O
meta-analysis	O
of	O
high	O
quality	O
clinical	O
trials	O
found	O
that	O
when	O
used	O
at	O
low	O
therapeutic	O
doses	O
amphetamine	B-Drug
produces	O
modest	O
yet	O
unambiguous	O
improvements	O
in	O
cognition	O
including	O
working	O
memory	O
long-term	O
episodic	O
inhibitory	O
control	O
some	O
aspects	O
attention	O
normal	O
healthy	O
adults;	O
these	O
cognition-enhancing	O
effects	O
are	O
known	O
to	O
be	O
partially	O
mediated	O
through	O
the	O
indirect	O
activation	O
both	O
dopamine	O
receptor	O
D1	O
adrenoceptor	O
2	O
prefrontal	O
cortex	O

An	O
alternative	O
proposed	O
cause	O
is	O
inhibition	O
of	O
17-hydroxylase	O
and	O
hence	O
sex	O
steroid	O
metabolism	O
by	O
spironolactone	B-Drug
consequent	O
changes	O
in	O
hormone	O
levels	O

All	O
formulations	O
of	O
bicalutamide	B-Drug
are	O
specifically	O
indicated	O
for	O
the	O
treatment	O
prostate	O
cancer	O
alone	O
or	O
in	O
combination	O
with	O
surgical	O
medication	O
castration	O

Alphaprodine	B-Drug
is	O
closely	O
related	O
to	O
desomorphine	B-Drug
in	O
steric	O
configuration	O

By	O
1100	O
BC	O
opium	B-Drug
was	O
cultivated	O
on	O
Cyprus	O
where	O
surgical-quality	O
knives	O
were	O
used	O
to	O
score	O
the	O
poppy	O
pods	O
and	O
traded	O
smoked	O

Infrequent	O
adverse	O
reactions	O
in	O
patients	O
taking	O
opioids	O
for	O
pain	O
relief	O
include:	O
dose-related	O
respiratory	O
depression	O
especially	O
with	O
more	O
potent	O
confusion	O
hallucinations	O
delirium	O
urticaria	O
hypothermia	O
bradycardia/tachycardia	O
orthostatic	O
hypotension	O
dizziness	O
headache	O
urinary	O
retention	O
ureteric	O
or	O
biliary	O
spasm	O
muscle	O
rigidity	O
myoclonus	O
high	O
doses	O
and	O
flushing	O
due	O
to	O
histamine	O
release	O
except	O
fentanyl	B-Drug
remifentanil	B-Drug

Some	O
studies	O
found	O
that	O
like	O
other	O
NMDA	O
receptor	O
antagonists	O
PCP	B-Drug
can	O
cause	O
a	O
kind	O
of	O
brain	O
damage	O
called	O
Olney's	O
lesions	O
in	O
rats	O

The	O
pure	O
cocaine	B-Drug
base	O
can	O
be	O
recovered	O
from	O
the	O
mixture	O
by	O
extraction	O
freebase	O
or	O
acid-base	O
hydrochloride	O
using	O
common	O
organic	O
solvents	O
such	O
as	O
methylene	O
chloride	O
acetone	O

The	O
officers	O
suspected	O
he	O
was	O
smuggling	O
heroin	B-Drug
from	O
Mexico	O
but	O
found	O
instead	O
688	O
Dexedrine	B-Drug
capsules	O
amphetamines	O
and	O
475	O
Equanil	B-Drug
sedatives	O
or	O
tranquilizers	O
tablets	O
that	O
the	O
singer	O
had	O
hidden	O
inside	O
his	O
guitar	O
case	O

The	O
deactivation	O
of	O
catecholamines	O
via	O
methylation	O
produces	O
alkaloids	O
such	O
as	O
mescaline	B-Drug

]	O
Cannabis	O
Latin	O
or	O
scientific	O
name	O
for	O
the	O
entire	O
plant	O
hemp	O
legally	O
named	O
marijuana	O
marihuana	B-Drug
in	O
some	O
jurisdictions	O

Lespedeza	O
capitata	O
bicolor	O
DMT	O
5-MeO-DMT	B-Drug
in	O
leaves	O
and	O
roots	O
var	O

Folkman	O
persuaded	O
the	O
patient's	O
doctor	O
to	O
try	O
thalidomide	B-Drug
and	O
that	O
conducted	O
a	O
clinical	O
trial	O
of	O
for	O
people	O
with	O
multiple	O
myeloma	O
in	O
which	O
about	O
third	O
subjects	O
responded	O
treatment	O

Following	O
Exum's	O
revelations	O
the	O
IAAF	O
acknowledged	O
that	O
at	O
1988	O
Olympic	O
Trials	O
USOC	O
indeed	O
followed	O
correct	O
procedures	O
in	O
dealing	O
with	O
eight	O
positive	O
findings	O
for	O
ephedrine	B-Drug
and	O
ephedrine-related	O
compounds	O
low	O
concentration	O

Spironolactone	B-Drug
is	O
rapidly	O
and	O
extensively	O
metabolized	O
in	O
the	O
liver	O
upon	O
oral	O
administration	O
has	O
a	O
very	O
short	O
terminal	O
half-life	O
of	O
1	O

It	O
is	O
closely	O
related	O
to	O
the	O
drug	O
prodine	B-Drug
only	O
difference	O
being	O
that	O
meprodine	B-Drug
has	O
an	O
ethyl	O
group	O
rather	O
than	O
a	O
methyl	O
at	O
3-position	O
of	O
piperidine	O
ring	O

Thalidomide	B-Drug
can	O
prevent	O
menstruation	O

Hemp	O
seed	O
ingredients	O
which	O
do	O
not	O
naturally	O
contain	O
THC	O
or	O
CBD	B-Drug
but	O
may	O
be	O
contaminated	O
with	O
trace	O
amounts	O
on	O
the	O
outside	O
during	O
harvesting	O
were	O
declared	O
by	O
US	O
Food	O
and	O
Drug	O
Administration	O
FDA	O
as	O
Generally	O
recognized	O
safe	O
GRAS	O
in	O
December	O
2018	O

Only	O
of	O
a	O
few	O
these	O
compounds	O
were	O
widely	O
used	O
including	O
rolicyclidine	B-Drug
PCPy	O
eticyclidine	B-Drug
PCE	B-Drug
and	O
tenocyclidine	B-Drug
TCP	B-Drug

Clomifene	B-Drug
is	O
marketed	O
under	O
many	O
brand	O
names	O
worldwide	O
including	O
Beclom	O
Bemot	O
Biogen	O
Blesifen	O
Chloramiphene	O
Clofert	O
Clomene	O
ClomHEXAL	O
Clomi	O
Clomid	B-Drug
Clomidac	O
Clomifen	O
Clomifencitrat	O
Clomifne	O
citrate	I-Drug
Clomifeni	O
citras	O
Clomifeno	O
Clomifert	O
Clomihexal	O
Clomiphen	O
Clomiphene	B-Drug
Citrate	O
Cloninn	O
Clostil	O
Clostilbegyt	O
Clovertil	O
Clovul	O
Dipthen	O
Dufine	O
Duinum	O
Fensipros	O
Fertab	O
Fertec	O
Fertex	O
Ferticlo	O
Fertil	O
Fertilan	O
Fertilphen	O
Fertin	O
Fertomid	O
Ferton	O
Fertotab	O
Fertyl	O
Fetrop	O
Folistim	O
Genoclom	O
Genozym	O
Hete	O
I-Clom	O
Ikaclomin	O
Klofit	O
Klomen	O
Klomifen	O
Lomifen	O
MER	O
41	O
Milophene	O
Ofertil	O
Omifin	O
Ova-mit	O
Ovamit	O
Ovinum	O
Ovipreg	O
Ovofar	O
Ovuclon	O
Ovulet	O
Pergotime	O
Pinfetil	O
Profertil	O
Prolifen	O
Provula	O
Reomen	O
Serofene	O
Serophene	O
Serpafar	O
Surole	O
Tocofeno	O
and	O
Zimaquin	O

This	O
helps	O
avoid	O
detection	O
but	O
reduces	O
the	O
CBD	B-Drug
production	O
of	O
plant	O

However	O
controlled	O
studies	O
have	O
found	O
the	O
symptomatic	O
effectiveness	O
of	O
dextromethorphan	B-Drug
similar	O
to	O
placebo	O

Alsoa	O
police	O
officer	O
who	O
went	O
undercover	O
to	O
buy	O
crystal	B-Drug
meth	I-Drug
died	O
in	O
an	O
operation	O
after	O
suspected	O
drug	O
user	O
Dolofrina's	O
companion	O
discovered	O
the	O
ruse	O

The	O
most	O
dangerous	O
adverse	O
effect	O
of	O
fentanyl	B-Drug
is	O
respiratory	O
depression	O
that	O
decreased	O
sensitivity	O
to	O
carbon	O
dioxide	O
leading	O
reduced	O
rate	O
breath	O
intake	O
which	O
can	O
cause	O
complications	O
or	O
suffocation	O

